PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Edwards, N; Harrison, A				Edwards, N; Harrison, A			The hospital of the future - Planning hospitals with limited evidence: a research and policy problem	BRITISH MEDICAL JOURNAL			English	Article									NHS Confederat, London SW1P 4ND, England; Kings Fund, London W1M 0AN, England		Edwards, N (corresponding author), NHS Confederat, London SW1P 4ND, England.							*BRIT MED ASS ROYA, 1998, PROV AC GEN HOSP SER; FERGUSON B, 1997, CONCENTRATION CHOICE; HARRISON AJ, 1998, IMPLEMENTING WHITE P; Hensher M, 1999, BRIT MED J, V319, P911, DOI 10.1136/bmj.319.7214.911; *JOINT CONS COMM, 1999, ORG AC GEN HOSP SERV; *MED SCH U LOND SU, 1997, CONTR LOND AC MED HE; Pollock AM, 1997, BRIT MED J, V314, P1266, DOI 10.1136/bmj.314.7089.1266; Posnett J, 1999, BRIT MED J, V319, P1063, DOI 10.1136/bmj.319.7216.1063; RAFTERY J, 1998, J HLTH SERV RES POL, V3, P153; *SCOTT OFF DEP HLT, 1998, AC SERV REV REP; *SECR STAT HLTH, 1997, CMND3807; VETTER N, 1995, HOSPITAL CTR EXCELLE	12	17	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1361	1363		10.1136/bmj.319.7221.1361	http://dx.doi.org/10.1136/bmj.319.7221.1361			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567152	Green Published			2022-12-28	WOS:000083930200033
J	Himsworth, RL; Goldacre, MJ				Himsworth, RL; Goldacre, MJ			Does time spent in hospital in the final 15 years of life increase with age at death? A population based study	BRITISH MEDICAL JOURNAL			English	Article							CARE		Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England; Univ Oxford, Inst Hlth Sci, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Cambridge; University of Oxford	Himsworth, RL (corresponding author), Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England.							GOLDACRE MJ, 1988, BRIT MED J, V296, P583, DOI 10.1136/bmj.296.6621.583; HENDERSON J, 1990, BRIT MED J, V301, P17, DOI 10.1136/bmj.301.6742.17; vanWeel C, 1997, LANCET, V350, P1159, DOI 10.1016/S0140-6736(97)08312-8; Victor C R, 1994, Qual Health Care, V3, P210, DOI 10.1136/qshc.3.4.210	4	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1338	1339		10.1136/bmj.319.7221.1338	http://dx.doi.org/10.1136/bmj.319.7221.1338			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567138	Green Published, Bronze			2022-12-28	WOS:000083930200025
J	Dobson, A				Dobson, A			Is raised serum uric acid a cause of cardiovascular disease or death?	LANCET			English	Editorial Material							HEART-DISEASE; MORTALITY; RISK		Univ Newcastle, Dept Stat, Newcastle, NSW 2308, Australia	University of Newcastle	Dobson, A (corresponding author), Univ Newcastle, Dept Stat, Newcastle, NSW 2308, Australia.							Culleton BF, 1999, ANN INTERN MED, V131, P7, DOI 10.7326/0003-4819-131-1-199907060-00003; FREEDMAN DS, 1995, AM J EPIDEMIOL, V141, P637, DOI 10.1093/oxfordjournals.aje.a117479; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; LEVINE W, 1989, J CLIN EPIDEMIOL, V42, P257, DOI 10.1016/0895-4356(89)90061-9; LEVYA F, 1997, EUR HEART J, V18, P858; Neter J., 1996, APPL LINEAR STAT MOD; Newland H, 1975, Med Hypotheses, V1, P152, DOI 10.1016/0306-9877(75)90011-0; ROSE BD, 1994, CLIN PHYSL ACID BASE; TAUBES G, 1995, SCIENCE, V269, P164, DOI 10.1126/science.7618077; Wannamethee SG, 1997, HEART, V78, P147, DOI 10.1136/hrt.78.2.147; Ward HJ, 1998, LANCET, V352, P670, DOI 10.1016/S0140-6736(05)60816-1	11	35	36	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1578	1578		10.1016/S0140-6736(99)00260-3	http://dx.doi.org/10.1016/S0140-6736(99)00260-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560670				2022-12-28	WOS:000083551000007
J	O'Connor, V; El Far, O; Bofill-Cardona, E; Nanoff, C; Freissmuth, M; Karschin, A; Airas, JM; Betz, H; Boehm, S				O'Connor, V; El Far, O; Bofill-Cardona, E; Nanoff, C; Freissmuth, M; Karschin, A; Airas, JM; Betz, H; Boehm, S			Calmodulin dependence of presynaptic metabotropic glutamate receptor signaling	SCIENCE			English	Article							HIPPOCAMPAL SYNAPSES; CALCIUM; PROTEIN; CHANNELS; INHIBITION; COMPLEX	Glutamatergic neurotransmission is controlled by presynaptic metabotropic glutamate receptors (mGluRs). A subdomain in the intracellular carboxyl-terminal tail of group III mGluRs binds calmodulin and heterotrimeric guanosine triphosphate-binding protein (G protein) beta gamma subunits in a mutually exclusive manner. Mutations interfering with calmodulin binding and calmodulin antagonists inhibit G protein-mediated modulation of ionic currents by mGluR 7. Calmodulin antagonists also prevent inhibition of excitatory neurotransmission via presynaptic mGluRs. These results reveal a novel mechanism of presynaptic modulation in which Ca2+-calmodulin is required to release G protein beta gamma subunits from the C-tail of group III mGluRs in order to mediate glutamatergic autoinhibition.	Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany; Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Max Planck Inst Biophys Chem, D-37070 Gottingen, Germany	Max Planck Society; University of Vienna; Max Planck Society	Betz, H (corresponding author), Max Planck Inst Brain Res, Dept Neurochem, Deutschordenstr 46, D-60528 Frankfurt, Germany.		Far, Oussama El/D-4225-2017; EL FAR, Oussama/P-9915-2019	Far, Oussama El/0000-0002-7473-8345; EL FAR, Oussama/0000-0002-7473-8345; Freissmuth, Michael/0000-0001-9398-1765; Boehm, Stefan/0000-0002-0205-2459; nanoff, christian/0000-0002-8857-2470				BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Boehm S, 1997, J NEUROSCI, V17, P4066; Bradley SR, 1996, J NEUROSCI, V16, P2044; Bushell TJ, 1996, BRIT J PHARMACOL, V117, P1457, DOI 10.1111/j.1476-5381.1996.tb15306.x; CHAPMAN PF, 1995, NEURON, V14, P591, DOI 10.1016/0896-6273(95)90315-1; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; ELFAR O, UNPUB; Flor PJ, 1997, NEUROPHARMACOLOGY, V36, P153, DOI 10.1016/S0028-3908(96)00176-1; GIETZEN K, 1982, BIOCHEM J, V207, P541, DOI 10.1042/bj2070541; HINRICHSEN RD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P277, DOI 10.1016/0304-419X(93)90010-A; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; LEUNG PC, 1984, J BIOL CHEM, V259, P2742; MINKAMI R, 1997, J BIOL CHEM, V272, P20291; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NANOFF C, 1995, MOL PHARMACOL, V48, P806; OCONNOR V, UNPUB; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; PIN JP, 1995, CURR OPIN NEUROBIOL, V5, P342, DOI 10.1016/0959-4388(95)80047-6; Saugstad JA, 1997, MOL PHARMACOL, V51, P119, DOI 10.1124/mol.51.1.119; Scanziani M, 1997, NATURE, V385, P630, DOI 10.1038/385630a0; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Thomas NK, 1996, NEUROPHARMACOLOGY, V35, P637; THOMPSON SM, 1993, TRENDS NEUROSCI, V16, P222, DOI 10.1016/0166-2236(93)90160-N; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758	30	134	136	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1180	1184		10.1126/science.286.5442.1180	http://dx.doi.org/10.1126/science.286.5442.1180			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550060	Green Submitted			2022-12-28	WOS:000083534200050
J	Cortez-Pinto, H; Chatham, J; Chacko, VP; Arnold, C; Rashid, A; Diehl, AM				Cortez-Pinto, H; Chatham, J; Chacko, VP; Arnold, C; Rashid, A; Diehl, AM			Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis - A pilot study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; DISEASE; PREVALENCE; METABOLISM; OBESITY; STEATOSIS	Context The mechanisms that drive progression from fatty liver to steatohepatitis and cirrhosis are unknown. In animal models, obese mice with fatty livers are vulnerable to liver adenosine triphosphate (ATP) depletion and necrosis, suggesting that altered hepatic energy homeostasis may be involved. Objective To determine ii patients with fatty liver disease exhibit impaired recovery from hepatic ATP depletion. Design Laboratory analysis of liver ATP stores monitored by nuclear magnetic resonance spectroscopy before and after transient hepatic ATP depletion was induced by fructose injection. The study was conducted between July 15 and August 30, 1998. Setting University hospital. Patients Eight consecutive adults with biopsy-proven nonalcoholic steatohepatitis and 7 healthy age- and sex-matched controls. Main Outcome Measure Level of ATP 1 hour after fructose infusion in patients vs controls. Results In patients, serum aminotransferase levels were increased (P = .02 vs controls); albumin and bilirubin values were normal and clinical evidence of portal hypertension was absent in both groups. However, 2 patients had moderate fibrosis and 1 had cirrhosis on liver biopsy. Mean serum glucose, cholesterol, and triglyceride levels were similar between groups but patients weighed significantly more than controls (P = .02). Liver ATP levels were similar in the 2 groups before fructose infusion and decreased similarly in both after fructose infusion (P = .01 vs initial ATP levels). However, controls replenished their hepatic ATP stores during the 1-hour follow-up period (P<.02 vs minimum ATP) but patients did not. Hence, patients' hepatic ATP levels were lower than those of controls at the end of the study (P = .04), Body mass index (BMI) correlated inversely with ATP recovery, even in controls (R = -0.768; P = .07), Although BMI was greater in patients than controls (P = .02) and correlated strongly with fatty liver and serum aminotransferase elevations, neither of the latter 2 parameters nor the histologic severity of fibrosis strongly predicted hepatic ATP recovery. Conclusions These data suggest that recovery from hepatic ATP depletion becomes progressively less efficient as body mass increases in healthy controls and is severely impaired in patients with obesity-related nonalcoholic steatohepatitis.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Diehl, AM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 912 Ross Bldg,720 Rutland St, Baltimore, MD 21205 USA.	amdiehl@welchlink.welch.jhu.edu	Cortez-Pinto, Helena/A-3586-2012	Chatham, John/0000-0001-7180-9948				BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; Boesch C, 1997, MAGN RESON IMAGING, V15, P1067, DOI 10.1016/S0730-725X(97)00163-X; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Caldwell SH, 1999, HEPATOLOGY, V29, P664, DOI 10.1002/hep.510290347; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Czaja AJ, 1998, J HEPATOL, V29, P198, DOI 10.1016/S0168-8278(98)80004-4; ELHASSAN AY, 1992, BRIT J RADIOL, V65, P774, DOI 10.1259/0007-1285-65-777-774; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FRAHM J, 1989, MAGNET RESON MED, V9, P79, DOI 10.1002/mrm.1910090110; HODGSON M, 1991, BRIT J IND MED, V48, P690; ITURRIAGA H, 1988, AM J CLIN NUTR, V47, P235, DOI 10.1093/ajcn/47.2.235; LEE RG, 1989, HUM PATHOL, V20, P594, DOI 10.1016/0046-8177(89)90249-9; LEE RG, 1995, HEPATOLOGY, V21, P1742, DOI 10.1002/hep.1840210636; Lonardo A, 1997, ITAL J GASTROENTEROL, V29, P351; LUDWIG J, 1980, MAYO CLIN PROC, V55, P347; Naveau S, 1997, HEPATOLOGY, V25, P108, DOI 10.1002/hep.510250120; NOMURA H, 1988, JPN J MED, V27, P142, DOI 10.2169/internalmedicine1962.27.142; OBERHAENSLI RD, 1986, BRIT J RADIOL, V59, P695, DOI 10.1259/0007-1285-59-703-695; OKOLO P, 1998, SLEISENGER FORDTRANS, P1215; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114; Sheth SG, 1997, ANN INTERN MED, V126, P137, DOI 10.7326/0003-4819-126-2-199701150-00008; TERRIER F, 1989, RADIOLOGY, V171, P557, DOI 10.1148/radiology.171.2.2704824; THALER H, 1975, CLIN GASTROENTEROL, V4, P273; WEISS RG, 1990, NEW ENGL J MED, V323, P1593, DOI 10.1056/NEJM199012063232304; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557	28	362	374	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1659	1664		10.1001/jama.282.17.1659	http://dx.doi.org/10.1001/jama.282.17.1659			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553793	Bronze			2022-12-28	WOS:000083368400032
J	Marrone, M				Marrone, M			Desmond Bardon - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1204	1204		10.1136/bmj.319.7218.1204	http://dx.doi.org/10.1136/bmj.319.7218.1204			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541533	Green Published			2022-12-28	WOS:000083536200058
J	Watts, C; Kumaranayake, L				Watts, C; Kumaranayake, L			Thinking big: scaling-up HIV-1 interventions in sub-Saharan Africa	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Watts, C (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.							[Anonymous], 1997, CONFR AIDS PUBL PRIO; KUMARANAYAKE L, 1998, COSTING GUIDELINES H; Osborne C M, 1997, AIDS, V11 Suppl B, pS135; *UNICEF, 1999, PROGR NAT; *WHO, 1999, WHO REP 1999	5	13	14	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1492	1492		10.1016/S0140-6736(99)00365-7	http://dx.doi.org/10.1016/S0140-6736(99)00365-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551493				2022-12-28	WOS:000083411300007
J	Kobayashi, M; Furuya, H; Holland, PWH				Kobayashi, M; Furuya, H; Holland, PWH			Evolution - Dicyemids are higher animals	NATURE			English	Article							HOX		Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; Kyoto Univ, Grad Sch Sci, Dept Zool, Kyoto 606, Japan; Osaka Univ, Dept Biol, Grad Sch Sci, Toyonaka, Osaka 560, Japan	University of Reading; Kyoto University; Osaka University	Kobayashi, M (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.			Holland, Peter/0000-0003-1533-9376				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Bayascas JR, 1998, DEV GENES EVOL, V208, P467, DOI 10.1007/s004270050204; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; de Rosa R, 1999, NATURE, V399, P772, DOI 10.1038/21631; KATAYAMA T, 1995, BIOL BULL-US, V189, P81, DOI 10.2307/1542458; Martinez DE, 1998, NATURE, V393, P748, DOI 10.1038/31616; STUNKARD HW, 1954, Q REV BIOL, V29, P230, DOI 10.1086/400243; Van Beneden E, 1876, B ACAD R BELG, V41, P1160	9	67	68	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					762	762		10.1038/44513	http://dx.doi.org/10.1038/44513			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548100	Bronze			2022-12-28	WOS:000083368700041
J	Helmstadter, A				Helmstadter, A			Ether and the chemical-contact dissolution of gallstones	LANCET			English	Article							STONES		Univ Frankfurt, Dept Biochem Pharm & Food Technol, D-63303 Dreieich, Germany	Goethe University Frankfurt	Helmstadter, A (corresponding author), Univ Frankfurt, Dept Biochem Pharm & Food Technol, Theodor Heuss Str 30B, D-63303 Dreieich, Germany.							ALLAN MJ, 1985, NEW ENGL J MED, V312, P217; DAMAT R, 1970, DICT BIOGRAPHIE FRAN, V12, P714; DURANDE JF, 1791, BEOBACHRUNGEN WURCKU, P25; DURANDE JF, 1791, BEOBACHTUNGEN WURCKU, P22; DURANDE JF, 1791, BEOBACHTUNGEN WURCKU; DURANDE JF, 1790, OBSERVATIONS EFFICAC; FOERSTER EC, 1989, LANCET, V1, P954; FROBEN SA, 1730, PHILOS T, V413, P283; HALLER JS, 1984, SOUTHERN MED J, V77, P750, DOI 10.1097/00007611-198406000-00021; ISSEKUTZ B, 1971, GESCH ARZNEIMITTELFO, P294; Klimpel V, 1986, Z Gesamte Inn Med, V41, P506; Klimpel V, 1987, Z Arztl Fortbild (Jena), V81, P93; MCNULTY J, 1991, GUT, V32, P1550, DOI 10.1136/gut.32.12.1550; MICHAND M, 1855, BIOGRAPHIE UNIVERSEL, V12, P77; NEOPTOLEMOS JP, 1989, GUT, V30, pA736; Strickland RA, 1996, MAYO CLIN PROC, V71, P1015, DOI 10.1016/S0025-6196(11)63779-8; SWOBODNIK W, 1988, LANCET, V2, P216; VON GIZYCKI F, 1952, Pharmazie, V7, P303; VONGIZYCKI F, 1956, VEROFF INT GESELL GE, V8, P91; WALDENBURG L, 1870, HDB ALLGEMEINEN SPEC, P147; WALKER JW, 1891, LANCET, V1, P874; Zakko Salam, 1992, Recenti Progressi in Medicina, V83, P416; [No title captured]; 1989, LANCET, V2, P249	24	4	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1376	1377		10.1016/S0140-6736(99)04136-7	http://dx.doi.org/10.1016/S0140-6736(99)04136-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533879				2022-12-28	WOS:000083149900041
J	Snape, MD; Sawyer, SM; Nash, MC				Snape, MD; Sawyer, SM; Nash, MC			Weight loss and purpura	LANCET			English	Article							ANOREXIA-NERVOSA		Royal Childrens Hosp, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne	Nash, MC (corresponding author), Royal Childrens Hosp, Flemington Rd, Parkville, Vic 3052, Australia.			Snape, Matthew/0000-0003-0531-5426				ALLOWAY R, 1985, J NEUROL NEUROSUR PS, V48, P1015, DOI 10.1136/jnnp.48.10.1015; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; SHARP CW, 1993, BRIT J PSYCHIAT, V162, P452, DOI 10.1192/bjp.162.4.452; SHUR E, 1988, BRIT J PSYCHIAT, V153, P72, DOI 10.1192/bjp.153.1.72; WARREN MP, 1973, AM J OBSTET GYNECOL, V117, P435, DOI 10.1016/0002-9378(73)90053-7	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1352	1352		10.1016/S0140-6736(99)08095-2	http://dx.doi.org/10.1016/S0140-6736(99)08095-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533865				2022-12-28	WOS:000083149900014
J	Golubitsky, M; Stewart, I; Buono, PL; Collins, JJ				Golubitsky, M; Stewart, I; Buono, PL; Collins, JJ			Symmetry in locomotor central pattern generators and animal gaits	NATURE			English	Article							COUPLED OSCILLATORS; QUADRUPEDAL GAITS; TRANSITIONS; CHAINS	Animal locomotion is controlled, in part, by a central pattern generator (CPG), which is an intraspinal network of neurons capable of generating a rhythmic output(1-4). The spatio-temporal symmetries of the quadrupedal gaits walk, trot and pace(5-8) lead to plausible assumptions about the symmetries of locomotor CPGs(9-11). These assumptions imply that the CPG of a quadruped should consist of eight nominally identical subcircuits, arranged in an essentially unique matter. Here we apply analogous arguments to myriapod CPGs. Analyses based on symmetry applied to these networks lead to testable predictions, including a distinction between primary and secondary gaits, the existence of a new primary gait called 'jump', and the occurrence of half-integer wave numbers in myriapod gaits. For bipeds, our analysis also predicts two gaits with the out-of-phase symmetry of the walk and two gaits with the in-phase symmetry of the hop. We present data that support each of these predictions. This work suggests that symmetry can be used to infer a plausible dass of CPG network architectures from observed patterns of animal gaits.	Univ Houston, Dept Math, Houston, TX 77204 USA; Univ Warwick, Inst Math, Coventry CV4 7AL, W Midlands, England; Boston Univ, Dept Biomed Engn, Ctr Biodynam, Boston, MA 02215 USA	University of Houston System; University of Houston; University of Warwick; Boston University	Golubitsky, M (corresponding author), Univ Houston, Dept Math, Houston, TX 77204 USA.			Buono, Pietro-Luciano/0000-0003-1460-4465				Alexander R. M., 1977, MECH ENERGETICS ANIM, P168; ALEXANDER RM, 1983, J ZOOL, V201, P135, DOI 10.1111/j.1469-7998.1983.tb04266.x; BUONO PL, UNPUB J MATH BIOL; BUONO PL, 1998, THESIS U HOUSTON; COLLINS FS, 1993, HUM GENOME NEWS, V5, P3; COLLINS JJ, 1992, J MATH BIOL, V30, P827; COLLINS JJ, 1993, BIOL CYBERN, V68, P287, DOI 10.1007/BF00201854; COLLINS JJ, 1994, BIOL CYBERN, V71, P95, DOI 10.1007/BF00197312; DELCOMYN F, 1980, SCIENCE, V210, P492, DOI 10.1126/science.7423199; DEUEL NR, 1987, J BIOMECH, V20, P645, DOI 10.1016/0021-9290(87)90285-5; FULL RJ, 1991, J EXP BIOL, V158, P369; Gambaryan P.P., 1974, MAMMALS RUN ANATOMIC; Golubitsky M, 1998, PHYSICA D, V115, P56, DOI 10.1016/S0167-2789(97)00222-4; GOLUBITSKY M, 1988, SINGULARITIES GROUPS, V2, P275; HILDEBRA.M, 1965, SCIENCE, V150, P701, DOI 10.1126/science.150.3697.701; HILDEBRAND M, 1989, BIOSCIENCE, V39, P766, DOI 10.2307/1311182; Hildebrand M., 1976, NEURAL CONTROL LOCOM, V18, P202, DOI DOI 10.1007/978-1-4757-0964-3_9; KOPELL N, 1990, SIAM J APPL MATH, V50, P1014, DOI 10.1137/0150062; KOPELL N, 1986, COMMUN PUR APPL MATH, V39, P623, DOI 10.1002/cpa.3160390504; Kopell N., 1988, MATH BIOSCI, V89, P14; LEACH DH, 1979, J EQUINE MED SURG, V3, P436; Mann R, 1982, DISORDERS OF THE FOO, P37; MANN RA, 1986, AM J SPORT MED, V14, P501, DOI 10.1177/036354658601400614; MANTON S. M., 1965, J LINN SOC LONDON ZOOL, V45, P251; SCHONER G, 1990, J THEOR BIOL, V142, P359, DOI 10.1016/S0022-5193(05)80558-2; SELVERSTON AI, 1980, BEHAV BRAIN SCI, V3, P535, DOI 10.1017/S0140525X00006580; SHIK ML, 1976, PHYSIOL REV, V56, P465, DOI 10.1152/physrev.1976.56.3.465	27	282	287	0	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					693	695		10.1038/44416	http://dx.doi.org/10.1038/44416			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537106				2022-12-28	WOS:000083207400055
J	Peterschmitt, MJ; Simmons, JR; Levy, HL				Peterschmitt, MJ; Simmons, JR; Levy, HL			Reduction of false negative results in screening of newborns for homocystinuria.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEFICIENCY; SPECIMEN	Background: Mental retardation and other medical problems (including ectopia lentis, osteoporosis, and thromboembolism) in patients who have homocystinuria as a result of a deficiency of cystathionine beta-synthase can be prevented by the screening of newborns with measurement of blood methionine, followed by the early treatment of affected infants. Many infants with this disorder, however, are not identified by screening and have irreversible brain damage. Methods: We reviewed the results of neonatal screening for homocystinuria over a period of 32 years in New England. Additional specimens were requested for repeated analysis when blood methionine measurements were at or above the established cutoff level. Homocystinuria due to cystathionine beta-synthase deficiency was confirmed by quantitative amino acid analyses. Results: For the first 23.5 years of the review period, the blood methionine cutoff value was 2 mg per deciliter (134 micromol per liter). Among the 2.2 million infants screened during that period, 8 with homocystinuria were identified (1:275,000). In 1990, the cutoff value was reduced to 1 mg per deciliter (67 mu mol per liter). Among the 1.1 million infants screened in the subsequent 8.5 years, 7 with the disorder were identified (1:157,000). During the latter period, the specimens were collected from six of the seven infants when they were two days of age or less; five of the six had blood methionine concentrations below 2 mg per deciliter. Use of the reduced cutoff level increased the false positive rate from 0.006 percent to 0.03 percent. Conclusions: A cutoff level for blood methionine of 1 mg per deciliter in neonatal screening tests for homocystinuria should identify affected infants who have only slightly elevated concentrations of methionine and reduce the frequency of false negative results. (N Engl J Med 1999;341:1572-6.) (C) 1999, Massachusetts Medical Society.	Childrens Hosp, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; State Lab Inst, New England Newborn Screening Program, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Levy, HL (corresponding author), Childrens Hosp, Div Genet, 300 Longwood Ave,IC-106, Boston, MA 02115 USA.	levy_h@al.tch.harvard.edu						BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; CUNNINGHAM CG, 1995, EARLY HOSP DISCHARGE, P31; DOHERTY LB, 1991, PEDIATRICS, V87, P240; EFRON ML, 1964, NEW ENGL J MED, V270, P1378, DOI 10.1056/NEJM196406252702602; Gaustadnes M, 1999, NEW ENGL J MED, V340, P1513, DOI 10.1056/NEJM199905133401915; GUTHRIE R, 1968, Birth Defects Original Article Series, V4, P92; *IL DEP PUBL HLTH, 1996, NEWB SCREEN OV NEWB; Krans JP, 1998, EUR J PEDIATR, V157, pS50, DOI 10.1007/PL00014304; Levy H.L., 1971, INHERITED DISORDERS, P235; LEVY HL, 1970, LANCET, V2, P522; MORRISON AS, 1992, MONOGRAPHS EPIDEMIOL, V19; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; Naughten ER, 1998, EUR J PEDIATR, V157, pS84, DOI 10.1007/PL00014310; Pang S, 1993, SCREENING, V2, P105, DOI 10.1016/0925-6164(93)90024-D; VERKERK PH, 1993, AM J PUBLIC HEALTH, V83, P868, DOI 10.2105/AJPH.83.6.868; WAGSTAFF J, 1991, J PEDIATR-US, V118, P569, DOI 10.1016/S0022-3476(05)83383-9; WALRAVEN C, 1995, SCREENING, V4, P1, DOI 10.1016/0925-6164(95)00110-8; Walter JH, 1998, EUR J PEDIATR, V157, pS71, DOI 10.1007/PL00014308; Watanabe Toshiyuki, 1997, Journal of Medical Investigation, V44, P95; WHITEMAN PD, 1979, ARCH DIS CHILD, V54, P593, DOI 10.1136/adc.54.8.593; Wilcken DEL, 1997, J INHERIT METAB DIS, V20, P295, DOI 10.1023/A:1005373209964; Yap S, 1998, J INHERIT METAB DIS, V21, P738, DOI 10.1023/A:1005445132327	22	37	43	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1999	341	21					1572	1576		10.1056/NEJM199911183412103	http://dx.doi.org/10.1056/NEJM199911183412103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	256GF	10564686				2022-12-28	WOS:000083717000003
J	Gunnell, D; Smith, GD; McConnachie, A; Greenwood, R; Upton, M; Frankel, S				Gunnell, D; Smith, GD; McConnachie, A; Greenwood, R; Upton, M; Frankel, S			Separating in-utero and postnatal influences on later disease	LANCET			English	Article							ADULT	Associations of birthweight with leg length and trunk length are similar. Childhood exposures rather than Inutero programming may underlie specific associations seen between leg length and mortality.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Glasgow, Dept Gen Practice, Glasgow, Lanark, Scotland	University of Bristol; University of Glasgow	Gunnell, D (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall,Whiteladies Rd, Bristol BS8 2PR, Avon, England.		Davey Smith, George/A-7407-2013; Gunnell, David/ABE-6653-2020	Davey Smith, George/0000-0002-1407-8314; Gunnell, David/0000-0002-0829-6470; Upton, Mark/0000-0003-0839-1141				ALBANES D, 1988, CANCER RES, V48, P1658; Barker DJP, 1998, MOTHERS BABIES DIS L; Gunnell DJ, 1998, J EPIDEMIOL COMMUN H, V52, P142, DOI 10.1136/jech.52.3.142; Kuh D, 1997, LIFE COURSE APPROACH; LOW A, 1952, GROWTH CHILDREN 66 B	5	37	37	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1526	1527		10.1016/S0140-6736(99)02937-2	http://dx.doi.org/10.1016/S0140-6736(99)02937-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551505				2022-12-28	WOS:000083411300019
J	Nuttin, B; Cosyns, P; Demeulemeester, H; Gybels, J; Meyerson, B				Nuttin, B; Cosyns, P; Demeulemeester, H; Gybels, J; Meyerson, B			Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder	LANCET			English	Article								Chronic electrical stimulation instead of bilateral capsulotomy was done in four selected patients with long-standing treatment-resistant obsessive-compulsive disorder. In three of them beneficial effects were observed.	Katholieke Univ Leuven, Dept Neurosurg, Lab Expt Neurosurg & Neuroanat, B-3000 Louvain, Belgium; Univ Instelling Antwerp, Dept Psychiat, Antwerp, Belgium; Karolinska Inst Hosp, Dept Clin Neurosci, Neurosurg Sect, Stockholm, Sweden	KU Leuven; Universite Catholique Louvain; University of Antwerp; Karolinska Institutet; Karolinska University Hospital	Nuttin, B (corresponding author), Katholieke Univ Leuven, Dept Neurosurg, Lab Expt Neurosurg & Neuroanat, B-3000 Louvain, Belgium.							Cosyns P, 1994, Adv Tech Stand Neurosurg, V21, P239; Lippitz BE, 1999, NEUROSURGERY, V44, P452, DOI 10.1097/00006123-199903000-00005; McNair D.M., 1971, MANUAL PROFILES MOOD; MEYERSON BA, 1998, TXB STEREOTACTIC FUN, P1955	4	504	546	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1526	1526		10.1016/S0140-6736(99)02376-4	http://dx.doi.org/10.1016/S0140-6736(99)02376-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551504				2022-12-28	WOS:000083411300018
J	Rees, J				Rees, J			Understanding barrier function of the skin	LANCET			English	Editorial Material									Univ Newcastle Upon Tyne, Sch Med, Dept Dermatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Rees, J (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Dermatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.							BODDE H, 1996, J INVEST DERMATOL, V5, P1155; Hashimoto T, 1999, J DERMATOL SCI, V20, P81, DOI 10.1016/S0923-1811(99)00014-6; HILLIS WD, 1993, CURR BIOL, V3, P79; Schaefer H., 1996, SKIN BARRIER; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shuster S., 1978, DERMATOLOGY INTERNAL, P116; WERNER Y, 1985, ACTA DERM-VENEREOL, V65, P102; Williams M L, 1998, J Investig Dermatol Symp Proc, V3, P75	8	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1491	1492		10.1016/S0140-6736(99)00281-0	http://dx.doi.org/10.1016/S0140-6736(99)00281-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551492				2022-12-28	WOS:000083411300006
J	Sodroski, JG				Sodroski, JG			HIV-1 entry inhibitors in the side pocket	CELL			English	Review							ENVELOPE GLYCOPROTEIN; PEPTIDE INHIBITOR; ATOMIC-STRUCTURE; GP41; REPLICATION; FUSION		Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Sodroski, JG (corresponding author), Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.							CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; Ferrer M, 1999, NAT STRUCT BIOL, V6, P953; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884	18	85	112	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					243	246		10.1016/S0092-8674(00)81655-4	http://dx.doi.org/10.1016/S0092-8674(00)81655-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555140	Bronze			2022-12-28	WOS:000083440600002
J	Armstrong, K; Schwartz, JS; Asch, DA				Armstrong, K; Schwartz, JS; Asch, DA			Direct sale of sildenafil (Viagra) to consumers over the Internet	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL INFORMATION; QUALITY		Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Armstrong, K (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.			Asch, David/0000-0002-7970-286X	NCI NIH HHS [CA73619] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berger A, 1998, BMJ, V317, P824; CAPPASSO T, 1999, STATE J REGISTE 0506, P9; Cheitlin MD, 1999, CIRCULATION, V99, P168, DOI 10.1161/01.CIR.99.1.168; Dorozynski A, 1996, BRIT MED J, V313, P1033; DOULIN T, 1999, COLUMBUS DISPA 0513, pA1; Dyer C, 1996, BRIT MED J, V313, P645; Eysenbach G, 1998, BRIT MED J, V317, P1496, DOI 10.1136/bmj.317.7171.1496; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Greenaway NJ, 1999, LANCET, V353, P330, DOI 10.1016/S0140-6736(05)74889-3; HADDON J, 1999, MORNING EDITION 0511; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; LEE TH, 1999, HARVARD HEART LETT, V9, P7; Marwick C, 1999, JAMA-J AM MED ASSOC, V281, P975, DOI 10.1001/jama.281.11.975; McDonald CJ, 1998, JAMA-J AM MED ASSOC, V280, P1325, DOI 10.1001/jama.280.15.1325; OSTROM CM, 1999, SEATTLE TIMES   0512, pA1; PERRIN J, 1998, PHARM J, V260, P707; Seaboldt JA, 1997, AM J HEALTH-SYST PH, V54, P1732, DOI 10.1093/ajhp/54.15.1732; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Skolnick AA, 1997, JAMA-J AM MED ASSOC, V278, P1723; SLIVKA J, 1999, SEATTLE POST IN 0507, pC1; TAYLOR C, 1999, TIME            0524, P73; Wang T, 1997, Methods Mol Biol, V72, P1	22	69	71	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1389	1392		10.1056/NEJM199910283411810	http://dx.doi.org/10.1056/NEJM199910283411810			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249XE	10536133				2022-12-28	WOS:000083357800010
J	Beck, S; Geraghty, D; Inoko, H; Rowen, L; Aguado, B; Bahram, S; Campbell, RD; Forbes, SA; Guillaudeux, T; Hood, L; Horton, R; Janer, M; Jasoni, C; Madan, A; Milne, S; Neville, M; Oka, A; Qin, S; Ribas-Despuig, G; Rogers, J; Shiina, T; Spies, T; Tamiya, G; Tashiro, H; Trowsdale, J; Vu, Q; Williams, L; Yamazaki, M				Beck, S; Geraghty, D; Inoko, H; Rowen, L; Aguado, B; Bahram, S; Campbell, RD; Forbes, SA; Guillaudeux, T; Hood, L; Horton, R; Janer, M; Jasoni, C; Madan, A; Milne, S; Neville, M; Oka, A; Qin, S; Ribas-Despuig, G; Rogers, J; Shiina, T; Spies, T; Tamiya, G; Tashiro, H; Trowsdale, J; Vu, Q; Williams, L; Yamazaki, M		MHC Sequencing Consortium	Complete sequence and gene map of a human major histocompatibility complex	NATURE			English	Article							HUMAN MHC; DNA-REPLICATION; CLASS-II; REGION; LOCUS; END	Here we report the first complete sequence and gene map of a human major histocompatibility complex (MHC), a region on chromosome 6 which is essential to the immune system (reviewed in ref. 1). When it was discovered over 50 years ago the region was thought to specify histocompatibility genes, but their nature has been resolved only in the last two decades. Although many of the 224 identified gene loci (128 predicted to be expressed) are still of unknown function, we estimate that about 40% of the expressed genes have immune system function. Over 50% of the MHC has been sequenced twice, in different haplotypes, giving insight into the extraordinary polymorphism and evolution of this region. Several genes, particularly of the MHC class II and III regions, can be traced by sequence similarity and synteny to over 700 million years ago, dearly predating the emergence of the adaptive immune system some 400 million years ago. The sequence is expected to be invaluable for the identification of many common disease loci. In the past, the search for these loci has been hampered by the complexity of high gene density and linkage disequilibrium.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Sanger Ctr, Hinxton CB10 1SA, England; Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 25911, Japan; Univ Washington, Seattle, WA 98195 USA; HGMP Resource Ctr, Hinxton CB10 1SB, England; Univ Cambridge, Dept Pathol, Div Immunol, Cambridge CB2 1QP, England; Ctr Rech Immunol & Hematol, Strasbourg, France; Fujiya Co Ltd, Biosci Res Lab, Kanagawa 257, Japan	Fred Hutchinson Cancer Center; Wellcome Trust Sanger Institute; Tokai University; University of Washington; University of Washington Seattle; University of Cambridge	Geraghty, D (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.		Ribas-Despuig, Gloria/M-6190-2017; Aguado, Begoña/R-4496-2019; Bahram, Seiamak/GZA-7150-2022; Ribas, Gloria/K-3379-2013	Ribas, Gloria/0000-0001-6883-4130; Tamiya, Gen/0000-0002-0597-415X; Bowcock, Anne/0000-0001-8691-9090; Shiina, Takashi/0000-0002-2067-6708; Bahram, Seiamak/0000-0002-6928-9952; Aguado, Begona/0000-0003-4043-6944	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BODMER WF, 1972, NATURE, V237, P139, DOI 10.1038/237139a0; Dawkins R, 1999, IMMUNOL REV, V167, P275, DOI 10.1111/j.1600-065X.1999.tb01399.x; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; FUKAGAWA T, 1995, GENOMICS, V25, P184, DOI 10.1016/0888-7543(95)80124-5; Gruen JR, 1997, BLOOD, V90, P4252; Guillaudeux T, 1998, P NATL ACAD SCI USA, V95, P9494, DOI 10.1073/pnas.95.16.9494; HAINO M, 1994, J BIOL CHEM, V269, P2619; HAMILIN JL, 1995, CURR OPIN GENE DEV, V5, P153; Horton R, 1998, J MOL BIOL, V282, P71, DOI 10.1006/jmbi.1998.2018; Kasahara M, 1999, IMMUNOL REV, V167, P17, DOI 10.1111/j.1600-065X.1999.tb01379.x; KLEIN J, 1986, NATURAL HIST MAJOR H; LIMM TM, 1993, HUM IMMUNOL, V38, P57, DOI 10.1016/0198-8859(93)90520-B; Ruddy DA, 1997, GENOME RES, V7, P441, DOI 10.1101/gr.7.5.441; Satta Y, 1999, IMMUNOL REV, V167, P367, DOI 10.1111/j.1600-065X.1999.tb01405.x; Stephens R, 1999, J MOL BIOL, V291, P789, DOI 10.1006/jmbi.1999.3004; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; Tenzen T, 1997, MOL CELL BIOL, V17, P4043, DOI 10.1128/MCB.17.7.4043; Tiwari J.L., 1985, HLA DIS ASS; Trachtulec Z, 1997, GENOMICS, V44, P1, DOI 10.1006/geno.1997.4839; TROWSDALE J, 1997, IMMUNOL TODAY S, V18	20	823	850	0	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					921	923		10.1038/44853	http://dx.doi.org/10.1038/44853			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553908				2022-12-28	WOS:000083464700060
J	Ludwig, DS; Pereira, MA; Kroenke, CH; Hilner, JE; Van Horn, L; Slattery, ML; Jacobs, DR				Ludwig, DS; Pereira, MA; Kroenke, CH; Hilner, JE; Van Horn, L; Slattery, ML; Jacobs, DR			Dietary fiber, weight gain, and cardiovascular disease risk factors in young adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; GLYCEMIC INDEX; CLINICAL IMPLICATIONS; INSULIN SENSITIVITY; FASTING INSULIN; CARDIA; HYPERLIPIDEMIA; CARBOHYDRATE; RESISTANCE	Context Dietary composition may affect insulin secretion, and high insulin levels, in turn, may increase the risk for cardiovascular disease (CVD). Objective To examine the role of fiber consumption and its association with insulin levels, weight gain, and other CVD risk factors compared with other major dietary components. Design and Setting The Coronary Artery Risk Development in Young Adults (CARDIA) Study, a multicenter population-based cohort study of the change in CVD risk factors over 10 years (1985-1986 to 1995-1996) in Birmingham, Ala; Chicago, III; Minneapolis, Minn; and Oakland, Calif. Participants A total of 2909 healthy black and white adults, 18 to 30 years of age at enrollment. Main Outcome Measures Body weight. insulin levels, and other CVD risk factors at year 10, adjusted for baseline values. Results After adjustment for potential confounding factors, dietary fiber showed linear associations from lowest to highest quintiles of intake with the following. body weight (whites: 174.8-166.7 lb [78.3-75.0 kg], P < .001; blacks: 185.6-177.6 lb [83.5-79.9 kg], P = .001), waist-to-hip ratio (whites, 0.813-0.801, P = .004; blacks: 0.809-0.799, P = .05), fasting insulin adjusted for body mass index (whites: 77.8-72.2 pmol/L [11.2-10.4 mu U/mL], P = .007; blacks: 92.4-82.6 pmol/L [13.3-11.9 mu U/mL], P = .01) and 2-hour postglucose insulin adjusted for body mass index (whites: 261.1-234.7 pmol/L [37.6-33.8 mu U/mL], P = .03; blacks: 370.2-259.7 pmol/L [53.3-37.4 mu U/m L], P < .001). Fiber was also associated with blood pressure and levels of triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and fibrinogen; these associations were substantially attenuated by adjustment for fasting insulin level. In comparison with fiber, intake of fat, carbohydrate, and protein had inconsistent or weak associations with all CVD risk factors. Conclusions Fiber consumption predicted insulin levels, weight gain, and other CVD risk factors more strongly than did total or saturated fat consumption. High-fiber diets may protect against obesity and CVD by lowering insulin levels.	Childrens Hosp, Dept Med, Div Endocrinol, Boston, MA 02115 USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; Univ Alabama Birmingham, CARDIA Coordinating Ctr, Birmingham, AL USA; Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL USA; Univ Utah, Sch Med, Salt Lake City, UT USA	Harvard University; Boston Children's Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Alabama System; University of Alabama Birmingham; Northwestern University; Utah System of Higher Education; University of Utah	Ludwig, DS (corresponding author), Childrens Hosp, Dept Med, Div Endocrinol, 300 Longwood Ave, Boston, MA 02115 USA.			Pereira, Mark/0000-0002-6704-5276; Jacobs, David/0000-0002-7232-0543; Ludwig, David/0000-0003-3307-8544	NHLBI NIH HHS [N01-HC-48047, N01-HC-48048, N01-HC-48049] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC048049, N01HC048047, N01HC048048] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		American Heart Association, 1997, 1998 HEART STROK STA; ANDERSON JW, 1986, AM J GASTROENTEROL, V81, P907; Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; BJORCK I, 1994, AM J CLIN NUTR, V59, p699S, DOI 10.1093/ajcn/59.3.699S; BOGARDUS C, 1985, AM J PHYSIOL, V248, pE286, DOI 10.1152/ajpendo.1985.248.3.E286; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; Cusin Isabelle, 1992, International Journal of Obesity, V16, pS1; Daly ME, 1997, AM J CLIN NUTR, V66, P1072, DOI 10.1093/ajcn/66.5.1072; Folsom AR, 1998, INT J OBESITY, V22, P48, DOI 10.1038/sj.ijo.0800542; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FRIEDMAN GD, 1988, J CLIN EPIDEMIOL, V41, P1105, DOI 10.1016/0895-4356(88)90080-7; Frost G, 1999, LANCET, V353, P1045, DOI 10.1016/S0140-6736(98)07164-5; FUKAGAWA NK, 1990, AM J CLIN NUTR, V52, P524, DOI 10.1093/ajcn/52.3.524; GRANFELDT Y, 1995, EUR J CLIN NUTR, V49, P189; Hsueh Willa A., 1998, American Journal of Medicine, V105, p4S, DOI 10.1016/S0002-9343(98)00205-8; Jacobs David R Jr, 1989, J Cardiopulm Rehabil, V9, P448, DOI 10.1097/00008483-198911000-00003; Jacobs DR, 1999, AM J PUBLIC HEALTH, V89, P322, DOI 10.2105/AJPH.89.3.322; JENKINS DJA, 1985, P SOC EXP BIOL MED, V180, P422, DOI 10.3181/00379727-180-42199; JENKINS DJA, 1985, AM J CLIN NUTR, V42, P604, DOI 10.1093/ajcn/42.4.604; Kleinbaum D, 1988, APPL REGRESSION ANAL; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; Lamarche B, 1998, JAMA-J AM MED ASSOC, V279, P1955, DOI 10.1001/jama.279.24.1955; LENFANT C, 1994, MORBIDITY MORTALITY, V0043; Liu Kiang, 1994, Ethnicity and Disease, V4, P15; Ludwig DS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e26; MCDONALD A, 1991, J AM DIET ASSOC, V91, P1104; Odeleye OE, 1997, DIABETES, V46, P1341, DOI 10.2337/diabetes.46.8.1341; Pereira Mark A, 1998, CVD Prev, V1, P231; POTTER JG, 1981, AM J CLIN NUTR, V34, P328, DOI 10.1093/ajcn/34.3.328; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Ruige JB, 1998, CIRCULATION, V97, P996; STEVENS J, 1988, J AM DIET ASSOC, V88, P939; Storlien LH, 1997, ANN NY ACAD SCI, V827, P287, DOI 10.1111/j.1749-6632.1997.tb51842.x; TROUT DL, 1993, AM J CLIN NUTR, V58, P873, DOI 10.1093/ajcn/58.6.873; WARNICK GR, 1982, CLIN CHEM, V28, P1379; Willett WC, 1998, AM J CLIN NUTR, V67, p556S, DOI 10.1093/ajcn/67.3.556S; WOLEVER TMS, 1991, AM J CLIN NUTR, V54, P846, DOI 10.1093/ajcn/54.5.846; Wolk A, 1999, JAMA-J AM MED ASSOC, V281, P1998, DOI 10.1001/jama.281.21.1998	40	487	504	0	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1539	1546		10.1001/jama.282.16.1539	http://dx.doi.org/10.1001/jama.282.16.1539			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546693	Bronze			2022-12-28	WOS:000083277800021
J	Bisharat, N; Agmon, V; Finkelstein, R; Raz, R; Ben-Dror, G; Lerner, L; Soboh, S; Colodner, R; Cameron, DN; Wykstra, DL; Swerdlow, DL; Farmer, JJ				Bisharat, N; Agmon, V; Finkelstein, R; Raz, R; Ben-Dror, G; Lerner, L; Soboh, S; Colodner, R; Cameron, DN; Wykstra, DL; Swerdlow, DL; Farmer, JJ		Israel Vibrio Study Grp	Clinical, epidemiological, and microbiological features of Vibrio vulnificus biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel	LANCET			English	Article							GULF-COAST; BENECKEA VULNIFICUS; FISH; MANIFESTATIONS; ENVIRONMENT; FLORIDA	Background Vibrio vulnificus is a gram-negative bacterium that causes septicaemia and wound infection. Cases occur sporadically, and no previous outbreaks due to a common source or a clonal strain have been reported. In the summer and autumn of 1996 and 1997, an outbreak of invasive V vulnificus infection occurred in Israel in people who had recently handled fresh, whole fish purchased from artificial fish-ponds. Methods We reviewed clinical and epidemiological information, and undertook an environmental investigation to assess disease characteristics, modes of transmission, phenotypic characteristics of the bacterium, and fish-marketing policy. The clonal nature of 19 isolates was studied by biotyping, pulsed-field gel electrophoresis, and restriction-fragment length polymorphism (RFLP) analysis of a PCR fragment. Findings During 1996-97, 62 cases of wound infection and bacteraemia occurred. 57 patients developed cellulitis, four had necrotising fasciitis, and one developed osteomyelitis. In all cases, the fish were cultivated in inland fish-ponds. In the summer of 1996, fish-pond managers initiated a new marketing policy, in which fish were sold alive instead of being packed in ice. Phenotypically, the isolates had five atypical biochemical test results. The isolates were non-typeable by pulsed-field gel electrophoresis, and all had the same PCR-RFLP pattern which had not been seen previously. Interpretation The cause of the outbreak was a new strain of V vulnificus, classified as biogroup 3. A new fish-marketing policy that began in 1996 may have exposed susceptible people to the organism.	HaEmek Med Ctr, Infect Dis Unit, IL-18101 Afula, Israel; HaEmek Med Ctr, Microbiol Lab, IL-18101 Afula, Israel; Govt Cent Labs, Jerusalem, Israel; Rambam Med Ctr, Infect Dis Unit, Haifa, Israel; Poriah Med Ctr, Dept Med, Tiberias, Israel; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Lab Sect, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA	Emek Medical Center; Emek Medical Center; Rambam Health Care Campus; Technion Israel Institute of Technology; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Bisharat, N (corresponding author), HaEmek Med Ctr, Infect Dis Unit, IL-18101 Afula, Israel.			Colodner, Raul/0000-0001-9752-1053				[Anonymous], MANUAL CLIN MICROBIO; Bisharat N, 1996, LANCET, V348, P1585, DOI 10.1016/S0140-6736(05)66199-5; BLAKE PA, 1979, NEW ENGL J MED, V300, P1, DOI 10.1056/NEJM197901043000101; BLAKE PA, 1980, ANNU REV MICROBIOL, V34, P341, DOI 10.1146/annurev.mi.34.100180.002013; Brenner D J, 1978, Prog Clin Pathol, V7, P71; BURRAS N, 1985, APPL ENVIRON MICROB, V50, P989; CAMERON D, 1997, 97 C AM SOC MICR; CAMERON D, 1998, INT C EM INF DIS; Centers for Disease Control and Prevention (CDC), 1993, MMWR MORB MORTAL WKL, V42, P405; CHUANG YC, 1992, CLIN INFECT DIS, V15, P271, DOI 10.1093/clinids/15.2.271; Dalsgaard A, 1996, EUR J CLIN MICROBIOL, V15, P227, DOI 10.1007/BF01591359; DEPAOLA A, 1994, APPL ENVIRON MICROB, V60, P984, DOI 10.1128/AEM.60.3.984-988.1994; ELLIOT EL, 1992, FOOD DRUG ADM BACTER, P111; FANG FC, 1992, CLIN INFECT DIS, V15, P1071, DOI 10.1093/clind/15.6.1071; Farmer J. J., 1992, The Prokaryotes. A handbook on the biology of bacteria: ecophysiology, isolation, identification, applications. Volume III.., P2952; FARMER JJ, 1979, LANCET, V2, P903; FARMER JJ, 1985, MANUAL CLIN MICROBIO, P282; Hlady WG, 1996, J INFECT DIS, V173, P1176, DOI 10.1093/infdis/173.5.1176; HOLLIS DG, 1976, J CLIN MICROBIOL, V3, P425; HOWARD RJ, 1985, SURGERY, V98, P126; KELLY MT, 1982, APPL ENVIRON MICROB, V44, P820, DOI 10.1128/AEM.44.4.820-824.1982; KLONTZ KC, 1988, ANN INTERN MED, V109, P318, DOI 10.7326/0003-4819-109-4-318; LEVINE WC, 1993, J INFECT DIS, V167, P479, DOI 10.1093/infdis/167.2.479; MORRIS JG, 1987, APPL ENVIRON MICROB, V53, P193, DOI 10.1128/AEM.53.1.193-195.1987; Oliver J., 1989, FOODBORNE BACTERIAL, P569; OLIVER JD, 1983, APPL ENVIRON MICROB, V45, P985, DOI 10.1128/AEM.45.3.985-998.1983; OVERMAN T, 1986, J CLIN MICROBIOL, V24, P715; SERA H, 1972, B JPN SOC SCI FISH, V38, P853; TACKET CO, 1984, J INFECT DIS, V149, P558, DOI 10.1093/infdis/149.4.558; Tamplin M., 1995, P 1994 VIBR VULN WOR, P75; TISON DL, 1982, APPL ENVIRON MICROB, V44, P640, DOI 10.1128/AEM.44.3.640-646.1982; Weinstein MR, 1997, NEW ENGL J MED, V337, P589, DOI 10.1056/NEJM199708283370902; WRIGHT AC, 1981, INFECT IMMUN, V34, P503, DOI 10.1128/IAI.34.2.503-507.1981	33	228	236	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1421	1424		10.1016/S0140-6736(99)02471-X	http://dx.doi.org/10.1016/S0140-6736(99)02471-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543668				2022-12-28	WOS:000083277400011
J	Law, DA; DeGuzman, FR; Heiser, P; Ministri-Madrid, K; Killeen, N; Phillips, DR				Law, DA; DeGuzman, FR; Heiser, P; Ministri-Madrid, K; Killeen, N; Phillips, DR			Integrin cytoplasmic tyrosine motif is required for outside-in alpha IIb beta 3 signalling and platelet function	NATURE			English	Article							CELL-ADHESION; IIB-IIIA; PHOSPHORYLATION; PROTEIN; TRANSDUCTION; ACTIVATION; DOMAINS	Integrins not only bind adhesive ligands(1), they also act as signalling receptors(2), Both functions allow the integrin alpha IIb beta 3 to mediate platelet aggregation(3), Platelet agonists activate alpha IIb beta 3 (inside-out signalling) to allow the binding of soluble fibrinogen. Subsequent platelet aggregation leads to outside-in alpha IIb beta 3 signalling, which results in calcium mobilization(4), tyrosine phosphorylation of numerous proteins(5,6) including beta 3 itself(7) increased cytoskeletal reorganisations and further activation of alpha IIb beta 3 (ref, 2). Thus, outside-in signals enhance aggregation, although the mechanisms and functional consequences of specific signalling events remain unclear, Here we describe a mouse that expresses an alpha IIb beta 3 in which the tyrosines in the integrin cytoplasmic tyrosine motif have been mutated to phenylalanines. These mice are selectively impaired in outside-in alpha IIb beta 3 signalling, with defective aggregation and clot-retraction responses in vitro, and an in vivo bleeding defect which is characterized by a pronounced tendency to rebleed, These data provide evidence for an important role of outside-in signalling in platelet physiology, Furthermore, they identify the integrin cytoplasmic tyrosine motif as a key mediator of beta-integrin signals and a potential target for new therapeutic agents.	COR Therapeut Inc, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Phillips, DR (corresponding author), COR Therapeut Inc, 256 E Grand Ave, S San Francisco, CA 94080 USA.			Heiser, Patrick/0000-0002-8831-4973; DeGuzman, Francis/0000-0002-4479-1129				Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; CHEN YP, 1994, BLOOD, V84, P1857; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COLLER BS, 1990, NEW ENGL J MED, V322, P32; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FOX JEB, 1993, J BIOL CHEM, V268, P25973; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Law DA, 1999, BLOOD, V93, P2645, DOI 10.1182/blood.V93.8.2645.408k13_2645_2652; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; Romzek NC, 1998, MOL BIOL CELL, V9, P2715, DOI 10.1091/mbc.9.10.2715; Shattil S, 1998, BLOOD, V91, P1; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; YAMAGUCHI K, 1993, AM J HEMATOL, V44, P106, DOI 10.1002/ajh.2830440207; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	23	256	264	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					808	811		10.1038/44599	http://dx.doi.org/10.1038/44599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548108				2022-12-28	WOS:000083368700057
J	Watson, M; Haviland, JS; Greer, S; Davidson, J; Bliss, JM				Watson, M; Haviland, JS; Greer, S; Davidson, J; Bliss, JM			Influence of psychological response on survival in breast cancer: a population-based cohort study	LANCET			English	Article							MAC SCALE; QUESTIONNAIRE MEASURE; MENTAL ADJUSTMENT; EMOTIONAL CONTROL	Background The psychological response to breast cancer, such as a fighting spirit or an attitude of helplessness and hopelessness toward the disease, has been suggested as a prognostic factor with an influence on survival. We have investigated the effect of psychological response on disease outcome in a large cohort of women with early-stage breast cancer. Methods 578 women with early-stage breast cancer were enrolled in a prospective survival study. Psychological response was measured by the mental adjustment to cancer (MAC) scale, the Courtauld emotional control (CEC) scale, and the hospital anxiety and depression (HAD) scale 4-12 weeks and 12 months after diagnosis. The women were followed up for at least 5 years. Cox's proportional-hazards regression was used to obtain the hazard ratios for the measures of psychological response, with adjustment for known clinical factors associated with survival. Findings At 5 years, 395 women were alive and without relapse, 50 were alive with relapse, and 133 had died. There was a significantly increased risk of death from all causes by 5 years in women with a high score on the HAD scale category of depression (hazard ratio 3.59 [95% CI 1.39-9.24]). There was a significantly increased risk of relapse or death at 5 years in women with high scores on the helplessness and hopelessness category of the MAC scale compared with those with a low score in this category (1.55 [1.07-2.25]). There were no significant results found for the category of "fighting spirit". Interpretation For 5-year event-free survival a high helplessness/hopelessness score has a moderate but detrimental effect. A high score for depression is linked to a significantly reduced chance of survival; however, this result is based on a small number of patients and should be interpreted with caution.	Royal Marsden Hosp NHS Trust, Sutton SM2 5PT, Surrey, England; Royal Marsden Hosp NHS Trust, London, England; Inst Canc Res, Sutton, Surrey, England; St Raphaels Hosp, Surrey, England	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Watson, M (corresponding author), Royal Marsden Hosp NHS Trust, Sutton SM2 5PT, Surrey, England.			Bliss, Judith/0000-0001-7957-7424; Haviland, Joanne/0000-0001-5728-3636				BUDDEBERG C, 1991, PSYCHOTHER PSYCHOSOM, V55, P151, DOI 10.1159/000288423; Clarke M, 1998, LANCET, V351, P1451; COPPER CL, 1993, PSYCHOL MED, V23, P653; GOLDSTEIN DA, 1989, PSYCHOL HEALTH, V3, P245, DOI DOI 10.1080/08870448908400384; GREER S, 1979, LANCET, V2, P785, DOI 10.1016/S0140-6736(79)92127-5; GREER S, 1989, J PSYCHOSOM RES, V33, P373, DOI 10.1016/0022-3999(89)90027-5; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; HOLLAND J C, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P237; JAMISON RN, 1987, J CLIN ONCOL, V5, P768, DOI 10.1200/JCO.1987.5.5.768; LEVY SM, 1988, PSYCHOSOM MED, V50, P520, DOI 10.1097/00006842-198809000-00008; MOOREY S, 1991, BRIT J PSYCHIAT, V158, P255, DOI 10.1192/bjp.158.2.255; MORRIS T, 1980, CANCER DETECTION PRE, V3, P102; Nordin K, 1999, PSYCHO-ONCOLOGY, V8, P250, DOI 10.1002/(SICI)1099-1611(199905/06)8:3<250::AID-PON379>3.3.CO;2-A; PETTINGALE KW, 1985, LANCET, V1, P750; Schnoll RA, 1998, PSYCHO-ONCOLOGY, V7, P424, DOI 10.1002/(SICI)1099-1611(1998090)7:5<424::AID-PON322>3.0.CO;2-2; WATSON M, 1991, PSYCHOL MED, V21, P51, DOI 10.1017/S0033291700014641; WATSON M, 1984, J PSYCHOSOM RES, V28, P467, DOI 10.1016/0022-3999(84)90080-1; WATSON M, 1983, J PSYCHOSOM RES, V27, P299, DOI 10.1016/0022-3999(83)90052-1; WATSON M, 1988, PSYCHOL MED, V18, P203, DOI 10.1017/S0033291700002026; Watson M, 1989, MENTAL ADJUSTMENT CA; WEISMAN AD, 1977, COPING VULNERABILITY; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	22	474	482	0	24	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1331	1336		10.1016/S0140-6736(98)11392-2	http://dx.doi.org/10.1016/S0140-6736(98)11392-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	246DV	10533861	Green Accepted			2022-12-28	WOS:000083149900010
J	Celli, J; Duijf, P; Hamel, BCJ; Bamshad, M; Kramer, B; Smits, APT; Newbury-Ecob, R; Hennekam, RCM; Van Buggenhout, G; van Haeringen, B; Woods, CG; van Essen, AJ; de Waal, R; Vriend, G; Haber, DA; Yang, A; McKeon, F; Brunner, HG; van Bokhoven, H				Celli, J; Duijf, P; Hamel, BCJ; Bamshad, M; Kramer, B; Smits, APT; Newbury-Ecob, R; Hennekam, RCM; Van Buggenhout, G; van Haeringen, B; Woods, CG; van Essen, AJ; de Waal, R; Vriend, G; Haber, DA; Yang, A; McKeon, F; Brunner, HG; van Bokhoven, H			Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome	CELL			English	Article							SPLIT FOOT LOCUS; LIMB DEVELOPMENT; GENE; PROTEIN; EXPRESSION; SEQUENCE; DATABASE; COMPLEX; DEFECTS; MODEL	EEC syndrome is an autosomal dominant disorder characterized by ectrodactyly, ectodermal dysplasia, and facial clefts. We have mapped the genetic defect in several EEC syndrome families to a region of chromosome 3q27 previously implicated in the EEC-like disorder, limb mammary syndrome (LMS). Analysis of the p63 gene, a homolog of p53 located in the critical LMS/EEC interval, revealed heterozygous mutations in nine unrelated EEC families. Eight mutations result in amino acid substitutions that are predicted to abolish the DNA binding capacity of p63. The ninth is a frameshift mutation that affects the p63 alpha, but not p63 beta and p63 gamma isotypes. Transactivation studies with these mutant p63 isotypes provide a molecular explanation for the dominant character of p63 mutations in EEC syndrome.	Univ Nijmegen Hosp, Dept Human Genet 417, NL-6500 HB Nijmegen, Netherlands; Univ Utah, Hlth Sci Ctr, Dept Pediat, Salt Lake City, UT 84112 USA; Shriners Hosp Children, Intermt Unit, Salt Lake City, UT 84112 USA; Royal Hosp Sick Children, United Bristol Healthcare NHS Trust Clin Genet Se, Bristol BS2 8BJ, Avon, England; Univ Amsterdam, Acad Med Ctr, Inst Human Genet, NL-1105 AZ Amsterdam, Netherlands; Univ Hosp Gasthuisberg, Ctr Human Genet, B-3000 Louvain, Belgium; Leiden Univ, Med Ctr, Dept Clin Genet, NL-2333 SA Leiden, Netherlands; St James Univ Hosp, Dept Clin Genet, Leeds LS9 7TF, W Yorkshire, England; Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands; Univ Nijmegen Hosp, Dept Pathol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, CMBI, NL-6500 GL Nijmegen, Netherlands; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Radboud University Nijmegen; Utah System of Higher Education; University of Utah; Bristol Royal Hospital For Children; University of Amsterdam; Academic Medical Center Amsterdam; KU Leuven; University Hospital Leuven; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Saint James's University Hospital; University of Groningen; Radboud University Nijmegen; Radboud University Nijmegen; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	van Bokhoven, H (corresponding author), Univ Nijmegen Hosp, Dept Human Genet 417, Box 9101, NL-6500 HB Nijmegen, Netherlands.		van Bokhoven, Hans/D-8764-2012; woods, christopher g/A-1361-2010; Brunner, Han/C-9928-2013; Vriend, G./H-8112-2014; Waal, R.M.W./L-4739-2015; Vriend, Gert/D-6730-2011; Duijf, Pascal H.G./E-7110-2012; Bokhoven, J.H.L.M. van van/H-8015-2014	Duijf, Pascal H.G./0000-0001-8646-9843; Bokhoven, J.H.L.M. van van/0000-0002-2153-9254				AHMAD M, 1987, HUM GENET, V75, P169, DOI 10.1007/BF00591081; CHINEA G, 1995, PROTEINS, V23, P415, DOI 10.1002/prot.340230315; Chitayat D, 1996, AM J MED GENET, V61, P45, DOI 10.1002/(SICI)1096-8628(19960102)61:1<45::AID-AJMG9>3.0.CO;2-W; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; CZEIZEL AE, 1993, J MED GENET, V30, P593, DOI 10.1136/jmg.30.7.593; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EVANS JA, 1994, AM J MED GENET, V49, P52, DOI 10.1002/ajmg.1320490111; Gorlin RJ, 1990, PLAST RECONSTR SURG; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSON KR, 1995, GENOMICS, V29, P457, DOI 10.1006/geno.1995.9981; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREMER H, 1994, HUM MOL GENET, V3, P299, DOI 10.1093/hmg/3.2.299; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Niswander L, 1997, CURR OPIN GENET DEV, V7, P530, DOI 10.1016/S0959-437X(97)80082-2; NUNES ME, 1995, HUM MOL GENET, V4, P2165, DOI 10.1093/hmg/4.11.2165; O'Quinn JR, 1998, AM J HUM GENET, V62, P130, DOI 10.1086/301687; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Roelfsema NM, 1996, CLIN DYSMORPHOL, V5, P115, DOI 10.1097/00019605-199604000-00003; ROTHSCHILD AR, 1996, J MED GENET, V33, P996; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHERER SW, 1994, HUM MOL GENET, V3, P1345; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Seto ML, 1997, TERATOLOGY, V56, P262, DOI 10.1002/(SICI)1096-9926(199710)56:4<262::AID-TERA5>3.0.CO;2-0; Shimada A, 1999, CANCER RES, V59, P2781; SHUBER AP, 1993, HUM MOL GENET, V2, P153, DOI 10.1093/hmg/2.2.153; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; van Bokhoven H, 1999, AM J HUM GENET, V64, P538, DOI 10.1086/302246; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	43	528	546	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					143	153		10.1016/S0092-8674(00)81646-3	http://dx.doi.org/10.1016/S0092-8674(00)81646-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535733	Green Published, Bronze			2022-12-28	WOS:000083159700005
J	Koonin, EV; Aravind, L; Hofmann, K; Tschopp, J; Dixit, VM				Koonin, EV; Aravind, L; Hofmann, K; Tschopp, J; Dixit, VM			Apoptosis - Searching for FLASH domains	NATURE			English	Article							SEQUENCES; DATABASE		NIH, Natl Lib Med, NCBI, Bethesda, MD 20894 USA; Texas A&M Univ, Dept Biol, College Stn, TX USA; MEMOREC Stoffel GmbH, Bioinformat Grp, D-50829 Cologne, Germany; Univ Lausanne, Inst Biochem, Lausanne Branch, CH-1066 Epalinges, Switzerland; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Texas A&M University System; Texas A&M University College Station; University of Lausanne; Roche Holding; Genentech	Koonin, EV (corresponding author), NIH, Natl Lib Med, NCBI, Bethesda, MD 20894 USA.		Hofmann, Kay/D-6714-2011; dixit, vishva m/A-4496-2012	Hofmann, Kay/0000-0002-2289-9083; dixit, vishva m/0000-0001-6983-0326; Aravind, L/0000-0003-0771-253X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; Brenner SE, 1998, P NATL ACAD SCI USA, V95, P6073, DOI 10.1073/pnas.95.11.6073; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Hubbard TJP, 1997, NUCLEIC ACIDS RES, V25, P236, DOI 10.1093/nar/25.1.236; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Park J, 1998, J MOL BIOL, V284, P1201, DOI 10.1006/jmbi.1998.2221; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Wootton JC, 1996, METHOD ENZYMOL, V266, P554	12	21	23	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					662	662		10.1038/44317	http://dx.doi.org/10.1038/44317			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537104	Green Published			2022-12-28	WOS:000083207400045
J	McCartney, MR; Dunin-Borkowski, RE; Scheinfein, MR; Smith, DJ; Gider, S; Parkin, SSP				McCartney, MR; Dunin-Borkowski, RE; Scheinfein, MR; Smith, DJ; Gider, S; Parkin, SSP			Origin of magnetization decay in spin-dependent tunnel junctions	SCIENCE			English	Article							MAGNETORESISTANCE; EXCHANGE	Spin-dependent tunnel junctions based on magnetically hard and soft ferromagnetic Layers separated by a thin insulating barrier have emerged as prime candidates for information storage., However, the observed instability of the magnetically hard reference Layer, Leading to magnetization decay during field cycling of the adjacent soft layer, is a serious concern for future device applications. Using Lorentz electron microscopy and micromagnetic simulations, the hard-layer decay was found to result from large fringing fields surrounding magnetic domain walls in the magnetically soft layer. The formation and motion of these walls causes statistical flipping of magnetic moments in randomly oriented grains of the hard layer, with a progressive trend toward disorder and eventual demagnetization.	Arizona State Univ, Ctr Solid State Sci, Tempe, AZ 85287 USA; Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA; IBM Corp, Almaden Res Ctr, San Jose, CA 95120 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; International Business Machines (IBM)	McCartney, MR (corresponding author), Arizona State Univ, Ctr Solid State Sci, Tempe, AZ 85287 USA.		Smith, David J/C-1995-2013; Parkin, Stuart/D-2521-2012; Dunin-Borkowski, Rafal/G-5597-2012	Smith, David J/0000-0002-8810-4386; Parkin, Stuart/0000-0003-4702-6139; Dunin-Borkowski, Rafal/0000-0001-8082-0647				BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; BINASCH G, 1989, PHYS REV B, V39, P4828, DOI 10.1103/PhysRevB.39.4828; CHAPMAN JN, 1984, J PHYS D APPL PHYS, V17, P623, DOI 10.1088/0022-3727/17/4/003; DIENY B, 1991, J APPL PHYS, V69, P4772; Gallagher WJ, 1997, J APPL PHYS, V81, P3741, DOI 10.1063/1.364744; Gider S, 1998, SCIENCE, V281, P797, DOI 10.1126/science.281.5378.797; HUBERT A, 1970, PHYS STATUS SOLIDI, V38, P699, DOI 10.1002/pssb.19700380221; MOODERA JS, 1995, PHYS REV LETT, V74, P3273, DOI 10.1103/PhysRevLett.74.3273; Parkin SSP, 1999, J APPL PHYS, V85, P5828, DOI 10.1063/1.369932; PARKIN SSP, 1990, PHYS REV LETT, V64, P2304, DOI 10.1103/PhysRevLett.64.2304; SCHEINFEIN MR, 1991, PHYS REV B, V43, P3395, DOI 10.1103/PhysRevB.43.3395; ZHENG Y, 1997, J APPL PHYS, V81, P5470; [No title captured]	13	39	39	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1337	1340		10.1126/science.286.5443.1337	http://dx.doi.org/10.1126/science.286.5443.1337			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558984				2022-12-28	WOS:000083675500036
J	Su, XZ; Ferdig, MT; Huang, YM; Huynh, CQ; Liu, A; You, JT; Wootton, JC; Wellems, TE				Su, XZ; Ferdig, MT; Huang, YM; Huynh, CQ; Liu, A; You, JT; Wootton, JC; Wellems, TE			A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum	SCIENCE			English	Article							CROSS; RESISTANCE; SEQUENCE	Genetic investigations of malaria require a genome-wide, high-resolution Linkage map of Plasmodium falciparum. A genetic cross was used to construct such a map from 901 markers that fall into 14 inferred Linkage groups corresponding to the 14 nuclear chromosomes. Meiotic crossover activity in the genome proved high (17 kilobases per centimorgan) and notably uniform over chromosome length. Gene conversion events and spontaneous microsatellite length changes were evident in the inheritance data. The markers, map, and recombination parameters are facilitating genome sequence assembly, Localization of determinants for such traits as virulence and drug resistance, and genetic studies of parasite field populations.	NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Guangxi Inst Parasit Dis Control, Nanning, Guangxi, Peoples R China; Natl Lib Med, Computat Biol Branch, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Wellems, TE (corresponding author), NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA.		Ferdig, Michael/C-6627-2016	Su, Xinzhuan/0000-0003-3246-3248	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000483, Z01AI000483] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [Z01LM000026, ZIALM000026] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Butler D, 1997, NATURE, V388, P701, DOI 10.1038/41826; DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; HASTINGS PJ, 1992, MUTAT RES, V284, P97, DOI 10.1016/0027-5107(92)90026-X; HINTERBERG K, 1994, EMBO J, V13, P4174, DOI 10.1002/j.1460-2075.1994.tb06735.x; KARLIN S, 1979, ADV APPL PROBAB, V11, P479, DOI 10.2307/1426950; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LIBERMAN U, 1984, J MATH BIOL, V21, P1, DOI 10.1007/BF00275218; LINCOLN SE, 1992, GENOMICS, V14, P604, DOI 10.1016/S0888-7543(05)80158-2; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; Su XZ, 1998, EXP PARASITOL, V89, P262, DOI 10.1006/expr.1998.4299; Su XZ, 1996, GENOMICS, V33, P430, DOI 10.1006/geno.1996.0218; VAIDYA AB, 1995, MOL BIOCHEM PARASIT, V69, P65, DOI 10.1016/0166-6851(94)00199-W; WALKERJONAH A, 1992, MOL BIOCHEM PARASIT, V51, P313, DOI 10.1016/0166-6851(92)90081-T; Wang P, 1997, MOL MICROBIOL, V23, P979, DOI 10.1046/j.1365-2958.1997.2821646.x; WELLEMS TE, 1987, CELL, V49, P633, DOI 10.1016/0092-8674(87)90539-3; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0	18	280	287	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1351	1353		10.1126/science.286.5443.1351	http://dx.doi.org/10.1126/science.286.5443.1351			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558988	Green Submitted			2022-12-28	WOS:000083675500040
J	Ades, AE; Sculpher, MJ; Gibb, DM; Gupta, R; Ratcliffe, J				Ades, AE; Sculpher, MJ; Gibb, DM; Gupta, R; Ratcliffe, J			Cost effectiveness analysis of antenatal HIV screening in United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							TO-CHILD TRANSMISSION; ZIDOVUDINE; STRATEGIES; INFECTION; IMPACT; AIDS	Objective To assess the cost effectiveness of universal antenatal HIV screening compared with selective screening in the United Kingdom. Design Incremental cost effectiveness analysis relating additional costs of screening to life years gained. Maternal and paediatric costs and life years were combined. Setting United Kingdom. Main outcome measures Number of districts for which universal screening would be cost effective compared with selective screening under various conditions. Results On base case assumptions, a new diagnosis of a pregnant woman with HIV results in a gain of 6.392 life years and additional expenditure of pound 14 833. If decision makers are prepared to pay up to pound 10 000 for an additional life year, this would imply a net benefit of pound 49 090 (range pound 12 300-pound 59 000), which would be available to detect each additional infected woman in an antenatal screening programme. In London, universal antenatal screening would be cost effective compared with a selective screening under any reasonable assumptions about screening costs. Outside London, universal screening with uptake above 90% would be cost effective with a pound 0.60 HIV antibody test cost and up to 3.5 minutes for pretest discussion. Cost effectiveness of universal testing is lower if selective testing can achieve high uptake among those at higher risk. A universal strategy with only 50% uptake may not be less cost effective in low prevalence districts and may cost more and be less effective than a well run selective strategy. Conclusions Universal screening with pretest discussion should be adopted throughout the United Kingdom as part of routine antenatal care as long as test costs can be kept low and uptake high.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England; York Univ, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England	University of London; University College London; University of York - UK; Brunel University	Ades, AE (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.		Ratcliffe, Julie/G-3169-2017	Ratcliffe, Julie/0000-0001-7365-1988; Gibb, Diana/0000-0002-9738-5490; Sculpher, Mark/0000-0003-3746-9913				Ades AE, 1999, AIDS, V13, P271, DOI 10.1097/00002030-199902040-00016; ADES AE, 25 BRUN U HLTH EC RE; Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1994, REG COST EFF STUD 19; *DEP HLTH, 1999, 1999183 DEP HLTH; *DEP HLTH, 1994, PLCO945 DEP HLTH; *DEP HLTH, 1995, POL APPR HLTH; Ecker JL, 1996, AM J OBSTET GYNECOL, V174, P716, DOI 10.1016/S0002-9378(96)70455-6; GIBB D, 1998, GUIDELINES MANAGEMEN; Gibb DM, 1999, AIDS, V13, P1569, DOI 10.1097/00002030-199908200-00018; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; Gorsky RD, 1996, PUBLIC HEALTH REP, V111, P335; LEWIS R, 1995, AM J OBSTET GYNECOL, V173, P1329, DOI 10.1016/0002-9378(95)91381-5; Mauskopf JA, 1996, JAMA-J AM MED ASSOC, V276, P132, DOI 10.1001/jama.276.2.132; Parry J V, 1993, Clin Diagn Virol, V1, P167, DOI 10.1016/0928-0197(93)90011-S; Postma MJ, 1999, BMJ-BRIT MED J, V318, P1656, DOI 10.1136/bmj.318.7199.1656; Raleigh VS, 1997, J EPIDEMIOL COMMUN H, V51, P649, DOI 10.1136/jech.51.6.649; Ratcliffe J, 1998, AIDS, V12, P1381, DOI 10.1097/00002030-199811000-00021; Sculpher MJ, 1998, AIDS, V12, P1371, DOI 10.1097/00002030-199811000-00020; SIMPSON WM, 1999, HLTH TECHNOLOGY ASSE, P3; Sperling RS, 1998, AIDS, V12, P1805, DOI 10.1097/00002030-199814000-00012; Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X98018002S09; STOTO MA, 1998, REDUCING ODDS PREVEN, P397; Stringer JSA, 1999, JAMA-J AM MED ASSOC, V281, P1946, DOI 10.1001/jama.281.20.1946; Tookey PA, 1998, J MED SCREEN, V5, P133, DOI 10.1136/jms.5.3.133	26	33	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1230	1234		10.1136/bmj.319.7219.1230	http://dx.doi.org/10.1136/bmj.319.7219.1230			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550083	Bronze, Green Published			2022-12-28	WOS:000083625600022
J	Jehle, PM; Micheler, C; Jehle, DR; Breitig, D; Boehm, BB				Jehle, PM; Micheler, C; Jehle, DR; Breitig, D; Boehm, BB			Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens	LANCET			English	Article							QUALITY-OF-LIFE; DIABETES-MELLITUS; INJECTOR; KINETICS; THERAPY	Background Neutral protamine Hagedorn (NPH) insulin is one of the most commonly used insulins in insulin pens. NPH in pen cartridges is in a two-phase solution with either a solvent or a short-acting insulin, and needs adequate mixing for complete resuspension. We assessed whether NPH insulin is accurately resuspended by patients and the association of suspension errors with diabetes control. Methods 109 patients (39 with type 1 diabetes) who had received conventional diabetic education had the NPH content of their cartridges measured by an optical system; a control cartridge was designated as 100%. A questionnaire was used to assess clinical details and insulin suspension habits. After the information about residual insulin error was known, all 109 patients were instructed to resuspend their insulin by rolling and tipping the pen 20 times. 52 patients were randomly selected to have cartridges reanalysed 3 months or 6 months later and to complete another questionnaire. Findings Only 10 (9%) of 109 patients tipped and rolled their pen more than ten times. NPH insulin content ranged from 5% to 214% and varied by more than 20% in 71 (65%) of 109 cartridges. There was no relation between inadequate suspension and the frequency of hypoglycaemic episodes (r=0.2, p=0.08). For all patients, there was a correlation between the absolute error of NPH suspension and cycles of rolling and tipping the pen (r=-0.23, p<0.05). After education on resuspending the pen's contents, data were available from 44 of 52 patients; suspension errors decreased in 35 (80%), were unchanged in three (7%), and increased in six (13%). The 35 patients with improved NPH insulin suspension had fewer mean hypoglycaemic episodes per month compared with the previous period (0.4 [SD 0.1] vs 1.0 [0.3], p<0.05). Mean HbA(1c) values in patients with improved suspension quality did not differ from baseline (8.4% [0.3] vs 8.9% [0.4], p=0.07). Mixing of NPH insulin by a mechanical device showed that at least 20 cycles were necessary before complete resuspension was obtained. Interpretation Inadequate NPH insulin suspension is common. We recommended that patients tip pens that contain NPH insulin at least 20 times, since inadequate mixing may impair diabetes control.	Univ Hosp Ulm, Div Nephrol, Ulm, Germany; Univ Hosp Ulm, Div Endocrinol, Ulm, Germany; Univ Ulm, Isotope Div, Ulm, Germany	Ulm University; Ulm University; Ulm University	Jehle, PM (corresponding author), Univ Ulm, Dept Internal Med 2, Div Nephrol, Robert Koch Str 8, D-89081 Ulm, Germany.		Boehm, Bernhard Otto/F-8750-2015					*AM DIAB ASS, 1998, DIABETES CARE S1, V21, pS72; Andersson PO, 1997, DIABETES RES CLIN PR, V36, P169, DOI 10.1016/S0168-8227(97)00048-X; BAK JF, 1987, DIABETES RES CLIN EX, V6, P155; BERGER M, 1982, DIABETES CARE, V5, P77, DOI 10.2337/diacare.5.2.77; BROGDEN RN, 1987, DRUGS, V34, P650; BUYSSCHAERT M, 1988, DIABETES METAB, V14, P75; BUYSSCHAERT M, 1989, LANCET, V1, P965; Chantelau E, 1997, PATIENT EDUC COUNS, V30, P167, DOI 10.1016/S0738-3991(96)00964-0; CHASE HP, 1991, J ADOLESCENT HEALTH, V12, P373, DOI 10.1016/0197-0070(91)90050-V; DINNEEN SF, 1991, IRISH J MED SCI, V160, P286, DOI 10.1007/BF02948414; FISKEN RA, 1989, DIABETES RES CLIN EX, V11, P195; GINSBERG BH, 1994, HORM METAB RES, V26, P584, DOI 10.1055/s-2007-1001764; HARDY KJ, 1991, DIABETIC MED, V8, P69, DOI 10.1111/j.1464-5491.1991.tb01518.x; JORGENSEN JOL, 1988, DIABETIC MED, V5, P574, DOI 10.1111/j.1464-5491.1988.tb01054.x; MURRAY DP, 1988, DIABETIC MED, V5, P750, DOI 10.1111/j.1464-5491.1988.tb01102.x; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SKYLER JS, 1988, MED CLIN N AM, V72, P1337, DOI 10.1016/S0025-7125(16)30710-6; STEINEMANN MA, 1990, THER UMSCH, V47, P22; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; 1989, LANCET, V1, P307	21	119	128	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1604	1607		10.1016/S0140-6736(98)12459-5	http://dx.doi.org/10.1016/S0140-6736(98)12459-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560676				2022-12-28	WOS:000083551000013
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1978: Werner Arber (b 1929); Hamilton O Smith (b 1931); Daniel Nathans (b 1928)	LANCET			English	Article									Univ Illinois, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60612 USA.								0	2	2	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1567	1567		10.1016/S0140-6736(05)76606-X	http://dx.doi.org/10.1016/S0140-6736(05)76606-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551539				2022-12-28	WOS:000083411300068
J	Huang, JF; Yang, Y; Sepulveda, H; Shi, WX; Hwang, I; Peterson, PA; Jackson, MR; Sprent, J; Cai, ZL				Huang, JF; Yang, Y; Sepulveda, H; Shi, WX; Hwang, I; Peterson, PA; Jackson, MR; Sprent, J; Cai, ZL			TCR-mediated internalization of peptide-MHC complexes acquired by T cells	SCIENCE			English	Article							CLASS-II MOLECULES; TRANSGENIC MICE; LYMPHOCYTES-T; RECEPTOR; ANTIGEN; ACTIVATION; VIRUS; PROTEIN; REQUIREMENTS; RECOGNITION	Peptide-major histocompatibility complex protein complexes (pMHCs) on antigen-presenting cells (APCs) are central to T cell activation. Within minutes of peptide-specific T cells interacting with APCs, pMHCs on APCs formed clusters at the site of T cell contact. Thereafter, these clusters were acquired by T cells and internalized through T cell receptor-mediated endocytosis. During this process, T cells became sensitive to peptide-specific Lysis by neighboring T cells (fratricide). This form of immunoregulation could explain the "exhaustion" of T cell responses that is induced by high viral Loads and may serve to downregulate immune responses.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Scripps Res Inst, Res Inst, Dept Immunol, IMM4, La Jolla, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	Cai, ZL (corresponding author), RW Johnson Pharmaceut Res Inst, 3210 Merryfield Row, San Diego, CA 92121 USA.			Hwang, Inkyu/0000-0001-8997-6090				BORROW P, 1991, J EXP MED, V174, P203, DOI 10.1084/jem.174.1.203; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; Cai ZL, 1997, J EXP MED, V185, P641, DOI 10.1084/jem.185.4.641; Cai ZL, 1996, P NATL ACAD SCI USA, V93, P14736, DOI 10.1073/pnas.93.25.14736; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HWANG I, UNPUB; LIE WR, 1991, J EXP MED, V173, P449, DOI 10.1084/jem.173.2.449; LORBER MI, 1982, J IMMUNOL, V128, P2798; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; NEPOM JT, 1981, J IMMUNOL, V127, P888; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Preckel T, 1997, J EXP MED, V185, P1803, DOI 10.1084/jem.185.10.1803; PULLEN JK, 1991, J IMMUNOL, V146, P2145; SAIZAWA MK, 1992, J CELL BIOCHEM, V16, P54; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; Shen ZH, 1997, J IMMUNOL, V158, P2723; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266	31	367	379	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					952	954		10.1126/science.286.5441.952	http://dx.doi.org/10.1126/science.286.5441.952			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542149				2022-12-28	WOS:000083368500044
J	Jakicic, JM; Winters, C; Lang, W; Wing, RR				Jakicic, JM; Winters, C; Lang, W; Wing, RR			Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; SHORT BOUTS; MAINTENANCE; OBESITY; PREVALENCE; THERAPY; PROGRAM; LONG	Context Enhancing participation in long-term exercise may translate into improved long-term weight loss in overweight adults. Objectives To compare the effects of intermittent with traditional continuous exercise on weight loss, adherence, and fitness, and to examine the effect of combining intermittent exercise with that using home exercise equipment. Design Randomized trial from September 1996 through September 1998. Setting and Participants A total of 148 sedentary, overweight (mean [SD] body mass index, 32.8 [4.0] kg/m(2)) women (mean [SD] age, 36.7 [5.6] years) in a university-based weight control program. Interventions Eighteen-month behavioral weight control program with 3 groups: long-bout exercise (LB), multiple short-bout exercise (SB), or multiple short-bout exercise with home exercise equipment (SBEQ) using a treadmill. Main Outcome Measures Body weight, body composition, cardiorespiratory fitness, and exercise adherence. Results Of 148 subjects, 115 (78%) completed the 18-month program. At 18 months, mean (SD) weight loss was significantly greater in subjects in the SBEQ group compared with subjects in the SE group (-7.4 [7.8] kg vs -3.7 [6.6] kg; P<.05). Mean (SD) weight loss for subjects in the LB group (-5.8 [7.1] kg) was not significantly different than for subjects in the SE or SBEQ groups. Subjects in the SBEQ group maintained a higher level of exercise than subjects in both the SE and LB groups (P<.05) at 13 to 18 months of treatment. All groups showed an increase in cardiorespiratory fitness from baseline to 18 months, with no difference between groups. Mean (SD) weight loss at 18 months was significantly greater in individuals exercising more than 200 min/wk throughout the intervention (-13.1 [8.0] kg) compared with individuals exercising 150 to 200 min/wk (-8.5 [5.8] kg) or less than 150 min/wk (-3.5 [6.5] kg) (P<.05). Conclusions Compared with the LB group, subjects in the SE group did not experience improved long-term weight loss, exercise participation, or cardiorespiratory fitness. Access to home exercise equipment facilitated the maintenance of SE, which may improve long-term weight loss. A dose-response relationship exists between amount of exercise and long-term weight loss in overweight adult women.	Brown Univ, Miriam Hosp, Sch Med, Providence, RI 02906 USA; Univ Pittsburgh, Pittsburgh, PA USA	Brown University; Lifespan Health Rhode Island; Miriam Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jakicic, JM (corresponding author), Brown Univ, Miriam Hosp, Sch Med, Rise Bldg,164 Summit Ave, Providence, RI 02906 USA.	jjakicic@lifespan.org			NHLBI NIH HHS [HL56127] Funding Source: Medline; NIDDK NIH HHS [DK46204] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056127] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM COLL SPORTS ME, 1995, ACSM GUID EX TEST PR, P274; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; Callaway CW., 1988, ANTHROPOMETRIC STAND, P39; DEBUSK RF, 1990, AM J CARDIOL, V65, P1010, DOI 10.1016/0002-9149(90)91005-Q; DUBIN D, 1989, RAPID INTERPRETATION, P57; Dunn AL, 1999, JAMA-J AM MED ASSOC, V281, P327, DOI 10.1001/jama.281.4.327; EBISU T, 1985, Japanese Journal of Physical Education, V30, P37; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; JAKICIC JM, 1995, INT J OBESITY, V19, P382; Jakicic JM, 1997, AM J HEALTH PROMOT, V11, P363, DOI 10.4278/0890-1171-11.5.363; JAKICIC JM, 1995, INT J OBESITY, V19, P893; Klem ML, 1997, AM J CLIN NUTR, V66, P239, DOI 10.1093/ajcn/66.2.239; Kuczmarski RJ, 1997, OBES RES, V5, P542, DOI 10.1002/j.1550-8528.1997.tb00575.x; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; *NIH, 1998, OBES RES, V6, P464; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PERRI MG, 1986, J CONSULT CLIN PSYCH, V54, P670, DOI 10.1037/0022-006X.54.5.670; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Pronk N P, 1994, Obes Res, V2, P587; Raynor DA, 1998, RES Q EXERCISE SPORT, V69, P99, DOI 10.1080/02701367.1998.10607674; Rosner B., 2010, FUNDAMENTALS BIOSTAT; Schoeller DA, 1997, AM J CLIN NUTR, V66, P551, DOI 10.1093/ajcn/66.3.551; WADDEN TA, 1994, J CONSULT CLIN PSYCH, V62, P165, DOI 10.1037/0022-006X.62.1.165; WING RR, 1988, DIABETOLOGIA, V31, P902; [No title captured]	26	343	349	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1554	1560		10.1001/jama.282.16.1554	http://dx.doi.org/10.1001/jama.282.16.1554			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	248MB	10546695	Bronze			2022-12-28	WOS:000083277800023
J	Mokdad, AH; Serdula, MK; Dietz, WH; Bowman, BA; Marks, JS; Koplan, JP				Mokdad, AH; Serdula, MK; Dietz, WH; Bowman, BA; Marks, JS; Koplan, JP			The spread of the obesity epidemic in the United States, 1991-1998	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTISTATE TELEPHONE SURVEY; WEIGHT; ADULTS; OVERWEIGHT; TRENDS; HEIGHT	Context The increasing prevalence of obesity is a major public health concern, since obesity is associated with several chronic diseases. Objective To monitor trends in state-specific data and to examine changes in the prevalence of obesity among adults. Design Cross-sectional random-digit telephone survey (Behavioral Risk Factor Surveillance System) of noninstitutionalized adults aged 18 years or older conducted by the Centers for Disease Control and Prevention and state health departments from 1991 to 1998. Setting States that participated in the Behavioral Risk Factor Surveillance System. Main Outcome Measures Body mass index calculated from self-reported weight and height. Results The prevalence of obesity (defined as a body mass index greater than or equal to 30 kg/m(2)) increased from 12.0% in 1991 to 17.9% in 1998. A steady increase was observed in all states; in both sexes; across age groups, races, educational levels; and occurred regardless of smoking status. The greatest magnitude of increase was found in the following groups: 18- to 29-year-olds (7.1% to 12.1%), those with some college education (10.6% to 17.8%), and those of Hispanic ethnicity (11.6% to 20.8%), The magnitude of the increased prevalence varied by region (ranging from 31.9% for mid Atlantic to 67.2% for South Atlantic, the area with the greatest increases) and by state (ranging from 11.3% for Delaware to 101.8% for Georgia, the state with the greatest increases). Conclusions Obesity continues to increase rapidly in the United States. To alter this trend, strategies and programs for weight maintenance as well as weight reduction must become a higher public health priority.	Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Off Director, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Mokdad, AH (corresponding author), Ctr Dis Control & Prevent, Div Nutr & Phys Act, 4770 Buford Hwy NE,Mailstop K26, Atlanta, GA 30341 USA.	ahm1@cdc.gov						ADAY LA, 1989, DESIGNING CONDUCTING, P79; [Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; BRAY GA, 1992, OBESITY, P301; CAPERSEN CJ, DEP HLTH HUMAN SERVI; CASPERSEN CJ, 1987, P 21 NAT M PUBL HLTH; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Galuska DA, 1996, AM J PUBLIC HEALTH, V86, P1729, DOI 10.2105/AJPH.86.12.1729; NELSON DE, 1998, P SECT SURV METH AM; PALTA M, 1982, AM J EPIDEMIOL, V115, P223, DOI 10.1093/oxfordjournals.aje.a113294; PISUNYER FX, 1991, AM J CLIN NUTR, V53, pS1595; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; *SAS I INC, 1998, SAS SYST COMP PROGR; SERDULA MK, 1994, AM J PUBLIC HEALTH, V84, P1821, DOI 10.2105/AJPH.84.11.1821; SHAH BV, 1997, SUDAN USERS MANUAL R; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WHO. World Health Organization, 1995, TECHNICAL REPORT SER, V854; WILLIAMSON DF, 1992, AM J PUBLIC HEALTH, V82, P1251, DOI 10.2105/AJPH.82.9.1251; Wolf A M, 1996, Am J Clin Nutr, V63, p466S, DOI 10.1093/ajcn/63.3.466	19	1654	1700	3	56	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1519	1522		10.1001/jama.282.16.1519	http://dx.doi.org/10.1001/jama.282.16.1519			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	248MB	10546690	Bronze			2022-12-28	WOS:000083277800018
J	Robinson, TN				Robinson, TN			Reducing children's television viewing to prevent obesity - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; BODY-COMPOSITION; SHUTTLE TEST; FITNESS; FAT; ADOLESCENTS; OVERWEIGHT; POPULATION; HEALTH; RISK	Context Some observational studies have found an association between television viewing and child and adolescent adiposity, Objective To assess the effects of reducing television, videotape, and video game use on changes in adiposity, physical activity, and dietary intake. Design Randomized controlled school-based trial conducted from September 1996 to April 1997. Setting Two sociodemographically and scholastically matched public elementary schools in San Jose, Calif. Participants Of 198 third- and fourth-grade students, who were given parental consent to participate, 192 students (mean age, 8.9 years) completed the study. Intervention Children in 1 elementary school received an 18-lesson, 6-month classroom curriculum to reduce television, videotape, and video game use. Main Outcome Measures Changes in measures of height, weight, triceps skinfold thickness, waist and hip circumferences, and cardiorespiratory fitness; self-reported media use, physical activity, and dietary behaviors; and parental report of child and family behaviors. The primary outcome measure was body mass index, calculated as weight in kilograms divided by the square of height in meters. Results Compared with controls, children in the intervention group had statistically significant relative decreases in body mass index (intervention vs control change: 18.38 to 18.67 kg/m(2) vs 18.10 to 18.81 kg/m(2), respectively; adjusted difference -0.45 kg/m2 [95% confidence interval {CI}, -0.73 to -0.17], P = .002), triceps skinfold thickness (intervention vs control change: 14.55 to 15.47 mm vs 13.97 to 16.46 mm, respectively; adjusted difference, -1.47 mm [95% CI, -2.41 to -0.54]; P = .002), waist circumference (intervention vs control change: 60.48 to 63.57 cm vs 59.51 to 64.73 cm, respectively; adjusted difference, -2.30 cm [95% CI, -3.27 to -1.33]; P < .001), and waist to-hip ratio (intervention vs control change: 0.83 to 0.83 vs 0.82 to 0.84, respectively; adjusted difference, -0.02 [95% CI, -0.03 to -0.01]; P < .001). Relative to controls, intervention group changes were accompanied by statistically significant decreases in children's reported television viewing and meals eaten in front of the television. There were no statistically significant differences between groups for changes in high-fat food intake, moderate-to-vigorous physical activity, and cardiorespiratory fitness. Conclusions Reducing television, videotape, and video game use may be a promising, population-based approach to prevent childhood obesity.	Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Dept Pediat, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Dept Med, Palo Alto, CA 94304 USA	Stanford University; Stanford University	Robinson, TN (corresponding author), Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Dept Pediat, 1000 Welch Rd, Palo Alto, CA 94304 USA.		Fahimifar, Sepideh/M-5303-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054102] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL54102] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAIDI SB, 1993, CHEST, V103, P1135, DOI 10.1378/chest.103.4.1135; AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; Andersen RE, 1998, JAMA-J AM MED ASSOC, V279, P938, DOI 10.1001/jama.279.12.938; ANDERSON DR, 1985, CHILD DEV, V56, P1345, DOI 10.1111/j.1467-8624.1985.tb00202.x; *ANN PUBL POL CTR, 1997, TEL HOM 1997 SURV PA; Armstrong CA, 1998, AM J HEALTH PROMOT, V12, P363, DOI 10.4278/0890-1171-12.6.363; BANDURA A, 1986, SOCIAL FDN THOUTHT A; BARANOWSKI T, 1986, J AM DIET ASSOC, V86, P1381; BLOCK G, 1989, J NUTR EDUC, V21, P199; BOREHAM CAG, 1990, J SPORT MED PHYS FIT, V30, P19; BRACHT GH, 1968, AM EDUC RES J, V5, P437, DOI 10.3102/00028312005004437; COOK TD, 1979, QUASI EXPT DESIGN AN; Dietz WH, 1998, J PEDIATR-US, V132, P191; DIETZ WH, 1985, PEDIATRICS, V75, P807; DURANT RH, 1994, PEDIATRICS, V94, P449; DuRant RH, 1996, PEDIATR EXERC SCI, V8, P15, DOI 10.1123/pes.8.1.15; Dwyer JT, 1998, AM J CLIN NUTR, V67, P602, DOI 10.1093/ajcn/67.4.602; EPSTEIN LH, 1995, HEALTH PSYCHOL, V14, P109, DOI 10.1037/0278-6133.14.2.109; Epstein LH, 1998, PEDIATRICS, V101, P554; GORN GJ, 1982, J CONSUM RES, V9, P200, DOI 10.1086/208913; Gortmaker SL, 1996, ARCH PEDIAT ADOL MED, V150, P356, DOI 10.1001/archpedi.1996.02170290022003; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; JASON LA, 1985, J APPL BEHAV ANAL, V18, P269, DOI 10.1901/jaba.1985.18-269; JASON LA, 1993, CHILD FAM BEHAV THER, V15, P45, DOI 10.1300/J019v15n03_04; JEFFREY DB, 1982, HLTH ED Q, V9, P78; KRAEMER H C, 1990, Annals of Behavioral Medicine, V12, P112, DOI 10.1207/s15324796abm1203_3; Kraemer HC, 1997, ARCH GEN PSYCHIAT, V54, P337; Leger LA, 1988, J SPORT SCI, V6, P93, DOI 10.1080/02640418808729800; LIU NYS, 1992, RES Q EXERCISE SPORT, V63, P360, DOI 10.1080/02701367.1992.10608757; LOCARD E, 1992, INT J OBESITY, V16, P721; Lohman T. G., 1998, ANTROPOMETRIC STANDA; Mahoney C, 1992, Br J Sports Med, V26, P45; MEDRICH EA, 1979, J COMMUN, V29, P171, DOI 10.1111/j.1460-2466.1979.tb01730.x; Murray DM, 1998, DESIGN ANAL GROUP RA; National Center for Health Statistics N, 1996, NHANES 3 ANTHR PROC; OBARZANEK E, 1994, AM J CLIN NUTR, V60, P15, DOI 10.1093/ajcn/60.1.15; PATE RR, 1987, J PHYS ED RECREATION, V58, P93; RESNICOW K, 1993, ANN NY ACAD SCI, V699, P154, DOI 10.1111/j.1749-6632.1993.tb18847.x; Resnicow K, 1997, ANN EPIDEMIOL, V7, pS14, DOI 10.1016/S1047-2797(97)80005-1; Robinson TN, 1998, JAMA-J AM MED ASSOC, V279, P959, DOI 10.1001/jama.279.12.959; ROBINSON TN, 1993, PEDIATRICS, V91, P273; Robinson TN, 1995, J HLTH ED, V26, pS91, DOI [DOI 10.1080/10556699.1995.10603155, 10.1080/10556699.1995.10603155]; ROSE G, 1992, CORONARY HEART DIS E; Sallis JF, 1996, MED SCI SPORT EXER, V28, P840, DOI 10.1097/00005768-199607000-00011; SHANNON B, 1991, J NUTR EDUC, V23, P262; SIMONSMORTON BG, 1990, AM J PREV MED, V6, P218, DOI 10.1016/S0749-3797(18)31008-0; TARAS HL, 1989, J DEV BEHAV PEDIATR, V10, P176, DOI 10.1097/00004703-198908000-00003; Troiano RP, 1998, PEDIATRICS, V101, P497; TUCKER LA, 1986, ADOLESCENCE, V21, P797; VANMECHELEN W, 1986, EUR J APPL PHYSIOL O, V55, P503, DOI 10.1007/BF00421645; WINN M, 1987, UNPLUGGING PLUG DRUG; WOLF AM, 1993, AM J PUBLIC HEALTH, V83, P1625, DOI 10.2105/AJPH.83.11.1625; WOLIN MS, 1984, ADV CYCLIC NUCLEOTID, V17, P267	53	1255	1281	3	262	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1561	1567		10.1001/jama.282.16.1561	http://dx.doi.org/10.1001/jama.282.16.1561			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	248MB	10546696				2022-12-28	WOS:000083277800024
J	Yanovski, JA; Yanovski, SZ				Yanovski, JA; Yanovski, SZ			Recent advances in basic obesity research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; LEPTIN RECEPTOR; FRAMESHIFT MUTATION; REARED APART; EARLY-ONSET; GENE; WEIGHT; MICE; PROTEIN; INTERVENTION		NICHHD, Unit Growth & Obes, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NICHHD, Div Digest Dis & Nutr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Yanovski, JA (corresponding author), NICHHD, Unit Growth & Obes, Dev Endocrinol Branch, NIH, Bldg 10,Room 10N262,10 Ctr Dr,MSC 1862, Bethesda, MD 20892 USA.	jy15i@nih.gov		Yanovski, Jack/0000-0001-8542-1637	CENTER FOR INFORMATION TECHNOLOGY [ZIACT000268, Z01CT000268] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000641] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000641] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Allison DB, 1996, INT J OBESITY, V20, P501; [Anonymous], 1996, NUTRITION, V12, P397; Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Barlow SE, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e29; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1999, CURR OPIN ENDOCRINOL, V6, P163; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; GREENBERG AS, 1998, DIABETES S, V47, pLB16; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hill JO, 1997, PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH, P88; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Karlsson J, 1998, INT J OBESITY, V22, P113, DOI 10.1038/sj.ijo.0800553; Klem ML, 1997, AM J CLIN NUTR, V66, P239, DOI 10.1093/ajcn/66.2.239; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Perusse L, 1999, OBES RES, V7, P111, DOI 10.1002/j.1550-8528.1999.tb00398.x; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; ROLLS BJ, 1995, AM J CLIN NUTR, V62, P1086; Sjostrom CD, 1997, OBES RES, V5, P519; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; World Health Organization, 1997, PROGR NUTR FAM REPR; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	37	63	66	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1504	1506		10.1001/jama.282.16.1504	http://dx.doi.org/10.1001/jama.282.16.1504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546681				2022-12-28	WOS:000083277800001
J	Owen, JS				Owen, JS			Role of ABC1 gene in cholesterol efflux and atheroprotection	LANCET			English	Editorial Material									UCL, Royal Free & Univ Coll Med Sch, Dept Med, London NW3 2PF, England	University of London; University College London	Owen, JS (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Med, London NW3 2PF, England.		Owen, James/C-5908-2009; Owen, James S./AAP-8628-2020					Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Greaves DR, 1998, CURR OPIN LIPIDOL, V9, P425, DOI 10.1097/00041433-199810000-00006; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Oram JF, 1996, J LIPID RES, V37, P2473; Osborne TF, 1998, CURR OPIN LIPIDOL, V9, P137, DOI 10.1097/00041433-199804000-00010; Rothblat GH, 1999, J LIPID RES, V40, P781; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Thompson GR, 1999, CURR OPIN LIPIDOL, V10, P201, DOI 10.1097/00041433-199906000-00002; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109	16	15	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1402	1403		10.1016/S0140-6736(99)00297-4	http://dx.doi.org/10.1016/S0140-6736(99)00297-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543661				2022-12-28	WOS:000083277400004
J	Hartman, JJ; Vale, RD				Hartman, JJ; Vale, RD			Microtubule disassembly by ATP-dependent oligomerization of the AAA enzyme katanin	SCIENCE			English	Article							SENSITIVE FUSION PROTEIN; CRYSTAL-STRUCTURE; DOMAIN; NSF; CENTROSOME; DYNAMICS; COMPLEX; SPINDLE	Katanin, a member of the AAA adenosine triphosphatase (ATPase) superfamily, uses nucleotide hydrolysis energy to sever and disassemble microtubules. Many AAA enzymes disassemble stable protein-protein complexes, but their mechanisms are not well understood. A fluorescence resonance energy transfer assay demonstrated that the p60 subunit of katanin oligomerized in an adenosine triphosphate (ATP)- and microtubule-dependent manner. Oligomerization increased the affinity of katanin for microtubules and stimulated its ATPase activity. After hydrolysis of ATP, microtubule-bound katanin oligomers disassembled microtubules and then dissociated into free katanin monomers. Coupling a nucleotide-dependent oligomerization cycle to the disassembly of a target protein complex may be a general feature of ATP-hydrolyzing AAA domains.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vale, RD (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	vale@phy.ucsf.edu						Ahmad FJ, 1999, J CELL BIOL, V145, P305, DOI 10.1083/jcb.145.2.305; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hartman JJ, 1998, CELL, V93, P277, DOI 10.1016/S0092-8674(00)81578-0; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; MCNALLY FJ, 1993, CELL, V75, P419, DOI 10.1016/0092-8674(93)90377-3; MCNALLY FJ, UNPUB; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TSIEN R, COMMUNICATION; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201	28	176	182	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					782	785		10.1126/science.286.5440.782	http://dx.doi.org/10.1126/science.286.5440.782			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531065				2022-12-28	WOS:000083303200057
J	Mao, ZX; Bonni, A; Xia, F; Nadal-Vicens, M; Greenberg, ME				Mao, ZX; Bonni, A; Xia, F; Nadal-Vicens, M; Greenberg, ME			Neuronal activity-dependent cell survival mediated by transcription factor MEF2	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; GENE-EXPRESSION; CREB PHOSPHORYLATION; ACTIVATION; NUCLEUS; CALCIUM; DEATH; DROSOPHILA; MYOGENESIS; APOPTOSIS	During mammalian development, electrical activity promotes the calcium-dependent survival of neurons that have made appropriate synaptic connections. However, the mechanisms by which calcium mediates neuronal survival during development are not well characterized. A transcription-dependent mechanism was identified by which calcium influx into neurons promoted cell survival. The transcription factor MEF2 was selectively expressed in newly generated postmitotic neurons and was required for the survival of these neurons. Calcium influx into cerebellar granule neurons Led to activation of p38 mitogen-activated protein kinase-dependent phosphorylation and activation of MEF2. Once activated, MEF2 regulated neuronal survival by stimulating MEF2-dependent gene transcription. These findings demonstrate that MEF2 is a calcium-regulated transcription factor and define a function for MEF2 during nervous system development that is distinct from previously Well-characterized functions of MEF2 during muscle differentiation.	Childrens Hosp, Dept Neurol, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Charlestown, MA 02129 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Greenberg, ME (corresponding author), Childrens Hosp, Dept Neurol, Div Neurosci, Boston, MA 02115 USA.		Xia, Fen/G-3708-2013		NICHD NIH HHS [P30-HD18655] Funding Source: Medline; NINDS NIH HHS [NS28829, 5T32NS07112] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007112, R01NS028829, R37NS028829] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHAMBERS AE, 1994, GENE DEV, V8, P1324, DOI 10.1101/gad.8.11.1324; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FRANKLIN JL, 1994, ANN NY ACAD SCI, V747, P195; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; GEISERT EE, 1989, NEUROSCI LETT, V102, P137, DOI 10.1016/0304-3940(89)90068-2; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; IKESHIMA H, 1995, NEUROSCI LETT, V200, P117, DOI 10.1016/0304-3940(95)12092-I; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Lin MH, 1997, DEV BIOL, V182, P240, DOI 10.1006/dbio.1996.8484; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MAO Z, UNPUB; Miller TM, 1997, J BIOL CHEM, V272, P9847; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MONTMINY MR, 1986, J NEUROSCI, V6, P1171; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; Santella L, 1997, FASEB J, V11, P1091, DOI 10.1096/fasebj.11.13.9367344; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	32	432	449	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					785	790		10.1126/science.286.5440.785	http://dx.doi.org/10.1126/science.286.5440.785			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531066				2022-12-28	WOS:000083303200058
J	Meshnick, SR				Meshnick, SR			Drug-resistant Pneumocystis carinii	LANCET			English	Editorial Material							POLYMORPHISMS; MUTATIONS; FAILURE; GENE		Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Meshnick, SR (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.							Castro M, 1998, Semin Respir Infect, V13, P296; Kazanjian P, 1998, AIDS, V12, P873, DOI 10.1097/00002030-199808000-00009; Lane BR, 1997, J INFECT DIS, V175, P482, DOI 10.1093/infdis/175.2.482; Mei Q, 1998, LANCET, V351, P1631, DOI 10.1016/S0140-6736(05)77687-X; Vedantam G, 1998, MICROB DRUG RESIST, V4, P91, DOI 10.1089/mdr.1998.4.91; Walker DJ, 1998, J INFECT DIS, V178, P1767, DOI 10.1086/314509; WALZER PD, 1992, ANTIMICROB AGENTS CH, V36, P1935, DOI 10.1128/AAC.36.9.1935	7	18	18	2	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1318	1319		10.1016/S0140-6736(99)00240-8	http://dx.doi.org/10.1016/S0140-6736(99)00240-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533856				2022-12-28	WOS:000083149900005
J	Bhatt, RR; Ferrell, JE				Bhatt, RR; Ferrell, JE			The protein kinase p90 Rsk as an essential mediator of cytostatic factor activity	SCIENCE			English	Article							XENOPUS EGG EXTRACTS; SPINDLE ASSEMBLY CHECKPOINT; MAP KINASE; CELL-CYCLE; MOS; TRANSITION; MATURATION; METAPHASE; PREVENTS; OOCYTES	Persistent activation of p42 mitogen-activated protein kinase (p42 MAPK) during mitosis induces a "cytostatic factor" arrest, the arrest responsible for preventing the parthenogenetic activation of unfertilized eggs. The protein kinase p90 Rsk is a substrate of p42 MAPK; thus, the role of p90 Rsk in p42 MAPK-induced mitotic arrest was examined. Xenopus laevis egg extracts immunodepleted of Rsk lost their capacity to undergo mitotic arrest in response to activation of the Mos-MEK-1-p42 MAPK cascade of protein kinases. Replenishing Rsk-depleted extracts with catalytically competent Rsk protein restored the ability of the extracts to undergo mitotic arrest. Rsk appears to be essential for cytostatic factor arrest.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Ferrell, JE (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM016415] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16415, GM46383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Abrieu A, 1996, J CELL SCI, V109, P239; Bhatt R., UNPUB; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Chau ASS, 1998, BIOL CELL, V90, P565, DOI 10.1016/S0248-4900(99)80014-8; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; MALLER JL, 1995, TRENDS BIOCHEM SCI, V20, P524, DOI 10.1016/S0968-0004(00)89122-7; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	22	143	151	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1362	1365		10.1126/science.286.5443.1362	http://dx.doi.org/10.1126/science.286.5443.1362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558991				2022-12-28	WOS:000083675500043
J	Venn, A; Watson, L; Bruinsma, F; Giles, G; Healy, D				Venn, A; Watson, L; Bruinsma, F; Giles, G; Healy, D			Risk of cancer after use of fertility drugs with in-vitro fertilisation	LANCET			English	Article							EPITHELIAL OVARIAN-CANCER; INFERTILE WOMEN; BREAST-CANCER; COHORT; FERTILIZATION	Background We investigated the incidence of invasive cancer of the breast, ovary, and uterus in a cohort of patients who had undergone in-vitro-fertilisation (IVF) treatment and examined whether cause of infertility or exposure to fertility drugs to induce superovulation was associated with an increased cancer risk. Method Ten Australian IVF clinics provided data for women who had been referred far IVF before Jan 1, 1994. The frequencies of invasive breast, ovarian, and uterine cancer were assessed by record linkage to population-based cancer registries and the national death index. The observed number of cancers was compared with the expected number calculated by application of age-standardised general-population cancer rates to the cohort. Standardised incidence ratios (SIRs) were derived from the ratio of observed to expected cases. Findings The cohort consisted of 29 700 women: 20 656 were exposed to fertility drugs and 9044 were not, 143 breast cancers, 13 ovarian cancers, and 12 cancers of the uterus occurred among these women. For breast and ovarian cancer the incidence was no greater than expected (SIR 0.91 [95% CI 0.74-1.13] for breast cancer and 0.88 [0.42-1.84] for ovarian cancer in the exposed group and 0.95 [0.73-1.23] for breast cancer and 1.16 [0.52-2.59] for ovarian cancer in the unexposed group). The incidence of uterine cancer was no higher than expected in the exposed group (1.09 [0.45-2.61]) but was significantly higher in the unexposed group (2.47 [1.18-5.18]). Women with unexplained infertility had significantly more cancers of the ovary and uterus than expected (2.64 [1.10-6.35] and 4.59 [1.91-11.0], whole cohort). Analysis of cancer incidence within 12 months of exposure to fertility drugs with IVF showed that incidence was significantly higher than expected for breast and uterine cancer (1.96 [1.22-3.15] and 4.96 [1.24-19.8]). Interpretation Women who have been exposed to fertility drugs with IVF seem to have a transient increase in the risk of having breast or uterine cancer diagnosed in the first year after treatment, though the incidence overall is no greater than expected. Unexplained infertility was associated with an increased risk of a diagnosis of ovarian or uterine cancer.	La Trobe Univ, Ctr Study Mothers & Childrens Hlth, Carlton, Vic 3053, Australia; Anticanc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia; Monash Univ, Monash Med Ctr, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia; Monash IVF, Richmond, Vic, Australia	La Trobe University; Monash University	Venn, A (corresponding author), La Trobe Univ, Ctr Study Mothers & Childrens Hlth, 251 Faraday St, Carlton, Vic 3053, Australia.		Venn, Alison J/J-2803-2013	Giles, Graham/0000-0003-4946-9099				Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; DEMOUZON J, 1997, J ASSIST REPROD GEN, V14, pS251; FRANCESCHI S, 1994, HUM REPROD, V9, P1673, DOI 10.1093/oxfordjournals.humrep.a138771; HARLOW BL, 1986, J NATL CANCER I, V76, P399; Kroman N, 1997, BRIT MED J, V315, P851, DOI 10.1136/bmj.315.7112.851; KVALE G, 1988, CANCER RES, V48, P6217; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; LAVECCHIA C, 1995, LANCET, V346, P1628; MACLACHLAN V, 1989, NEW ENGL J MED, V320, P1233, DOI 10.1056/NEJM198905113201902; Modan B, 1998, AM J EPIDEMIOL, V147, P1038; Mosgaard BJ, 1997, FERTIL STERIL, V67, P1005, DOI 10.1016/S0015-0282(97)81431-8; Potashnik G, 1999, FERTIL STERIL, V71, P853, DOI 10.1016/S0015-0282(99)00085-0; Ricci E, 1999, HUM REPROD, V14, P1653, DOI 10.1093/humrep/14.6.1653; ROSSING MA, 1995, LANCET, V346, P1627; Rossing MA, 1996, GYNECOL ONCOL, V60, P3, DOI 10.1006/gyno.1996.0002; ROSSING MA, 1994, NEW ENGL J MED, V331, P771, DOI 10.1056/NEJM199409223311204; Shushan A, 1996, FERTIL STERIL, V65, P13, DOI 10.1016/S0015-0282(16)58020-0; Sundstrom I, 1997, ACTA OBSTET GYN SCAN, V76, P238, DOI 10.1111/j.1600-0412.1997.tb07852.x; VENN A, 1995, LANCET, V346, P995, DOI 10.1016/S0140-6736(95)91687-3; VENN R, 1995, LANCET, V346, P1627; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427	21	268	282	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1586	1590		10.1016/S0140-6736(99)05203-4	http://dx.doi.org/10.1016/S0140-6736(99)05203-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560672				2022-12-28	WOS:000083551000009
J	Vickers, A; Zollman, C				Vickers, A; Zollman, C			ABC of complementary medicine - The manipulative therapies: osteopathy and chiropractic	BRITISH MEDICAL JOURNAL			English	Review																		BURN L, 1998, MANUAL MED MANIPULAT; DIGIOVANNA EL, 1996, OSTEOPATHIC APPROACH; Kaptchuk TJ, 1998, ARCH INTERN MED, V158, P2215, DOI 10.1001/archinte.158.20.2215	3	36	36	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1176	1179		10.1136/bmj.319.7218.1176	http://dx.doi.org/10.1136/bmj.319.7218.1176			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541511	Green Published			2022-12-28	WOS:000083536200026
J	Marshall, J; Oberwinkler, J				Marshall, J; Oberwinkler, J			The colourful world of the mantis shrimp	NATURE			English	Article							STOMATOPOD CRUSTACEANS; COMPOUND EYES; OIL DROPLETS; PHOTORECEPTORS; COLOR; RETINA; VISION		Univ Queensland, VTHRC, Brisbane, Qld 4071, Australia; Univ Groningen, Dept Neurobiophys, NL-9747 AG Groningen, Netherlands	University of Queensland; University of Groningen	Marshall, J (corresponding author), Univ Queensland, VTHRC, Brisbane, Qld 4071, Australia.			Oberwinkler, Johannes/0000-0002-8541-3626; Marshall, Justin/0000-0001-9006-6713				Arikawa K, 1999, VISION RES, V39, P1, DOI 10.1016/S0042-6989(98)00070-4; CALDWELL RL, 1976, SCI AM, V234, P80, DOI 10.1038/scientificamerican0176-80; CRONIN TW, 1989, J COMP PHYSIOL A, V166, P261; CRONIN TW, 1994, VISION RES, V34, P2639, DOI 10.1016/0042-6989(94)90221-6; CRONIN TW, 1989, NATURE, V339, P137, DOI 10.1038/339137a0; HARDIE RC, 1986, TRENDS NEUROSCI, V9, P419, DOI 10.1016/0166-2236(86)90136-0; Hart NS, 1998, J EXP BIOL, V201, P1433; Marshall NJ, 1996, J COMP PHYSIOL A, V179, P473; MARSHALL NJ, 1991, PHILOS T ROY SOC B, V334, P33, DOI 10.1098/rstb.1991.0096; MARSHALL NJ, 1988, NATURE, V333, P557, DOI 10.1038/333557a0; NEUMEYER C, 1991, EVOLUTION EYE VISUAL, V2, P284; Osorio D, 1997, VISION RES, V37, P3299, DOI 10.1016/S0042-6989(97)00136-3; SELIGER HH, 1994, J COMP PHYSIOL A, V175, P475; SMITH RC, 1981, APPL OPTICS, V20, P177, DOI 10.1364/AO.20.000177; TOVEE MJ, 1995, TRENDS ECOL EVOL, V10, P455, DOI 10.1016/S0169-5347(00)89179-X; Vorobyev M, 1998, J COMP PHYSIOL A, V183, P621, DOI 10.1007/s003590050286	16	87	90	10	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	1999	401	6756					873	874		10.1038/44751	http://dx.doi.org/10.1038/44751			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553902				2022-12-28	WOS:000083464700043
J	Roach, JC; Siegel, AF; van den Engh, G; Trask, B; Hood, L				Roach, JC; Siegel, AF; van den Engh, G; Trask, B; Hood, L			Gaps in the Human Genome Project	NATURE			English	Editorial Material									Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Washington, Dept Management Sci, Seattle, WA 98195 USA; Univ Washington, Dept Finance, Seattle, WA 98195 USA; Univ Washington, Dept Stat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Roach, JC (corresponding author), Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA.							Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Jang WH, 1999, TRENDS GENET, V15, P284, DOI 10.1016/S0168-9525(99)01762-X; KRAPIVSKY PL, 1992, J STAT PHYS, V69, P135, DOI 10.1007/BF01053786; Mahairas GG, 1999, P NATL ACAD SCI USA, V96, P9739, DOI 10.1073/pnas.96.17.9739; ROACH JC, 1995, GENOMICS, V26, P345, DOI 10.1016/0888-7543(95)80219-C; Roach JC, 1995, GENOME RES, V5, P464, DOI 10.1101/gr.5.5.464; Siegel AF, 1999, GENOME RES, V9, P297; Siegrist W, 1998, MELANOMA RES, V8, P113, DOI 10.1097/00008390-199804000-00003; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Venter JC, 1996, NATURE, V381, P364, DOI 10.1038/381364a0; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401	11	13	13	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					843	845		10.1038/44684	http://dx.doi.org/10.1038/44684			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553897				2022-12-28	WOS:000083464700021
J	Beecham, L				Beecham, L			Helping non-consultant career grade doctors	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1140	1140						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531124				2022-12-28	WOS:000083419500070
J	Jarecki, J; Johnson, E; Krasnow, MA				Jarecki, J; Johnson, E; Krasnow, MA			Oxygen regulation of airway branching in Drosophila is mediated by branchless FGF	CELL			English	Article							TRACHEAL CELL-MIGRATION; RECEPTOR HOMOLOG; BETA-GALACTOSIDASE; FUSION PROTEIN; EXPRESSION; BREATHLESS; GROWTH; SYSTEM; MORPHOGENESIS; ANGIOGENESIS	The Drosophila tracheal (respiratory) system is a tubular epithelial network that delivers oxygen to internal tissues. Sprouting of the major tracheal branches is stereotyped and controlled by hard-wired developmental cues. Here we show that ramification of the fine terminal branches is variable and regulated by oxygen, and that this process is controlled by a local signal or signals produced by oxygen-starved cells. We provide evidence that the critical signal is Branchless (Bnl) FGF, the same growth factor that patterns the major branches during embryogenesis. During larval life, oxygen deprivation stimulates expression of Bnl, and the secreted growth factor functions as a chemoattractant that guides new terminal branches to the expressing cells. Thus, a single growth factor is reiteratively used to pattern each level of airway branching, and the change in branch patterning results from a switch from developmental to physiological control of its expression.	Stanford Univ, Sch Med, Dept Biochem, Howard Hughes Med Inst, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Krasnow, MA (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Howard Hughes Med Inst, Stanford, CA 94305 USA.	krasnow@cmgm.stanford.edu						AFFOLTER M, 1994, DEVELOPMENT, V120, P743; Arias A.M., 1993, DEV DROSOPHILA, P609; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUNNINGHAM EL, 1974, J APPL PHYSIOL, V37, P362, DOI 10.1152/jappl.1974.37.3.362; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Guillemin K, 1996, DEVELOPMENT, V122, P1353; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOCKE M, 1958, Q J MICROSC SCI, V99, P373; MEINHARDT H, 1976, DIFFERENTIATION, V6, P117, DOI 10.1111/j.1432-0436.1976.tb01478.x; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; Nagao M, 1996, FEBS LETT, V387, P161, DOI 10.1016/0014-5793(96)00484-X; ONEILL JW, 1994, BIOTECHNIQUES, V17, P870; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; PERRIMON N, 1991, DEV GENET, V12, P238, DOI 10.1002/dvg.1020120309; Pignoni F, 1997, DEVELOPMENT, V124, P271; Pihan J.C., 1972, Bulletin de la Societe Zoologique de France, V97, P351; PIHAN JC, 1971, J EMBRYOL EXP MORPH, V26, P497; REICHMANFRIED M, 1995, MECH DEVELOP, V52, P265, DOI 10.1016/0925-4773(95)00407-R; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ruhle H, 1932, Z WISS ZOOL ABT A, V141, P159; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shiga Y, 1996, DEV GROWTH DIFFER, V38, P99; Shilo BZ, 1997, COLD SPRING HARB SYM, V62, P241; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SMITH DE, 1987, J CELL BIOL, V105, P771, DOI 10.1083/jcb.105.2.771; Smith EL, 1996, BONE, V18, pS45, DOI 10.1016/8756-3282(95)00379-7; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Vincent S, 1997, DEVELOPMENT, V124, P2741; WALGENBACH KJ, 1995, NAT MED, V1, P453, DOI 10.1038/nm0595-453; WIGGLESWORTH VB, 1954, Q J MICROSC SCI, V95, P115; XU T, 1993, DEVELOPMENT, V117, P1223; [No title captured]	42	189	190	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	1999	99	2					211	220		10.1016/S0092-8674(00)81652-9	http://dx.doi.org/10.1016/S0092-8674(00)81652-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535739	Bronze			2022-12-28	WOS:000083159700011
J	Sawaya, MR; Guo, SY; Tabor, S; Richardson, CC; Ellenberger, T				Sawaya, MR; Guo, SY; Tabor, S; Richardson, CC; Ellenberger, T			Crystal structure of the helicase domain from the replicative helicase-primase of bacteriophage T7	CELL			English	Article							HEPATITIS-C VIRUS; STRAND DNA-SYNTHESIS; GENE-4 PROTEIN; RNA HELICASE; HEXAMERIC HELICASES; DUPLEX DNA; NUCLEOTIDE; BINDING; MECHANISM; MUTANT	Helicases that unwind DNA at the replication fork are ring-shaped oligomeric enzymes that move along one strand of a DNA duplex and catalyze the displacement of the complementary strand in a reaction that is coupled to nucleotide hydrolysis. The helicase domain of the replicative helicase-primase protein from bacteriophage T7 crystallized as a helical filament that resembles the Escherichia coli RecA protein, an ATP-dependent DNA strand exchange factor. When viewed in projection along the helical axis of the crystals, six protomers of the T7 helicase domain resemble the hexameric rings seen in electron microscopic images of the intact T7 helicase-primase. Nucleotides bind at the interface between pairs of adjacent subunits where an arginine is near the gamma-phosphate of the nucleotide in trans. The bound nucleotide stabilizes the folded conformation of a DNA-binding motif located near the center of the ring. These and other observations suggest how conformational changes are coupled to DNA unwinding activity.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	tome@hms.harvard.edu		Sawaya, Michael/0000-0003-0874-9043				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; BROWN WC, 1989, J BIOL CHEM, V264, P6748; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Egelman EH, 1996, STRUCTURE, V4, P759, DOI 10.1016/S0969-2126(96)00081-0; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; EVANS SV, 1993, J MOL GRAPHICS, V11, P127; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Korolev S, 1998, PROTEIN SCI, V7, P605, DOI 10.1002/pro.5560070309; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Leslie AGW, 1999, BIOCHEM SOC T, V27, P37, DOI 10.1042/bst0270037; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park K, 1998, J BIOL CHEM, V273, P5260, DOI 10.1074/jbc.273.9.5260; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Trikha J, 1999, NUCLEIC ACIDS RES, V27, P1728, DOI 10.1093/nar/27.7.1728; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; Wittinghofer A, 1998, BIOL CHEM, V379, P933; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; YONG YQ, 1995, J BIOL CHEM, V270, P24509, DOI 10.1074/jbc.270.41.24509; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101	60	237	239	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	1999	99	2					167	177		10.1016/S0092-8674(00)81648-7	http://dx.doi.org/10.1016/S0092-8674(00)81648-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535735	Bronze			2022-12-28	WOS:000083159700007
J	Aritomi, M; Kunishima, N; Okamoto, T; Kuroki, R; Ota, Y; Morikawa, K				Aritomi, M; Kunishima, N; Okamoto, T; Kuroki, R; Ota, Y; Morikawa, K			Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme	NATURE			English	Article							COLONY-STIMULATING FACTOR; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; GROWTH-HORMONE; LIGAND-BINDING; GRANULOCYTE; CSF; IDENTIFICATION; DIMERIZATION; REGION	Granulocyte colony-stimulating factor (GCSF) is the principal growth factor regulating the maturation, proliferation and differentiation of the precursor cells of neutrophilic granulocytes' and is used to treat neutropenia(2), GCSF is a member of the long-chain subtype of the class 1 cytokine superfamily, which includes growth hormone, erythropoietin, interleukin 6 and oncostatin M (ref. 3), Here we have determined the crystal structure of GCSF complexed to the BN-BC domains, the principal ligand-binding region of the GCSF receptor (GCSFR). The two receptor domains form a complex in a 2:2 ratio with the ligand, with a noncrystallographic pseudo-twofold axis through primarily the interdomain region and secondarily the BC domain. This structural view of a gp130-type receptor-ligand complex presents a new molecular basis for cytokine-receptor recognition.	Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Biomol Engn Res Inst, Suita, Osaka 5650874, Japan	Kirin Brewery Company Limited	Morikawa, K (corresponding author), Biomol Engn Res Inst, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	morikawa@beri.co.jp	Kunishima, Naoki/N-7464-2015	Kunishima, Naoki/0000-0001-9826-9902; Aritomi, Masaharu/0000-0003-3002-8779				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Covell DG, 1997, J MOL BIOL, V269, P281, DOI 10.1006/jmbi.1997.1028; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; Hiraoka O, 1995, BIOSCI BIOTECH BIOCH, V59, P2351, DOI 10.1271/bbb.59.2351; HIRAOKA O, 1994, FEBS LETT, V356, P255, DOI 10.1016/0014-5793(94)01278-4; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; Horan TP, 1998, PROTEIN EXPRES PURIF, V14, P45, DOI 10.1006/prep.1998.0942; KUGA T, 1994, Patent No. 8317; Layton JE, 1997, J BIOL CHEM, V272, P29735, DOI 10.1074/jbc.272.47.29735; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ReidhaarOlson JF, 1996, BIOCHEMISTRY-US, V35, P9034, DOI 10.1021/bi952705x; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Yamasaki K, 1997, NAT STRUCT BIOL, V4, P498, DOI 10.1038/nsb0697-498; Yamasaki M, 1998, BIOSCI BIOTECH BIOCH, V62, P1528, DOI 10.1271/bbb.62.1528	30	118	130	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	1999	401	6754					713	718		10.1038/44394	http://dx.doi.org/10.1038/44394			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537111				2022-12-28	WOS:000083207400060
J	Friend, SH				Friend, SH			How DNA microarrays and expression profiling will affect clinical practice	BRITISH MEDICAL JOURNAL			English	Article								In Plato's cave the participants ale surrounded by shadows that allow them to see reality by careful examination, Similarly, we doctors at the end of the 20th century have found many Indirect tests that allow us to follow what is happening in our patients' bodies and tells, We have learnt to cope with the fact that we cannot find drugs unless we pull proteins from those tells and develop inhibitors against them in the artificial context of a test tube, Imagine now a different world in which it would be possible simultaneously to follow many changes that were happening in tells, Imagine a doctor's office where you could take a blood sample from a patient and get an indication of where that patient's heart disease, kidney disease, and depression were plotted in a matrix, allowing us, as darters, to see both the patient's relative state of health and any predisposition for other renditions or disorders.	Rosetta Inpharmat, Kirkland, WA 98034 USA	Merck & Company	Friend, SH (corresponding author), Rosetta Inpharmat, Kirkland, WA 98034 USA.							DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Khan J, 1998, CANCER RES, V58, P5009; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467	5	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1999	319	7220					1306	U77		10.1136/bmj.319.7220.1306	http://dx.doi.org/10.1136/bmj.319.7220.1306			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257MZ	10559058	Green Published			2022-12-28	WOS:000083786900027
J	Hector, A; Schmid, B; Beierkuhnlein, C; Caldeira, MC; Diemer, M; Dimitrakopoulos, PG; Finn, JA; Freitas, H; Giller, PS; Good, J; Harris, R; Hogberg, P; Huss-Danell, K; Joshi, J; Jumpponen, A; Korner, C; Leadley, PW; Loreau, M; Minns, A; Mulder, CPH; O'Donovan, G; Otway, SJ; Pereira, JS; Prinz, A; Read, DJ; Scherer-Lorenzen, M; Schulze, ED; Siamantziouras, ASD; Spehn, EM; Terry, AC; Troumbis, AY; Woodward, FI; Yachi, S; Lawton, JH				Hector, A; Schmid, B; Beierkuhnlein, C; Caldeira, MC; Diemer, M; Dimitrakopoulos, PG; Finn, JA; Freitas, H; Giller, PS; Good, J; Harris, R; Hogberg, P; Huss-Danell, K; Joshi, J; Jumpponen, A; Korner, C; Leadley, PW; Loreau, M; Minns, A; Mulder, CPH; O'Donovan, G; Otway, SJ; Pereira, JS; Prinz, A; Read, DJ; Scherer-Lorenzen, M; Schulze, ED; Siamantziouras, ASD; Spehn, EM; Terry, AC; Troumbis, AY; Woodward, FI; Yachi, S; Lawton, JH			Plant diversity and productivity experiments in European grasslands	SCIENCE			English	Article							ECOSYSTEM PROCESSES; SPECIES-DIVERSITY; BIODIVERSITY; MODEL	At eight European field sites, the impact of Loss of plant diversity on primary productivity was simulated by synthesizing grassland communities with different numbers of plant species. Results differed in detail at each Location, but there was an overall Log-Linear reduction of average aboveground biomass with Loss of species. For a given number of species, communities with fewer functional groups were Less productive. These diversity effects occurred along with differences associated with species composition and geographic Location. Niche complementarity and positive species interactions appear to play a role in generating diversity-productivity relationships within sites in addition to sampling from the species pool.	Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Ascot SL5 7PY, Berks, England; Univ Zurich, Inst Umweltwissensch, CH-8057 Zurich, Switzerland; Univ Bayreuth, Lehrstuhl Biogeog, D-95440 Bayreuth, Germany; Univ Tecn Lisboa, Dept Engn Florestal & Bot, P-1399 Lisbon, Portugal; Univ Aegean, Dept Environm Studies, Biodivers Conservat Lab, GR-81100 Lesbos, Greece; Univ Coll Cork, Dept Zool & Anim Ecol, Cork, Ireland; Swedish Univ Agr Sci, Dept Forest Ecol, SE-90183 Umea, Sweden; Swedish Univ Agr Sci, Dept Agr Res No Sweden, Crop Sci Sect, SE-90403 Umea, Sweden; Univ Basel, Inst Bot, CH-4056 Basel, Switzerland; Ecole Normale Super, Ecol Lab, F-72530 Paris 05, France; Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; Max Planck Inst Geochem, Jena, Germany	Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Zurich; University of Bayreuth; Universidade de Lisboa; University of Aegean; University College Cork; Swedish University of Agricultural Sciences; Swedish University of Agricultural Sciences; University of Basel; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); University of Sheffield; Max Planck Society	Hector, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Silwood Pk, Ascot SL5 7PY, Berks, England.	a.hector01@ic.ac.uk	Hector, Andrew/H-4199-2011; Spehn, Eva/B-7070-2018; Freitas, Helena/A-2803-2010; Högberg, Peter/B-2916-2012; Giller, Paul/AAB-1187-2021; Caldeira, Maria/D-4107-2013; Schulze, Ernst-Detlef/K-9627-2014; Woodward, Ian F/B-7762-2008; Finn, John A/D-4635-2009; Scherer-Lorenzen, Michael/AGB-4140-2022; Beierkuhnlein, Carl/ABF-9693-2021; Körner, Christian/B-6592-2014; Leadley, Paul/E-4773-2012; Schmid, Bernhard/C-8625-2009; Woodward, Frank Ian/P-4530-2019; Freitas, Helena/ABE-6998-2020; Read, David/C-2454-2013; Beierkuhnlein, Carl/ABF-8797-2021	Hector, Andrew/0000-0002-1309-7716; Freitas, Helena/0000-0002-1907-9615; Högberg, Peter/0000-0002-2849-2719; Giller, Paul/0000-0002-0641-7152; Caldeira, Maria/0000-0002-3586-8526; Finn, John A/0000-0003-3616-5563; Scherer-Lorenzen, Michael/0000-0001-9566-590X; Beierkuhnlein, Carl/0000-0002-6456-4628; Körner, Christian/0000-0001-7768-7638; Schmid, Bernhard/0000-0002-8430-3214; Dimitrakopoulos, Panayiotis/0000-0002-8374-4392; Joshi, Jasmin/0000-0002-4210-2465; Spehn, Eva M./0000-0002-5172-3415; Pereira, Joao/0000-0002-3658-5587				Aarssen LW, 1997, OIKOS, V80, P183, DOI 10.2307/3546531; Allison GW, 1999, AM NAT, V153, P26, DOI 10.1086/303144; [Anonymous], 1997, NATURES SERVICES; DICASTRI F, 1973, MEDITERRANEAN TYPE E; Diemer Matthias, 1997, Bulletin of the Geobotanical Institute ETH, V63, P95; Garnier E, 1997, ACTA OECOL, V18, P657, DOI 10.1016/S1146-609X(97)80049-5; GIVNISH TJ, 1994, NATURE, V371, P113, DOI 10.1038/371113b0; Grime JP, 1997, SCIENCE, V277, P1260, DOI 10.1126/science.277.5330.1260; Harper J. L, 1977, POPULATION BIOL PLAN; Hector A, 1998, OIKOS, V82, P597, DOI 10.2307/3546380; Hodgson JG, 1998, FUNCT ECOL, V12, P843, DOI 10.1046/j.1365-2435.1998.00253.x; Hooper DU, 1997, SCIENCE, V277, P1302, DOI 10.1126/science.277.5330.1302; Huston MA, 1997, OECOLOGIA, V110, P449, DOI 10.1007/s004420050180; LAWTON JH, 1994, OIKOS, V71, P367, DOI 10.2307/3545824; Lawton JH, 1998, FUNCT ECOL, V12, P848; Loreau M, 1998, OIKOS, V82, P600, DOI 10.2307/3546381; Loreau M, 1998, P NATL ACAD SCI USA, V95, P5632, DOI 10.1073/pnas.95.10.5632; MOONEY HA, 1981, ECOSYSTEMS WORLD, V11; Mulder CPH, 1999, ECOL LETT, V2, P237; NAEEM S, 1994, NATURE, V368, P734, DOI 10.1038/368734a0; Naeem S, 1996, OIKOS, V76, P259, DOI 10.2307/3546198; SPEHN EM, IN PRESS FUNCT ECOL; THOMAS PE, 1994, J AM SOC NEPHROL, V5, P734; Tilman D, 1997, OIKOS, V80, P185, DOI 10.2307/3546532; Tilman D, 1997, SCIENCE, V277, P1300, DOI 10.1126/science.277.5330.1300; Tilman D, 1997, P NATL ACAD SCI USA, V94, P1857, DOI 10.1073/pnas.94.5.1857; Tilman D, 1996, NATURE, V379, P718, DOI 10.1038/379718a0; Wardle DA, 1997, SCIENCE, V277, P1296, DOI 10.1126/science.277.5330.1296	28	1412	1586	50	1027	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1123	1127		10.1126/science.286.5442.1123	http://dx.doi.org/10.1126/science.286.5442.1123			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550043				2022-12-28	WOS:000083534200033
J	Norcini, JJ				Norcini, JJ			Recertification in the United States	BRITISH MEDICAL JOURNAL			English	Article							CERTIFICATION		Amer Board Internal Med, Philadelphia, PA 19106 USA	American Board of Internal Medicine	Norcini, JJ (corresponding author), Amer Board Internal Med, 510 Walnut St,Suite 1700, Philadelphia, PA 19106 USA.			Norcini, John/0000-0002-8464-4115				*AM BOARD MED SPEC, 1999, 1999 ABMS ANN REP RE; BENSON JA, 1991, ANN INTERN MED, V114, P238, DOI 10.7326/0003-4819-114-3-238; BREADEN DG, 1987, RECERTIFICATION MED; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Hofer TP, 1999, JAMA-J AM MED ASSOC, V281, P2098, DOI 10.1001/jama.281.22.2098; KREMER BK, 1991, EVAL HEALTH PROF, V14, P187, DOI 10.1177/016327879101400204; MCAULIFFE WE, 1979, MILBANK FUND Q, V57, P118, DOI 10.2307/3349751; MUNGER BS, 1994, RECERTIFICATION NEW; Norcini J, 1994, CERTIFICATION RECERT; NORCINI JJ, 1994, ACAD MED, V69, pS90, DOI 10.1097/00001888-199410000-00053; NORCINI JJ, 1998, EVALUATING RESIDENTS; NORCINI JJ, 1993, ED PROFESSIONALS RES; RAMSEY PG, 1993, JAMA-J AM MED ASSOC, V269, P1655, DOI 10.1001/jama.269.13.1655; RAMSEY PG, 1989, ANN INTERN MED, V110, P719, DOI 10.7326/0003-4819-110-9-719; Webster G., 1989, FINAL REPORT PATIENT	17	44	44	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1183	1185		10.1136/bmj.319.7218.1183	http://dx.doi.org/10.1136/bmj.319.7218.1183			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541514	Green Published			2022-12-28	WOS:000083536200029
J	Spiegel, K; Leproult, R; Van Cauter, E				Spiegel, K; Leproult, R; Van Cauter, E			Impact of sleep debt on metabolic and endocrine function	LANCET			English	Article							INSULIN SENSITIVITY; CELL FUNCTION; SECRETION; CORTISOL; MECHANISMS; PHASE; AGE	Background Chronic sleep debt is becoming increasingly common and affects millions of people in more-developed countries. Sleep debt is currently believed to have no adverse effect on health. We investigated the effect of sleep debt on metabolic and endocrine functions. Methods We assessed carbohydrate metabolism, thyrotropic function, activity of the hypothalamo-pituitary-adrenal axis, and sympathovagal balance in 11 young men after time in bed had been restricted to 4 h per night for 6 nights. We compared the sleep-debt condition with measurements taken at the end of a sleep-recovery period when participants were allowed 12 h in bed per night for 6 nights. Findings Glucose tolerance was lower in the sleep-debt condition than in the fully rested condition (p<0.02), as were thyrotropin concentrations (p<0.01). Evening cortisol concentrations were raised (p=0.0001) and activity of the sympathetic nervous system was increased in the sleep-debt condition (p<0.02). Interpretation Sleep debt has a harmful impact on carbohydrate metabolism and endocrine function. The effects are similar to those seen in normal ageing and, therefore, sleep debt may increase the severity of age-related chronic disorders.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Van Cauter, E (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	evcauter@medicine.bsd.uchicago.edu	Spiegel, Karine/H-4456-2017		NCRR NIH HHS [RR-00055] Funding Source: Medline; NIA NIH HHS [P01 AG-11412] Funding Source: Medline; NIDDK NIH HHS [R01 DK-41814] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011412] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLAN JS, 1994, J CLIN ENDOCR METAB, V79, P508, DOI 10.1210/jc.79.2.508; BENINGTON JH, 1995, PROG NEUROBIOL, V45, P347, DOI 10.1016/0301-0082(94)00057-O; BERGMAN RN, 1989, DIABETES, V38, P1512, DOI 10.2337/diabetes.38.12.1512; Bliwise DL, 1996, SLEEP, V19, P462, DOI 10.1093/sleep/19.6.462; Bonnet MH, 1994, PRINCIPLES PRACTICE, P50; Broman JE, 1996, NEUROPHYSIOL CLIN, V26, P30, DOI 10.1016/0987-7053(96)81532-2; CATALANO PM, 1993, AM J PHYSIOL, V264, pE60, DOI 10.1152/ajpendo.1993.264.1.E60; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; DINGES DF, 1995, ADV NEUROIMMUNOL, V5, P97, DOI 10.1016/0960-5428(95)00002-J; Dinges DF, 1997, SLEEP, V20, P267; FABER OK, 1978, DIABETES, V27, P170, DOI 10.2337/diab.27.1.S170; FRIEDMANN J, 1977, PSYCHOPHYSIOLOGY, V14, P245, DOI 10.1111/j.1469-8986.1977.tb01169.x; Garcia GV, 1997, J AM GERIATR SOC, V45, P813, DOI 10.1111/j.1532-5415.1997.tb01507.x; GUMBINER B, 1989, DIABETES, V38, P1549, DOI 10.2337/diabetes.38.12.1549; HORNE JA, 1988, WHY WE SLEEP; KAHN CR, 1995, PRINCIPLES PRACTICE, P1210; KAHN CR, 1995, PRINCIPLES PRACTICE, P1198; KAHN SE, 1993, DIABETES, V42, P1663, DOI 10.2337/diabetes.42.11.1663; Kern W, 1996, J GERONTOL A-BIOL, V51, pM3, DOI 10.1093/gerona/51A.1.M3; Leproult R, 1997, SLEEP, V20, P865; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; Otzenberger H, 1998, AM J PHYSIOL-HEART C, V275, pH946, DOI 10.1152/ajpheart.1998.275.3.H946; Parmeggiani P. L., 1994, PRINCIPLES PRACTICE, P194; PRIGEON RL, 1995, METABOLISM, V44, P1259, DOI 10.1016/0026-0495(95)90026-8; Reaven GM, 1996, NEW ENGL J MED, V334, P374, DOI 10.1056/NEJM199602083340607; Rechtschaffen A., 1968, BRAIN INFORM SERVICE; THOMAS M, 1998, 14 EUR C SLEEP RES, P1; VANCAUTER E, 1992, DIABETES, V41, P368, DOI 10.2337/diabetes.41.3.368; VANCAUTER E, 1994, AM J PHYSIOL, V266, pE953, DOI 10.1152/ajpendo.1994.266.6.E953; VanCauter E, 1996, J CLIN ENDOCR METAB, V81, P2468, DOI 10.1210/jc.81.7.2468; VANCAUTER E, 1997, MG CLIN NEUROSC, V15, P144; WEBB WB, 1975, B PSYCHONOMIC SOC, V6, P47; WEHR TA, 1993, AM J PHYSIOL, V265, pR846, DOI 10.1152/ajpregu.1993.265.4.R846	33	2331	2408	15	292	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1999	354	9188					1435	1439		10.1016/S0140-6736(99)01376-8	http://dx.doi.org/10.1016/S0140-6736(99)01376-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543671				2022-12-28	WOS:000083277400014
J	Aurora, P; Whitehead, B; Wade, A; Bowyer, J; Whitmore, P; Rees, PG; Tsang, VT; Elliott, MJ; de Leval, M				Aurora, P; Whitehead, B; Wade, A; Bowyer, J; Whitmore, P; Rees, PG; Tsang, VT; Elliott, MJ; de Leval, M			Lung transplantation and life extension in children with cystic fibrosis	LANCET			English	Article							HEART; SURVIVAL	Background Lung transplantation has been available as therapy for end-stage lung disease since the early 1980s, but survival after transplantation remains poor, with continued controversy as to the survival benefit from the procedure. We examined the effect of lung or heart-lung transplantation on the survival of a cohort of children with cystic fibrosis and severe lung disease. Methods Between May, 1988, and May, 1998, 124 children with cystic fibrosis were accepted for lung transplantation. 47 received transplants, 68 died while they awaited organs, and nine remained on the active waiting list. We constructed a proportional-hazards model that used variables of prognostic significance in this population. By including transplant status as a time-dependent covariate, we were able to calculate a hazard ratio for transplantation. Date of entry into the study was the dale when children were added to the list for transplantation, and measurements were taken at this time. Children were accepted for transplantation if they had a life expectancy of 2 years or less, a poor quality of life, and no contraindications to transplantation. Findings After 1 year, 35 (74%) children were still alive; after 5 years 12 (33%) children were alive. The univariate hazard ratio for transplantation was 0.41 (95% CI 0.23-0.74; p=0.003). Transplantation remained significantly associated with survival after correction for differences in age, sex, height-corrected forced expiratory volume in 1 s, minimum oxygen saturation during a 12 min walk, haemoglobin concentration, albumin concentration, and age-corrected resting heart rate (hazard ratio 0.31 [0.13-0.72]; p=0.007). Interpretation If centres follow our criteria for accepting patients for transplantation, and achieve similar survival after transplantation, they could expect a survival benefit for their patients in line with our results.	Great Ormond St Hosp Children NHS Trust, Cardioresp & Crit Care Directorate, London WC1N 3JH, England; Greenwich Hosp, Inst Child Hlth, London, England; Greenwich Hosp, Dept Paediat, London, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Aurora, P (corresponding author), Great Ormond St Hosp Children, Resp Unit, Cardiac Wing, Level 6, London WC1N 3JH, England.		Elliott, Martin J/E-9229-2010	Elliott, Martin J/0000-0002-3913-9099				Cox D. R., 1984, ANAL SURVIVAL DATA; Geertsma A, 1998, J HEART LUNG TRANSPL, V17, P511; Hosenpud JD, 1998, LANCET, V351, P24, DOI 10.1016/S0140-6736(97)06405-2; Hosenpud JD, 1997, J HEART LUNG TRANSPL, V16, P691; Kalbfleish J., 1980, STAT ANAL FAILURE TI; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; Mankad Pankaj S., 1997, P167; Milla CE, 1998, CHEST, V113, P1230, DOI 10.1378/chest.113.5.1230; ROSENTHAL M, 1993, THORAX, V48, P794, DOI 10.1136/thx.48.8.794; SHARPLES L, 1993, J HEART LUNG TRANSPL, V12, P669; TURNBULL BW, 1974, J AM STAT ASSOC, V69, P74, DOI 10.2307/2285502; WHITEHEAD BF, 1995, EUR J CARDIO-THORAC, V9, P1, DOI 10.1016/S1010-7940(05)80040-5	12	74	75	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1591	1593		10.1016/S0140-6736(99)03031-7	http://dx.doi.org/10.1016/S0140-6736(99)03031-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560673				2022-12-28	WOS:000083551000010
J	Neuberger, J; James, O				Neuberger, J; James, O			Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage	LANCET			English	Editorial Material							RETRANSPLANTATION; CHILDREN; ADULTS; ACCESS; AGE		Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, W Midlands, England; Univ Newcastle, Freeman Hosp, Dept Med, Newcastle Upon Tyne, Tyne & Wear, England	University of Birmingham; Newcastle Freeman Hospital; Newcastle University - UK	Neuberger, J (corresponding author), Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, W Midlands, England.	J.M.Neuberger@bham.ac.uk	Neuberger, James/ABG-3010-2020					*AM MED ASS COUNC, 1997, CLIN TRANSPLANT, V11, P49; [Anonymous], 1991, LANCET, V337, P1470; BELLE SH, 1966, CLIN TRANSPL, P15; Benjamin M, 1997, Liver Transpl Surg, V3, P337, DOI 10.1002/lt.500030322; DIXON J, 1991, LANCET, V337, P891, DOI 10.1016/0140-6736(91)90213-9; Doyle HR, 1996, TRANSPLANTATION, V61, P1499, DOI 10.1097/00007890-199605270-00016; Eaton S, 1998, J MED ETHICS, V24, P166, DOI 10.1136/jme.24.3.166; EGHTESAD B, 1994, HEPATOLOGY, V20, pS56, DOI 10.1016/0270-9139(94)90274-7; Glannon W, 1998, J MED PHILOS, V23, P31, DOI 10.1076/jmep.23.1.31.2595; Jain A, 1998, TRANSPL P, V30, P1403, DOI 10.1016/S0041-1345(98)00290-5; Jansen PLM, 1998, NETH J MED, V52, P53, DOI 10.1016/S0300-2977(97)00083-1; Keeffe EB, 1998, LIVER TRANSPLANT SUR, V4, pS108; Lucey M R, 1998, Transplantation, V66, P956, DOI 10.1097/00007890-199810150-00034; Marino IR, 1998, LIVER TRANSPLANT SUR, V4, pS115; Mullen MA, 1996, CAN MED ASSOC J, V154, P337; Neuberger J, 1998, BMJ-BRIT MED J, V317, P172, DOI 10.1136/bmj.317.7152.172; Neuberger J, 1998, LIVER TRANSPLANT SUR, V4, pS51; Pereira SP, 1998, GUT, V42, P883, DOI 10.1136/gut.42.6.883; Peters TG, 1996, ARCH INTERN MED, V156, P2419, DOI 10.1001/archinte.156.21.2419; *SEL COMM EXP ORG, 1996, M ORG SHORT CURR STA; Spital A, 1998, TRANSPLANTATION, V65, P1187, DOI 10.1097/00007890-199805150-00008; Steinbrook R, 1997, NEW ENGL J MED, V336, P436, DOI 10.1056/NEJM199702063360610; Tang H, 1998, GUT, V43, P140, DOI 10.1136/gut.43.1.140; TuttleNewhall JE, 1997, TRANSPLANTATION, V63, P255, DOI 10.1097/00007890-199701270-00014; Ubel PA, 1996, MED DECIS MAKING, V16, P234, DOI 10.1177/0272989X9601600307; Varekamp I, 1998, SOC SCI MED, V47, P113, DOI 10.1016/S0277-9536(98)00012-4; Wong T, 1997, TRANSPLANTATION, V64, P878, DOI 10.1097/00007890-199709270-00015; Zetterman RK, 1998, TRANSPLANTATION, V66, P500, DOI 10.1097/00007890-199808270-00015	28	128	129	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	1999	354	9190					1636	1639		10.1016/S0140-6736(99)90002-8	http://dx.doi.org/10.1016/S0140-6736(99)90002-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560692				2022-12-28	WOS:000083551000046
J	Teichmann, D; Grobusch, MP; Wesselmann, H; Temmesfeld-Wollbruck, B; Breuer, T; Dietel, M; Emmerich, P; Schmitz, H; Suttorp, N				Teichmann, D; Grobusch, MP; Wesselmann, H; Temmesfeld-Wollbruck, B; Breuer, T; Dietel, M; Emmerich, P; Schmitz, H; Suttorp, N			A haemorrhagic fever from the Cote d'Ivoire	LANCET			English	Article									Humboldt Univ, Charite, Dept Med Infect Dis, D-13353 Berlin, Germany; Humboldt Univ, Charite, Inst Pathol, Berlin, Germany; Bernhard Nocht Inst Trop Med, Dept Virol, Hamburg, Germany; Robert Koch Inst, Dept Infect Dis Epidemiol, D-1000 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Bernhard Nocht Institut fur Tropenmedizin; Robert Koch Institute	Teichmann, D (corresponding author), Humboldt Univ, Charite, Dept Med Infect Dis, Augustenburger Pl 1, D-13353 Berlin, Germany.			Temmesfeld-Wollbruck, Bettina/0000-0003-3930-3538; Suttorp, Norbert/0000-0002-3958-1151				Center for Disease Control and Prevention, 1988, MMWR-MORBID MORTAL W, V37, P1; Laue T, 1999, J CLIN MICROBIOL, V37, P2543, DOI 10.1128/JCM.37.8.2543-2547.1999; LEPINIEC L, 1994, J GEN VIROL, V75, P417, DOI 10.1099/0022-1317-75-2-417; NOLLASALAS J, 1989, LANCET, V2, P1275, DOI 10.1016/S0140-6736(89)91877-1; TANAKA M, 1993, J VIROL METHODS, V41, P311, DOI 10.1016/0166-0934(93)90020-R	5	30	31	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1608	1608		10.1016/S0140-6736(99)09233-8	http://dx.doi.org/10.1016/S0140-6736(99)09233-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560677				2022-12-28	WOS:000083551000014
J	Broecker, WS; Sutherland, S; Peng, TH				Broecker, WS; Sutherland, S; Peng, TH			A possible 20th-century slowdown of Southern Ocean deep water formation	SCIENCE			English	Article							WEDDELL SEA; BOTTOM-WATER; THERMOHALINE CIRCULATION; LAST DEGLACIATION; CLIMATE-CHANGE; DISTRIBUTIONS; ACCUMULATION; TEMPERATURE; HOLOCENE; BALANCE	Chlorofluorocarbon-11 inventories for the deep Southern Ocean appear to confirm physical oceanographic and geochemical studies in the Southern Ocean, which suggest that no more than 5 x 10(6) cubic meters per second of ventilated deep water is currently being produced. This result conflicts with conclusions based on the distributions of the carbon-14/carbon ratio and a quasi-conservative property, PO4*, in the deep sea, which seem to require an ;average of about 15 x 10(6) cubic meters per second of Southern Ocean deep ventilation over about the past 800 years. A major reduction in Southern Ocean deep water production during the 20th century (from high rates during the Little Ice Age) may explain this apparent discordance. If this is true, a seesawing of deep water production between the northern Atlantic and Southern oceans may lie at the heart of the 1500-year ice-rafting cycle.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; NOAA, Atlantic Oceanog & Meteorol Lab, Ocean Chem Div, Miami, FL 33149 USA	Columbia University; National Oceanic Atmospheric Admin (NOAA) - USA; Atlantic Oceanographic & Meteorological Laboratory (AOML)	Broecker, WS (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.							ALLEY RB, 1993, NATURE, V362, P527, DOI 10.1038/362527a0; Barber DC, 1999, NATURE, V400, P344, DOI 10.1038/22504; BAYER R, 1991, MAR CHEM, V35, P123, DOI 10.1016/S0304-4203(09)90012-3; Bergthorsson P., 1969, JOKULL, V19, P94; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; BOYLE EA, 1992, ANNU REV EARTH PL SC, V20, P245, DOI 10.1146/annurev.ea.20.050192.001333; BOYLE EA, 1987, NATURE, V330, P35, DOI 10.1038/330035a0; Broecker W.S., 1991, OCEANOGRAPHY, V4, P79, DOI DOI 10.5670/0CEAN0G.1991.07; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P119, DOI 10.1029/97PA03707; Broecker WS, 1998, J GEOPHYS RES-OCEANS, V103, P15833, DOI 10.1029/98JC00248; Broecker WS, 1997, SCIENCE, V278, P1582, DOI 10.1126/science.278.5343.1582; CARMACK E C, 1975, Deep-Sea Research and Oceanographic Abstracts, V22, P77, DOI 10.1016/0011-7471(75)90097-2; CARMACK EC, 1973, DEEP-SEA RES, V20, P927, DOI 10.1016/0011-7471(73)90112-5; CLOW G, COMMUNICATION; Duplessy JC, 1988, PALEOCEANOGRAPHY, V3, P343, DOI 10.1029/PA003i003p00343; FAHRBACH E, 1995, J MAR RES, V53, P515, DOI 10.1357/0022240953213089; FOLDVIK A, 1985, ANTARCT RES SER, V43, P5, DOI DOI 10.1029/AR043P0005; FOSTER TD, 1976, J PHYS OCEANOGR, V6, P36, DOI 10.1175/1520-0485(1976)006<0036:TASSIT>2.0.CO;2; FOSTER TD, 1980, DEEP-SEA RES, V27, P367, DOI 10.1016/0198-0149(80)90032-1; GAD F, 1970, HIST GREENLAND, V2; GILL AE, 1973, DEEP-SEA RES, V20, P111, DOI 10.1016/0011-7471(73)90048-X; GORDON AL, 1993, SCIENCE, V262, P95, DOI 10.1126/science.262.5130.95; Grove JM, 1988, LITTLE ICE AGE; Hughen KA, 1998, NATURE, V391, P65, DOI 10.1038/34150; KEIGWIN L, IN PRESS P NATL ACAD; Kerr RA, 1999, SCIENCE, V284, P2069, DOI 10.1126/science.284.5423.2069; KILLWORTH PD, 1977, DEEP-SEA RES, V24, P427, DOI 10.1016/0146-6291(77)90482-9; LEA D, 1989, NATURE, V338, P751, DOI 10.1038/338751a0; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; MEESE DA, 1994, SCIENCE, V266, P1680, DOI 10.1126/science.266.5191.1680; MESSERLI B, 1978, ARCTIC ALPINE RES, V10, P247; MICHEL RL, 1978, J GEOPHYS RES-OCEANS, V83, P6192, DOI 10.1029/JC083iC12p06192; OPPO DW, 1987, EARTH PLANET SC LETT, V86, P1, DOI 10.1016/0012-821X(87)90183-X; Orsi AH, 1999, PROG OCEANOGR, V43, P55, DOI 10.1016/S0079-6611(99)00004-X; PEACOCK S, IN PRESS GEOPHYSICAL, V114; SCHLOSSER P, 1991, MAR CHEM, V35, P97, DOI 10.1016/S0304-4203(09)90011-1; SMETHIE WM, IN PRESS DEEP SEA RE; SOWERS T, 1995, SCIENCE, V269, P210, DOI 10.1126/science.269.5221.210; Stocker TF, 1998, SCIENCE, V282, P61, DOI 10.1126/science.282.5386.61; WEISS RF, 1979, DEEP-SEA RES, V26, P1093, DOI 10.1016/0198-0149(79)90059-1; ZAUCKER F, 1992, J GEOPHYS RES-ATMOS, V97, P2765, DOI 10.1029/91JD01699	41	130	130	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1132	1135		10.1126/science.286.5442.1132	http://dx.doi.org/10.1126/science.286.5442.1132			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550046				2022-12-28	WOS:000083534200036
J	Ladabaum, U; McDonnell, WM				Ladabaum, U; McDonnell, WM			Barrett's esophagus with high-grade dysplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Michigan, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Ladabaum, U (corresponding author), Univ Michigan, Ann Arbor, MI 48109 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1999	341	19					1439	1439		10.1056/NEJM199911043411905	http://dx.doi.org/10.1056/NEJM199911043411905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XR	10547407				2022-12-28	WOS:000083472100005
J	Webster, G				Webster, G			Serving two masters: Medical practice vs administrative ethics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University	Webster, G (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1678	1679		10.1001/jama.282.17.1678	http://dx.doi.org/10.1001/jama.282.17.1678			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553800	hybrid			2022-12-28	WOS:000083368400039
J	Walker, AJ; Cross, SS; Harrison, RF				Walker, AJ; Cross, SS; Harrison, RF			Visualisation of biomedical datasets by use of growing cell structure networks: a novel diagnostic classification technique	LANCET			English	Article								Background Medical research produces large multivariable datasets that are difficult to visualise and interpret intuitively. We describe a novel growing cell structure (GCS) technique that compresses multidimensional datasets into two dimensional maps with colour overlays that can be visually interpreted. Methods The two-dimensional map is self-discovered from the training set by distribution of cases to different nodes according to similarity between the cases at each node. Nodes are added to the map until there is no further significant reduction in error. The Parzen window method is used to estimate the probability distribution of the training cases, and this probability is converted to posterior class probabilities by use of Bayes' theorem. Classification performance can be assessed by means of receiver operating characteristic (ROC) curves. Colour maps of the Values of each input variable at each node are constructed, which illustrate the relation between each input variable and the overall distribution of cases in the network map. Findings From a dataset of 11 input variables from 692 fine-needle aspirate samples from breast lesions, a 32-node network produced an area under the ROC curve of 0.96, which was not significantly different from that for logistic regression (0.98, z=1.09, p>0.05). Colour maps of the input variables showed that some variables had discrete distributions over exclusively benign or malignant areas of the network, and were thus discriminant, whereas others, such as foamy macrophages, covered both benign and malignant regions. Interpretation This technique produces dimensional compression that allows multidimensional data to be displayed as two-dimensional colour images. This envisioning of information allows the highly developed visuospatial abilities of human observers to perceive subtle inter-relations in the dataset.	Univ Sheffield, Sch Med, Dept Pathol, Sheffield S10 2RX, S Yorkshire, England; Univ Sheffield, Sch Med, Dept Automat Control & Syst Engn, Sheffield, S Yorkshire, England; Princeton Univ, Dept Mech & Aerosp Engn, Princeton, NJ 08544 USA	University of Sheffield; University of Sheffield; Princeton University	Cross, SS (corresponding author), Univ Sheffield, Sch Med, Dept Pathol, Sheffield S10 2RX, S Yorkshire, England.	s.s.cross@sheffield.ac.uk	Harrison, Robert/B-9034-2008	Harrison, Robert/0000-0002-9323-8637; Cross, Simon/0000-0003-2044-1754				CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; FRITZKE B, 1994, NEURAL NETWORKS, V7, P1441, DOI 10.1016/0893-6080(94)90091-4; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hjalmarson A, 1999, LANCET, V353, P2001; KOHONEN T, 1982, BIOL CYBERN, V43, P59, DOI 10.1007/BF00337288; PARZEN E, 1962, ANN MATH STAT, V33, P1065, DOI 10.1214/aoms/1177704472; POWSNER SM, 1994, LANCET, V344, P386, DOI 10.1016/S0140-6736(94)91406-0; WELLS CA, 1994, CYTOPATHOLOGY, V5, P316, DOI 10.1111/j.1365-2303.1994.tb00437.x; [No title captured]; [No title captured]; [No title captured]	12	31	32	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	1999	354	9189					1518	1521		10.1016/S0140-6736(99)02186-8	http://dx.doi.org/10.1016/S0140-6736(99)02186-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551499				2022-12-28	WOS:000083411300013
J	Arstila, TP; Casrouge, A; Baron, V; Even, J; Kanellopoulos, J; Kourilsky, P				Arstila, TP; Casrouge, A; Baron, V; Even, J; Kanellopoulos, J; Kourilsky, P			A direct estimate of the human alpha beta T cell receptor diversity	SCIENCE			English	Article							ANTIGEN RECEPTOR; REPERTOIRE; SELECTION; LYMPHOCYTES; RECOGNITION; CHAINS	Generation and maintenance of an effective repertoire of T cell antigen receptors are essential to the immune system, yet the number of distinct T cell receptors (TCRs) expressed by the estimated 10(12) T cells in the human body is not known. In this study, TCR gene amplification and sequencing showed that there are about 10(6) different beta chains in the blood, each pairing, on the average, with at Least 25 different alpha chains. In the memory subset, the diversity decreased to 1 x 10(5) to 2 x 10(5) different beta chains, each pairing with only a single alpha chain. Thus, the naive repertoire is highly diverse, whereas the memory compartment, here one-third of the T cell population, contributes Less than 1 percent of the total diversity.	Inst Pasteur, INSERM, U277, Unite Biol Mol Gene, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Arstila, TP (corresponding author), Univ Helsinki, Haartman Inst, Dept Virol, Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	petteri.arstila@helsinki.fi	Yang, Chen/G-1379-2010					ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Arden Bernhard, 1995, Immunogenetics, V42, P501; ARGAET VP, 1994, J EXP MED, V180, P2335, DOI 10.1084/jem.180.6.2335; BENIT C, 1995, J IMMUNOL, V154, P5103; Berzins SP, 1998, J EXP MED, V187, P1839, DOI 10.1084/jem.187.11.1839; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; CASROUGE A, 1998, J EXP MED, V187, P1871; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; FERRADINI L, UNPUB; HALL MA, 1995, HUM IMMUNOL, V43, P207, DOI 10.1016/0198-8859(95)00013-T; McMahan CJ, 1998, IMMUNITY, V9, P637, DOI 10.1016/S1074-7613(00)80661-5; Nanki T, 1998, J IMMUNOL, V161, P228; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0; Rodewald HR, 1998, ADV IMMUNOL, V69, P1, DOI 10.1016/S0065-2776(08)60606-9; ROSENBERG WMC, 1992, EUR J IMMUNOL, V22, P541, DOI 10.1002/eji.1830220237; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; Trigueros C, 1998, J EXP MED, V188, P1401, DOI 10.1084/jem.188.8.1401; Wagner UG, 1998, P NATL ACAD SCI USA, V95, P14447, DOI 10.1073/pnas.95.24.14447	26	647	705	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					958	961		10.1126/science.286.5441.958	http://dx.doi.org/10.1126/science.286.5441.958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542151				2022-12-28	WOS:000083368500046
J	Kagan, CR; Mitzi, DB; Dimitrakopoulos, CD				Kagan, CR; Mitzi, DB; Dimitrakopoulos, CD			Organic-inorganic hybrid materials as semiconducting channels in thin-film field-effect transistors	SCIENCE			English	Article							HIGH-MOBILITY; QUANTUM-WELL; TRANSPORT; PENTACENE; DEVICE	Organic-inorganic hybrid materials promise both the superior carrier mobility of inorganic semiconductors and the processability of organic materials. A thin-film field-effect transistor having an organic-inorganic hybrid material as the semiconducting channel was demonstrated. Hybrids based on the perovskite structure crystallize from solution to form oriented molecular-scale composites of alternating organic and inorganic sheets. Spin-coated thin films of the semiconducting perovskite (C6H5C2H4NH3)(2)Snl(4) form the conducting channel, with field-effect mobilities of 0.6 square centimeters per volt-second and current modulation greater than 10(4). Molecular engineering of the organic and inorganic components of the hybrids is expected to further improve device performance for low-cost thin-film transistors.	IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA	International Business Machines (IBM)	Kagan, CR (corresponding author), IBM Corp, Thomas J Watson Res Ctr, POB 218, Yorktown Hts, NY 10598 USA.		Mitzi, David B/B-6260-2012	Mitzi, David B/0000-0001-5189-4612				Bao Z, 1996, APPL PHYS LETT, V69, P4108, DOI 10.1063/1.117834; BROWN AR, 1995, SCIENCE, V270, P972, DOI 10.1126/science.270.5238.972; Brown AR, 1997, SYNTHETIC MET, V88, P37, DOI 10.1016/S0379-6779(97)80881-8; BURROUGHES JH, 1988, NATURE, V335, P137, DOI 10.1038/335137a0; Dimitrakopoulos CD, 1996, J APPL PHYS, V80, P2501, DOI 10.1063/1.363032; Dimitrakopoulos CD, 1999, SCIENCE, V283, P822, DOI 10.1126/science.283.5403.822; Dimitrakopoulos CD, 1998, SYNTHETIC MET, V92, P47, DOI 10.1016/S0379-6779(98)80021-0; DODABALAPUR A, 1995, SCIENCE, V268, P270, DOI 10.1126/science.268.5208.270; Era M, 1997, CHEM MATER, V9, P8, DOI 10.1021/cm960434m; GARNIER F, 1994, SCIENCE, V265, P1684, DOI 10.1126/science.265.5179.1684; Herwig PT, 1999, ADV MATER, V11, P480, DOI 10.1002/(SICI)1521-4095(199904)11:6<480::AID-ADMA480>3.0.CO;2-U; HOROWITZ G, 1989, SOLID STATE COMMUN, V72, P381, DOI 10.1016/0038-1098(89)90121-X; Liang KN, 1998, CHEM MATER, V10, P403, DOI 10.1021/cm970568f; Mitzi DB, 1999, PROG INORG CHEM, V48, P1, DOI 10.1002/9780470166499.ch1; MITZI DB, 1995, J SOLID STATE CHEM, V114, P159, DOI 10.1006/jssc.1995.1023; MITZI DB, 1994, NATURE, V369, P467, DOI 10.1038/369467a0; Mitzi DB, 1999, CHEM MATER, V11, P542, DOI 10.1021/cm9811139; Nelson SF, 1998, APPL PHYS LETT, V72, P1854, DOI 10.1063/1.121205; PAPAVASSILIOU GC, 1994, SOLID STATE COMMUN, V91, P695, DOI 10.1016/0038-1098(94)00435-8; SHUR M, 1989, J APPL PHYS, V66, P3371, DOI 10.1063/1.344481; TSUMURA A, 1986, APPL PHYS LETT, V49, P1210, DOI 10.1063/1.97417; XU CQ, 1991, SOLID STATE COMMUN, V79, P249, DOI 10.1016/0038-1098(91)90644-B	22	1648	1790	29	943	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					945	947		10.1126/science.286.5441.945	http://dx.doi.org/10.1126/science.286.5441.945			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542146				2022-12-28	WOS:000083368500041
J	Severinghaus, JP; Brook, EJ				Severinghaus, JP; Brook, EJ			Abrupt climate change at the end of the last glacial period inferred from trapped air in polar ice	SCIENCE			English	Article							YOUNGER DRYAS EVENT; PAST 110,000 YEARS; NORTH-ATLANTIC; GREENLAND CLIMATE; OCEAN; CORE; TRANSITION; MODEL; ACCUMULATION; TEMPERATURE	The last glacial period was terminated by an abrupt warming event in the North Atlantic similar to 15,000 years before the present, and warming events of similar age have been reported from Low Latitudes. Understanding the mechanism of this termination requires that the precise relative timing of abrupt climate warming in the tropics versus the North Atlantic be known. Nitrogen and argon isotopes in trapped air in Greenland ice show that the Greenland Summit warmed 9 +/- 3 degrees C over a period of several decades, beginning 14,672 years ago. Atmospheric methane concentrations rose abruptly over a similar to 50-year period and began their increase 20 to 30 years after the onset of the abrupt Greenland warming. These data suggest that tropical climate became warmer or wetter (or both) similar to 20 to 80 years after the onset of Greenland warming, supporting a North Atlantic rather than a tropical trigger for the climate event.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92037 USA; Washington State Univ, Dept Geol, Vancouver, WA 98686 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; Washington State University	Severinghaus, JP (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, 9500 Gilman Dr, La Jolla, CA 92037 USA.	jseveringhaus@ucsd.edu; brook@vancower.wsu.edu	Brook, Edward/AAB-7807-2021					Agustsdottir AM, 1999, GEOPHYS RES LETT, V26, P1333, DOI 10.1029/1999GL900084; ALLEY RB, 1993, NATURE, V362, P527, DOI 10.1038/362527a0; Alley RB, 1990, ANN GLACIOL, V14, P6; Battle M, 1996, NATURE, V383, P231, DOI 10.1038/383231a0; Behl RJ, 1996, NATURE, V379, P243, DOI 10.1038/379243a0; BENDER M, 1994, NATURE, V372, P663, DOI 10.1038/372663a0; Blunier T, 1997, GEOPHYS RES LETT, V24, P2683, DOI 10.1029/97GL02658; BOND GC, 1995, SCIENCE, V267, P1005, DOI 10.1126/science.267.5200.1005; Boyle EA, 1997, GEOPHYS RES LETT, V24, P273, DOI 10.1029/97GL00081; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; Brook EJ, 1996, SCIENCE, V273, P1087, DOI 10.1126/science.273.5278.1087; Brook EJ, 1999, GEOPH MONOG SERIES, V112, P165; Chapman S, 1917, PHILOS MAG, V33, P248, DOI 10.1080/14786440308635635; CHAPPELLAZ J, 1993, NATURE, V366, P443, DOI 10.1038/366443a0; CHARLES CD, 1994, SCIENCE, V263, P508, DOI 10.1126/science.263.5146.508; CRAIG H, 1988, SCIENCE, V242, P1675, DOI 10.1126/science.242.4886.1675; Crowley T. J., 1991, PALEOCLIMATOLOGY; Cuffey KM, 1997, J GEOPHYS RES-OCEANS, V102, P26383, DOI 10.1029/96JC03981; CUFFEY KM, 1995, SCIENCE, V270, P455, DOI 10.1126/science.270.5235.455; DahlJensen D, 1998, SCIENCE, V282, P268, DOI 10.1126/science.282.5387.268; DALLENBACH A, IN PRESS GEOPHYS RES; DANSGAARD W, 1989, NATURE, V339, P532, DOI 10.1038/339532a0; DEBEAULIEU JL, 1992, QUATERNARY SCI REV, V11, P431, DOI 10.1016/0277-3791(92)90025-4; Fairbanks RG, 1990, PALEOCEANOGRAPHY, V5, P937, DOI 10.1029/PA005i006p00937; Fawcett PJ, 1997, PALEOCEANOGRAPHY, V12, P23, DOI 10.1029/96PA02711; FROLKING S, 1994, GLOBAL BIOGEOCHEM CY, V8, P385, DOI 10.1029/94GB01839; Grew K.E., 1952, THERMAL DIFFUSION GA; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; HERRON MM, 1980, J GLACIOL, V25, P373, DOI 10.3189/S0022143000015239; Hostetler SW, 1999, J GEOPHYS RES-ATMOS, V104, P3947, DOI 10.1029/1998JD200067; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; KOC N, 1994, GEOLOGY, V22, P523, DOI 10.1130/0091-7613(1994)022<0523:ROTHLN>2.3.CO;2; Lindemann FA, 1919, PHILOS MAG, V37, P523, DOI 10.1080/14786440508635912; MANABE S, 1995, NATURE, V378, P165, DOI 10.1038/378165a0; MARTINERIE P, 1995, J GEOPHYS RES-ATMOS, V100, P14291, DOI 10.1029/95JD00826; MAYEWSKI PA, 1994, SCIENCE, V263, P1747, DOI 10.1126/science.263.5154.1747; Meese DA, 1997, J GEOPHYS RES-OCEANS, V102, P26411, DOI 10.1029/97JC00269; PATERSON WSB, 1969, PHYSICS GLACIERS; PRINN RG, 1995, SCIENCE, V269, P187, DOI 10.1126/science.269.5221.187; RAHMSTORF S, 1995, NATURE, V378, P145, DOI 10.1038/378145a0; Schulz H, 1998, NATURE, V393, P54, DOI 10.1038/31750; SCHWANDER J, 1989, PHYS CH EAR, V8, P53; Schwander J, 1997, J GEOPHYS RES-ATMOS, V102, P19483, DOI 10.1029/97JD01309; Schwander J., 1988, ANN GLACIOL, V10, P141, DOI [10.1017/s0260305500004328, 10.1017/S0260305500004328, DOI 10.1017/S0260305500004328]; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; SOWERS T, 1989, J GEOPHYS RES-ATMOS, V94, P5137, DOI 10.1029/JD094iD04p05137; Steig EJ, 1998, SCIENCE, V282, P92, DOI 10.1126/science.282.5386.92; Stuiver M, 1995, QUATERNARY RES, V44, P341, DOI 10.1006/qres.1995.1079; Taylor KC, 1997, SCIENCE, V278, P825, DOI 10.1126/science.278.5339.825; TAYLOR KC, 1993, NATURE, V361, P432, DOI 10.1038/361432a0; Thompson LG, 1998, SCIENCE, V282, P1858, DOI 10.1126/science.282.5395.1858	52	367	382	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					930	934		10.1126/science.286.5441.930	http://dx.doi.org/10.1126/science.286.5441.930			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542141				2022-12-28	WOS:000083368500036
J	Lewis, DL; Garrison, AW; Wommack, KE; Whittemore, A; Steudler, P; Melillo, J				Lewis, DL; Garrison, AW; Wommack, KE; Whittemore, A; Steudler, P; Melillo, J			Influence of environmental changes on degradation of chiral pollutants in soils	NATURE			English	Article							ENANTIOSELECTIVE DEGRADATION; HERBICIDE	Numerous anthropogenic chemicals of environmental concern-including some phenoxy acid herbicides, organophosphorus insecticides, polychlorinated biphenyls, phthalates, freon substitutes and some DDT derivatives-are chiral. Their potential biological effects, such as toxicity, mutagenicity, carcinogenicity, and endocrine disrupter activity, are generally enantiomer-selective, and different enantiomers are preferentially degraded (transformed) by micro-organisms in various environments(1-8). Here we use field and laboratory experiments to demonstrate that environmental changes in soils can alter these preferences, and to suggest that the preferences shift owing to different groups of related microbial genotypes being activated by different environmental changes. In Brazilian soils, almost all pasture samples preferentially transformed the non-herbicidal enantiomer of dichlorprop ((RS)-2-(2,4-dichlorophenoxy)propionic acid), while most forest samples either transformed the herbicidal enantiomer more readily or as rapidly as the non-herbicidal enantiomer. Organic nutrient enrichments shifted enantioselectivity for methyl dichlorprop ((RS)-methyl 2-(2,4-dichlorophenoxy)propionic acid) strongly towards preferentially removing the non-herbicidal enantiomer in soils from Brazil and North America, potentially increasing phytotoxicity of its residues relative to that of the racemate. Assessments of the risks chemical pollutants pose to public health and the environment need to take into account the chiral selectivity of microbial transformation processes and their alteration by environmental changes, especially for pesticides as up to 25 per cent are chiral(9).	US EPA, Ecosyst Res Div, Natl Exposure Res Lab, Athens, GA 30605 USA; Univ Georgia, Dept Marine Sci, Athens, GA 30602 USA; Marine Biol Lab, Ctr Ecosyst, Woods Hole, MA 02542 USA	United States Environmental Protection Agency; University System of Georgia; University of Georgia; Marine Biological Laboratory - Woods Hole	Lewis, DL (corresponding author), US EPA, Ecosyst Res Div, Natl Exposure Res Lab, Athens, GA 30605 USA.			Lewis, David/0000-0003-0777-2460				Aigner EJ, 1998, ENVIRON SCI TECHNOL, V32, P1162, DOI 10.1021/es970750h; AKKERMANS ADL, 1995, MOL MICROBIAL ECOLOG, P1; BUSER HP, 1997, CHIRAL SEPARATIONS, pCH5; FALCONER RL, 1995, ENVIRON SCI TECHNOL, V29, P1297, DOI 10.1021/es00005a023; Fulthorpe RR, 1998, APPL ENVIRON MICROB, V64, P1620; Garrison AW, 1996, ENVIRON SCI TECHNOL, V30, P2449, DOI 10.1021/es950552v; HOLLIBAUGH JT, 1979, ESTUAR COAST MAR SCI, V9, P215, DOI 10.1016/0302-3524(79)90116-6; JANTUNEN LM, 1996, GEOPHYS RES, V108, P28837; Kohler HPE, 1997, CHIMIA, V51, P947; Lewis DL, 1996, NATURE, V381, P731, DOI 10.1038/381731a0; Lukewille A, 1997, GLOB CHANGE BIOL, V3, P13, DOI 10.1046/j.1365-2486.1997.00088.x; MOYER CL, 1994, APPL ENVIRON MICROB, V60, P871, DOI 10.1128/AEM.60.3.871-879.1994; MULLER MD, 1995, ENVIRON SCI TECHNOL, V29, P2031, DOI 10.1021/es00008a023; PETERJOHN WT, 1994, ECOL APPL, V4, P617, DOI 10.2307/1941962; TETT VA, 1994, FEMS MICROBIOL ECOL, V14, P191, DOI 10.1111/j.1574-6941.1994.tb00105.x; Wiberg K, 1998, ANAL CHEM, V70, P3845, DOI 10.1021/ac980064g; Williams A, 1996, PESTIC SCI, V46, P3, DOI 10.1002/(SICI)1096-9063(199601)46:1&lt;3::AID-PS337&gt;3.0.CO;2-J; Zipper C, 1998, ENVIRON SCI TECHNOL, V32, P2070, DOI 10.1021/es970880q; 1998, CHEM ENG NEWS, V76, P83	19	331	361	8	218	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					898	901		10.1038/44801	http://dx.doi.org/10.1038/44801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553905				2022-12-28	WOS:000083464700053
J	Simon, I; Tenzen, T; Reubinoff, BE; Hillman, D; McCarrey, JR; Cedar, H				Simon, I; Tenzen, T; Reubinoff, BE; Hillman, D; McCarrey, JR; Cedar, H			Asynchronous replication of imprinted genes is established in the gametes and maintained during development	NATURE			English	Article							ALLELE-SPECIFIC REPLICATION; MOUSE; REGION; EXPRESSION; MECHANISMS; CELLS; H19; HYBRIDIZATION; METHYLATION; TRANSITION	Genomic imprinting is characterized by allele-specific expression of multiple genes within large chromosomal domains' that undergo DNA replication asynchronously during S phase(2,3). Here we show, using both fluorescence in situ hybridization analysis and S-phase fractionation techniques, that differential replication timing is associated with imprinted genes in a variety of fell types, and is already present in the pre-implantation embryo soon after fertilization. This pattern is erased before meiosis in the germ line, and parent-specific replication timing is then reset in late gametogenesis in both the male and female. Thus, asynchronous replication timing is established in the gametes and maintained throughout development, indicating that it may function as a primary epigenetic marker for distinguishing between the parental alleles.	Hebrew Univ Jerusalem, Dept Cellular Biochem, IL-91120 Jerusalem, Israel; Natl Inst Genet, Dept Evolut Genet, Mishima, Shizuoka 4118540, Japan; Hadassah Ein Kerem Univ Hosp, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel; SW Fdn Biomed Res, Dept Genet, San Antonio, TX 78228 USA	Hebrew University of Jerusalem; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Hebrew University of Jerusalem; Hadassah University Medical Center; Texas Biomedical Research Institute	Cedar, H (corresponding author), Hebrew Univ Jerusalem, Dept Cellular Biochem, IL-91120 Jerusalem, Israel.			Simon, Itamar/0000-0002-8517-1903; Reubinoff, Benjamin/0000-0003-0353-1299				BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Caspary T, 1998, MOL CELL BIOL, V18, P3466, DOI 10.1128/MCB.18.6.3466; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Davis TL, 1999, GENOMICS, V58, P18, DOI 10.1006/geno.1999.5813; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; Gabriel JM, 1998, P NATL ACAD SCI USA, V95, P14857, DOI 10.1073/pnas.95.25.14857; Greally JM, 1998, HUM MOL GENET, V7, P91, DOI 10.1093/hmg/7.1.91; GUNARATNE PH, 1995, GENE DEV, V9, P808, DOI 10.1101/gad.9.7.808; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HARPER JC, 1994, HUM REPROD, V9, P721, DOI 10.1093/oxfordjournals.humrep.a138577; Hogan B, 1994, MANIPULATING MOUSE E; KAWAME H, 1995, HUM MOL GENET, V4, P2287, DOI 10.1093/hmg/4.12.2287; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KNOLL JHM, 1994, NAT GENET, V6, P41, DOI 10.1038/ng0194-41; LASALLE JM, 1995, NAT GENET, V9, P386, DOI 10.1038/ng0495-386; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; McCarrey J, 1993, CELL MOL BIOL TESTIS, P58; MCCARREY JR, 1987, J EXP ZOOL, V242, P107, DOI 10.1002/jez.1402420116; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; Riviere I, 1998, IMMUNITY, V9, P217, DOI 10.1016/S1074-7613(00)80604-4; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; Shemer R., 1996, Epigenetic mechanisms of gene regulation., P215; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; Tenzen T, 1997, MOL CELL BIOL, V17, P4043, DOI 10.1128/MCB.17.7.4043; Windham CQ, 1997, DEV GENET, V20, P29, DOI 10.1002/(SICI)1520-6408(1997)20:1<29::AID-DVG4>3.0.CO;2-B; Wines ME, 1998, GENOMICS, V51, P223, DOI 10.1006/geno.1998.5347	30	131	132	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					929	932		10.1038/44866	http://dx.doi.org/10.1038/44866			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553911				2022-12-28	WOS:000083464700063
J	Allison, DB; Fontaine, KR; Manson, JE; Stevens, J; VanItallie, TB				Allison, DB; Fontaine, KR; Manson, JE; Stevens, J; VanItallie, TB			Annual deaths attributable to obesity in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; MORTALITY; WEIGHT; OVERWEIGHT; PREVALENCE; DISEASE; WOMEN	Context Obesity is a major health problem in the United States, but the number of obesity-attributable deaths has not been rigorously estimated. Objective To estimate the number of deaths, annually, attributable to obesity among US adults. Design Data from 5 prospective cohort studies (the Alameda Community Health Study, the Framingham Heart Study, the Tecumseh Community Hearth Study, the American Cancer Society Cancer Prevention Study I, and the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study) and 1 published study (the Nurses' Health Study) in conjunction with 1991 national statistic; on body mass index distributions, population size, and overall deaths. Subjects Adults, 18 years or older in 1991, classified by body mass index (kg/m(2)) as overweight (25-30), obese (30-35), and severely obese (>35), Main Outcome Measure Relative hazard ratio (HR) of death for obese or overweight persons. Results The estimated number of annual deaths attributable to obesity varied with the cohort used to calculate the HRs, but findings were consistent overall. More than 80% of the estimated obesity-attributable deaths occurred among individuals with a body mass index of more than 30 kg/m(2). When HRs were estimated for all eligible subjects from ail 6 studies, the mean estimate of deaths attributable to obesity in the United States was 280 184 (range, 236 111-341 153),Hazard ratios also were calculated from data for nonsmokers or never-smokers only. When these HRs were applied to the entire population (assuming the HR applied to all individuals), the mean estimate for obesity-attributable death was 324 940 (range, 262 541-383 410). Conclusions The estimated number of annual deaths attributable to obesity among US adults is approximately 280 000 based on HRs from all subjects and 325 000 based on HRs from only nonsmokers and never-smokers.	Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Obes Res Ctr, New York, NY 10025 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Med, Baltimore, MD USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Univ N Carolina, Dept Nutr, Chapel Hill, NC USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Allison, DB (corresponding author), Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Obes Res Ctr, 1090 Amsterdam Ave,14th Floor, New York, NY 10025 USA.	dba8@columbia.edu	Kohn, Geoffrey P/A-9056-2009	Allison, David/0000-0003-3566-9399	NIDDK NIH HHS [P30DK26687, R01DK51716] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051716, P30DK026687] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allison D B, 1995, Endocr Pract, V1, P353; Allison DB, 1999, ANN EPIDEMIOL, V9, P132, DOI 10.1016/S1047-2797(98)00039-8; Allison DB, 1997, AM J EPIDEMIOL, V146, P672; Allison DB, 1999, AM J PUBLIC HEALTH, V89, P1194, DOI 10.2105/AJPH.89.8.1194; Allison DB, 1999, OBES RES, V7, P342, DOI 10.1002/j.1550-8528.1999.tb00417.x; Amler RW, 1987, AM J PREV MED, V3, P181; BERKHAM LF, 1983, HLTH WAYS LIVING ALA; Cox C S, 1997, Vital Health Stat 1, P1; Cox D. R., 1984, ANAL SURVIVAL DATA; D'AGOSTINO R. B., 1988, NIH PUBLICATION, V88-2970; DAGOSTINO RB, 1989, P AM STAT ASS SESQ 1, P707; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; Durazo-Arvizu RA, 1998, AM J EPIDEMIOL, V147, P739, DOI 10.1093/oxfordjournals.aje.a009518; EPSTEIN FH, 1970, ARCH ENVIRON HEALTH, V21, P402, DOI 10.1080/00039896.1970.10667258; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Fontaine K., 1998, DIS MANAG HLTH OUT, V3, P61; FORSTER J, 1995, PATIENT CARE, V29, P152; HAHN RA, 1990, JAMA-J AM MED ASSOC, V264, P2654, DOI 10.1001/jama.264.20.2654; Hill JO, 1998, PEDIATRICS, V101, P570, DOI 10.1542/peds.101.3.570; HOCHSTIM JR, 1970, COMMUNITY EPIDEMIOLO; ILIENFELD AM, 1980, FDN EPIDEMIOLOGY; *KNOLL PHARM CO, 1999, MER PAT SUPP PACK; KOLATA G, 1998, NY TIMES        0101, P2; Kuczmarski RJ, 1997, OBES RES, V5, P542, DOI 10.1002/j.1550-8528.1997.tb00575.x; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; Manson JE, 1996, NEW ENGL J MED, V335, P659, DOI 10.1056/NEJM199608293350910; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MEISOL P, 1998, BALTIMORE SUN   0723, P3; *MORT STAT BRANCH, 1993, MMWR-MORBID MORTAL W, V42, P897; *MORT STAT BRANCH, 1993, MMWR-MORBID MORTAL W, V42, P891; NAPIER JA, 1962, AM J PUBLIC HEALTH N, V52, P208, DOI 10.2105/AJPH.52.2.208; NAPIER JA, 1970, COMMUNITY EPIDEMIOLO; *NHANES, 1997, BOOK CD ROM; PETITTI D, 1994, META ANAL DECISION A; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; SEIDELL JC, 1998, HDB OBESITY, P79; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; Stevens J, 1999, AM J EPIDEMIOL, V150, P399, DOI 10.1093/oxfordjournals.aje.a010019; Troiano RP, 1996, INT J OBESITY, V20, P63; *US CENS BUR, 1998, 1990 US CENS DAT; Wilding J, 1998, NATURE, V391, P759, DOI 10.1038/35793; WILL GF, 1997, NEWSWEEK        0707, P82; World Health Organization,, 1998, WHO TECHN REP SER	47	1272	1312	2	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1530	1538		10.1001/jama.282.16.1530	http://dx.doi.org/10.1001/jama.282.16.1530			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546692	Bronze			2022-12-28	WOS:000083277800020
J	Galuska, DA; Will, JC; Serdula, MK; Ford, ES				Galuska, DA; Will, JC; Serdula, MK; Ford, ES			Are health care professionals advising obese patients to lose weight?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; PHYSICIAN ADVICE; PRACTITIONERS; PROMOTION; ATTITUDES; BEHAVIOR	Context Implementation of the National Institutes of Health's 1998 guidelines, which recommended that health care professionals advise obese patients to lose weight, required baseline data for evaluation. Objectives To describe the proportion and characteristics of obese persons advised to lose weight by their health care professional during the previous 12 months and to determine whether the advice was associated with reported attempts to lose weight. Design The Behavioral Risk Factor Surveillance System, a random-digit telephone survey conducted in 1996 by state health departments. Setting Population-based sample from 50 states and the District of Columbia. Participants A total of 22 835 adults, 18 years and older, classified as obese (body mass index greater than or equal to 30 kg/m(2)), who had visited their physician for a routine checkup during the previous 12 months. Main Outcome Measures Reported advice from a health care professional to lose weight, and reported attempts to lose weight. Results Forty-two percent of participants reported that their hearth care professional advised them to lose weight. Using multivariate logistic regression analysis, we found that the persons who were more likely to receive advice were female, middle aged, had higher levels of education, lived in the northeast, reported poorer perceived health, were more obese, and had diabetes mellitus. Persons who reported receiving advice to lose weight were significantly more likely to report trying to lose weight than those who did not (OR, 2.79; 95% CI, 2.53-3.08). Conclusions Less than half of obese adults report being advised to lose weight by health care professionals. Barriers to counseling need to be identified and addressed.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr & Phys Activ, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Galuska, DA (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr & Phys Activ, 4770 Bufford Hwy,MS K26, Atlanta, GA 30341 USA.							[Anonymous], 1998, CLIN GUID ID EV TREA; CAMPBELL MK, 1994, AM J PUBLIC HEALTH, V84, P783, DOI 10.2105/AJPH.84.5.783; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Fontaine KR, 1998, ARCH FAM MED, V7, P381, DOI 10.1001/archfami.7.4.381; Ford ES, 1998, J CLIN EPIDEMIOL, V51, P55, DOI 10.1016/S0895-4356(97)00225-4; FRIEDMAN C, 1994, AM J PREV MED, V10, P367, DOI 10.1016/S0749-3797(18)30567-1; HORM J, 1993, ANN INTERN MED, V119, P672, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00009; JANES GR, 1995, US DEP HLTH HUMAN SE; KOTTKE TE, 1984, PREV MED, V13, P215; Kristeller JL, 1997, PREV MED, V26, P542, DOI 10.1006/pmed.1997.0171; KUSHNER RF, 1995, PREV MED, V24, P546, DOI 10.1006/pmed.1995.1087; LEWIS BS, 1993, PREV MED, V22, P110, DOI 10.1006/pmed.1993.1008; LOGSDON DN, 1989, AM J PREV MED, V5, P249, DOI 10.1016/S0749-3797(18)31065-1; NELSON DE, 1998, P SECT SURV METH AM; ORLEANS CT, 1985, PREV MED, V14, P636, DOI 10.1016/0091-7435(85)90083-0; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; PRICE JH, 1987, AM J PREV MED, V3, P339; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; SERDULA MK, 1993, ANN INTERN MED, V119, P667, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00008; Shah BV, 1997, SUDAAN USERS MANUAL; SWIWBURN BA, 1998, AM J PUBLIC HEALTH, V88, P288; WECHSLER H, 1983, NEW ENGL J MED, V308, P97, DOI 10.1056/NEJM198301133080211; WOODWELL DA, 1997, ADV DATA VITAL HLTH, V295; Yeager KK, 1996, AM J PREV MED, V12, P238, DOI 10.1016/S0749-3797(18)30318-0	24	478	486	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1576	1578		10.1001/jama.282.16.1576	http://dx.doi.org/10.1001/jama.282.16.1576			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546698	Bronze			2022-12-28	WOS:000083277800026
J	Almond, S				Almond, S			A lesson to be learnt - A word out of place	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1105	1105		10.1136/bmj.319.7217.1105	http://dx.doi.org/10.1136/bmj.319.7217.1105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531102	Green Published			2022-12-28	WOS:000083419500024
J	Bi, GQ; Poo, MM				Bi, GQ; Poo, MM			Distributed synaptic modification in neural networks induced by patterned stimulation	NATURE			English	Article							LONG-TERM POTENTIATION; PLASTICITY; DEPRESSION; HIPPOCAMPUS; NEURONS; COMPUTATION; INFORMATION; SIGNAL; TIME	Activity-dependent changes in synaptic efficacy or connectivity are critical for the development(1), signal processing(2) and learning and memory functions(3-6) of the nervous system. Repetitive correlated spiking of pre- and postsynaptic neurons can induce a persistent increase or decrease in synaptic strength, depending on the timing of the pre- and postsynaptic excitation(7-13). Previous studies on such synaptic modifications have focused on synapses made by the stimulated neuron. Here we examine, in networks of cultured hippocampal neurons, whether and how localized stimulation can modify synapses that are remote from the stimulated neuron. We found that repetitive paired-pulse stimulation of a single neuron for brief periods induces persistent strengthening or weakening of specific polysynaptic pathways in a manner that depends on the interpulse interval. These changes can be accounted for by correlated pre- and postsynaptic excitation at distant synaptic sites, resulting from different transmission delays along separate pathways. Thus, through such a 'delay-line' mechanism, temporal information coded in the timing of individual spikes(14-17) can be converted into and stored as spatially distributed patterns of persistent synaptic modifications in a neural network.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Bi, GQ (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Bi, Guo-Qiang/E-5075-2013	Bi, Guo-Qiang/0000-0001-8735-3818				Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; Abeles M., 1991, CORTICONICS; Bell CC, 1997, NATURE, V387, P278, DOI 10.1038/387278a0; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Buonomano DV, 1997, P NATL ACAD SCI USA, V94, P10403, DOI 10.1073/pnas.94.19.10403; BUZSAKI G, 1988, BRAIN RES, V455, P192, DOI 10.1016/0006-8993(88)90133-3; CARR CE, 1990, J NEUROSCI, V10, P3227; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; Debanne D, 1998, J PHYSIOL-LONDON, V507, P237, DOI 10.1111/j.1469-7793.1998.237bu.x; Fitzsimonds RM, 1997, NATURE, V388, P439, DOI 10.1038/41267; Gerstner W, 1996, NATURE, V383, P76, DOI 10.1038/383076a0; Goda Y, 1996, CURR BIOL, V6, P375, DOI 10.1016/S0960-9822(02)00499-2; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kristan WB, 1998, NAT NEUROSCI, V1, P643, DOI 10.1038/3640; LEVY WB, 1983, NEUROSCIENCE, V8, P791, DOI 10.1016/0306-4522(83)90010-6; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; MILES R, 1987, NATURE, V329, P724, DOI 10.1038/329724a0; Moore JW, 1998, TIMING OF BEHAVIOR, P3; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Squire L. R., 1987, MEMORY BRAIN; Strong SP, 1998, PHYS REV LETT, V80, P197, DOI 10.1103/PhysRevLett.80.197; TANK DW, 1987, P NATL ACAD SCI USA, V84, P1896, DOI 10.1073/pnas.84.7.1896; TURRIGIANO G, 1994, SCIENCE, V264, P974, DOI 10.1126/science.8178157; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665	30	183	190	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					792	796		10.1038/44573	http://dx.doi.org/10.1038/44573			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548104				2022-12-28	WOS:000083368700053
J	Bellomo, G; Narducci, PL; Rondoni, F; Pastorelli, G; Stangoni, G; Angeli, G; Verdecchia, P				Bellomo, G; Narducci, PL; Rondoni, F; Pastorelli, G; Stangoni, G; Angeli, G; Verdecchia, P			Prognostic value of 24-hour blood pressure in pregnancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WHITE-COAT HYPERTENSION; OFFICE; PREECLAMPSIA	Context Elevated blood pressure (BP) measured at the physician's office may reflect true hypertension or white coat hypertension (WCH). The prognostic value of WCH among pregnant women is unknown. Objective To assess the prognostic value of WCH in pregnancy. Design Prospective cohort study conducted between September 1994 and October 1997. Setting Community hospital. Patients Women without preexisting hypertension and not treated with antihypertensive drugs and with high (n = 148) or normal (n = 106) office BP thigh office BP was defined as greater than or equal to 140 mm Hg systolic and/or greater than or equal to 90 mm Hg diastolic) matched for gestational age during their third trimester of pregnancy. All women underwent 24-hour noninvasive BP monitoring, and women without hypertension on 24-hour monitoring (125/74 mm Hg or less for average 24-hour BP) with office hypertension were classified as having WCH. Women were followed up through the end of pregnancy. Main Outcome Measures Duration of pregnancy, gestational hypertension, preeclampsia or eclampsia, cesarean delivery, placental and neonatal weight, and length of maternal and neonatal hospital stays for those with and without elevated office BP. Results After application of exclusion criteria, data for 7 women were removed from the analysis. For the remaining subjects, in the group with elevated BP, prevalence of WCH was 29.2% (42/144), Duration of pregnancy was similar in the normotensive and WCH groups (39.6 vs 39.8 weeks; P = .50), but shorter (38.3 weeks; P<.001) in the true hypertension group. Incidence of preeclampsia was similar in the normotensive and WCH groups (5.8% vs 7.1%; P = .86) but higher in the true hypertension group (61.7%; P<.001). Frequency of cesarean delivery was lower in the normotensive (12.4%) than in the WCH (45.2%; P = .008) and true hypertension (41.1%; P = .009) groups. Neonatal weight was lower (P<.001) in the true hypertension (mean, 2911 g) than in the normotensive (3336 g) and WCH groups (3435 g), which did not differ (P = .68). The duration of neonatal hospital stay did not differ between the normotensive and the WCH group (5.3 vs 6.9 days; P = .13) but was longer in the true hypertension group (12.3 days; P<.001). Conclusions In women with elevated BP during their third trimester of pregnancy, 24-hour BP was superior to office BP (distinguishing true hypertension from WCH) for prediction of the outcome of pregnancy. Outcomes in the normotensive and WCH group were comparable, but the increased incidence of cesarean delivery in the WCH group may reflect decision-making processes influenced by office BP.	Assisi Hosp, Div Med, Assisi, Italy; Assisi Hosp, Div Obstet, Assisi, Italy; Assisi Hosp, Div Neonatol, Assisi, Italy; Hosp R Silvestrini, Cardiovasc Dept, Perugia, Italy		Bellomo, G (corresponding author), Via San Bonaventura 2, I-06121 Perugia, Italy.							Barron WM, 1995, MED DISORDERS PREGNA, P1; BELLOMO G, 1995, J HUM HYPERTENS, V9, P617; BENEDETTO C, 1996, ITAL J GYNAECOL OBST, V4, P129; Biswas A, 1997, ACTA OBSTET GYN SCAN, V76, P829, DOI 10.3109/00016349709024360; Brown MA, 1998, AM J OBSTET GYNECOL, V178, P836, DOI 10.1016/S0002-9378(98)70501-0; CARDILLO C, 1993, HYPERTENSION, V21, P836, DOI 10.1161/01.HYP.21.6.836; CAVALLINI MC, 1995, HYPERTENSION, V26, P413, DOI 10.1161/01.HYP.26.3.413; Churchill D, 1996, OBSTET GYNECOL, V88, P455, DOI 10.1016/0029-7844(96)00192-5; Churchill D, 1997, LANCET, V349, P7, DOI 10.1016/S0140-6736(96)06297-6; CLARK S, 1991, OBSTET GYNECOL, V77, P152; Ferrara LA, 1997, J HYPERTENS, V15, P979, DOI 10.1097/00004872-199715090-00008; Glen SK, 1996, LANCET, V348, P654, DOI 10.1016/S0140-6736(96)02303-3; GOSSE P, 1993, HYPERTENSION, V22, P766, DOI 10.1161/01.HYP.22.5.766; HALLIGAN A, 1993, J HYPERTENS, V11, P869, DOI 10.1097/00004872-199308000-00014; Hermida RC, 1997, HYPERTENSION, V30, P1531, DOI 10.1161/01.HYP.30.6.1531; Homuth V, 1994, Zentralbl Gynakol, V116, P267; JOHENNING AR, 1992, AM J OBSTET GYNECOL, V167, P577, DOI 10.1016/S0002-9378(11)91552-X; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; KRAKOFF LR, 1988, AM HEART J, V116, P1152, DOI 10.1016/0002-8703(88)90180-9; MURRAY C, 1992, AM J OBSTET GYNECOL, V167, P52, DOI 10.1016/S0002-9378(11)91624-X; Peek M, 1996, OBSTET GYNECOL, V88, P1030, DOI 10.1016/S0029-7844(96)00350-X; Penny JA, 1998, AM J OBSTET GYNECOL, V178, P521, DOI 10.1016/S0002-9378(98)70432-6; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; Pickering TG., 1991, AMBULATORY MONITORIN; Pipkin FB, 1998, J HYPERTENS, V16, P221, DOI 10.1097/00004872-199816020-00013; Pose-Reino A., 1996, Blood Pressure, V5, P264, DOI 10.3109/08037059609078058; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Shennan A, 1996, LANCET, V347, P139, DOI 10.1016/S0140-6736(96)90338-4; STAESSEN JA, 1993, J HYPERTENS, V11, P1289; Verdecchia, 1998, Blood Press Monit, V3, P147; Verdecchia P, 1996, LANCET, V348, P1444, DOI 10.1016/S0140-6736(04)70084-7; VERDECCHIA P, 1995, AM J HYPERTENS, V8, P790, DOI 10.1016/0895-7061(95)00151-E; WHITE WB, 1989, JAMA-J AM MED ASSOC, V261, P873; 1990, AM J OBSTET GYNECOL, V163, P1689	34	99	103	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1447	1452		10.1001/jama.282.15.1447	http://dx.doi.org/10.1001/jama.282.15.1447			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535435	Bronze			2022-12-28	WOS:000083111000030
J	Steiner, MJ				Steiner, MJ			Contraceptive effectiveness - What should the counseling message be?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Family Hlth Int, Res Triangle Pk, NC 27709 USA		Steiner, MJ (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.	msteiner@fhi.org						Fu HS, 1999, FAM PLANN PERSPECT, V31, P56, DOI 10.2307/2991640; GODWIN K, 1999, BR J FAM PLANN, V93, P896; Raymond E, 1999, OBSTET GYNECOL, V93, P896, DOI 10.1016/S0029-7844(99)00002-2; Steiner M, 1996, OBSTET GYNECOL, V88, pS24, DOI 10.1016/0029-7844(96)00251-7; Trussell J, 1999, FAM PLANN PERSPECT, V31, P64, DOI 10.2307/2991641; TRUSSELL J, 1998, CONTRACEPTIVE TECHNO, P211	6	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1405	1407		10.1001/jama.282.15.1405	http://dx.doi.org/10.1001/jama.282.15.1405			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535416				2022-12-28	WOS:000083111000001
J	Westhof, E				Westhof, E			RNA catalysis - Chemical diversity in RNA cleavage	SCIENCE			English	Editorial Material							DELTA VIRUS RIBOZYME; HAMMERHEAD RIBOZYME; CRYSTAL-STRUCTURE; MECHANISM		CNRS, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Westhof, E (corresponding author), CNRS, Inst Biol Mol & Cellulaire, 15 Rue R Descartes, F-67084 Strasbourg, France.	westhof@ibmc.u-strasbg.fr						Been MD, 1997, EUR J BIOCHEM, V247, P741, DOI 10.1111/j.1432-1033.1997.00741.x; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; Earnshaw DJ, 1998, NUCLEIC ACIDS RES, V26, P5551, DOI 10.1093/nar/26.24.5551; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; Fersht A., 1985, ENZYME STRUCTURE MEC; Geyer CR, 1997, CHEM BIOL, V4, P579, DOI 10.1016/S1074-5521(97)90244-1; Grosjean H., 1998, MODIFICATION EDITING, DOI [10.1128/9781555818296, DOI 10.1128/9781555818296]; Lilley DMJ, 1999, CURR OPIN STRUC BIOL, V9, P330, DOI 10.1016/S0959-440X(99)80044-X; Nesbitt S, 1997, CHEM BIOL, V4, P619, DOI 10.1016/S1074-5521(97)90247-7; Perreault DM, 1997, ANGEW CHEM INT EDIT, V36, P432, DOI 10.1002/anie.199704321; Perrotta AT, 1999, SCIENCE, V286, P123, DOI 10.1126/science.286.5437.123; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; Roth A, 1998, P NATL ACAD SCI USA, V95, P6027, DOI 10.1073/pnas.95.11.6027; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Sigurdsson ST, 1998, COLD SPRING HARBOR M, P339; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; TANNER NK, 1994, CURR BIOL, V4, P488, DOI 10.1016/S0960-9822(00)00109-3; TANNER NK, 1998, RIBOZYMES GENE THERA, P23	19	14	14	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	1999	286	5437					61	62		10.1126/science.286.5437.61	http://dx.doi.org/10.1126/science.286.5437.61			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10532891				2022-12-28	WOS:000082907400031
J	Costello, A; Azad, K				Costello, A; Azad, K			Shameem Ahmed - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1373	1373		10.1136/bmj.319.7221.1373	http://dx.doi.org/10.1136/bmj.319.7221.1373			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567162	Green Published			2022-12-28	WOS:000083930200053
J	Murali-Krishna, K; Lau, LL; Sambhara, S; Lemonnier, F; Altman, J; Ahmed, R				Murali-Krishna, K; Lau, LL; Sambhara, S; Lemonnier, F; Altman, J; Ahmed, R			Persistence of memory CD8 T cells in MHC class I-deficient mice	SCIENCE			English	Article							SURVIVAL; MATURE; MOLECULES; ANTIGEN; LYMPHOCYTES; SELECTION; NAIVE; VIVO; IMMUNOGLOBULIN; PROLIFERATION	An understanding of how T cell memory is maintained is crucial for the rational design of vaccines. Memory T tells were shown to persist indefinitely in major histocompatibility complex (MHC) class I-deficient mice and retained the ability to make rapid cytokine responses upon reencounter with antigen. In addition, memory CD8 T cells, unlike naive cells, divided without MHC-T cell receptor interactions. This "homeostatic" proliferation is Likely to be important in maintaining memory T cell numbers in the periphery. Thus, after naive CD8 T cells differentiate into memory cells, they evolve an MHC class I-independent "life-style" and do not require further stimulation with specific or cross-reactive antigen for their maintenance.	Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Pasteur Merieux Connaught Canada, N York, ON M2R 3TA, Canada; Inst Pasteur, Dept SIDA & Retrovirus, F-75724 Paris, France	Emory University; Emory University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Ahmed, R (corresponding author), Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA.		Sambhara, Suryaprakash/AAC-4428-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030048, R01AI030048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021496] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30048] Funding Source: Medline; NINDS NIH HHS [NS21496] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; AHMED R, 1996, SCIENCE, V272, P55; Bachmann MF, 1999, J EXP MED, V189, P1521, DOI 10.1084/jem.189.10.1521; Bachmann MF, 1999, EUR J IMMUNOL, V29, P291, DOI 10.1002/(SICI)1521-4141(199901)29:01<291::AID-IMMU291>3.0.CO;2-K; Barthlott T, 1998, J IMMUNOL, V161, P3992; Bender J, 1999, J EXP MED, V190, P367, DOI 10.1084/jem.190.3.367; BEVERLEY PCL, 1990, IMMUNOL TODAY, V11, P203, DOI 10.1016/0167-5699(90)90083-L; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; Boursalian TE, 1999, J IMMUNOL, V162, P3795; Brocker T, 1997, J EXP MED, V186, P1223, DOI 10.1084/jem.186.8.1223; Bruno L, 1996, EUR J IMMUNOL, V26, P3179, DOI 10.1002/eji.1830261251; BRUNO L, 1995, IMMUNITY, V2, P37, DOI 10.1016/1074-7613(95)90077-2; Cho BK, 1999, P NATL ACAD SCI USA, V96, P2976, DOI 10.1073/pnas.96.6.2976; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Ernst B, 1999, IMMUNITY, V11, P173, DOI 10.1016/S1074-7613(00)80092-8; Fitzpatrick DR, 1998, J EXP MED, V188, P103, DOI 10.1084/jem.188.1.103; Goldrath AW, 1999, IMMUNITY, V11, P183, DOI 10.1016/S1074-7613(00)80093-X; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; Irving BA, 1998, SCIENCE, V280, P905, DOI 10.1126/science.280.5365.905; Kedl RM, 1998, J IMMUNOL, V161, P674; Kirberg J, 1997, J EXP MED, V186, P1269, DOI 10.1084/jem.186.8.1269; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Markiewicz MA, 1998, P NATL ACAD SCI USA, V95, P3065, DOI 10.1073/pnas.95.6.3065; MCDONAGH M, 1995, IMMUNOLOGY, V84, P514; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Nesic D, 1998, J IMMUNOL, V160, P3705; PEREIRA P, 1991, INT IMMUNOL, V3, P1077, DOI 10.1093/intimm/3.11.1077; Pestano GA, 1999, SCIENCE, V284, P1187, DOI 10.1126/science.284.5417.1187; Pihlgren M, 1996, J EXP MED, V184, P2141, DOI 10.1084/jem.184.6.2141; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SPRENT J, 1991, J EXP MED, V174, P717, DOI 10.1084/jem.174.3.717; SPRENT J, 1997, CURR OPIN IMMUNOL, V9, P37; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; Viret C, 1999, IMMUNITY, V10, P559, DOI 10.1016/S1074-7613(00)80055-2; Vugmeyster Y, 1998, P NATL ACAD SCI USA, V95, P12492, DOI 10.1073/pnas.95.21.12492; Zimmermann C, 1996, J EXP MED, V183, P1367, DOI 10.1084/jem.183.4.1367; Zimmermann C, 1999, EUR J IMMUNOL, V29, P284, DOI 10.1002/(SICI)1521-4141(199901)29:01<284::AID-IMMU284>3.0.CO;2-C; Zinkernagel RM, 1997, IMMUNOL TODAY, V18, P258, DOI 10.1016/S0167-5699(97)80017-5	50	613	636	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1377	1381		10.1126/science.286.5443.1377	http://dx.doi.org/10.1126/science.286.5443.1377			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558996				2022-12-28	WOS:000083675500048
J	Felix, CA				Felix, CA			Evidence of early start for common acute lymphoblastic leukaemia	LANCET			English	Editorial Material							TEL GENE; LEUKEMIA; CHILDHOOD; FUSION; HEREDITARY; CHILDREN; CANCER		Univ Penn, Childrens Hosp Philadelphia, Sch Med, Joseph Stokes Jr Res Inst,Dept Pediat,Div Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Felix, CA (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Joseph Stokes Jr Res Inst,Dept Pediat,Div Oncol, Philadelphia, PA 19104 USA.							Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; Borkhardt A, 1997, BLOOD, V90, P571, DOI 10.1182/blood.V90.2.571.571_571_577; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GREAVES MF, 1985, LEUKEMIA RES, V9, P715, DOI 10.1016/0145-2126(85)90281-4; GREAVES MF, 1993, LEUKEMIA, V7, P349; GURNEY JG, 1995, CANCER, V75, P2186, DOI 10.1002/1097-0142(19950415)75:8<2186::AID-CNCR2820750825>3.0.CO;2-F; Knudson AG, 1997, ANN NY ACAD SCI, V833, P58, DOI 10.1111/j.1749-6632.1997.tb48593.x; LINET MS, 1997, NEW ENGL J MED, V337, P44; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Rubnitz JE, 1997, J CLIN ONCOL, V15, P1150, DOI 10.1200/JCO.1997.15.3.1150; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Wiemels JL, 1999, CANCER RES, V59, P4075	16	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1486	1487		10.1016/S0140-6736(99)00339-6	http://dx.doi.org/10.1016/S0140-6736(99)00339-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551488	hybrid			2022-12-28	WOS:000083411300002
J	Larcombe, J				Larcombe, J			Clinical evidence - Urinary tract infection in children	BRITISH MEDICAL JOURNAL			English	Review							PRIMARY VESICOURETERAL REFLUX; CHILDHOOD; PYELONEPHRITIS; MANAGEMENT; FOLLOW; TRIAL											Benador D, 1997, LANCET, V349, P17, DOI 10.1016/S0140-6736(96)06126-0; BERG UB, 1992, J UROLOGY, V148, P1715, DOI 10.1016/S0022-5347(17)37012-X; Dick PT, 1996, J PEDIATR-US, V128, P15, DOI 10.1016/S0022-3476(96)70422-5; Garin EH, 1998, PEDIATR NEPHROL, V12, P249, DOI 10.1007/s004670050448; Greenfield SP, 1997, J UROLOGY, V158, P574, DOI 10.1016/S0022-5347(01)64556-7; JACOBSON SH, 1989, BMJ-BRIT MED J, V299, P703, DOI 10.1136/bmj.299.6701.703; Jodal U, 1987, Infect Dis Clin North Am, V1, P713; LOHR JA, 1977, PEDIATRICS, V59, P562; MARTINELL J, 1995, PEDIATR NEPHROL, V9, P131, DOI 10.1007/BF00860724; MOFFATT M, 1988, AM J DIS CHILD, V142, P57, DOI 10.1001/archpedi.1988.02150010067024; PYLKKANEN J, 1981, ACTA PAEDIATR SCAND, V70, P879, DOI 10.1111/j.1651-2227.1981.tb06244.x; Sciagra R, 1996, J UROLOGY, V155, P2052, DOI 10.1016/S0022-5347(01)66104-4; SHANON A, 1990, J PEDIATR-US, V117, P171, DOI 10.1016/S0022-3476(05)80525-6; SMELLIE JM, 1981, KIDNEY INT, V20, P717, DOI 10.1038/ki.1981.201; SMELLIE JM, 1976, BRIT MED J, V2, P203, DOI 10.1136/bmj.2.6029.203; SMELLIE JM, 1978, LANCET, V2, P175; SMELLIE JM, 1992, J UROLOGY, V148, P1676, DOI 10.1016/S0022-5347(17)37000-3; SMELLIE JM, 1992, PEDIATR NEPHROL, V6, P223, DOI 10.1007/BF00878353; Stark H, 1997, PEDIATR NEPHROL, V11, P174, DOI 10.1007/s004670050252; WEISS R, 1992, J UROLOGY, V148, P1667, DOI 10.1016/S0022-5347(17)36998-7	20	45	49	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1173	1175		10.1136/bmj.319.7218.1173	http://dx.doi.org/10.1136/bmj.319.7218.1173			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541510	Green Published			2022-12-28	WOS:000083536200025
J	Shann, F				Shann, F			Haemophilus influenzae pneumonia: type b or non-type b?	LANCET			English	Editorial Material							PAPUA-NEW-GUINEA; CHILDREN; ETIOLOGY; PAKISTAN		Royal Childrens Hosp, Intens Care Unit, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne	Shann, F (corresponding author), Royal Childrens Hosp, Intens Care Unit, Flemington Rd, Parkville, Vic 3052, Australia.		Shann, Frank/C-9510-2011					ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008; GRATTEN M, 1991, PAPUA NEW GUINEA MED, V34, P185; MOXON ER, 1991, REV INFECT DIS, V13, pS518; MUSHER DM, 1982, ARCH INTERN MED, V142, P448, DOI 10.1001/archinte.142.3.632; SHANN F, 1984, LANCET, V2, P537; STGEME JW, 1993, INFECT AGENT DIS, V2, P1; Straus WL, 1998, LANCET, V352, P270, DOI 10.1016/S0140-6736(97)10294-X; Utsunomiya Y, 1998, J TROP PEDIATRICS, V44, P338, DOI 10.1093/tropej/44.6.338; WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553; WEINBERG GA, 1990, REV INFECT DIS, V12, pS1017; WEINBERG GA, 1989, J INFECT DIS, V160, P634, DOI 10.1093/infdis/160.4.634; WONG SN, 1991, J PAEDIATR CHILD H, V27, P113, DOI 10.1111/j.1440-1754.1991.tb00364.x	12	20	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1488	1490		10.1016/S0140-6736(99)00232-9	http://dx.doi.org/10.1016/S0140-6736(99)00232-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551490				2022-12-28	WOS:000083411300004
J	Ahmed, A; Sesti, F; Ilan, N; Shih, TM; Sturley, SL; Goldstein, SAN				Ahmed, A; Sesti, F; Ilan, N; Shih, TM; Sturley, SL; Goldstein, SAN			A molecular target for viral killer toxin: TOK1 potassium channels	CELL			English	Article							DOUBLE-STRANDED-RNA; RECTIFYING K+ CHANNEL; 2 PORE DOMAINS; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL DOMAINS; HANSENULA-ANOMALA; YEAST; PREPROTOXIN; EXPRESSION; GENE	Killer strains of S. cerevisiae harbor double-stranded RNA viruses and secrete protein toxins that kill virus-free cells. The K1 killer toxin acts on sensitive yeast cells to perturb potassium homeostasis and cause cell death. Here, the toxin is shown to activate the plasma membrane potassium channel of S. cerevisiae, TOK1. Genetic deletion of TOK1 confers toxin resistance; overexpression increases susceptibility. Cells expressing TOK1 exhibit toxin-induced potassium flux; those without the gene do not. K1 toxin acts in the absence of other viral or yeast products: toxin synthesized from a cDNA increases open probability of single TOK1 channels (via reversible destabilization of closed states) whether channels are studied in yeast cells or X. laevis oocytes.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, Dept Physiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, Dept Pediat, New York, NY 10032 USA	Yale University; Yale University; Columbia University; Columbia University	Goldstein, SAN (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pediat, 333 Cedar St, New Haven, CT 06536 USA.	steve.goldstein@yale.edu	Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061; Ahmed, Aamir/0000-0001-7405-5336				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; ALAIDROOS K, 1978, CAN J MICROBIOL, V24, P228, DOI 10.1139/m78-041; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Bertl A, 1998, J MEMBRANE BIOL, V162, P67, DOI 10.1007/s002329900343; BOONE C, 1990, J CELL BIOL, V110, P1833, DOI 10.1083/jcb.110.5.1833; BOONE C, 1986, CELL, V46, P105, DOI 10.1016/0092-8674(86)90864-0; BOSTIAN KA, 1984, CELL, V36, P741, DOI 10.1016/0092-8674(84)90354-4; Brachmann CB, 1998, YEAST, V14, P115; BUSSEY H, 1979, J BACTERIOL, V140, P888, DOI 10.1128/JB.140.3.888-892.1979; BUSSEY H, 1981, ADV MICROB PHYSIOL, V22, P93, DOI 10.1016/S0065-2911(08)60326-4; BUSSEY H, 1976, ANTIMICROB AGENTS CH, V9, P352, DOI 10.1128/AAC.9.2.352; BUSSEY H, 1990, EXPERIENTIA, V46, P193, DOI 10.1007/BF02027313; BUSSEY H, 1973, J BACTERIOL, V113, P1193, DOI 10.1128/JB.113.3.1193-1197.1973; CHENG RH, 1994, J MOL BIOL, V244, P255, DOI 10.1006/jmbi.1994.1726; Colquhoun David, 1995, P483; DELAPENA P, 1980, BIOCHEM BIOPH RES CO, V96, P544, DOI 10.1016/0006-291X(80)91390-X; DELAPENA P, 1981, J BIOL CHEM, V256, P420; Fairman C, 1999, J MEMBRANE BIOL, V168, P149, DOI 10.1007/s002329900505; Goldstein SAN, 1998, J MOL MED-JMM, V76, P13, DOI 10.1007/s109-1998-8100-0; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; ICHO T, 1989, J BIOL CHEM, V264, P6716; Ilan N, 1999, BIOPHYS J, V76, pA411; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KURZWEILOVA H, 1993, FOLIA MICROBIOL, V38, P524, DOI 10.1007/BF02814408; Loukin SH, 1997, EMBO J, V16, P4817, DOI 10.1093/emboj/16.16.4817; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Magliani W, 1997, CLIN MICROBIOL REV, V10, P369, DOI 10.1128/CMR.10.3.369; Bevan E. A., 1963, Genetics today. Proceedings of the XI International Congress of Genetics, The Hague, The Netherlands, September 1963., V1, P202; MARTINAC B, 1990, P NATL ACAD SCI USA, V87, P6228, DOI 10.1073/pnas.87.16.6228; McIntosh J M, 1999, Methods Enzymol, V294, P605; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; MURPHY N, 1986, LANCET, V1, P291; PALFREE RGE, 1979, EUR J BIOCHEM, V93, P487, DOI 10.1111/j.1432-1033.1979.tb12847.x; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; PETTOELLOMANTOVANI M, 1995, GASTROENTEROLOGY, V109, P1900, DOI 10.1016/0016-5085(95)90757-2; POLONELLI L, 1986, MYCOPATHOLOGIA, V96, P103, DOI 10.1007/BF00436668; Roberts SK, 1999, J BACTERIOL, V181, P291, DOI 10.1128/JB.181.1.291-297.1999; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; Schmitt MJ, 1995, ARCH MICROBIOL, V164, P435; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SIKORSKI RS, 1989, GENETICS, V122, P19; SKIPPER N, 1984, EMBO J, V3, P107, DOI 10.1002/j.1460-2075.1984.tb01769.x; SKIPPER N, 1977, J BACTERIOL, V129, P668, DOI 10.1128/JB.129.2.668-677.1977; STARMER WT, 1987, CAN J MICROBIOL, V33, P783, DOI 10.1139/m87-134; STURLEY SL, 1986, EMBO J, V5, P3381, DOI 10.1002/j.1460-2075.1986.tb04654.x; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; THIELE DJ, 1982, NUCLEIC ACIDS RES, V10, P6903, DOI 10.1093/nar/10.21.6903; VANVUUREN HJJ, 1992, AM J ENOL VITICULT, V43, P119; Vergani P, 1997, FEBS LETT, V405, P337, DOI 10.1016/S0014-5793(97)00211-1; WICKNER RB, 1974, J BACTERIOL, V117, P1356, DOI 10.1128/JB.117.3.1356-1357.1974; Wickner RB, 1996, ANNU REV GENET, V30, P109, DOI 10.1146/annurev.genet.30.1.109; WICKNER RB, 1992, ANNU REV MICROBIOL, V46, P347, DOI 10.1146/annurev.micro.46.1.347; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; ZHU H, 1991, MOL CELL BIOL, V11, P175, DOI 10.1128/MCB.11.1.175	56	70	72	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	1999	99	3					283	291		10.1016/S0092-8674(00)81659-1	http://dx.doi.org/10.1016/S0092-8674(00)81659-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555144	hybrid			2022-12-28	WOS:000083440600006
J	He, TC; Chan, TA; Vogelstein, B; Kinzler, KW				He, TC; Chan, TA; Vogelstein, B; Kinzler, KW			PPAR delta is an APC-regulated target of nonsteroidal anti-inflammatory drugs	CELL			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; TUMOR-SUPPRESSOR PROTEIN; HUMAN COLORECTAL-CANCER; RETINOID-X-RECEPTOR; PEROXISOME-PROLIFERATOR; BETA-CATENIN; FATTY-ACIDS; COLON-CANCER; ANTIINFLAMMATORY DRUGS; ADENOMATOUS POLYPOSIS	PPAR delta was identified as a target of APC through the analysis of global gene expression profiles in human colorectal cancer (CRC) cells. PPAR delta expression was elevated in CRCs and repressed by APC in CRC cells. This repression was mediated by beta-catenin/Tcf-4-responsive elements in the PPAR delta promotor. The ability of PPARs to bind eicosanoids suggested that PPAR delta might be a target of chemopreventive nonsteroidal anti-inflammatory drugs (NSAIDs). Reporters containing PPAR delta-responsive elements were repressed by the NSAID sulindac. Furthermore, sulindac was able to disrupt the ability of PPAR delta to bind its recognition sequences. These findings suggest that NSAIDs inhibit tumorigenesis through inhibition of PPAR delta, the gene for which is normally regulated by APC.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Howard Hughes Med Inst, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University	Kinzler, KW (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.	kinzlke@welchlink.welch.jhu.edu	Chan, Timothy A/ABD-5850-2021		NCI NIH HHS [R37 CA057345, P50 CA062924, CA57345, CA62924, R01 CA057345] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924, R37CA057345, R01CA057345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahnen DJ, 1998, EUR J SURG, V164, P111, DOI 10.1080/11024159850191544; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Charalambous D, 1998, J GASTROEN HEPATOL, V13, P1195; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; JOW L, 1995, J BIOL CHEM, V270, P3836, DOI 10.1074/jbc.270.8.3836; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NARISAWA T, 1984, J CANCER RES CLIN, V108, P239, DOI 10.1007/BF00402475; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2909; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Reddy BS, 1999, CANCER RES, V59, P3387; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; SANO H, 1995, CANCER RES, V55, P3785; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Shattuck-Brandt RL, 1999, MOL CARCINOGEN, V24, P177, DOI 10.1002/(SICI)1098-2744(199903)24:3<177::AID-MC4>3.0.CO;2-6; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Simmons DL, 1999, P NATL ACAD SCI USA, V96, P3275, DOI 10.1073/pnas.96.6.3275; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thun MJ, 1997, ADV EXP MED BIOL, V400, P395; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VANDENHEUVEL JP, 1999, J NUTR, V129, P575; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	61	980	1029	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	1999	99	3					335	345		10.1016/S0092-8674(00)81664-5	http://dx.doi.org/10.1016/S0092-8674(00)81664-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555149	Green Accepted, hybrid			2022-12-28	WOS:000083440600011
J	Lahn, BT; Page, DC				Lahn, BT; Page, DC			Four evolutionary strata on the human X chromosome	SCIENCE			English	Article							HUMAN Y-CHROMOSOME; MAMMALIAN SEX-CHROMOSOMES; KALLMANN SYNDROME GENE; PROTEIN-KINASE GENE; RNA-BINDING PROTEIN; PSEUDOAUTOSOMAL REGION; HUMAN GENOME; MARSUPIAL-X; INACTIVATION; HOMOLOG	Human sex chromosomes evolved from autosomes. Nineteen ancestral autosomal genes persist as differentiated homologs on the X and Y chromosomes. The ages of individual X-Y gene pairs (measured by nucleotide divergence) and the Locations of their X members on the X chromosome were found to be highly correlated. Age decreased in stepwise fashion from the distal long arm to the distal short arm in at least four "evolutionary strata." Human sex chromosome evolution was probably punctuated by at Least four events, each suppressing X-Y recombination in one stratum, without disturbing gene order on the X chromosome. The first event, which marked the beginnings of X-Y differentiation, occurred about 240 to 320 million years ago, shortly after divergence of the mammalian and avian lineages.	MIT, Howard Hughes Med Inst, Whitehead Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lahn, BT (corresponding author), MIT, Howard Hughes Med Inst, Whitehead Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	dcpage@wi.mit.edu			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000257] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00257] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; BENGTSSON BO, 1987, ANN HUM GENET, V51, P57, DOI 10.1111/j.1469-1809.1987.tb00865.x; BLAIR HJ, 1994, GENOMICS, V19, P215, DOI 10.1006/geno.1994.1050; Brown CJ, 1997, AM J HUM GENET, V60, P1333, DOI 10.1086/515488; Bull J.J., 1983, EVOLUTION SEX DETERM; CHANDRA HS, 1985, P NATL ACAD SCI USA, V82, P6947, DOI 10.1073/pnas.82.20.6947; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Delbridge ML, 1999, NAT GENET, V22, P223, DOI 10.1038/10279; DELCASTILLO I, 1992, NAT GENET, V2, P305, DOI 10.1038/ng1292-305; DEVER TE, 1994, J BIOL CHEM, V269, P3212; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; FOSTER JW, 1994, P NATL ACAD SCI USA, V91, P1927, DOI 10.1073/pnas.91.5.1927; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; Fridolfsson AK, 1998, P NATL ACAD SCI USA, V95, P8147, DOI 10.1073/pnas.95.14.8147; GONDO H, 1987, J IMMUNOL, V139, P3840; Graves JAM, 1995, PHILOS T R SOC B, V350, P305, DOI 10.1098/rstb.1995.0166; Graves JAM, 1996, ANNU REV GENET, V30, P233, DOI 10.1146/annurev.genet.30.1.233; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; INCERTI B, 1992, NAT GENET, V2, P311, DOI 10.1038/ng1292-311; Jegalian K, 1998, NATURE, V394, P776, DOI 10.1038/29522; Jones MH, 1996, HUM MOL GENET, V5, P1695, DOI 10.1093/hmg/5.11.1695; KLINK A, 1995, HUM MOL GENET, V4, P869, DOI 10.1093/hmg/4.5.869; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; Li W. H, 1997, MOL EVOLUTION; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Mazeyrat S, 1999, NAT GENET, V22, P224, DOI 10.1038/10282; Meroni G, 1996, HUM MOL GENET, V5, P423, DOI 10.1093/hmg/5.4.423; Mitchell MJ, 1998, HUM MOL GENET, V7, P429, DOI 10.1093/hmg/7.3.429; MITCHELL MJ, 1992, NATURE, V359, P528, DOI 10.1038/359528a0; Mu J, 1997, J BIOL CHEM, V272, P27589, DOI 10.1074/jbc.272.44.27589; NAKAHORI Y, 1991, GENOMICS, V9, P264, DOI 10.1016/0888-7543(91)90251-9; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PILBEAM D, 1984, SCI AM, V250, P84, DOI 10.1038/scientificamerican0384-84; Rice WR, 1996, BIOSCIENCE, V46, P331, DOI 10.2307/1312947; Schiebel K, 1997, HUM MOL GENET, V6, P1985, DOI 10.1093/hmg/6.11.1985; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SILVER LM, 1993, TRENDS GENET, V9, P250, DOI 10.1016/0168-9525(93)90090-5; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; SPENCER JA, 1991, GENOMICS, V9, P598, DOI 10.1016/0888-7543(91)90352-F; SPENCER JA, 1991, GENOMICS, V11, P339, DOI 10.1016/0888-7543(91)90141-Z; STEVANOVIC M, 1993, HUM MOL GENET, V2, P2013, DOI 10.1093/hmg/2.12.2013; SUN C, IN PRESS NATURE GENE; TODER R, 1995, HUM GENET, V95, P22; Toder R, 1998, MAMM GENOME, V9, P373, DOI 10.1007/s003359900772; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; WATSON JM, 1992, GENOMICS, V14, P785, DOI 10.1016/S0888-7543(05)80187-9; WELLER PA, 1995, HUM MOL GENET, V4, P859, DOI 10.1093/hmg/4.5.859; Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9; WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7	58	653	676	1	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					964	967		10.1126/science.286.5441.964	http://dx.doi.org/10.1126/science.286.5441.964			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542153				2022-12-28	WOS:000083368500048
J	Vanholder, R; Lameire, N				Vanholder, R; Lameire, N			Does biocompatibility of dialysis membranes affect recovery of renal function and survival?	LANCET			English	Editorial Material							PROGNOSTIC FACTORS; FAILURE; MULTICENTER; RISK		State Univ Ghent Hosp, Dept Med, Div Renal, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital	Vanholder, R (corresponding author), State Univ Ghent Hosp, Dept Med, Div Renal, B-9000 Ghent, Belgium.							Assouad M., 1996, Journal of the American Society of Nephrology, V7, P1437; Brivet FG, 1996, CRIT CARE MED, V24, P192, DOI 10.1097/00003246-199602000-00003; COSENTINO F, 1994, NEPHROL DIAL TRANSPL, V9, P179; Gastaldello K., 1996, Journal of the American Society of Nephrology, V7, P1447; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; Himmelfarb J, 1998, J AM SOC NEPHROL, V9, P257; Himmelfarb J, 1997, Adv Ren Replace Ther, V4, P72; KURTAL H, 1995, ARTIF ORGANS, V19, P391, DOI 10.1111/j.1525-1594.1995.tb02347.x; Liano F, 1996, KIDNEY INT, V50, P811, DOI 10.1038/ki.1996.380; Mehta Ravindra, 1996, Journal of the American Society of Nephrology, V7, P1457; Neveu H, 1996, NEPHROL DIAL TRANSPL, V11, P293, DOI 10.1093/oxfordjournals.ndt.a027256; SCHIFFL H, 1995, ASAIO J, V41, pM709, DOI 10.1097/00002480-199507000-00104; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; SCHULMAN G, 1991, KIDNEY INT, V40, P1069, DOI 10.1038/ki.1991.316; Splendiani G, 1996, ARTIF ORGANS, V20, P281, DOI 10.1111/j.1525-1594.1996.tb04442.x	15	20	20	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1316	1318		10.1016/S0140-6736(99)00298-6	http://dx.doi.org/10.1016/S0140-6736(99)00298-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533855				2022-12-28	WOS:000083149900004
J	Kelley, JL; Graves, JA; Magurran, AE				Kelley, JL; Graves, JA; Magurran, AE			Familiarity breeds contempt in guppies	NATURE			English	Article							POECILIA-RETICULATA; BEHAVIOR; FISH		Univ St Andrews, Inst Environm & Evolutionary Biol, St Andrews KY16 9TS, Fife, Scotland	University of St Andrews	Kelley, JL (corresponding author), Univ St Andrews, Inst Environm & Evolutionary Biol, Bute Bldg, St Andrews KY16 9TS, Fife, Scotland.		Kelley, Jennifer L./H-5177-2014; Magurran, Anne E/D-7463-2013	Kelley, Jennifer L./0000-0002-8223-7241; Magurran, Anne/0000-0002-0036-2795				ADLER NT, 1978, BIOL DETERMINANTS SE, P656; DUGATKIN LA, 1993, REV FISH BIOL FISHER, V3, P368, DOI 10.1007/BF00043386; FARR JA, 1977, EVOLUTION, V31, P162, DOI 10.1111/j.1558-5646.1977.tb00993.x; Griffiths SW, 1997, ANIM BEHAV, V53, P945, DOI 10.1006/anbe.1996.0315; Griffiths SW, 1998, ANIM BEHAV, V56, P689, DOI 10.1006/anbe.1998.0767; Griffiths SW, 1997, P ROY SOC B-BIOL SCI, V264, P547, DOI 10.1098/rspb.1997.0078; HEINRICH W, 1986, BIOL ZBL, V105, P491; Houde A.E., 1997, SEX COLOR MATE CHOIC; Hughes KA, 1999, ANIM BEHAV, V58, P907, DOI 10.1006/anbe.1999.1225; Liley N. R., 1966, Behaviour Suppl, V13, P1; MAGURRAN AE, 1994, P ROY SOC B-BIOL SCI, V258, P89, DOI 10.1098/rspb.1994.0147; MILINSKI M, 1990, BEHAV ECOL SOCIOBIOL, V27, P17; WILSON JR, 1963, J COMP PHYSIOL PSYCH, V56, P636, DOI 10.1037/h0042469	13	121	122	1	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					661	662		10.1038/44314	http://dx.doi.org/10.1038/44314			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537103				2022-12-28	WOS:000083207400043
J	Bowling, A				Bowling, A			Ageism in cardiology	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; RATIONING HEALTH-CARE; CORONARY-REVASCULARIZATION; ELDERLY PEOPLE; UNSTABLE ANGINA; UNITED-KINGDOM; THROMBOLYSIS; DEBATE; ANGIOGRAPHY; EXCLUSION		UCL Royal Free & UCL Med Sch, Ctr Hlth Informat & Multiprofess Educ, Res Unit Ageing & Populat Studies, London N19 5NF, England	University of London; University College London	Bowling, A (corresponding author), 222 Euston Rd, London NW1 2DA, England.	a.bowling.chime@ucl.ac.uk						*AUD COMM, 1995, DEAR OUR HEARTS COMM; BLACK N, 1995, J EPIDEMIOL COMMUN H, V49, P408, DOI 10.1136/jech.49.4.408; BLACK N, 1994, BRIT HEART J, V72, P317; Bowling A, 1996, BRIT MED J, V312, P670; BOWLING A, 1993, WHAT PEOPLE SAY PRIO; BOWLING A, 1999, J EPIDEMIOL COMMUN H, V53, P658; Bugeja G, 1997, BRIT MED J, V315, P1059, DOI 10.1136/bmj.315.7115.1059; *CARN I, 1993, LIF WORK LIV 3 AG FI; Cheitlin MD, 1996, CLIN GERIATR MED, V12, P195, DOI 10.1016/S0749-0690(18)30253-2; DUDLEY NJ, 1992, AGE AGEING, V21, P95, DOI 10.1093/ageing/21.2.95; ELDER AT, 1991, BRIT MED J, V303, P950, DOI 10.1136/bmj.303.6808.950; Evans JG, 1997, BRIT MED J, V314, P822, DOI 10.1136/bmj.314.7083.822; Frankel, 1996, PRIORITY SETTING HLT; GAFFNEY B, 1995, BRIT HEART J, V73, P385; Gilbert T, 1999, HEART, V82, P138, DOI 10.1136/hrt.82.2.138; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; McMechan SR, 1998, BMJ-BRIT MED J, V317, P1334, DOI 10.1136/bmj.317.7169.1334; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; Pilote L, 1996, NEW ENGL J MED, V335, P1198, DOI 10.1056/NEJM199610173351606; RIVLIN MM, 1995, BRIT MED J, V310, P1179, DOI 10.1136/bmj.310.6988.1179; *ROYAL COLL PHYS, 1991, CARD INT ELD PAT; Sculpher MJ, 1998, HEALTH TECHNOL ASSES, V2, P1; Stone PH, 1996, JAMA-J AM MED ASSOC, V275, P1104, DOI 10.1001/jama.275.14.1104; Sutton GC, 1997, BMJ-BRIT MED J, V315, P1032, DOI 10.1136/bmj.315.7115.1032; Wenger NK, 1997, BMJ-BRIT MED J, V315, P1085, DOI 10.1136/bmj.315.7115.1085; Williams A, 1997, BRIT MED J, V314, P820, DOI 10.1136/bmj.314.7083.820; Woods KL, 1996, LANCET, V347, P1203, DOI 10.1016/S0140-6736(96)90732-1; Yusuf S, 1998, LANCET, V352, P507, DOI 10.1016/S0140-6736(97)11162-X	29	138	138	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1353	1355		10.1136/bmj.319.7221.1353	http://dx.doi.org/10.1136/bmj.319.7221.1353			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567146	Green Published			2022-12-28	WOS:000083930200030
J	Lacroix, A; Hamet, P; Boutin, J				Lacroix, A; Hamet, P; Boutin, J			Leuprolide acetate therapy in luteinizing hormone-dependent Cushing's syndrome.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; CHORIONIC-GONADOTROPIN RECEPTORS; ADRENAL ADENOMA; ADRENOCORTICAL ADENOMA; PREGNANCY; TESTOSTERONE; EXPRESSION; WOMAN; TUMOR; HCG		CHUM, Hotel Dieu, Res Ctr, Dept Med,Div Endocrinol, Montreal, PQ H2W 1T8, Canada	Laval University; Universite de Montreal	Lacroix, A (corresponding author), CHUM, Hotel Dieu, Res Ctr, Dept Med,Div Endocrinol, 3850 St Urbain, Montreal, PQ H2W 1T8, Canada.		Lacroix, Andre/AAI-5645-2020					Arnaldi G, 1998, J CLIN ENDOCR METAB, V83, P2029, DOI 10.1210/jc.83.6.2029; Barnes RB, 1997, J CLIN ENDOCR METAB, V82, P1746, DOI 10.1210/jc.82.6.1746; Chabre O, 1998, J CLIN ENDOCR METAB, V83, P3134, DOI 10.1210/jc.83.9.3134; CLOSE CF, 1993, CLIN ENDOCRINOL, V39, P375, DOI 10.1111/j.1365-2265.1993.tb02380.x; deHerder WW, 1996, J CLIN ENDOCR METAB, V81, P3168, DOI 10.1210/jc.81.9.3168; DELANGE WE, 1980, CLIN ENDOCRINOL, V12, P21, DOI 10.1111/j.1365-2265.1980.tb03128.x; IDA K, 1997, CLIN ENDOCRINOL, V47, P739; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; Lacroix A, 1999, ENDOCRINOLOGIST, V9, P9, DOI 10.1097/00019616-199901000-00004; Lacroix A, 1997, J CLIN ENDOCR METAB, V82, P2414, DOI 10.1210/jc.82.8.2414; Lacroix A, 1997, NEW ENGL J MED, V337, P1429, DOI 10.1056/NEJM199711133372004; Lebrethon MC, 1998, J CLIN ENDOCR METAB, V83, P4514, DOI 10.1210/jc.83.12.4514; LEFEBVRE H, 1992, NEUROSCIENCE, V47, P999, DOI 10.1016/0306-4522(92)90047-6; Lefebvre H, 1998, HORM METAB RES, V30, P398, DOI 10.1055/s-2007-978904; LEINONEN P, 1991, CLIN ENDOCRINOL, V34, P31, DOI 10.1111/j.1365-2265.1991.tb01732.x; MATSUKURA S, 1980, CANCER RES, V40, P3768; MILLINGTON DS, 1976, ACTA ENDOCRINOL-COP, V82, P561, DOI 10.1530/acta.0.0820561; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; MIRCESCU H, 1998, 80 ANN M END SOC NEW, P80; N'Diaye N, 1998, HORM METAB RES, V30, P440, DOI 10.1055/s-2007-978912; N'Diaye N, 1999, J CLIN ENDOCR METAB, V84, P2616, DOI 10.1210/jc.84.8.2616; Pabon JE, 1996, J CLIN ENDOCR METAB, V81, P2397, DOI 10.1210/jc.81.6.2397; Rao CV, 1996, J PHYSIOL PHARMACOL, V47, P41; RESCHINI E, 1978, OBSTET GYNECOL, V51, P598, DOI 10.1097/00006250-197805000-00019; REZNIK Y, 1992, NEW ENGL J MED, V327, P981, DOI 10.1056/NEJM199210013271403; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SERONFERRE M, 1978, J CLIN ENDOCR METAB, V46, P834; SMITH HC, 1978, AUST NZ J MED, V8, P171, DOI 10.1111/j.1445-5994.1978.tb04506.x; TAKAHASHI H, 1978, ACTA ENDOCRINOL-COP, V89, P701, DOI 10.1530/acta.0.0890701; Wallace C, 1996, J CLIN ENDOCR METAB, V81, P15, DOI 10.1210/jc.81.1.15; WIELAND RG, 1971, OBSTET GYNECOL, V38, P841; Willenberg HS, 1998, NEW ENGL J MED, V339, P27, DOI 10.1056/NEJM199807023390105	32	175	181	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1999	341	21					1577	1581		10.1056/NEJM199911183412104	http://dx.doi.org/10.1056/NEJM199911183412104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	256GF	10564687				2022-12-28	WOS:000083717000004
J	Stevens, A; Milne, R; Lilford, R; Gabbay, J				Stevens, A; Milne, R; Lilford, R; Gabbay, J			Keeping pace with new technologies: systems needed to identify and evaluate them	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Of the three major pressures on health services worldwide-changing demography, growing expectations, and new healthcare interventions (technologies)-the last is generating the most concern and the most dramatic responses, New healthcare technologies are becoming mote numerous, more expensive, and possibly more effective than ever before. About 50 new drugs are launched each year, and the number of new devices, procedures, and ways of providing tare is growing all the time.	Univ Birmingham, Dept Publ Hlth & Epidemiol, Birmingham B15 2TT, W Midlands, England; Univ Southampton, Natl Coordinating Ctr Hlth Technol Assessment, Southampton SO16 7PX, Hants, England; Univ Southampton, Southampton SO16 5ST, Hants, England	University of Birmingham; University of Southampton; University of Southampton	Stevens, A (corresponding author), Univ Birmingham, Dept Publ Hlth & Epidemiol, Birmingham B15 2TT, W Midlands, England.	A.J.Stevens@bham.ac.uk						*ADV GROUP HLTH TE, 1992, ASS EFF HLTH TECHN P; BIRKS J, 1999, COCHRANE LIB; Buxton M, 1996, J Health Serv Res Policy, V1, P35; CHASE D, IN PRESS INT J TECH; Donaldson M, 1992, SETTING PRIORITIES H; EDDY DM, 1989, INT J TECHNOL ASSESS, V5, P484; *HLTH TECHN ASS PR, 1998, ANN REP NHS HLTH TEC; Kelly CA, 1997, BRIT MED J, V314, P693, DOI 10.1136/bmj.314.7082.693; Lilford R, 1998, J Health Serv Res Policy, V3, P159; LILFORD R, IN PRESS BMJ; LILFORD R, 1999, J HLTH SERV RES POLI, V3, P164; MILNE R, 1998, RES DEV NHS EV EV EF; ROBERT G, 1999, INT J TECHNOL ASSESS, V3, P13; Rosen R, 1999, BRIT MED J, V319, P1292, DOI 10.1136/bmj.319.7220.1292; Sculpher M, 1997, J Health Serv Res Policy, V2, P26; STEIN K, 1997, 69 WESS I HLTH RES D; STEVENS A, 1995, HLTH TRENDS, V27, P1994; WOOLF SH, 1990, J CLIN EPIDEMIOL, V43, P891, DOI 10.1016/0895-4356(90)90073-X	18	12	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	1999	319	7220					1291	U36		10.1136/bmj.319.7220.1291	http://dx.doi.org/10.1136/bmj.319.7220.1291			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257MZ	10559044	Green Published			2022-12-28	WOS:000083786900013
J	Gross, SD; Schwab, MS; Lewellyn, AL; Maller, JL				Gross, SD; Schwab, MS; Lewellyn, AL; Maller, JL			Induction of metaphase arrest in cleaving Xenopus embryos in by the protein kinase p90(Rsk)	SCIENCE			English	Article							OOCYTE MATURATION; MAP KINASE; MOS; PHOSPHORYLATION; DOMAINS; ACTIVATION; PP90(RSK); CELLS	Before fertilization, vertebrate eggs are arrested in metaphase of meiosis II by cytostatic factor (CSF), an activity that requires activation of the mitogen-activated protein kinase (MAPK) pathway. To investigate whether CSF arrest is mediated by the protein kinase p90(Rsk), which is phosphorylated and activated by MAPK, a constitutively activated (CA) form of Rsk was expressed in Xenopus embryos. Expression of CA Rsk resulted in cleavage arrest, and cytological analysis showed that arrested blastomeres were in M phase with prominent spindles characteristic of meiotic metaphase. Thus, Rsk appears to be the mediator of MAPK-dependent CSF arrest in vertebrate unfertilized eggs.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.			Gross, Stefan/0000-0002-5645-7304	NIDDK NIH HHS [DK28353] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; FUKASAWA K, 1995, P NATL ACAD SCI USA, V92, P3430, DOI 10.1073/pnas.92.8.3430; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; MOLLER DE, 1994, AM J PHYSIOL, V266, P351; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Roy LM, 1996, ONCOGENE, V12, P2203; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	20	133	141	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1365	1367		10.1126/science.286.5443.1365	http://dx.doi.org/10.1126/science.286.5443.1365			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558992				2022-12-28	WOS:000083675500044
J	Jonas, EA; Buchanan, J; Kaczmarek, LK				Jonas, EA; Buchanan, J; Kaczmarek, LK			Prolonged activation of mitochondrial conductances during synaptic transmission	SCIENCE			English	Article							SQUID GIANT SYNAPSE; PERMEABILITY TRANSITION PORE; DIVALENT-CATIONS; OUTER-MEMBRANE; POSTTETANIC POTENTIATION; TRANSMITTER RELEASE; CHANNEL ACTIVITY; CA2+ TRANSIENTS; CALCIUM; MODULATION	Although ion channels have been detected in mitochondria, scientists have not been able to record ion transport in mitochondria of intact cells. A Variation of the patch clamp technique was used to record ion channel activity from intracellular organelles in the presynaptic terminal of the squid. Electron microscopy indicated that mitochondria are numerous in this terminal and are the only organelles compatible with the tips of the pipettes. Before synaptic stimulation, channel activity was infrequent and its conductance was small, although Large conductances (similar to 0.5 to 2.5 nanosiemens) could be detected occasionally. During a train of action potentials, the conductance of the mitochondrial membrane increased up to 60-fold, The conductance increased after a delay of several hundred milliseconds and continued to increase after stimulation had stopped. Recovery occurred over tens of seconds.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Stanford Univ, Med Ctr, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	Yale University; Stanford University	Kaczmarek, LK (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.	leonard.kaczmarek@yale.edu						ADAMS V, 1989, BIOCHIM BIOPHYS ACTA, V981, P213, DOI 10.1016/0005-2736(89)90031-X; ANTONENKO YN, 1994, BBA-BIOMEMBRANES, V1194, P247, DOI 10.1016/0005-2736(94)90306-9; AUGUSTINE GJ, 1984, J PHYSIOL-LONDON, V346, P257, DOI 10.1113/jphysiol.1984.sp015020; Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BRDICZKA D, 1994, J BIOL CHEM, V269, P27640; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; CHARLTON MP, 1978, J GEN PHYSIOL, V72, P471, DOI 10.1085/jgp.72.4.471; Colombini M, 1996, Ion Channels, V4, P169; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; Dresbach T, 1998, J NEUROSCI, V18, P2923; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Jonas EA, 1997, NEURON, V19, P7, DOI 10.1016/S0896-6273(00)80343-8; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Juin P, 1997, J BIOL CHEM, V272, P6044, DOI 10.1074/jbc.272.9.6044; KINNALLY KW, 1991, BIOCHEM BIOPH RES CO, V176, P1183, DOI 10.1016/0006-291X(91)90410-9; KINNALLY KW, 1994, MOL BIOL MITOCHONDRI, P169; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LEHNINGE.AL, 1970, BIOCHEM J, V119, P128; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; Peng YY, 1998, J NEUROPHYSIOL, V80, P186, DOI 10.1152/jn.1998.80.1.186; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; Pivovarova NB, 1998, J GEN PHYSIOL, V112, p39A; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Schatz G, 1998, NATURE, V395, P439, DOI 10.1038/26620; Scorrano L, 1997, J BIOL CHEM, V272, P12295, DOI 10.1074/jbc.272.19.12295; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V28, P127; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; SZABO I, 1992, J BIOL CHEM, V267, P2940; Tang YG, 1997, NEURON, V18, P483, DOI 10.1016/S0896-6273(00)81248-9	45	76	77	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1999	286	5443					1347	1350		10.1126/science.286.5443.1347	http://dx.doi.org/10.1126/science.286.5443.1347			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558987				2022-12-28	WOS:000083675500039
J	Puigserver, P; Adelmant, C; Wu, ZD; Fan, M; Xu, JM; O'Malley, B; Spiegelman, BM				Puigserver, P; Adelmant, C; Wu, ZD; Fan, M; Xu, JM; O'Malley, B; Spiegelman, BM			Activation of PPAR gamma coactivator-1 through transcription factor docking	SCIENCE			English	Article							STEROID-RECEPTOR COACTIVATOR-1; HISTONE ACETYLTRANSFERASE; ONCOPROTEIN; BINDING; SRC-1; E1A	Transcriptional coactivators have been viewed as constitutively active components, using transcription factors mainly to Localize their functions. Here, it is shown that PPAR gamma coactivator-1 (PGC-1) promotes transcription through the assembly of a complex that includes the histone acetyltransferases steroid receptor coactivator-1 (SRC-1) and CREB binding protein (CBP)/p300. PGC-1 has a Low inherent transcriptional activity when it is not bound to a transcription factor. The docking of PGC-1 to peroxisome proliferator-activated receptor gamma (PPAR gamma) stimulates an apparent conformational change in PGC-1 that permits binding of SRC-1 and CBP/p300, resulting in a Large increase in transcriptional activity. Thus, transcription factor docking switches on the activity of a coactivator protein.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77040 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Baylor College of Medicine	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054477, R56DK054477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZU Z, 1999, CELL, V98, P115	21	465	489	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1999	286	5443					1368	1371		10.1126/science.286.5443.1368	http://dx.doi.org/10.1126/science.286.5443.1368			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558993				2022-12-28	WOS:000083675500045
J	Jones, R; Pearson, J; McGregor, S; Cawsey, AJ; Barrett, A; Craig, N; Atkinson, JM; Gilmour, WH; McEwen, J				Jones, R; Pearson, J; McGregor, S; Cawsey, AJ; Barrett, A; Craig, N; Atkinson, JM; Gilmour, WH; McEwen, J			Randomised trial of personalised computer based information for cancer patients	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; NEEDS; RADIOTHERAPY; CONSULTATION; AUDIOTAPES; EDUCATION; EFFICACY; SCALE	Objective To compare the use and effect of a computer based information system for cancer patients that is personalised using each patient's medical record with a system providing only general information and with information provided in booklets. Design Randomised trial with three groups. Data collected at start of radiotherapy, one week later (when information provided), three weeks later, and three months later. Participants 525 patients started radical radiotherapy; 438 completed follow up. Interventions Two groups were offered information via computer (personalised or general information, or both) with open access to computer thereafter; the third group was offered a selection of information booklets. Outcomes Patients' views and preferences, use of computer and information, and psychological status; doctors' perceptions; cost of interventions. Results More patients offered the personalised information said that they had learnt something new thought the information was relevant, used the computer again, and showed their computer printouts to others. There were no major differences in doctors' perceptions of patients. More of the general computer group were anxious at three months. With an electronic patient record system, in the long run the personalised information system would cost no more than the general system. Full access to booklets cost twice as much as the general system. Conclusions Patients preferred computer systems that provided information from their medical records to systems that just provided general information. This has implications for the design and implementation of electronic patient record systems and reliance on general sources of patient information.	Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Heriot Watt Univ, Dept Comp Sci, Edinburgh EH14 4AS, Midlothian, Scotland; Univ Glasgow, Western Infirm, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow; Heriot Watt University; Beatson Oncology Centre; University of Glasgow	Jones, R (corresponding author), Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland.							Bailey AJ, 1998, J CLIN ONCOL, V16, P3082, DOI 10.1200/JCO.1998.16.9.3082; Bental DS, 1999, PATIENT EDUC COUNS, V36, P171, DOI 10.1016/S0738-3991(98)00133-5; BUCHANAN BG, 1995, ARTIF INTELL MED, V7, P117, DOI 10.1016/0933-3657(94)00029-R; *DEP HLTH, 1998, NHS INF HLTH; DUNN SM, 1993, J CLIN ONCOL, V11, P2279, DOI 10.1200/JCO.1993.11.11.2279; FALLOWFIELD L, 1995, PSYCHO-ONCOLOGY, V4, P197, DOI 10.1002/pon.2960040305; GILHOOLY MLM, 1991, J MED ETHICS, V17, P138, DOI 10.1136/jme.17.3.138; GLIMELIUS B, 1995, PATIENT EDUC COUNS, V25, P171, DOI 10.1016/0738-3991(94)00655-6; Hall A, 1999, EUR J CANCER, V35, P79, DOI 10.1016/S0959-8049(98)00308-6; Harris KA, 1998, CANCER PRACT, V6, P39, DOI 10.1046/j.1523-5394.1998.1998006039.x; HATHAWAY D, 1986, NURS RES, V35, P269; HINDS C, 1995, CANCER NURS, V18, P374; HIRST G, 1997, P 6 INT C US MOD SAR, P107; Jones R, 1999, BRIT MED J, V319, P1247, DOI 10.1136/bmj.319.7219.1247; JONES R, 1994, ELECT PATIENT RECORD; Jones R B, 1993, Health Bull (Edinb), V51, P34; Kreuter MW, 1996, HEALTH EDUC RES, V11, P97, DOI 10.1093/her/11.1.97; Luker KA, 1996, J ADV NURS, V23, P487, DOI 10.1111/j.1365-2648.1996.tb00010.x; MARSHALL WR, 1984, J FAM PRACTICE, V19, P659; MCGARRY E, 1998, CURRENT PERSPECTIVES, P277; MCHUGH P, 1995, BRIT J CANCER, V71, P388, DOI 10.1038/bjc.1995.79; Meredith C, 1996, BMJ-BRIT MED J, V313, P724; MILLER SM, 1995, CANCER, V76, P167, DOI 10.1002/1097-0142(19950715)76:2<167::AID-CNCR2820760203>3.0.CO;2-K; Morton AR, 1998, CURRENT PERSPECTIVES, P94; *NAT CTR ALL, 1996, PAT CTR CANC SERV WH; OSMAN LM, 1994, BRIT MED J, V308, P568, DOI 10.1136/bmj.308.6928.568; RAPOPORT Y, 1993, ANN ONCOL, V4, P69, DOI 10.1093/oxfordjournals.annonc.a058365; SCHWARTZ LP, 1979, HEART LUNG, V8, P540; STREET RL, 1995, CANCER, V76, P2275, DOI 10.1002/1097-0142(19951201)76:11<2275::AID-CNCR2820761115>3.0.CO;2-S; TATTERSALL MHN, 1994, J CLIN ONCOL, V12, P1305, DOI 10.1200/JCO.1994.12.6.1305; WATSON M, 1988, PSYCHOL MED, V18, P203, DOI 10.1017/S0033291700002026; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	32	111	111	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1241	1247		10.1136/bmj.319.7219.1241	http://dx.doi.org/10.1136/bmj.319.7219.1241			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	254RH	10550090	Bronze, Green Published			2022-12-28	WOS:000083625600026
J	Buschbeck, E; Ehmer, B; Hoy, R				Buschbeck, E; Ehmer, B; Hoy, R			Chunk versus point sampling: Visual imaging in a small insect	SCIENCE			English	Article							SPIDER CUPIENNIUS-SALEI; ONE BRAIN; EYES; SYSTEMS	The eyes of strepsipteran insects are very unusual among living insects. In their anatomical organization they may form a modern counterpart to the structural plan proposed for the eyes of some trilobites. Externally they differ from the usual "insect plan" by presenting far fewer but much larger lenses. Beneath each lens is its own independent retina. Anatomical and optical measurements indicate that each of these units is image-forming, so that the visual field is subdivided into and represented by "chunks," unlike the conventional insect compound eye that decomposes the visual image in a pointwise manner. This results in profound changes In the neural centers for vision and implies major evolutionary changes.	Cornell Univ, Ithaca, NY 14853 USA	Cornell University	Ehmer, B (corresponding author), Cornell Univ, Mudd Hall, Ithaca, NY 14853 USA.							BRUNO MS, 1977, J COMP PHYSIOL, V120, P123, DOI 10.1007/BF00619310; DUELLI P, 1994, CELL TISSUE RES, V187, P417; FORDYCE D, 1993, PALEOBIOLOGY, V19, P288, DOI 10.1017/S0094837300000282; GILBERT C, 1994, ANNU REV ENTOMOL, V39, P23; HORRIDGE GA, 1977, ENDEAVOUR, V1, P7, DOI 10.1016/0160-9327(77)90004-7; Kinzelbach R., 1971, Handb Zool Berl, V4, P1; Land M.F., 1981, HDB SENSORY PHYSL, P471, DOI DOI 10.1007/978-3-642-66907-14; LAND MF, 1969, J EXP BIOL, V51, P443; MACCARTHY H R, 1991, Journal of the Entomological Society of British Columbia, V88, P27; MEIXNER J, 1936, HDB ZOOLOGIE, P1349; Nilsson D.-E., 1989, P30; Paulus H.F., 1979, P299; ROSCH P, 1913, Z NATURWISS, V50, P97; Sanchez D., 1915, TRAB LAB INVEST BIOL, V13, P1, DOI DOI 10.5962/BHL.TITLE.37839; SNYDER AW, 1977, J COMP PHYSIOL, V116, P161, DOI 10.1007/BF00605401; STRAUSFELD NJ, 1993, J COMP NEUROL, V328, P63, DOI 10.1002/cne.903280105; STRAUSFELD NJ, 1993, J COMP NEUROL, V328, P43, DOI 10.1002/cne.903280104; Strohm Karl, 1910, Zoologischer Anzeiger Leipzig, V36; TOH Y, 1994, CELL TISSUE RES, V278, P125, DOI 10.1007/BF00305784; WACHMANN E, 1972, Z ZELLFORSCH MIK ANA, V123, P411, DOI 10.1007/BF00335640; WARRANT EJ, 1993, PROG NEUROBIOL, V40, P413, DOI 10.1016/0301-0082(93)90017-M; WILSON M, 1978, J COMP PHYSIOL, V124, P297, DOI 10.1007/BF00661380	22	54	56	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1178	1180		10.1126/science.286.5442.1178	http://dx.doi.org/10.1126/science.286.5442.1178			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550059				2022-12-28	WOS:000083534200049
J	Zijlstra, F; Hoorntje, JCA; de Boer, MJ; Reiffers, S; Miedema, K; Ottervanger, JP; van't Hof, AWJ; Suryapranata, H				Zijlstra, F; Hoorntje, JCA; de Boer, MJ; Reiffers, S; Miedema, K; Ottervanger, JP; van't Hof, AWJ; Suryapranata, H			Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY CORONARY ANGIOPLASTY; LEFT-VENTRICULAR FUNCTION; INTRAVENOUS STREPTOKINASE; CONSERVATIVE TREATMENT; IMMEDIATE ANGIOPLASTY; SECONDARY PREVENTION; HEART-DISEASE; LIMITATION; ISCHEMIA; SIZE	Background As compared with thrombolytic therapy, primary coronary angioplasty results in a higher rate of patency of the infarct-related coronary artery, lower rates of stroke and reinfarction, and higher in-hospital or 30-day survival rates. However, the comparative long-term efficacy of these two approaches has not been carefully studied. Methods We randomly assigned a total of 395 patients with acute myocardial infarction to treatment with angioplasty or intravenous streptokinase. Clinical information was collected for a mean (+/-SD) of 5+/-2 years, and medical charges associated with the two treatments were compared. Results A total of 194 patients were assigned to undergo primary angioplasty, and 201 to receive streptokinase. Mortality was 13 percent in the angioplasty group, as compared with 24 percent in the streptokinase group (relative risk, 0.54; 95 percent confidence interval, 0.36 to 0.87). Nonfatal reinfarction occurred in 6 percent and 22 percent of the two groups, respectively (relative risk, 0.27; 95 percent confidence interval, 0.15 to 0.52). The combined incidence of death and nonfatal reinfarction was also lower among patients assigned to angioplasty than among those assigned to streptokinase, with a relative risk of 0.13 (95 percent confidence interval, 0.05 to 0.37) for early events (within the first 30 days) and a relative risk of 0.62 (95 percent confidence interval, 0.43 to 0.91) for late events (after 30 days). The rates of readmission for heart failure and ischemia were also lower among patients in the angioplasty group than among patients in the streptokinase group. Total medical charges per patient were lower in the angioplasty group ($16,090) than in the streptokinase group ($16,813, P=0.05). Conclusions As compared with thrombolytic therapy with streptokinase, primary coronary angioplasty is associated with better clinical outcomes over five years. (N Engl J Med 1999;341:1413-9.) (C)1999, Massachusetts Medical Society.	Hosp Weezenlanden, Dept Cardiol, NL-8011 JW Zwolle, Netherlands; Hosp Weezenlanden, Dept Nucl Med, NL-8011 JW Zwolle, Netherlands; Hosp Weezenlanden, Dept Clin Chem, NL-8011 JW Zwolle, Netherlands		Zijlstra, F (corresponding author), Hosp Weezenlanden, Dept Cardiol, Groot Wezenland 20, NL-8011 JW Zwolle, Netherlands.	v.derks@diagram-zwolle.nl	de Boer, M.J./H-8014-2014; Suryapranata, H./H-8095-2014					[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BONNEUX L, 1994, AM J PUBLIC HEALTH, V84, P20, DOI 10.2105/AJPH.84.1.20; CALIFF RM, 1990, CIRCULATION, V82, P1847, DOI 10.1161/01.CIR.82.5.1847; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1430, DOI 10.1136/bmj.316.7142.1430; COX DR, 1972, J R STAT SOC B, V34, P187; DEBOER MJ, 1994, CIRCULATION, V90, P753, DOI 10.1161/01.CIR.90.2.753; DEBOER MJ, 1995, EUR HEART J, V16, P1347, DOI 10.1093/oxfordjournals.eurheartj.a060741; DEBOER MJ, 1995, AM J CARDIOL, V76, P830, DOI 10.1016/S0002-9149(99)80238-0; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; Goldberg RJ, 1999, ARCH INTERN MED, V159, P15, DOI 10.1001/archinte.159.1.15; GRANGER CB, 1993, DRUGS, V45, P894; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Julian DG, 1996, EUR HEART J, V17, P43; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLONER RA, 1992, J AM COLL CARDIOL, V20, P314, DOI 10.1016/0735-1097(92)90096-6; Lange RA, 1996, NEW ENGL J MED, V335, P1311; Madsen JK, 1997, CIRCULATION, V96, P748; McCormick D, 1999, ARCH INTERN MED, V159, P561, DOI 10.1001/archinte.159.6.561; Mehta RH, 1998, BMJ-BRIT MED J, V316, P838, DOI 10.1136/bmj.316.7134.838; MEHTA RH, 1998, BMJ-BRIT MED J, V317, P1516; Meier B, 1995, CATHETER CARDIO DIAG, V36, P295, DOI 10.1002/ccd.1810360402; MEIJER A, 1993, CIRCULATION, V87, P1524, DOI 10.1161/01.CIR.87.5.1524; Morgan S, 1999, BRIT MED J, V318, P368, DOI 10.1136/bmj.318.7180.368; Neumann FJ, 1998, CIRCULATION, V98, P2695, DOI 10.1161/01.CIR.98.24.2695; NORRIS RM, 1998, LANCET, V351, P104; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; SIMOONS ML, 1986, J AM COLL CARDIOL, V7, P717, DOI 10.1016/S0735-1097(86)80329-1; Suryapranata H, 1998, CIRCULATION, V97, P2502, DOI 10.1161/01.CIR.97.25.2502; The GUSTO Angiographic Investigators, 1994, NEW ENGL J MED, V330, P516; Weaver WD, 1998, JAMA-J AM MED ASSOC, V279, P1876; ZIJLSTRA F, 1993, NEW ENGL J MED, V329, P432; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	35	486	519	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1999	341	19					1413	1419		10.1056/NEJM199911043411901	http://dx.doi.org/10.1056/NEJM199911043411901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XR	10547403				2022-12-28	WOS:000083472100001
J	Middleton, J				Middleton, J			The blues and pellagra: a public health detective story	BRITISH MEDICAL JOURNAL			English	Editorial Material									Sandwell Hlth Author, London, England		Middleton, J (corresponding author), Sandwell Hlth Author, London, England.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1209	1209		10.1136/bmj.319.7218.1209	http://dx.doi.org/10.1136/bmj.319.7218.1209			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541539	Green Published			2022-12-28	WOS:000083536200072
J	Lee, MJ; Thangada, S; Claffey, KP; Ancellin, N; Liu, CH; Kluk, M; Volpi, M; Sha'afi, RI; Hla, T				Lee, MJ; Thangada, S; Claffey, KP; Ancellin, N; Liu, CH; Kluk, M; Volpi, M; Sha'afi, RI; Hla, T			Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate	CELL			English	Article							PROTEIN-COUPLED RECEPTOR; DEPENDENT NEURITE RETRACTION; CAPILLARY-TUBE FORMATION; FIBROBLAST GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; ANGIOGENESIS INVITRO; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; MOLECULAR-CLONING; RHO	Vascular endothelial cells undergo morphogenesis into capillary networks in response to angiogenic factors. We show here that sphingosine-1-phosphate (SPP), a platelet-derived bioactive lipid, activates the EDG-1 and -3 subtypes of G protein-coupled receptors on endothelial cells to regulate angiogenesis. SPP induces the G(i)/mitogen-activated protein kinase/cell survival pathway and the smalt GTPase Rho- and Rac-coupled adherens junction assembly. Both EDG-1- and EDG-3-regulated signaling pathways are required for endothelial cell morphogenesis into capillary-like networks. Indeed, SPP synergized with polypeptide angiogenic growth factors in the formation of mature neovessels in vivo. These data define SPP as a novel regulator of angiogenesis.	Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol, Farmington, CT 06030 USA	University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol, Farmington, CT 06030 USA.		Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NCI NIH HHS [CA64436] Funding Source: Medline; NHLBI NIH HHS [HL54710] Funding Source: Medline; NIDDK NIH HHS [DK45659] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064436, R01CA064436] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; ANDELLIN N, 1999, J BIOL CHEM, V274, P18997; Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Esser S, 1998, J CELL SCI, V111, P1853; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HLA T, 1990, J BIOL CHEM, V265, P9308; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Ilan N, 1998, J CELL SCI, V111, P3621; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Liu CH, 1997, GENOMICS, V43, P15, DOI 10.1006/geno.1997.4759; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PASSANITI A, 1992, LAB INVEST, V67, P519; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Satake S, 1998, BIOCHEM BIOPH RES CO, V244, P642, DOI 10.1006/bbrc.1998.8313; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; VOLPI M, 1988, J CELL BIOL, V107, P2533, DOI 10.1083/jcb.107.6.2533; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yatomi Y, 1997, J BIOCHEM, V121, P969	49	827	854	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					301	312		10.1016/S0092-8674(00)81661-X	http://dx.doi.org/10.1016/S0092-8674(00)81661-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555146	Bronze			2022-12-28	WOS:000083440600008
J	Lowell, BB				Lowell, BB			PPAR gamma: An essential regulator of adipogenesis and modulator of fat cell function	CELL			English	Review							BINDING PROTEIN-ALPHA; ACTIVATED RECEPTOR-GAMMA; ADIPOCYTE DIFFERENTIATION; GENE; EXPRESSION; PROMOTES; LIGAND; MICE		Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Lowell, BB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.							Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Fajas L, 1999, MOL CELL BIOL, V19, P5495; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	21	318	341	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					239	242		10.1016/S0092-8674(00)81654-2	http://dx.doi.org/10.1016/S0092-8674(00)81654-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555139	Bronze			2022-12-28	WOS:000083440600001
J	Okano, M; Bell, DW; Haber, DA; Li, E				Okano, M; Bell, DW; Haber, DA; Li, E			DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development	CELL			English	Article							EMBRYONIC STEM-CELLS; ICF SYNDROME; MOUSE CELLS; GERM-LINE; CYTOSINE-5 METHYLTRANSFERASES; DENOVO METHYLATION; RETROVIRAL GENOMES; DE-NOVO; GENE; EXPRESSION	The establishment of DNA methylation patterns requires de novo methylation that occurs predominantly during early development and gametogenesis in mice. Here we demonstrate that two recently identified DNA methyltransferases, Dnmt3a and Dnmt3b, are essential for de novo methylation and for mouse development. inactivation of both genes by gene targeting blocks de novo methylation in ES cells and early embryos, but it has no effect on maintenance of imprinted methylation patterns. Dnmt3a and Dnmt3b also exhibit nonoverlapping functions in development, with Dnmt3b specifically required for methylation of centromeric minor satellite repeats. Mutations of human DNMT3B are found in ICF syndrome, a developmental defect characterized by hypomethylation of pericentromeric repeats. Our results indicate that both Dnmt3a and Dnmt3b function as de novo methyltransferases that play important roles in normal development and disease.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Canc Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Li, E (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Cardiovasc Res Ctr, Charlestown, MA 02129 USA.	en@cvrc.mgh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA082389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052106] Funding Source: NIH RePORTER; NCI NIH HHS [CA82389] Funding Source: Medline; NIGMS NIH HHS [GM52106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BROCKDORFF N, 1997, GENOMIC IMPRINTING, P191; CARPENTER NJ, 1988, J PEDIATR-US, V112, P757, DOI 10.1016/S0022-3476(88)80698-X; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; EHRLICH M, 1999, DNA ALTERATIONS CANC; FEIL R, 1994, DEVELOPMENT, V120, P2933; Hasties ND, 1989, GENETIC VARIANTS STR, P559; Hogan B, 1994, MANIPULATING MOUSE E; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Jahner D., 1984, DNA METHYLATION BIOC, P189; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Ji WZ, 1997, MUTAT RES-FUND MOL M, V379, P33, DOI 10.1016/S0027-5107(97)00088-2; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li E., 1997, V18, P1; Liu WG, 1998, NUCLEIC ACIDS RES, V26, P1396, DOI 10.1093/nar/26.6.1396; MONK M, 1987, DEVELOPMENT, V99, P371; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; Razin A., 1993, Experientia Supplementum (Basel), V64, P343; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SMEETS DFCM, 1994, HUM GENET, V94, P240; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; Wijmenga C, 1998, AM J HUM GENET, V63, P803, DOI 10.1086/302021; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125	47	4201	4403	16	379	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	1999	99	3					247	257		10.1016/S0092-8674(00)81656-6	http://dx.doi.org/10.1016/S0092-8674(00)81656-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555141	Bronze			2022-12-28	WOS:000083440600003
J	Shatursky, O; Heuck, AP; Shepard, LA; Rossjohn, J; Parker, MW; Johnson, AE; Tweten, RK				Shatursky, O; Heuck, AP; Shepard, LA; Rossjohn, J; Parker, MW; Johnson, AE; Tweten, RK			The mechanism of membrane insertion for a cholesterol-dependent cytolysin: A novel paradigm for pore-forming toxins	CELL			English	Article							PERFRINGOLYSIN-O; PROTECTIVE ANTIGEN; THETA-TOXIN; BINDING; IDENTIFICATION; HEMOLYSIN; BILAYERS; DOMAIN	Perfringolysin O (PFO), a water-soluble monomeric cytolysin secreted by pathogenic Clostridium perfringens, oligomerizes and forms large pores upon encountering cholesterol-containing membranes. Whereas all pore-forming bacterial toxins examined previously have been shown to penetrate the membrane using a single amphipathic beta hairpin per polypeptide, cysteine-scanning mutagenesis and multiple independent fluorescence techniques here reveal that each PFO monomer contains a second domain involved in pore formation, and that each of the two amphipathic a hairpins completely spans the membrane. In the soluble monomer, these transmembrane segments are folded into six alpha helices. The insertion of two transmembrane hairpins per toxin monomer and the major change in secondary structure are striking and define a novel paradigm far the mechanism of membrane insertion by a cytolytic toxin.	Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; St Vincents Inst Med Res, Ian Potter Fdn, Prot Crystallog Lab, Fitzroy, Vic 3065, Australia	Texas A&M University System; Texas A&M University College Station; University of Oklahoma System; University of Oklahoma Health Sciences Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; St. Vincent's Institute of Medical Research	Johnson, AE (corresponding author), Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA.		Rossjohn, Jamie/F-9032-2013; Parker, Michael W/F-9069-2013; Johnson, Arthur E/G-3457-2012	Rossjohn, Jamie/0000-0002-2020-7522; Parker, Michael W/0000-0002-3101-1138; 	NIAID NIH HHS [R01 AI037657, AI37657] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037657, R37AI037657] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; MENESTRINA G, 1990, TOXICON, V28, P477, DOI 10.1016/0041-0101(90)90292-F; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TWETEN RK, 1995, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 2ND EDITION, P207	16	288	292	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					293	299		10.1016/S0092-8674(00)81660-8	http://dx.doi.org/10.1016/S0092-8674(00)81660-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555145	Bronze			2022-12-28	WOS:000083440600007
J	Beecham, L				Beecham, L			Charity calls for better service for minority ethnic groups	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1140	1140						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	250ZE	10531124				2022-12-28	WOS:000083419500071
J	Turner, S				Turner, S			Place of pharmacotherapy in post-traumatic stress disorder	LANCET			English	Editorial Material									Camden & Islington Community Trust, Traumat Stress Clin, London W1P 1LB, England; UCL, London W1P 1LB, England	University of London; University College London; University of London; University College London	Turner, S (corresponding author), Camden & Islington Community Trust, Traumat Stress Clin, London W1P 1LB, England.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Connor KM, 1999, BRIT J PSYCHIAT, V175, P17, DOI 10.1192/bjp.175.1.17; Foa EB, 1999, J CLIN PSYCHIAT S16, V60; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Shapiro F., 2018, EYE MOVEMENT DESENSI, V2; Van Etten ML, 1998, CLIN PSYCHOL PSYCHOT, V5, P126, DOI 10.1002/(SICI)1099-0879(199809)5:3<126::AID-CPP153>3.3.CO;2-8; Yehuda R, 1998, REV PSYCHIAT SER, V17, P97	7	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1999	354	9188					1404	1405		10.1016/S0140-6736(99)00245-7	http://dx.doi.org/10.1016/S0140-6736(99)00245-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	248LY	10543663				2022-12-28	WOS:000083277400006
J	Lukas, C; Sorensen, CS; Kramer, E; Santoni-Rugiu, E; Lindeneg, C; Peters, JM; Bartek, J; Lukas, J				Lukas, C; Sorensen, CS; Kramer, E; Santoni-Rugiu, E; Lindeneg, C; Peters, JM; Bartek, J; Lukas, J			Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex	NATURE			English	Article							S-PHASE PROGRESSION; CELL-CYCLE; RETINOBLASTOMA-PROTEIN; MITOTIC CYCLINS; PROTEOLYSIS; MITOSIS; ACTIVATION; FAMILY; UBIQUITIN; YEAST	In mammalian somatic-cell cycles, progression through the G1-phase restriction point and initiation of DNA replication are controlled by the ability of the retinoblastoma tumour-suppressor protein (pRb) family to regulate the E2F/DP transcription factors(1,2). Continuing transcription of E2F target genes beyond the G1/S transition is required for coordinating S-phase progression with cell division(3-5), a process driven by cyclin-B-dependent kinase(6,7) and anaphase-promoting complex (APC)-mediated proteolysis(8). How E2F-dependent events at G1/S transition are orchestrated with cyclin B and APC activity remains unknown. Here, using an in vivo assay to measure protein stability in real time during the cell cycle, we show that repression of E2F activity or inhibition of cyclin-A-dependent kinase in S phase triggers the destruction of cyclin B1 through the re-assembly of APC, the ubiquitin ligase that is essential for mitotic cyclin proteolysis(9), with its activatory subunit Cdh1 (refs 10-13). Phosphorylation-deficient mutant Cdh1 or immunodepletion of cyclin A resulted in assembly of active Cdh1-APC even in S-phase cells. These results implicate an E2F-dependent, cyclin A/Cdk2-mediated phosphorylation of Cdh1 in the timely accumulation of cyclin B1 and the coordination of cell-cycle progression during the post-restriction point period.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark; Res Inst Mol Pathol, A-1030 Vienna, Austria	Danish Cancer Society; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Santoni-Rugiu, Eric/H-4913-2019; Bartek, Jiri/G-5870-2014; Santoni-Rugiu, Eric/AAH-3368-2020; Kramer, Edgar/A-9288-2012	Santoni-Rugiu, Eric/0000-0002-2283-3535; Kramer, Edgar/0000-0002-4882-4143; Lukas, Claudia/0000-0001-7169-6883; Sorensen, Claus/0000-0001-6022-9710				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; IOWNSLEY FM, 1998, TRENDS CELL BIOL, V8, P238; Irniger S, 1997, J CELL SCI, V110, P1523; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	30	249	255	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					815	818		10.1038/44611	http://dx.doi.org/10.1038/44611			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548110				2022-12-28	WOS:000083368700059
J	Khaw, KT				Khaw, KT			How many how old, how soon?	BRITISH MEDICAL JOURNAL			English	Article									Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Gerontol Unit, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Khaw, KT (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Gerontol Unit, Box 251, Cambridge CB2 2QQ, England.		Khaw, Kay-Tee/AAZ-3209-2021					BONE M, 1995, HLTH EXPECTANCY ITS; BOYCE WJ, 1985, LANCET, V1, P150; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; *GOV AC DEP, 1999, SERIES PP3 GOV ACT D, V21; GRUNDY E, 1997, HLTH ADULT BRITAIN 1, P182; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; Khaw KT, 1997, BMJ-BRIT MED J, V315, P1090, DOI 10.1136/bmj.315.7115.1090	7	57	57	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1350	1352		10.1136/bmj.319.7221.1350	http://dx.doi.org/10.1136/bmj.319.7221.1350			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567145	Green Published			2022-12-28	WOS:000083930200029
J	Prentice, A				Prentice, A			Fortnightly review - Medical management of menorrhagia	BRITISH MEDICAL JOURNAL			English	Review							LEVONORGESTREL INTRAUTERINE SYSTEM; TRANEXAMIC ACID; IDIOPATHIC MENORRHAGIA; NORETHISTERONE; MENSTRUATION; HYSTERECTOMY; TRIAL		Rosie Hosp, Dept Obstet & Gynaecol, Cambridge CB2 2SW, England		Prentice, A (corresponding author), Rosie Hosp, Dept Obstet & Gynaecol, Box 223, Cambridge CB2 2SW, England.							ANDERSCH B, 1988, ACTA OBSTET GYN SCAN, V67, P645, DOI 10.3109/00016348809004279; Barrington JW, 1997, BRIT J OBSTET GYNAEC, V104, P614, DOI 10.1111/j.1471-0528.1997.tb11542.x; Bonnar J, 1996, BRIT MED J, V313, P579; COOKE I, 1999, COCHRANE LIB; Coulter A, 1999, BRIT MED J, V318, P318, DOI 10.1136/bmj.318.7179.318; COULTER A, 1988, SOC SCI MED, V27, P987, DOI 10.1016/0277-9536(88)90289-4; Crosignani PG, 1997, OBSTET GYNECOL, V90, P257, DOI 10.1016/S0029-7844(97)00226-3; DOCKERAY CJ, 1987, EUR J OBSTET GYN R B, V24, P309, DOI 10.1016/0028-2243(87)90156-0; ELDRED JM, 1994, OBSTET GYNECOL, V84, P775; FARQUHAR CM, 1996, AUST NZ J OBSTET GYN, V36, P1; HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455; HAYNES PJ, 1979, RES CLIN FORUMS, V1, P73; *INT MED STAT, 1994, UK IR; Irvine GA, 1998, BRIT J OBSTET GYNAEC, V105, P592, DOI 10.1111/j.1471-0528.1998.tb10172.x; JANSSEN CAH, 1995, OBSTET GYNECOL, V85, P977, DOI 10.1016/0029-7844(95)00062-V; Kadir RA, 1998, LANCET, V351, P485, DOI 10.1016/S0140-6736(97)08248-2; KRASSAS GE, 1994, CLIN ENDOCRINOL, V40, P641, DOI 10.1111/j.1365-2265.1994.tb03016.x; Lahteenmaki P, 1998, BMJ-BRIT MED J, V316, P1122, DOI 10.1136/bmj.316.7138.1122; LETHABY A, 1999, COCHRANE LIB; *MORI, 1990, WOM HLTH 1990; National Advisory Committee on Health and Disability, 1998, GUID MAN HEAV MENSTR; *NHS DISS CTR, 1995, EFF HLTH CAR B, V9; PAUL C, 1988, NEW ZEAL MED J, V101, P809; PRESTON JT, 1995, BRIT J OBSTET GYNAEC, V102, P401, DOI 10.1111/j.1471-0528.1995.tb11293.x; *ROYAL COLL OBST G, 1998, IN MAN MEN EV BAS CL; SCOTT JC, 1964, AM J OBSTET GYNECOL, V90, P161, DOI 10.1016/0002-9378(64)90476-4; SILVERBERG SG, 1986, INT J GYNECOL PATHOL, V5, P235, DOI 10.1097/00004347-198609000-00005; SMITH SK, 1981, BRIT J OBSTET GYNAEC, V88, P434, DOI 10.1111/j.1471-0528.1981.tb01009.x; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x	29	39	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1343	1345		10.1136/bmj.319.7221.1343	http://dx.doi.org/10.1136/bmj.319.7221.1343			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567142	Green Published			2022-12-28	WOS:000083930200027
J	Swain, SL; Hu, H; Huston, G				Swain, SL; Hu, H; Huston, G			Class II-independent generation of CD4 memory T cells from effecters	SCIENCE			English	Article							ANTIGEN; SURVIVAL; RECEPTOR; NAIVE; MOLECULES; REQUIREMENTS; LYMPHOCYTES; MICE; TH1	The factors required for the generation of memory CD4 T cells remain unclear, and whether there is a continuing requirement for antigen stimulation is critical to design of vaccine strategies. CD4 effecters generated in vitro from naive CD4 T cells of mice efficiently gave rise to small resting memory cells after transfer to class II-deficient hosts, indicating no requirement for further antigen or class ii recognition.	Trudeau Inst Inc, Biomed Res Labs, Saranac Lake, NY 12983 USA	Trudeau Institute	Swain, SL (corresponding author), Trudeau Inst Inc, Biomed Res Labs, 100 Algonquin Ave, Saranac Lake, NY 12983 USA.							Brocker T, 1997, J EXP MED, V186, P1223, DOI 10.1084/jem.186.8.1223; DECKER G, UNPUB; Dubey C, 1996, J IMMUNOL, V157, P3280; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Kirberg J, 1997, J EXP MED, V186, P1269, DOI 10.1084/jem.186.8.1269; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; Linton PJ, 1996, J EXP MED, V184, P1891, DOI 10.1084/jem.184.5.1891; Markiewicz MA, 1998, P NATL ACAD SCI USA, V95, P3065, DOI 10.1073/pnas.95.6.3065; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; Nesic D, 1998, J IMMUNOL, V160, P3705; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; Rogers PR, 1998, J IMMUNOL, V161, P3844; Rooke R, 1997, IMMUNITY, V7, P123, DOI 10.1016/S1074-7613(00)80515-4; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; SWAIN SL, UNPUB; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	22	345	354	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1381	1383		10.1126/science.286.5443.1381	http://dx.doi.org/10.1126/science.286.5443.1381			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558997				2022-12-28	WOS:000083675500049
J	Curtis, AB; Ridzon, R; Vogel, R; McDonough, S; Hargreaves, J; Ferry, J; Valway, S; Onorato, IM				Curtis, AB; Ridzon, R; Vogel, R; McDonough, S; Hargreaves, J; Ferry, J; Valway, S; Onorato, IM			Extensive transmission of Mycobacterium tuberculosis from a child	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGENITAL TUBERCULOSIS; INFECTION; OUTBREAK	Background and Methods Young children rarely transmit tuberculosis. In July 1998, infectious tuberculosis was identified in a nine-year-old boy in North Dakota who was screened because extrapulmonary tuberculosis had been diagnosed in his female guardian. The child, who had come from the Republic of the Marshall Islands in 1996, had bilateral cavitary tuberculosis. Because he was the only known possible source for his female guardian's tuberculosis, an investigation of the child's contacts was undertaken. We identified family, school, day-care, and other social contacts and notified these people of their exposure. We asked the contacts to complete a questionnaire and performed tuberculin skin tests. Results Of the 276 contacts of the child whom we tested, 56 (20 percent) had a positive tuberculin skin test (induration of at least 10 mm), including 3 of the child's 4 household members, 16 of his 24 classroom contacts, 10 of 32 school-bus riders, and 9 of 61 daycare contacts. A total of 118 persons received preventive therapy, including 56 young children who were prescribed preventive therapy until skin tests performed at least 12 weeks after exposure were negative. The one additional case identified was in the twin brother of the nine-year-old patient. The twin was not considered infectious on the basis of a sputum smear that was negative on microscopical examination. Conclusions This investigation shows that a young child can transmit Mycobacterium tuberculosis to a large number of contacts. Children with tuberculosis, especially cavitary or laryngeal tuberculosis, should be considered potentially infectious, and screening of their contacts for infection with M. tuberculosis or active tuberculosis may be required. (N Engl J Med 1999;341:1491-5.) (C) 1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30333 USA; N Dakota Dept Hlth, Bismarck, ND USA; Altru Hlth Care Syst, Grand Forks, ND USA; Nelson Griggs Dist Hlth Unit, Mcville, ND USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Curtis, AB (corresponding author), Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV STD & TB Prevent, Mailstop E-10,1600 Clifton Rd, Atlanta, GA 30333 USA.							ARIANO E, 1994, EPIDEMIOL INFECT, V113, P83, DOI 10.1017/S0950268800051499; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; CANTWELL MF, 1994, NEW ENGL J MED, V330, P1051, DOI 10.1056/NEJM199404143301505; *CDCP, 1998, REP TUB US 1997, P15; Costello C., 1993, 33 INT C ANT AG CHEM, P367; HALL CB, 1994, PEDIATRICS, V93, P131; HOGE CW, 1994, AM J EPIDEMIOL, V139, P520, DOI 10.1093/oxfordjournals.aje.a117035; HUSEN L, 1971, CHEST, V60, P540, DOI 10.1378/chest.60.6.540; KENT DC, 1967, ARCH ENVIRON HEALTH, V14, P580, DOI 10.1080/00039896.1967.10664795; LAWRENCE RM, 1996, TUBERCULOSIS, P675; Lee LH, 1998, CLIN INFECT DIS, V27, P474, DOI 10.1086/514690; LINCOLN EDITH M., 1965, ADVANCES TUBERC RES, V14, P157; PETER G, 1997, RED BOOK REPORT COMM, P541; RABALAIS G, 1991, LANCET, V338, P825, DOI 10.1016/0140-6736(91)90719-6; Raffalli J, 1996, ARCH INTERN MED, V156, P1053, DOI 10.1001/archinte.156.10.1053; Ridzon R, 1997, J PEDIATR-US, V131, P863, DOI 10.1016/S0022-3476(97)70034-9; SCHMIDEK HH, 1967, CAN MED ASSOC J, V97, P178; SMITH MHD, 1992, TXB PEDIAT INFECT DI, V2, P1321; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VARTERESIANKARANFIL L, 1988, NEW ENGL J MED, V319, P1018; *WHO, 1997, WHOTB97225; Yusuf HR, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.3.e9	22	128	130	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1999	341	20					1491	1495		10.1056/NEJM199911113412002	http://dx.doi.org/10.1056/NEJM199911113412002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RK	10559449				2022-12-28	WOS:000083625800002
J	Halligan, S; Fenlon, HM				Halligan, S; Fenlon, HM			Science, medicine, and the future - Virtual colonoscopy	BRITISH MEDICAL JOURNAL			English	Review							CT; COLONOGRAPHY; COLOGRAPHY; NEOPLASMS; POLYPS		St Marks Hosp, Intestinal Imaging Ctr, Harrow HA1 3UJ, Middx, England; Mater Misericordiae Hosp, Dept Radiol, Dublin, Ireland	Imperial College London; Mater Misericordiae University Hospital; University College Dublin	Halligan, S (corresponding author), St Marks Hosp, Intestinal Imaging Ctr, Harrow HA1 3UJ, Middx, England.		Halligan, Steve/C-5875-2009	Halligan, Steve/0000-0003-0632-5108				Amin Z, 1996, CLIN RADIOL, V51, P56, DOI 10.1016/S0009-9260(96)80221-2; Dachman AH, 1998, AM J ROENTGENOL, V171, P989, DOI 10.2214/ajr.171.4.9762982; Fenlon HM, 1997, AM J ROENTGENOL, V169, P453, DOI 10.2214/ajr.169.2.9242753; Fenlon HM, 1998, GUT, V43, P806, DOI 10.1136/gut.43.6.806; Fenlon HM, 1999, RADIOLOGY, V210, P423, DOI 10.1148/radiology.210.2.r99fe21423; FINK M, 1994, BRIT MED J, V308, P101; Hara AK, 1997, GASTROENTEROLOGY, V112, pA575; Hara AK, 1997, RADIOLOGY, V205, P59, DOI 10.1148/radiology.205.1.9314963; HOUNDFIELD GN, 1973, BRIT J RADIOL, V46, P1016, DOI 10.1259/0007-1285-46-552-1016; KALENDER WA, 1990, RADIOLOGY, V176, P181, DOI 10.1148/radiology.176.1.2353088; KAY CL, 1997, RADIOLOGY, V205, P195; Luboldt W, 1998, RADIOLOGY, V207, P59, DOI 10.1148/radiology.207.1.9530299; REX DK, 1997, GASTROINTEST ENDOSC, V45, pAB116; Royster AP, 1997, AM J ROENTGENOL, V169, P1237, DOI 10.2214/ajr.169.5.9353434; Vining DJ, 1994, AM J ROENTGENOL, V162, P104	15	30	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1249	1252		10.1136/bmj.319.7219.1249	http://dx.doi.org/10.1136/bmj.319.7219.1249			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550093	Green Published			2022-12-28	WOS:000083625600028
J	Kilburn, KH				Kilburn, KH			Does exposure to fine aluminium dust affect the brain?	LANCET			English	Editorial Material							NERVOUS-SYSTEM; WORKERS; MANGANESE		Univ So Calif, Sch Med, Lab Environm Sci, Los Angeles, CA 90033 USA	University of Southern California	Kilburn, KH (corresponding author), Univ So Calif, Sch Med, Lab Environm Sci, Los Angeles, CA 90033 USA.							Akila R, 1999, OCCUP ENVIRON MED, V56, P632, DOI 10.1136/oem.56.9.632; BASTPETTERSEN R, 1994, AM J IND MED, V25, P649, DOI 10.1002/ajim.4700250505; Kilburn KH, 1998, ARCH ENVIRON HEALTH, V53, P257, DOI 10.1080/00039899809605706; Kilburn KH, 1998, ARCH ENVIRON HEALTH, V53, P329, DOI 10.1080/00039899809605717; LONGSTRETH WT, 1985, ARCH INTERN MED, V145, P1972, DOI 10.1001/archinte.145.11.1972; MCLAUGHLIN AIG, 1962, BRIT J IND MED, V19, P253; PERL DP, 1987, LANCET, V1, P1028; RIFAT SL, 1990, LANCET, V336, P1162, DOI 10.1016/0140-6736(90)92775-D; ROELS HA, 1992, BRIT J IND MED, V49, P25; Sim M, 1997, OCCUP ENVIRON MED, V54, P229, DOI 10.1136/oem.54.4.229; Sjogren B, 1996, OCCUP ENVIRON MED, V53, P32, DOI 10.1136/oem.53.1.32; VANDERVOET GB, 1994, INTOXICATIONS NERV 1, P273; Westberg H, 1999, ARCH ENVIRON HEALTH, V54, P364, DOI 10.1080/00039899909602502; WHITE DM, 1992, ARCH INTERN MED, V152, P1443, DOI 10.1001/archinte.152.7.1443	14	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1575	1577		10.1016/S0140-6736(99)00295-0	http://dx.doi.org/10.1016/S0140-6736(99)00295-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560668				2022-12-28	WOS:000083551000005
J	Wilson, A; Grimshaw, G; Baker, R; Thompson, J				Wilson, A; Grimshaw, G; Baker, R; Thompson, J			Differentiating between audit and research: postal survey of health authorities' views	BRITISH MEDICAL JOURNAL			English	Article									Univ Leicester, Leicester Gen Hosp, Dept Gen Practice & Primary Hlth Care, Clin Governance Res & Dev Unit, Leicester LE5 4PW, Leics, England; Univ Leicester, Dept Ophthalmol, Leicester LE2 7LX, Leics, England	University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester; University of Leicester	Wilson, A (corresponding author), Univ Leicester, Leicester Gen Hosp, Dept Gen Practice & Primary Hlth Care, Clin Governance Res & Dev Unit, Leicester LE5 4PW, Leics, England.							Department of Health The Caldicott Committee, 1997, REP REV PAT ID INF; *LEIGH BARR CONS C, 1994, STAND LOC ETH COMM F; *MRC, 1993, MED RES COUNC SCI ST; *ROYAL COLL PHYS L, 1996, GUID PRACT ETH COMM; Scott PV, 1997, BRIT MED J, V315, P60, DOI 10.1136/bmj.315.7099.60b	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1235	1235		10.1136/bmj.319.7219.1235	http://dx.doi.org/10.1136/bmj.319.7219.1235			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550084	Bronze, Green Published			2022-12-28	WOS:000083625600023
J	Ananth, CV; Berkowitz, GS; Savitz, DA; Lapinski, RH				Ananth, CV; Berkowitz, GS; Savitz, DA; Lapinski, RH			Placental abruption and adverse perinatal outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREGNANCY; RISK; ASPIRIN; COCAINE; MODELS; RATIO; RACE	Context Pregnancies complicated by abruption result in increased frequency of perinatal death and decreased fetal size and gestational duration, yet the extent of placental separation and its effect on these adverse outcomes is unknown. Objective To assess the contribution of placental abruption and extent of placental separation to stillbirth, preterm delivery, and fetal growth restriction. Design Hospital-based, retrospective cohort study. Setting Mount Sinai Hospital, New York City, NY. Participants A total of 53 371 pregnancies occurring in 40 789 women who were delivered of singleton births between 1986 and 1996. Main Outcome Measures Risks and relative risks for stillbirth (>20 weeks), preterm delivery (<37 weeks), and fetal growth restriction (birth weight below 10th percentile for gestational age) in relation to abruption. Results The incidence of abruption was 1% (n = 530), Abruption was associated with an 8.9-fold (95% confidence interval [CI], 6.0-13.0) adjusted relative risk (aRR) of stillbirth. Preterm birth proportions among women with and without abruption were 39.6% and 9.1%, respectively, yielding an aRR of 3.9 (95% CI, 3.5-4.4). In the abruption group, 14.3% of neonates were growth restricted, compared with 8.1% among all other births (aRR, 2.0; 95% CI, 1.5-2.4). Extent of placental separation had a profound effect on stillbirth (aRR for 75% separation, 31.5; 95% CI, 17.0-58.4), although evident only among those with at least 50% separation. However, the risk of preterm delivery was substantially increased even for mild abruptions (aRR for 25% separation, 5.5; 95% CI, 4.2-7.3). Conclusions In this cohort, placental abruption had a profound impact on stillbirth, preterm delivery, and fetal growth restriction. The risk of stillbirth was dramatically increased for severe placental separation, but preterm delivery was common even among women with lesser degrees of placental separation.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Obstet Gynecol & Reprod Sci, Div Epidemiol & Biostat, New Brunswick, NJ 08901 USA; Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY USA; Mt Sinai Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY USA; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill	Ananth, CV (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Obstet Gynecol & Reprod Sci, Div Epidemiol & Biostat, 125 Paterson St, New Brunswick, NJ 08901 USA.		Savitz, David A/I-2211-2014	Ananth, Cande/0000-0002-0410-2595				Ananth CV, 1999, OBSTET GYNECOL, V93, P622, DOI 10.1016/S0029-7844(98)00408-6; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; BERKOWITZ GS, 1992, AM J EPIDEMIOL, V135, P965, DOI 10.1093/oxfordjournals.aje.a116408; CREASY RK, 1993, AM J OBSTET GYNECOL, V168, P1223, DOI 10.1016/0002-9378(93)90373-Q; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; FLEMING AD, 1991, CRIT CARE CLIN, V7, P865, DOI 10.1016/S0749-0704(18)30285-9; FUCHS F, 1993, PRETERM BIRTH, P217; HARRIS BA, 1985, OBSTET GYNECOL, V66, P774; HAUTH JC, 1993, AM J OBSTET GYNECOL, V168, P1083, DOI 10.1016/0002-9378(93)90351-I; HIBBARD BM, 1966, OBSTET GYNECOL, V27, P155; HURD WW, 1983, OBSTET GYNECOL, V61, P467; Kistin N, 1996, PAEDIATR PERINAT EP, V10, P269, DOI 10.1111/j.1365-3016.1996.tb00050.x; Kline J, 1997, AM J PUBLIC HEALTH, V87, P352, DOI 10.2105/AJPH.87.3.352; KNAB DR, 1978, OBSTET GYNECOL, V52, P625; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; NAEYE RL, 1980, OBSTET GYNECOL, V55, P701; NISWANDER KR, 1966, AM J OBSTET GYNECOL, V95, P838, DOI 10.1016/0002-9378(66)90088-3; SAFTLAS AF, 1991, OBSTET GYNECOL, V78, P1081; SCHIFF E, 1989, NEW ENGL J MED, V321, P351, DOI 10.1056/NEJM198908103210603; WOLF EJ, 1992, J MATERN FETAL MED, V14, P206; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; ZHANG J, 1995, OBSTET GYNECOL, V86, P200, DOI 10.1016/0029-7844(95)00142-E	23	225	231	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1646	1651		10.1001/jama.282.17.1646	http://dx.doi.org/10.1001/jama.282.17.1646			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553791	Bronze			2022-12-28	WOS:000083368400030
J	Gray, JAM				Gray, JAM			Postmodern medicine	LANCET			English	Editorial Material							BREAST-CANCER; TRIALS; QUALITY; WOMEN; BIAS		Univ Oxford, Inst Hlth Sci, Oxford OX3 7LF, England	University of Oxford	Gray, JAM (corresponding author), Univ Oxford, Inst Hlth Sci, Oxford OX3 7LF, England.							ABASSI K, 1998, BRIT MED J, V316, P484; ANGEL M, 1992, SCI TRIAL; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Beck Ulrich., 1992, RISK SOC; Berger P.L, 1966, SOCIAL CONSTRUCTION; BOYLE TC, 1981, ROAD WELLVILLE; Brody H, 1997, J Am Board Fam Pract, V10, P72; BUNKER JP, 1995, J ROY COLL PHYS LOND, V29, P105; Buster S., 1994, BMJ-BRIT MED J, V309, P1542; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; Donabedian A, 1980, EXPLORATIONS QUALITY, V1; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Eddy DM, 1997, ANN INTERN MED, V127, P1035, DOI 10.7326/0003-4819-127-11-199712010-00017; FAHEY T, 1995, BRIT MED J, V311, P1056, DOI 10.1136/bmj.311.7012.1056; Gellner E., 1992, POSTMODERNISM REASON; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; HALBSERSTAM D, 1973, BEST BRIGHTEST; Illich I., 1976, LIMITS MED MED NEMES; KNOWLES J, 1997, DOING BETTER FEELING; Lipkin M, 1996, ANN INTERN MED, V124, P511, DOI 10.7326/0003-4819-124-5-199603010-00010; McKeown T., 1965, MED MODERN SOC; Moore TJ, 1995, DEADLY MED WHY 10 10; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; Street RL, 1997, MED DECIS MAKING, V17, P298, DOI 10.1177/0272989X9701700306; Weil A., 1995, SPONTANEOUS HEALING	26	58	60	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1550	1553		10.1016/S0140-6736(98)08482-7	http://dx.doi.org/10.1016/S0140-6736(98)08482-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551517				2022-12-28	WOS:000083411300043
J	Wiemels, JL; Cazzaniga, G; Daniotti, M; Eden, OB; Addison, GM; Masera, G; Saha, V; Biondi, A; Greaves, MF				Wiemels, JL; Cazzaniga, G; Daniotti, M; Eden, OB; Addison, GM; Masera, G; Saha, V; Biondi, A; Greaves, MF			Prenatal origin of acute lymphoblastic leukaemia in children	LANCET			English	Article							CHILDHOOD LEUKEMIA; INFANT LEUKEMIAS; IDENTICAL-TWINS; BLOOD SPOTS; FUSION; CANCER; GENE; DETERMINANTS; MALIGNANCY; ETIOLOGY	Background There is little current insight into the natural history of childhood leukaemia or the timing of relevant mutational events. TEL-AML1 gene fusion due to chromosomal translocation is frequently-seen in the common form of childhood acute lymphoblastic leukaemia. We investigated whether this abnormality arises prenatally. Methods We identified, by reverse-transcriptase PCR screening of blood or bone marrow, TEL-AML1 fusion in 12 children, plus a pair of identical twins, aged 2-5 years from Italy and the UK, who had newly diagnosed acute lymphoblastic leukaemia. We amplified and sequenced the genomic TEL-AMLI fusion gene with a long-distance inverse PCR method. Primers were designed that could be used in short-range PCR to screen for patient-specific, leukaemia clone-specific TEL-AMLI genomic fusion sequences in neonatal blood spots from each child. Findings We initially identified TEL-AMLI fusion sequences in blood spots from the identical twins, diagnosed with concordant acute lymphoblastic leukaemia at age 4 years, who shared a single or clonotypic TEL-AMLI sequence that suggested prenatal origin in one twin. Three children were excluded because control genes could not be amplified. Of the other nine patients, six had positive blood spots. Blood spots that were classified as negative were uninformative. Interpretation Our findings showed that childhood acute lymphoblastic leukaemia is frequently initiated by a chromosome translocation event in utero. Studies in identical twins show however that such an event is insufficient for clinical leukaemia and that a postnatal promotional event is also required.	Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Univ Milan, Osped San Gerardo, Ctr Ric Tettamanti, Pediat Clin, Milan, Italy; Christie Hosp NHS Trust, Acad Unit Paediat Oncol, Manchester M20 4BX, Lancs, England; Royal Manchester Childrens Hosp, Dept Clin Biochem, Manchester M27 1HA, Lancs, England; Royal London Hosp, Dept Paediat Haematol & Oncol, London E1 1BB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; San Gerardo Hospital; University of Milan; Christie NHS Foundation Trust; Christie Hospital; Royal Manchester Children's Hospital; Barts Health NHS Trust; Royal London Hospital	Greaves, MF (corresponding author), Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England.		Biondi, Andrea/AAX-1865-2020; Biondi, Andrea/K-9997-2016; Cazzaniga, Giovanni/K-6338-2016	Biondi, Andrea/0000-0002-6757-6173; Saha, Vaskar/0000-0002-2916-9649; Cazzaniga, Giovanni/0000-0003-2955-4528				Alexander FE, 1998, BRIT J CANCER, V77, P818, DOI 10.1038/bjc.1998.133; BHATIA S, 1999, CHILDHOOD LEUKEMIAS, P38; BITHELL JF, 1975, BRIT J CANCER, V31, P271, DOI 10.1038/bjc.1975.62; Borkhardt A, 1997, BLOOD, V90, P571, DOI 10.1182/blood.V90.2.571.571_571_577; Buckley JD, 1996, MED PEDIATR ONCOL, V26, P223, DOI 10.1002/(SICI)1096-911X(199604)26:4<223::AID-MPO1>3.0.CO;2-L; CHESSELLS JM, 1977, LANCET, V2, P1307; COMEAU AM, 1993, J PEDIATR-US, V123, P252, DOI 10.1016/S0022-3476(05)81697-X; *COMM MED ASP RAD, 1996, INC CANC LEUK YOUNG; DRAPER GJ, 1974, 11 INT CANC C, P150; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; Ford AM, 1997, BLOOD, V89, P281, DOI 10.1182/blood.V89.1.281.281_281_285; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Greaves M, 1999, EUR J CANCER, V35, P173, DOI 10.1016/S0959-8049(98)00433-X; GREAVES M, 1993, BLOOD, V82, P1043; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GREAVES MF, 1985, LEUKEMIA RES, V9, P715, DOI 10.1016/0145-2126(85)90281-4; GREAVES MF, 1988, LEUKEMIA, V2, P120; GREAVES MF, 1993, LEUKEMIA, V7, P349; JINKS DC, 1989, HUM GENET, V81, P363, DOI 10.1007/BF00283692; Kersey JH, 1997, BLOOD, V90, P4243, DOI 10.1182/blood.V90.11.4243.4243_4243_4251; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; MAKOWSKI GS, 1995, NUCLEIC ACIDS RES, V23, P3788, DOI 10.1093/nar/23.18.3788; OCHS J, 1996, LEUKEMIA, P419; Parkin DM, 1998, IARC SCI PUBLICATION, V144; PUI CH, 1995, LEUKEMIA, V9, P762; RAIMONDI SC, 1993, BLOOD, V81, P2237; Raskin S, 1992, PCR Methods Appl, V2, P154; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; RODVALL Y, 1990, INT J CANCER, V46, P362, DOI 10.1002/ijc.2910460304; Roman E, 1997, BRIT J CANCER, V76, P406, DOI 10.1038/bjc.1997.399; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SAHA V, 1993, ARCH DIS CHILD, V68, P771, DOI 10.1136/adc.68.6.771; Smith MA, 1997, J NATL CANCER I, V89, P1542, DOI 10.1093/jnci/89.20.1542; Taylor GM, 1996, LEUKEMIA, P210; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Wiemels JL, 1999, CANCER RES, V59, P4075	39	451	459	0	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1499	1503		10.1016/S0140-6736(99)09403-9	http://dx.doi.org/10.1016/S0140-6736(99)09403-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551495				2022-12-28	WOS:000083411300009
J	Lee, JO; Yang, HJ; Georgescu, MM; Di Cristofano, A; Maehama, T; Shi, YG; Dixon, JE; Pandolfi, P; Pavletich, NP				Lee, JO; Yang, HJ; Georgescu, MM; Di Cristofano, A; Maehama, T; Shi, YG; Dixon, JE; Pandolfi, P; Pavletich, NP			Crystal structure of the PTEN tumor suppressor: Implications for its phosphoinositide phosphatase activity and membrane association	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; C2 DOMAIN; PHOSPHOLIPID-BINDING; CYTOSOLIC PHOSPHOLIPASE-A2; GLIOMA-CELLS; SYNAPTOTAGMIN; GENE; RECOGNITION; CANCER; DELTA	The PTEN tumor suppressor is mutated in diverse human cancers and in hereditary cancer predisposition syndromes. PTEN is a phosphatase that can act on both polypeptide and phosphoinositide substrates in vitro. The PTEN structure reveals a phosphatase domain that is similar to protein phosphatases but has an enlarged active site important for the accommodation of the phosphoinositide substrate. The structure also reveals that PTEN has a C2 domain. The PTEN C2 domain binds phospholipid membranes in vitro, and mutation of basic residues that could mediate this reduces PTEN's membrane affinity and its ability to suppress the growth of glioblastoma tumor cells. The phosphatase and C2 domains associate across an extensive interface, suggesting that the C2 domain may serve to productively position the catalytic domain on the membrane.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Grad Sch Med Sci, Sloan Kettering Div, Dept Pharmacol, New York, NY 10021 USA; Rockefeller Univ, Mol Oncol Lab, New York, NY 10021 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Rockefeller University; University of Michigan System; University of Michigan; Princeton University	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	nikola@xray2.mskcc.org	Lee, Jie-Oh/AAG-4302-2020; Maehama, Tomohiko/AAX-8926-2020; Lee, Jie-Oh/C-1581-2011; Di Cristofano, Antonio/B-4148-2016; Georgescu, Maria-Magdalena/AAJ-6359-2020; di cristofano, antonio/AAJ-3796-2020; Maehama, Tomohiko/HGB-4896-2022	di cristofano, antonio/0000-0003-2537-3228; Maehama, Tomohiko/0000-0002-9685-2317; Lee, Jie-Oh/0000-0001-6519-6049; Shi, Yigong/0000-0003-2030-168X	NCI NIH HHS [CA09673] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Miller RT, 1996, FASEB J, V10, P171, DOI 10.1096/fasebj.10.1.8566539; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Pappa H, 1998, STRUCT FOLD DES, V6, P885, DOI 10.1016/S0969-2126(98)00090-2; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328	42	821	859	6	107	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	1999	99	3					323	334		10.1016/S0092-8674(00)81663-3	http://dx.doi.org/10.1016/S0092-8674(00)81663-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555148	Bronze			2022-12-28	WOS:000083440600010
J	Rohani, P; Earn, DJD; Grenfell, BT				Rohani, P; Earn, DJD; Grenfell, BT			Opposite patterns of synchrony in sympatric disease metapopulations	SCIENCE			English	Article							INSECT POPULATION; MEASLES DYNAMICS; TIME-SERIES; CHAOS; VACCINATION; PERTUSSIS; TRANSMISSION; PERSISTENCE; ENGLAND; WALES	Measles epidemics in UK cities, which were regular and highly synchronous before vaccination, are known to have become irregular and spatially uncorrelated in the vaccine era. Whooping cough shows the reverse pattern, namely a shift from spatial incoherence and irregularity before vaccination to regular, synchronous epidemics afterward. Models show that these patterns can arise from disease-specific responses to dynamical noise. This analysis has implications for vaccination strategies and illustrates the power of comparative dynamical studies of sympatric metapopulations.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge	Rohani, P (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	pej@zoo.cam.ac.uk		rohani, pejman/0000-0002-7221-3801; Earn, David/0000-0002-7562-1341				AGUR Z, 1993, P NATL ACAD SCI USA, V90, P11698, DOI 10.1073/pnas.90.24.11698; ANDERSON R M, 1991; ARON JL, 1990, THEOR POPUL BIOL, V38, P58, DOI 10.1016/0040-5809(90)90003-E; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; Bjornstad ON, 1999, ECOLOGY, V80, P622, DOI 10.2307/176640; Bjornstad ON, 1998, J ANIM ECOL, V67, P110, DOI 10.1046/j.1365-2656.1998.00168.x; Bolker BM, 1996, P NATL ACAD SCI USA, V93, P12648, DOI 10.1073/pnas.93.22.12648; CLARKSON JA, 1985, INT J EPIDEMIOL, V14, P153, DOI 10.1093/ije/14.1.153; Costantino RF, 1997, SCIENCE, V275, P389, DOI 10.1126/science.275.5298.389; Earn DJD, 1998, P ROY SOC B-BIOL SCI, V265, P7, DOI 10.1098/rspb.1998.0256; EARN DJD, UNPUB; ELLNER S, 1995, AM NAT, V145, P343, DOI 10.1086/285744; FINE PEM, 1982, LANCET, V1, P666; Grenfell B, 1997, TRENDS ECOL EVOL, V12, P395, DOI 10.1016/S0169-5347(97)01174-9; Grenfell BT, 1998, NATURE, V394, P674, DOI 10.1038/29291; GRENFELL BT, 1995, P ROY SOC B-BIOL SCI, V259, P97, DOI 10.1098/rspb.1995.0015; GRENFELL BT, 1992, J ROY STAT SOC B MET, V54, P383; GRENFELL BT, 1989, PROC R SOC SER B-BIO, V236, P213, DOI 10.1098/rspb.1989.0022; Grenfell BT, 1998, ECOL LETT, V1, P63; GRENFELL BT, 1999, CHAOS REAL DATA ANAL; HASSELL MP, 1991, NATURE, V353, P255, DOI 10.1038/353255a0; HASSELL MP, 1977, J ANIM ECOL, V46, P249, DOI 10.2307/3959; Hethcote HW, 1997, MATH BIOSCI, V145, P89, DOI 10.1016/S0025-5564(97)00014-X; Higgins K, 1997, SCIENCE, V276, P1431, DOI 10.1126/science.276.5317.1431; LEVINS R, 1969, Bulletin of the Entomological Society of America, V15, P237; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; Miller E, 1997, DEV BIOLOGICALS, V89, P15; Miller E, 1992, Commun Dis Rep CDR Rev, V2, pR152; NOKES DJ, 1997, J MATH APPL MED BIOL, V12, P29; Rohani P, 1998, P ROY SOC B-BIOL SCI, V265, P2033, DOI 10.1098/rspb.1998.0537; ROHANI P, UNPUB; SCHENZLE D, 1984, J MATH APPL MED BIOL, V1, P169; Scott PT, 1997, AM FAM PHYSICIAN, V56, P1121; Shulgin B, 1998, B MATH BIOL, V60, P1123, DOI 10.1016/S0092-8240(98)90005-2; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0	35	230	235	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					968	971		10.1126/science.286.5441.968	http://dx.doi.org/10.1126/science.286.5441.968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542154				2022-12-28	WOS:000083368500049
J	Lehman, R				Lehman, R			In praise of hunch backing	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1143	1143		10.1136/bmj.319.7217.1143	http://dx.doi.org/10.1136/bmj.319.7217.1143			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531129	Green Published			2022-12-28	WOS:000083419500072
J	Rahn, KH; Barenbrock, M; Fritschka, E; Heinecke, A; Lippert, J; Schroeder, K; Hauser, I; Wagner, K; Neumayer, HH				Rahn, KH; Barenbrock, M; Fritschka, E; Heinecke, A; Lippert, J; Schroeder, K; Hauser, I; Wagner, K; Neumayer, HH			Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial	LANCET			English	Article							CALCIUM-CHANNEL BLOCKERS; ALLOGRAFT RECIPIENTS; HYPERTENSION; DILTIAZEM; BLOCKADE; KIDNEY; RATS; VASOCONSTRICTION; INHIBITION; ANTAGONIST	Background Calcium antagonists such as nitrendipine reduce the effects of cyclosporin on renal haemodynamics, however, their long-term efficacy has not been established. We did a randomised trial to investigate the effects of nitrendipine on renal function in renal-transplant patients treated with cyclosporin. Methods 253 renal-transplant patients were recruited: 52 normotensive patients (diastolic blood pressure <90 mm Hg) were assigned placebo and 57 nitrendipine 5 mg twice daily; 71 hypertensive patients (diastolic blood pressure >90 to <115 mm Hg) were assigned placebo and 73 nitrendipine 10 mg twice daily. Nitrendipine was increased to 20 mg twice daily if the target diastolic blood pressure (<90 mm Hg) was not achieved. The patients were seen once a month for 24 months; blood pressure and serum creatinine concentration were recorded at each visit. Analysis was by intention to treat. Findings 63 patients were withdrawn (35 nitrendipine, 28 placebo). The mean serum creatinine concentration at baseline was slightly higher in the nitrendipine group (146.7 mu mol/L [SE 4.42]) than in the placebo group (137.0 mu mol/L [3.54]. At the 24-month endpoint or at dropout, serum creatinine concentration was significantly higher in the 123 patients in the placebo group than the 130 patients in the nitrendipine group (160.8 [7.1] vs 148.5 [5.3], p for effect of treatment=0.025, analysis of covariance in a two-way classification; 95% CI for difference -1.77 to -22.98). At study entry, the blood pressures of the placebo and the nitrendipine groups were almost identical. At 24 months, blood pressure was higher in the normotensive patients given a placebo than in those patients given nitrendipine. By contrast, blood-pressure values were similar in those hypertensive patients given a placebo and those given nitrendipine at the end of treatment. Interpretation The calcium antagonist nitrendipine has no adverse effects on kidney function In renal-transplant patients with cyclosporin. The drug has a small but significant nephroprotective effect, that is independent of the drug's antihypertensive action.	Univ Munster, Dept Med, D-48149 Munster, Germany; Univ Essen Gesamthsch, Dept Med, D-4300 Essen 1, Germany; Univ Munster, Inst Biomath, Munster, Germany; Univ Berlin, Dept Med, Berlin, Germany; Univ Erlangen Nurnberg, Dept Med, D-8520 Erlangen, Germany	University of Munster; University of Duisburg Essen; University of Erlangen Nuremberg	Rahn, KH (corresponding author), Univ Munster, Dept Med, Albert Schweitzer Str 33, D-48149 Munster, Germany.	rahn@uni-muenster.de						AEOPUR MS, 1989, NEPHRON, V52, P227; Armitage P., 2008, STAT METHODS MED RES; BARENBROCK M, 1995, CLIN NEPHROL, V43, P388; BRUECKNER D, 1993, NAUNYNSCHMIEDEBER S1, V347, pR45; BRUNNER FP, 1989, KIDNEY INT, V36, P969, DOI 10.1038/ki.1989.289; CHAPMAN JR, 1987, TRANSPLANTATION, V43, P860, DOI 10.1097/00007890-198743060-00018; CHEIGH JS, 1985, TRANSPLANT P, V17, P174; CHRYSOSTOMOU A, 1993, TRANSPLANTATION, V55, P300, DOI 10.1097/00007890-199302000-00014; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; ENGLISH J, 1987, TRANSPLANTATION, V44, P135, DOI 10.1097/00007890-198707000-00027; FLEMING JT, 1987, AM J PHYSIOL, V253, pF1157, DOI 10.1152/ajprenal.1987.253.6.F1157; GRIFFIN KA, 1995, J CLIN INVEST, V96, P793, DOI 10.1172/JCI118125; Kloke HJ, 1998, KIDNEY INT, V53, P1559, DOI 10.1046/j.1523-1755.1998.00912.x; LOUTZENHISER R, 1987, AM J CARDIOL, V59, pA72, DOI 10.1016/0002-9149(87)90180-9; LUKE RG, 1991, J AM SOC NEPHROL, V2, pS37; MOURAD G, 1993, KIDNEY INT, V43, P419, DOI 10.1038/ki.1993.61; NEUMAYER HH, 1992, KIDNEY INT, V41, pS87; PAUL LC, 1995, KIDNEY INT, V47, P1491, DOI 10.1038/ki.1995.211; PETERS J, 1995, KIDNEY INT S52, V48, pS97; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; RUGGENENTI P, 1993, KIDNEY INT, V43, P706, DOI 10.1038/ki.1993.101; SCHACHTER M, 1988, J HYPERTENS, V6, P511, DOI 10.1097/00004872-198807000-00001; SENNESAEL J, 1995, HYPERTENSION, V26, P436, DOI 10.1161/01.HYP.26.3.436; VANDERSCHAAF MR, 1995, HYPERTENSION, V25, P77, DOI 10.1161/01.HYP.25.1.77; VENIANT M, 1994, KIDNEY INT, V46, P421, DOI 10.1038/ki.1994.290; VONBORTEL L, 1989, EUR J CLIN PHARMACOL, V36, P467; WAGNER K, 1987, AM J NEPHROL, V7, P287, DOI 10.1159/000167487; WANDEL E, 1987, J CARDIOVASC PHAR S4, V9, pS295; WENZEL UO, 1992, HYPERTENSION, V20, P233, DOI 10.1161/01.HYP.20.2.233; YOSHIDA Y, 1989, KIDNEY INT, V35, P654, DOI 10.1038/ki.1989.35; [No title captured]	31	64	66	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1999	354	9188					1415	1420		10.1016/S0140-6736(99)08421-4	http://dx.doi.org/10.1016/S0140-6736(99)08421-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543667				2022-12-28	WOS:000083277400010
J	Rudolph, U; Crestani, F; Benke, D; Brunig, I; Benson, JA; Fritschy, JM; Martin, JR; Bluethmann, H; Mohler, H				Rudolph, U; Crestani, F; Benke, D; Brunig, I; Benson, JA; Fritschy, JM; Martin, JR; Bluethmann, H; Mohler, H			Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes	NATURE			English	Article							ANTI-ANXIETY AGENTS; SINGLE HISTIDINE; DIAZEPAM; PHARMACOLOGY; SUBUNITS; ETHANOL; MOUSE	GABA(A) (gamma-aminobutyric acid(A)) receptors are molecular substrates for the regulation of vigilance, anxiety, muscle tension, epileptogenic activity and memory functions, which is evident from the spectrum of actions elicited by clinically effective drugs acting at their modulatory benzodiazepine-binding site. Here we show, by introducing a histidine-to-arginine point mutation at position 101 of the murine alpha 1-subunit gene, that alpha 1-type GABA(A) receptors, which are mainly expressed in cortical areas and thalamus(1), are rendered insensitive to allosteric modulation by benzodiazepine-site ligands, whilst regulation by the physiological neurotransmitter gamma-aminobutyric acid is preserved. alpha 1(H101R) mice failed to show the sedative, amnesic and partly the anticonvulsant action of diazepam. In contrast, the anxiolytic-like, myorelaxant, motor-impairing and ethanol-potentiating effects were fully retained, and are attributed to the nonmutated GABA(A) receptors found in the limbic system (alpha 2, alpha 5), in monoaminergic neurons (alpha 3) and in motoneurons (alpha 2, alpha 5)(1). Thus, benzodiazepine-induced behavioural responses are mediated by specific GABA(A) receptor subtypes in distinct neuronal circuits, which is of interest for drug design.	Univ Zurich, Inst Pharmacol, CH-8057 Zurich, Switzerland; ETH Zurich, CH-8057 Zurich, Switzerland; Ciba Geigy AG, Div Pharma, Preclin Res, CH-4002 Basel, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Novartis	Rudolph, U (corresponding author), Univ Zurich, Inst Pharmacol, Winterthurestr 190, CH-8057 Zurich, Switzerland.			Fritschy, Jean-Marc/0000-0002-8552-3702				Barnard EA, 1998, PHARMACOL REV, V50, P291; Benson JA, 1998, FEBS LETT, V431, P400, DOI 10.1016/S0014-5793(98)00803-5; BERNARD F, 1996, ZOLPIDEM UPDATE ITS, P21; BEUZEN A, 1995, PHYSIOL BEHAV, V58, P111, DOI 10.1016/0031-9384(95)00013-9; BONETTI EP, 1988, PHARMACOL BIOCHEM BE, V31, P733, DOI 10.1016/0091-3057(88)90259-6; BONETTI EP, 1982, PSYCHOPHARMACOLOGY, V78, P8, DOI 10.1007/BF00470579; BRAESTRUP C, 1977, NATURE, V269, P702, DOI 10.1038/269702a0; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; HUNKELER W, 1981, NATURE, V290, P514, DOI 10.1038/290514a0; KLEINGOOR C, 1993, NEUROREPORT, V4, P187, DOI 10.1097/00001756-199302000-00018; Knoflach F, 1996, MOL PHARMACOL, V50, P1253; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; MELCHIOR CL, 1992, PHARMACOL BIOCHEM BE, V42, P605, DOI 10.1016/0091-3057(92)90005-Z; MISSLIN R, 1989, BEHAV PROCESS, V18, P119, DOI 10.1016/S0376-6357(89)80010-5; MOHLER H, 1977, SCIENCE, V198, P849, DOI 10.1126/science.918669; VOGEL JR, 1971, PSYCHOPHARMACOLOGIA, V21, P1, DOI 10.1007/BF00403989; WIELAND HA, 1992, J BIOL CHEM, V267, P1426	19	944	972	1	103	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					796	800		10.1038/44579	http://dx.doi.org/10.1038/44579			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548105				2022-12-28	WOS:000083368700054
J	Shamoo, Y; Steitz, TA				Shamoo, Y; Steitz, TA			Building a replisome from interacting pieces: Sliding clamp complexed to a peptide from DNA polymerase and a polymerase editing complex	CELL			English	Article							3'-5' EXONUCLEASE ACTIVITY; I KLENOW FRAGMENT; CRYSTAL-STRUCTURE; REPLICATION COMPLEX; CONSERVED REGION; BINDING-PROTEIN; III HOLOENZYME; BACTERIOPHAGE-T4; SUBUNIT; SITES	We have solved the crystal structures of the bacteriophage RB69 sliding clamp, its complex with a peptide essential for DNA polymerase interactions, and the DNA polymerase complexed with primer-template DNA. The editing complex structure shows a partially melted duplex DNA exiting from the exonuclease domain at an unexpected angle and significant changes in the protein structure. The clamp complex shows the C-terminal 11 residues of polymerase bound in a hydrophobic pocket, and it allows docking of the editing and clamp structures together. The peptide binds to the sliding clamp at a position identical to that of a replication inhibitor peptide bound to PCNA, suggesting that the replication inhibitor protein p21(CIP1) functions by competing with eukaryotic polymerases for the same binding pocket on the clamp.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009	Shamoo, Yousif/0000-0001-9241-8962	NIGMS NIH HHS [GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Baker RP, 1998, P NATL ACAD SCI USA, V95, P3507, DOI 10.1073/pnas.95.7.3507; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Berdis AJ, 1996, P NATL ACAD SCI USA, V93, P12822, DOI 10.1073/pnas.93.23.12822; BERNAD A, 1990, GENE, V94, P45, DOI 10.1016/0378-1119(90)90466-5; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Gibbs E, 1997, J BIOL CHEM, V272, P2373; Goodrich LD, 1997, BIOCHEMISTRY-US, V36, P10474, DOI 10.1021/bi9708949; GOPALAKRISHNAN V, 1994, J BIOL CHEM, V269, P21123; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOUNG I, 1991, VIROLOGY, V184, P235, DOI 10.1016/0042-6822(91)90840-8; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN TC, 1994, J BIOL CHEM, V269, P19286; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; NICHOLLS KA, 1993, BIOPHYS J, V64, pA166; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; Reha-Krantz LJ, 1998, J BIOL CHEM, V273, P22969, DOI 10.1074/jbc.273.36.22969; Rice LM, 1998, J APPL CRYSTALLOGR, V31, P798, DOI 10.1107/S0021889898006645; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Soumillion P, 1998, BIOCHEMISTRY-US, V37, P1819, DOI 10.1021/bi972526a; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P438; SPICER EK, 1982, J BIOL CHEM, V257, P8972; STOCKI SA, 1995, J MOL BIOL, V254, P15, DOI 10.1006/jmbi.1995.0595; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TINKER RL, 1995, J BIOL CHEM, V270, P15899, DOI 10.1074/jbc.270.26.15899; WANG CC, 1995, J BIOL CHEM, V270, P26558, DOI 10.1074/jbc.270.44.26558; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wu P, 1998, BIOCHEMISTRY-US, V37, P14748, DOI 10.1021/bi980835a; Yeh LS, 1998, J BACTERIOL, V180, P2005, DOI 10.1128/JB.180.8.2005-2013.1998	54	306	323	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					155	166		10.1016/S0092-8674(00)81647-5	http://dx.doi.org/10.1016/S0092-8674(00)81647-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535734	hybrid			2022-12-28	WOS:000083159700006
J	Sireteanu, R				Sireteanu, R			Neuroscience - Switching on the infant brain	SCIENCE			English	Editorial Material							LECTURE		Max Planck Inst Brain Res, Dept Neurophysiol, D-60496 Frankfurt, Germany; Goethe Univ Frankfurt, Dept Physiol Psychol, D-6000 Frankfurt, Germany	Max Planck Society; Goethe University Frankfurt	Sireteanu, R (corresponding author), Max Planck Inst Brain Res, Dept Neurophysiol, D-60496 Frankfurt, Germany.	sireteanu@mpih-frankfurt.mpg.de						Klinke R, 1999, SCIENCE, V285, P1729, DOI 10.1126/science.285.5434.1729; Maurer D, 1999, SCIENCE, V286, P108, DOI 10.1126/science.286.5437.108; Mitchell DE, 1998, CURR BIOL, V8, P1179, DOI 10.1016/S0960-9822(07)00489-7; MOHN G, 1986, CLIN VISION SCI, V1, P51; SCHATZ CS, 1996, P NATL ACAD SCI USA, V93, P602; TELLER DY, 1986, DEV MED CHILD NEUROL, V28, P779; Teller DY, 1997, INVEST OPHTH VIS SCI, V38, P2183; Vital-Durand F, 1996, Strabismus, V4, P89, DOI 10.3109/09273979609055044; VONNOORDEN GK, 1985, INVEST OPHTH VIS SCI, V26, P1704; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003	10	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					59	+		10.1126/science.286.5437.59	http://dx.doi.org/10.1126/science.286.5437.59			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10532890				2022-12-28	WOS:000082907400030
J	Hall, DMB				Hall, DMB			Children in an ageing society	BRITISH MEDICAL JOURNAL			English	Article							LIFE		Community Hlth Sheffield, Sheffield S5 7AU, S Yorkshire, England; Univ Sheffield, No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England	Northern General Hospital; University of Sheffield	Hall, DMB (corresponding author), Community Hlth Sheffield, Community Sci Bldg, Sheffield S5 7AU, S Yorkshire, England.							ACHESON D, 1998, INDEPENDENT INQUIRY, P67; Fiorentino L, 1998, ARCH DIS CHILD, V79, P306, DOI 10.1136/adc.79.4.306; HEALY J, 1997, FAMILY MATTERS PAREN; HUTTON JL, 1994, BRIT MED J, V309, P431, DOI 10.1136/bmj.309.6952.431; Kagitcibasi C., 1996, FAMILY HUMAN DEV CUL; McAllister F., 1998, CHOOSING CHILDLESSNE; *OFF NAT STAT, 1997, OFF NAT STAT FM1, V26, P59; *OFF NAT STAT, 1987, OFF NAT STAT FM1, V16, P73; *OFF POP CENS SURV, 1995, HLTH OUR CHILDR DE S; Walker A., 1997, BRITAIN DIVIDED GROW; Walker A., 1998, UNCERTAIN FUTURES PE	11	9	9	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1356	1358		10.1136/bmj.319.7221.1356	http://dx.doi.org/10.1136/bmj.319.7221.1356			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567149	Green Published			2022-12-28	WOS:000083930200031
J	Wilson, CB				Wilson, CB			Sensors in medicine	BRITISH MEDICAL JOURNAL			English	Article								Sensors are devices that detect physical, chemical, and biological signals and provide a way for those signals to be measured and recorded.(1) Physical properties that tan be sensed include temperature, pressure, vibration, sound lever, light intensity, load or weight, flow rate of gases and liquids, amplitude of magnetic and electronic fields, and concentrations of many substances in gaseous, liquid, or solid form. Although sensors of today ale where computers were in 1970 medical applications of sensors are taking off because of advances in microchip technologies and molecular chemistry.(2 3)	Inst Future, Menlo Park, CA 94025 USA		Wilson, CB (corresponding author), Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.							ALLGOOD GO, 1999, SENSORS          MAY, P70; BUERK G, 1993, BIOSENSORS THEORY AP; *FOOD DRUG ADM, 1999, SUMM M CLIN CHEM CLI; Fraden J., 1996, HDB MODERN SENSORS; FRANK R, 1996, UNDERSTANDING SMART; HELLMAN H, 1997, YOUR SENSES; JOSEPH H, 1997, SENSORS          APR, P47; Pitt B, 1999, NEW ENGL J MED, V341, P70, DOI 10.1056/NEJM199907083410202; POLLACK A, 1999, NY TIMES        0211; Regis Ed., 1995, NANOEMERGING SCI NAN; ROBINSON K, 1999, PHOTONICS SPECTR JAN, P43; SOLOVY A, 1998, HOSPITALS HLTH  0705; WIEBE C, 1999, AM MED NEWS     0621; Zenner HP, 1998, LANCET, V352, P1751, DOI 10.1016/S0140-6736(98)00076-2; 1999, CNN INTERACTIVE  JAN, P28	15	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1999	319	7220					1288	U27		10.1136/bmj.319.7220.1288	http://dx.doi.org/10.1136/bmj.319.7220.1288			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257MZ	10559041	Green Published			2022-12-28	WOS:000083786900010
J	Keefe, R; Dave, V; Allman, D; Wiest, D; Kappes, DJ				Keefe, R; Dave, V; Allman, D; Wiest, D; Kappes, DJ			Regulation of lineage commitment distinct from positive selection	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; T-CELLS; THYMIC SELECTION; INTERMEDIATE STEPS; CD8 LINEAGE; THYMOCYTES; MICE; MODEL; GENERATION; EXPRESSION	Developing alpha beta T cells diverge into the CD4 and CD8 Lineages as they mature in the thymus. It is unclear whether Lineage commitment is mechanistically distinct from the process that selects for the survival of T cells with useful T cell receptor (TCR) specificities (positive selection). In HD mice, which Lack mature CD4(+) T cells, major histocompatibility complex (MHC) class II-restricted T cells are redirected to the CD8 lineage independent of MHC class I expression. However, neither TCR-mediated signaling nor positive selection is impaired. Thus, the HD mutation provides genetic evidence that lineage commitment may be mechanistically distinct from positive selection.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Kappes, DJ (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Wiest, David/0000-0002-0792-3188	NATIONAL CANCER INSTITUTE [P30CA006927, R01CA074620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034472] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA74620] Funding Source: Medline; NIAID NIH HHS [AI34472] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLMAN D, UNPUB; ASHTONRICKARDT PG, 1994, IMMUNOL TODAY, V15, P362, DOI 10.1016/0167-5699(94)90174-0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; Dave VP, 1998, P NATL ACAD SCI USA, V95, P8187, DOI 10.1073/pnas.95.14.8187; DAVE VP, UNPUB; Gabor MJ, 1997, EUR J IMMUNOL, V27, P2010, DOI 10.1002/eji.1830270827; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; KAPPES DJ, UNPUB; KAYE J, 1992, J IMMUNOL, V148, P3342; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KEEFE R, UNPUB; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KIRBERG J, 1994, J EXP MED, V180, P25, DOI 10.1084/jem.180.1.25; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KYDD R, 1995, J IMMUNOL, V155, P3806; LUCAS B, 1994, J IMMUNOL, V153, P53; Lucas B, 1996, IMMUNITY, V5, P461, DOI 10.1016/S1074-7613(00)80502-6; LUNDBERG K, 1995, J EXP MED, V181, P1643, DOI 10.1084/jem.181.5.1643; Matechak EO, 1996, IMMUNITY, V4, P337, DOI 10.1016/S1074-7613(00)80247-2; Punt JA, 1996, J EXP MED, V184, P2091, DOI 10.1084/jem.184.6.2091; RAVICHANDRAN KS, 1994, J EXP MED, V179, P727, DOI 10.1084/jem.179.2.727; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SCOLLAY R, 1980, J IMMUNOL, V124, P2845; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; SUZUKI H, 1995, IMMUNITY, V2, P413, DOI 10.1016/1074-7613(95)90149-3; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Wiest DL, 1997, IMMUNITY, V6, P663, DOI 10.1016/S1074-7613(00)80442-2; YAMASHITA I, 1993, INT IMMUNOL, V5, P1139, DOI 10.1093/intimm/5.9.1139	33	86	87	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1149	1153		10.1126/science.286.5442.1149	http://dx.doi.org/10.1126/science.286.5442.1149			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550051				2022-12-28	WOS:000083534200041
J	Kroger, N; Deutzmann, R; Sumper, M				Kroger, N; Deutzmann, R; Sumper, M			Polycationic peptides from diatom biosilica that direct silica nanosphere formation	SCIENCE			English	Article							CELL-WALLS; PROTEIN; MORPHOGENESIS; ACID	Diatom cell walls are regarded as a paradigm for controlled production of nanostructured silica, but the mechanisms allowing biosilicification to proceed at ambient temperature at high rates have remained enigmatic. A set of polycationic peptides (called silaffins) isolated from diatom cell walls were shown to generate networks of silica nanospheres within seconds when added to a solution of silicic acid. Silaffins contain covalently modified Lysine-Lysine elements. The first Lysine bears a polyamine consisting of 6 to 11 repeats of the N-methyl-propylamine unit. The second Lysine was identified as epsilon-N,N-dimethyl-lysine. These modifications drastically influence the silica-precipitating activity of silaffins.	Univ Regensburg, Lehrstuhl Biochem 1, D-93053 Regensburg, Germany	University of Regensburg	Kroger, N (corresponding author), Univ Regensburg, Lehrstuhl Biochem 1, D-93053 Regensburg, Germany.	nils.kroeger@vkl.uni-regensburg.de						BOROWITZKA MA, 1978, J PHYCOL, V14, P10; Cha JN, 1999, P NATL ACAD SCI USA, V96, P361, DOI 10.1073/pnas.96.2.361; CHIAPPINO ML, 1977, PROTOPLASMA, V93, P205, DOI 10.1007/BF01275654; GORDON R, 1994, INT REV CYTOL, V150, P243; HECKY RE, 1973, MAR BIOL, V19, P323, DOI 10.1007/BF00348902; Iler R. K, 1979, CHEM SILICA; Kroger N, 1996, EUR J BIOCHEM, V239, P259, DOI 10.1111/j.1432-1033.1996.0259u.x; Kroger N, 1997, EUR J BIOCHEM, V250, P99, DOI 10.1111/j.1432-1033.1997.00099.x; LINDQUIST GM, 1976, J COLLOID INTERF SCI, V55, P45, DOI 10.1016/0021-9797(76)90007-2; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; Mann S, 1996, NATURE, V382, P313, DOI 10.1038/382313a0; Mann S., 1989, BIOMINERALIZATION CH; Mizutani T, 1998, B CHEM SOC JPN, V71, P2017, DOI 10.1246/bcsj.71.2017; NAKAJIMA T, 1969, SCIENCE, V164, P1400, DOI 10.1126/science.164.3886.1400; OLIVER S, 1995, NATURE, V378, P47, DOI 10.1038/378047a0; Pickett-Heaps J., 1990, PROGR PHYCOLOGICAL R, V7, P1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID AMM, 1979, PROTOPLASMA, V100, P267, DOI 10.1007/BF01279316; Shimizu K, 1998, P NATL ACAD SCI USA, V95, P6234, DOI 10.1073/pnas.95.11.6234; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWIFT DM, 1992, J PHYCOL, V28, P202, DOI 10.1111/j.0022-3646.1992.00202.x; Volcani B., 1981, SILICON SILICEOUS ST, P157; Vrieling EG, 1999, J PHYCOL, V35, P548, DOI 10.1046/j.1529-8817.1999.3530548.x	23	1129	1180	13	330	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1129	1132		10.1126/science.286.5442.1129	http://dx.doi.org/10.1126/science.286.5442.1129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550045				2022-12-28	WOS:000083534200035
J	Cavalli, G; Paro, R				Cavalli, G; Paro, R			Epigenetic inheritance of active chromatin after removal of the main transactivator	SCIENCE			English	Article							DROSOPHILA BITHORAX COMPLEX; POLYCOMB-PROTEIN; DOMAIN BOUNDARY; MELANOGASTER; TRITHORAX; GENE; EXPRESSION; ELEMENTS; BINDING	The Drosophila Polycomb and trithorax group proteins act through chromosomal elements such as Fab-7 to maintain repressed or active gene expression, respectively. A Fab-7 element is switched from a silenced to a mitotically heritable active state by an embryonic pulse of transcription. Here, histone H4 hyperacetylation was found to be associated with Fab-7 after activation, suggesting that H4 hyperacetylation may be a heritable epigenetic tag of the activated element, Activated Fab-7 enables transcription of a gene even after withdrawal of the primary transcription factor. This feature may allow epigenetic maintenance of active states of developmental genes after decay of their early embryonic regulators.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Inst Human Genet, F-34396 Montpellier, France	Ruprecht Karls University Heidelberg; Universite de Montpellier	Paro, R (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.		cavalli, giacomo/Z-2754-2019; Cavalli, Giacomo/A-7958-2008	cavalli, giacomo/0000-0003-3709-3469; Cavalli, Giacomo/0000-0003-3709-3469				BREILING A, IN PRESS MOL CELL BI; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; FAUVARQUE MO, 1995, MECH DEVELOP, V52, P343, DOI 10.1016/0925-4773(95)00412-T; Gellon G, 1998, BIOESSAYS, V20, P116, DOI 10.1002/(SICI)1521-1878(199802)20:2<116::AID-BIES4>3.3.CO;2-N; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; Hagstrom K, 1997, GENETICS, V146, P1365; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; LaJeunesse D, 1996, DEVELOPMENT, V122, P2189; Mihaly J, 1997, DEVELOPMENT, V124, P1809; Orlando V, 1998, EMBO J, V17, P5141, DOI 10.1093/emboj/17.17.5141; Paro R., 1996, EPIGENETIC MECH GENE, P507; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Strutt H, 1997, MOL CELL BIOL, V17, P6773, DOI 10.1128/MCB.17.12.6773; Tillib S, 1999, MOL CELL BIOL, V19, P5189; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	24	198	209	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					955	958		10.1126/science.286.5441.955	http://dx.doi.org/10.1126/science.286.5441.955			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542150				2022-12-28	WOS:000083368500045
J	Mathews, S; Donoghue, MJ				Mathews, S; Donoghue, MJ			The root of angiosperm phylogeny inferred from duplicate phytochrome genes	SCIENCE			English	Article							SEED PLANT PHYLOGENY; DATA SETS; SEQUENCES; EVOLUTION; ORIGIN; DIVERSIFICATION; PARSIMONY; DIVERSITY; FAMILY	An analysis of duplicate phytochrome genes (PHYA and PHYC) is used to root the angiosperms, thereby avoiding the inclusion of highly diverged outgroup sequences. The results unambiguously place the root near Amborella tone species, New Caledonia) and resolve water Lilies (Nymphaeales, similar to 70 species, cosmopolitan), followed by Austrobaileya tone species, Australia), as early branches. These findings bear directly on the interpretation of morphological evolution and diversification within angiosperms.	Harvard Univ Herbaria, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA	Harvard University	Mathews, S (corresponding author), Harvard Univ Herbaria, Dept Organism & Evolutionary Biol, 22 Divin Ave, Cambridge, MA 02138 USA.	smathews@oeb.harvard.edu	Mathews, Sarah/A-6513-2015	Mathews, Sarah/0000-0002-5518-7541				BOWE LM, IN PRESS P NATL ACAD; CARLQUIST S, 1992, AM J BOT, V79, P660, DOI 10.2307/2444882; Carlquist S, 1975, ECOLOGICAL STRATEGIE; Chase MW, 1998, AUST SYST BOT, V11, P215, DOI 10.1071/SB97010; CHAW SM, IN PRESS P NATL ACAD; Donoghue MJ, 1998, MOL PHYLOGENET EVOL, V9, P489, DOI 10.1006/mpev.1998.0511; DOYLE JA, 1986, BOT REV, V52, P321, DOI 10.1007/BF02861082; DOYLE JA, 1993, PALEOBIOLOGY, V19, P141, DOI 10.1017/S0094837300015840; Doyle JA, 1996, INT J PLANT SCI, V157, pS3, DOI 10.1086/297401; ENDRESS PK, UNPUB; Farris JS, 1995, SYST BIOL, V44, P570, DOI 10.2307/2413663; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; GRAHAM SV, UNPUB; Hansen A, 1999, MOL BIOL EVOL, V16, P1006, DOI 10.1093/oxfordjournals.molbev.a026176; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; Howe GT, 1998, MOL BIOL EVOL, V15, P160, DOI 10.1093/oxfordjournals.molbev.a025912; Igersheim A, 1997, BOT J LINN SOC, V124, P213, DOI 10.1006/bojl.1997.0102; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; Kim JH, 1996, SYST BIOL, V45, P363, DOI 10.2307/2413570; Larson A., 1994, P371; Lavin M, 1998, AM J BOT, V85, P412, DOI 10.2307/2446334; MATHEWS S, 1995, ANN MO BOT GARD, V82, P296, DOI 10.2307/2399882; Mathews S, 1997, PLANT CELL ENVIRON, V20, P666, DOI 10.1046/j.1365-3040.1997.d01-117.x; MATHEWS SM, UNPUB; Nandi OI, 1998, ANN MO BOT GARD, V85, P137, DOI 10.2307/2992003; PARKINSON CJ, UNPUB; QIU YL, IN PRESS NATURE; Renner SS, 1999, AM J BOT, V86, P1301, DOI 10.2307/2656778; SANDERSON MJ, 1994, SCIENCE, V264, P1590, DOI 10.1126/science.264.5165.1590; Sang T, 1997, MOL BIOL EVOL, V14, P994, DOI 10.1093/oxfordjournals.molbev.a025716; Schneider EL, 1996, AM J BOT, V83, P1236, DOI 10.2307/2446207; Schneider-Poetsch HAW, 1998, PHYSIOL PLANTARUM, V102, P612, DOI 10.1034/j.1399-3054.1998.1020417.x; Soltis DE, 1997, ANN MO BOT GARD, V84, P1, DOI 10.2307/2399952; SOLTIS PS, IN PRESS NATURE; SWOFFORD D, 1999, PAUP 4 0; THEIN LB, UNPUB; WELLER SG, 1995, MONOG SYST BOTAN, V53, P355; WHITEHOUSE HLK, 1950, ANN BOT-LONDON, V14, P199, DOI 10.1093/oxfordjournals.aob.a083243; Winter KU, 1999, P NATL ACAD SCI USA, V96, P7342, DOI 10.1073/pnas.96.13.7342; YOUNG DA, 1981, SYST BOT, V6, P313, DOI 10.2307/2418445	40	347	362	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					947	950		10.1126/science.286.5441.947	http://dx.doi.org/10.1126/science.286.5441.947			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542147				2022-12-28	WOS:000083368500042
J	Smith, R				Smith, R			The NHS in Dumfries and Galloway: straining but optimistic	BRITISH MEDICAL JOURNAL			English	Article									BMJ, London WC1H 9TD, England		Smith, R (corresponding author), BMJ, London WC1H 9TD, England.							DUMFRIES, 1980, BMJ, V281, P438; *JOINT WORK PART B, 1998, PROV AC HOSP SERV; *SCOTT EX HLTH DEP, 1999, FAIR SHAR ALL REP NA; SCOTT P, 1977, STAYING; Smith R, 1999, BRIT MED J, V319, P2, DOI 10.1136/bmj.319.7201.2; SMITH R, 1989, BRIT MED J, V299, P727, DOI 10.1136/bmj.299.6701.727	6	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1123	1127		10.1136/bmj.319.7217.1123	http://dx.doi.org/10.1136/bmj.319.7217.1123			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531111	Green Published			2022-12-28	WOS:000083419500034
J	Howdeshell, KL; Hotchkiss, AK; Thayer, KA; Vandenbergh, JG; vom Saal, FS				Howdeshell, KL; Hotchkiss, AK; Thayer, KA; Vandenbergh, JG; vom Saal, FS			Environmental toxins - Exposure to bisphenol A advances puberty	NATURE			English	Article									Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Zool, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Howdeshell, KL (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.	vomsaalf@missouri.edu						COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; EVEN MD, 1992, J REPROD FERTIL, V96, P709, DOI 10.1530/jrf.0.0960709; GRAY LE, 1992, ADV MOD ENV, V21, P203; HermanGiddens ME, 1997, PEDIATRICS, V99, P505, DOI 10.1542/peds.99.4.505; HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1321, DOI 10.1093/oxfordjournals.aje.a116444; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.2307/3433065; PANAGIOTOPOULOU K, 1990, CANCER CAUSE CONTROL, V1, P119, DOI 10.1007/BF00053162; Paulozzi LJ, 1997, PEDIATRICS, V100, P831, DOI 10.1542/peds.100.5.831; SAAL FSV, 1989, J ANIM SCI, V67, P1824; TAKAO Y, 1999, J HEALTH SCI, V45, P39; VANDENBERGH JG, 1969, ENDOCRINOLOGY, V84, P658, DOI 10.1210/endo-84-3-658; VOMSAAL FS, 1981, J REPROD FERTIL, V62, P633, DOI [10.1530/jrf.0.0620633, 10.1530/jrf.0.0620033]; VOMSAAL FS, 1998, FORUM APPL RES PUBLI, V13, P11	14	657	688	5	131	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					763	764		10.1038/44517	http://dx.doi.org/10.1038/44517			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548101				2022-12-28	WOS:000083368700043
J	Yawn, BP; Yawn, RA; Hodge, D; Shaughnessy, WJ; Ilstrup, D; Jacobsen, SJ				Yawn, BP; Yawn, RA; Hodge, D; Shaughnessy, WJ; Ilstrup, D; Jacobsen, SJ			A population-based study of school scoliosis screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADOLESCENT IDIOPATHIC SCOLIOSIS; NATURAL-HISTORY; EPIDEMIOLOGY	Context Although school-based screening programs for adolescent idiopathic scoliosis are mandated in 26 states in the United States, few program outcomes data exist regarding the effectiveness of such programs. Objective To determine the effectiveness of a community-based school scoliosis screening program. Design, Setting, and Participants Retrospective cohort study of children who attended kindergarten or first grade at public or private schools in Rochester, Minn, during 1979-1982. Children were followed up until age 19 years or until they left the school district. Main Outcome Measures Number of children diagnosed and treated for scoliosis, based on results from scoliosis screenings performed annually in grades 5 through 9, linked to community medical records data; performance characteristics of the screening program. Results Of the 2242 children screened, 92 (4.1%) were referred for further evaluation. Of these, 68 (74%) had documented medical or chiropractic evaluation of scoliosis. School screening identified 5 of the 9 children treated for scoliosis but resulted in referrals for another 87 children who were not treated. The cumulative incidence of diagnosed scoliosis in this population was 1.8% (95% confidence interval [CI], 1.2%-2.3 %) for curves of more than 10 degrees, 1.0% (95% CI, 0.6%-1.5%) for curves of at least 20 degrees, and 0.4% (95% CI, 0.1%-0.6%) for curves of 40 degrees or more; 0.4% (0.5% of girls and 0.3% of boys) were treated for scoliosis. The positive predictive value of the school screening program for the identification of treated scoliosis was 0.05 (95% CI, 0.048-0.052), with 448 children needed to screen to identify 1 child who subsequently received treatment. The percent positive agreement across consecutive years of screening varied from 7% to 30%. Conclusion In this population, school scoliosis screening identified some children who went on to receive treatment but referred many more who did not. These data should be considered in making decisions regarding school scoliosis screening.	Olmsted Med Ctr, Dept Res, Rochester, MN 55904 USA; Mayo Clin, Biostat Sect, Rochester, MN USA; Mayo Clin, Clin Epidemiol Sect, Rochester, MN USA; Mayo Clin, Dept Orthoped, Rochester, MN USA	Olmsted Medical Center; Mayo Clinic; Mayo Clinic; Mayo Clinic	Yawn, BP (corresponding author), Olmsted Med Ctr, Dept Res, 210 9th St SE, Rochester, MN 55904 USA.		shaughnessy, william/AAJ-4458-2020	Jacobsen, Steven/0000-0002-8174-8533	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30582] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMENDT LE, 1990, PHYS THER, V70, P108, DOI 10.1093/ptj/70.2.108; ASHWORTH MA, 1988, SPINE, V13, P1187, DOI 10.1097/00007632-198810000-00024; BERG O, 1993, J AM BOARD FAM PRACT, V6, P497; BERWICK DM, 1985, PEDIAT REV, V5, P238; BUNNELL WP, 1984, J BONE JOINT SURG AM, V66A, P1381, DOI 10.2106/00004623-198466090-00010; BUNNELL WP, 1986, SPINE, V11, P773, DOI 10.1097/00007632-198610000-00003; BUNNELL WP, 1993, SPINE, V18, P1572, DOI 10.1097/00007632-199309000-00001; BURWELL RG, 1988, SPINE, V13, P1192; DICKSON RA, 1980, BRIT MED J, V281, P265, DOI 10.1136/bmj.281.6235.265; DIGUISEPPI C, 1996, US PREVENTIVE SERVIC; GORE DR, 1981, PEDIATRICS, V67, P196; LEAVER JM, 1982, INT J EPIDEMIOL, V11, P101, DOI 10.1093/ije/11.2.101; LONSTEIN JE, 1982, J BONE JOINT SURG AM, V64, P481, DOI 10.2106/00004623-198264040-00002; LONSTEIN JE, 1988, SPINE, V13, P1198, DOI 10.1097/00007632-198810000-00029; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; MONTGOMERY SA, 1990, INT CLIN PSYCHOPHARM, V5, P67; MORAIS T, 1985, AM J PUBLIC HEALTH, V75, P1377, DOI 10.2105/AJPH.75.12.1377; NACHEMSON AL, 1995, J BONE JOINT SURG AM, V77A, P815, DOI 10.2106/00004623-199506000-00001; OHTSUKA Y, 1988, SPINE, V13, P1251, DOI 10.1097/00007632-198811000-00008; PRUIJS JEH, 1992, SPINE, V17, P431, DOI 10.1097/00007632-199204000-00009; RENSHAW TS, 1988, CLIN ORTHOP RELAT R, P26; ROBITAILLE Y, 1984, INT J EPIDEMIOL, V13, P319, DOI 10.1093/ije/13.3.319; ROGALA EJ, 1978, J BONE JOINT SURG AM, V60, P173, DOI 10.2106/00004623-197860020-00005; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P153; Skaggs DL, 1996, J BONE JOINT SURG AM, V78A, P151, DOI 10.2106/00004623-199601000-00024; SMYRNIS T, 1987, ORTHOPEDICS, V10, P921; Soucacos PN, 1997, J BONE JOINT SURG AM, V79A, P1498, DOI 10.2106/00004623-199710000-00006; WILLNER S, 1982, ACTA ORTHOP SCAND, V53, P233, DOI 10.3109/17453678208992208; WOOLF SH, 1993, JAMA-J AM MED ASSOC, V269, P2664; Yawn BP, 1996, J SCHOOL HEALTH, V66, P171, DOI 10.1111/j.1746-1561.1996.tb06269.x	30	101	106	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1427	1432		10.1001/jama.282.15.1427	http://dx.doi.org/10.1001/jama.282.15.1427			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535432	Bronze			2022-12-28	WOS:000083111000027
J	Marcil, M; Brooks-Wilson, A; Clee, SM; Roomp, K; Zhang, LH; Yu, L; Collins, JA; van Dam, M; Molhuizen, HOF; Loubster, O; Ouellette, BFF; Sensen, CW; Fichter, K; Mott, S; Denis, M; Boucher, B; Pimstone, S; Genest, J; Kastelein, JJP; Hayden, MR				Marcil, M; Brooks-Wilson, A; Clee, SM; Roomp, K; Zhang, LH; Yu, L; Collins, JA; van Dam, M; Molhuizen, HOF; Loubster, O; Ouellette, BFF; Sensen, CW; Fichter, K; Mott, S; Denis, M; Boucher, B; Pimstone, S; Genest, J; Kastelein, JJP; Hayden, MR			Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux	LANCET			English	Article							SUBSTRATE-SPECIFICITY; TANGIER-DISEASE; APOA-I; LIPOPROTEIN; HYPERCATABOLISM; TRANSPORTER; FIBROBLASTS; DYSTROPHY; POSITION; LIPASE	Background A low concentration of HDL cholesterol is the most common lipoprotein abnormality in patients with premature atherosclerosis. We have shown that Tangier disease, a rare and severe form of HDL deficiency characterised by a biochemical defect in cellular cholesterol efflux, is caused by mutations in the ATP-binding-cassette (ABC1) gene. This gene codes for the cholesterol-efflux regulatory protein (CERP). We investigated the presence of mutations in this gene in patients with familiar HDL deficiency. Methods Three French-Canadian families and one Dutch family with familial HDL deficiency were studied. Fibroblasts from the proband of each family were defective in cellular cholesterol efflux. Genomic DNA of each proband was used for mutation detection with primers flanking each exon of the ABC1 gene, and for sequencing of the entire coding region of the gene. PCR and restriction-fragment length polymorphism assays specific to each mutation were used to investigate segregation of the mutation in each family, and to test for absence of the mutation in DNA from normal controls. Findings A different mutation was detected in ABC1 in each family studied. Each mutation either created a stop codon predicted to result in truncation of CERP, or altered a conserved aminoacid residue. Each mutation segregated with low concentrations of HDL-cholesterol in the family, and was not observed in more than 500 control chromosomes tested. Interpretation These data show that mutations in ABC1 are the major cause of familial HDL deficiency associated with defective cholesterol efflux, and that CERP has an essential role in the formation of HDL. Our findings highlight the potential of modulation of ABC1 as a new route for increasing HDL concentrations.	Xenon Biores Inc, NRC Innovat Ctr, Vancouver, BC, Canada; Univ British Columbia, Womens & Childrens Hosp, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 1M9, Canada; Acad Med Ctr, Dept Vasc Med, NL-1005 AZ Amsterdam, Netherlands; Clin Res Inst Montreal, Cardiovasc Genet Lab, Montreal, PQ H2W 1R7, Canada; NRC, Inst Marine Biosci, Halifax, NS, Canada	National Research Council Canada; University of British Columbia; University of Amsterdam; Academic Medical Center Amsterdam; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; National Research Council Canada	Hayden, MR (corresponding author), Ctr Mol Med & Therapeut, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	mrh@cmmt.ubc.ca	Clee, Susanne/F-7312-2010; Collins, Jennifer/AAE-1895-2020; Kastelein, John/AAF-7950-2020; Hayden, Michael R/D-8581-2011; Brooks-Wilson, Angela/E-9399-2012; Sensen, Christoph W./C-1798-2013; Clee, Susanne/AAC-4278-2020; van Dam, Marjel/AFT-3071-2022	Clee, Susanne/0000-0001-7946-688X; Hayden, Michael R/0000-0001-5159-1419; Brooks-Wilson, Angela/0000-0003-1009-6408; Sensen, Christoph W./0000-0001-9604-8962; Ouellette, B. F. Francis/0000-0003-4676-675X; van Dam, Marjel/0000-0001-9802-7516				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Batal R, 1998, ARTERIOSCL THROM VAS, V18, P655, DOI 10.1161/01.ATV.18.4.655; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P161, DOI 10.1016/0021-9150(82)90136-8; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CHEUNG MC, 1993, J CLIN INVEST, V91, P522, DOI 10.1172/JCI116231; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; Eberhart GP, 1998, J CLIN ENDOCR METAB, V83, P836, DOI 10.1210/jc.83.3.836; EISENBERG S, 1984, J LIPID RES, V25, P1017; EMMERICH J, 1993, ARTERIOSCLER THROMB, V13, P1299, DOI 10.1161/01.ATV.13.9.1299; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Kuivenhoven JA, 1997, J LIPID RES, V38, P191; Kuivenhoven JA, 1997, ARTERIOSCL THROM VAS, V17, P560, DOI 10.1161/01.ATV.17.3.560; MARCIL M, 1995, ARTERIOSCL THROM VAS, V15, P1015, DOI 10.1161/01.ATV.15.8.1015; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; ROSENTHAL A, 1993, NUCLEIC ACIDS RES, V21, P173, DOI 10.1093/nar/21.1.173; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schuler GD, 1998, METHOD BIOCHEM ANAL, V39, P145; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; Taguchi Y, 1997, BIOCHEMISTRY-US, V36, P8883, DOI 10.1021/bi970553v; Taguchi Y, 1997, FEBS LETT, V413, P142, DOI 10.1016/S0014-5793(97)00899-5; TALMUD P, 1982, GENET EPIDEMIOL, V45, P161; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toh S, 1999, AM J HUM GENET, V64, P739, DOI 10.1086/302292; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	35	299	316	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1999	354	9187					1341	1346		10.1016/S0140-6736(99)07026-9	http://dx.doi.org/10.1016/S0140-6736(99)07026-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533863				2022-12-28	WOS:000083149900012
J	Tabara, H; Sarkissian, M; Kelly, WG; Fleenor, J; Grishok, A; Timmons, L; Fire, A; Mello, CC				Tabara, H; Sarkissian, M; Kelly, WG; Fleenor, J; Grishok, A; Timmons, L; Fire, A; Mello, CC			The rde-1 gene, RNA interference, and transposon silencing in C-elegans	CELL			English	Article							DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; ANTISENSE RNA; MESSENGER-RNA; SEQUENCE; EXPRESSION; ELEMENTS; GERMLINE; EMBRYOS	Double-stranded (ds) RNA can induce sequence-specific inhibition of gene function in several organisms. However, both the mechanism and the physiological role of the interference process remain mysterious. In order to study the interference process, we have selected C. elegans mutants resistant to dsRNA-mediated interference (RNAi). Two loci, rde-1 and rde-4, are defined by mutants strongly resistant to RNAi but with no obvious defects in growth or development. We show that rde-1 is a member of the piwi/sting/argonaute/zwille/elF2C gene family conserved from plants to vertebrates. Interestingly, several, but not all, RNAi-deficient strains exhibit mobilization of the endogenous transposons. We discuss implications for the mechanism of RNAi and the possibility that one natural function of RNAi is transposon silencing.	Univ Massachusetts, Ctr Canc, Program Mol Med, Dept Cell Biol, Worcester, MA 01605 USA; Carnegie Inst Sci, Dept Embryol, Baltimore, MD 21210 USA	University of Massachusetts System; University of Massachusetts Worcester; Carnegie Institution for Science	Mello, CC (corresponding author), Univ Massachusetts, Ctr Canc, Program Mol Med, Dept Cell Biol, Worcester, MA 01605 USA.	craig.mello@ummed.edu	Pillay, Nischalan/F-9536-2012	Fire, Andrew/0000-0001-6217-8312	NICHD NIH HHS [HD08353] Funding Source: Medline; NIGMS NIH HHS [GM37706, R01 GM037706, GM58800] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058800] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; Anandalakshmi R, 1998, P NATL ACAD SCI USA, V95, P13079, DOI 10.1073/pnas.95.22.13079; Beclin C, 1998, VIROLOGY, V252, P313, DOI 10.1006/viro.1998.9457; Benfey PN, 1999, CURR BIOL, V9, pR171, DOI 10.1016/S0960-9822(99)80105-5; Birchler JA, 1999, NAT GENET, V21, P148, DOI 10.1038/5926; Bohmert K, 1998, EMBO J, V17, P170, DOI 10.1093/emboj/17.1.170; Boyd L, 1996, DEVELOPMENT, V122, P3075; BRENNER S, 1974, GENETICS, V77, P71; Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; COLLINS J, 1989, GENETICS, V121, P47; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; COLLINS JJ, 1994, GENETICS, V137, P771; Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; Elmayan T, 1998, PLANT CELL, V10, P1747, DOI 10.1105/tpc.10.10.1747; FIRE A, 1991, DEVELOPMENT, V113, P503; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Henikoff S, 1998, BIOESSAYS, V20, P532, DOI 10.1002/(SICI)1521-1878(199807)20:7<532::AID-BIES3>3.3.CO;2-0; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Kelly WG, 1998, DEVELOPMENT, V125, P2451; Kelly WG, 1997, GENETICS, V146, P227; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Lynn K, 1999, DEVELOPMENT, V126, P469; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; MORI I, 1988, GENETICS, V120, P397; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Moussian B, 1998, EMBO J, V17, P1799, DOI 10.1093/emboj/17.6.1799; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; ROY AL, 1988, BIOCHEMISTRY-US, V27, P8203, DOI 10.1021/bi00421a033; Schmidt A, 1999, GENETICS, V151, P749; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Tabara H, 1999, DEVELOPMENT, V126, P1; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; VANDERKEYL H, 1994, DEV DYNAM, V201, P86, DOI 10.1002/aja.1002010109; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; WILLIAMS BD, 1992, GENETICS, V131, P609; YUAN JY, 1991, P NATL ACAD SCI USA, V88, P3334, DOI 10.1073/pnas.88.8.3334; Zou C, 1998, GENE, V211, P187, DOI 10.1016/S0378-1119(98)00107-3	57	951	1088	3	77	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	1999	99	2					123	132		10.1016/S0092-8674(00)81644-X	http://dx.doi.org/10.1016/S0092-8674(00)81644-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535731	Bronze			2022-12-28	WOS:000083159700003
J	Lin, RCY; Wang, WYS; Morris, BJ				Lin, RCY; Wang, WYS; Morris, BJ			High penetrance, overweight and glucocorticoid receptor variant: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENE		Univ Sydney, Dept Physiol, Gene Lab, Sydney, NSW 2006, Australia; Univ Sydney, Inst Biomed Res, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Morris, BJ (corresponding author), Univ Sydney, Dept Physiol, Gene Lab, Bldg F13, Sydney, NSW 2006, Australia.	brianm@physiol.usyd.edu.au	Wang, William/E-7862-2013; Lin, Ruby CY/A-1636-2009	Wang, William/0000-0002-5369-5446; Lin, Ruby CY/0000-0003-4163-511X				Clement K, 1996, INT J OBESITY, V20, P507; Huizenga NATM, 1998, J CLIN ENDOCR METAB, V83, P144, DOI 10.1210/jc.83.1.144; Koper JW, 1997, HUM GENET, V99, P663, DOI 10.1007/s004390050425; Meirhaeghe A, 1999, LANCET, V353, P896, DOI 10.1016/S0140-6736(99)00251-2; Takami S, 1999, AM J PHYSIOL-HEART C, V276, pH1379, DOI 10.1152/ajpheart.1999.276.4.H1379	5	84	87	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	1999	319	7221					1337	1338		10.1136/bmj.319.7221.1337	http://dx.doi.org/10.1136/bmj.319.7221.1337			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567137	Green Published, Bronze			2022-12-28	WOS:000083930200024
J	Arunachalam, S				Arunachalam, S			Informatics in clinical practice in developing countries: still early days	BRITISH MEDICAL JOURNAL			English	Article								Tamil Nadu will soon become the first state in India to provide telemedicine in the public setter when the local hospital in Thiruvallur is connected to the Chennai Medical College (about 40 km away) through an integrated services digital network (ISDN) line and linked terminals. Tamil Nadu cannot yet connect every district and taluk hospital to the nearest medical college because the ISDN facility is not available in many plates outside Chennai. This reflects misplaced priorities in a country which has developed technologies for launching missiles and satellites and for producing nuclear bombs; provides cellular telephones, colour televisions, and luxury cars for the rich; and sends thousands of computer professionals to the United States every year. The story is the same everywhere in the developing world.	MS Swaminethan Res Fdn, Chennai 600113, India		Arunachalam, S (corresponding author), MS Swaminethan Res Fdn, Chennai 600113, India.		ARUNACHALAM, SUBBIAH/B-9925-2009	ARUNACHALAM, SUBBIAH/0000-0002-4398-4658				ARUNACHALAM S, 1999, J INFORM SCI, V25, P427; COIERA E, 1998, GUIDE MED INFORMATIC; *INT TEL UN, 1997, WORLD TEL S DEV COUN; *INT TEL UN, 1999, TABL BAS IND; RAO M, 1999, INTERNET EMERGING KE; *UN DEV PROGR, 1999, HUM DEV REP 1998, P167; *UN DEV PROGR, 1999, HUM DEV REP 1999, P62; 1999, INT TELECOMMUNICATIO; 1999, BMJ, P318; 1999, INMARSAT TELEMEDICIN; 1999, SATELIFE	11	3	4	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1999	319	7220					1297	U54		10.1136/bmj.319.7220.1297	http://dx.doi.org/10.1136/bmj.319.7220.1297			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	257MZ	10559050	Green Accepted, Green Published			2022-12-28	WOS:000083786900019
J	West, KA; Anderson, DR; McAlister, VC; Hewlett, TJC; Belitsky, P; Smith, JW; Kelton, JG				West, KA; Anderson, DR; McAlister, VC; Hewlett, TJC; Belitsky, P; Smith, JW; Kelton, JG			Alloimmune thrombocytopenia after organ transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMPLIFICATION; ALLOANTIGENS; RECIPIENT; ANTIGEN; PURPURA		Dalhousie Univ, Dept Med, Div Nephrol, Halifax, NS, Canada; Dalhousie Univ, Dept Med, Div Hematol, Halifax, NS, Canada; Dalhousie Univ, Dept Surg, Halifax, NS B3H 4H2, Canada; Dalhousie Univ, Dept Urol, Halifax, NS, Canada; McMaster Univ, Dept Med, Div Hematol, Hamilton, ON, Canada; Canadian Blood Serv, Hamilton, ON, Canada	Dalhousie University; Dalhousie University; Dalhousie University; Dalhousie University; McMaster University; Canadian Blood Services	West, KA (corresponding author), QEII Hlth Sci Ctr, Dickson Ctr 5087, 5820 Univ Ave, Halifax, NS B3H 249, Canada.		McAlister, Vivian/B-9881-2008	McAlister, Vivian/0000-0002-2479-6862; Anderson, David/0000-0003-0845-1722				BEIN G, 1992, TISSUE ANTIGENS, V39, P68, DOI 10.1111/j.1399-0039.1992.tb01909.x; BLANCHETTE VS, 1990, BRIT J HAEMATOL, V74, P209, DOI 10.1111/j.1365-2141.1990.tb02567.x; BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107; FRIEND PJ, 1990, NEW ENGL J MED, V323, P807, DOI 10.1056/NEJM199009203231207; GOLDMAN M, 1994, TRANSFUS MED REV, V8, P123, DOI 10.1016/S0887-7963(94)70104-8; GREGOIRE JR, 1993, J AM SOC NEPHROL, V4, P1122; KNOOP C, 1994, TRANSPLANTATION, V58, P1335; MacLennan ICM, 1997, IMMUNOL REV, V156, P53, DOI 10.1111/j.1600-065X.1997.tb00958.x; MUELLERECKHARDT C, 1989, BLUT, V59, P145, DOI 10.1007/BF00320268; SMITH JW, 1995, BLOOD, V86, P2807; Suthanthiran M, 1996, AM J KIDNEY DIS, V28, P159, DOI 10.1016/S0272-6386(96)90297-8; UNKELBACH K, 1995, BRIT J HAEMATOL, V89, P169, DOI 10.1111/j.1365-2141.1995.tb08925.x; WATERS AH, 1989, BLOOD REV, V3, P83, DOI 10.1016/0268-960X(89)90002-7; Williamson LM, 1998, BLOOD, V92, P2280, DOI 10.1182/blood.V92.7.2280.2280_2280_2287	14	38	38	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1999	341	20					1504	1507		10.1056/NEJM199911113412004	http://dx.doi.org/10.1056/NEJM199911113412004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RK	10559451				2022-12-28	WOS:000083625800004
J	Gross, R				Gross, R			Leg lengthening	LANCET			English	Editorial Material							LIMB		Med Univ S Carolina, Dept Orthopaed, Charleston, SC 29424 USA	Medical University of South Carolina	Gross, R (corresponding author), Med Univ S Carolina, Dept Orthopaed, Charleston, SC 29424 USA.							Aldegheri R, 1999, J BONE JOINT SURG AM, V81A, P624, DOI 10.2106/00004623-199905000-00004; ANDERSON WV, 1967, MODERN TRENDS ORTHOP, P1; Cheng JCY, 1998, J BONE JOINT SURG BR, V80B, P772, DOI 10.1302/0301-620X.80B5.8475; Codivilla A., 1905, J BONE JOINT SURG, Vs2, P353; DEBASTIANI G, 1987, J PEDIATR ORTHOPED, V7, P129; GROSS RH, 1971, J BONE JOINT SURG AM, VA 53, P693, DOI 10.2106/00004623-197153040-00008; ILIZAROV GA, 1990, CLIN ORTHOP RELAT R, P8; Mahomed NN, 1998, AM J MED GENET, V78, P30, DOI 10.1002/(SICI)1096-8628(19980616)78:1<30::AID-AJMG7>3.0.CO;2-P; MOSCA V, 1986, ORTHOP T, V10, P462; Sharma M, 1996, J PEDIATR ORTHOPED, V16, P438, DOI 10.1097/01241398-199607000-00004; SOFIELD HA, 1958, J BONE JOINT SURG AM, V40, P311, DOI 10.2106/00004623-195840020-00006; WAGNER H, 1978, CLIN ORTHOP RELAT R, P125; 1988, LANCET, V1, P1032	13	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1574	1575		10.1016/S0140-6736(99)00221-4	http://dx.doi.org/10.1016/S0140-6736(99)00221-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560667				2022-12-28	WOS:000083551000004
J	Rossing, MA; Daling, JR				Rossing, MA; Daling, JR			Complexity of surveillance for cancer risk associated with in-vitro fertilisation	LANCET			English	Editorial Material							OVARIAN-CANCER; INFERTILE WOMEN; BREAST-CANCER; UNITED-STATES; COHORT		Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Rossing, MA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.							Bristow RE, 1996, FERTIL STERIL, V66, P499; Glud E, 1998, EPIDEMIOL REV, V20, P237, DOI 10.1093/oxfordjournals.epirev.a017983; Nieto JJ, 1999, LANCET, V354, P649, DOI 10.1016/S0140-6736(99)02250-3; RISCH HA, 1994, AM J EPIDEMIOL, V140, P585, DOI 10.1093/oxfordjournals.aje.a117296; Rodriguez C, 1998, CANCER CAUSE CONTROL, V9, P645, DOI 10.1023/A:1008845106869; Rossing MA, 1996, GYNECOL ONCOL, V60, P3, DOI 10.1006/gyno.1996.0002; ROSSING MA, 1994, NEW ENGL J MED, V331, P771, DOI 10.1056/NEJM199409223311204; ROSSING MA, 1996, J BR FERTIL SOC, V1, P46; VENN A, 1995, LANCET, V346, P995, DOI 10.1016/S0140-6736(95)91687-3; Weiss HA, 1998, CANCER CAUSE CONTROL, V9, P331, DOI 10.1023/A:1008881305738; Weiss NS, 1996, EPIDEMIOLOGY, V7, P319; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427	12	11	11	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1573	1574		10.1016/S0140-6736(99)90309-4	http://dx.doi.org/10.1016/S0140-6736(99)90309-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560666				2022-12-28	WOS:000083551000003
J	Abernethy, DR; Schwartz, JB				Abernethy, DR; Schwartz, JB			Calcium-antagonist drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SMOOTH-MUSCLE CELLS; ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; VENTRICULAR RATE CONTROL; CORONARY-ARTERY DISEASE; CHANNEL BLOCKERS; CONTROLLED TRIAL; ANGIOTENSIN-II; MEDIATED VASOCONSTRICTION; CARDIOVASCULAR EVENTS		Georgetown Univ, Med Ctr, Div Clin Pharmacol, Washington, DC 20007 USA; Northwestern Univ, Med Ctr, Div Clin Pharmacol & Geriatr, Chicago, IL 60611 USA	Georgetown University; Northwestern University	Abernethy, DR (corresponding author), NIA, Clin Invest Lab, Gerontol Res Ctr, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.				NIA NIH HHS [AG-08226-08, AG-00768-02] Funding Source: Medline; NIGMS NIH HHS [GM-08386-09] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008226] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABERNETHY DR, 1986, ANN INTERN MED, V105, P329, DOI 10.7326/0003-4819-105-3-329; Abernethy DR, 1997, J CLIN INVEST, V99, P2297, DOI 10.1172/JCI119405; ABERNETHY DR, 1990, CLIN PHARMACOL THER, V48, P76, DOI 10.1038/clpt.1990.120; Abernethy DR, 1997, AM J HYPERTENS, V10, pS13, DOI 10.1016/S0895-7061(97)00018-6; ABERNETHY DR, 1988, CLIN PHARMACOKINET, V15, P1, DOI 10.2165/00003088-198815010-00001; ANDRAWIS NS, 1992, J PHARMACOL EXP THER, V261, P879; ANDRAWIS NS, 1992, CLIN PHARMACOL THER, V52, P583, DOI 10.1038/clpt.1992.195; ANDRAWIS NS, 1992, BIOCHEM BIOPH RES CO, V183, P767, DOI 10.1016/0006-291X(92)90549-Z; ANTMAN E, 1980, NEW ENGL J MED, V302, P1269, DOI 10.1056/NEJM198006053022301; Bakris GL, 1997, HYPERTENSION, V29, P744, DOI 10.1161/01.HYP.29.3.744; Bakris GL, 1996, KIDNEY INT, V50, P1641, DOI 10.1038/ki.1996.480; Black HR, 1998, ARCH INTERN MED, V158, P573; Black HR, 1997, ARCH INTERN MED, V157, P2413; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; BUHLER FR, 1983, HYPERTENSION, V5, P94; Byington RP, 1997, LANCET, V350, P1075, DOI 10.1016/S0140-6736(05)70455-4; Cohn JN, 1997, CIRCULATION, V96, P856, DOI 10.1161/01.cir.96.3.856; COHN PF, 1994, CLIN CARDIOL, V17, P415, DOI 10.1002/clc.4960170803; Crepaldi G, 1998, DIABETES CARE, V21, P104, DOI 10.2337/diacare.21.1.104; Doppenschmitt S, 1999, J PHARMACOL EXP THER, V288, P348; DROOGMANS G, 1987, PFLUG ARCH EUR J PHY, V409, P7, DOI 10.1007/BF00584744; DUNSELMAN PHJM, 1990, EUR HEART J, V11, P200, DOI 10.1093/oxfordjournals.eurheartj.a059684; DWORKIN LD, 1993, KIDNEY INT, V43, P808, DOI 10.1038/ki.1993.114; ELKAYAM U, 1990, CIRCULATION, V82, P1954, DOI 10.1161/01.CIR.82.6.1954; EPSTEIN M, 1995, ARCH INTERN MED, V155, P2150, DOI 10.1001/archinte.155.20.2150; Epstein M, 1997, AM J CARDIOL, V79, P9, DOI 10.1016/S0002-9149(97)00266-X; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Fitzpatrick AL, 1997, CANCER, V80, P1438, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6; Freher M, 1999, CURR PROB CARDIOLOGY, V24, P236; GELMERS HJ, 1988, NEW ENGL J MED, V318, P203, DOI 10.1056/NEJM198801283180402; GOTO K, 1989, P NATL ACAD SCI USA, V86, P3915, DOI 10.1073/pnas.86.10.3915; Grossman E, 1997, AM J CARDIOL, V80, P1453, DOI 10.1016/S0002-9149(97)00722-4; GUENGERICH FP, 1991, J MED CHEM, V34, P1838, DOI 10.1021/jm00110a012; HANSEN JF, 1990, AM J CARDIOL, V66, P779; Hansen JF, 1997, AM J CARDIOL, V79, P738, DOI 10.1016/S0002-9149(96)00860-0; HENRY PD, 1981, J CLIN INVEST, V68, P1366, DOI 10.1172/JCI110384; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; HOFER CA, 1993, AM J MED, V95, P431, DOI 10.1016/0002-9343(93)90314-F; Hohnloser SH, 1997, PACE, V20, P1989, DOI 10.1111/j.1540-8159.1997.tb03606.x; Hole DJ, 1998, J HYPERTENS, V16, P119, DOI 10.1097/00004872-199816010-00017; Hunter J, 1997, ADV DRUG DELIVER REV, V25, P129, DOI 10.1016/S0169-409X(97)00497-3; Ishikawa K, 1997, CIRCULATION, V95, P2368, DOI 10.1161/01.CIR.95.10.2368; JARIWALLA AG, 1978, BRIT MED J, V1, P1181, DOI 10.1136/bmj.1.6121.1181; JESPERSEN CM, 1993, EUR HEART J, V14, P540, DOI 10.1093/eurheartj/14.4.540; KAMEYAMA M, 1985, PFLUG ARCH EUR J PHY, V405, P285, DOI 10.1007/BF00582573; KELLY JG, 1992, CLIN PHARMACOKINET, V22, P416, DOI 10.2165/00003088-199222060-00002; KLEIN HO, 1982, CIRCULATION, V65, P998, DOI 10.1161/01.CIR.65.5.998; KLINER RA, 1987, AM J CARDIOL, V59, pB84; KOLARS JC, 1992, J CLIN INVEST, V90, P1871, DOI 10.1172/JCI116064; KROEMER HK, 1992, J PHARMACOL EXP THER, V260, P1052; KROEMER HK, 1993, N-S ARCH PHARMACOL, V348, P332; KUHLMANN J, 1987, ARZNEIMITTEL-FORSCH, V37-1, P545; LEE TH, 1986, AM J MED, V80, P1203, DOI 10.1016/0002-9343(86)90688-1; LEWIS EJ, 1993, NEW ENGL J MED, V330, P152; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; LITTLER WA, 1995, BRIT HEART J, V73, P428; LOUTZENHISER R, 1985, AM J PHYSIOL, V249, P619; Lown KS, 1997, J CLIN INVEST, V99, P2545, DOI 10.1172/JCI119439; LUBSEN J, 1986, BRIT HEART J, V56, P400; LUNDSTROM T, 1990, J AM COLL CARDIOL, V16, P86, DOI 10.1016/0735-1097(90)90461-W; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MESSERLI FH, 1995, ANN INTERN MED, V123, P888, DOI 10.7326/0003-4819-123-11-199512010-00015; MILLARD RW, 1983, CIRC RES, V52, P29; MITRA R, 1985, SCIENCE, V229, P269, DOI 10.1126/science.2409600; Morel N, 1998, BRIT J PHARMACOL, V125, P1005, DOI 10.1038/sj.bjp.0702162; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; NELSON MT, 1988, NATURE, V336, P382, DOI 10.1038/336382a0; OHYA Y, 1991, CIRC RES, V68, P763, DOI 10.1161/01.RES.68.3.763; Olsen JH, 1997, HYPERTENSION, V29, P1091, DOI 10.1161/01.HYP.29.5.1091; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; PICHARD L, 1990, DRUG METAB DISPOS, V18, P711; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; PooleWilson PA, 1997, EUR HEART J, V18, P31; PRICE WA, 1986, J CLIN PHARMACOL, V26, P717, DOI 10.1002/j.1552-4604.1986.tb02980.x; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Rengo F, 1996, AM J CARDIOL, V77, P365, DOI 10.1016/S0002-9149(97)89365-4; REUTER H, 1977, J PHYSIOL-LONDON, V264, P49, DOI 10.1113/jphysiol.1977.sp011657; Rosenberg L, 1998, JAMA-J AM MED ASSOC, V279, P1000, DOI 10.1001/jama.279.13.1000; Roth M, 1996, P NATL ACAD SCI USA, V93, P5478, DOI 10.1073/pnas.93.11.5478; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; SCHMITT R, 1995, ARTERIOSCL THROM VAS, V15, P1161, DOI 10.1161/01.ATV.15.8.1161; SCHWARTZ JB, 1993, J AM GERIATR SOC, V41, P967, DOI 10.1111/j.1532-5415.1993.tb06763.x; SCHWARTZ JB, 1994, CLIN PHARMACOL THER, V55, P509, DOI 10.1038/clpt.1994.64; SCHWARTZ JB, 1987, AM J CARDIOL, V59, P1111, DOI 10.1016/0002-9149(87)90858-7; Schwartz JB, 1996, DRUG AGING, V9, P24, DOI 10.2165/00002512-199609010-00003; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOWERS JR, 1994, HYPERTENSION, V23, P145; SPEDDING M, 1992, PHARMACOL REV, V44, P363; Staessen JA, 1998, HYPERTENSION, V32, P410, DOI 10.1161/01.HYP.32.3.410; Stearne MR, 1998, BRIT MED J, V317, P713; STONE PH, 1980, ANN INTERN MED, V93, P886, DOI 10.7326/0003-4819-93-6-886; STONE PH, 1990, CIRCULATION, V82, P1962, DOI 10.1161/01.CIR.82.6.1962; STONE PH, 1987, AM J CARDIOL, V59, pB101, DOI 10.1016/0002-9149(87)90089-0; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; TSIEN RW, 1972, NATURE-NEW BIOL, V240, P181, DOI 10.1038/newbio240181a0; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; UEMATSU D, 1989, STROKE, V20, P1531, DOI 10.1161/01.STR.20.11.1531; WATERS D, 1990, CIRCULATION, V82, P1940, DOI 10.1161/01.CIR.82.6.1940; Wyse DG, 1997, AM J CARDIOL, V79, P1198; YUSUF S, 1995, CIRCULATION, V92, P1079, DOI 10.1161/01.CIR.92.5.1079	103	298	308	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1999	341	19					1447	1457		10.1056/NEJM199911043411907	http://dx.doi.org/10.1056/NEJM199911043411907			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XR	10547409				2022-12-28	WOS:000083472100007
J	Henney, JE				Henney, JE			Infections from endoscopes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.							1999, MMWR, V48, P557	1	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1613	1613		10.1001/jama.282.17.1613	http://dx.doi.org/10.1001/jama.282.17.1613			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553774				2022-12-28	WOS:000083368400008
J	Chiang, TL				Chiang, TL			Economic transition and changing relation between income inequality and mortality in Taiwan: regression analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; HEALTH	Objective To examine the changing relation between income inequality and mortality through different stages of economic development in Taiwan. Design Regression analysis of mortality on income inequality for three index years: 1976, 1985, and 1995, Setting 21 counties and cities in Taiwan. Main outcome measures All age mortality and age specific mortality in children under age 5. Results When median household disposable income was controlled for, the association between income inequality and mortality became stronger in 1995 than in 1976. Especially, the association between income inequality and mortality in children aged under 5, with adjustment for differences in median household disposable income, changed from non-significant in 1976 to highly significant in 1995. In 1995, the level of household income after adjustment for income distribution no longer had a bearing on mortality in children under 5, Conclusion The health of the population is affected more by relative income than by absolute income after a country has changed from a developing to a developed economy.	Natl Taiwan Univ, Coll Publ Hlth, Inst Hlth Policy & Management, Taipei 10018, Taiwan	National Taiwan University	Chiang, TL (corresponding author), Natl Taiwan Univ, Coll Publ Hlth, Inst Hlth Policy & Management, Taipei 10018, Taiwan.	tlchiang@ha.mc.ntu.edu.tw	Chiang, Tung-liang/B-9237-2009	CHIANG, TUNG-LIANG/0000-0002-7876-3943				Armitage P., 2001, STAT METHODS MED RES; Chiang TL, 1997, HEALTH POLICY, V39, P225, DOI 10.1016/S0168-8510(96)00877-9; Daly MC, 1998, MILBANK Q, V76, P315, DOI 10.1111/1468-0009.00094; Goldstone L., 1983, UNDERSTANDING MED ST; Kaplan GA, 1997, AM J PUBLIC HEALTH, V87, P1409, DOI 10.2105/AJPH.87.9.1409; Kaplan GA, 1996, BRIT MED J, V312, P999; Kawachi I, 1997, AM J PUBLIC HEALTH, V87, P1491, DOI 10.2105/AJPH.87.9.1491; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; Kennedy BP, 1996, BRIT MED J, V312, P1194; Kuo S. W. Y., 1981, TAIWAN SUCCESS STORY; Kuznets S, 1955, AM ECON REV, V45, P1; Li K. T., 1988, EVOLUTION POLICY TAI; *REP CHIN COUNC EC, 1998, TAIW STAT DAT BOOK 1; *REP CHIN DEP HLTH, 1998, HLTH VIT STAT, V1; *REP CHIN MIN INT, 1995, TAIW FUK DEM FACT BO; Smith GD, 1996, BRIT MED J, V313, P1584, DOI 10.1136/bmj.313.7072.1584; Walberg P, 1998, BRIT MED J, V317, P312, DOI 10.1136/bmj.317.7154.312; WILKINSON R, 1996, UNHEALTHY SOC AFFICT; Wilkinson RG, 1998, SOCIOL HEALTH ILL, V20, P578, DOI 10.1111/1467-9566.00120; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; Wilkinson RG, 1997, BRIT MED J, V314, P591, DOI 10.1136/bmj.314.7080.591	21	55	56	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	1999	319	7218					1162	1165		10.1136/bmj.319.7218.1162	http://dx.doi.org/10.1136/bmj.319.7218.1162			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	253BF	10541504	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000083536200020
J	Minamisawa, S; Hoshijima, M; Chu, GX; Ward, CA; Frank, K; Gu, YS; Martone, ME; Wang, YB; Ross, J; Kranias, EG; Giles, WR; Chien, KR				Minamisawa, S; Hoshijima, M; Chu, GX; Ward, CA; Frank, K; Gu, YS; Martone, ME; Wang, YB; Ross, J; Kranias, EG; Giles, WR; Chien, KR			Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy	CELL			English	Article							HEART-FAILURE; CARDIAC-HYPERTROPHY; MYOCARDIAL-CONTRACTILITY; VENTRICULAR MYOCYTES; TRANSGENIC MICE; GENE-EXPRESSION; PROTEIN; KINASE; MOUSE; PHOSPHORYLATION	Dilated cardiomyopathy and end-stage heart failure result in multiple defects in cardiac excitation-contraction coupling. Via complementation of a genetically based mouse model of dilated cardiomyopathy, we now provide evidence that progressive chamber dilation and heart failure are dependent on a Ca2+ cycling defect in the cardiac sarcoplasmic reticulum. The ablation of a muscle-specific sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) inhibitor, phospholamban, rescued the spectrum of phenotypes that resemble human heart failure. Inhibition of phospholamban-SERCA2a interaction via in vivo expression of a phospholamban point mutant dominantly activated the contractility of ventricular muscle cells. Thus, interfering with phospholamban-SERCA2a interaction may provide a novel therapeutic approach for preventing the progression of dilated cardiomyopathy.	Univ Calif San Diego, UCSD Salk Program Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Calgary, Sch Med, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; University of Calgary	Chien, KR (corresponding author), Univ Calif San Diego, UCSD Salk Program Mol Med, La Jolla, CA 92093 USA.			Wang, Yibin/0000-0003-0852-0767; Minamisawa, Susumu/0000-0003-4728-2116	NCRR NIH HHS [P40RR12358] Funding Source: Medline; NHLBI NIH HHS [HL52318, HL26057] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012358] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026057, P50HL052318, R37HL026057] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Balke CW, 1998, CARDIOVASC RES, V37, P290, DOI 10.1016/S0008-6363(97)00272-1; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; Chen J, 1999, J CLIN INVEST, V103, P1483, DOI 10.1172/JCI7297; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; CHIEN KR, 1999, MOL BASIS CARDIOVASC, P211; CHRISTENSEN G, 1999, IN PRESS CIRCULATION; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; FELDMAN AM, 1988, J CLIN INVEST, V82, P189, DOI 10.1172/JCI113569; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; Hasenfuss G, 1998, CARDIOVASC RES, V37, P279, DOI 10.1016/S0008-6363(97)00277-0; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Koss KL, 1997, BASIC RES CARDIOL, V92, P17, DOI 10.1007/BF00794064; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Lindner M, 1998, J MOL CELL CARDIOL, V30, P743, DOI 10.1006/jmcc.1997.0626; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Martone ME, 1999, J NEUROSCI, V19, P1988; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; MEYER M, 1995, CIRCULATION, V92, P778, DOI 10.1161/01.CIR.92.4.778; Minamisawa S, 1999, J BIOL CHEM, V274, P10066, DOI 10.1074/jbc.274.15.10066; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORGAN JP, 1991, NEW ENGL J MED, V325, P625; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Palakodeti V, 1997, AM J PHYSIOL-HEART C, V273, pH1283, DOI 10.1152/ajpheart.1997.273.3.H1283; PIESKE B, 1995, CIRCULATION, V92, P1169, DOI 10.1161/01.CIR.92.5.1169; Qi M, 1997, AM J PHYSIOL-HEART C, V272, pH2416, DOI 10.1152/ajpheart.1997.272.5.H2416; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Santana LF, 1998, J GEN PHYSIOL, V112, p11A; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; Schmidt U, 1999, AM J PHYSIOL-HEART C, V277, pH474, DOI 10.1152/ajpheart.1999.277.2.H474; Schwinger RHG, 1999, J MOL CELL CARDIOL, V31, P479, DOI 10.1006/jmcc.1998.0897; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SORDAHL LA, 1973, AM J PHYSIOL, V224, P497, DOI 10.1152/ajplegacy.1973.224.3.497; Tada M, 1998, TRENDS CARDIOVAS MED, V8, P330, DOI 10.1016/S1050-1738(98)00032-2; TADA M, 1982, MOL CELL BIOCHEM, V46, P73; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Ward CA, 1997, J PHYSIOL-LONDON, V500, P631, DOI 10.1113/jphysiol.1997.sp022048; WHITMER JT, 1988, CIRC RES, V62, P81, DOI 10.1161/01.RES.62.1.81	52	397	406	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					313	322		10.1016/S0092-8674(00)81662-1	http://dx.doi.org/10.1016/S0092-8674(00)81662-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555147	Bronze			2022-12-28	WOS:000083440600009
J	Raaymakers, TWM; Rinkel, GJE; van Gijn, J; Greebe, P; Algra, A; Buskens, E; Buys, PC; Ramos, LMP; Witkamp, TD; Mali, WPTM; Tulleken, CAF; Limburg, M; Gorissen, A; Vonk, CM; Bossuyt, PMM; Bonsel, GJ; Verbeeten, B; Hulsmans, FJ; Albrecht, KW				Raaymakers, TWM; Rinkel, GJE; van Gijn, J; Greebe, P; Algra, A; Buskens, E; Buys, PC; Ramos, LMP; Witkamp, TD; Mali, WPTM; Tulleken, CAF; Limburg, M; Gorissen, A; Vonk, CM; Bossuyt, PMM; Bonsel, GJ; Verbeeten, B; Hulsmans, FJ; Albrecht, KW		Magnetic Resonance Angiography Rel	Risks and benefits of screening for intracranial aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrhage	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNRUPTURED CEREBRAL ANEURYSMS; SACCULAR ANEURYSMS; NATURAL-HISTORY; MR-ANGIOGRAPHY; RUPTURE; SURGERY	Background The first-degree relatives of patients who have subarachnoid hemorrhage from ruptured intracranial aneurysms are themselves at risk for subarachnoid hemorrhage. We studied the benefits and risks of screening for aneurysms in the first-degree relatives of patients with sporadic subarachnoid hemorrhage. Methods We screened 626 first-degree relatives (parents, siblings, or children) of 160 patients with sporadic subarachnoid hemorrhage, from a prospective series of 193 consecutive index patients. Magnetic resonance angiography was the screening tool, and conventional angiography was used as the reference test in subjects thought to have aneurysms. Six months after elective operation, outcome was assessed by means of the modified Rankin scale of neurologic function. This observational study design was combined with a decision-analysis model to estimate the effectiveness of screening. The efficiency of screening was defined by the number of relatives who needed to be screened in order to prevent one subarachnoid hemorrhage. Results Aneurysms were found in 25 of 626 first-degree relatives (4.0 percent; 95 percent confidence interval, 2.6 to 5.8 percent). Eighteen underwent surgery, which resulted in a decrease in function in 11 (disabling in 1). Five had medium-sized aneurysms that were 5 to 11 mm in diameter, 11 had small aneurysms that were less than 5 mm, and 2 had both small and medium-sized aneurysms. On average, surgery increased estimated life expectancy by 2.5 years for these 18 subjects (or by 0.9 month per person screened), at the expense of 19 years of decreased function per person. The number of relatives who would need to be screened in order to prevent 1 subarachnoid hemorrhage on a lifetime basis was 149, and 298 would have to be screened in order to prevent 1 fatal subarachnoid hemorrhage. Conclusions Implementation of a screening program for the first-degree relatives of patients with sporadic subarachnoid hemorrhage does not seem warranted at this time, since the resulting slight increase in life expectancy does not offset the risk of postoperative sequelae. (N Engl J Med 1999;341:1344-50.) (C) 1999, Massachusetts Medical Society.	Univ Utrecht Hosp, Dept Neurol, NL-3584 CX Utrecht, Netherlands; Julius Ctr Patient Oriented Res, Utrecht, Netherlands; Acad Med Ctr, Dept Neurosurg, Amsterdam, Netherlands; Acad Med Ctr, Dept Radiol, Amsterdam, Netherlands; Acad Med Ctr, Dept Neurol, Amsterdam, Netherlands; Acad Med Ctr, Dept Clin Epidemiol & Biostat, Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Raaymakers, TWM (corresponding author), Univ Utrecht Hosp, Dept Neurol, H2-128,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.		Bossuyt, Patrick M./B-4557-2016; Bossuyt, Patrick M/AAR-1183-2021; Mali, Willem PThM/I-1123-2014; van Gijn, Jan/A-9444-2008	Bossuyt, Patrick M./0000-0003-4427-0128; Bossuyt, Patrick M/0000-0003-4427-0128; Mali, Willem PThM/0000-0003-4391-0904; 				ASARI S, 1993, CLIN NEUROL NEUROSUR, V95, P205, DOI 10.1016/0303-8467(93)90125-Z; Atlas SW, 1997, RADIOLOGY, V203, P807, DOI 10.1148/radiology.203.3.9169709; Auger R G, 1991, J Stroke Cerebrovasc Dis, V1, P174, DOI 10.1016/S1052-3057(10)80014-X; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BROMBERG JEC, 1995, BRIT MED J, V311, P288, DOI 10.1136/bmj.311.7000.288; Caplan LR, 1998, NEW ENGL J MED, V339, P1774, DOI 10.1056/NEJM199812103392409; CHANG HS, 1995, J NEUROSURG, V83, P413, DOI 10.3171/jns.1995.83.3.0413; Crawley F, 1999, STROKE, V30, P312, DOI 10.1161/01.STR.30.2.312; Eskesen V, 1987, Br J Neurosurg, V1, P47, DOI 10.3109/02688698709034340; Eskesen V, 1988, Br J Neurosurg, V2, P379, DOI 10.3109/02688698809001009; HABBEMA JDF, 1990, STAT MED, V9, P1229, DOI 10.1002/sim.4780091104; HEISERMAN JE, 1994, AM J NEURORADIOL, V15, P1401; Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; INAGAWA T, 1992, SURG NEUROL, V38, P364, DOI 10.1016/0090-3019(92)90023-G; Inomiya K, 1995, Medinfo, V8 Pt 2, P889; JUVELA S, 1993, J NEUROSURG, V79, P174, DOI 10.3171/jns.1993.79.2.0174; Kojima M, 1998, NEUROSURGERY, V43, P776, DOI 10.1097/00006123-199810000-00026; KOROGI Y, 1994, RADIOLOGY, V193, P181, DOI 10.1148/radiology.193.1.8090889; LEBLANC R, 1994, NEUROSURGERY, V35, P9, DOI 10.1227/00006123-199407000-00002; LOCKSLEY HB, 1966, J NEUROSURG, V25, P321, DOI 10.3171/jns.1966.25.3.0321; MCCORMICK WF, 1970, J NEUROSURG, V33, P422, DOI 10.3171/jns.1970.33.4.0422; Mizoi K, 1995, SURG NEUROL, V44, P114, DOI 10.1016/0090-3019(95)00035-6; OBUCHOWSKI NA, 1995, J NEUROSURG, V83, P42, DOI 10.3171/jns.1995.83.1.0042; PRZELOMSKI MM, 1986, NEUROLOGY, V36, P584, DOI 10.1212/WNL.36.4.584; Raaymakers TWM, 1998, NEUROLOGY, V51, P1125, DOI 10.1212/WNL.51.4.1125; Raaymakers TWM, 1998, STROKE, V29, P1531, DOI 10.1161/01.STR.29.8.1531; RANKIN J, 1957, Scott Med J, V2, P200; Rembold CM, 1998, BMJ-BRIT MED J, V317, P307, DOI 10.1136/bmj.317.7154.307; Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251; RONKAINEN A, 1995, RADIOLOGY, V195, P35, DOI 10.1148/radiology.195.1.7892491; Ronkainen A, 1998, STROKE, V29, P359, DOI 10.1161/01.STR.29.2.359; Ronkainen A, 1997, LANCET, V349, P380, DOI 10.1016/S0140-6736(97)80009-8; SCHIEVINK WI, 1995, J NEUROSURG, V83, P426, DOI 10.3171/jns.1995.83.3.0426; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Tas R F, 1998, Maandstat Bevolking, V46, P8; Wiebers D, 1999, NEW ENGL J MED, V340, P744; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401; WIEBERS DO, 1987, J NEUROSURG, V66, P23, DOI 10.3171/jns.1987.66.1.0023; WILMS G, 1996, NEURORADIOLOGY, V38, P20; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606; ZACKS DJ, 1980, ARCH NEUROL-CHICAGO, V37, P39, DOI 10.1001/archneur.1980.00500500069010	41	92	95	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1344	1350						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249XE	10536126				2022-12-28	WOS:000083357800003
J	Mulligan, J; Voss, LD				Mulligan, J; Voss, LD			Identifying very fat and very thin children: test of criterion standards for screening test	BRITISH MEDICAL JOURNAL			English	Article							BODY-MASS INDEX		Univ Southampton, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	University of Southampton	Mulligan, J (corresponding author), Univ Southampton, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.							FREEMAN JV, 1995, INT J EPIDEMIOL, V24, P970, DOI 10.1093/ije/24.5.970; Hulse J A, 1995, J Med Screen, V2, P168; Power C, 1997, AM J CLIN NUTR, V66, P1094, DOI 10.1093/ajcn/66.5.1094; Prentice AM, 1998, BRIT MED J, V317, P1401, DOI 10.1136/bmj.317.7170.1401; Ruderman N, 1998, DIABETES, V47, P699, DOI 10.2337/diabetes.47.5.699	5	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1103	1104		10.1136/bmj.319.7217.1103	http://dx.doi.org/10.1136/bmj.319.7217.1103			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531099	Bronze, Green Published			2022-12-28	WOS:000083419500022
J	Underhill, DM; Ozinsky, A; Hajjar, AM; Stevens, A; Wilson, CB; Bassetti, M; Aderem, A				Underhill, DM; Ozinsky, A; Hajjar, AM; Stevens, A; Wilson, CB; Bassetti, M; Aderem, A			The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens	NATURE			English	Article							DROSOPHILA HOST-DEFENSE; GENE; FAMILY; MYD88; LIPOPOLYSACCHARIDE; 18-WHEELER; EXPRESSION; ADAPTER; COMPLEX; MICE	Macrophages orchestrate innate immunity by phagocytosing pathogens and coordinating inflammatory responses(1). Effective defence requires the host to discriminate between different pathogens. The specificity of innate immune recognition in Drosophila is mediated by the Toll family of receptors(2,3); Toll mediates anti-fungal responses, whereas 18-wheeler mediates anti-bacterial defence(4-6). A large number of Toll homologues have been identified in mammals, and Toll-like receptor 4 is critical in responses to Gram-negative bacteria(7-11). Here we show that Toll-like receptor 2 is recruited specifically to macrophage phagosomes containing yeast, and that a point mutation in the receptor abrogates inflammatory responses to yeast and Gram-positive bacteria, but not to Gram-negative bacteria. Thus, during the phagocytosis of pathogens, two classes of innate immune receptors cooperate to mediate host defence: phagocytic receptors, such as the mannose receptor, signal particle internalization, and the Toll-like receptors sample the contents of the vacuole and trigger an inflammatory response appropriate to defence against the specific organism.	Univ Washington, Dept Immunol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Aderem, A (corresponding author), Univ Washington, Dept Immunol, Box 357650, Seattle, WA 98195 USA.	aaderem@u.washington.edu	Bassetti, Matteo/L-3081-2019; UNDERHILL, DAVID/ABE-2185-2021	Underhill, David/0000-0002-2989-658X; Hajjar, Adeline/0000-0002-4838-8070				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; ELDON E, 1994, DEVELOPMENT, V120, P885; FREUDENBERG MA, 1991, INFECT IMMUN, V59, P2110, DOI 10.1128/IAI.59.6.2110-2115.1991; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Heine H, 1999, J IMMUNOL, V162, P6971; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Medzhitov R, 1998, P NATL ACAD SCI USA, V95, P429, DOI 10.1073/pnas.95.2.429; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Sweetser MT, 1998, J BIOL CHEM, V273, P34775, DOI 10.1074/jbc.273.52.34775; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Underhill DM, 1998, J BIOL CHEM, V273, P33619, DOI 10.1074/jbc.273.50.33619; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshimura A, 1999, J IMMUNOL, V163, P1	27	1148	1209	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					811	815		10.1038/44605	http://dx.doi.org/10.1038/44605			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548109				2022-12-28	WOS:000083368700058
J	Feldblum, PJ; Chen-Mok, M; Bwayo, JJ; Omari, M; Kuyoh, M; Ryan, KA				Feldblum, PJ; Chen-Mok, M; Bwayo, JJ; Omari, M; Kuyoh, M; Ryan, KA			Intracluster correlation of STD prevalence in a community intervention trial in Kenya	LANCET			English	Article							HEART-HEALTH-PROGRAM; DESIGN; CLUSTER	This study is a cluster-randomised, community intervention trial to measure the impact of female condom introduction on STD prevalence among Kenyan agricultural workers. The intracluster correlation coefficient of baseline STD prevalences at the 12 sites was 0.0011.	Family Hlth Int, Res Triangle Pk, NC 27709 USA; Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya; Family Hlth Int, Nairobi, Kenya; Univ Costa Rica, Fac Ciencias Econ, Escuda Estadist, San Jose, Costa Rica	University of Nairobi; Universidad Costa Rica	Feldblum, PJ (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.							Bland JM, 1997, BRIT MED J, V315, P600; Campbell MK, 1998, BMJ-BRIT MED J, V317, P1171, DOI 10.1136/bmj.317.7167.1171; DONNER A, 1987, STAT MED, V6, P43, DOI 10.1002/sim.4780060106; HANNAN PJ, 1994, EPIDEMIOLOGY, V5, P88, DOI 10.1097/00001648-199401000-00013; MURRAY DM, 1995, AM J EPIDEMIOL, V142, P569, DOI 10.1093/oxfordjournals.aje.a117677	5	10	10	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1356	1357		10.1016/S0140-6736(99)02668-9	http://dx.doi.org/10.1016/S0140-6736(99)02668-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533869				2022-12-28	WOS:000083149900018
J	Tucker, JB				Tucker, JB			Modification of attitudes to influence survival from breast cancer	LANCET			English	Editorial Material									Univ Virginia, Dept Psychiat Med, Div Personal Studies, Charlottesville, VA 22908 USA	University of Virginia	Tucker, JB (corresponding author), Univ Virginia, Dept Psychiat Med, Div Personal Studies, Charlottesville, VA 22908 USA.							Burstein HJ, 1999, NEW ENGL J MED, V340, P1733, DOI 10.1056/NEJM199906033402206; Cunningham AJ, 1998, PSYCHO-ONCOL, V7, P508, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<508::AID-PON376>3.0.CO;2-7; Everson SA, 1996, PSYCHOSOM MED, V58, P113, DOI 10.1097/00006842-199603000-00003; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; Holland J C, 1997, Oncology (Williston Park), V11, P109; Payne DK, 1999, PSYCHOSOMATICS, V40, P64, DOI 10.1016/S0033-3182(99)71273-9; Roth AJ, 1998, CANCER, V82, P1904, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1904::AID-CNCR13>3.0.CO;2-X; SOBEL DS, 1995, PSYCHOSOM MED, V57, P234, DOI 10.1097/00006842-199505000-00005; SPIEGEL D, 1989, LANCET, V2, P888	9	8	9	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1999	354	9187					1320	1320		10.1016/S0140-6736(99)99187-0	http://dx.doi.org/10.1016/S0140-6736(99)99187-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	246DV	10533858				2022-12-28	WOS:000083149900007
J	Burzlaff, NI; Rutledge, PJ; Clifton, IJ; Hensgens, CMH; Pickford, M; Adlington, RM; Roach, PL; Baldwin, JE				Burzlaff, NI; Rutledge, PJ; Clifton, IJ; Hensgens, CMH; Pickford, M; Adlington, RM; Roach, PL; Baldwin, JE			The reaction cycle of isopenicillin N synthase observed by X-ray diffraction	NATURE			English	Article							PENICILLIN BIOSYNTHESIS; LACTAM FORMATION; CRYSTALLOGRAPHY; PROGRAM; SULFUR	Isopenicillin N synthase (IPNS), a non-haem iron-dependent oxidase, catalyses the biosynthesis of isopenicillin N (IPN), the precursor of all penicillins and cephalosporins'. The key steps in this reaction are the two iron-dioxygen-mediated ring closures of the tripeptide delta-(L-alpha-aminoadipoyl)-L-cysteinyl-D-valin (ACV). It has been proposed that the four-membered beta-lactam ring forms initially, associated with a highly oxidized iron(rv)-oxo (ferryl) moiety, which subsequently mediates closure of the five-membered thiazolidine ring(2). Here we describe observation of the IPNS reaction in crystals by X-ray crystallography. IPNS.Fe2+.substrate crystals were grown anaerobically(3,4), exposed to high pressures of oxygen to promote reaction and frozen, and their structures were elucidated by X-ray diffraction. Using the natural substrate ACV, this resulted in the IPNS.Fe2+.IPN product complex. With the substrate analogue, delta-(L-alpha-aminoadipoyl)-L-cysteinyl-L-S-methyl-cysteine (ACmC) in the crystal, the reaction cycle was interrupted at the monocyclic stage. These mono- and bicyclic structures support our hypothesis of a two-stage reaction sequence leading to penicillin. Furthermore, the formation of a monocyclic sulphoxide product from ACmC is most simply explained by the interception of a high-valency iron-ore species.	Univ Oxford, Dyson Perrins Lab, Oxford OX1 3QY, England; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QY, England; Univ Oxford, Lab Mol Biophys, Oxford OX1 3QY, England	University of Oxford; University of Oxford; University of Oxford	Baldwin, JE (corresponding author), Univ Oxford, Dyson Perrins Lab, S Parks Rd, Oxford OX1 3QY, England.	jack.baldwin@chem.oz.ac.uk	Roach, Peter/AAW-7071-2021; Roach, Peter/C-6248-2013; Rutledge, Peter J/D-6253-2012	Rutledge, Peter/0000-0002-0767-5196				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN JE, 1984, J CHEM SOC CHEM COMM, P984, DOI 10.1039/c39840000984; BALDWIN JE, 1988, NAT PROD REP, V5, P129, DOI 10.1039/np9880500129; BALDWIN JE, 1988, J CHEM SOC CHEM COMM, P1128, DOI 10.1039/c39880001128; BALDWIN JE, 1990, CHEM REV, V90, P1079, DOI 10.1021/cr00105a001; BALDWIN JE, 1988, J CHEM SOC CHEM COMM, P1125, DOI 10.1039/c39880001125; BALDWIN JE, 1986, J CHEM SOC CHEM COMM, P110, DOI 10.1039/c39860000110; Berendzen J, 1998, BIOPHYS J, V74, pA250; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; HAJDU J, 1993, ANNU REV BIOPH BIOM, V22, P467, DOI 10.1146/annurev.bb.22.060193.002343; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRIAUCIUNAS A, 1991, J BIOL CHEM, V266, P11779; LEE SK, 1993, J BIOL CHEM, V268, P21569; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RIGAU JJ, 1970, J ORG CHEM, V35, P3655, DOI 10.1021/jo00836a013; Roach PL, 1996, EUR J BIOCHEM, V242, P736, DOI 10.1111/j.1432-1033.1996.0736r.x; Roach PL, 1997, NATURE, V387, P827, DOI 10.1038/42990; SCHLICHTING I, 1997, FASEB J, V1, pP2; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6	21	162	163	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	1999	401	6754					721	724		10.1038/44400	http://dx.doi.org/10.1038/44400			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537113				2022-12-28	WOS:000083207400062
J	Stephenson, J				Stephenson, J			Shingles vaccine trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					625	625		10.1001/jama.282.7.625	http://dx.doi.org/10.1001/jama.282.7.625			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10532854				2022-12-28	WOS:000082033700008
J	GOLOUBINOFF, P; CHRISTELLER, JT; GATENBY, AA; LORIMER, GH				GOLOUBINOFF, P; CHRISTELLER, JT; GATENBY, AA; LORIMER, GH			RECONSTITUTION OF ACTIVE DIMERIC RIBULOSE BISPHOSPHATE CARBOXYLASE FROM AN UNFOLDED STATE DEPENDS ON 2 CHAPERONIN PROTEINS AND MG-ATP	NATURE			English	Article									DUPONT CO,DEPT CENT RES & DEV,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880	DuPont			Christeller, John T/E-6904-2010	Goloubinoff, Pierre/0000-0002-4802-0807				ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261; CHAPMAN MS, 1987, NATURE, V329, P354, DOI 10.1038/329354a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHORY J, 1985, J BACTERIOL, V161, P307, DOI 10.1128/JB.161.1.307-313.1985; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ELLIS RJ, 1988, PHOTOSYNTH RES, V16, P101, DOI 10.1007/BF00039488; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1989, BIOCHEM SOC SYMP, V55, P145; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GATENBY AA, 1988, EMBO J, V7, P1307, DOI 10.1002/j.1460-2075.1988.tb02945.x; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; LANDRY SJ, 1989, J BIOL CHEM, V264, P9090; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MEHRA V, 1986, P NATL ACAD SCI USA, V83, P7013, DOI 10.1073/pnas.83.18.7013; MUSGROVE JE, 1986, PHILOS T ROY SOC B, V313, P419, DOI 10.1098/rstb.1986.0048; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; PIERCE J, 1985, APPL ENVIRON MICROB, V49, P1094, DOI 10.1128/AEM.49.5.1094-1100.1985; PIERCE J, 1986, ARCH BIOCHEM BIOPHYS, V245, P483, DOI 10.1016/0003-9861(86)90241-9; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROY H, 1982, J CELL BIOL, V94, P20, DOI 10.1083/jcb.94.1.20; ROY H, 1988, BIOCHIM BIOPHYS ACTA, V957, P323, DOI 10.1016/0167-4838(88)90221-X; SCHNEIDER G, 1986, EMBO J, V5, P3409, DOI 10.1002/j.1460-2075.1986.tb04662.x; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; TABITA FR, 1974, J BIOL CHEM, V249, P3459; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TORRESRUIZ JA, 1988, ARCH BIOCHEM BIOPHYS, V261, P196, DOI 10.1016/0003-9861(88)90118-X; VODKIN MH, 1988, J BACTERIOL, V170, P1227, DOI 10.1128/jb.170.3.1227-1234.1988	42	646	660	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 21	1989	342	6252					884	889		10.1038/342884a0	http://dx.doi.org/10.1038/342884a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF637	10532860				2022-12-28	WOS:A1989CF63700049
J	Beecham, L				Beecham, L			GMC wants a tougher restoration procedure	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1319	1319						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567118				2022-12-28	WOS:000083930200007
J	Wintemute, GJ; Parham, CA; Beaumont, JJ; Wright, M; Drake, C				Wintemute, GJ; Parham, CA; Beaumont, JJ; Wright, M; Drake, C			Mortality among recent purchasers of handguns.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLICTED GUNSHOT WOUNDS; GUN OWNERSHIP; PREVENTING SUICIDE; VIOLENT DEATH; UNITED-STATES; RISK-FACTORS; FIREARMS; WOMEN; RATES; HOMICIDE	Background: There continues to be considerable controversy over whether ownership of a handgun increases or decreases the risk of violent death. Methods: We conducted a population-based cohort study to compare mortality among 238,292 persons who purchased a handgun in California in 1991 with that in the general adult population of the state. The observation period began with the date of handgun purchase (15 days after the purchase application) and ended on December 31, 1996. The standardized mortality ratio (the ratio of the number of deaths observed among handgun purchasers to the number expected on the basis of age- and sex-specific rates among adults in California) was the principal outcome measure. Results: In the first year after the purchase of a handgun, suicide was the leading cause of death among handgun purchasers, accounting for 24.5 percent of all deaths and 51.9 percent of deaths among women 21 to 44 years old. The increased risk of suicide by any method among handgun purchasers (standardized mortality ratio, 4.31) was attributable entirely to an excess risk of suicide with a firearm (standardized mortality ratio, 7.12). In the first week after the purchase of a handgun, the rate of suicide by means of firearms among purchasers (644 per 100,000 person-years) was 57 times as high as the adjusted rate in the general population. Mortality from all causes during the first year after the purchase of a handgun was greater than expected for women (standardized mortality ratio, 1.09), and the entire increase was attributable to the excess number of suicides by means of a firearm. As compared with the general population, handgun purchasers remained at increased risk for suicide by firearm over the study period of up to six years, and the excess risk among women in this cohort (standardized mortality ratio, 15.50) remained greater than that among men (standardized mortality ratio, 3.23). The risk of death by homicide with a firearm was elevated among women (standardized mortality ratio at one year, 2.20; at six years, 2.01) but low among men (standardized mortality ratio at one year, 0.84; at six years, 0.79). Conclusions: The purchase of a handgun is associated with a substantial increase in the risk of suicide by firearm and by any method. The increase in the risk of suicide by firearm is apparent within a week after the purchase of a handgun and persists for at least six years. (N Engl J Med 1999;341:1583-9.) (C) 1999, Massachusetts Medical Society.	Univ Calif Davis, Med Ctr, Violence Prevent Res Program, Sacramento, CA 95817 USA	University of California System; University of California Davis	Wintemute, GJ (corresponding author), Univ Calif Davis, Med Ctr, Violence Prevent Res Program, 2315 Stockton Blvd, Sacramento, CA 95817 USA.							ALLEBECK P, 1988, BRIT MED J, V297, P176, DOI 10.1136/bmj.297.6642.176; Bailey JE, 1997, ARCH INTERN MED, V157, P777, DOI 10.1001/archinte.157.7.777; Beautrais AL, 1996, AUST NZ J PSYCHIAT, V30, P741, DOI 10.3109/00048679609065040; BOOR M, 1990, PSYCHOL REP, V66, P923, DOI 10.2466/PR0.66.3.923-930; BRENT DA, 1991, JAMA-J AM MED ASSOC, V266, P2989, DOI 10.1001/jama.266.21.2989; *BUR CENS, 1992, 1990 CENS POP, V1; CANTOR CH, 1995, MED J AUSTRALIA, V162, P583, DOI 10.5694/j.1326-5377.1995.tb138547.x; CARRINGTON PJ, 1994, AM J PSYCHIAT, V151, P606; Clarke R. V., 1989, SUICIDE CLOSING EXIT; Cook PJ, 1996, GUNS AM RESULTS COMP; Cummings P, 1997, AM J PUBLIC HEALTH, V87, P974, DOI 10.2105/AJPH.87.6.974; DEMOORE GM, 1994, MED J AUSTRALIA, V160, P421, DOI 10.5694/j.1326-5377.1994.tb138267.x; *DEP FIN, 1993, 93P3 DEP FIN; FRIERSON RL, 1989, HOSP COMMUNITY PSYCH, V40, P841; FRIERSON RL, 1990, PSYCHOSOMATICS, V31, P67, DOI 10.1016/S0033-3182(90)72219-0; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; Hirschfeld RMA, 1997, NEW ENGL J MED, V337, P910, DOI 10.1056/NEJM199709253371307; HOYERT DL, 1999, NAT VITAL STAT REP, V47, P105; Kaplan GA, 1996, BRIT MED J, V312, P1253; Kaplan GA, 1996, BRIT MED J, V312, P999; Kaplan MS, 1996, GERONTOLOGIST, V36, P530, DOI 10.1093/geront/36.4.530; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1992, J TRAUMA, V33, P1, DOI 10.1097/00005373-199207000-00001; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KILLIAS M, 1993, CAN MED ASSOC J, V148, P1721; Kleck G, 1995, J CRIM LAW CRIM, V86, P150, DOI 10.2307/1144004; Kleck G., 1993, J QUANT CRIMINOL, V9, P249, DOI [10.1007/BF01064462, DOI 10.1007/BF01064462]; Lewis G, 1997, BRIT J PSYCHIAT, V171, P351, DOI 10.1192/bjp.171.4.351; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; MARZUK PM, 1992, ARCH GEN PSYCHIAT, V49, P451; McCauley J, 1997, JAMA-J AM MED ASSOC, V277, P1362, DOI 10.1001/jama.277.17.1362; MCDOWALL D, 1994, AM J PUBLIC HEALTH, V84, P1982, DOI 10.2105/AJPH.84.12.1982; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; Neeleman J, 1998, LANCET, V351, P93, DOI 10.1016/S0140-6736(97)06364-2; OToole BI, 1995, SUICIDE LIFE-THREAT, V25, P475; PETERSON LG, 1985, AM J PSYCHIAT, V142, P228; Plutchik R, 1995, PHARMACOPSYCHIATRY, V28, P47, DOI 10.1055/s-2007-979620; POKORNY AD, 1983, ARCH GEN PSYCHIAT, V40, P249; *PUBL HLTH SERV, 1999, SURG GEN CALL ACT PR; Rivara FP, 1997, JAMA-J AM MED ASSOC, V278, P569, DOI 10.1001/jama.278.7.569; Rosenman SJ, 1998, MED J AUSTRALIA, V169, P100, DOI 10.5694/j.1326-5377.1998.tb140193.x; SCHWEGEL J, 1997, DEFINITIVE BABY NAME; SHELEY JF, 1998, NAT I JUST PUBL; SLOAN JH, 1990, NEW ENGL J MED, V322, P369, DOI 10.1056/NEJM199002083220605; Smith TW, 1995, J CRIM LAW CRIM, V86, P133, DOI 10.2307/1144003; Smith TW, 1997, J CRIM LAW CRIM, V87, P1462, DOI 10.2307/1144022; SORLIE PD, 1995, AM J PUBLIC HEALTH, V85, P949, DOI 10.2105/AJPH.85.7.949; Teret SP, 1998, NEW ENGL J MED, V339, P813, DOI 10.1056/NEJM199809173391206; Wallace D, 1998, AM J PUBLIC HEALTH, V88, P1853, DOI 10.2105/AJPH.88.12.1853; WARNER K, 1999, 3 NAT OUTL S CRIM CA; WINTEMUTE GJ, 1987, J TRAUMA, V27, P532, DOI 10.1097/00005373-198705000-00013	51	166	167	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1999	341	21					1583	1589		10.1056/NEJM199911183412106	http://dx.doi.org/10.1056/NEJM199911183412106			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	256GF	10564689				2022-12-28	WOS:000083717000006
J	Duong, T; Ades, AE; Gibb, DM; Tookey, PA; Masters, J				Duong, T; Ades, AE; Gibb, DM; Tookey, PA; Masters, J			Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data	BRITISH MEDICAL JOURNAL			English	Article							ZIDOVUDINE PROPHYLAXIS; CESAREAN-SECTION	Objective To estimate and interpret time trends in vertical transmission rates for HIV using data from national obstetric and paediatric surveillance registers. Design Prospective study of HIV infected women reported through obstetric surveillance. HIV infection status of the child and onset of AIDS were reported through paediatric surveillance. Rates of Vertical transmission and progression to AIDS rate were estimated by methods that take account of incomplete follow up of children with indeterminate infection status and delay in AIDS reporting. Setting British Isles. Subjects Pregnant women infected with HIV whose infection was diagnosed before delivery, and their babies. Main outcome measures Mother to child transmission of infection and progression to AIDS in children. Results By January 1999, 800 children born to diagnosed HN infected women who had not breast fed had been reported. Vertical transmission rates rose to 19.6% (95% confidence interval 8.0% to 32.5%) in 1993 before falling to 2.2% (0% to 7.8%) in 1998, Between 1995 and 1998 use of antiretroviral treatment increased significantly each year, reaching 97% of live births in 1998. The rate of elective caesarean section remained constant, at around 40%, up to 1997 but increased to 62% in 1998, Caesarean section and antiretroviral treatment together were estimated to reduce risk of transmission from 31.6% (13.6% to 52.2%) to 4.2% (0.8% to 8.5%). The proportion of infected children developing AIDS in the first 6 months fell from 17.7% (6.8% to 30.8%) before 1994 to 7.2% (0% to 15.7%) after, coinciding with increased use of prophylaxis against Pneumocystis carinii pneumonia. Conclusions In the British Isles both HIV related morbidity and vertical transmission are being reduced through increased use of interventions.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England; Med Res Ctr, Clin Trials Unit, Mortimer Market Ctr, London WC1E 6AU, England	University of London; University College London; Medical Research Council Clinical Trials Unit	Ades, AE (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.		Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387; Gibb, Diana/0000-0002-9738-5490				Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; CIRIA LM, 1998, 12 WORLD AIDS C GEN; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Dempster A. P., 1977, JRSSSB, V39, P1; Dunn DT, 1996, J AM STAT ASSOC, V91, P935, DOI 10.2307/2291712; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; *EUR MOD DEL COLL, 1999, MANDET, V353, P1035; FISCUS S, 1998, 12 WORLD AIDS C GEN; GALVAAO NO, 1998, 12 WORLD AIDS C GEN; GIBB DM, 1993, GUIDELINES MANAGEMEN, P1; Kind C, 1998, AIDS, V12, P205, DOI 10.1097/00002030-199802000-00011; LINDEGREN ML, 1999, 6 C RETR OPP INF CHI; Lorenzi P, 1998, AIDS, V12, pF241, DOI 10.1097/00002030-199818000-00002; Maguire A, 1997, AIDS, V11, P1851, DOI 10.1097/00002030-199715000-00010; Mandelbrot L, 1998, JAMA-J AM MED ASSOC, V280, P55, DOI 10.1001/jama.280.1.55; Newell ML, 1996, AIDS, V10, P1675; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; RAKUSAN TA, 1998, 12 WORLD AIDS C GEN; ROSENBERG PS, 1990, J ACQ IMMUN DEF SYND, V3, P49; *US PUBL HLTH SERV, 1995, MMWR-MORBID MORTAL W, V44, P1	21	58	60	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1227	1229		10.1136/bmj.319.7219.1227	http://dx.doi.org/10.1136/bmj.319.7219.1227			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550082	Bronze, Green Published			2022-12-28	WOS:000083625600021
J	Fisk, NM; Trew, G				Fisk, NM; Trew, G			Two's company, three's a crowd for embryo transfer	LANCET			English	Editorial Material							IN-VITRO FERTILIZATION; 2 EMBRYOS; PREGNANCY; BIRTHS; COST		Queen Charlottes Hosp, Imperial Coll, Sch Med,Dept Maternal & Fetal Med, Div Paediat Obstet & Gynaecol, London W6 0XG, England; Queen Charlottes Hosp, Imperial Coll, Sch Med,Dept Reprod Sci & Med, Div Paediat Obstet & Gynaecol, London W6 0XG, England; Hammersmith Hosp, London W6 0XG, England	Imperial College London; Imperial College London; Imperial College London	Fisk, NM (corresponding author), Queen Charlottes Hosp, Imperial Coll, Sch Med,Dept Maternal & Fetal Med, Div Paediat Obstet & Gynaecol, London W6 0XG, England.		Fisk, Nicholas M/B-2126-2009	Fisk, Nicholas M/0000-0003-0031-7975				Blickstein I, 1999, NEW ENGL J MED, V341, P1313, DOI 10.1056/NEJM199910213411714; Bustillo M, 1999, FERTIL STERIL, V71, P798; Edwards RG, 1999, HUM REPROD, V14, P1, DOI 10.1093/humrep/14.1.1; Evans M. I., 1999, American Journal of Obstetrics and Gynecology, V180, pS28; Gerris J, 1999, HUM REPROD, V14, P2581, DOI 10.1093/humrep/14.10.2581; *HUM FERT EMBR AUT, 1998, 7 HUM FERT EMBR AUTH; Lass A, 1998, FERTIL STERIL, V70, P1030, DOI 10.1016/S0015-0282(98)00353-7; Liao XH, 1997, SCOT MED J, V42, P76, DOI 10.1177/003693309704200304; LOGEROTLEBRUN H, 1995, FERTIL STERIL, V64, P746; *OFF NAT STAT, 1997, OFF NAT STAT SER DH3, V30; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239; Roest J, 1997, FERTIL STERIL, V67, P290, DOI 10.1016/S0015-0282(97)81913-9; STAESSEN C, 1993, HUM REPROD, V8, P1650, DOI 10.1093/oxfordjournals.humrep.a137907; Templeton A, 1998, NEW ENGL J MED, V339, P573, DOI 10.1056/NEJM199808273390901; VAUTHIERBROUZES D, 1994, FERTIL STERIL, V62, P339; Wolner-Hanssen P, 1998, HUM REPROD, V13, P88, DOI 10.1093/humrep/13.1.88	16	25	25	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1572	1573		10.1016/S0140-6736(99)00290-1	http://dx.doi.org/10.1016/S0140-6736(99)00290-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560665				2022-12-28	WOS:000083551000002
J	Raju, TNK				Raju, TNK			The Nobel chronicles - 1979: Allan Macleod Cormack (b 1924) and Sir Godfrey Newbold Hounsfield (b 1919)	LANCET			English	Editorial Material									Univ Illinois, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital									0	20	20	1	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1653	1653		10.1016/S0140-6736(05)77147-6	http://dx.doi.org/10.1016/S0140-6736(05)77147-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560712				2022-12-28	WOS:000083551000073
J	Liu, C; Fan, YY; Liu, M; Cong, HT; Cheng, HM; Dresselhaus, MS				Liu, C; Fan, YY; Liu, M; Cong, HT; Cheng, HM; Dresselhaus, MS			Hydrogen storage in single-walled carbon nanotubes at room temperature	SCIENCE			English	Article							DIAMETER DISTRIBUTION	Masses of single-walled carbon nanotubes (SWNTs) with a large mean diameter of about 1.85 nanometers, synthesized by a semicontinuous hydrogen are discharge method, were employed for hydrogen adsorption experiments in their as-prepared and pretreated states. A hydrogen storage capacity of 4.2 weight percent, or a hydrogen to carbon atom ratio of: 0.52, was achieved reproducibly at room temperature under a modestly high pressure (about 10 megapascal) for a SWNT sample of about 500 milligram weight that was soaked in hydrochloric acid and then heat-treated in vacuum. Moreover, 78.3 percent of the adsorbed hydrogen (3.3 weight percent) could be released under ambient pressure at room temperature, while the release of the residual stored hydrogen (0.9 weight percent) required some heating of the sample. Because the SWNTs can be easily produced and show reproducible and modestly high hydrogen uptake at room temperature, they show promise as an effective hydrogen storage material.	Chinese Acad Sci, Inst Met Res, Shenyang 110015, Peoples R China; MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA	Chinese Academy of Sciences; Institute of Metal Research, CAS; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Dresselhaus, MS (corresponding author), Chinese Acad Sci, Inst Met Res, 72 Wenhua Rd, Shenyang 110015, Peoples R China.		Way, James Douglas/A-9408-2010; 李, 莹/C-5680-2012; Cheng, Hui-Ming/B-8682-2012	Way, James Douglas/0000-0001-9612-8508; Cheng, Hui-Ming/0000-0002-5387-4241				Bandow S, 1998, PHYS REV LETT, V80, P3779, DOI 10.1103/PhysRevLett.80.3779; Brown SDM, 1998, MATER RES SOC SYMP P, V497, P157; Chambers A, 1998, J PHYS CHEM B, V102, P4253, DOI 10.1021/jp980114l; Chen P, 1999, SCIENCE, V285, P91, DOI 10.1126/science.285.5424.91; Cheng HM, 1998, CHEM PHYS LETT, V289, P602, DOI 10.1016/S0009-2614(98)00479-5; Dillon AC, 1997, NATURE, V386, P377, DOI 10.1038/386377a0; Journet C, 1997, NATURE, V388, P756, DOI 10.1038/41972; KIANG CH, 1995, CARBON, V33, P903, DOI 10.1016/0008-6223(95)00019-A; Liu C, 1999, CARBON, V37, P1865, DOI 10.1016/S0008-6223(99)00196-7; Rao AM, 1997, SCIENCE, V275, P187, DOI 10.1126/science.275.5297.187; Ye Y, 1999, APPL PHYS LETT, V74, P2307, DOI 10.1063/1.123833	11	1820	1962	17	632	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1127	1129		10.1126/science.286.5442.1127	http://dx.doi.org/10.1126/science.286.5442.1127			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550044				2022-12-28	WOS:000083534200034
J	Newble, D; Paget, N; McLaren, B				Newble, D; Paget, N; McLaren, B			Revalidation in Australia and New Zealand: approach of Royal Australasian College of Physicians	BRITISH MEDICAL JOURNAL			English	Article									Univ Sheffield, No Gen Hosp, Dept Med Educ, Sheffield S5 7AU, S Yorkshire, England; Royal Australasian Coll Physicians, Sydney, NSW 2000, Australia	Northern General Hospital; University of Sheffield	Newble, D (corresponding author), Univ Sheffield, No Gen Hosp, Dept Med Educ, Sheffield S5 7AU, S Yorkshire, England.							DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; NEWBLE D, 1994, CERTIFICATION RECERT; Newble DI, 1996, J ROY COLL PHYS LOND, V30, P252; Newble DI, 1997, ADVANCES IN MEDICAL EDUCATION, P567; PAGET NS, 1996, J CONTINUING ED HLTH, V16, P103	5	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1185	1188		10.1136/bmj.319.7218.1185	http://dx.doi.org/10.1136/bmj.319.7218.1185			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541515	Green Published			2022-12-28	WOS:000083536200030
J	Parbrook, EO				Parbrook, EO			Overcoming the problem - Take a lodger	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1179	1179		10.1136/bmj.319.7218.1179	http://dx.doi.org/10.1136/bmj.319.7218.1179			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541512	Green Published			2022-12-28	WOS:000083536200027
J	Kafitz, KW; Rose, CR; Thoenen, H; Konnerth, A				Kafitz, KW; Rose, CR; Thoenen, H; Konnerth, A			Neurotrophin-evoked rapid excitation through TrkB receptors	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; CULTURED HIPPOCAMPAL-NEURONS; SYNAPTIC TRANSMISSION; BRAIN; BDNF; RAT; LOCALIZATION; PLASTICITY; RELEASE; POTENTIATION	Neurotrophins are a family of structurally related proteins that regulate the survival, differentiation and maintenance of function of different populations of peripheral and central neurons(1-3). They are also essential for modulating activity-dependent neuronal plasticity(4-7). Here we show that neurotrophins elicit action potentials in central neurons. Even at low concentrations, brain-derived neurotrophic factor (BDNF) excited neurons in the hippocampus, cortex and cerebellum. We found that BDNF and neurotrophin-4/5 depolarized neurons just as rapidly as the neurotransmitter glutamate, even at a more than thousand-fold lower concentration. Neurotrophin-3 produced much smaller responses, and nerve growth factor was ineffective. The neurotrophin-induced depolarization resulted from the activation of a sodium ion conductance which was reversibly blocked by K-252a, a protein kinase blocker which prefers tyrosine kinase Trk receptors(8). Our results demonstrate a very rapid excitatory action of neurotrophins, placing them among the most potent endogenous neuro-excitants in the mammalian central nervous system described so far.	Tech Univ Munich, Inst Physiol, D-80802 Munich, Germany; Univ Saarlandes, Inst Physiol 1, D-66421 Homburg, Germany; Max Planck Inst Neurobiol, D-82152 Martinsried, Germany	Technical University of Munich; Saarland University; Max Planck Society	Konnerth, A (corresponding author), Tech Univ Munich, Inst Physiol, Biedersteinerstr 29, D-80802 Munich, Germany.							BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BERNAL I, 1993, STRUCT CHEM, V4, P131, DOI 10.1007/BF00677373; Berninger B, 1996, CURR OPIN NEUROBIOL, V6, P324, DOI 10.1016/S0959-4388(96)80115-2; Blochl A, 1996, MOL CELL NEUROSCI, V7, P173, DOI 10.1006/mcne.1996.0014; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Canossa M, 1997, P NATL ACAD SCI USA, V94, P13279, DOI 10.1073/pnas.94.24.13279; Cellerino A, 1996, PROG NEUROBIOL, V50, P333; Cellerino A, 1996, PROG NEUROBIOL, V49, P53, DOI 10.1016/0301-0082(96)00008-1; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; Ibanez CF, 1998, TRENDS NEUROSCI, V21, P438, DOI 10.1016/S0166-2236(98)01266-1; IP NY, 1993, J NEUROSCI, V13, P3394; KAHLE P, 1994, J NEUROSCI RES, V38, P599, DOI 10.1002/jnr.490380512; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; Korte M, 1996, P NATL ACAD SCI USA, V93, P12547, DOI 10.1073/pnas.93.22.12547; LESSMANN V, 1994, NEUROREPORT, V6, P21; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; RINGSTEDT T, 1993, DEV BRAIN RES, V72, P119, DOI 10.1016/0165-3806(93)90165-7; Rose CR, 1997, J PHYSIOL-LONDON, V499, P573, DOI 10.1113/jphysiol.1997.sp021951; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Suen PC, 1997, P NATL ACAD SCI USA, V94, P8191, DOI 10.1073/pnas.94.15.8191; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Yan Q, 1997, J COMP NEUROL, V382, P546; Yan Q, 1997, J COMP NEUROL, V378, P135; Zhou XF, 1996, NEUROSCIENCE, V74, P945, DOI 10.1016/S0306-4522(96)00237-0	32	455	464	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					918	921		10.1038/44847	http://dx.doi.org/10.1038/44847			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553907				2022-12-28	WOS:000083464700059
J	Pagel, M				Pagel, M			Inferring the historical patterns of biological evolution	NATURE			English	Review							PHYLOGENETICALLY INDEPENDENT CONTRASTS; CORRELATED EVOLUTION; MOLECULAR EVIDENCE; METAZOAN PHYLA; PHYLOGENIES; CHARACTERS; SEQUENCES; RECONSTRUCTION; RATES; BIRDS	Phylogenetic trees describe the pattern of descent amongst a group of species. With the rapid accumulation of DNA sequence data, more and more phylogenies are being constructed based upon sequence comparisons. The combination of these phylogenies with powerful new statistical approaches for the analysis of biological evolution is challenging widely held beliefs about the history and evolution of life on Earth.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of Reading	Pagel, M (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.		Rohlf, F J/A-8710-2008					Arnason U, 1998, J MOL EVOL, V47, P718, DOI 10.1007/PL00006431; Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; BOWLER PJ, 1991, C DARWIN MAN HIS INF; BOWRING SA, 1993, SCIENCE, V261, P1293, DOI 10.1126/science.11539488; Bromham L, 1998, P NATL ACAD SCI USA, V95, P12386, DOI 10.1073/pnas.95.21.12386; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Bull JJ, 1997, GENETICS, V147, P1497; COLLINS TM, 1994, SYST BIOL, V43, P482, DOI 10.2307/2413547; Cooper A, 1997, SCIENCE, V275, P1109, DOI 10.1126/science.275.5303.1109; Crandall KA, 1999, MOL BIOL EVOL, V16, P372, DOI 10.1093/oxfordjournals.molbev.a026118; Darwin Charles, 1888, ORIGIN SPECIES MEANS, VSixth; Durham WH., 1991, COEVOLUTION GENES CU; EDWARDS AWF, 1972, LIKELIHOOD; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FITCH WM, 1991, P NATL ACAD SCI USA, V88, P4270, DOI 10.1073/pnas.88.10.4270; Foote M, 1999, NATURE, V398, P415, DOI 10.1038/18872; Fortey R., 1997, LIFE UNAUTHORISED BI; Galtier N, 1999, SCIENCE, V283, P220, DOI 10.1126/science.283.5399.220; GARLAND T, 1992, SYST BIOL, V41, P18, DOI 10.2307/2992503; Golding GB, 1998, MOL BIOL EVOL, V15, P355, DOI 10.1093/oxfordjournals.molbev.a025932; GOULD SJ, 1993, NATURE, V366, P223, DOI 10.1038/366223a0; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Harvey PH, 1998, P ROY SOC B-BIOL SCI, V265, P1691, DOI 10.1098/rspb.1998.0490; Healy SD, 1996, BRAIN BEHAV EVOLUT, V47, P195, DOI 10.1159/000113239; Hecht M.K., 1986, Oxford Surveys in Evolutionary Biology, V3, P1; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; HILLIS DM, 1992, SCIENCE, V255, P589, DOI 10.1126/science.1736360; Hillis DM., 1996, MOL SYSTEMATICS, V2nd; Holden C, 1997, HUM BIOL, V69, P605; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Jerison HJ., 1973, EVOLUTION BRAIN INTE; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; Johnston J., 1963, ECONOMETRIC METHODS; Kerr RA, 1999, SCIENCE, V284, P412; Koshi JM, 1996, J MOL EVOL, V42, P313, DOI 10.1007/BF02198858; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; Larget B, 1999, MOL BIOL EVOL, V16, P750, DOI 10.1093/oxfordjournals.molbev.a026160; Li W. H, 1997, MOL EVOLUTION; MADDISON DR, 1994, ANNU REV ENTOMOL, V39, P267, DOI 10.1146/annurev.en.39.010194.001411; MADDISON WP, 1990, EVOLUTION, V44, P539, DOI 10.2307/2409434; MARTIN RD, 1981, NATURE, V293, P57, DOI 10.1038/293057a0; MARTINS EP, 1991, EVOLUTION, V45, P534, DOI [10.2307/2409910, 10.1111/j.1558-5646.1991.tb04328.x]; Martins EP, 1997, AM NAT, V149, P646, DOI 10.1086/286013; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; Mooers AO, 1999, SYST BIOL, V48, P623, DOI 10.1080/106351599260193; Mooers AO, 1999, AM NAT, V154, P249, DOI 10.1086/303226; Omland KE, 1997, EVOLUTION, V51, P1381, DOI [10.1111/j.1558-5646.1997.tb01461.x, 10.2307/2411190]; OMLAND KE, 1994, SYST BIOL, V43, P369, DOI 10.2307/2413674; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Pagel M, 1999, SYST BIOL, V48, P612, DOI 10.1080/106351599260184; PAGEL M, 1994, P ROY SOC B-BIOL SCI, V255, P37, DOI 10.1098/rspb.1994.0006; Pagel M, 1997, ZOOL SCR, V26, P331, DOI 10.1111/j.1463-6409.1997.tb00423.x; PAGEL M, 1993, J THEOR BIOL, V164, P191, DOI 10.1006/jtbi.1993.1148; PAGEL MD, 1989, SCIENCE, V244, P1589, DOI 10.1126/science.2740904; PAGEL MD, 1992, J THEOR BIOL, V156, P431, DOI 10.1016/S0022-5193(05)80637-X; Price T, 1997, PHILOS T ROY SOC B, V352, P519, DOI 10.1098/rstb.1997.0036; PURVIS A, 1994, J THEOR BIOL, V167, P293, DOI 10.1006/jtbi.1994.1071; PURVIS A, 1995, PHILOS T ROY SOC B, V348, P405, DOI 10.1098/rstb.1995.0078; Rambaut A, 1998, MOL BIOL EVOL, V15, P442, DOI 10.1093/oxfordjournals.molbev.a025940; RAUP DM, 1991, MASS EXTINCTIONS BAD; Ricklefs RE, 1996, OIKOS, V77, P167, DOI 10.2307/3545598; RIDLEY M, 1981, EXPLANATION ORGANIC; Rolland C, 1998, AM NAT, V151, P514, DOI 10.1086/286137; Roux KH, 1998, P NATL ACAD SCI USA, V95, P11804, DOI 10.1073/pnas.95.20.11804; Schluter D, 1997, EVOLUTION, V51, P1699, DOI 10.1111/j.1558-5646.1997.tb05095.x; SCHLUTER D, 1995, NATURE, V377, P108, DOI 10.1038/377108a0; Strauss E, 1999, SCIENCE, V283, P1435, DOI 10.1126/science.283.5407.1435; Tuffley C, 1997, B MATH BIOL, V59, P581, DOI 10.1016/S0092-8240(97)00001-3; URSING BM, 1998, P R SOC LOND B, V265, P2252; Valentine JW, 1996, DEV BIOL, V173, P373, DOI 10.1006/dbio.1996.0033; Vila C, 1997, SCIENCE, V276, P1687, DOI 10.1126/science.276.5319.1687; Williams G. C., 1992, NATURAL SELECTION; Wilson IJ, 1998, GENETICS, V150, P499; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568; YANG ZH, 1995, GENETICS, V141, P1641; Yeager M, 1999, IMMUNOL REV, V167, P45, DOI 10.1111/j.1600-065X.1999.tb01381.x	77	3203	3238	22	589	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	1999	401	6756					877	884		10.1038/44766	http://dx.doi.org/10.1038/44766			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553904				2022-12-28	WOS:000083464700048
J	Richards, A; Gleeson, M				Richards, A; Gleeson, M			Recent advances - Otolaryngology	BRITISH MEDICAL JOURNAL			English	Review							ENDOSCOPIC SINUS SURGERY; CEREBROSPINAL-FLUID RHINORRHEA; SENSORINEURAL HEARING-LOSS; DIVERTICULOTOMY; PREVENTION; IMPLANT		Guys Hosp, Dept Otolaryngol & Skull Base Surg, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust	Gleeson, M (corresponding author), Guys Hosp, Dept Otolaryngol & Skull Base Surg, London SE1 9RT, England.							Alberti P.W, 1998, NOISE HEALTH, V1, P3; Baldwin DL, 1998, CLIN OTOLARYNGOL, V23, P244; Bernstein JM, 1998, OTOLARYNG HEAD NECK, V118, P800, DOI 10.1016/S0194-5998(98)70272-4; Gan R Z, 1997, Ear Nose Throat J, V76, P297; GASKINS RE, 1994, AM J RHINOL, V8, P271, DOI 10.2500/105065894781874151; Hehar SS, 1997, J LARYNGOL OTOL, V111, P1056, DOI 10.1017/S0022215100139325; Hughes RGM, 1997, J LARYNGOL OTOL, V111, P125, DOI 10.1017/S0022215100136643; Koay B, 1997, J LARYNGOL OTOL, V111, P946, DOI 10.1017/S0022215100139039; Koay CB, 1996, CLIN OTOLARYNGOL, V21, P371, DOI 10.1111/j.1365-2273.1996.tb01091.x; Lenarz T, 1998, LARYNGO RHINO OTOL, V77, P247, DOI 10.1055/s-2007-996970; MARAN AGD, 1986, CLIN OTOLARYNGOL, V11, P219, DOI 10.1111/j.1365-2273.1986.tb01923.x; MAY M, 1994, LARYNGOSCOPE, V104, P1080; Otto SR, 1998, OTOLARYNG HEAD NECK, V118, P291, DOI 10.1016/S0194-5998(98)70304-3; Prasher D, 1998, LANCET, V352, P1240, DOI 10.1016/S0140-6736(05)70483-9; Ramadan HH, 1999, LARYNGOSCOPE, V109, P27, DOI 10.1097/00005537-199901000-00006; Senior BA, 1998, LARYNGOSCOPE, V108, P151, DOI 10.1097/00005537-199802000-00001; Snik AFM, 1998, CLIN OTOLARYNGOL, V23, P414, DOI 10.1046/j.1365-2273.1998.00169.x; Wax MK, 1997, OTOLARYNG HEAD NECK, V116, P442, DOI 10.1016/S0194-5998(97)70292-4; WOUTERS B, 1990, ACTA GASTRO-ENT BELG, V53, P323; Yamasoba T, 1999, HEARING RES, V127, P31, DOI 10.1016/S0378-5955(98)00178-6; 1997, OROLARYNGOL HEAD NEC, V117, pS1	21	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1110	1113		10.1136/bmj.319.7217.1110	http://dx.doi.org/10.1136/bmj.319.7217.1110			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531105	Green Published			2022-12-28	WOS:000083419500027
J	White, NJ				White, NJ			Variation in virulence of dengue virus	LANCET			English	Editorial Material							HEMORRHAGIC-FEVER; SHOCK SYNDROME; PATHOGENESIS		Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand	Mahidol University	White, NJ (corresponding author), Mahidol Univ, Fac Trop Med, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.		White, Nicholas J/I-4629-2012; White, Nick/AAC-6527-2019	White, Nick/0000-0002-1897-1978				Bhamarapravati Natth, 1997, P367; CHUNGUE E, 1993, J GEN VIROL, V74, P2765, DOI 10.1099/0022-1317-74-12-2765; Dar L, 1999, EMERG INFECT DIS, V5, P589, DOI 10.3201/eid0504.990427; Falconar AKI, 1997, ARCH VIROL, V142, P897, DOI 10.1007/s007050050127; Gubler DJ, 2014, DENGUE AND DENGUE HEMORRHAGIC FEVER, 2ND EDITION, P1, DOI 10.1079/9781845939649.0001; HALSTEAD SB, 1970, YALE J BIOL MED, V42, P311; HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0; KOURI GP, 1989, B WORLD HEALTH ORGAN, V67, P375; Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999; NIMMANNITYA S, 1987, SE ASIAN J TROP MED, V20, P325; SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932; Trent D. W., 1990, Applied Virology Research, V2, P293; Worobey M, 1999, P NATL ACAD SCI USA, V96, P7352, DOI 10.1073/pnas.96.13.7352	13	19	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1999	354	9188					1401	1402		10.1016/S0140-6736(99)00236-6	http://dx.doi.org/10.1016/S0140-6736(99)00236-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543660				2022-12-28	WOS:000083277400003
J	Cremona, O; Di Paolo, G; Wenk, MR; Luthi, A; Kim, WT; Takei, K; Daniell, L; Nemoto, Y; Shears, SB; Flavell, RA; McCormick, DA; De Camilli, P				Cremona, O; Di Paolo, G; Wenk, MR; Luthi, A; Kim, WT; Takei, K; Daniell, L; Nemoto, Y; Shears, SB; Flavell, RA; McCormick, DA; De Camilli, P			Essential role of phosphoinositide metabolism in synaptic vesicle recycling	CELL			English	Article							NERVE-TERMINALS; INOSITOL PHOSPHOLIPIDS; NONUNIFORM PROBABILITY; MEDIATED ENDOCYTOSIS; TRANSFER PROTEIN; YEAST GOLGI; BINDING; MEMBRANE; DYNAMIN; SYNAPTOJANIN	Growing evidence suggests that phosphoinositides play an important role in membrane traffic. A polyphosphoinositide phosphatase, synaptojanin 1, was identified as a major presynaptic protein associated with endocytic coated intermediates. We report here that synaptojanin 1-deficient mice exhibit neurological defects and die shortly after birth. In neurons of mutant animals, PI(4,5)beta(2) levels are increased, and clathrin-coated vesicles accumulate in the cytomatrix-rich area that surrounds the synaptic vesicle cluster in nerve endings. In cell-free assays, reduced phosphoinositide phosphatase activity correlated with increased association of clathrin coats with liposomes. Intracellular recording in hippocampal slices revealed enhanced synaptic depression during prolonged high-frequency stimulation followed by delayed recovery. These results provide genetic evidence far a crucial role of phosphoinositide metabolism in synaptic vesicle recycling.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Univ Piemonte Orientale A Avogadro, Dipartimento Sci Med, I-28100 Novara, Italy; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University; University of Eastern Piedmont Amedeo Avogadro; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06510 USA.		Shears, Stephen B/C-6335-2019; Cremona, Ottavio/AAB-8793-2019; McCormick, David A/J-2649-2015; Wenk, Markus Rene/D-1441-2014; Kobelt, Liza/F-5926-2011; Luthi, Anita/ABE-1411-2021	Shears, Stephen B/0000-0001-7309-8916; Cremona, Ottavio/0000-0001-9462-1040; McCormick, David A/0000-0002-9803-8335; Luthi, Anita/0000-0002-4954-4143; Takei, Kohji/0000-0002-6555-9425	NINDS NIH HHS [NS26143, NS46128, NS36251] Funding Source: Medline; Telethon [D.061, D.111] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036251, R37NS026143, R37NS036251, R01NS026143, R29NS026143] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Auger K. R., 1990, METHODS INOSITIDE RE, P159; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Banker G., 1991, CULTURING NERVE CELL; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; GUSTAFSSON J, 1998, NEUROSCI SOC ABSTR, V327, P19; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; HARRIS KM, 1995, NEUROPHARMACOLOGY, V34, P1387, DOI 10.1016/0028-3908(95)00142-S; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; HAWTHORNE JN, 1979, J NEUROCHEM, V32, P5, DOI 10.1111/j.1471-4159.1979.tb04503.x; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HOKIN MR, 1953, J BIOL CHEM, V203, P967; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lee A, 1999, CURR BIOL, V9, P261, DOI 10.1016/S0960-9822(99)80115-8; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mikoshiba K, 1999, CHEM PHYS LIPIDS, V98, P59, DOI 10.1016/S0009-3084(99)00018-3; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; Ryan TA, 1996, J CELL BIOL, V134, P1219, DOI 10.1083/jcb.134.5.1219; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Singer-Kruger B, 1998, J CELL SCI, V111, P3347; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; VERHAGE M, 1997, NEUR SOC ABSTR, V23, P1168; Wiedemann C, 1998, J NEUROSCI, V18, P5594; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; Woscholski R, 1997, J BIOL CHEM, V272, P9625; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	59	611	628	4	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					179	188		10.1016/S0092-8674(00)81649-9	http://dx.doi.org/10.1016/S0092-8674(00)81649-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535736	hybrid			2022-12-28	WOS:000083159700008
J	Debarbieux, L; Beckwith, J				Debarbieux, L; Beckwith, J			Electron avenue: Pathways of disulfide bond formation and isomerization	CELL			English	Review							ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; PERIPLASMIC PROTEIN; FORMATION INVIVO; GENE; DSBA		Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Beckwith, J (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.			Debarbieux, Laurent/0000-0001-6875-5758				ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; Aslund F, 1999, J BACTERIOL, V181, P1375; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BELIN P, 1994, MOL GEN GENET, V242, P23, DOI 10.1007/BF00277344; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Debarbieux L, 1998, P NATL ACAD SCI USA, V95, P10751, DOI 10.1073/pnas.95.18.10751; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; FRAND AR, 1999, IN PRESS MOL CELL, V4; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; Kishigami S, 1996, GENES CELLS, V1, P201, DOI 10.1046/j.1365-2443.1996.d01-233.x; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; Walker KW, 1997, J BIOL CHEM, V272, P8845	21	73	76	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					117	119		10.1016/S0092-8674(00)81642-6	http://dx.doi.org/10.1016/S0092-8674(00)81642-6			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535729	Green Submitted, Bronze			2022-12-28	WOS:000083159700001
J	Folsch, H; Ohno, H; Bonifacino, JS; Mellman, I				Folsch, H; Ohno, H; Bonifacino, JS; Mellman, I			A novel clathrin adaptor complex mediates basolateral targeting in polarized epithelial cells	CELL			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; DARBY CANINE KIDNEY; MDCK CELLS; SORTING SIGNALS; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEINS; PLASMA-MEMBRANE; STRUCTURAL REQUIREMENTS; GOLGI-COMPLEX; FC-RECEPTORS	Although polarized epithelial cells are well known to maintain distinct apical and basolateral plasma membrane domains, the mechanisms responsible for targeting membrane proteins to the apical or basolateral surfaces have remained elusive. We have identified a novel form of the AP-1 clathrin adaptor complex that contains as one of its subunits mu 1B, an epithelial cell-specific homolog of the ubiquitously expressed mu 1A. LLC-PK1 kidney epithelial cells do not express mu 1B and missort many basolateral proteins to the apical surface. Stable expression of mu 1B selectively restored basolateral targeting, improved the overall organization of LLC-PK1 monolayers, and had no effect on apical targeting. We conclude that basolateral sorting is mediated by an epithelial cell-specific version of the AP-1 complex containing mu 1B.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ludwig Inst Canc Res, New Haven, CT 06520 USA; NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Kanazawa Univ, Canc Res Inst, Div Mol Membrane Biol, Kanazawa, Ishikawa 9200934, Japan	Yale University; Ludwig Institute for Cancer Research; Yale University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Kanazawa University	Mellman, I (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.		Ohno, Hiroshi/L-7899-2014; Mellman, Ira/ABG-5896-2020	Ohno, Hiroshi/0000-0001-8776-9661; Bonifacino, Juan S./0000-0002-5673-6370; Folsch, Heike/0000-0003-0897-0311	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029765] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29765] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.physiol.51.1.755; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Keller P, 1997, J CELL SCI, V110, P3001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; WEISZ OA, 1992, J BIOL CHEM, V267, P22282; Wilton JC, 1996, BIOESSAYS, V18, P229, DOI 10.1002/bies.950180310; Winckler B, 1999, NEURON, V23, P637, DOI 10.1016/S0896-6273(01)80021-0; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	46	420	422	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					189	198		10.1016/S0092-8674(00)81650-5	http://dx.doi.org/10.1016/S0092-8674(00)81650-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535737	hybrid			2022-12-28	WOS:000083159700009
J	Ketting, RF; Haverkamp, THA; van Luenen, HGAM; Plasterk, RHA				Ketting, RF; Haverkamp, THA; van Luenen, HGAM; Plasterk, RHA			mut-7 of C-elegans, required for transposon silencing and RNA interference, is a homolog of Werner syndrome helicase and RNaseD	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DE-NOVO METHYLATION; M HYBRID DYSGENESIS; DNA-BINDING DOMAIN; TC3 TRANSPOSASE; MUTATOR ACTIVITY; MOLECULAR-BASIS; IN-VITRO; EXCISION; ELEMENTS	While all known natural isolates of C. elegans contain multiple copies of the Tc1 transposon, which are active in the soma, Tc1 transposition is fully silenced in the germline of many strains. We mutagenized one such silenced strain and isolated mutants in which Tct had been activated in the germline ("mutators"). Interestingly, many other transposons of unrelated sequence had also become active. Most of these mutants are resistant to RNA interference (RNAi). We found one of the mutated genes, mut-7, to encode a protein with homology to RNaseD. This provides support for the notion that RNAi works by dsRNA-directed, enzymatic RNA degradation. We propose a model in which MUT-7, guided by transposon-derived dsRNA, represses transposition by degrading transposon-specific messengers, thus preventing transposase production and transposition.	Netherlands Canc Inst, Div Mol Biol, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Plasterk, RHA (corresponding author), Netherlands Canc Inst, Div Mol Biol, Ctr Biomed Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	rplas@nki.nl	Haverkamp, Thomas H.A./H-2783-2019; Haverkamp, Thomas/B-3479-2008	Haverkamp, Thomas H.A./0000-0002-3070-9745; Ketting, Rene/0000-0001-6161-5621; van Luenen, Henri/0000-0002-5584-7968				Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; BABITY JM, 1990, MOL GEN GENET, V222, P65, DOI 10.1007/BF00283024; BINGHAM PM, 1982, CELL, V29, P995, DOI 10.1016/0092-8674(82)90463-9; Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739; BRYAN GJ, 1988, SCIENCE, V240, P215, DOI 10.1126/science.2832948; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; COLLINS J, 1989, GENETICS, V121, P47; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; COLLINS JJ, 1994, GENETICS, V137, P771; COLLOMS SD, 1994, NUCLEIC ACIDS RES, V22, P5548, DOI 10.1093/nar/22.25.5548; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; EIDE D, 1985, P NATL ACAD SCI USA, V82, P1756, DOI 10.1073/pnas.82.6.1756; EMMONS SW, 1984, CELL, V36, P599, DOI 10.1016/0092-8674(84)90339-8; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grant SR, 1999, CELL, V96, P303, DOI 10.1016/S0092-8674(00)80541-3; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; Jones AL, 1998, EMBO J, V17, P6385, DOI 10.1093/emboj/17.21.6385; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Kelly WG, 1997, GENETICS, V146, P227; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; MOERMAN DG, 1984, GENETICS, V108, P859; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; MORI I, 1990, MOL GEN GENET, V220, P251, DOI 10.1007/BF00260490; MORI I, 1988, GENETICS, V120, P397; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; PEREIRA A, 1986, EMBO J, V5, P835, DOI 10.1002/j.1460-2075.1986.tb04292.x; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; RUBIN GM, 1982, CELL, V29, P987, DOI 10.1016/0092-8674(82)90462-7; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Smyth DR, 1997, CURR BIOL, V7, pR793, DOI 10.1016/S0960-9822(06)00407-6; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; VANLUENEN HGAM, 1993, EMBO J, V12, P2513, DOI 10.1002/j.1460-2075.1993.tb05906.x; vanPouderoyen G, 1997, EMBO J, V16, P6044, DOI 10.1093/emboj/16.19.6044; VOS JC, 1993, GENE DEV, V7, P1244, DOI 10.1101/gad.7.7a.1244; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; VOS JC, 1994, EMBO J, V13, P6125, DOI 10.1002/j.1460-2075.1994.tb06959.x; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959	45	573	647	2	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	1999	99	2					133	141		10.1016/S0092-8674(00)81645-1	http://dx.doi.org/10.1016/S0092-8674(00)81645-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535732	Bronze			2022-12-28	WOS:000083159700004
J	Graef, IA; Mermelstein, PG; Stankunas, K; Neilson, JR; Deisseroth, K; Tsien, RW; Crabtree, GR				Graef, IA; Mermelstein, PG; Stankunas, K; Neilson, JR; Deisseroth, K; Tsien, RW; Crabtree, GR			L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons	NATURE			English	Article							LONG-TERM DEPRESSION; GLYCOGEN-SYNTHASE KINASE-3; LYMPHOCYTE-T ACTIVATION; CREB PHOSPHORYLATION; GENE-EXPRESSION; CYCLOSPORINE-A; NF-ATC; CALCINEURIN; INDUCTION; TRANSCRIPTION	The molecular basis of learning and memory has been the object of several recent advances, which have focused attention on calcium-regulated pathways controlling transcription. One of the molecules implicated by pharmacological, biochemical and genetic approaches is the calcium/calmodulin-regulated phosphatase, calcineurin(1-5). In lymphocytes, calcineurin responds to specific calcium signals and regulates expression of several immediate early genes by controlling the nuclear import of the NF-ATc family of transcription factors(6-9). Here we show that NF-ATc4/NF-AT3 (ref. 10) in hippocampal neurons can rapidly translocate from cytoplasm to nucleus and activate NF-AT-dependent transcription in response to electrical activity or potassium depolarization. The calcineurin-mediated translocation is critically dependent on calcium entry through L-type voltage-gated calcium channels. GSK-3 can phosphorylate NF-ATc4, promoting its export from the nucleus and antagonizing NF-ATc4-dependent transcription. Furthermore, we show that induction of the inositol 1,4,5-trisphosphate receptor type 1 is controlled by the calcium/calcineurin/NF-ATc pathway. This provides a new perspective on the function of calcineurin in the central nervous system and indicates that NF-AT-mediated gene expression may be involved in the induction of hippocampal synaptic plasticity and memory formation.	Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Beckman Ctr Mol & Genet Med, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University	Crabtree, GR (corresponding author), Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA.							Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FLEXNER LB, 1967, SCIENCE, V155, P1377, DOI 10.1126/science.155.3768.1377; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KASONO K, 1995, NEUROREPORT, V6, P569, DOI 10.1097/00001756-199502000-00040; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lu YF, 1996, NEUROSCI LETT, V205, P103, DOI 10.1016/0304-3940(96)12384-3; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Reyes M, 1996, J NEUROSCI, V16, P5951; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Zhou P, 1998, CELL, V92, P687, DOI 10.1016/S0092-8674(00)81136-8; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	30	404	417	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					703	708		10.1038/44378	http://dx.doi.org/10.1038/44378			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537109				2022-12-28	WOS:000083207400058
J	Kannus, P; Palvanen, M; Kaprio, J; Parkkari, J; Koskenvuo, M				Kannus, P; Palvanen, M; Kaprio, J; Parkkari, J; Koskenvuo, M			Genetic factors and osteoporotic fractures in elderly people: prospective 25 year follow up of a nationwide cohort of elderly Finnish twins	BRITISH MEDICAL JOURNAL			English	Article							BONE-MINERAL DENSITY; HIP FRACTURE; RISK-FACTORS; WHITE WOMEN; MASS; DETERMINANTS; FALL; MEN; EPIDEMIOLOGY; ZYGOSITY	Objective To determine whether genetic factors partly explain variation in risk of osteoporotic fracture, the true end point of the osteoporosis problem. Design Prospective 15 year follow up of a nationwide cohort of elderly Finnish twins. Setting The Finnish twin cohort and the national hospital discharge register, covering the entire 5 million population of Finland. Subjects All same sex twin pairs born before 1946. The cohort contained 2308 monozygotic and 5241 dizygotic twin pairs (15 098 people) at the beginning of follow up. Main outcome measure The number and concordance of osteoporotic fractures in the twin pairs, 1972-96. Results 786 cohort members sustained an osteoporotic fracture. In women, the pairwise concordance rate for fracture (that is, the relative number of twin pairs in whom the fracture affected both twins in a pair) was 9.5% (95% confidence interval 5.3% to 15.5%) in monozygotic pairs and 7.9% (5.2% to 11.4%) in dizygotic pairs. In men, the figures were 9.9% (4.4% to 18.5%) and 2.3% (0.6% to 5.7%). Conclusions Susceptibility to osteoporotic fractures in elderly Finns is not strongly influenced by genetic factors, especially in elderly women. The traditional strategy for prevention of osteoporotic fractures-that is, increasing peak bone mass and preventing age related bone loss-should be changed to include new elements such as prevention of falls and protection of the critical anatomical sites of the body when a fall occurs.	UKK Inst Hlth Promot, Accident & Trauma Res Ctr, FIN-33501 Tampere, Finland; UKK Inst Hlth Promot, Tampere Res Ctr Sports Med, FIN-33501 Tampere, Finland; Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland; Univ Turku, Dept Publ Hlth, FIN-20520 Turku, Finland	UKK Institute; UKK Institute; University of Helsinki; University of Turku	Kannus, P (corresponding author), UKK Inst, Kaupinpuistonkatu 1, FIN-33500 Tampere, Finland.		Kaprio, Jaakko/A-1820-2008	Kaprio, Jaakko/0000-0002-3716-2455				CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; COOPER C, 1993, AM J EPIDEMIOL, V137, P1001, DOI 10.1093/oxfordjournals.aje.a116756; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7; DeLaet CEDH, 1997, BRIT MED J, V315, P221, DOI 10.1136/bmj.315.7102.221; DEMPSTER DW, 1993, LANCET, V341, P797, DOI 10.1016/0140-6736(93)90570-7; EMERY EM, 1976, METHODOLOGY MED GENE; EVANS RA, 1988, ANN INTERN MED, V109, P870, DOI 10.7326/0003-4819-109-11-870; Falconer D. S., 1981, INTRO QUANTITATIVE G; FLICKER L, 1995, J BONE MINER RES, V10, P1607; Fox KM, 1998, OSTEOPOROSIS INT, V8, P557, DOI 10.1007/s001980050099; GREENSPAN SL, 1994, JAMA-J AM MED ASSOC, V271, P128, DOI 10.1001/jama.271.2.128; HEATH AC, 1989, BEHAV GENET, V19, P9, DOI 10.1007/BF01065881; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; JABLON S, 1967, AM J HUM GENET, V19, P133; JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352; Kannus P, 1996, ANN INTERN MED, V125, P975, DOI 10.7326/0003-4819-125-12-199612150-00007; KANNUS P, 1995, LANCET, V346, P50, DOI 10.1016/S0140-6736(95)92679-8; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; KRALL EA, 1993, J BONE MINER RES, V8, P1; LAURITZEN JB, 1993, OSTEOPOROSIS INT, V3, P127, DOI 10.1007/BF01623273; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; LUTHJE P, 1995, ACTA ORTHOP SCAND, V66, P245; MAGNUS P, 1983, CLIN GENET, V24, P103; MARSHALL D, 1996, BRIT MED J, V312, P125; MELTON LJ, 1993, BONE, V14, pS1; NEALE MC, 1994, BEHAV GENET, V24, P239, DOI 10.1007/BF01067191; NEVITT MC, 1993, J AM GERIATR SOC, V41, P1226, DOI 10.1111/j.1532-5415.1993.tb07307.x; Nguyen TV, 1996, AM J EPIDEMIOL, V144, P255, DOI 10.1093/oxfordjournals.aje.a008920; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; ROSE RJ, 1988, J PERS SOC PSYCHOL, V54, P161, DOI 10.1037/0022-3514.54.1.161; SALMELA R, 1987, HOSPITAL, V49, P80; SARNA S, 1978, HUM HERED, V28, P241, DOI 10.1159/000152964; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476; Spector TD, 1996, BRIT MED J, V312, P940; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301	39	65	71	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1334	1337		10.1136/bmj.319.7221.1334	http://dx.doi.org/10.1136/bmj.319.7221.1334			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567136	Green Published, Bronze			2022-12-28	WOS:000083930200023
J	Kuppers, R; Klein, U; Hansmann, ML; Rajewsky, K				Kuppers, R; Klein, U; Hansmann, ML; Rajewsky, K			Cellular origin of human B-cell lymphomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							V-H GENES; REED-STERNBERG CELLS; PREDOMINANT HODGKINS-DISEASE; SHOWS SOMATIC HYPERMUTATION; VARIABLE REGION GENES; HEAVY-CHAIN GENE; PERIPHERAL-BLOOD; MULTIPLE-MYELOMA; BURKITTS-LYMPHOMA; INTRACLONAL HETEROGENEITY		Univ Cologne, Dept Internal Med, D-50931 Cologne, Germany; Univ Cologne, Inst Genet, D-50931 Cologne, Germany; Univ Frankfurt, Dept Pathol, D-6000 Frankfurt, Germany	University of Cologne; University of Cologne; Goethe University Frankfurt	Kuppers, R (corresponding author), Univ Cologne, Dept Internal Med, LFI E4 R706,Joseph Stelzmannstr 9, D-50931 Cologne, Germany.			Rajewsky, Klaus/0000-0002-6633-6370; Kuppers, Ralf/0000-0002-6691-7191				Aarts WM, 1998, BLOOD, V92, P3857, DOI 10.1182/blood.V92.10.3857.422k08_3857_3864; Agematsu K, 1997, EUR J IMMUNOL, V27, P2073, DOI 10.1002/eji.1830270835; Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Bahler DW, 1997, BLOOD, V89, P3335, DOI 10.1182/blood.V89.9.3335; BAHLER DW, 1991, BLOOD, V78, P1561; BAHLER DW, 1992, P NATL ACAD SCI USA, V89, P6770, DOI 10.1073/pnas.89.15.6770; BAKER BW, 1994, LEUKEMIA LYMPHOMA, V14, P291, DOI 10.3109/10428199409049681; BAKKUS MHC, 1992, BLOOD, V80, P2326; Braeuninger A, 1997, P NATL ACAD SCI USA, V94, P14211; Braeuninger A, 1997, P NATL ACAD SCI USA, V94, P9337, DOI 10.1073/pnas.94.17.9337; BRANDTZAEG P, 1989, GASTROENTEROLOGY, V97, P1562, DOI 10.1016/0016-5085(89)90406-X; Brauninger A, 1999, BLOOD, V93, P2679, DOI 10.1182/blood.V93.8.2679.408k05_2679_2687; Brauninger A, 1999, NEW ENGL J MED, V340, P1239, DOI 10.1056/NEJM199904223401604; BREZINSCHEK HP, 1995, J IMMUNOL, V155, P190; Brezinschek HP, 1997, J CLIN INVEST, V99, P2488, DOI 10.1172/JCI119433; CHAPMAN CJ, 1995, BLOOD, V85, P2176, DOI 10.1182/blood.V85.8.2176.bloodjournal8582176; Chapman CJ, 1996, BLOOD, V88, P3562, DOI 10.1182/blood.V88.9.3562.bloodjournal8893562; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; CLEARY ML, 1986, CELL, V44, P97, DOI 10.1016/0092-8674(86)90488-5; Cossman J, 1998, LAB INVEST, V78, P229; Davi F, 1996, BLOOD, V88, P3953, DOI 10.1182/blood.V88.10.3953.bloodjournal88103953; DAVIS TH, 1992, NEW ENGL J MED, V326, P1115, DOI 10.1056/NEJM199204233261704; Du M, 1996, LEUKEMIA, V10, P1190; DunnWalters DK, 1997, EUR J IMMUNOL, V27, P2959, DOI 10.1002/eji.1830271131; Fais F, 1998, J CLIN INVEST, V102, P1515, DOI 10.1172/JCI3009; Fischer M, 1997, J CLIN INVEST, V100, P1667, DOI 10.1172/JCI119691; Fischer M, 1998, EUR J IMMUNOL, V28, P2971, DOI 10.1002/(SICI)1521-4141(199809)28:09<2971::AID-IMMU2971>3.0.CO;2-3; GAIDANO G, 1998, LYMPHOMAS, P353; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P1313, DOI 10.1002/eji.1830161021; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HSU FJ, 1995, BLOOD, V86, P3072, DOI 10.1182/blood.V86.8.3072.bloodjournal8683072; HUANG CC, 1992, J CLIN INVEST, V89, P1331, DOI 10.1172/JCI115719; Hummel M, 1996, NEW ENGL J MED, V334, P405; HUMMEL M, 1994, BLOOD, V84, P403; Hussell T, 1996, J PATHOL, V178, P122, DOI 10.1002/(SICI)1096-9896(199602)178:2<122::AID-PATH486>3.0.CO;2-D; Ivanovski M, 1998, BLOOD, V91, P2433, DOI 10.1182/blood.V91.7.2433.2433_2433_2442; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JELINEK DF, 1986, J IMMUNOL, V136, P83; Jox A, 1999, BLOOD, V93, P3964, DOI 10.1182/blood.V93.11.3964.411k15_3964_3972; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; KLEIN U, 1993, EUR J IMMUNOL, V23, P3272, DOI 10.1002/eji.1830231232; KLEIN U, 1995, MOL MED, V1, P495, DOI 10.1007/BF03401587; Klein U, 1997, BLOOD, V89, P1288, DOI 10.1182/blood.V89.4.1288; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Klein U, 1998, IMMUNOL REV, V162, P261; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; Kuppers R, 1996, EUR J IMMUNOL, V26, P1794, DOI 10.1002/eji.1830260820; Kuppers R, 1998, ANNU REV IMMUNOL, V16, P471, DOI 10.1146/annurev.immunol.16.1.471; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; Kuppers R, 1997, EUR J IMMUNOL, V27, P1398, DOI 10.1002/eji.1830270616; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Liu Y J, 1996, Semin Immunol, V8, P169, DOI 10.1006/smim.1996.0021; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; Marafioti T, 1997, NEW ENGL J MED, V337, P453, DOI 10.1056/NEJM199708143370703; Meffre E, 1998, J EXP MED, V188, P765, DOI 10.1084/jem.188.4.765; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MORTARI F, 1993, J IMMUNOL, V150, P1348; NG VL, 1994, BLOOD, V83, P1067; NG VL, 1994, BLOOD, V84, P995; Niedobitek G, 1997, CANCER SURV, V30, P143; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; Nussenzweig MC, 1998, CELL, V95, P875, DOI 10.1016/S0092-8674(00)81711-0; Ohno T, 1997, NEW ENGL J MED, V337, P459, DOI 10.1056/NEJM199708143370704; Ottensmeier CH, 1998, BLOOD, V91, P4292, DOI 10.1182/blood.V91.11.4292.411a02_4292_4299; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Poetsch M, 1996, J CLIN ONCOL, V14, P963, DOI 10.1200/JCO.1996.14.3.963; Qin YF, 1997, LAB INVEST, V76, P477; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Razanajaona D, 1996, J IMMUNOL, V157, P1492; RIBOLDI P, 1994, BLOOD, V83, P2952, DOI 10.1182/blood.V83.10.2952.2952; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Stall A M, 1996, Semin Immunol, V8, P45, DOI 10.1006/smim.1996.0007; TAMARU J, 1995, AM J PATHOL, V147, P1398; Tangye SG, 1998, J EXP MED, V188, P1691, DOI 10.1084/jem.188.9.1691; Tierens A, 1998, BLOOD, V91, P2381, DOI 10.1182/blood.V91.7.2381.2381_2381_2386; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Vaandrager JW, 1998, BLOOD, V92, P2871, DOI 10.1182/blood.V92.8.2871.420k08_2871_2878; van den Berg A, 1999, AM J PATHOL, V154, P1685, DOI 10.1016/S0002-9440(10)65424-7; VANES JH, 1992, EUR J IMMUNOL, V22, P2761, DOI 10.1002/eji.1830221046; WAGNER SD, 1994, BLOOD, V83, P3647; Wilson PC, 1998, J EXP MED, V187, P59, DOI 10.1084/jem.187.1.59; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; ZHU DL, 1995, BLOOD, V85, P1603, DOI 10.1182/blood.V85.6.1603.bloodjournal8561603	92	528	544	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1999	341	20					1520	1529						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RK	10559454				2022-12-28	WOS:000083625800007
J	Bendszus, M; Koltzenburg, M; Burger, R; Warmuth-Metz, M; Hofmann, E; Solymosi, L				Bendszus, M; Koltzenburg, M; Burger, R; Warmuth-Metz, M; Hofmann, E; Solymosi, L			Silent embolism in diagnostic cerebral angiography and neurointerventional procedures: a prospective study	LANCET			English	Article							COMPLICATIONS; MICROEMBOLI; RISK; DSA	Background Cerebral angiography is associated with a small but definite risk of neurological complications with an unknown incidence of clinically silent embolism. We assessed the neurological complication rate compared with the frequency of silent embolism after angiography Methods We used diffusion-weighted magnetic resonance imaging (MRI) before and after angiography to assess embolic events. 100 consecutive angiographies (66 diagnostic and 34 interventional procedures) were done on 91 patients. Patients underwent neurological assessment before, immediately after, and 1 day after angiography. Findings Before angiography, no abnormalities were seen on diffusion-weighted MRI. Diffusion-weighted MRI showed 42 bright lesions in 23 patients after 23 procedures (17 diagnostic, six interventional) in a pattern consistent with embolic events. There was no new neurological deficit after any angiographic procedure. After diagnostic angiography in patients with a history of vasculopathy, the frequency of lesions was significantly higher than in patients without vascular risk factors (12 [44%] of 27 vs five [13%] of 39 patients, p=0.03), in diagnostic angiography, the appearance of lesions was significantly correlated with whether Vessels were difficult to probe (p=0.01), amount of contrast medium needed (p<0.01), fluoroscopy time (p<0.01), and use of additional catheters (p=0.02). Interpretation After diagnostic and interventional cerebral angiography, embolic events are more frequent than the apparent neurological complication rate. In diagnostic procedures, the incidence of embolism is closely related to a vascular risk profile.	Univ Wurzburg, Dept Neuroradiol, D-97080 Wurzburg, Germany; Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany; Univ Wurzburg, Dept Neurosurg, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg	Bendszus, M (corresponding author), Univ Wurzburg, Dept Neuroradiol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.		Koltzenburg, Martin/C-1349-2008; Solymosi, László/E-6449-2018	Koltzenburg, Martin/0000-0001-9181-5966; Solymosi, László/0000-0001-9647-8647				DAGIRMANJIAN A, 1993, AM J ROENTGENOL, V161, P1037, DOI 10.2214/ajr.161.5.7903842; DAVIES KN, 1993, J NEUROL NEUROSUR PS, V56, P967, DOI 10.1136/jnnp.56.9.967; DION JE, 1987, STROKE, V18, P997, DOI 10.1161/01.STR.18.6.997; EARNEST F, 1984, AM J ROENTGENOL, V142, P247, DOI 10.2214/ajr.142.2.247; GRZYSKA U, 1990, NEURORADIOLOGY, V32, P296, DOI 10.1007/BF00593048; HEISERMAN JE, 1994, AM J NEURORADIOL, V15, P1401; Horowitz MB, 1998, INTERV NEURORADIOL, V4, P27, DOI 10.1177/159101999800400103; MARKUS H, 1993, LANCET, V341, P784, DOI 10.1016/0140-6736(93)90561-T; MOODY DM, 1990, ANN NEUROL, V28, P477, DOI 10.1002/ana.410280403; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P432; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; WAUGH JR, 1992, RADIOLOGY, V182, P243, DOI 10.1148/radiology.182.1.1727290; Woolfenden AR, 1997, STROKE, V28, P2311, DOI 10.1161/01.STR.28.11.2311	13	371	386	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1594	1597		10.1016/S0140-6736(99)07083-X	http://dx.doi.org/10.1016/S0140-6736(99)07083-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560674				2022-12-28	WOS:000083551000011
J	Cubitt, T				Cubitt, T			A memorable moment - Love and respect after 30 years	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1261	1261		10.1136/bmj.319.7219.1261	http://dx.doi.org/10.1136/bmj.319.7219.1261			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550098	Green Published			2022-12-28	WOS:000083625600034
J	Jones, R; Pearson, J; McGregor, S; Gilmour, WH; Atkinson, JM; Barrett, A; Cawsey, AJ; McEwen, J				Jones, R; Pearson, J; McGregor, S; Gilmour, WH; Atkinson, JM; Barrett, A; Cawsey, AJ; McEwen, J			Cross sectional survey of patients' satisfaction with information about cancer	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland; Heriot Watt Univ, Dept Comp Sci, Edinburgh EH14 4AS, Midlothian, Scotland	University of Glasgow; Beatson Oncology Centre; Heriot Watt University	Jones, R (corresponding author), Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland.							Carstairs V., 1991, DEPRIVATION HLTH SCO; Jones R, 1999, BRIT MED J, V319, P1241, DOI 10.1136/bmj.319.7219.1241; Meredith C, 1996, BMJ-BRIT MED J, V313, P724; National Cancer Alliance, 1996, PAT CTR CANC SERV WH; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	5	75	76	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1247	1248		10.1136/bmj.319.7219.1247	http://dx.doi.org/10.1136/bmj.319.7219.1247			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550091	Green Published, Bronze			2022-12-28	WOS:000083625600027
J	Kaessmann, H; Wiebe, V; Paabo, S				Kaessmann, H; Wiebe, V; Paabo, S			Extensive nuclear DNA sequence diversity among chimpanzees	SCIENCE			English	Article							EVOLUTION; MITOCHONDRIAL; RECOMBINATION; HUMANS; GENOME; TREES; BIAS	Although data on nucleotide sequence variation in the human nuclear genome have begun to accumulate, Little is known about genomic diversity in chimpanzees (Pan troglodytes) and bonobos (Pan paniscus). A 10,154-base pair sequence on the chimpanzee X chromosome is reported, representing all major subspecies and bonobos. Comparison to humans shows the diversity of the chimpanzee sequences to be almost four times as high and the age of the most recent common ancestor three times as great as the corresponding values of humans. Phylogenetic analyses show the sequences from the different chimpanzee subspecies to be intermixed and the distance between some chimpanzee sequences to be greater than the distance between them and the bonobo sequences.	Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany	Max Planck Society	Kaessmann, H (corresponding author), Max Planck Inst Evolutionary Anthropol, Inselstr 22, D-04103 Leipzig, Germany.		Kaessmann, Henrik/B-4989-2013	Kaessmann, Henrik/0000-0001-7563-839X				Bailey WJ, 1992, MOL PHYLOGENET EVOL, V1, P97, DOI 10.1016/1055-7903(92)90024-B; BONTROP RE, 1995, IMMUNOL REV, V143, P33, DOI 10.1111/j.1600-065X.1995.tb00669.x; Burckhardt F, 1999, NUCLEIC ACIDS RES, V27, P138, DOI 10.1093/nar/27.1.138; Cooper G, 1998, HUM MOL GENET, V7, P1425, DOI 10.1093/hmg/7.9.1425; Deinard A, 1999, J HUM EVOL, V36, P687, DOI 10.1006/jhev.1999.0298; ELLEGREN H, 1995, NAT GENET, V11, P360, DOI 10.1038/ng1295-360; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Gagneux P, 1999, P NATL ACAD SCI USA, V96, P5077, DOI 10.1073/pnas.96.9.5077; Harding RM, 1997, AM J HUM GENET, V60, P772; Hill W. C. O., 1969, P22; HORAI S, 1992, J MOL EVOL, V35, P32, DOI 10.1007/BF00160258; HUDSON RR, 1987, GENETICS, V116, P153; HUDSON RR, 1985, GENETICS, V111, P147; Jorde LB, 1998, BIOESSAYS, V20, P126, DOI 10.1002/(SICI)1521-1878(199802)20:2<126::AID-BIES5>3.0.CO;2-R; Kaessmann H, 1999, NAT GENET, V22, P78, DOI 10.1038/8785; KUHNER MK, 1995, GENETICS, V140, P1421; LI WH, 1987, NATURE, V326, P93, DOI 10.1038/326093a0; MORIN PA, 1994, SCIENCE, V265, P1193, DOI 10.1126/science.7915048; Nachman MW, 1998, GENETICS, V150, P1133; Nagaraja R, 1997, GENOME RES, V7, P210, DOI 10.1101/gr.7.3.210; NOWAK RM, 1991, MAMMALS WORLD, V1; PAMILO P, 1988, MOL BIOL EVOL, V5, P568; PESOLE G, 1992, MOL BIOL EVOL, V9, P587; REYNOLDS V, 1971, FOLIA PRIMATOL, V14, P129, DOI 10.1159/000155344; Ruvolo M, 1997, MOL BIOL EVOL, V14, P248, DOI 10.1093/oxfordjournals.molbev.a025761; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; TAJIMA F, 1989, GENETICS, V123, P585; VERVAECKE H, 1992, MAMMALIA, V56, P667; vonHaeseler A, 1996, NAT GENET, V14, P135, DOI 10.1038/ng1096-135; Whiten A, 1999, NATURE, V399, P682, DOI 10.1038/21415; Wilson JF, 1998, BIOL CHEM, V379, P1287; Wise CA, 1997, MOL BIOL EVOL, V14, P707, DOI 10.1093/oxfordjournals.molbev.a025810	32	178	179	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1159	1162		10.1126/science.286.5442.1159	http://dx.doi.org/10.1126/science.286.5442.1159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550054				2022-12-28	WOS:000083534200044
J	Gottlieb, S				Gottlieb, S			COX 2 inhibitors might be useful in cancer prevention	BRITISH MEDICAL JOURNAL			English	News Item																		Sheehan KM, 1999, JAMA-J AM MED ASSOC, V282, P1254, DOI 10.1001/jama.282.13.1254	1	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1155	1155		10.1136/bmj.319.7218.1155	http://dx.doi.org/10.1136/bmj.319.7218.1155			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541498	Green Published			2022-12-28	WOS:000083536200014
J	Mann, MJ; Whittemore, AD; Donaldson, MC; Belkin, M; Conte, MS; Polak, JF; Orav, EJ; Ehsan, A; Dell'Acqua, G; Dzau, VJ				Mann, MJ; Whittemore, AD; Donaldson, MC; Belkin, M; Conte, MS; Polak, JF; Orav, EJ; Ehsan, A; Dell'Acqua, G; Dzau, VJ			Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial	LANCET			English	Article							HUMAN SAPHENOUS-VEIN; SMOOTH-MUSCLE CELLS; INTENSIVE SURVEILLANCE; PATENCY; HYPERPLASIA; ACTIVATION; DISEASE; INJURY; KINASE; OLIGONUCLEOTIDES	Background Cell-cycle blockade by ex-vivo gene therapy of experimental vein grafts inhibits the neointimal hyperplasia and subsequent accelerated atherosclerosis that lead to human bypass-graft failure. In a prospective, randomised, controlled trial, we investigated the safety and biological efficacy of intraoperative gene therapy in patients receiving bypass vein grafts. Methods We studied gene therapy that uses decoy oligodeoxynucleotide, which binds and inactivates the pivotal cell-cycle transcription factor E2F. 41 patients were randomly assigned untreated (16), E2F-decoy-treated (17), or scrambled-oligodeoxynucleotide-treated (eight) human infrainguinal vein grafts. Oligonucleotide was delivered to grafts intraoperatively by ex-vivo pressure-mediated transfection. The primary endpoints were safety and inhibition of target cell-cycle regulatory genes and of DNA synthesis in the grafts. Analysis was by intention to treat. Findings Mean transfection efficiency was 89.0% (SD 1.9). Proliferating-cell nuclear antigen and c-myc mRNA concentrations and bromodeoxyuridine incorporation were decreased in the EF2-decoy group by medians of 73% [IQR 53-84], 70% [50-79], and 74% [56-83], respectively) but not in the scrambled-oligodeoxynucleotide group (p<0.0001). Groups did not differ for postoperative complication rates. At 12 months, fewer graft occlusions, revisions, or critical stenoses were seen in the E2F-decoy group than in the untreated group (hazard ratio 0.34 [95% CI 0.12-0.99]). Interpretation Intraoperative transfection of human bypass vein grafts with E2F-decoy oligodeoxynucleotide is safe, feasible, and can achieve sequence-specific inhibition of cell-cycle gene expression and DNA replication. Application of this genetic-engineering strategy may lower failure rates of human primary bypass vein grafting.	Brigham & Womens Hosp, Dept Med, Off Chairman, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Dzau, VJ (corresponding author), Brigham & Womens Hosp, Dept Med, Off Chairman, Tower 1,75 Francis St, Boston, MA 02115 USA.			Ehsan, Afshin/0000-0003-1470-6760				BERGAMINI T, 1995, ANN SURG, V221, P507, DOI 10.1097/00000658-199505000-00008; Braun-Dullaeus RC, 1998, CIRCULATION, V98, P82, DOI 10.1161/01.CIR.98.1.82; BREWSTER DC, 1983, SURG GYNECOL OBSTET, V157, P437; CAMPEAU L, 1984, NEW ENGL J MED, V311, P1329, DOI 10.1056/NEJM198411223112101; COX JL, 1991, PROG CARDIOVASC DIS, V34, P45, DOI 10.1016/0033-0620(91)90019-I; CROSS KS, 1988, ANN SURG, V208, P631, DOI 10.1097/00000658-198811000-00015; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; GRONDIN CM, 1989, CIRCULATION, V79, P24; Haywood GA, 1997, CIRCULATION, V95, P1201; HEAGERTY AM, 1991, J HUM HYPERTENS, V5, P3; IDU MM, 1993, J VASC SURG, V17, P42, DOI 10.1016/0741-5214(93)90008-A; Koffi I, 1999, AM J HYPERTENS, V12, P732, DOI 10.1016/S0895-7061(99)00050-3; Landry DB, 1997, AM J PATHOL, V151, P1085; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; LUNDELL A, 1995, J VASC SURG, V21, P26, DOI 10.1016/S0741-5214(95)70241-5; Mann MJ, 1999, P NATL ACAD SCI USA, V96, P6411, DOI 10.1073/pnas.96.11.6411; Mann MJ, 1997, J CLIN INVEST, V99, P1295, DOI 10.1172/JCI119288; MANN MJ, 1995, P NATL ACAD SCI USA, V92, P4502, DOI 10.1073/pnas.92.10.4502; MANN MJ, 1997, J INVEST MED, V45, P224; MORISHITA R, 1994, GENE, V149, P13, DOI 10.1016/0378-1119(94)90406-5; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; Motwani JG, 1998, CIRCULATION, V97, P916, DOI 10.1161/01.CIR.97.9.916; ONEIL GS, 1994, J THORAC CARDIOV SUR, V107, P699; PARK TC, 1993, J VASC SURG, V18, P61, DOI 10.1067/mva.1993.42071; Reardon MJ, 1997, J CARDIOVASC SURG, V38, P201; RUTHERFORD RB, 1988, J VASC SURG, V7, P718, DOI 10.1016/0741-5214(88)90020-1; RUTHERFORD RB, 1986, J VASC SURG, V4, P80; TANAKA H, 1993, CIRCULATION, V88, P1788, DOI 10.1161/01.CIR.88.4.1788; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZWOLAK RM, 1987, J VASC SURG, V5, P126, DOI 10.1067/mva.1987.avs0050126	31	317	351	2	19	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1493	1498		10.1016/S0140-6736(99)09405-2	http://dx.doi.org/10.1016/S0140-6736(99)09405-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551494				2022-12-28	WOS:000083411300008
J	Vickers, A; Zollman, C				Vickers, A; Zollman, C			ABC of complementary medicine - Homoeopathy	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England									LECKRIDGE B, 1997, HOMOEPATHY PRIMARY C; SWAYNE J, 1998, HOMOEOPATHIC METHOD	2	40	41	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1115	1118		10.1136/bmj.319.7217.1115	http://dx.doi.org/10.1136/bmj.319.7217.1115			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531108	Green Published			2022-12-28	WOS:000083419500031
J	Youn, HD; Sun, L; Prywes, R; Liu, JO				Youn, HD; Sun, L; Prywes, R; Liu, JO			Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2	SCIENCE			English	Article							ORPHAN STEROID-RECEPTOR; NUR77; GENE; CALCINEURIN; LYMPHOCYTES; PROTEINS; DEATH	T cell receptor (TCR)-induced apoptosis of thymocytes is media ted by calcium-dependent expression of the steroid receptors Nur77 and Nor1, Nur77 expression is controlled by the transcription factor myocyte enhancer factor 2 (MEF2), but how MEF2 is activated by calcium signaling is still obscure. Cabin1, a calcineurin inhibitor, was found to regulate MEF2. MEF2 was normally sequestered by Cabin1 in a transcriptionally inactive state. TCR engagement led to an increase in intracellular calcium concentration and the dissociation of MEF2 from Cabin1, as a result of competitive binding of activated calmodulin to Cabin1. The interplay between Cabin1, MEF2, and calmodulin defines a distinct signaling pathway from the TCR to the Nur77 promoter during T cell apoptosis.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Columbia University	Liu, JO (corresponding author), MIT, Ctr Canc Res, Cambridge, MA 02139 USA.		Youn, Hong-Duk/J-2774-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055783] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55783] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Winoto A, 1997, CURR OPIN IMMUNOL, V9, P365, DOI 10.1016/S0952-7915(97)80083-0; Wong B, 1997, CURR OPIN IMMUNOL, V9, P358, DOI 10.1016/S0952-7915(97)80082-9; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YOUN HD, UNPUB DATA; YOUN HW, UNPUB; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	21	225	234	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					790	793		10.1126/science.286.5440.790	http://dx.doi.org/10.1126/science.286.5440.790			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531067				2022-12-28	WOS:000083303200059
J	Kuiper, HA; Noteborn, HPJM; Peijnenburg, AACM				Kuiper, HA; Noteborn, HPJM; Peijnenburg, AACM			Adequacy of methods for testing the safety of genetically modified foods	LANCET			English	Editorial Material							PROTEIN; RATS; RESTRICTION		Wageningen Univ & Res Ctr, Natl Inst Qual Control Agr Prod, NL-6700 AE Wageningen, Netherlands	Wageningen University & Research	Kuiper, HA (corresponding author), Wageningen Univ & Res Ctr, Natl Inst Qual Control Agr Prod, NL-6700 AE Wageningen, Netherlands.							FAO/WHO, 1996, JOINT FAO WHO EXP CO; KONNO A, 1993, MECH AGEING DEV, V72, P183, DOI 10.1016/0047-6374(93)90099-D; LEMOULLAC B, 1992, J NUTR, V122, P864, DOI 10.1093/jn/122.4.864; Lopez HW, 1998, J NUTR, V128, P1192, DOI 10.1093/jn/128.7.1192; Millstone E, 1999, NATURE, V401, P525, DOI 10.1038/44006; *NAT RES COUNC COM, 1995, NUTR REQ LAB AN, P23; NOTEBORN HPJ, IN PRESS J BIOTECHNO; Noteborn HPJM, 1995, ACS SYM SER, V605, P134; OECD, 1996, FOOD SAF EV; *OECD, 1981, OECD GUID TEST CHEM, V407; *OECD, 1993, SAF EV FOODS DER MOD; VANHAL NLW, IN PRESS J BIOTECHNO; WALKER R, 1978, CHEM TOXICOLOGY FOOD, V3, P339	13	50	55	0	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1315	1316		10.1016/S0140-6736(99)00341-4	http://dx.doi.org/10.1016/S0140-6736(99)00341-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533854				2022-12-28	WOS:000083149900003
J	Young, ED; Ash, RD; England, P; Rumble, D				Young, ED; Ash, RD; England, P; Rumble, D			Fluid flow in chondritic parent bodies: Deciphering the compositions of planetesimals	SCIENCE			English	Article							OXYGEN-ISOTOPE FRACTIONATION; SOLAR NEBULA; METAMORPHISM; COMPONENTS; CAI	Alteration of the Allende meteorite caused shifts in oxygen isotope ratios along a single mass fractionation Line, if alteration was caused by aqueous fluid, the pattern of oxygen isotope fractionation can be explained only by flow of reactive water down a temperature gradient. Down-temperature flow of aqueous fluid within planetesimals is sufficient to explain the mineralogical and oxygen isotopic diversity among CV, CM, and CI carbonaceous chondrites and displacement of the terrestrial planets from the primordial slope 1.00 line on the oxygen three-isotope plot.	Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England; Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA	University of Oxford; Carnegie Institution for Science	Young, ED (corresponding author), Univ Oxford, Dept Earth Sci, Parks Rd, Oxford OX1 3PR, England.		Rumble, Douglas/AAU-3930-2020; England, Philip C/A-1920-2010; Ash, Richard/AAD-4888-2021	Rumble, Douglas/0000-0002-7440-9189; England, Philip C/0000-0002-9024-8901; Ash, Richard/0000-0003-2144-5917; Young, Edward/0000-0002-1299-0801				ASH RD, 1999, LUNAR PLANET SCI C, V30; BAKER L, 1998, LUNAR PLANET SCI C, V29; BREARLEY AJ, 1999, REV MINERAL, V36, P3; BREARLEY AJ, 1999, LUNAR PLANET SCI C, V30; Choi BG, 1998, NATURE, V392, P577, DOI 10.1038/33356; Clayton RN, 1999, GEOCHIM COSMOCHIM AC, V63, P2089, DOI 10.1016/S0016-7037(99)00090-3; CLAYTON RN, 1984, EARTH PLANET SC LETT, V67, P151, DOI 10.1016/0012-821X(84)90110-9; CLAYTON RN, 1991, GEOCHEM SOC SPEC PUB, V3, P3; DIPPLE GM, 1992, GEOCHIM COSMOCHIM AC, V56, P3539, DOI 10.1016/0016-7037(92)90397-2; ELLIS AJ, 1959, AM J SCI, V257, P217, DOI 10.2475/ajs.257.3.217; FISHER GW, 1978, GEOCHIM COSMOCHIM AC, V42, P1035, DOI 10.1016/0016-7037(78)90292-2; GOODING JL, 1984, LUNAR PLANET SCI C, V15, P228; GRIMM RE, 1989, ICARUS, V82, P244, DOI 10.1016/0019-1035(89)90038-9; HASHIMOTO A, 1992, GEOCHIM COSMOCHIM AC, V56, P511, DOI 10.1016/0016-7037(92)90148-C; Jones SB, 1999, WATER RESOUR RES, V35, P929, DOI 10.1029/1998WR900091; Kennedy AK, 1997, GEOCHIM COSMOCHIM AC, V61, P1541, DOI 10.1016/S0016-7037(97)00004-5; KROT AN, 1995, METEORITICS, V30, P748, DOI 10.1111/j.1945-5100.1995.tb01173.x; MATSUHISA Y, 1979, GEOCHIM COSMOCHIM AC, V43, P1131, DOI 10.1016/0016-7037(79)90099-1; Mayeda T.K., 1998, LUNAR PLANET SCI C, V29; Meibom A, 1999, METEORIT PLANET SCI, V34, P7, DOI 10.1111/j.1945-5100.1999.tb01728.x; NORTHROP DA, 1966, J GEOL, V74, P174, DOI 10.1086/627153; RIETMEIJER FJM, 1985, NATURE, V313, P293, DOI 10.1038/313293a0; ROWE MW, 1994, GEOCHIM COSMOCHIM AC, V58, P5341, DOI 10.1016/0016-7037(94)90317-4; RUBIN AE, 1997, METEORIT PLANET SCI, V32, P321; RUSSELL SS, 1997, METEORIT PLANET SCI, V32, pA88; Sahijpal S, 1999, METEORIT PLANET SCI, V34, pA101; Sears DWG, 1999, METEORIT PLANET SCI, V34, P497, DOI 10.1111/j.1945-5100.1999.tb01360.x; Seyfried MS, 1997, J HYDROL, V202, P95, DOI 10.1016/S0022-1694(97)00061-9; SWINDLE TD, 1988, GEOCHIM COSMOCHIM AC, V52, P2215, DOI 10.1016/0016-7037(88)90124-X; Taitel Y, 1996, CHEM ENG SCI, V51, P695, DOI 10.1016/0009-2509(95)00320-7; Wasson J. T., 1985, METEORITES THEIR REC; WASSON JT, 1988, PHILOS T R SOC A, V325, P535, DOI 10.1098/rsta.1988.0066; Wilson L, 1999, METEORIT PLANET SCI, V34, P479, DOI 10.1111/j.1945-5100.1999.tb01355.x; WILSON L, 1998, LUNAR PLANET SCI C, V29; Young ED, 1998, SCIENCE, V282, P452, DOI 10.1126/science.282.5388.452; YOUNG ED, 1995, REV GEOPHYSICS S, P41; ZHENG YF, 1993, EARTH PLANET SC LETT, V120, P247, DOI 10.1016/0012-821X(93)90243-3; ZHENG YF, 1991, GEOCHIM COSMOCHIM AC, V55, P2299	38	158	158	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1331	1335		10.1126/science.286.5443.1331	http://dx.doi.org/10.1126/science.286.5443.1331			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558982				2022-12-28	WOS:000083675500034
J	Sanchez, Y; Bachant, J; Wang, H; Hu, FH; Liu, D; Tetzlaff, M; Elledge, SJ				Sanchez, Y; Bachant, J; Wang, H; Hu, FH; Liu, D; Tetzlaff, M; Elledge, SJ			Control of the DNA damage checkpoint by Chk1 and Rad53 protein kinases through distinct mechanisms	SCIENCE			English	Article							ANAPHASE-PROMOTING COMPLEX; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BUDDING YEAST; TYROSINE PHOSPHORYLATION; PDS1P; INHIBITOR; DESTRUCTION; TRANSITION; METAPHASE	In response to DNA damage, cells activate checkpoint pathways that prevent cell cycle progression. In fission yeast and mammals, mitotic arrest in response to DNA damage requires inhibitory Cdk phosphorylation regulated by Chk1. This study indicates that Chk1 is required for function of the DNA damage checkpoint in Saccharomyces cerevisiae but acts through a distinct mechanism maintaining the abundance of Pds1, an anaphase inhibitor. Unlike other checkpoint mutants, chk1 mutants were only mildly sensitive to DNA damage, indicating that checkpoint functions besides cell cycle arrest influence damage sensitivity. Another kinase, Rad53, was required to both maintain active cyclin-dependent kinase 1, Cdk1(Cdc28), and prevent anaphase entry after checkpoint activation. Evidence suggests that Rad53 exerts its role in checkpoint control through regulation of the Polo kinase Cdc5. These results support a model in which Chk1 and Rad53 function in parallel through Pds1 and Cdc5, respectively, to prevent anaphase entry and mitotic exit after DNA damage. This model provides a possible explanation for the role of Cdc5 in DNA damage checkpoint adaptation.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	Elledge, SJ (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, 1 Baylor Plaza, Houston, TX 77030 USA.		Sanchez, Yolanda/L-2847-2014	Sanchez, Yolanda/0000-0002-7650-9319	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044664, R37GM044664] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44664] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Pati D, 1997, MOL CELL BIOL, V17, P3037, DOI 10.1128/MCB.17.6.3037; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SANCHEZ Y, UNPUB; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; WEINERT TA, 1993, GENETICS, V134, P63; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85	28	445	454	2	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1166	1171		10.1126/science.286.5442.1166	http://dx.doi.org/10.1126/science.286.5442.1166			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550056				2022-12-28	WOS:000083534200046
J	Molbak, K; Baggesen, DL; Aarestrup, FM; Ebbesen, JM; Engberg, J; Frydendahl, K; Gerner-Smidt, P; Petersen, AM; Wegener, HC				Molbak, K; Baggesen, DL; Aarestrup, FM; Ebbesen, JM; Engberg, J; Frydendahl, K; Gerner-Smidt, P; Petersen, AM; Wegener, HC			An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GYRA GENE; SEROVAR TYPHIMURIUM; PRODUCTION ANIMALS; PHAGE TYPES; HUMANS; MUTATIONS; DENMARK	Background Food-borne salmonella infections have become a major problem in industrialized countries. The strain of Salmonella enterica serotype typhimurium known as definitive phage type 104 (DT104) is usually resistant to five drugs: ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline. An increasing proportion of DT104 isolates also have reduced susceptibility to fluoroquinolones. Methods The Danish salmonella surveillance program determines the phage types of all typhimurium strains from the food chain, and in the case of suspected outbreaks, five-drug-resistant strains are characterized by molecular methods. All patients infected with five-drug-resistant typhimurium are interviewed to obtain clinical and epidemiologic data. In 1998, an outbreak of salmonella occurred, in which the strain of typhimurium DT104 was new to Denmark. We investigated this outbreak and report our findings here. Results Until 1997, DT104 infections made up less than 1 percent of all human salmonella infections. The strain isolated from patients in the first community outbreak of DT104 in Denmark, in 1998, was resistant to nalidixic acid and had reduced susceptibility to fluoroquinolones. The outbreak included 25 culture-confirmed cases. Eleven patients were hospitalized, and two died. The molecular epidemiology and data from patients indicated that the primary source was a Danish swine herd. Furthermore, the investigation suggested reduced clinical effectiveness of treatment with fluoroquinolones. Conclusions Our investigation of an outbreak of DT104 documented the spread of quinolone-resistant bacteria from food animals to humans; this spread was associated with infections that were difficult to treat. Because of the increase in quinolone resistance in salmonella, the use of fluoroquinolones in food animals should be restricted. (N Engl J Med 1999;341:1420-5.) (C)1999, Massachusetts Medical Society.	Statens Serum Inst, DK-2300 Copenhagen S, Denmark; Danish Vet Lab, Copenhagen, Denmark; Danish Food & Vet Adm, Copenhagen, Denmark; Danish Zoonosis Ctr, Copenhagen, Denmark	Statens Serum Institut	Molbak, K (corresponding author), Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen S, Denmark.			Petersen, Andreas Munk/0000-0003-0531-0553; Wegener, Henrik Caspar/0000-0002-6888-2121; Aarestrup, Frank/0000-0002-7116-2723; Molbak, Kare/0000-0002-3100-4990; Engberg, Jorgen/0000-0001-9042-1631				ANDERSON ES, 1977, J HYG-CAMBRIDGE, V78, P297, DOI 10.1017/S0022172400056187; Anglim Anne M., 1995, P1525; BAGGESEN DL, 1994, ACTA VET SCAND, V35, P349; CALLOW B R, 1959, J Hyg (Lond), V57, P346; *DIV EM OTH COMM D, 1997, P WHO M BERL GERM 13; Glynn MK, 1998, NEW ENGL J MED, V338, P1333, DOI 10.1056/NEJM199805073381901; Griggs DJ, 1996, ANTIMICROB AGENTS CH, V40, P1009, DOI 10.1128/AAC.40.4.1009; HALD T, 1998, ANN REPORT ZOONOSES; HOLMBERG SD, 1984, NEW ENGL J MED, V311, P617, DOI 10.1056/NEJM198409063111001; National Committee for Clinical Laboratory Standars, 1999, M100S9 NCCLS; OLSEN JE, 1994, J MED MICROBIOL, V40, P15, DOI 10.1099/00222615-40-1-15; Ouabdesselam S, 1996, MICROB DRUG RESIST, V2, P299, DOI 10.1089/mdr.1996.2.299; Piddock LJV, 1998, J ANTIMICROB CHEMOTH, V41, P635, DOI 10.1093/jac/41.6.635; Ridley A, 1998, MICROB DRUG RESIST, V4, P113, DOI 10.1089/mdr.1998.4.113; Ruiz J, 1997, J MED MICROBIOL, V46, P623, DOI 10.1099/00222615-46-7-623; Seyfarth AM, 1997, J ANTIMICROB CHEMOTH, V40, P67, DOI 10.1093/jac/40.1.67; Threlfall EJ, 1996, LANCET, V347, P1053, DOI 10.1016/S0140-6736(96)90199-3; Vasallo FJ, 1998, CLIN INFECT DIS, V26, P535, DOI 10.1086/517087; Wain J, 1997, CLIN INFECT DIS, V25, P1404, DOI 10.1086/516128; WEGENER HC, 1994, APMIS, V102, P521, DOI 10.1111/j.1699-0463.1994.tb05200.x; WISTROM J, 1995, J ANTIMICROB CHEMOTH, V36, P23, DOI 10.1093/jac/36.1.23; YOSHIDA H, 1990, ANTIMICROB AGENTS CH, V34, P1271, DOI 10.1128/AAC.34.6.1271	22	347	360	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1999	341	19					1420	1425		10.1056/NEJM199911043411902	http://dx.doi.org/10.1056/NEJM199911043411902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XR	10547404	Bronze			2022-12-28	WOS:000083472100002
J	Hayden, FG; Atmar, RL; Schilling, M; Johnson, C; Poretz, D; Paar, D; Huson, L; Ward, P; Mills, RG				Hayden, FG; Atmar, RL; Schilling, M; Johnson, C; Poretz, D; Paar, D; Huson, L; Ward, P; Mills, RG		Oseltamivir Study Grp	Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							A H5N1 VIRUS; PROPHYLAXIS; INFECTION; RIMANTADINE; AMANTADINE; EFFICACY; MICE	Background Safe and effective antiviral agents are needed to prevent infection with influenza A and B viruses. Oseltamivir (GS4104), which can be administered orally, is the prodrug of GS4071, a potent and selective inhibitor of influenzavirus neuraminidases. We studied the use of oseltamivir for longterm prophylaxis against influenza in two placebo-controlled, double-blind trials at different U.S. sites during the winter of 1997-1998. Methods We randomly assigned 1559 healthy, nonimmunized adults 18 to 65 years old to receive either oral oseltamivir (75 mg given once or twice daily, for a total daily dose of 75 or 150 mg) or placebo for six weeks during a peak period of local influenzavirus activity. The primary end point with respect to efficacy was laboratory-confirmed influenza-like illness (defined as a temperature of at least 37.2 degrees C accompanied by at least one respiratory and at least one systemic symptom). Results In the two studies combined, the risk of influenza among subjects assigned to either once-daily or twice-daily oseltamivir (1.2 percent and 1.3 percent, respectively) was lower than that among subjects assigned to placebo (4.8 percent; P<0.001 and P=0.001 for the comparison with once-daily and twice-daily oseltamivir, respectively). The protective efficacy of oseltamivir in the two active-treatment groups combined was 74 percent (95 percent confidence interval, 53 to 88 percent) at all the sites combined and 82 percent (95 percent confidence interval, 60 to 93 percent) at sites in Virginia, where the rate of influenza infection was higher than the overall rate. For culture-proved influenza, the rate of protective efficacy in the two oseltamivir groups combined was 87 percent (95 percent confidence interval, 65 to 96 percent). The rate of laboratory-confirmed influenza infection was lower with oseltamivir than with placebo (5.3 percent vs. 10.6 percent, P<0.001). Oseltamivir was well tolerated but was associated with a greater frequency of nausea (12.1 percent and 14.6 percent in the once-daily and twice-daily groups, respectively) and vomiting (2.5 percent and 2.7 percent, respectively) than was placebo (nausea, 7.1 percent; vomiting, 0.8 percent). However, the frequency of premature discontinuation of drug or placebo was similar among the three groups (3.1 to 4.0 percent). Conclusions Oseltamivir administered daily for six weeks by the oral route is safe and effective for the prevention of influenza. (N Engl J Med 1999;341: 1336-43.) (C) 1999, Massachusetts Medical Society.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Eastern Virginia Med Sch, Norfolk, VA 23501 USA; Baylor Coll Med, Houston, TX 77030 USA; Pharmaceut Res Associates, Lenexa, KS USA; Univ Texas, Galveston, TX 77555 USA; Infect Dis Physicians, Fairfax, VA USA; Roche Global Dev, Welwyn Garden City, Herts, England; Gilead Sci Inc, Foster City, CA 94404 USA	University of Virginia; Eastern Virginia Medical School; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; Roche Holding; Gilead Sciences	Hayden, FG (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 473, Charlottesville, VA 22908 USA.		Atmar, Robert/AFQ-5392-2022	Atmar, Robert/0000-0001-9989-6772; Ward, Penelope/0000-0002-7585-4313; Schilling, Margo/0000-0001-9684-9866				[Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 38 INT C ANT AG CHEM; Calfee DP, 1998, DRUGS, V56, P537, DOI 10.2165/00003495-199856040-00003; CALFEE DP, 1998, 38 ANN INT C ANT AG, P334; Claas ECJ, 1998, LANCET, V351, P1292; DOLIN R, 1982, NEW ENGL J MED, V307, P580, DOI 10.1056/NEJM198209023071002; DOUGLAS RG, 1990, NEW ENGL J MED, V322, P443, DOI 10.1056/NEJM199002153220706; Hayden FG, 1996, ANTIVIRAL DRUG RESIS, P59; Hayden Frederick G., 1997, Journal of Infectious Diseases, V176, pS56, DOI 10.1086/514177; HAYDEN PG, IN PRESS JAMA; KEYSER LA, 1998, 38 INT C ANT AG CHEM, P335; Kim CU, 1997, J AM CHEM SOC, V119, P681, DOI 10.1021/ja963036t; Li WX, 1998, ANTIMICROB AGENTS CH, V42, P647, DOI 10.1128/AAC.42.3.647; Libow LS, 1996, J AM GERIATR SOC, V44, P1153, DOI 10.1111/j.1532-5415.1996.tb01363.x; Mendel DB, 1998, ANTIMICROB AGENTS CH, V42, P640, DOI 10.1128/AAC.42.3.640; Monto Arnold S., 1997, Journal of Infectious Diseases, V176, pS32, DOI 10.1086/514172; Monto AS, 1999, JAMA-J AM MED ASSOC, V282, P31, DOI 10.1001/jama.282.1.31; MONTO AS, 1995, ANTIMICROB AGENTS CH, V39, P2224, DOI 10.1128/AAC.39.10.2224; NOETHER GE, 1957, J AM STAT ASSOC, V52, P36, DOI 10.2307/2281398; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Sidwell RW, 1998, ANTIVIR RES, V37, P107, DOI 10.1016/S0166-3542(97)00065-X; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; TREANOR JJ, 1998, 38 INT C ANT AG CHEM, P21; VANVORIS LP, 1982, ANN INTERN MED, V96, P153, DOI 10.7326/0003-4819-96-2-153; Westfall P.H., 1993, RESAMPLING BASED MUL; WOOD ND, 1997, 37 INT C ANT AG CHEM, P25; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9; 1998, MMWR MORB MORTAL WKL, V47, P196	28	338	360	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1336	1343		10.1056/NEJM199910283411802	http://dx.doi.org/10.1056/NEJM199910283411802			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249XE	10536125				2022-12-28	WOS:000083357800002
J	Nicholl, B				Nicholl, B			Cecil Thompson Buchanan Adams - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1138	1138		10.1136/bmj.319.7217.1138	http://dx.doi.org/10.1136/bmj.319.7217.1138			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531123	Green Published			2022-12-28	WOS:000083419500058
J	Wren, BG; McFarland, K; Edwards, L				Wren, BG; McFarland, K; Edwards, L			Micronised transdermal progesterone and endometrial response	LANCET			English	Article							CYCLE	Sequential transdermal progesterone administered with continuous transdermal oestrogen was insufficient to increase circulating blood progesterone concentrations or induce a secretory response in proliferating endometrium.	Royal Hosp Women, Sydney Menopause Ctr, Randwick, NSW 2021, Australia		Wren, BG (corresponding author), Royal Hosp Women, Sydney Menopause Ctr, Randwick, NSW 2021, Australia.							CHANG KJ, 1995, FERTIL STERIL, V63, P785, DOI 10.1016/S0015-0282(16)57482-2; FERENCZY A, 1979, AM J OBSTET GYNECOL, V133, P859, DOI 10.1016/0002-9378(79)90302-8; LEE JR, 1990, LANCET, V336, P1327, DOI 10.1016/0140-6736(90)93017-J; Lee JR, 1998, LANCET, V352, P905, DOI 10.1016/S0140-6736(05)60044-X; PRIOR JC, 1990, ENDOCR REV, V11, P386, DOI 10.1210/edrv-11-2-386	5	18	18	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1447	1448		10.1016/S0140-6736(99)03430-3	http://dx.doi.org/10.1016/S0140-6736(99)03430-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543679				2022-12-28	WOS:000083277400022
J	Sutton, KG; McRory, JE; Guthrie, H; Murphy, TH; Snutch, TP				Sutton, KG; McRory, JE; Guthrie, H; Murphy, TH; Snutch, TP			P/Q-type calcium channels mediate the activity-dependent feedback of syntaxin-1A	NATURE			English	Article							BRAIN CA2+ CHANNELS; GENE-EXPRESSION; TRANSCRIPTION; NEURONS; PROTEIN; CREB; PHOSPHORYLATION; IDENTIFICATION; COMPLEX; FORMS	Spatial and temporal changes in intracellular calcium concentrations are critical for controlling gene expression in neurons(1-5). In many neurons, activity-dependent calcium influx through L-type channels stimulates transcription that depends on the transcription factor CREB by activating a calmodulin-dependent pathway(6-11). Here we show that selective influx of calcium through P/Q-type channels(12-14) is responsible for activating expression of syntaxin-1A, a presynaptic protein that mediates vesicle docking, fusion and neurotransmitter release. The initial P/Q-type calcium signal is amplified by release of calcium from intracellular stores and acts through phosphorylation that is dependent on the calmodulin-dependent kinase CaM K II/IV, protein kinase A and mitogen-activated protein kinase kinase, Initiation of syntaxin-1A expression is rapid and short-lived, with syntaxin-1A ultimately interacting with the P/Q-type calcium channel to decrease channel availability. Our results define an activity-dependent feedback pathway that may regulate synaptic efficacy and function in the nervous system.	Univ British Columbia, Dept Psychiat, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Psychiat, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Snutch, TP (corresponding author), Univ British Columbia, Dept Psychiat, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada.	snutch@zoology.ubc.ca	Snutch, Terrance P/L-3464-2019; Murphy, Timothy/AAW-1975-2021; Murphy, Timothy H/I-4982-2014	Snutch, Terrance P/0000-0001-5182-1296; Murphy, Timothy/0000-0002-0093-4490; Murphy, Timothy H/0000-0002-0093-4490				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Betz A, 1997, J BIOL CHEM, V272, P2520; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Daly C, 1997, J NEUROSCI, V17, P2365; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HONER WG, 1993, BRAIN RES, V609, P9, DOI 10.1016/0006-8993(93)90848-H; Kim K, 1997, P NATL ACAD SCI USA, V94, P14782, DOI 10.1073/pnas.94.26.14782; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MartinMoutot N, 1996, J BIOL CHEM, V271, P6567, DOI 10.1074/jbc.271.12.6567; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Sheng ZH, 1998, J BIOENERG BIOMEMBR, V30, P335, DOI 10.1023/A:1021985521748; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694	30	101	106	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					800	804		10.1038/44586	http://dx.doi.org/10.1038/44586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548106				2022-12-28	WOS:000083368700055
J	Levinson, W; Gorawara-Bhat, R; Dueck, R; Egener, B; Kao, A; Kerr, C; Lo, B; Perry, D; Pollitz, K; Reifsteck, S; Stein, T; Santa, J; Kemp-White, M				Levinson, W; Gorawara-Bhat, R; Dueck, R; Egener, B; Kao, A; Kerr, C; Lo, B; Perry, D; Pollitz, K; Reifsteck, S; Stein, T; Santa, J; Kemp-White, M			Resolving disagreements in the patient-physician relationship - Tools for improving communication in managed care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FINANCIAL INCENTIVES; MEDICAL-CARE; ETHICAL PRACTICE; NATIONAL SURVEY; HEALTH PLANS; SKILLS; TRUST; DOCTOR; INTERVIEW; COMPENSATION	Managed care uses financial incentives and restrictions on tests and procedures to attempt to influence physician decision making and limit costs. Increasingly, the public is questioning whether physicians are truly making decisions based on the patient's best interest or are unduly influenced by economic incentives. These circumstances lead to the potential for disagreements and conflict in the patient-physician relationship. We convened a group of individuals in October 1998, including patient representatives, leaders from health care organizations, practicing physicians, communication experts, and medical ethicists, to articulate the types of disagreements emerging in the patient-physician relationship as a result of managed care. We addressed 3 specific scenarios physicians may encounter, including allocation, illustrated by a patient who is referred to a different ophthalmologist based on a new arrangement in the physician's group; access, illustrated by a patient who wishes to see his own physician for a same-day visit rather than a nurse specialist; and financial incentives, illustrated by a patient who expects to have a test performed and a physician who does not believe the test is necessary but is afraid the patient will think the physician is not ordering the test because of financial incentives. Using these scenarios, we suggest communication strategies that physicians can use to decrease the potential for disagreements. In addition, we propose strategies that health plans or physician groups can use to alleviate or resolve these disagreements.	Univ Chicago, Dept Med, Gen Internal Med Sect, Chicago, IL 60627 USA; Univ Chicago, Program Physician Patient Commun Res, Chicago, IL 60627 USA; Pk Nicollet Clin, Hlth Syst Minnesota, St Louis Pk, MN USA; NW Ctr Physician Patient Commun, Portland, OR USA; Amer Med Assoc, Chicago, IL USA; 21st Century Consumer, Alamo, CA USA; Univ Calif San Francisco, Program Med Eth, San Francisco, CA USA; Georgetown Univ, Inst Hlth Care Res & Policy, Washington, DC USA; Carle Clin Assoc, Champaign, IL USA; Kaiser Permanente Med Grp, Oakland, CA USA; Bayer Inst Hlth Care Commun, W Haven, CT USA	University of Chicago; University of Chicago; American Medical Association; University of California System; University of California San Francisco; Georgetown University; Kaiser Permanente; Permanente Medical Groups; Bayer AG	Levinson, W (corresponding author), Univ Chicago, Dept Med, Gen Internal Med Sect, 5841 S Maryland Ave,MC 2007, Chicago, IL 60627 USA.							*ADV COMM CONS PRO, 1997, BILL RIGHTS RESP REP; Baile W F, 1997, J Cancer Educ, V12, P166; BEIER L, 1998, CHICAGO TRIBUNE 0102, pA21; BELLET PS, 1991, JAMA-J AM MED ASSOC, V266, P1831, DOI 10.1001/jama.266.13.1831; BRANCH WT, 1993, JAMA-J AM MED ASSOC, V269, P1667, DOI 10.1001/jama.269.13.1667; CLEARY PD, 1991, HEALTH AFFAIR, V10, P254, DOI 10.1377/hlthaff.10.4.254; *COUNC ETH JUD AFF, 1999, REF PAT DISCL LIM; DiMatteo M R, 1980, J Community Health, V6, P18; Dugdale DC, 1999, J GEN INTERN MED, V14, pS34, DOI 10.1046/j.1525-1497.1999.00263.x; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; Emanuel EJ, 1998, J HEALTH POLIT POLIC, V23, P635; Fallowfield L, 1998, J CLIN ONCOL, V16, P1961, DOI 10.1200/JCO.1998.16.5.1961; Feldman DS, 1998, ARCH INTERN MED, V158, P1626, DOI 10.1001/archinte.158.15.1626; Fisher R., 2011, GETTING YES NEGOTIAT; FISHER S, 1983, SOCIAL ORG DOCTOR PA, P135; GASK L, 1988, MED EDUC, V22, P132, DOI 10.1111/j.1365-2923.1988.tb00423.x; GLASSON J, 1995, JAMA-J AM MED ASSOC, V273, P330, DOI 10.1001/jama.1995.03520280076044; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; Goold SD, 1999, J GEN INTERN MED, V14, pS26, DOI 10.1046/j.1525-1497.1999.00267.x; Goold SD, 1998, J HEALTH POLIT POLIC, V23, P687; Gray BH, 1997, HEALTH AFFAIR, V16, P34, DOI 10.1377/hlthaff.16.1.34; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; GREENFIELD S, 1989, MED CARE S, V27, pS110; GRUMBACH K, 1998, NEW ENGL J MED, V339, P21; Hall MA, 1998, ANN INTERN MED, V128, P395, DOI 10.7326/0003-4819-128-5-199803010-00009; HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HILLMAN AL, 1991, HEALTH AFFAIR, V10, P138, DOI 10.1377/hlthaff.10.4.138; Inlander C. B, 1997, TAKE THIS BOOK HOSP; JOHNSON GT, 1990, NEW ENGL J MED, V322, P195, DOI 10.1056/NEJM199001183220310; Joos SK, 1996, J GEN INTERN MED, V11, P147, DOI 10.1007/BF02600266; Kao AC, 1998, JAMA-J AM MED ASSOC, V280, P1708, DOI 10.1001/jama.280.19.1708; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; Kassirer JP, 1998, NEW ENGL J MED, V339, P397, DOI 10.1056/NEJM199808063390608; KASSIRER JP, 1993, NEW ENGL J MED, V328, P1268, DOI 10.1056/NEJM199304293281710; Kassirer JP, 1998, NEW ENGL J MED, V339, P1543, DOI 10.1056/NEJM199811193392109; LaPuma J, 1995, Trends Health Care Law Ethics, V10, P73; LARSON E, 1996, TIME MAGAZINE   0122, P147; Lazare A, 1995, MED INTERVIEW, P50; Lazare A., 1995, MED INTERVIEW CLIN C, P3; LEVINSON DF, 1987, NEW ENGL J MED, V317, P1729, DOI 10.1056/NEJM198712313172708; LEVINSON W, 1993, J GEN INTERN MED, V8, P318, DOI 10.1007/BF02600146; LEVINSON W, 1993, MED CARE, V31, P285, DOI 10.1097/00005650-199304000-00001; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; LEVINSON W, 1994, JAMA-J AM MED ASSOC, V272, P1619, DOI 10.1001/jama.272.20.1619; LEVINSON W, 1996, SGIM FORUM, V19, P3; LEWIS CC, 1991, PEDIATRICS, V88, P351; LIPKIN M, 1996, TXB PRIMARY CARE MED, P2; Lo B, 1999, J GEN INTERN MED, V14, pS41, DOI 10.1046/j.1525-1497.1999.00270.x; Loewy EH, 1998, ARCH INTERN MED, V158, P2419, DOI 10.1001/archinte.158.22.2419; Maguire P, 1996, EUR J CANCER, V32, P1457; Mechanic D, 1998, J HEALTH POLIT POLIC, V23, P661; MEYER M, 1997, NEWSWEEK        0317, P45; MILLER T, IN PRESS JAMA; Pearson SD, 1998, NEW ENGL J MED, V339, P689, DOI 10.1056/NEJM199809033391009; Pellegrino ED, 1995, J CLIN ETHIC, V6, P312; PETER R, 1997, ACCESS SPECIALISTS P; Phillips DF, 1998, JAMA-J AM MED ASSOC, V280, P2060, DOI 10.1001/jama.280.24.2060; Putnam SM., 1995, MED INTERVIEW, P530; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; Rosenberg EE, 1997, ARCH FAM MED, V6, P279, DOI 10.1001/archfami.6.3.279; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; ROWLANDMORIN PA, 1990, EVAL HEALTH PROF, V13, P168, DOI 10.1177/016327879001300202; SCHIEDERMAYER D, 1995, PERSPECT BIOL MED, V38, P238; Schmittdiel J, 1997, JAMA-J AM MED ASSOC, V278, P1596, DOI 10.1001/jama.278.19.1596; SEIGLER M, 1992, J AM GERIATR SOC, V40, P410; SPIRO H, 1992, ANN INTERN MED, V116, P843, DOI 10.7326/0003-4819-116-10-843; STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127; *STAT CA MAN HLTH, 1998, IMPR MAN HLTH CAR CA; Stein T S, 1999, Eff Clin Pract, V2, P63; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; STOBO JD, 1994, AM J MED, V97, P1; Suchman AL, 1997, JAMA-J AM MED ASSOC, V277, P678, DOI 10.1001/jama.277.8.678; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920; Ware J E Jr, 1983, Eval Program Plann, V6, P291, DOI 10.1016/0149-7189(83)90009-5; WASSERMAN RC, 1984, PEDIATRICS, V74, P1047	78	42	44	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1477	1483		10.1001/jama.282.15.1477	http://dx.doi.org/10.1001/jama.282.15.1477			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	245LT	10535441	Bronze			2022-12-28	WOS:000083111000036
J	Caplan, AL; McGee, G; Magnus, D				Caplan, AL; McGee, G; Magnus, D			What is immoral about eugenics?	BRITISH MEDICAL JOURNAL			English	Article								It is a "given" in discussions of genetic engineering that no sensible person tan be in favour of eugenics. The main reason for this presumption is that so much horror, misery, and mayhem have been tarried out in the name of eugenics in the 20th century that no person with any metal sense could think otherwise.(1-3) In fact, the abysmal history of murder and sterilisation undertaken in the name of rare hygiene and the "improvement" of the human species again and again in this century is so overpowering that the risk of reoccurrence, sliding down what has proved time and time again to be an extremely slick, slippery slope, does seem enough to bring all ethical argument in favour of eugenics to an end.	Univ Penn Hlth Syst, Ctr Bioeth, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Caplan, AL (corresponding author), Univ Penn Hlth Syst, Ctr Bioeth, Philadelphia, PA 19104 USA.							Annas George J., 1992, NAZI DOCTORS NUREMBE; CAPLAN A, 1990, WHEN MED WENT MAD; KITCHER P, 1997, LIVES COME; MCGEE G, 1998, HASTINGS CTR REPORT, V28, P84; MCGEE G, 1997, PERFECT BABY; Reilly Philip R., 1991, SURG SOLUTION	6	21	21	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1999	319	7220					1284	U19		10.1136/bmj.319.7220.1284	http://dx.doi.org/10.1136/bmj.319.7220.1284			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257MZ	10559038	Green Published, Green Submitted			2022-12-28	WOS:000083786900007
J	Chiba, Y; Ishikawa, M; Kijima, F; Tyson, RH; Kim, J; Yamamoto, A; Nambara, E; Leustek, T; Wallsgrove, RM; Naito, S				Chiba, Y; Ishikawa, M; Kijima, F; Tyson, RH; Kim, J; Yamamoto, A; Nambara, E; Leustek, T; Wallsgrove, RM; Naito, S			Evidence for autoregulation of cystathionine gamma-synthase mRNA stability in Arabidopsis	SCIENCE			English	Article							STORAGE PROTEIN GENE; METHIONINE BIOSYNTHESIS; THALIANA MUTANT; MOSAIC-VIRUS; GUS FUSIONS; EXPRESSION; PLANTS; MULTIPLICATION; PROTOPLASTS; PROMOTER	Control of messenger RNA (mRNA) stability serves as an important mechanism, for regulating gene expression. Analysis of Arabidopsis mutants that overaccumulate soluble methionine (Met) revealed that the gene for cystathionine gamma-synthase (CCS), the key enzyme in Met biosynthesis, is regulated at the Level of mRNA stability, Transfection experiments with wild-type and mutant forms of the CCS gene suggest that an amino acid sequence encoded by the first exon of CCS acts in cis to destabilize its own mRNA in a process that is activated by Met or one of its metabolites.	Hokkaido Univ, Grad Sch Agr, Div Appl Biosci, Sapporo, Hokkaido 0608589, Japan; AFRC, Inst Arable Crops Res, Dept Biochem & Physiol, Harpenden AL5 2JQ, Herts, England; Rutgers State Univ, Biotechnol Ctr Agr & Environm, New Brunswick, NJ 08901 USA	Hokkaido University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; Rutgers State University New Brunswick	Naito, S (corresponding author), Hokkaido Univ, Grad Sch Agr, Div Appl Biosci, Sapporo, Hokkaido 0608589, Japan.	naito@abs.agr.hokudai.ac.jp	Chiba, Yukako/AAA-9238-2019; Chiba, Yukako/B-7057-2009; Nambara, Eiji/E-5533-2012	Chiba, Yukako/0000-0002-7329-2775				ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; CHIBA Y, UNPUB; DATKO AH, 1978, PLANT PHYSIOL, V62, P629, DOI 10.1104/pp.62.4.629; FUJIWARA T, 1991, PLANT CELL REP, V9, P602, DOI 10.1007/BF00231797; GIOVANELLI J, 1990, SULFUR NUTRITION AND SULFUR ASSIMILATION IN HIGHER PLANTS, P33; GUZMAN P, 1988, NUCLEIC ACIDS RES, V16, P11091, DOI 10.1093/nar/16.23.11091; HIRAI MY, 1994, PLANT CELL PHYSIOL, V35, P927; INABA K, 1994, PLANT PHYSIOL, V104, P881, DOI 10.1104/pp.104.3.881; ISHIKAWA M, 1993, J VIROL, V67, P5328, DOI 10.1128/JVI.67.9.5328-5338.1993; JEFFERSON RA, 1987, EMBO J, V6, P3901; Kim J., 1999, Plant Physiology, V120, P635; Kim JS, 1996, PLANT MOL BIOL, V32, P1117, DOI 10.1007/BF00041395; LAST RL, 1988, SCIENCE, V240, P305, DOI 10.1126/science.240.4850.305; LEGUEN L, 1994, MOL GEN GENET, V245, P390, DOI 10.1007/BF00290120; Matthews BF, 1999, BOOK SOIL P, P205; NAITO S, 1994, PLANT PHYSIOL, V104, P497, DOI 10.1104/pp.104.2.497; NEWMAN TC, 1993, PLANT CELL, V5, P701, DOI 10.1105/tpc.5.6.701; Ravanel S, 1998, BIOCHEM J, V331, P639, DOI 10.1042/bj3310639; Ravanel S, 1998, P NATL ACAD SCI USA, V95, P7805, DOI 10.1073/pnas.95.13.7805; Rogers EE, 1997, PLANT CELL, V9, P305, DOI 10.1105/tpc.9.3.305; ROGNES SE, 1986, PLANT SCI, V43, P45, DOI 10.1016/0168-9452(86)90106-8; Rose AB, 1997, PLANT J, V11, P455, DOI 10.1046/j.1365-313X.1997.11030455.x; SAKATA Y, 1994, BIOSCI BIOTECH BIOCH, V58, P2104, DOI 10.1271/bbb.58.2104; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; THOMPSON GA, 1982, PLANT PHYSIOL, V69, P1077, DOI 10.1104/pp.69.5.1077; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALLSGROVE RM, 1983, PLANT PHYSIOL, V71, P780, DOI 10.1104/pp.71.4.780; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; Yoshii M, 1998, J VIROL, V72, P8731, DOI 10.1128/JVI.72.11.8731-8737.1998	31	145	156	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1999	286	5443					1371	1374		10.1126/science.286.5443.1371	http://dx.doi.org/10.1126/science.286.5443.1371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558994				2022-12-28	WOS:000083675500046
J	Sidorin, I; Gurnis, M; Helmberger, DV				Sidorin, I; Gurnis, M; Helmberger, DV			Evidence for a ubiquitous seismic discontinuity at the base of the mantle	SCIENCE			English	Article							SHEAR VELOCITY STRUCTURE; D''; BENEATH; MODELS; SLAB	A sharp discontinuity at the base of Earth's mantle has been suggested from seismic waveform studies; the observed travel time and amplitude variations have been interpreted as changes in the depth of a spatially intermittent discontinuity. Most of the observed variations in travel times and the spatial intermittance of the seismic triplication can be reproduced by a ubiquitous first-order discontinuity superimposed on global seismic velocity structure derived from tomography. The observations can be modeled by a solid-solid phase transition that has a 200-kilometer elevation above the core-mantle boundary under adiabatic temperatures and a Clapeyron slope of about 6 megapascal per kelvin.	CALTECH, Seismol Lab 252 21, Pasadena, CA 91125 USA	California Institute of Technology	Gurnis, M (corresponding author), CALTECH, Seismol Lab 252 21, Pasadena, CA 91125 USA.							Breger L, 1998, GEOPHYS RES LETT, V25, P5, DOI 10.1029/97GL03359; CHRISTENSEN UR, 1984, J GEOPHYS RES, V89, P4389, DOI 10.1029/JB089iB06p04389; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; GAHERTY JB, 1992, J GEOPHYS RES-SOL EA, V97, P417, DOI 10.1029/91JB02347; GARNERO EJ, 1993, PHYS EARTH PLANET IN, V79, P335, DOI 10.1016/0031-9201(93)90113-N; GRAND SP, 1994, J GEOPHYS RES-SOL EA, V99, P11591, DOI 10.1029/94JB00042; Grand SP., 1997, GSA TODAY, V7, P1; Kendall JM, 1996, GEOPHYS RES LETT, V23, P399, DOI 10.1029/95GL02659; LAY T, 1983, GEOPHYS J ROY ASTR S, V75, P799, DOI 10.1111/j.1365-246X.1983.tb05010.x; LAY T, 1989, GEOPHYS RES LETT, V16, P605, DOI 10.1029/GL016i007p00605; Liu XF, 1998, EARTH PLANET SC LETT, V160, P343, DOI 10.1016/S0012-821X(98)00095-8; MASTERS G, 1999, 11 ANN IRIS WORKSH 9; NATAF HC, 1993, GEOPHYS RES LETT, V20, P2371, DOI 10.1029/93GL02686; NI S, IN PRESS GEOPHYS J I; RUSSELL S, 1998, EOS S, V79, P618; Sidorin I, 1998, EARTH PLANET SC LETT, V163, P31, DOI 10.1016/S0012-821X(98)00172-1; Sidorin I, 1999, J GEOPHYS RES-SOL EA, V104, P15005, DOI 10.1029/1999JB900065; Sidorin I, 1998, GEODYNAMICS, V28, P209; STIXRUDE L, 1990, J GEOPHYS RES-SOLID, V95, P19311, DOI 10.1029/JB095iB12p19311; van der Hilst RD, 1999, SCIENCE, V283, P1885, DOI 10.1126/science.283.5409.1885; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528; Wysession ME, 1998, GEODYNAMICS, V28, P273; Wysession ME, 1999, SCIENCE, V284, P120, DOI 10.1126/science.284.5411.120; YOUNG CJ, 1990, J GEOPHYS RES-SOLID, V95, P17385, DOI 10.1029/JB095iB11p17385; YOUNG CJ, 1987, PHYS EARTH PLANET IN, V49, P37, DOI 10.1016/0031-9201(87)90131-2	25	141	147	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1326	1331		10.1126/science.286.5443.1326	http://dx.doi.org/10.1126/science.286.5443.1326			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558981				2022-12-28	WOS:000083675500033
J	Heiserman, JE				Heiserman, JE			Silent embolism after cerebral angiography - what harm?	LANCET			English	Editorial Material							CAROTID ANGIOGRAPHY; ASSOCIATION; MICROEMBOLI; STROKE		St Josephs Hosp & Med Ctr, Barrow Neurol Inst, Div Neuroradiol, Phoenix, AZ 85013 USA	Barrow Neurological Institute; St. Joseph's Hospital and Medical Center	Heiserman, JE (corresponding author), St Josephs Hosp & Med Ctr, Barrow Neurol Inst, Div Neuroradiol, Phoenix, AZ 85013 USA.							Braekken SK, 1998, J NEUROL NEUROSUR PS, V65, P573; DAGIRMANJIAN A, 1993, AM J ROENTGENOL, V161, P1037, DOI 10.2214/ajr.161.5.7903842; DEBRUN GM, 1982, AM J ROENTGENOL, V139, P139, DOI 10.2214/ajr.139.1.139; Gerraty RP, 1996, STROKE, V27, P1543, DOI 10.1161/01.STR.27.9.1543; Kidwell CS, 1999, STROKE, V30, P1174, DOI 10.1161/01.STR.30.6.1174; MARKUS H, 1993, LANCET, V341, P784, DOI 10.1016/0140-6736(93)90561-T; Schwamm LH, 1998, STROKE, V29, P2268, DOI 10.1161/01.STR.29.11.2268; Singer MB, 1998, STROKE, V29, P133, DOI 10.1161/01.STR.29.1.133	8	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1577	1578		10.1016/S0140-6736(99)00277-9	http://dx.doi.org/10.1016/S0140-6736(99)00277-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560669				2022-12-28	WOS:000083551000006
J	Deshpande, G; Calhoun, G; Yanowitz, JL; Schedl, PD				Deshpande, G; Calhoun, G; Yanowitz, JL; Schedl, PD			Novel functions of nanos in downregulating mitosis and transcription during the development of the Drosophila germline	CELL			English	Article							POSTERIOR MORPHOGEN NANOS; SYNCYTIAL EMBRYOS; SEX DETERMINATION; CELL-DEVELOPMENT; GENE-EXPRESSION; BODY PATTERN; OSKAR; POLE; MIGRATION; RNA	It has previously been shown that germ cells in embryos derived from nos mutant mothers do not migrate to the primitive gonad and prematurely express several germline-specific markers. In the studies reported here, we have traced these defects back to the syncytial blastoderm stage. We show that pole cells in nos(-) embryos fail to establish/maintain transcriptional quiescence; the sex determination gene Sex-lethal (Sxl) and the segmentation genes fushi tarazu and even-skipped are ectopically activated in nos- germ cells. We show that nos- germ cells are unable to attenuate the cell cycle and instead continue dividing. Unexpectedly, removal of the Sxl gene in the zygote mitigates both the migration and mitotic defects of nos(-) germ cells. Supporting the conclusion that Sri is an important target for nos repression, ectopic, premature expression of Sxl protein in germ cells disrupts migration and stimulates mitotic activity.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Deshpande, G (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Yanowitz, Judith L/AGJ-8504-2022	Yanowitz, Judith L/0000-0001-6886-8787				Asaoka M, 1998, MECH DEVELOP, V78, P153, DOI 10.1016/S0925-4773(98)00164-6; Batchelder C, 1999, GENE DEV, V13, P202, DOI 10.1101/gad.13.2.202; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; CHOU TB, 1992, GENETICS, V131, P643; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; DAHMUS ME, 1996, J BIOL CHEM, V265, P19185; DALBY B, 1992, DEVELOPMENT, V115, P989; DESHPANDE G, 1995, MOL CELL BIOL, V15, P4430; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FOE VE, 1983, J CELL SCI, V61, P31; Forbes A, 1998, DEVELOPMENT, V125, P679; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, CELL, V18, P577; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; ILMENSEE K, 1976, DEV BIOL, V49, P40; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JAGLARZ MK, 1995, DEVELOPMENT, V121, P3495; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; Lehmann Ruth, 1995, Seminars in Developmental Biology, V6, P25, DOI 10.1016/S1044-5781(06)80082-4; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Seydoux G, 1997, DEVELOPMENT, V124, P2191; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; Su TT, 1998, DEV BIOL, V196, P160, DOI 10.1006/dbio.1998.8855; Su TT, 1998, GENE DEV, V12, P1495, DOI 10.1101/gad.12.10.1495; Van Doren M, 1998, CURR BIOL, V8, P243; WARRIOR R, 1994, DEV BIOL, V166, P180, DOI 10.1006/dbio.1994.1306; Wei Y, 1998, TRENDS CELL BIOL, V8, P266; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Williamson A, 1996, ANNU REV CELL DEV BI, V12, P365, DOI 10.1146/annurev.cellbio.12.1.365; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97	37	123	130	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					271	281		10.1016/S0092-8674(00)81658-X	http://dx.doi.org/10.1016/S0092-8674(00)81658-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555143	Bronze			2022-12-28	WOS:000083440600005
J	Mayer, TU; Kapoor, TM; Haggarty, SJ; King, RW; Schreiber, SL; Mitchison, TJ				Mayer, TU; Kapoor, TM; Haggarty, SJ; King, RW; Schreiber, SL; Mitchison, TJ			Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen	SCIENCE			English	Article							MICROTUBULE MOTOR; KINESIN MOTORS; PROTEINS; CELLS	Small molecules that perturb specific protein functions are valuable tools for dissecting complex processes in mammalian cells. A combination of two phenotype-based screens, one based on a specific posttranslational modification, the other visualizing microtubules and chromatin, was used to identify compounds that affect mitosis. One compound, here named monastrol, arrested mammalian cells in mitosis with monopolar spindles. In vitro, monastrol specifically inhibited the motility of the mitotic kinesin Eg5, a motor protein required for spindle bipolarity. All previously known small molecules that specifically affect the mitotic machinery target tubulin. Monastrol will therefore be a particularly useful tool for studying mitotic mechanisms.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Inst Chem & Cell Biol, Boston, MA 02115 USA; Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute; Harvard University	Mayer, TU (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Haggarty, Stephen J/M-9495-2016	Haggarty, Stephen J/0000-0002-7872-168X; Mayer, Thomas/0000-0001-6954-2287	NATIONAL CANCER INSTITUTE [P01CA078048] Funding Source: NIH RePORTER; NCI NIH HHS [CA78048] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson HJ, 1998, EXP CELL RES, V238, P498, DOI 10.1006/excr.1997.3862; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; CRAMER LP, 1994, CURR OPIN CELL BIOL, V6, P82, DOI 10.1016/0955-0674(94)90120-1; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HAGGARTY SJ, UNPUB; Hamel E, 1996, MED RES REV, V16, P207, DOI 10.1002/(SICI)1098-1128(199603)16:2<207::AID-MED4>3.3.CO;2-I; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Jordan MA, 1998, METHOD ENZYMOL, V298, P252, DOI 10.1016/S0076-6879(98)98024-7; Kapoor TM, 1999, P NATL ACAD SCI USA, V96, P9106, DOI 10.1073/pnas.96.16.9106; Lewandowski K, 1999, J COMB CHEM, V1, P105, DOI 10.1021/cc980014p; Mitchison TJ, 1994, CHEM BIOL, V1, P3, DOI 10.1016/1074-5521(94)90034-5; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; Sakowicz R, 1998, SCIENCE, V280, P292, DOI 10.1126/science.280.5361.292; SAXTON WM, 1994, METHOD CELL BIOL, V44, P279, DOI 10.1016/S0091-679X(08)60919-X; Schreiber SL, 1998, BIOORGAN MED CHEM, V6, P1127, DOI 10.1016/S0968-0896(98)00126-6; Stockwell BR, 1999, CHEM BIOL, V6, P71, DOI 10.1016/S1074-5521(99)80004-0; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3	20	1534	1655	3	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					971	974		10.1126/science.286.5441.971	http://dx.doi.org/10.1126/science.286.5441.971			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542155	Green Submitted			2022-12-28	WOS:000083368500050
J	Humphrey, ME				Humphrey, ME			An endoscopic Jack-o'-Lantern	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Humphrey, ME (corresponding author), 3923 Waring Rd,Suite A, Oceanside, CA 92056 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1358	1358		10.1056/NEJM199910283411805	http://dx.doi.org/10.1056/NEJM199910283411805			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249XE	10536128				2022-12-28	WOS:000083357800005
J	Must, A; Spadano, J; Coakley, EH; Field, AE; Colditz, G; Dietz, WH				Must, A; Spadano, J; Coakley, EH; Field, AE; Colditz, G; Dietz, WH			The disease burden associated with overweight and obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	North-American-Association-for-the-Study-of-Obesity Meeting	NOV 10, 1997	CANCUN, MEXICO	N Amer Assoc Study Obesity			BODY-MASS INDEX; CORONARY HEART-DISEASE; FAT DISTRIBUTION; WOMEN; MORTALITY; RISK; PREVALENCE; WEIGHT; POPULATION; PREDICTORS	Context Overweight and obesity are increasing dramatically in the United States and most likely contribute substantially to the burden of chronic health conditions. Objective To describe the relationship between weight status and prevalence of health conditions by severity of overweight and obesity in the US population. Design and Setting Nationally representative cross-sectional survey using data from the Third National Health and Nutrition Examination Survey (NHANES III), which was conducted in 2 phases from 1988 to 1994. Participants A total of 16 884 adults, 25 years and older, classified as overweight and obese (body mass index [BMI] greater than or equal to 25 kg/m(2)) based on National Institutes of Health recommended guidelines. Main Outcome Measures Prevalence of type 2 diabetes mellitus, gallbladder disease, coronary heart disease, high blood cholesterol level, high blood pressure, or osteoarthritis, Results Sixty-three percent of men and 55% of women had a body mass index of 25 kg/m(2) or greater. A graded increase in the prevalence ratio (PR) was observed with increasing severity of overweight and obesity for all of the health outcomes except for coronary heart disease in men and high blood cholesterol level in both men and women. With normal-weight individuals as the reference, for individuals with BMIs of at least 40 kg/m(2) and who were younger than 55 years, PRs were highest for type 2 diabetes for men (PR, 18.1; 95% confidence interval [CI], 6.7-46.8) and women (PR, 12.9; 95% CI, 5.7-28.1) and gallbladder disease for men (PR, 21.1; 95% CI, 4.1-84.2) and women (PR, 5.2; 95% CI, 2.9-8.9). Prevalence ratios generally were greater in younger than in older adults. The prevalence of having 2 or more health conditions increased with weight status category across all racial and ethnic subgroups. Conclusions Based on these results, more than half of all US adults are considered overweight or obese. The prevalence of obesity-related comorbidities emphasizes the need for concerted efforts to prevent and treat obesity rather than just its associated comorbidities.	Tufts Univ, Sch Med, Dept Family Med & Community Hlth, Boston, MA 02111 USA; Tufts Univ, USDA, Human Nutr Res Ctr, Medford, MA 02155 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Tufts Univ New England Med Ctr, Dept Pediat Gastroenterol & Nutr, Boston, MA USA; Ctr Dis Control & Prevent, Ctr Dis Prevent & Hlth Promot, Div Nutr & Phys Activ, Atlanta, GA USA	Tufts University; Tufts University; United States Department of Agriculture (USDA); Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Tufts Medical Center; Centers for Disease Control & Prevention - USA	Must, A (corresponding author), Tufts Univ, Sch Med, Dept Family Med & Community Hlth, 136 Harrison Ave, Boston, MA 02111 USA.	amust@hnrc.tufts.edu	Colditz, Graham/A-3963-2009; Field, Alison/AAA-4508-2021; Kohn, Geoffrey P/A-9056-2009	Colditz, Graham/0000-0002-7307-0291; 				ANDRES R, 1993, ANN INTERN MED, V119, P737, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00022; [Anonymous], 1994, VITAL HLTH STAT, V1, P1; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; BURTON BT, 1985, INT J OBESITY, V9, P155; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; Drewnowski A, 1997, NUTR REV, V55, P31, DOI 10.1111/j.1753-4887.1997.tb01593.x; Ernst ND, 1997, J AM DIET ASSOC, V97, pS47, DOI 10.1016/S0002-8223(97)00729-3; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; FORBES GB, 1970, METABOLIS, V19, P653, DOI 10.1016/0026-0495(70)90062-4; HANSEN RG, 1995, J IND ECON, V43, P261, DOI 10.2307/2950579; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Huang ZP, 1998, ANN INTERN MED, V128, P81, DOI 10.7326/0003-4819-128-2-199801150-00001; HYPERTENSION DETECTION FOLLOW-UP, 1977, AM J EPIDEMIOL, V106, P351; Kassirer JP, 1998, NEW ENGL J MED, V338, P52, DOI 10.1056/NEJM199801013380109; KUMANYIKA S, 1987, EPIDEMIOL REV, V9, P31, DOI 10.1093/oxfordjournals.epirev.a036307; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LEE J, 1984, AM J PUBLIC HEALTH, V74, P376, DOI 10.2105/AJPH.74.4.376; National Center for Health Statistics, 1996, 3 NAT HLTH NUTR EX S; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; Rose G, 1982, CARDIOVASCULAR SURVE; SAVAGE P J, 1991, Ethnicity and Disease, V1, P200; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; Shah BV, 1997, SOFTWARE STAT ANAL C; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; Stevens J, 1998, OBES RES, V6, P268, DOI 10.1002/j.1550-8528.1998.tb00349.x; STEVENS J, 1992, ARCH INTERN MED, V152, P1257, DOI 10.1001/archinte.152.6.1257; Sundquist J, 1999, AM J PUBLIC HEALTH, V89, P723, DOI 10.2105/AJPH.89.5.723; *US DEP HHS, 1996, LAB PROD US NHANES, V3; *USDA, 1995, HOM GARD B, V232; WHO, 1997, OBESITY PREVENTING M; *WHO MONICA PROJ, 1989, INT J EPIDEMIOL S1, V18, pS46; WIENPAHL J, 1990, J CLIN EPIDEMIOL, V43, P949, DOI 10.1016/0895-4356(90)90078-4; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; Winkleby MA, 1999, JAMA-J AM MED ASSOC, V281, P1006, DOI 10.1001/jama.281.11.1006; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; ZILLIKENS MC, 1990, AM J CLIN NUTR, V52, P45, DOI 10.1093/ajcn/52.1.45; [No title captured]	39	3209	3307	10	380	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1523	1529		10.1001/jama.282.16.1523	http://dx.doi.org/10.1001/jama.282.16.1523			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	248MB	10546691				2022-12-28	WOS:000083277800019
J	Beecham, L				Beecham, L			Juniors' pay offer will not mean a pay cut	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1140	1140						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531124				2022-12-28	WOS:000083419500068
J	Johnston, K; Brown, J				Johnston, K; Brown, J			Two view mammography at incident screens: cost effectiveness analysis of policy options	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the cost effectiveness of two view mammography at incident screens. Design Incremental cost effectiveness analyses recognising differences in current reading policy, based on effectiveness data from an observational study. Setting Breast screening programmes in England and Wales. Main outcome measures Health service costs, cancers detected, incremental cost effectiveness ratios per cancer detected, whole time equivalent staff. Results For programmes currently using one view with some form of double reading, the incremental cost effectiveness ratio of two view mammography art incident screens ranged between pound 6589 and pound 6716, depending on the reading policy. For programmes currently using one view with single reading, two policy options were found to be more efficient than two view single reading: one view with double reading (arbitration; incremental cost effectiveness ratio of pound 210) and two view double reading (arbitration). Tf programmes using one view with single reading changed to double reading (arbitration) and then subsequently to two views double reading (arbitration), additional cancers could be detected with an incremental cost effectiveness ratio of pound 7983. The implementation cost of two view mammography at incident screens in programmes in England and Wales would be pound 2.9 million and would require 13.4 whole time equivalent radiologists. Conclusions The cost effectiveness of two view mammography at incident screens depends on the film reading policy. A policy of two view mammography at incident screens in England and Wales would be efficient only if programmes using single reading moved to double reading. Given limited resources, priority should be given to introducing double reading in the subset of programmes currently using single reading as this requires fewer additional radiologists and is more cost effective.	Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford OX3 7LF, England; Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England	University of Oxford; Brunel University	Johnston, K (corresponding author), Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford OX3 7LF, England.							Blanks R G, 1996, J Med Screen, V3, P79; Blanks RG, 1998, J MED SCREEN, V5, P195, DOI 10.1136/jms.5.4.195; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Brown J, 1996, BRIT MED J, V312, P809; BRYAN S, 1995, J EPIDEMIOL COMMUN H, V49, P70, DOI 10.1136/jech.49.1.70; Forrest APM, 1986, BREAST CANC SCREENIN; JOHNSTON K, 1996, NHS COSTS BREAST SCR; Karlsson G, 1996, PHARMACOECONOMICS, V9, P113, DOI 10.2165/00019053-199609020-00003; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; *NHS, 1995, QUAL NAT HLTH SERV B; WALD NJ, 1995, BRIT MED J, V311, P1189, DOI 10.1136/bmj.311.7014.1189; WARREN RML, 1995, BRIT J RADIOL, V68, P958, DOI 10.1259/0007-1285-68-813-958	12	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1097	1102		10.1136/bmj.319.7217.1097	http://dx.doi.org/10.1136/bmj.319.7217.1097			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531098	Green Published, Bronze			2022-12-28	WOS:000083419500021
J	Watts, DM; Porter, KR; Putvatana, P; Vasquez, B; Calampa, C; Hayes, CG; Halstead, SB				Watts, DM; Porter, KR; Putvatana, P; Vasquez, B; Calampa, C; Hayes, CG; Halstead, SB			Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever	LANCET			English	Article							HEMORRHAGIC-FEVER; SHOCK SYNDROME; MOLECULAR EVOLUTION; TYPE-2 VIRUS; RISK-FACTORS; IDENTIFICATION; NUCLEOTIDE; ANTIBODIES; EPIDEMIC; THAILAND	Background Population-based epidemiological studies have shown that infection with dengue type 2 (DEN-2) virus in individuals previously infected with a different serotype of the virus is a major risk factor for dengue haemorrhagic fever and dengue shock syndrome. However, the western hemisphere was spared epidemics of these two syndromes, until the introduction of a southeast Asian DEN-2 genotype. Possibly American DEN-2 genotype strains lacked properties necessary to cause severe disease. We report on a major epidemic of DEN-2 in Peru in 1995, about 5 years after an epidemic of DEN-1 in the same population. Methods In Iquitos, a city of 344 686 inhabitants in Peru, cases of dengue fever were studied prospectively from 1990. Acute phase of illness serum samples from patients were tested for virus in C6/36 cells, and virus isolates were identified by immunofluorescence. Isolates of dengue 2 virus obtained from patients during an outbreak of mild febrile illness in 1995 were sequenced to determine the genotype. Serological analysis of paired samples from the patients was done with an IgM capture ELISA and an indirect IgG ELISA. In addition, serum samples collected annually between 1993 and 1996 from a large cohort of students were tested for dengue IgG antibody by an ELISA. Serum samples from a random sample of 129 students from this cohort were tested for dengue neutralising antibodies to quantify the serotype specific infection rates. Findings Among the 129 students (aged 7-20 years in 1993) who had serum samples available before and after the epidemic, 78 (60.5%) had a secondary DEN-2 virus infection. By extrapolation, 49 266 of the 81 479 children (aged 5-14 years) in Iquitos would have experienced such infections. From previous studies, between 887 and 10 247 cases of dengue haemorrhagic fever and dengue shock syndrome would have been expected. No cases were found. DEN-2 isolates were of the American genotype. Interpretation This prospective study shows that secondary infection by the American DEN-2 genotype did not cause dengue haemorrhagic fever and dengue shock syndrome.	USN, Med Res Ctr Detachment, AMEMB NAMRID, Unit 3800, Bethesda, MD USA; Peruvian Navy, Ctr Med Naval, Bellavista, Callao, Peru; Loreto Reg Minist Hlth, Iquitos, Loreto, Peru; Off Naval Res, Arlington, VA 22217 USA	United States Department of Defense; United States Navy; United States Department of Defense; United States Navy	Watts, DM (corresponding author), USN, Med Res Ctr, Detachment AMEMB NAMRID, Unit 3800, APO, AA 34031 USA.	Watts@namrid.sld.pe	Porter, Kevin/A-8027-2011					BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172; CHUNGUE E, 1993, J GEN VIROL, V74, P2765, DOI 10.1099/0022-1317-74-12-2765; DEUBEL V, 1988, VIROLOGY, V165, P234, DOI 10.1016/0042-6822(88)90677-0; Duangchanda Sumlee, 1994, Southeast Asian Journal of Tropical Medicine and Public Health, V25, P243; Graham RR, 1999, AM J TROP MED HYG, V61, P412, DOI 10.4269/ajtmh.1999.61.412; GUZMAN MG, 1995, AM J TROP MED HYG, V52, P241, DOI 10.4269/ajtmh.1995.52.241; GUZMAN MG, 1990, AM J TROP MED HYG, V42, P179, DOI 10.4269/ajtmh.1990.42.179; Halstead S.B., 1980, TOGAVIRUSES BIOL STR, p107e173; HALSTEAD SB, 1967, JPN J MED SCI BIOL, VS 20, P96; Halstead Scott B., 1997, P23; Hayes CG, 1996, AM J TROP MED HYG, V55, P459, DOI 10.4269/ajtmh.1996.55.459; HENCHAL EA, 1983, AM J TROP MED HYG, V32, P164, DOI 10.4269/ajtmh.1983.32.164; KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411; KLIKS SC, 1989, AM J TROP MED HYG, V40, P444, DOI 10.4269/ajtmh.1989.40.444; KOURI G, 1988, B PAN AM HLTH ORG, V20, P24; Kyaw-Zin-Thant, 1995, Southeast Asian J Trop Med Public Health, V26, P664; Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999; Mangada MNM, 1998, VIROLOGY, V244, P458, DOI 10.1006/viro.1998.9093; MORENS DM, 1985, J CLIN MICROBIOL, V22, P250, DOI 10.1128/JCM.22.2.250-254.1985; NEFF JM, 1967, AM J EPIDEMIOL, V86, P162, DOI 10.1093/oxfordjournals.aje.a120722; Phillips I, 1992, Bull Pan Am Health Organ, V26, P201; Pinheiro Fransisco P., 1997, World Health Statistics Quarterly, V50, P161; Rico-Hesse R, 1998, AM J TROP MED HYG, V58, P96, DOI 10.4269/ajtmh.1998.58.96; RICOHESSE R, 1990, VIROLOGY, V174, P479, DOI 10.1016/0042-6822(90)90102-W; RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504; ROSEN L, 1977, AM J TROP MED HYG, V26, P337, DOI 10.4269/ajtmh.1977.26.337; RUSSELL PK, 1968, AM J TROP MED HYG, V17, P600, DOI 10.4269/ajtmh.1968.17.600; SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932; SRIVASTAVA VK, 1990, ANN TROP PAEDIATR, V10, P329, DOI 10.1080/02724936.1990.11747453; TESH RB, 1979, AM J TROP MED HYG, V28, P1053, DOI 10.4269/ajtmh.1979.28.1053; Thein S, 1997, AM J TROP MED HYG, V56, P566, DOI 10.4269/ajtmh.1997.56.566; Watts DM, 1998, AM J TROP MED HYG, V58, P35, DOI 10.4269/ajtmh.1998.58.35; 1994, PAHO SCI PUB, V548, P98; 1993, EPIDEMIOL B PAN AM H, V14, P1	34	218	231	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1999	354	9188					1431	1434		10.1016/S0140-6736(99)04015-5	http://dx.doi.org/10.1016/S0140-6736(99)04015-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543670				2022-12-28	WOS:000083277400013
J	Ebrahim, S				Ebrahim, S			Demographic shifts and medical training	BRITISH MEDICAL JOURNAL			English	Article							CURRICULUM		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Ebrahim, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.							Bax NDS, 1997, MED EDUC, V31, P347, DOI 10.1046/j.1365-2923.1997.00676.x; Bennett G., 1995, ESSENTIALS HLTH CARE; BRINDLE D, 1999, GUARDIAN        0623; DICKINSON EJ, 1990, LANCET, V335, P778, DOI 10.1016/0140-6736(90)90881-5; EBRAHIM S, 1996, EPIDEMIOLOGY OLD AGE; Harden RM, 1997, MED EDUC, V31, P264, DOI 10.1111/j.1365-2923.1997.tb02923.x; Lorraine V, 1998, Fam Med, V30, P15; MCGOUGH R, 1967, PENGUIN MODERN POETS, V10, P91; TURPIE I, 1995, GERONTOL GERIATR ED, V15, P29; YOUNG A, 1989, LANCET, V2, P263; 1999, INT REV SYLLABUS GER	11	29	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1358	1360		10.1136/bmj.319.7221.1358	http://dx.doi.org/10.1136/bmj.319.7221.1358			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567150	Green Published			2022-12-28	WOS:000083930200032
J	Zhang, ZQ; Schuler, T; Zupancic, M; Wietgrefe, S; Staskus, KA; Reimann, KA; Reinhart, TA; Rogan, M; Cavert, W; Miller, CJ; Veazey, RS; Notermans, D; Little, S; Danner, SA; Richman, DD; Havlir, D; Wong, J; Jordan, HL; Schacker, TW; Racz, P; Tenner-Racz, K; Letvin, NL; Wolinsky, S; Haase, AT				Zhang, ZQ; Schuler, T; Zupancic, M; Wietgrefe, S; Staskus, KA; Reimann, KA; Reinhart, TA; Rogan, M; Cavert, W; Miller, CJ; Veazey, RS; Notermans, D; Little, S; Danner, SA; Richman, DD; Havlir, D; Wong, J; Jordan, HL; Schacker, TW; Racz, P; Tenner-Racz, K; Letvin, NL; Wolinsky, S; Haase, AT			Sexual transmission and propagation of SIV and HIV in resting and activated CD4(+) T cells	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; ANTIRETROVIRAL THERAPY; DENDRITIC CELLS; RHESUS MACAQUES; VAGINAL TRANSMISSION; VIRAL REPLICATION; TYPE-1 INFECTION; IN-VITRO; CYCLE; LYMPHOCYTES	In sexual transmission of simian immunodeficiency virus, and early and later stages of human immunodeficiency virus-type 1 (HIV-1) infection, both viruses were found to replicate predominantly in CD4(+) T cells at the portal of entry and in Lymphoid tissues, infection was propagated not only in activated and proliferating T cells but also, surprisingly, in resting T cells. The infected proliferating cells correspond to the short-lived population that produces the bulk of HIV-1. Most of the HIV-1-infected resting T cells persisted after antiretroviral therapy. Latently and chronically infected cells that may be derived from this population pose challenges to eradicating infection and developing an effective vaccine.	Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA; Harvard Univ, Beth Israel Hosp, Div Viral Pathogenesis, Boston, MA 02215 USA; Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA; Calif Reg Primate Res Ctr, Davis, CA 95616 USA; Univ Amsterdam, Acad Med Ctr, Acad Hosp, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Northwestern Univ, Sch Med, Div Infect Dis, Chicago, IL 60611 USA; San Diego VA Hlth Care Syst, La Jolla, CA 92093 USA	University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Beth Israel Deaconess Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Amsterdam; Academic Medical Center Amsterdam; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Minnesota System; University of Minnesota Twin Cities; Bernhard Nocht Institut fur Tropenmedizin; Northwestern University	Haase, AT (corresponding author), Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA.		Little, Susan/AAA-6116-2019; Wolinsky, Steven/B-2893-2012	Wolinsky, Steven/0000-0002-9625-6697	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI028246, R01AI138565, R01AI038565] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00168] Funding Source: Medline; NIAID NIH HHS [AI 28246, AI 38565] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Benoist C, 1997, SCIENCE, V276, P2000, DOI 10.1126/science.276.5321.2000; BRAHIC M, 1989, CURR TOP MICROBIOL, V143, P9; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BURKRINSKY MI, 1991, SCIENCE, V254, P423; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chou CS, 1997, P NATL ACAD SCI USA, V94, P1361, DOI 10.1073/pnas.94.4.1361; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Freitas AA, 1997, SCIENCE, V277, P1950, DOI 10.1126/science.277.5334.1950; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; HAASE AT, 1986, NATURE, V322, P130, DOI 10.1038/322130a0; Hirsch VM, 1998, NAT MED, V4, P1401, DOI 10.1038/3992; Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; Markiewicz MA, 1998, P NATL ACAD SCI USA, V95, P3065, DOI 10.1073/pnas.95.6.3065; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Miller C. J., 1992, Laboratory Investigation, V68, P129; Miller CJ, 1998, J VIROL, V72, P3248, DOI 10.1128/JVI.72.4.3248-3258.1998; MILLER CJ, 1992, J MED PRIMATOL, V21, P64; *NAT RES COUNC, 1996, GUID CAR US LAB; Orendi JM, 1998, J INFECT DIS, V178, P1279, DOI 10.1086/314451; Ostrowski MA, 1999, J VIROL, V73, P6430, DOI 10.1128/JVI.73.8.6430-6435.1999; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Schacker TW, 1998, ANN INTERN MED, V128, P613, DOI 10.7326/0003-4819-128-8-199804150-00001; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPINA CA, 1995, J VIROL, V69, P2977, DOI 10.1128/JVI.69.5.2977-2988.1995; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; Stahl-Hennig C, 1999, SCIENCE, V285, P1261, DOI 10.1126/science.285.5431.1261; Sutton RE, 1998, J VIROL, V72, P5781, DOI 10.1128/JVI.72.7.5781-5788.1998; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TANG SB, 1995, J VIROL, V69, P5659, DOI 10.1128/JVI.69.9.5659-5665.1995; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	41	699	710	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1353	1357		10.1126/science.286.5443.1353	http://dx.doi.org/10.1126/science.286.5443.1353			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558989				2022-12-28	WOS:000083675500041
J	Boulton, F				Boulton, F			An hour that might have made history - Before transfusion became established procedure	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1257	1257		10.1136/bmj.319.7219.1257	http://dx.doi.org/10.1136/bmj.319.7219.1257			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550096	Green Published			2022-12-28	WOS:000083625600032
J	Deniz, AA; Peters, KS; Snyder, GJ				Deniz, AA; Peters, KS; Snyder, GJ			Experimental determination of the antiaromaticity of cyclobutadiene	SCIENCE			English	Article							AB-INITIO CALCULATIONS; MM3 FORCE-FIELD; RESOLVED PHOTOACOUSTIC CALORIMETRY; MOLECULAR-ORBITAL THEORY; STABILIZATION ENERGIES; CONJUGATED HYDROCARBONS; ELECTRONIC-STRUCTURE; RESONANCE ENERGIES; ORGANIC COMPOUNDS; ANTI-AROMATICITY	Photoacoustic calorimetry was used to quantify the antiaromaticity of 1,3-cyclobutadiene (CBD) by measuring the heat release accompanying its formation via photofragmentation of a polycyclic precursor. In combination with quantum yield measurements and thermochemical calculations, this measurement provides an enthalpy of formation for CBD of 114 +/- 11 (2 sigma) kilocalories per mole (kcal/mol), The extraordinary reactivity of this prototypical antiaromatic hydrocarbon had previously made its heat of formation inaccessible except by theoretical calculations. Relative to a hypothetical strainless, conjugated diene reference, CBD is destabilized by a total of 87 kcal/mol, 32 kcal/mol of which can be attributed to ring strain and 55 kcal/mol to antiaromaticity (compared with 21 kcal/mol for the aromatic stabilization of benzene). Relative to a reference with isolated double bonds, CBD's antiaromaticity is 48 kcal/mol (compared with 32 kcal/mol for the aromaticity of benzene).	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Chicago, Dept Chem, Chicago, IL 60637 USA	University of Colorado System; University of Colorado Boulder; University of Chicago	Snyder, GJ (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	kevin.peters@colorado.edu; gsnyder@ucsd.edu	Snyder, G J/I-2263-2015					ALLINGER NL, 1990, J COMPUT CHEM, V11, P848, DOI 10.1002/jcc.540110708; ALLINGER NL, 1989, J AM CHEM SOC, V111, P8551, DOI 10.1021/ja00205a001; ALLINGER NL, 1990, J COMPUT CHEM, V11, P868, DOI 10.1002/jcc.540110709; ALLINGER NL, 1990, J AM CHEM SOC, V112, P8293, DOI 10.1021/ja00179a012; ALTMAN J, 1968, TETRAHEDRON, V24, P975, DOI 10.1016/0040-4020(68)88047-0; [Anonymous], 1967, CYCLOBUTADIENE RELAT; BALLY T, 1980, TETRAHEDRON, V36, P343, DOI 10.1016/0040-4020(80)87003-7; BAULD NL, 1978, J AM CHEM SOC, V100, P6920, DOI 10.1021/ja00490a025; Benson S.W, 1976, THERMOCHEMICAL KINET; BENSON SW, 1969, CHEM REV, V69, P279, DOI 10.1021/cr60259a002; Berson JA, 1996, ANGEW CHEM INT EDIT, V35, P2750, DOI 10.1002/anie.199627501; BLOOMFIELD JJ, 1964, J AM CHEM SOC, V86, P2738, DOI 10.1021/ja01067a056; BOWMAN WD, 1976, J PHYS CHEM-US, V80, P2434, DOI 10.1021/j100562a025; BRASLAVSKY SE, 1992, CHEM REV, V92, P1381, DOI 10.1021/cr00014a007; BRESLOW R, 1973, ACCOUNTS CHEM RES, V6, P393, DOI 10.1021/ar50072a001; BRESLOW R, 1970, J AM CHEM SOC, V92, P427, DOI 10.1021/ja00705a637; BRESLOW R, 1973, J AM CHEM SOC, V95, P6688, DOI 10.1021/ja00801a027; BRESLOW R, 1970, J AM CHEM SOC, V92, P4139, DOI 10.1021/ja00716a069; BRESLOW R, 1963, J AM CHEM SOC, V85, P431, DOI 10.1021/ja00887a013; Breslow R, 1965, CHEM ENG NEWS, V43, P90, DOI 10.1021/cen-v043n026.p090; CARLOCK JT, 1978, TETRAHEDRON LETT, P5153; CARREIRA LA, 1975, J CHEM PHYS, V62, P3851, DOI 10.1063/1.431009; DENTZ AA, 1996, THESIS U CHICAGO, P68; DEWAR MJS, 1975, J AM CHEM SOC, V97, P2933, DOI 10.1021/ja00843a071; DEWAR MJS, 1971, J AM CHEM SOC, V93, P3437, DOI 10.1021/ja00743a023; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; DEWAR MJS, 1969, J AM CHEM SOC, V91, P789, DOI 10.1021/ja01032a001; DEWAR MJS, 1965, ADV CHEM PHYS, V8, P65; DISCH RL, 1985, J AM CHEM SOC, V107, P1904, DOI 10.1021/ja00293a018; Garratt P. J., 1986, AROMATICITY; GEORGE P, 1976, J CHEM SOC PERK T 2, P1222, DOI 10.1039/p29760001222; GEORGE P, 1976, TETRAHEDRON, V32, P1357, DOI 10.1016/0040-4020(76)85010-7; GEORGE P, 1984, J CHEM EDUC, V61, P225, DOI 10.1021/ed061p225; GEORGE P, 1975, THEOR CHIM ACTA, V38, P121, DOI 10.1007/BF00581469; GLUKHOVTSEV MN, 1995, J PHYS CHEM-US, V99, P6828, DOI 10.1021/j100018a012; Glukhovtsev MN, 1997, THEOCHEM-J MOL STRUC, V417, P123, DOI 10.1016/S0166-1280(97)00049-3; HADDON RC, 1982, PURE APPL CHEM, V54, P1129, DOI 10.1351/pac198254051129; HADDON RC, 1986, PURE APPL CHEM, V58, P129, DOI 10.1351/pac198658010129; HATCHARD CG, 1956, PROC R SOC LON SER-A, V235, P518, DOI 10.1098/rspa.1956.0102; HEHRE WJ, 1970, J AM CHEM SOC, V92, P4796, DOI 10.1021/ja00719a006; HEHRE WJ, 1975, J AM CHEM SOC, V97, P6941, DOI 10.1021/ja00857a002; HESS BA, 1983, J AM CHEM SOC, V105, P7500, DOI 10.1021/ja00364a600; HESS BA, 1987, J AM CHEM SOC, V109, P1615, DOI 10.1021/ja00240a002; HORNER M, 1977, ANGEW CHEM INT EDIT, V16, P410, DOI 10.1002/anie.197704101; HOU SY, 1979, CHEM PHYS LETT, V68, P282, DOI 10.1016/0009-2614(79)87201-2; Hrouda V, 1997, J PHYS CHEM A, V101, P3925, DOI 10.1021/jp964079z; Huckel E, 1931, Z PHYS, V70, P204, DOI 10.1007/BF01339530; HUNG RR, 1992, J AM CHEM SOC, V114, P351, DOI 10.1021/ja00027a050; Kistiakowsky GB, 1936, J AM CHEM SOC, V58, P146, DOI 10.1021/ja01292a043; Klarner F.-G., 1997, CHEM DIENES POLYENES, P547; KLARNER FG, 1982, ANGEW CHEM INT EDIT, V21, P139, DOI 10.1002/anie.198201391; KOLLMAR H, 1980, J AM CHEM SOC, V102, P2617, DOI 10.1021/ja00528a016; KOLLMAR H, 1981, J AM CHEM SOC, V103, P5292, DOI 10.1021/ja00408a004; LENOBLE WJ, 1980, ANGEW CHEM INT EDIT, V19, P841, DOI 10.1002/anie.198008413; Li ZR, 1999, J PHYS CHEM A, V103, P426, DOI 10.1021/jp982997m; LII JH, 1989, J AM CHEM SOC, V111, P8566, DOI 10.1021/ja00205a002; MAIER G, 1988, ANGEW CHEM INT EDIT, V27, P309, DOI 10.1002/anie.198803093; MAIER G, 1974, ANGEW CHEM INT EDIT, V13, P425, DOI 10.1002/anie.197404251; MARTIN HD, 1974, CHIMIA, V28, P12; MARTIN HD, 1973, SYNTHESIS-STUTTGART, P667; MASAMUNE S, 1972, J CHEM SOC CHEM COMM, P1268, DOI 10.1039/c39720001268; Minkin V. J., 1994, AROMATICITY ANTIAROM; MORAIS J, 1991, J PHYS CHEM-US, V95, P3885, DOI 10.1021/j100163a001; MUROV SL, 1993, HDB PHOTOCHEMISTRY, P299; MURRAY JS, 1994, INT J QUANTUM CHEM, V49, P575, DOI 10.1002/qua.560490503; Pan JW, 1999, J MOL STRUC-THEOCHEM, V468, P59, DOI 10.1016/S0166-1280(98)00496-5; Pedley J.B., 1986, THERMOCHEMICAL DATA, V2; PETERS KS, 1994, ANGEW CHEM INT EDIT, V33, P294, DOI 10.1002/anie.199402941; PETERS KS, 1990, KINETICS SPECTROSCOP, P37; PETTIT R, 1988, ORG SYNTH, V50-9, P422; PETTIT R, 1988, ORG SYNTH, V50-9, P310; POLITZER P, 1993, CAN J CHEM, V71, P1123, DOI 10.1139/v93-148; Rogers DW, 1996, J PHYS CHEM-US, V100, P17148, DOI 10.1021/jp961122+; Rogers DW, 1998, J PHYS CHEM A, V102, P1209, DOI 10.1021/jp9731720; Rogers DW, 1997, J PHYS CHEM A, V101, P4776, DOI 10.1021/jp970252v; Rogers DW, 1998, J ORG CHEM, V63, P7319, DOI 10.1021/jo980820i; ROSENSTOCK HM, 1982, RADIAT PHYS CHEM, V20, P7, DOI 10.1016/0146-5724(82)90056-5; RUDZKI JE, 1985, J AM CHEM SOC, V107, P7849, DOI 10.1021/ja00312a007; SCHAAD LJ, 1974, J CHEM EDUC, V51, P640, DOI 10.1021/ed051p640; SCHWEIG A, 1979, J AM CHEM SOC, V101, P4742, DOI 10.1021/ja00510a058; Shaik S, 1997, J MOL STRUC-THEOCHEM, V398, P155, DOI 10.1016/S0166-1280(96)04934-2; STALEY SW, 1989, J AM CHEM SOC, V111, P445, DOI 10.1021/ja00184a006; STEWART JJP, 1989, J COMPUT CHEM, V10, P209, DOI 10.1002/jcc.540100208; TURNER RB, 1968, J AM CHEM SOC, V90, P4315, DOI 10.1021/ja01018a022; VANELDIK R, 1989, CHEM REV, V89, P549, DOI 10.1021/cr00093a005; WAYNE GS, 1993, J AM CHEM SOC, V115, P9860, DOI 10.1021/ja00074a087	86	70	70	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1119	1122		10.1126/science.286.5442.1119	http://dx.doi.org/10.1126/science.286.5442.1119			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550042				2022-12-28	WOS:000083534200032
J	Grammatopoulos, DK; Hillhouse, EW				Grammatopoulos, DK; Hillhouse, EW			Role of corticotropin-releasing hormone in onset of labour	LANCET			English	Article							HUMAN-FETAL MEMBRANES; HUMAN MYOMETRIUM; BINDING PROTEIN; LOCAL STIMULATION; HUMAN PARTURITION; HUMAN-PREGNANCY; FACTOR CRF; RECEPTOR; PROGESTERONE; EXPRESSION	Corticotropin-releasing hormone (CRH) derived from the placenta is secreted into the maternal circulation in Targe amounts during the third trimester of human pregnancy and may have an important role in the onset of labour. Although the biological role of CRH remains enigmatic, the presence of functional CRH receptors in the myometrium suggests that CRH may modulate myometrial contractility and hence parturition. CRH action is mediated via multiple receptor subtypes and pregnancy results in differential receptor expression. These receptors are primarily linked to the adenylate cyclase second messenger system, which would help the Intracellular microenvironment to maintain the required myometrial quiescence. CRH can exert further actions such as inhibition of prostaglandin production to prevent contractions. At term under the influence of oxytocin there is a modification in the coupling mechanisms that leads to a decrease in the biological activity of the CRH receptor and in the generation of cyclic adenosine monophosphate which favours myometrial contractions. CRH, via distinct receptor subtypes, is then able to enhance the contractile response of the myometrium. This hypothesis places CRH in a central role in coordinating the smooth transition from a state of relaxation to one of contraction.	Univ Warwick, Dept Biol Sci, Sir Quinton Hazell Mol Med Res Ctr, Coventry CV4 7AL, W Midlands, England	University of Warwick	Grammatopoulos, DK (corresponding author), Univ Warwick, Dept Biol Sci, Sir Quinton Hazell Mol Med Res Ctr, Coventry CV4 7AL, W Midlands, England.			grammatopoulos, dimitris/0000-0002-6296-8290	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEHAN DP, 1989, J ENDOCRINOL, V122, P23, DOI 10.1677/joe.0.1220023; BENEDETTO C, 1994, AM J OBSTET GYNECOL, V171, P126, DOI 10.1016/0002-9378(94)90457-X; CAMBELL EA, 1987, J CLIN ENDOCR METAB, V64, P1054; Clifton VL, 1998, J CLIN ENDOCR METAB, V83, P3716, DOI 10.1210/jc.83.10.3716; CLIFTON VL, 1994, J CLIN ENDOCR METAB, V79, P666, DOI 10.1210/jc.79.2.666; EUROPEFINNER GN, 1994, J CLIN ENDOCR METAB, V79, P1835, DOI 10.1210/jc.79.6.1835; FUCHS AR, 1982, SCIENCE, V215, P1396, DOI 10.1126/science.6278592; GOLAND RS, 1993, J CLIN ENDOCR METAB, V77, P1174, DOI 10.1210/jc.77.5.1174; GOLAND RS, 1995, PLACENTA, V16, P375, DOI 10.1016/0143-4004(95)90095-0; GRAMMATOPOULOS D, 1995, J CLIN ENDOCR METAB, V80, P2388, DOI 10.1210/jc.80.8.2388; Grammatopoulos D, 1998, J CLIN ENDOCR METAB, V83, P2539, DOI 10.1210/jc.83.7.2539; Grammatopoulos D, 1996, J CLIN ENDOCR METAB, V81, P745, DOI 10.1210/jc.81.2.745; GRAMMATOPOULOS D, 1994, MOL CELL ENDOCRINOL, V99, P245, DOI 10.1016/0303-7207(94)90014-0; Grammatopoulos DK, 1999, J CLIN ENDOCR METAB, V84, P2204, DOI 10.1210/jc.84.6.2204; Grammatopoulos DK, 1999, ENDOCRINOLOGY, V140, P585, DOI 10.1210/en.140.2.585; HILLHOUSE EW, 1993, J CLIN ENDOCR METAB, V76, P736, DOI 10.1210/jc.76.3.736; JONES SA, 1989, BIOCHEM BIOPH RES CO, V159, P192, DOI 10.1016/0006-291X(89)92422-4; Karalis K, 1996, NAT MED, V2, P556, DOI 10.1038/nm0596-556; LINTON EA, 1990, J CLIN ENDOCR METAB, V70, P1574, DOI 10.1210/jcem-70-6-1574; LINTON EA, 1993, J CLIN ENDOCR METAB, V76, P260, DOI 10.1210/jc.76.1.260; MCLEAN M, 1995, NAT MED, V1, P460, DOI 10.1038/nm0595-460; MITCHELL BF, 1993, AM J OBSTET GYNECOL, V168, P1377, DOI 10.1016/S0002-9378(11)90768-6; PETRAGLIA F, 1987, NATURE, V328, P717, DOI 10.1038/328717a0; Petraglia F, 1996, J CLIN ENDOCR METAB, V81, P852, DOI 10.1210/jc.81.2.852; PETROCELLI T, 1993, ENDOCRINOLOGY, V133, P284, DOI 10.1210/en.133.1.284; QUARTERO HWP, 1989, PLACENTA, V10, P439, DOI 10.1016/0143-4004(89)90054-4; Rezapour M, 1996, STEROIDS, V61, P338, DOI 10.1016/0039-128X(96)00035-9; Rodriguez-Linares B, 1998, J ENDOCRINOL, V156, P15, DOI 10.1677/joe.0.1560015; Stevens MY, 1998, J CLIN ENDOCR METAB, V83, P4107, DOI 10.1210/jc.83.11.4107; Wallace EM, 1999, LANCET, V353, P1404, DOI 10.1016/S0140-6736(98)08229-4; WOLFE CDA, 1988, BRIT J OBSTET GYNAEC, V95, P1003, DOI 10.1111/j.1471-0528.1988.tb06504.x; ZUO J, 1994, J CLIN ENDOCR METAB, V79, P894, DOI 10.1210/jc.79.3.894	32	127	131	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1546	1549		10.1016/S0140-6736(99)03418-2	http://dx.doi.org/10.1016/S0140-6736(99)03418-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551516				2022-12-28	WOS:000083411300042
J	Kite, P; Dobbins, BM; Wilcox, MH; McMahon, MJ				Kite, P; Dobbins, BM; Wilcox, MH; McMahon, MJ			Rapid diagnosis of central-venous-catheter-related bloodstream infection without catheter removal	LANCET			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; BLOOD-STREAM INFECTION; ENDOLUMINAL BRUSH; IN-SITU; SEPSIS; CULTURES; PREVENTION; BACTEREMIA; TRIAL	Background Current methods for the diagnosis of bloodstream infection related to central venous catheters (CVC) are slow and in many cases require catheter removal. Since most CVC that are removed on suspicion of causing infection prove not to be infected, removal of catheters unnecessarily exposes patients to the risks associated with reinsertion. Methods The gram slain and acridine-orange leucocyte cytospin test (AOLC) is rapid (30 min), inexpensive, and requires only 100 mu L catheter blood (treated with edetic acid) and the use of light and ultraviolet microscopy. We assessed the gram stain and AOLC lest in suspected cases of catheter-related bloodstream infection, in comparison with two methods requiring catheter removal (tip roll and tip flush), and a third technique, done in situ (endoluminal brush) in conjunction with quantitative peripheral-blood cultures. Findings 128 cases of suspected catheter-related bloodstream infection were assessed in 124 adult surgical patients (median duration of CVC placement was 16 days). In 112 (88%) cases CVC blood was obtainable. Catheter-related bloodstream infection was diagnosed in 50 cases (culture of the same organism from the catheter, in significant numbers, and from peripheral-blood culture). The sensitivity of the gram stain and AOLC test was 96% and the specificity was 92%, with a positive predictive value of 91% and a negative predictive value of 97%. By comparison, the tip-roll, tip-flush, and endoluminal-brush methods had sensitivities of 90%, 95%, and 92%, and specificities of 55%, 76%, and 98%, respectively. Interpretation The gram stain and AOLC test is a simple, and rapid method for the diagnosis of catheter-related bloodstream infection. This diagnostic method compares favourably with other diagnostic methods, particularly those that require the removal of the catheter, and can permit early targeted antimicrobial therapy.	Univ Leeds, Gen Infirm, Dept Microbiol, Leeds LS1 3EX, W Yorkshire, England; Gen Infirm, Acad Surg Unit, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary; University of Leeds; Leeds General Infirmary	Wilcox, MH (corresponding author), Univ Leeds, Dept Microbiol, Leeds LS2 9JT, W Yorkshire, England.	markwi@pathology.leeds.ac.uk						BANERJEE SN, 1991, AM J MED, V91, pS87; Blot F, 1998, J CLIN MICROBIOL, V36, P105, DOI 10.1128/JCM.36.1.105-109.1998; BRUNBUISSON C, 1987, ARCH INTERN MED, V147, P873, DOI 10.1001/archinte.147.5.873; CAPDEVILA JA, 1992, EUR J CLIN MICROBIOL, V11, P403, DOI 10.1007/BF01961854; CLERI DJ, 1980, J INFECT DIS, V141, P781, DOI 10.1093/infdis/141.6.781; Darouiche RO, 1999, NEW ENGL J MED, V340, P1, DOI 10.1056/NEJM199901073400101; Dobbins BM, 1999, J CLIN PATHOL, V52, P165, DOI 10.1136/jcp.52.3.165; Kite P, 1997, J CLIN PATHOL, V50, P278, DOI 10.1136/jcp.50.4.278; Maki Dennis G., 1994, P155; MAKI DG, 1988, AM J MED, V85, P307, DOI 10.1016/0002-9343(88)90579-7; Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; Michel M, 1997, LANCET, V349, P1901, DOI 10.1016/S0140-6736(96)11192-2; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Raad I, 1998, LANCET, V351, P893, DOI 10.1016/S0140-6736(97)10006-X; RADD I, 1993, J INFECT DIS, V168, P400, DOI 10.1093/infdis/168.2.400; RUSHFORTH JA, 1993, LANCET, V342, P402, DOI 10.1016/0140-6736(93)92815-B; RYAN JA, 1974, NEW ENGL J MED, V290, P757, DOI 10.1056/NEJM197404042901401; SCHWARTZ C, 1990, J CLIN ONCOL, V8, P1591, DOI 10.1200/JCO.1990.8.9.1591; Segura M, 1996, ANN SURG, V223, P363, DOI 10.1097/00000658-199604000-00004; Sherertz RJ, 1997, J CLIN MICROBIOL, V35, P641, DOI 10.1128/JCM.35.3.641-646.1997; SITGESSERRA A, 1988, J CLIN MICROBIOL, V26, P1074, DOI 10.1128/JCM.26.5.1074-1076.1988; Tabaqchali S, 1997, LANCET, V350, P1644, DOI 10.1016/S0140-6736(05)64269-9; Tighe MJ, 1996, BRIT MED J, V313, P1528, DOI 10.1136/bmj.313.7071.1528; Weinstein MP, 1997, CLIN INFECT DIS, V24, P584, DOI 10.1093/clind/24.4.584; WIDMER AF, 1993, PREVENTION CONTROL N, P556; YAGUPSKY P, 1990, CLIN MICROBIOL REV, V3, P269, DOI 10.1128/CMR.3.3.269-279.1990	27	104	110	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	1999	354	9189					1504	1507		10.1016/S0140-6736(99)04070-2	http://dx.doi.org/10.1016/S0140-6736(99)04070-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551496				2022-12-28	WOS:000083411300010
J	Heymsfield, SB; Greenberg, AS; Fujioka, K; Dixon, RM; Kushner, R; Hunt, T; Lubina, JA; Patane, J; Self, B; Hunt, P; McCamish, M				Heymsfield, SB; Greenberg, AS; Fujioka, K; Dixon, RM; Kushner, R; Hunt, T; Lubina, JA; Patane, J; Self, B; Hunt, P; McCamish, M			Recombinant leptin for weight loss in obese and lean adults - A randomized, controlled, dose-escalation trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CEREBROSPINAL-FLUID LEPTIN; BODY-WEIGHT; MESSENGER-RNA; FOOD-INTAKE; OB PROTEIN; GENE; HUMANS; RESISTANCE; ADIPOSITY; TISSUE	Context The protein hormone leptin is important to the homeostatic regulation of body weight. Treatment with exogenous leptin may affect weight loss, Objective To determine the relationship between increasing doses of exogenous leptin administration and weight loss in both lean and obese adults. Design A randomized, double-blind, placebo-controlled, multicenter, escalating dose cohort trial conducted from April 1997 to October 1998. Setting Four university nutrition and obesity clinics and 2 contract clinical research clinics. Participants Fifty-four lean (body mass index, 20.0-27.5 kg/m(2); mean [SD] body weight, 72.0 [9.7] kg) and 73 obese (body mass index, 27.6-36.0 kg/m(2); mean [SD] body weight, 89.8 [11.4] kg) predominantly white (80%) men (n = 67) and women (n = 60) with mean (SD) age of 39 (10.3) years. Interventions Recombinant methionyl human leptin self-administered by daily morning subcutaneous injection (0 [placebo], 0.01, 0,03, 0.10, or 0.30 mg/kg). In part A, lean and obese subjects were treated for 4 weeks; in part B, obese subjects were treated for an additional 20 weeks. Lean subjects consumed a eucaloric diet to maintain body weight at the current value, and obese subjects were prescribed a diet that reduced their daily energy intake by 2100 kJ/d (500-kcal/d) from the amount needed to maintain a stable weight. Main Outcome Measures Body weight, body fat, and incidence of adverse events. Results Weight loss from baseline increased with increasing dose of leptin among all subjects at 4 weeks (P = .02) and among obese subjects at 24 weeks (P = .01) of treatment. Mean (SD) weight changes at 4 weeks ranged from -0.4 (2.0) kg for placebo (n = 36) to -1.9 kg (1.6) kg for the 0.1 mg/kg dose (n = 29). Mean (SD) weight changes at 24 weeks ranged from -0.7 (5.4) kg for the 0.01 mg/kg dose (n = 6) to -7.1 (8.5) kg for the 0.30 mg/kg dose (n = 8). Fat mass declined from baseline as dose increased among all subjects at 4 weeks (P = .002) and among obese subjects at 24 weeks of treatment (P = .004); more than 95% of weight loss was fat loss in the 2 highest dose cohorts at 24 weeks, Baseline serum leptin concentrations were not related to weight loss at week 4 (P = .88) or at week 24 (P = .76). No clinically significant adverse effects were observed on major organ systems. Mild-to-moderate reactions at the injection site were the most commonly reported adverse effects. Conclusions A dose-response relationship with weight and fat loss was observed with subcutaneous recombinant leptin injections in both lean and obese subjects, Based on this study, administration of exogenous leptin appears to induce weight loss in some obese subjects with elevated endogenous serum leptin concentrations. Additional research into the potential role for leptin and related hormones in the treatment of human obesity is warranted.	St Lukes Roosevelt Hosp, Weight Control Unit, New York, NY 10025 USA; Tufts Univ, New England Med Ctr, USDA, Human Nutr Res Ctr, Boston, MA 02111 USA; Scripps Clin, San Diego, CA USA; Covance Inc, Madison, WI USA; Univ Wisconsin, Madison, WI USA; Northwestern Univ, Chicago, IL USA; PPD Pharmaco Inc, Austin, TX USA; Amgen Inc, Dept Biostat, Thousand Oaks, CA USA; Amgen Inc, Dept Clin Affairs, Thousand Oaks, CA USA; Amgen Inc, Dept Int Clin Safety, Thousand Oaks, CA USA; Amgen Inc, Dept Prod Dev, Thousand Oaks, CA USA; Amgen Inc, Dept Clin Res, Thousand Oaks, CA USA	Mount Sinai St. Luke's; Mount Sinai West; Tufts Medical Center; Tufts University; United States Department of Agriculture (USDA); Scripps Research Institute; Covance; University of Wisconsin System; University of Wisconsin Madison; Northwestern University; Amgen; Amgen; Amgen; Amgen; Amgen	Heymsfield, SB (corresponding author), St Lukes Roosevelt Hosp, Weight Control Unit, 1090 Amsterdam Ave, New York, NY 10025 USA.		Heymsfield, Steven B/N-1968-2017	Heymsfield, Steven B/0000-0003-1127-9425	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000054] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00054] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ahren B, 1997, ENDOCRINE, V7, P1, DOI 10.1007/BF02778056; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Considine RV, 1997, INT J BIOCHEM CELL B, V29, P1255, DOI 10.1016/S1357-2725(97)00050-2; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Fujioka K, 1999, JAMA-J AM MED ASSOC, V282, P1517, DOI 10.1001/jama.282.16.1517; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; LAU D, 1998, 8 INT C OB AUG 29 SE; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mallard S. P., 1997, Pharmaceutical Research (New York), V14, pS78; Mantzoros C, 1997, J CLIN ENDOCR METAB, V82, P1845, DOI 10.1210/jc.82.6.1845; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pelleymounter MA, 1998, AM J PHYSIOL-REG I, V275, pR950, DOI 10.1152/ajpregu.1998.275.4.R950; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Seeley RJ, 1996, HORM METAB RES, V28, P664, DOI 10.1055/s-2007-979874; Shi ZQ, 1998, METABOLISM, V47, P1274, DOI 10.1016/S0026-0495(98)90336-5; Taylor SI, 1996, SCIENCE, V274, P1151, DOI 10.1126/science.274.5290.1151; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; [No title captured]	29	1002	1039	3	40	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1568	1575		10.1001/jama.282.16.1568	http://dx.doi.org/10.1001/jama.282.16.1568			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546697				2022-12-28	WOS:000083277800025
J	Bengtsson, BA				Bengtsson, BA			Rethink about growth-hormone therapy for critically ill patients	LANCET			English	Editorial Material							PROLONGED CRITICAL ILLNESS; ADULTS; GH		Sahlgrenska Univ Hosp, Res Ctr Endocrinol & Metab, SE-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Bengtsson, BA (corresponding author), Sahlgrenska Univ Hosp, Res Ctr Endocrinol & Metab, SE-41345 Gothenburg, Sweden.							BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Johannsson G, 1997, CLIN ENDOCRINOL, V47, P571, DOI 10.1046/j.1365-2265.1997.3271123.x; ROSS R, 1991, CLIN ENDOCRINOL, V35, P47, DOI 10.1111/j.1365-2265.1991.tb03495.x; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P1827, DOI 10.1210/jc.83.6.1827; Van den Berghe G, 1999, J CLIN ENDOCR METAB, V84, P1311, DOI 10.1210/jc.84.4.1311; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P309, DOI 10.1210/jc.83.2.309	7	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1403	1404		10.1016/S0140-6736(99)00330-X	http://dx.doi.org/10.1016/S0140-6736(99)00330-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543662				2022-12-28	WOS:000083277400005
J	Edman, K; Nollert, P; Royant, A; Belrhali, H; Pebay-Peyroula, E; Hajdu, J; Neutze, R; Landau, EM				Edman, K; Nollert, P; Royant, A; Belrhali, H; Pebay-Peyroula, E; Hajdu, J; Neutze, R; Landau, EM			High-resolution X-ray structure of an early intermediate in the bacteriorhodopsin photocycle	NATURE			English	Article							LIPIDIC CUBIC PHASES; ANGSTROM RESOLUTION; MEMBRANE-PROTEINS; PURPLE MEMBRANE; DIFFRACTION; CRYSTALLOGRAPHY; CRYSTALLIZATION; MODEL	Bacteriorhodopsin is the simplest known photon-driven proton pump(1) and as such provides a model for the study of a basic function in bioenergetics. Its seven transmembrane helices' encompass a proton translocation pathway containing the chromophore, a retinal molecule covalently bound to lysine 216 through a protonated Schiff base, and a series of proton donors and accepters. Photoisomerization of the all-trans retinal to the) 13-cis configuration initiates the vectorial translocation of a proton from the Schiff base, the primary proton donor, to the extracellular side, followed by reprotonation of the Schiff base from the cytoplasm. Here we describe the high-resolution X-ray structure of an early intermediate in the photocycle of bacteriorhodopsin, which is formed directly after photoexcitation. A key water molecule is dislocated, allowing the primary proton acceptor, Asp 85, to move. Movement of the main-chain Lys 216 locally disrupts the hydrogen-bonding network of helix G, facilitating structural changes later in the photocycle.	Univ Basel, Biozentrum, Dept Mol Microbiol, CH-4056 Basel, Switzerland; Uppsala Univ, Ctr Biomed, Dept Biochem, S-75123 Uppsala, Sweden; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Grenoble 1, CNRS, CEA, Inst Biol Struct, F-38027 Grenoble 2, France	University of Basel; Uppsala University; European Synchrotron Radiation Facility (ESRF); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Landau, EM (corresponding author), Univ Basel, Biozentrum, Dept Mol Microbiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.	neutze@xray.bmc.uu.se; landau@ubaclu.unibas.ch	Neutze, Richard/A-7573-2010; Royant, Antoine/G-3684-2012	Neutze, Richard/0000-0003-0986-6153; Royant, Antoine/0000-0002-1919-8649				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; BRAIMAN M, 1982, P NATL ACAD SCI-BIOL, V79, P403, DOI 10.1073/pnas.79.2.403; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulllough PA, 1999, J MOL BIOL, V286, P1663, DOI 10.1006/jmbi.1999.2570; DENCHER NA, 1989, P NATL ACAD SCI USA, V86, P7876, DOI 10.1073/pnas.86.20.7876; DOIG SJ, 1991, J PHYS CHEM-US, V95, P6372, DOI 10.1021/j100169a054; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GAT Y, 1993, J AM CHEM SOC, V115, P3772, DOI 10.1021/ja00062a052; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKASATO K, 1991, FEBS LETT, V292, P75; Nollert P, 1998, BIOCHEM SOC T, V26, P709, DOI 10.1042/bst0260709; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; Rummel G, 1998, J STRUCT BIOL, V121, P82, DOI 10.1006/jsbi.1997.3952; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SONG IK, 1991, KOREAN J CHEM ENG, V8, P33, DOI 10.1007/BF02697695; SUBRAMANIAM S, 1993, EMBO J, V12, P1; TAKEI H, 1994, J BIOL CHEM, V269, P7387; Ursby T, 1997, ACTA CRYSTALLOGR A, V53, P564, DOI 10.1107/S0108767397004522; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Vonck J, 1996, BIOCHEMISTRY-US, V35, P5870, DOI 10.1021/bi952663c; XIE A, 1990, BIOPHYS J, V58, P1127, DOI 10.1016/S0006-3495(90)82455-3; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	32	292	301	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					822	826		10.1038/44623	http://dx.doi.org/10.1038/44623			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548112				2022-12-28	WOS:000083368700061
J	Cirasino, L; Barbano, PR				Cirasino, L; Barbano, PR			Gangrene and type I cryoglobulinemia in multiple myeloma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Niguarda Ca Granada Hosp, I-20162 Milan, Italy		Cirasino, L (corresponding author), Niguarda Ca Granada Hosp, I-20162 Milan, Italy.								0	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1999	341	21					1582	1582		10.1056/NEJM199911183412105	http://dx.doi.org/10.1056/NEJM199911183412105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	256GF	10564688				2022-12-28	WOS:000083717000005
J	Jeon, M; Gardner, HF; Miller, EA; Deshler, J; Rougvie, AE				Jeon, M; Gardner, HF; Miller, EA; Deshler, J; Rougvie, AE			Similarity of the C-elegans developmental timing protein LIN-42 to circadian rhythm proteins	SCIENCE			English	Article							MINDED GENE ENCODES; CAENORHABDITIS-ELEGANS; SECONDARY STRUCTURE; NUCLEAR-PROTEIN; TIMELESS; PERIOD; CLOCK; TRANSCRIPTION; LOOP; EXPRESSION	The Caenorhabditis elegans heterochronic genes control the relative timing and sequence of many events during postembryonic development, including the terminal differentiation of the Lateral hypodermis, which occurs during the final (fourth) molt. Inactivation of the heterochronic gene lin-42 causes hypodermal terminal differentiation to occur precociously, during the third molt. LIN-42 most closely resembles the Period family of proteins from Drosophila and other organisms, proteins that function in another type of biological timing mechanism: the timing of circadian rhythms. Per mRNA Levels oscillate with an approximately 24-hour periodicity. lin-42 mRNA Levels also oscillate, but with a faster rhythm; the oscillation occurs relative to the approximately 6-hour molting cycles of postembryonic development.	Univ Minnesota, Dept Genet Cell Biol & Dev, St Paul, MN 55108 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Rougvie, AE (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, St Paul, MN 55108 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050227] Funding Source: NIH RePORTER; NICHD NIH HHS [HD007480] Funding Source: Medline; NIGMS NIH HHS [GM50227] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahante JE, 1998, GENETICS, V149, P1335; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; AMBROS V, 1997, C ELEGANS, V2, P501; Bettinger JC, 1996, DEVELOPMENT, V122, P2517; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; EVANS MMS, 1994, DEVELOPMENT, V120, P1971; FIRE A, COMMUNICATION; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; IWASAKI K, 1995, P NATL ACAD SCI USA, V92, P10317, DOI 10.1073/pnas.92.22.10317; JEON M, UNPUB; Johnstone IL, 1996, EMBO J, V15, P3633, DOI 10.1002/j.1460-2075.1996.tb00732.x; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Larminie CGC, 1996, DNA CELL BIOL, V15, P75, DOI 10.1089/dna.1996.15.75; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; LIU Z, 1990, THESIS HARVARD U; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; POETHIG RS, 1988, GENETICS, V119, P959; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; Telfer A, 1998, DEVELOPMENT, V125, P1889; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	33	137	144	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1141	1146		10.1126/science.286.5442.1141	http://dx.doi.org/10.1126/science.286.5442.1141			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550049				2022-12-28	WOS:000083534200039
J	Nordmann, A; Frach, B; Walker, T; Martina, B; Battegay, E				Nordmann, A; Frach, B; Walker, T; Martina, B; Battegay, E			Reliability of patients measuring blood pressure at home: prospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Basel Hosp, Dept Internal Med, Med Outpatient Div, CH-4031 Basel, Switzerland	University of Basel	Battegay, E (corresponding author), Univ Basel Hosp, Dept Internal Med, Med Outpatient Div, CH-4031 Basel, Switzerland.	battegay@ubaclu.unibas.ch						[Anonymous], 1997, ARCH INTERN MED, V157, P2413; AUDET AM, 1993, ANN INTERN MED, V118, P889, DOI 10.7326/0003-4819-118-11-199306010-00010; CAMPBELL NRC, 1995, CAN J CARDIOL SH, P18; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; Ohkubo T, 1998, J HYPERTENS, V16, P971, DOI 10.1097/00004872-199816070-00010	5	53	55	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	1999	319	7218					1172	1172		10.1136/bmj.319.7218.1172	http://dx.doi.org/10.1136/bmj.319.7218.1172			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541509	Bronze, Green Published			2022-12-28	WOS:000083536200024
J	Southgate, L; Pringle, M				Southgate, L; Pringle, M			Revalidation - Revalidation in the United Kingdom: general principles based on experience in general practice	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN PERFORMANCE		UCL Royal Free & Univ Coll, Sch Med, Ctr Hlth Informat & Med Educ, London N19 5NF, England; Royal Coll Gen Practitioners, London SW7 1PU, England	University of London; University College London; UCL Medical School	Southgate, L (corresponding author), UCL Royal Free & Univ Coll, Sch Med, Ctr Hlth Informat & Med Educ, Whittington Hosp Campus, London N19 5NF, England.	l.southgate@chime.ucl.ac.uk						BAKER R, 1990, BRIT J GEN PRACT, V40, P487; *BRIT MED ASS, 1998, MAK SELF REG WORK LO; Davis David A., 1995, JAMA (Journal of the American Medical Association), V274, P700, DOI 10.1001/jama.274.9.700; *DEP HLTH, 1998, REV CONT PROF DEV PR; *GEN MED COUNC, 1998, GOOD MED PRACT; Howie JGR, 1999, BMJ-BRIT MED J, V319, P738, DOI 10.1136/bmj.319.7212.738; McColl A, 1998, BMJ-BRIT MED J, V317, P1354, DOI 10.1136/bmj.317.7169.1354; NEWBLE D, 1994, CERTIFICATION RECERT; *NHS, 1998, NEW NHS MOD DEP NAT; PAGET NS, 1996, J CONTINUING ED HLTH, V16, P103; RAMSEY PG, 1993, JAMA-J AM MED ASSOC, V269, P1655, DOI 10.1001/jama.269.13.1655; Rhodes JM, 1999, J ROY COLL PHYS LOND, V33, P341; *ROYAL COLL GEN PR, 1999, GOOD MED PRACT GEN P; SOUTHGATE L, 1994, CERTIFICATION RECERT; Tanenbaum SJ, 1999, ACAD MED, V74, P757, DOI 10.1097/00001888-199907000-00008	15	41	42	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	1999	319	7218					1180	1183		10.1136/bmj.319.7218.1180	http://dx.doi.org/10.1136/bmj.319.7218.1180			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541513	Green Published			2022-12-28	WOS:000083536200028
J	Hamilton, AJ; Baulcombe, DC				Hamilton, AJ; Baulcombe, DC			A species of small antisense RNA in posttranscriptional gene silencing in plants	SCIENCE			English	Article							DOUBLE-STRANDED-RNA; TRANSGENIC PLANTS; VIRUS-RESISTANCE; EXPRESSION; INACTIVATION; SUPPRESSION; HOMOLOGY; SEQUENCE; DEGRADATION; DNA	Posttranscriptional gene silencing (PTGS) is a nucleotide sequence-specific defense mechanism that can target both cellular and viral mRNAs. Here, three types of transgene-induced PTGS and one example of virus-induced PTGS were analyzed in plants, In each case, antisense RNA complementary to the targeted mRNA was detected. These RNA molecules were of a uniform Length, estimated at 25 nucleotides, and their accumulation required either transgene sense transcription or RNA virus replication. Thus, the 25-nucleotide antisense RNA is Likely synthesized from an RNA template and may represent the specificity determinant of PTGS.	John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Baulcombe, DC (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Colney Lane, Norwich NR4 7UH, Norfolk, England.			Baulcombe, David/0000-0003-0780-6878				Anandalakshmi R, 1998, P NATL ACAD SCI USA, V95, P13079, DOI 10.1073/pnas.95.22.13079; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; Beclin C, 1998, VIROLOGY, V252, P313, DOI 10.1006/viro.1998.9457; Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739; Cogoni C, 1997, TRENDS PLANT SCI, V2, P438, DOI 10.1016/S1360-1385(97)90028-5; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; DOUGHERTY WG, 1995, CURR OPIN CELL BIOL, V7, P399, DOI 10.1016/0955-0674(95)80096-4; Elmayan T, 1996, PLANT J, V9, P787, DOI 10.1046/j.1365-313X.1996.9060787.x; English JJ, 1997, PLANT J, V12, P597, DOI 10.1046/j.1365-313X.1997.00597.x; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FLAVELL RB, 1994, P NATL ACAD SCI USA, V91, P3490, DOI 10.1073/pnas.91.9.3490; GRIERSON D, 1991, TRENDS BIOTECHNOL, V9, P122, DOI 10.1016/0167-7799(91)90042-G; HOBBS SLA, 1993, PLANT MOL BIOL, V21, P17, DOI 10.1007/BF00039614; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; MUELLER E, 1995, PLANT J, V7, P1001, DOI 10.1046/j.1365-313X.1995.07061001.x; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Palauqui JC, 1999, CURR BIOL, V9, P59, DOI 10.1016/S0960-9822(99)80016-5; Pruss G, 1997, PLANT CELL, V9, P859, DOI 10.1105/tpc.9.6.859; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; VAUCHERET H, 1993, CR ACAD SCI III-VIE, V316, P1471; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3	26	2085	2515	8	322	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					950	952		10.1126/science.286.5441.950	http://dx.doi.org/10.1126/science.286.5441.950			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542148				2022-12-28	WOS:000083368500043
J	de Groen, PC; Gores, GJ; LaRusso, NF; Gunderson, LL; Nagorney, DM				de Groen, PC; Gores, GJ; LaRusso, NF; Gunderson, LL; Nagorney, DM			Medical progress - Biliary tract cancers	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PRIMARY SCLEROSING CHOLANGITIS; BILE-DUCT CARCINOMA; FAMILIAL ADENOMATOUS POLYPOSIS; POSITRON-EMISSION-TOMOGRAPHY; HILAR CHOLANGIOCARCINOMA; GALLBLADDER-CANCER; INTRAHEPATIC CHOLANGIOCARCINOMA; CARCINOEMBRYONIC ANTIGEN; LIVER-TRANSPLANTATION; PERIAMPULLARY TUMORS		Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic	de Groen, PC (corresponding author), Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.							ADSON MA, 1973, SURG CLIN N AM, V53, P1203; Albores-Saavedra J., 1991, HISTOLOGICAL TYPING; ALDEN ME, 1994, INT J RADIAT ONCOL, V28, P945, DOI 10.1016/0360-3016(94)90115-5; [Anonymous], 1997, AJCC CANC STAGING MA; Bach AM, 1998, J ULTRAS MED, V17, P303; Bartlett D, 1996, BRIT J SURG, V83, P1076, DOI 10.1002/bjs.1800830812; Bergquist A, 1998, HEPATOLOGY, V27, P311, DOI 10.1002/hep.510270201; BHARGAVA AK, 1989, J CLIN LAB ANAL, V3, P370, DOI 10.1002/jcla.1860030610; BISMUTH H, 1992, ANN SURG, V215, P31, DOI 10.1097/00000658-199201000-00005; Bowling TE, 1996, GUT, V39, P852, DOI 10.1136/gut.39.6.852; Broome U, 1996, GUT, V38, P610, DOI 10.1136/gut.38.4.610; BRUCKNER HW, 1993, ACTA ONCOL, V32, P627, DOI 10.3109/02841869309092442; CALDAS C, 1994, CANCER RES, V54, P3568; CALLEA F, 1993, J SURG ONCOL, P131; CHIJIIWA K, 1995, INT SURG, V80, P61; CHIJIWA K, 1994, INT SURG, V79, P106; CHOW WH, 1994, CANCER CAUSE CONTROL, V5, P267, DOI 10.1007/BF01830247; CRAIG JR, 1986, ATLAS TUMOR PATHOLOG; CSENDES A, 1994, EUR J SURG, V160, P363; de Groen PC, 1998, ANN INTERN MED, V129, P107, DOI 10.7326/0003-4819-129-2-199807150-00009; Delbeke D, 1998, ARCH SURG-CHICAGO, V133, P510, DOI 10.1001/archsurg.133.5.510; DESA LA, 1991, GUT, V32, P1188, DOI 10.1136/gut.32.10.1188; DONOHUE JH, 1990, ARCH SURG-CHICAGO, V125, P237; DOOLEY WC, 1990, ANN SURG, V211, P649, DOI 10.1097/00000658-199006000-00001; DUTTA U, 1998, DIGESTION S3, V59, P576; Ekbom A, 1996, DIGEST DIS SCI, V41, P387, DOI 10.1007/BF02093833; FARGES O, 1995, SURGERY, V117, P146, DOI 10.1016/S0039-6060(05)80078-9; FARLEY DR, 1995, MAYO CLIN PROC, V70, P425, DOI 10.4065/70.5.425; Fong Y, 1996, BRIT J SURG, V83, P1712, DOI 10.1002/bjs.1800831217; Fong Y, 1998, CANCER-AM CANCER SOC, V83, P423, DOI 10.1002/(SICI)1097-0142(19980801)83:3<423::AID-CNCR9>3.0.CO;2-P; Foo ML, 1997, INT J RADIAT ONCOL, V39, P929, DOI 10.1016/S0360-3016(97)00299-X; Frezza EE, 1997, INT SURG, V82, P295; Fulcher AS, 1997, AM J ROENTGENOL, V169, P1501, DOI 10.2214/ajr.169.6.9393153; Furukawa H, 1998, ARCH SURG-CHICAGO, V133, P735, DOI 10.1001/archsurg.133.7.735; GOLDSTEIN RM, 1993, AM J SURG, V166, P768, DOI 10.1016/S0002-9610(05)80696-8; GONZALEZ DG, 1990, SEMIN LIVER DIS, V10, P131, DOI 10.1055/s-2008-1040466; Goss JA, 1997, ANN SURG, V225, P472, DOI 10.1097/00000658-199705000-00004; Goydos JS, 1998, ANN SURG, V227, P398, DOI 10.1097/00000658-199803000-00012; HAKAMADA K, 1998, DIGESTION S3, V59, P577; Hann LE, 1996, AM J ROENTGENOL, V167, P1017, DOI 10.2214/ajr.167.4.8819404; Hann LE, 1998, RADIOLOGY, V206, P651, DOI 10.1148/radiology.206.3.9494482; Hedstrom J, 1996, INT J CANCER, V66, P326, DOI 10.1002/(SICI)1097-0215(19960503)66:3<326::AID-IJC10>3.0.CO;2-9; HENSON DE, 1992, CANCER, V70, P1493, DOI 10.1002/1097-0142(19920915)70:6<1493::AID-CNCR2820700608>3.0.CO;2-U; HENSON DE, 1992, CANCER, V70, P1498, DOI 10.1002/1097-0142(19920915)70:6<1498::AID-CNCR2820700609>3.0.CO;2-C; Ito R, 1998, INT J ONCOL, V12, P1019; Itoh A, 1997, GASTROINTEST ENDOSC, V45, P251, DOI 10.1016/S0016-5107(97)70267-0; Iwatsuki S, 1998, J AM COLL SURGEONS, V187, P358, DOI 10.1016/S1072-7515(98)00207-5; Jarnagin WR, 1998, AM J SURG, V175, P453, DOI 10.1016/S0002-9610(98)00084-1; JEWKES AJ, 1991, EUR J SURG ONCOL, V17, P354; Johlin FC, 1998, HEPATOLOGY, V28, p393A; Kashihara T, 1998, J GASTROENTEROL, V33, P447, DOI 10.1007/s005350050112; Keiding S, 1998, HEPATOLOGY, V28, P700, DOI 10.1002/hep.510280316; KER C-G, 1989, Kaohsiung Journal of Medical Sciences, V5, P107; KER CG, 1991, J GASTROEN HEPATOL, V6, P505, DOI 10.1111/j.1440-1746.1991.tb00896.x; KLATSKIN G, 1965, AM J MED, V38, P241, DOI 10.1016/0002-9343(65)90178-6; Klempnauer J, 1997, CANCER-AM CANCER SOC, V79, P26, DOI 10.1002/(SICI)1097-0142(19970101)79:1<26::AID-CNCR5>3.3.CO;2-G; KORNER T, 1994, Z GASTROENTEROL, V32, P87; Kornfeld D, 1997, SCAND J GASTROENTERO, V32, P1042, DOI 10.3109/00365529709011222; Kuszyk BS, 1997, CRIT REV DIAGN IMAG, V38, P59; KUUSELA P, 1991, BRIT J CANCER, V63, P636, DOI 10.1038/bjc.1991.146; KUVSHINOFF BW, 1995, BRIT J SURG, V82, P1522, DOI 10.1002/bjs.1800821122; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Landis SH, 1998, CA-CANCER J CLIN, V48, P329; Landis SH, 1998, CA-CANCER J CLIN, V48, P192; Lieser M J, 1998, J Hepatobiliary Pancreat Surg, V5, P41, DOI 10.1007/PL00009949; Liu KJM, 1997, SURGERY, V122, P748, DOI 10.1016/S0039-6060(97)90083-0; LOWENFELS AB, 1989, INT J EPIDEMIOL, V18, P50, DOI 10.1093/ije/18.1.50; Madariaga JR, 1998, ANN SURG, V227, P70, DOI 10.1097/00000658-199801000-00011; Maeda I, 1996, Gan To Kagaku Ryoho, V23, P1607; Mansfield JC, 1997, GUT, V40, P671, DOI 10.1136/gut.40.5.671; MONSON JRT, 1991, ARCH SURG-CHICAGO, V126, P353; Nagino M, 1998, HEPATO-GASTROENTEROL, V45, P7; NAKAMURA S, 1994, ARCH SURG-CHICAGO, V129, P625; Nakao A, 1997, AM J GASTROENTEROL, V92, P1031; Nakeeb A, 1996, AM J SURG, V171, P147, DOI 10.1016/S0002-9610(99)80090-7; Nakeeb A, 1996, ANN SURG, V224, P463, DOI 10.1097/00000658-199610000-00005; Nath G, 1997, EUR J CANCER PREV, V6, P557, DOI 10.1097/00008469-199712000-00011; NICHOLS JC, 1993, MAYO CLIN PROC, V68, P874, DOI 10.1016/S0025-6196(12)60696-X; Nimura Y, 1998, ENDOSCOPY, V30, P182, DOI 10.1055/s-2007-1001245; Nimura Y, 1998, J Hepatobiliary Pancreat Surg, V5, P52; Nishijima T, 1997, JPN J CLIN ONCOL, V27, P13, DOI 10.1093/jjco/27.1.13; NORDBACK IH, 1994, SURGERY, V115, P597; OBOYLE MK, 1994, J ULTRAS MED, V13, P67; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; OGURA Y, 1991, WORLD J SURG, V15, P337, DOI 10.1007/BF01658725; Ortner MAEJ, 1998, GASTROENTEROLOGY, V114, P536, DOI 10.1016/S0016-5085(98)70537-2; Percy C., 1990, INT CLASSIFICATION D; PITT HA, 1995, CURR PROB SURG, V32, P1, DOI 10.1016/S0011-3840(05)80011-5; PITT HA, 1995, ANN SURG, V221, P788, DOI 10.1097/00000658-199506000-00017; POLK HC, 1966, GASTROENTEROLOGY, V50, P582; Prat F, 1998, GUT, V42, P76, DOI 10.1136/gut.42.1.76; Prinz R A, 1993, HPB Surg, V6, P319, DOI 10.1155/1993/25314; RAMAGE JK, 1995, GASTROENTEROLOGY, V108, P865, DOI 10.1016/0016-5085(95)90462-X; RANSOHOFF DF, 1993, ANN INTERN MED, V119, P606, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00010; REDING R, 1991, ANN SURG, V213, P236, DOI 10.1097/00000658-199103000-00010; Rijken AM, 1998, J SURG ONCOL, V68, P187; ROSEN CB, 1991, ANN SURG, V213, P21, DOI 10.1097/00000658-199101000-00004; Saini S, 1997, NEW ENGL J MED, V336, P1889, DOI 10.1056/NEJM199706263362607; Sakamoto E, 1998, ANN SURG, V227, P405, DOI 10.1097/00000658-199803000-00013; Sanabria JR, 1996, AM J SURG, V171, P136, DOI 10.1016/S0002-9610(99)80088-9; Sanz-Altamira PM, 1998, CANCER, V82, P2321, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2321::AID-CNCR4>3.0.CO;2-V; Sasaki A, 1998, BRIT J SURG, V85, P1206, DOI 10.1046/j.1365-2168.1998.00815.x; Sasaki M, 1996, HEPATOLOGY, V23, P258; SASAKI M, 1995, AM J PATHOL, V147, P574; Schechter M S, 1993, J Vasc Interv Radiol, V4, P819, DOI 10.1016/S1051-0443(93)71981-8; Schima W, 1997, CLIN RADIOL, V52, P213, DOI 10.1016/S0009-9260(97)80275-9; Schwartz LH, 1998, AM J ROENTGENOL, V170, P1491, DOI 10.2214/ajr.170.6.9609160; Segarra P, 1996, REV ESP ENFERM DIG, V88, P637; SEITZ JF, 1990, GASTROEN CLIN BIOL, V14, P889; Shin HR, 1996, INT J EPIDEMIOL, V25, P933, DOI 10.1093/ije/25.5.933; STROM BL, 1995, CANCER, V76, P1747, DOI 10.1002/1097-0142(19951115)76:10<1747::AID-CNCR2820761011>3.0.CO;2-L; Su WC, 1996, ONCOLOGY, V53, P488; Suto T, 1998, CANCER, V82, P86, DOI 10.1002/(SICI)1097-0142(19980101)82:1<86::AID-CNCR10>3.0.CO;2-9; TAN CK, 1995, GASTROENTEROLOGY, V108, P1908; Taschieri AM, 1995, HEPATO-GASTROENTEROL, V42, P597; Terada T, 1998, HUM PATHOL, V29, P175, DOI 10.1016/S0046-8177(98)90229-5; Tillich M, 1998, AM J ROENTGENOL, V171, P651, DOI 10.2214/ajr.171.3.9725291; Tio TL, 1996, GASTROINTEST ENDOSC, V44, P706, DOI 10.1016/S0016-5107(96)70056-1; Urego M, 1999, INT J RADIAT ONCOL, V44, P121, DOI 10.1016/S0360-3016(98)00509-4; vanDelden OM, 1997, J ULTRAS MED, V16, P7; VORAVUD N, 1989, HUM PATHOL, V20, P1163, DOI 10.1016/S0046-8177(89)80006-1; WASHBURN WK, 1995, ARCH SURG-CHICAGO, V130, P270; Watanapa P, 1996, BRIT J SURG, V83, P1062, DOI 10.1002/bjs.1800830809; Wiersema MJ, 1997, GASTROENTEROLOGY, V112, P1087, DOI 10.1016/S0016-5085(97)70164-1; YAMASHITA K, 1993, INT J CANCER, V55, P82, DOI 10.1002/ijc.2910550116; Yeo CJ, 1998, ANN SURG, V227, P821, DOI 10.1097/00000658-199806000-00005; Zatonski WA, 1997, JNCI-J NATL CANCER I, V89, P1132, DOI 10.1093/jnci/89.15.1132	127	741	746	4	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1368	1378		10.1056/NEJM199910283411807	http://dx.doi.org/10.1056/NEJM199910283411807			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249XE	10536130				2022-12-28	WOS:000083357800007
J	Draper, ES; Manktelow, B; Field, DJ; James, D				Draper, ES; Manktelow, B; Field, DJ; James, D			Prediction of survival for preterm births by weight and gestational age: restrospective population based study	BRITISH MEDICAL JOURNAL			English	Article							NEONATAL-MORTALITY; INFANTS; ORIGIN	Objective To produce current data on survival of preterm infants. Design Retrospective population based study. Setting Trent health region. Subjects All European and Asian live births, stillbirths, and late fetal losses from 22 to 32 weeks' gestation, excluding those with major congenital malformations, in women resident in the Trent health region between 1 January 1994 and 31 December 1997. Main outcome measures Birth weight and gestational age specific survival for both European and Asian infants (a) known to be alive at the onset of labour and (b) admitted for neonatal care. Results 738 deaths occurred in 3760 infants born between 22 and 32 weeks' gestation during the study period, giving an overall survival rate of 80.4%. The survival rate for the 3489 (92.8%) infants admitted for neonatal care was 86.6%. For European infants known to be alive at the onset of labour, significant variations in gestation specific survival by birth weight emerged from 24 weeks' gestation: survival ranged from 9% (95% confidence interval 7% to 13%) for infants of birth weight 250-499 g to 21% (16% to 28%) for those of 1000-1249 g. At 27 weeks' gestation, survival ranged from 55% (49% to 61%) for infants of birth weight 500-749 g (below the 10th centile) to 80% (76%, to 85%) for those of 1250-1499 g. Infants who were large for dates (greater than or equal to 27 weeks' gestation) had a slightly reduced, but not significant, predicted survival. Similar survival rates were observed for Asian infants. The odds ratio for the survival of infants from a multiple birth compared with singleton infants was 1.4 (1.1 to 1.8). Survival graphs for infants admitted for neonatal care are presented by sex. Conclusion Easy to use birth weight and gestational age specific predicted survival graphs for preterm infants facilitate decision making for clinicians and parents. It is important that these graphs are representative, are produced for a geographically defined population, and are not biased towards the outcomes of particular centres. Such graphs, produced in two stages, allow for the changing pattern of survival of infants from the start of the intrapartum period to immediately after admission for neonatal care.	Univ Leicester, Sch Med, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England; Leicester Royal Infirm, Dept Child Hlth, Leicester LE2 7LX, Leics, England; Univ Nottingham, Queens Med Ctr, Dept Obstet & Gynaecol, Nottingham NG7 2UH, England	University of Leicester; University of Leicester; University of Nottingham	Draper, ES (corresponding author), Univ Leicester, Sch Med, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England.		Draper, Elizabeth S/I-6304-2018; Manktelow, Bradley N/G-2794-2011; Draper, Elizabeth/S-6874-2019	Draper, Elizabeth S/0000-0001-9340-8176; Manktelow, Bradley N/0000-0002-3264-0323; Draper, Elizabeth/0000-0001-9340-8176				BURTON P, 1995, J EPIDEMIOL PUBLIC H, V48, P617; Cartlidge PHT, 1997, ACTA PAEDIATR, V86, P105, DOI 10.1111/j.1651-2227.1997.tb08842.x; CLARKE M, 1996, CONFIDENTIAL ENQUIRY; Cooper TR, 1998, PEDIATRICS, V101, P975, DOI 10.1542/peds.101.6.975; COPPER RL, 1993, AM J OBSTET GYNECOL, V168, P78, DOI 10.1016/S0002-9378(12)90889-3; FIELD D, 1987, PEDIAT PULMONOL, V8, P231; FIELD DJ, 1989, BRIT MED J, V299, P1305, DOI 10.1136/bmj.299.6711.1305; FIELD DJ, 1985, BMJ-BRIT MED J, V290, P1539, DOI 10.1136/bmj.290.6481.1539; FuentesAfflick E, 1997, AM J EPIDEMIOL, V145, P148, DOI 10.1093/oxfordjournals.aje.a009085; GREENBERG DN, 1993, PEDIATRICS, V91, P572; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Rennie JM, 1996, ARCH DIS CHILD-FETAL, V74, pF214, DOI 10.1136/fn.74.3.F214; Tin W, 1997, BMJ-BRIT MED J, V314, P107, DOI 10.1136/bmj.314.7074.107; VERLOOVEVANHORICK SP, 1986, LANCET, V1, P55; WOLF EJ, 1992, OBSTET GYNECOL, V80, P436; YUKSEL B, 1995, THORAX, V50, P773, DOI 10.1136/thx.50.7.773	16	157	167	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1093	1097		10.1136/bmj.319.7217.1093	http://dx.doi.org/10.1136/bmj.319.7217.1093			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531097	Bronze, Green Published			2022-12-28	WOS:000083419500020
J	Inskip, H				Inskip, H			Stillbirth and paternal preconceptional radiation exposure	LANCET			English	Editorial Material							SELLAFIELD		Univ Southampton, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England	University of Southampton	Inskip, H (corresponding author), Univ Southampton, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.		Inskip, Hazel/L-5467-2018	Inskip, Hazel/0000-0001-8897-1749				[Anonymous], 1998, CONFIDENTIAL ENQUIRY; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; Dummer TJB, 1998, INT J EPIDEMIOL, V27, P74, DOI 10.1093/ije/27.1.74; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; Kadir RA, 1999, BRIT MED J, V319, P92, DOI 10.1136/bmj.319.7202.92; MACONOCHIE N, 1999, BRIT MED J, V318, P53; SEVER LE, 1988, AM J EPIDEMIOL, V127, P226, DOI 10.1093/oxfordjournals.aje.a114799; Wakeford R., 1994, Journal of Radiological Protection, V14, P3, DOI 10.1088/0952-4746/14/1/001	8	10	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1400	1401		10.1016/S0140-6736(99)00289-5	http://dx.doi.org/10.1016/S0140-6736(99)00289-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543659				2022-12-28	WOS:000083277400002
J	Cabana, MD; Rand, CS; Powe, NR; Wu, AW; Wilson, MH; Abboud, PAC; Rubin, HR				Cabana, MD; Rand, CS; Powe, NR; Wu, AW; Wilson, MH; Abboud, PAC; Rubin, HR			Why don't physicians follow clinical practice guidelines? A framewouk for improvement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PRIMARY-CARE PHYSICIANS; HEPATITIS-B IMMUNIZATION; FAMILY PHYSICIANS; GENERAL-PRACTITIONERS; PREVENTIVE-SERVICES; HEALTH PROMOTION; DISEASE-CONTROL; OLDER WOMEN; ATTITUDES; PEDIATRICIANS	Context Despite wide promulgation, clinical practice guidelines have had limited effect on changing physician behavior. Little is known about the process and factors in; in changing physician practices in response to guidelines. Objective To review barriers to physician adherence to clinical practice guidelines. Data Sources We searched the MEDLINE, Educational Resources Information Center (ERIC), and HealthSTAR databases (January 1966 to January 1998); bibliographies; textbooks on health behavior or public health; and references supplied by experts to find English-language article titles that describe barriers to guideline adherence. Study Selection Of 5658 articles initially identified, we selected 76 published studies describing at least 1 barrier to adherence to clinical practice guidelines, practice parameters, clinical policies, or national consensus statements. One investigator screened titles to identify candidate articles, then 2 investigators independently reviewed the texts to exclude articles that did not match the criteria. Differences were resolved by consensus with a third investigator. Data Extraction Two investigators organized barriers to adherence into a framework according to their effect on physician knowledge, attitudes, or behavior. This organization was validated by 3 additional investigators. Data Synthesis The 76 articles included 120 different surveys investigating 293 potential barriers to physician guideline adherence, including awareness (n = 46), familiarity (n = 31), agreement (n = 33), self-efficacy (n = 19), outcome expectancy (n = 8), ability to overcome the inertia of previous practice (n = 14), and absence of external barriers to perform recommendations (n = 34). The majority of surveys (70 [58%] of 120) examined only 1 type of barrier. Conclusions Studies on improving physician guideline adherence may not be generalizable, since barriers in one setting may not be present in another. Our review offers a differential diagnosis for why physicians do not follow practice guidelines, as well as a rational approach toward improving guideline adherence and a framework for future research.	Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Psychiat, Baltimore, MD USA; Johns Hopkins Sch Med, Robert Wood Johnson Clin Scholars Program, Baltimore, MD USA; Johns Hopkins Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Johns Hopkins Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University	Cabana, MD (corresponding author), Univ Michigan Hlth Syst, Dept Pediat & Communicable Dis, Div Gen Pediat, D3255 Med Profess Bldg,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mcabana@umich.edu	Cabana, Michael/N-3306-2013; Wu, Albert/AAJ-4780-2021					Alston RP, 1997, ANAESTHESIA, V52, P328, DOI 10.1111/j.1365-2044.1997.92-az0092.x; *AM CANC SOC, 1985, CA CANC J CLIN, V35, P197; *AM CANC SOC, 1990, CA CANC J CLIN, V40, P77; ANDA RF, 1987, JAMA-J AM MED ASSOC, V257, P1916; AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; Balk SJ, 1997, J PEDIATR-US, V131, P325, DOI 10.1016/S0022-3476(97)70177-X; Bandura A., 1986, SOCIAL FDN THOUGHT A; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; BLACK JS, 1990, ARCH INTERN MED, V150, P389, DOI 10.1001/archinte.150.2.389; BRADLEY KA, 1995, J GEN INTERN MED, V10, P67, DOI 10.1007/BF02600228; BROWN ER, 1995, WOMENS HLTH RELATED; Bull FCL, 1997, PREV MED, V26, P866, DOI 10.1006/pmed.1997.0226; CHASSIN MR, 1990, J OCCUP ENVIRON MED, V32, P1199, DOI 10.1097/00043764-199012000-00015; Cheng TL, 1996, ARCH PEDIAT ADOL MED, V150, P682, DOI 10.1001/archpedi.1996.02170320028004; Christakis DA, 1998, PEDIATRICS, V101, P825, DOI 10.1542/peds.101.5.825; COCHI SL, 1986, AM J DIS CHILD, V140, P1226, DOI 10.1001/archpedi.1986.02140260028019; CRAIN EF, 1995, ARCH PEDIAT ADOL MED, V149, P893, DOI 10.1001/archpedi.1995.02170210067012; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; Davis DA, 1997, CAN MED ASSOC J, V157, P408; Feldman EL, 1998, ARCH FAM MED, V7, P58, DOI 10.1001/archfami.7.1.58; Ferguson SC, 1997, AM J PUBLIC HEALTH, V87, P1349, DOI 10.2105/AJPH.87.8.1349; Ferrier BM, 1996, CAN FAM PHYSICIAN, V42, P463; Field MJ, 1990, CLIN PRACTICE GUIDEL; Flocke S A, 1994, Arch Fam Med, V3, P1006, DOI 10.1001/archfami.3.11.1006; Fox RD., 1989, CHANGING LEARNING LI, P161; Freeborn DK, 1997, J GEN INTERN MED, V12, P619, DOI 10.1046/j.1525-1497.1997.07122.x; FREED GL, 1993, PEDIATRICS, V91, P699; FREED GL, 1993, J FAM PRACTICE, V36, P153; FREED GL, 1994, PEDIATRICS, V93, P747; GEERTSMA RH, 1982, J MED EDUC, V57, P752; GEMSON DH, 1987, NEW YORK STATE J MED, V87, P643; GIELEN AC, 1997, HLTH BEHAV HLTH ED; GLANZ K, 1995, J GEN INTERN MED, V10, P89, DOI 10.1007/BF02600234; GOLDMAN L, 1990, NEW ENGL J MED, V322, P1524, DOI 10.1056/NEJM199005243222110; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; Grilli R, 1996, SOC SCI MED, V43, P1283, DOI 10.1016/0277-9536(96)00040-8; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; GROL R, 1990, BRIT J GEN PRACT, V40, P361; Gupta L, 1997, MED J AUSTRALIA, V166, P69, DOI 10.5694/j.1326-5377.1997.tb138723.x; Hardern R D, 1997, Eur J Emerg Med, V4, P68, DOI 10.1097/00063110-199706000-00003; Hayward RSA, 1997, CAN MED ASSOC J, V156, P1715; Hayward RSA, 1997, CAN MED ASSOC J, V156, P1725; HIDDINK GJ, 1995, EUR J CLIN NUTR, V49, P842; HILL MN, 1988, AM J PUBLIC HEALTH, V78, P1190, DOI 10.2105/AJPH.78.9.1190; HUDAK BB, 1995, PEDIATRICS, V95, P55; Hutchison BG, 1996, CAN FAM PHYSICIAN, V42, P1693; HYMAN DJ, 1992, PUBLIC HEALTH REP, V107, P441; Jackson L, 1997, CAN FAM PHYSICIAN, V43, P649; JAFARI HS, 1995, PEDIATR INFECT DIS J, V14, P662, DOI 10.1097/00006454-199508000-00003; James PA, 1997, J FAM PRACTICE, V45, P341; Johnsson M, 1988, Int J Technol Assess Health Care, V4, P89; Kanouse DE, 1989, CHANGING MED PRACTIC; Kimura S, 1997, J FAM PRACTICE, V44, P361; Klabunde CN, 1997, AM J PREV MED, V13, P432, DOI 10.1016/S0749-3797(18)30137-5; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; KOTTKE TE, 1994, TOB CONTROL, V3, P46; KRAUS DM, 1994, ARCH PEDIAT ADOL MED, V148, P936, DOI 10.1001/archpedi.1994.02170090050007; LANGKAMP DL, 1992, PEDIATRICS, V89, P52; LANGNER NR, 1989, CAN MED ASSOC J, V141, P33; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; LOMAS J, 1993, MILBANK Q, V71, P439, DOI 10.2307/3350410; LORINO CO, 1990, SOUTHERN MED J, V83, P1280, DOI 10.1097/00007611-199011000-00012; LUCKMANN R, 1995, J FAM PRACTICE, V40, P547; MAIN DS, 1995, AM J PREV MED, V11, P54, DOI 10.1016/S0749-3797(18)30501-4; MANSFIELD CD, 1995, QUAL HEALTH CARE, V4, P350; McIlvain HE, 1997, J FAM PRACTICE, V44, P193; Meyers DG, 1997, AM J PREV MED, V13, P45, DOI 10.1016/S0749-3797(18)30224-1; NAYLOR CD, 1990, CAN MED ASSOC J, V142, P1069; Newton J, 1996, BRIT J GEN PRACT, V46, P513; Olesen F, 1997, SCAND J PRIM HEALTH, V15, P141, DOI 10.3109/02813439709018504; Pathman DE, 1996, MED CARE, V34, P873, DOI 10.1097/00005650-199609000-00002; PEARSALL FJ, 1995, ANAESTHESIA, V50, P649, DOI 10.1111/j.1365-2044.1995.tb15123.x; PIERRE KD, 1991, SOC SCI MED, V32, P1283; PRENDERGAST BD, 1995, BRIT HEART J, V74, P685; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; RESNICOW KA, 1989, PREV MED, V18, P101, DOI 10.1016/0091-7435(89)90057-1; Rimer B K, 1990, J Am Board Fam Pract, V3, P26; ROETZHEIM RG, 1995, J AM GERIATR SOC, V43, P1398, DOI 10.1111/j.1532-5415.1995.tb06621.x; Rogers E., 2003, DIFFUSION INNOVATION, VFifth; Salem-Schatz S R, 1997, HMO Pract, V11, P111; Saver BG, 1997, AM J PREV MED, V13, P358, DOI 10.1016/S0749-3797(18)30155-7; Schaffer SJ, 1998, ARCH PEDIAT ADOL MED, V152, P185; Schocken D D, 1992, J Fla Med Assoc, V79, P112; SCHUCKER B, 1991, ARCH INTERN MED, V151, P666, DOI 10.1001/archinte.151.4.666; Shamir R, 1998, PEDIATRICS, V101, P892, DOI 10.1542/peds.101.5.892; Shye D, 1995, HMO Pract, V9, P111; SIRIWARDENA AN, 1995, BRIT J GEN PRACT, V45, P643; Solberg LI, 1997, J FAM PRACTICE, V44, P451; Soltesz K S, 1995, Arch Fam Med, V4, P589, DOI 10.1001/archfami.4.7.589; STANGE KC, 1992, J FAM PRACTICE, V34, P409; STROSS JK, 1979, JAMA-J AM MED ASSOC, V241, P2622, DOI 10.1001/jama.241.24.2622; Taylor VM, 1996, J COMMUN HEALTH, V21, P277, DOI 10.1007/BF01794878; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; *US GEN ACC OFF, 1991, PRACT GUID EXP MED S; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; vanderVoort J, 1997, FAM PRACT, V14, P44, DOI 10.1093/fampra/14.1.44; Ward JE, 1997, MED J AUSTRALIA, V167, P362, DOI 10.5694/j.1326-5377.1997.tb125101.x; WECHSLER H, 1983, NEW ENGL J MED, V308, P97, DOI 10.1056/NEJM198301133080211; WEINBERGER M, 1991, J AM GERIATR SOC, V39, P22, DOI 10.1111/j.1532-5415.1991.tb05901.x; WEINGARTEN S, 1995, J GEN INTERN MED, V10, P138, DOI 10.1007/BF02599668; WELLS KB, 1986, AM J PUBLIC HEALTH, V76, P1009, DOI 10.2105/AJPH.76.8.1009; Wigder HN, 1996, ANN EMERG MED, V27, P606, DOI 10.1016/S0196-0644(96)70164-6; WILSON DM, 1988, JAMA-J AM MED ASSOC, V260, P1570, DOI 10.1001/jama.260.11.1570; WINKLER JD, 1985, ARCH INTERN MED, V145, P314, DOI 10.1001/archinte.145.2.314; Wolff M, 1998, Fam Med, V30, P117; WOO B, 1985, JAMA-J AM MED ASSOC, V254, P1480, DOI 10.1001/jama.254.11.1480; WOOLF SH, 1993, ARCH INTERN MED, V153, P2646, DOI 10.1001/archinte.153.23.2646; ZUCKER AR, 1995, CRIT CARE MED, V23, P767, DOI 10.1097/00003246-199504000-00028; 1995, MMWR MORB MORTAL WKL, V44, P747; 1995, MMWR MORB MORTAL WKL, V44, P753	111	4681	4755	7	265	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1458	1465		10.1001/jama.282.15.1458	http://dx.doi.org/10.1001/jama.282.15.1458			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	245LT	10535437				2022-12-28	WOS:000083111000032
J	Malcolm, L; Mays, N				Malcolm, L; Mays, N			New Zealand's independent practitioner associations: a working model of clinical governance in primary care?	BRITISH MEDICAL JOURNAL			English	Article							QUALITY IMPROVEMENT		Aotearoa Hlth, Lyttelton RD1, New Zealand; Treasury, Social Policy Branch, Wellington, New Zealand		Malcolm, L (corresponding author), Aotearoa Hlth, Lyttelton RD1, New Zealand.							Baker R, 1999, BRIT MED J, V318, P779, DOI 10.1136/bmj.318.7186.779; Bell DW, 1997, NEW ZEAL MED J, V110, P440; BEVAN G, 1998, SURVEY BUDGETARY RIS; Donaldson LJ, 1998, J EPIDEMIOL COMMUN H, V52, P73, DOI 10.1136/jech.52.2.73; Harris CM, 1996, BRIT MED J, V313, P1531, DOI 10.1136/bmj.313.7071.1531; Jansen P, 1997, NEW ZEAL MED J, V110, P85; KERR D, 1996, NZ MED J, V109, P354; Majeed A, 1999, BRIT MED J, V318, P772, DOI 10.1136/bmj.318.7186.772; Malbon G, 1998, Health Serv J, V108, P28; MALCOHN L, 1997, EVALUATION PHARM BUD; Malcolm L, 1997, BRIT MED J, V314, P1890, DOI 10.1136/bmj.314.7098.1890; Malcolm L, 1996, NEW ZEAL MED J, V109, P184; Malcolm L, 1999, NEW ZEAL MED J, V112, P162; MALCOLM L, IN PRESS DEV PRIMARY; MALCOLM LA, IN PRESS NZ MED J; MAYS N, 1998, TOTAL PURCHASING STE; MILBURN A, 1998, COMMUNICATION   0617; *NHS EX, 1998, CLIN GOV N THAM PAP; Rafferty T, 1997, BRIT MED J, V315, P166, DOI 10.1136/bmj.315.7101.166; REGEN E, 1999, 1 STARTING BLOCKS LE; Scally G, 1998, BRIT MED J, V317, P61, DOI 10.1136/bmj.317.7150.61; *SECR STAT HLTH, 1998, 1 CLASS SERV; Smith PC, 1999, BRIT MED J, V318, P776, DOI 10.1136/bmj.318.7186.776; STREET A, 1998, MANAGEMENT CHALLENGE	24	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1340	1342		10.1136/bmj.319.7221.1340	http://dx.doi.org/10.1136/bmj.319.7221.1340			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567141	Bronze, Green Published			2022-12-28	WOS:000083930200026
J	Huang, L; Kinnucan, E; Wang, GL; Beaudenon, S; Howley, PM; Huibregtse, JM; Pavletich, NP				Huang, L; Kinnucan, E; Wang, GL; Beaudenon, S; Howley, PM; Huibregtse, JM; Pavletich, NP			Structure of an E6AP-UbcH7 complex: Insights into ubiquitination by the E2-E3 enzyme cascade	SCIENCE			English	Article							ANGELMAN-SYNDROME; PROTEIN; E6-AP; P53; EXPRESSION; CLONING; UBE3A; UBCH7	The E6AP ubiquitin-protein Ligase (E3) mediates the human papillomavirus-induced degradation of the p53 tumor suppressor in cervical cancer and is mutated in Angelman syndrome, a neurological disorder. The crystal structure of the catalytic hect domain of E6AP reveals a bilobal structure with a broad catalytic cleft at the junction of the two Lobes. The cleft consists of conserved residues whose mutation interferes with ubiquitin-thioester bond formation and is the site of Angelman syndrome mutations. The crystal structure of the E6AP hect domain bound to the UbcH7 ubiquitin-conjugating enzyme (E2) reveals the determinants of E2-E3 specificity and provides insights into the transfer of ubiquitin from the E2 to the E3.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Rutgers State University New Brunswick; Harvard University; Harvard Medical School	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.		高, 雨莉/HGU-8187-2022	Howley, Peter/0000-0002-8668-9579				Albrecht U, 1997, NAT GENET, V17, P75, DOI 10.1038/ng0997-75; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Malzac P, 1998, AM J HUM GENET, V62, P1353, DOI 10.1086/301877; MAYER RJ, 1998, UBIQUITIN BIOL CELL, P429; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439	17	422	452	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1321	1326		10.1126/science.286.5443.1321	http://dx.doi.org/10.1126/science.286.5443.1321			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558980				2022-12-28	WOS:000083675500032
J	Vickers, A; Zollman, C				Vickers, A; Zollman, C			ABC of complementary medicine - Massage therapies	BRITISH MEDICAL JOURNAL			English	Review									Res Council Complementary Med, London, England									VICKERS A, 1998, MASSAGE AROMATHERAPY	1	63	64	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1254	1257		10.1136/bmj.319.7219.1254	http://dx.doi.org/10.1136/bmj.319.7219.1254			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550095	Green Published			2022-12-28	WOS:000083625600031
J	Henney, JE				Henney, JE			First antibacterial for VREF	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1613	1613		10.1001/jama.282.17.1613	http://dx.doi.org/10.1001/jama.282.17.1613			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553774				2022-12-28	WOS:000083368400007
J	Peckham, M				Peckham, M			Developing the National Health Service: a model for public services	LANCET			English	Article; Proceedings Paper	Conference on a Model for Health - Innovation and the Future of Health Services	JUN 08, 1999	ROYAL COLL PHYSICIANS, LONDON, ENGLAND		ROYAL COLL PHYSICIANS		UNITS; CARE		UCL, Sch Publ Policy, London WC1H 9EZ, England	University of London; University College London	Peckham, M (corresponding author), UCL, Sch Publ Policy, Rubin Bldg,29-30 Tavistock Sq, London WC1H 9EZ, England.	m.peckham@ucl.ac.uk						BROCK HW, 1980, NATION FIRED MOST HI; BUXTON M, 1997, 24 BRUN U DEP HLTH R, V1; Carlsson Bo, 1997, SYSTEMS INNOVATION T, P266; *DEP HLTH, 1992, ADV GROUP SETT PRIOR; DONALD A, 1998, FRONT LINE EVIDENCE; *DRUMCH ASTHM SUPP, 1998, DRUMCH 1 HLTH C SCH; Edquist C, 1997, SYSTEMS INNOVATION T, DOI DOI 10.1016/S0024-6301(98)90244-8; Fears R, 1999, SCIENCE, V284, P267, DOI 10.1126/science.284.5412.267; Firth-Cozens J, 1993, MED ACCIDENTS, P131; FirthCozens J, 1997, SOC SCI MED, V44, P1017, DOI 10.1016/S0277-9536(96)00227-4; Frankel S, 1999, LANCET, V353, P1304, DOI 10.1016/S0140-6736(98)06451-4; *HLTH LOND PROJ, 1998, HLTH LOND PUBL HLTH; House of Lords Select Committee on Science and Technology, 1988, PRIOR MED RES; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; LIGHT D, 1999, BRIT MED J, V315, P112; Majeed A, 1999, BRIT MED J, V318, P772, DOI 10.1136/bmj.318.7186.772; McGovern MM, 1999, JAMA-J AM MED ASSOC, V281, P835, DOI 10.1001/jama.281.9.835; NALEBUFF BJ, 1996, COOPETITION, P164; *NAT COORD CTR HLT, 1998, ANN REP HLTH TECHN A; *NHS CTR REV DISS, 1997, SCREEN PROST CANC, V2; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; PECKHAM M, 1999, MODEL HLTH INNOVATIO; RICHMOND M, 1999, IMPLICATIONS GENETIC; SHORTELL SM, 1994, MED CARE, V32, P508, DOI 10.1097/00005650-199405000-00009; *STROK ASS, 1999, BRIT MED J, V318, P1098; *WARW BUS SCH, 1999, HOT TOP ORG IMPR CO; WELLS P, 1999, GRESH COLL LECT FEB; Wyatt JC, 1998, BMJ-BRIT MED J, V317, P1041	29	14	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	1999	354	9189					1539	1545		10.1016/S0140-6736(99)08417-2	http://dx.doi.org/10.1016/S0140-6736(99)08417-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	250WB	10551515				2022-12-28	WOS:000083411300041
J	Motchoulski, A; Liscum, E				Motchoulski, A; Liscum, E			Arabidopsis NPH3: A NPH1 photoreceptor-interacting protein essential for phototropism	SCIENCE			English	Article							COILED COILS; LINKAGE MAP; PHOSPHORYLATION; FLAVOPROTEIN; ELONGATION; MUTATIONS; RESPONSES; DOMAIN; KINASE	Phototropism of Arabidopsis thaliana seedlings in response to a blue Light source is initiated by nonphototropic hypocotyl 1 (NPH1), a Light-activated serine-threonine protein kinase. Mutations in three Loci [NPH2, root phototropism 2 (RPT2), and NPH3] disrupt early signaling occurring downstream of the NPH1 photoreceptor, The NPH3 gene, now cloned, encodes a NPH1-interacting protein. NPH3 is a member of a large protein family, apparently specific to higher plants, and may function as an adapter or scaffold protein to bring together the enzymatic components of a NPH1-activated phosphorelay.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Liscum, E (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.	liscumm@missouri.edu		Liscum, Emmanuel/0000-0002-8672-9315				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; CHOI S, 1995, WEEDS WORLD, V2, P17; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Fankhauser C, 1999, CURR BIOL, V9, pR123, DOI 10.1016/S0960-9822(99)80078-5; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lasceve G, 1999, PLANT PHYSIOL, V120, P605, DOI 10.1104/pp.120.2.605; LISCUM E, 1991, PLANT CELL, V3, P685, DOI 10.1105/tpc.3.7.685; LISCUM E, 1995, PLANT CELL, V7, P473, DOI 10.1105/tpc.7.4.473; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MOTCHOULSKI A, UNPUB; NAGAO M, 1992, J BIOL CHEM, V267, P17925; Nakamura Y, 1997, DNA Res, V4, P401, DOI 10.1093/dnares/4.6.401; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Okada K., 1994, ARABIDOPSIS, P665; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHORT TW, 1993, PLANT PHYSIOL, V101, P647, DOI 10.1104/pp.101.2.647; Stowe-Evans EL, 1998, PLANT PHYSIOL, V118, P1265, DOI 10.1104/pp.118.4.1265	34	236	266	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					961	964		10.1126/science.286.5441.961	http://dx.doi.org/10.1126/science.286.5441.961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542152				2022-12-28	WOS:000083368500047
J	Sun, CH; Cai, ML; Gunasekera, AH; Meadows, RP; Wang, H; Chen, J; Zhang, HC; Wu, W; Xu, N; Ng, SC; Fesik, SW				Sun, CH; Cai, ML; Gunasekera, AH; Meadows, RP; Wang, H; Chen, J; Zhang, HC; Wu, W; Xu, N; Ng, SC; Fesik, SW			NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; BACULOVIRUS INHIBITOR; CELL-DEATH; MACROMOLECULES; GENE; IAP; COUPLINGS; CASPASES; FAMILY; SURVIVIN	The inhibitor-of-apoptosis (IAP) family of proteins, originally identified in baculoviruses(1), regulate programmed cell death in a variety of organisms(2-6), IAPs inhibit specific enzymes (caspases) in the death cascade(7-11) and contain one to three modules of a common 70-amino-acid motif called the BIR domain(12). Here we describe the nuclear magnetic resonance structure of a region encompassing the second BIR domain (BIR2) of a human IAP family member, XIAP (also called hILP or MIHA). The structure of the BIR domain consists of a three-stranded antiparallel beta-sheet and four alpha-helices and resembles a classical zinc finger(13). Unexpectedly, conserved amino acids within the linker region between the BIR1 and BIR2 domains were found to be critical for inhibiting caspase-3. The absence or presence of these residues may explain the differences in caspase inhibition observed for different truncated and full-length IAPs(10,11). Our data further indicate that these residues may bind to the active site and that the BIR domain may interact with an adjacent site on the enzyme.	Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA	Abbott Laboratories	Fesik, SW (corresponding author), Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA.							Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BRUNGER AT, 1992, XPLOR 3 1 ANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Rance M, 1999, J MAGN RESON, V136, P92, DOI 10.1006/jmre.1998.1626; RORUNDA I, 1996, NAT STRUCT BIOL, V3, P619; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024	30	288	322	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					818	822		10.1038/44617	http://dx.doi.org/10.1038/44617			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548111				2022-12-28	WOS:000083368700060
J	Hardy, S; Keel, SB; Ezkeowitz, RAB; Teitelbaum, J; Scully, RE; Doody, DP				Hardy, S; Keel, SB; Ezkeowitz, RAB; Teitelbaum, J; Scully, RE; Doody, DP			A five-month-old girl with coffee-grounds vomitus. Juvenile capillary hemangioma of the stomach.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PEPTIC-ULCER DISEASE; CHILDREN; HEMORRHAGE; DUPLICATION; MANAGEMENT; DIAGNOSIS; FEATURES		UMass Mem Hlth Care, Div Pediat Gastroenterol & Nutr, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Hardy, S (corresponding author), UMass Mem Hlth Care, Div Pediat Gastroenterol & Nutr, Worcester, MA 01605 USA.							ADEYEMI SD, 1979, ANN SURG, V190, P706, DOI 10.1097/00000658-197912000-00006; ALVAREZ F, 1983, J PEDIATR-US, V103, P696, DOI 10.1016/S0022-3476(83)80460-0; APT L, 1955, J PEDIATR-US, V47, P6, DOI 10.1016/S0022-3476(55)80118-7; BLAIS C, 1995, J PEDIATR SURG, V30, P1384, DOI 10.1016/0022-3468(95)90516-2; BONGIOVI JJ, 1967, ARCH SURG-CHICAGO, V95, P93; BURT RW, 1984, GASTROENTEROLOGY, V86, P295; DANIEL ES, 1982, MEDICINE, V61, P293, DOI 10.1097/00005792-198209000-00002; DRUMM B, 1988, PEDIATRICS, V82, P410; Enzinger FM, 1995, SOFT TISSUE TUMORS, V3, P581; GENTILKOCHER S, 1988, J PEDIATR-US, V113, P30, DOI 10.1016/S0022-3476(88)80524-9; GOYAL A, 1994, AM J GASTROENTEROL, V89, P613; GROSFELD JL, 1986, ARCH SURG-CHICAGO, V121, P530; GRUMBACH MM, 1985, WILLIAMS TXB ENDOCRI, P341; HASSALL E, 1991, DIGEST DIS SCI, V36, P417, DOI 10.1007/BF01298868; ILDSTAD ST, 1988, ANN SURG, V208, P184, DOI 10.1097/00000658-198808000-00009; KILBRIDGE PM, 1988, AM J DIS CHILD, V142, P1149, DOI 10.1001/archpedi.1988.02150110027012; LAMMERS R, 1893, THESIS GREIFSWALD; LEWIN KJ, 1996, ATLAS TUMOR PATHOL, P446; Long J A Jr, 1977, N Engl J Med, V297, P1070; MURTY TVM, 1992, J PEDIATR SURG, V27, P515, DOI 10.1016/0022-3468(92)90351-7; NORRIS HT, 1992, PATHOLOGY GASTROINTE, P224; Oranje A P, 1986, Pediatr Dermatol, V3, P304, DOI 10.1111/j.1525-1470.1986.tb00530.x; OSWALT CE, 1983, TEX MED, V79, P37; PINKERTON JA, 1972, ANN SURG, V175, P870, DOI 10.1097/00000658-197206010-00007; PRUKSAPONG C, 1979, J PEDIATR SURG, V14, P83, DOI 10.1016/S0022-3468(79)80583-7; SCHMITT B, 1986, J PEDIATR GASTR NUTR, V5, P155, DOI 10.1097/00005176-198601000-00031; THYRESSON HN, 1981, MAYO CLIN PROC, V56, P179; VASE P, 1986, GASTROENTEROLOGY, V91, P1079, DOI 10.1016/S0016-5085(86)80001-4; WAN YL, 1993, CLIN IMAG, V17, P210, DOI 10.1016/0899-7071(93)90113-2	29	4	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1999	341	21					1597	1603		10.1056/NEJM199911183412108	http://dx.doi.org/10.1056/NEJM199911183412108			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	256GF	10564691				2022-12-28	WOS:000083717000008
J	Bonni, A; Brunet, A; West, AE; Datta, SR; Takasu, MA; Greenberg, ME				Bonni, A; Brunet, A; West, AE; Datta, SR; Takasu, MA; Greenberg, ME			Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms	SCIENCE			English	Article							CEREBELLAR GRANULE NEURONS; PROTEIN-KINASE AKT; GENE-EXPRESSION; BINDING PROTEIN; BCL-2 FAMILY; PHOSPHORYLATION; APOPTOSIS; DEATH; CREB; CAMP	A mechanism by which the Ras-mitogen-activated protein kinase (MAPK) signaling pathway mediates growth factor-dependent cell survival was characterized. The MAPK-activated kinases, the Rsks, catalyzed the phosphorylation of the pro-apoptotic protein BAD at serine 112 both in vitro and in vivo. The Rsk-induced phosphorylation of BAD at serine 112 suppressed BAD-mediated apoptosis in neurons. Rsks also are known to phosphorylate the transcription factor CREB (cAMP response element-binding protein) at serine 133. Activated CREB promoted cell survival, and inhibition of CREB phosphorylation at serine 133 triggered apoptosis. These findings suggest that the MAPK signaling pathway promotes cell survival by a dual mechanism comprising the posttranslational modification and inactivation of a component of the cell death machinery and the increased transcription of pro-survival genes.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Greenberg, ME (corresponding author), Childrens Hosp, Div Neurosci, 300 Longwood Ave, Boston, MA 02115 USA.			Datta, Sandeep/0000-0002-8068-3862	NICHD NIH HHS [P01 HD 24926, NIHP30-HD18655] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Bonni A, 1997, CAN J NEUROL SCI, V24, P272, DOI 10.1017/S0317167100032935; BONNI A, UNPUB; BORASIO GD, 1989, NEURON, V2, P1087; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Datta SR, 1998, HORM SIGNALING, V1, P257; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; delPeso L, 1997, SCIENCE, V278, P687; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HENGARTNER MO, 1994, CURR OPIN GENE DEV, V4, P481; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; Minichiello L, 1996, GENE DEV, V10, P2849, DOI 10.1101/gad.10.22.2849; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; RICCIO A, 1996, MOL CELL BIOL, V16, P5546; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Schwartz PM, 1997, NEURON, V19, P269, DOI 10.1016/S0896-6273(00)80938-1; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SEGAL RA, 1992, NEURON, V9, P1041, DOI 10.1016/0896-6273(92)90064-K; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHIMAMURA A, UNPUB; Somers JP, 1999, MOL ENDOCRINOL, V13, P1364, DOI 10.1210/me.13.8.1364; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; XING J, UNPUB; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	54	1591	1674	6	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1358	1362		10.1126/science.286.5443.1358	http://dx.doi.org/10.1126/science.286.5443.1358			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558990				2022-12-28	WOS:000083675500042
J	Pages, G; Guerin, S; Grall, D; Bonino, FD; Smith, A; Anjuere, F; Auberger, P; Pouyssegur, J				Pages, G; Guerin, S; Grall, D; Bonino, FD; Smith, A; Anjuere, F; Auberger, P; Pouyssegur, J			Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice	SCIENCE			English	Article							PROTEIN-KINASE; NEGATIVE SELECTION; PATHWAYS; TYROSINE; INSULIN; DIFFERENTIATION; ACTIVATION; CASCADE	The p42 and p44 mitogen-activated protein kinases (MAPKs), also called Erk2 and Erk1, respectively, have been implicated in proliferation as well as in differentiation programs. The specific role of the p44 MAPK isoform in the whole animal was evaluated by generation of p44 MAPK-deficient mice by homologous recombination in embryonic stem cells. The p44 MAPK(-/-) mice were viable, fertile, and of normal size. Thus, p44 MAPK is apparently dispensable and p42 MAPK (Erk2) may compensate for its Loss. However, in p44 MAPK(-/-) mice, thymocyte maturation beyond the CD4(+)CD8(+) stage was reduced by half, with a similar diminution in the thymocyte subpopulation expressing high Levels of T cell receptor (CD3(high)). In p44 MAPK(-/-) thymocytes, proliferation in response to activation with a monoclonal antibody to the T cell receptor in the presence of phorbol myristate acetate was severely reduced even though activation of p42 MAPK was more sustained in these cells. The p44 MAPK apparently has a specific role in thymocyte development.	Ctr Antoine Lacassagne, Inst Signal Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice, France; Fac Med, INSERM, U364, F-06107 Nice, France; Fac Med, CJF 96 05, F-06107 Nice, France; Ctr Genome Res, Edinburgh, Midlothian, Scotland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Pages, G (corresponding author), Ctr Antoine Lacassagne, Inst Signal Dev Biol & Canc Res, CNRS, UMR 6543, 33 Ave Valornbrose, F-06189 Nice, France.		Pages, Gilles/N-7135-2017; Bonino, Ferruccio/B-7522-2013; Anjuere-Casile, Fabienne/O-5779-2016; AUBERGER, Patrick/G-1491-2013	Anjuere-Casile, Fabienne/0000-0003-3144-8652; AUBERGER, Patrick/0000-0002-2481-8275; Smith, Austin/0000-0002-3029-4682				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; Guerin S, 1997, FASEB J, V11, P376, DOI 10.1096/fasebj.11.5.9141505; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCKENZIE F, IN PRESS BIOCH BIOPH; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OShea CC, 1996, EUR J IMMUNOL, V26, P2350, DOI 10.1002/eji.1830261012; PAGES G, 1995, J BIOL CHEM, V270, P26986, DOI 10.1074/jbc.270.45.26986; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAGES G, UNPUB; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x	25	455	467	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1374	1377		10.1126/science.286.5443.1374	http://dx.doi.org/10.1126/science.286.5443.1374			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558995				2022-12-28	WOS:000083675500047
J	McSmith, A				McSmith, A			Prime minister launches NHS inspectorate	BRITISH MEDICAL JOURNAL			English	News Item																			0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1217	1217		10.1136/bmj.319.7219.1217	http://dx.doi.org/10.1136/bmj.319.7219.1217			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550066	Green Published			2022-12-28	WOS:000083625600006
J	Danesh, J; Youngman, L; Clark, S; Parish, S; Peto, R; Collins, R				Danesh, J; Youngman, L; Clark, S; Parish, S; Peto, R; Collins, R		Int Studies Infarct Survival ISIS	Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; RISK; AGE	Objectives To examine the association between coronary heart disease and chronic Helicobacter pylori infection. Design Case-control study of myocardial infarction at young ages and study of sibling pairs with one member affected and the other not. Setting United Kingdom. Participants 1122 survivors of suspected acute myocardial infarction at ages 30-49 (mean age 44 years) and 1122 age and sex matched controls with no history of coronary heart disease; 510 age and sex matched pairs of siblings (mean age 59 years) in which one sibling had survived myocardial infarction and one had no history of coronary heart disease. Main outcome measures Serological evidence of chronic infection with H pylori. Results 472 (42%) of the 1122 cases with early onset myocardial infarction were seropositive for H pylori antibodies compared with 272 (24%) of the 1122 age and sex matched controls, giving an odds ratio of 2.28 (99% confidence interval 1.80 to 2.90). This odds ratio fell to 1.87 (1.42 to 2.47; P < 0.0001) after smoking and indicators of socioeconomic status were adjusted for and to 1.75 (1.29 to 2.36) after additional adjustment for blood lipid concentrations and obesity. Only 158 of the 510 pairs of siblings were discordant for H pylori status; among these, 91 cases and 6'7 controls were seropositive (odds ratio 1.33 (0.86 to 2.05)). No strong correlations were observed between H pylori seropositivity and measurements of other risk factors for coronary heart disease (plasma lipids, fibrinogen, C reactive protein, albumin, etc). Conclusion In the context of results from other relevant studies, these two studies suggest a moderate association between coronary hear: disease and H pylori seropositivity that cannot be fully accounted for by other risk factors. But even if this association is causal and largely reversible by eradication of chronic infection, very large randomised trials would be needed to show this.	Univ Oxford, Radcliffe Infirm, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford OX2 6HE, England; Univ Oxford, Radcliffe Infirm, Nuffield Dept Clin Med, Epidemiol Studies Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Danesh, J (corresponding author), Univ Oxford, Radcliffe Infirm, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford OX2 6HE, England.							BLASER MJ, 1995, CANCER RES, V55, P562; Collins R, 1996, OXFORD TXB MED, V1, P21; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Danesh J, 1998, Expert Opin Investig Drugs, V7, P691, DOI 10.1517/13543784.7.5.691; Danesh J, 1998, BRIT MED J, V316, P1130, DOI 10.1136/bmj.316.7138.1130; Danesh J, 1999, BRIT MED J, V318, P843, DOI 10.1136/bmj.318.7187.843; FELDMAN RA, 1995, ALIMENT PHARM THER, V9, P21; GOODMAN KJ, 1995, INT J EPIDEMIOL, V24, P875, DOI 10.1093/ije/24.5.875; HUNT D, 1992, LANCET, V339, P753; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MALATY HM, 1994, ANN INTERN MED, V120, P982, DOI 10.7326/0003-4819-120-12-199406150-00002; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; Pasceri V, 1998, CIRCULATION, V97, P1675, DOI 10.1161/01.CIR.97.17.1675; Qizilbash N, 1995, LANCET, V346, P1647; SITAS F, 1991, GUT, V32, P25, DOI 10.1136/gut.32.1.25; Sonke GS, 1996, BRIT MED J, V313, P853; YARNELL JWG, 1992, EUR HEART J, V13, P1602, DOI 10.1093/oxfordjournals.eurheartj.a060111	19	122	127	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1157	1162		10.1136/bmj.319.7218.1157	http://dx.doi.org/10.1136/bmj.319.7218.1157			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541503	Green Published, Bronze			2022-12-28	WOS:000083536200019
J	Farr, BM				Farr, BM			Accuracy and cost-effectiveness of new tests for diagnosis of catheter-related bloodstream infections	LANCET			English	Editorial Material									Univ Virginia, Dept Med, Charlottesville, VA 22908 USA	University of Virginia	Farr, BM (corresponding author), Univ Virginia, Dept Med, Charlottesville, VA 22908 USA.							Blot F, 1999, LANCET, V354, P1071, DOI 10.1016/S0140-6736(98)11134-0; LEISURE MK, 1990, JAMA-J AM MED ASSOC, V264, P2111, DOI 10.1001/jama.264.16.2111; MERMEL LA, 1998, 38 INT C ANT AG CHEM; RAAD I, 1993, ARCH INTERN MED, V153, P1791, DOI 10.1001/archinte.153.15.1791; RADD I, 1993, J INFECT DIS, V168, P400, DOI 10.1093/infdis/168.2.400; Sherertz RJ, 1997, J CLIN MICROBIOL, V35, P641, DOI 10.1128/JCM.35.3.641-646.1997; SiegmanIgra Y, 1997, J CLIN MICROBIOL, V35, P928, DOI 10.1128/JCM.35.4.928-936.1997	7	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 30	1999	354	9189					1487	1488		10.1016/S0140-6736(99)00258-5	http://dx.doi.org/10.1016/S0140-6736(99)00258-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551489				2022-12-28	WOS:000083411300003
J	Wilton, LV; Stephens, MDB; Mann, RD				Wilton, LV; Stephens, MDB; Mann, RD			Visual field defect associated with vigabatrin: observational cohort study	BRITISH MEDICAL JOURNAL			English	Article							CONSTRICTION		Drug Safety Res Unit, Southampton SO31 1AA, Hants, England		Wilton, LV (corresponding author), Drug Safety Res Unit, Southampton SO31 1AA, Hants, England.							*COMM ADV TROP MED, 1998, CAN COMMUN DIS REP, V24, P1; Eke T, 1997, BRIT MED J, V314, P180, DOI 10.1136/bmj.314.7075.180; Mackenzie R, 1998, BRIT MED J, V316, P233; Mann RD, 1998, BRIT J CLIN PHARMACO, V46, P195, DOI 10.1046/j.1365-2125.1998.00774.x	4	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1165	1166		10.1136/bmj.319.7218.1165	http://dx.doi.org/10.1136/bmj.319.7218.1165			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541505	Bronze, Green Published			2022-12-28	WOS:000083536200021
J	Haass, C; De Strooper, B				Haass, C; De Strooper, B			Review: Neurobiology - The presenilins in Alzheimer's disease - Proteolysis holds the key	SCIENCE			English	Review							AMYLOID BETA-PROTEIN; C-TERMINAL FRAGMENTS; IN-VIVO; CAENORHABDITIS-ELEGANS; ENDOPLASMIC-RETICULUM; PRECURSOR PROTEIN; MISSENSE MUTATIONS; TRANSFECTED CELLS; TRANSGENIC MICE; EXPRESSION	Alzheimer's disease (AD) research has shown that patients with an inherited form of the disease carry mutations in the presenilin proteins or the amyloid precursor protein (APP). These disease-linked mutations result in increased production of the Longer form of amyloid-beta (the primary component of the amyloid deposits found in AD brains). However, it is not clear how the presenilins contribute to this increase. New findings now show that the presenilins affect APP processing through their effects on gamma-secretase, an enzyme that cleaves APP, Also, it is known that the presenilins are involved in the cleavage of the Notch receptor, hinting that they either directly regulate gamma-secretase activity or themselves are protease enzymes. These findings suggest that the presenilins may prove to be valuable molecular targets for the development of drugs to combat AD.	Univ Munich, Dept Biochem, Adolf Butenandt Inst, D-80539 Munich, Germany; Katholieke Univ Leuven VIB, Ctr Human Genet, Neuronal Cell Biol & Gene Transfer Lab, Louvain, Belgium	University of Munich; Flanders Institute for Biotechnology (VIB); KU Leuven	Haass, C (corresponding author), Univ Munich, Dept Biochem, Adolf Butenandt Inst, D-80539 Munich, Germany.	chaass@pbm.med.uni-muenchen.de; Bart.Destrooper@med.kuleuven.ac.be	De Strooper, Bart/F-6507-2012; de+Strooper, Bart/Z-1638-2019	De Strooper, Bart/0000-0001-5455-5819; 				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baumeister R, 1997, Genes Funct, V1, P149; Beher D, 1999, J NEUROCHEM, V72, P1564, DOI 10.1046/j.1471-4159.1999.721564.x; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brockhaus M, 1998, NEUROREPORT, V9, P1481, DOI 10.1097/00001756-199805110-00043; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Capell A, 1997, J NEUROCHEM, V69, P2432; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Culvenor JG, 1997, J NEUROSCI RES, V49, P719, DOI 10.1002/(SICI)1097-4547(19970915)49:6<719::AID-JNR6>3.0.CO;2-A; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Dewji NN, 1997, P NATL ACAD SCI USA, V94, P9926, DOI 10.1073/pnas.94.18.9926; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Efthimiopoulos S, 1998, J NEUROCHEM, V71, P2365; EVIN G, 1995, BIOCHEMISTRY-US, V34, P14185, DOI 10.1021/bi00043a024; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Haass C, 1998, J NEURAL TRANSM-SUPP, P159; Hartmann D, 1999, CURR BIOL, V9, P719, DOI 10.1016/S0960-9822(99)80331-5; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; JACOBSEN H, IN PRESS J BIOL CHEM; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kang DE, 1999, J NEUROSCI, V19, P4229; Kim TW, 1997, J BIOL CHEM, V272, P11006; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; LEIMER U, IN PRESS BIOCHEMISTR; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Qian S, 1998, NEURON, V20, P611, DOI 10.1016/S0896-6273(00)80999-X; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SAFTIG P, 1998, MOL BIOL ALZHEIMERS, P235; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schwarzman AL, 1999, P NATL ACAD SCI USA, V96, P7932, DOI 10.1073/pnas.96.14.7932; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; STEINER H, IN PRESS J BIOL CHEM; STEINER H, IN PRESS BIOCHEMISTR; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Van Broeckhoven C, 1995, NAT GENET, V11, P230; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	85	340	356	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					916	919		10.1126/science.286.5441.916	http://dx.doi.org/10.1126/science.286.5441.916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542139				2022-12-28	WOS:000083368500034
J	Chun, TW; Davey, RT; Engel, D; Lane, HC; Fauci, AS				Chun, TW; Davey, RT; Engel, D; Lane, HC; Fauci, AS			AIDS - Re-emergence of HIV after stopping therapy	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; ANTIRETROVIRAL THERAPY; INDINAVIR		NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Chun, TW (corresponding author), NIAID, Immunoregulat Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.		Chun, Tae-Wook/AAC-3101-2020; Chun, Tae-Wook/W-9187-2019	Chun, Tae-Wook/0000-0001-5153-7340				Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; CHUN TW, 1999, NAT MED, V5, P615; Cohen OJ, 1998, JAMA-J AM MED ASSOC, V280, P87, DOI 10.1001/jama.280.1.87; DAVEY RT, IN PRESS P NATL ACAD; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	10	329	333	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					874	875		10.1038/44755	http://dx.doi.org/10.1038/44755			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553903				2022-12-28	WOS:000083464700044
J	Parker, L; Pearce, MS; Dickinson, HO; Aitkin, M; Craft, AW				Parker, L; Pearce, MS; Dickinson, HO; Aitkin, M; Craft, AW			Stillbirths among offspring of male radiation workers at Sellafield nuclear reprocessing plant	LANCET			English	Article							CONGENITAL-MALFORMATIONS; IONIZING-RADIATION; TUMOR-INDUCTION; WEST CUMBRIA; MALE-MICE; INSTALLATION; IRRADIATION; LEUKEMIA; EXPOSURE; ENGLAND	Background Ionising radiation is a known mutagen, but few studies have examined transgenerational effects of paternal exposure in human beings. The workforce at the Sellafield nuclear reprocessing plant in the county of Cumbria, UK, is the most highly exposed workforce in western Europe and North America. This study, which is part of a larger programme of work investigating the health of the children of the Sellafield workforce, set out to find whether there was evidence of an association between stillbirth risk and paternal exposure to ionising radiation. Methods We collected details from birth registration documents for all singleton 248 097 livebirths and 3715 stillbirths in the county of Cumbria 1950-89. Within this cohort the 130 stillbirths and 9078 livebirths to partners of male radiation workers employed at Sellafield were identified. Logistic regression was' used to analyse the relation between stillbirth risk and father's preconceptional radiation exposure, with adjustment for social class, year of birth, father's age, and birth order. Findings A significant positive association was found between the risk of a baby being stillborn and the father's total exposure to external ionising radiation before conception (adjusted odds ratio per 100 mSv 1.24 [95% CI 1.04-1.45], p=0.009); The risk was higher for stillbirths with congenital anomaly and was highest for the nine stillbirths with neural-tube defects. The statistical models predicted that, were the association to be interpreted as causal, between 0 and 31.9 of the 130 stillbirths to the workforce may be attributable to father's radiation exposure. Interpretation The findings of an increased risk of stillbirth with increasing paternal occupational exposure to external radiation are qualitatively consistent with those from animal models, though the risk estimate is higher. Although we cannot exclude the possibility of an unmeasured risk factor for stillbirth, confounded with paternal preconceptional irradiation, extensive checks confirmed that the statistical models were a good fit to the data and there was not statistical evidence of unmeasured factors.	Newcastle Univ, Dept Child Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Newcastle Univ, Dept Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Parker, L (corresponding author), Royal Victoria Infirm, Sir James Spence Inst, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	Louise.Parker@ncl.ac.uk		PARKER, LOUISE/0000-0002-5188-8113; Pearce, Mark/0000-0002-0583-3779				Aitkin M, 1999, BIOMETRICS, V55, P117, DOI 10.1111/j.0006-341X.1999.00117.x; Aitkin M, 1996, STAT COMPUT, V6, P251, DOI 10.1007/BF00140869; ALBERMAN E, 1994, ARCH DIS CHILD, V70, P403, DOI 10.1136/adc.70.5.403; BOBROW M, 1988, 2 COMARE; BRENDER JD, 1990, AM J EPIDEMIOL, V131, P517, DOI 10.1093/oxfordjournals.aje.a115526; Breslow NE., 1987, STAT METHODS CANC RE, P81; BRIDGES BA, 1996, 4 COMARE; CARDIS E, 1994, LANCET, V344, P1039; CATTANACH BM, 1995, INT J RADIAT BIOL, V67, P607, DOI 10.1080/09553009514550721; Copp AJ, 1998, CURR OPIN NEUROL, V11, P97, DOI 10.1097/00019052-199804000-00003; Daher A, 1998, CARCINOGENESIS, V19, P1553, DOI 10.1093/carcin/19.9.1553; Denniston C, 1998, MUTAT RES-FUND MOL M, V405, P57, DOI 10.1016/S0027-5107(98)00146-8; Dickinson HO, 1996, J EPIDEMIOL COMMUN H, V50, P645, DOI 10.1136/jech.50.6.645; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; Draper GJ, 1997, BRIT MED J, V315, P1181, DOI 10.1136/bmj.315.7117.1181; Dummer TJB, 1998, INT J EPIDEMIOL, V27, P74, DOI 10.1093/ije/27.1.74; Dummer TJB, 1999, PAEDIATR PERINAT EP, V13, P131; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; *INT COMM RAD PROT, 1988, ICRP PUB, V54; KIRK KM, 1984, MUTAT RES, V125, P75, DOI 10.1016/0027-5107(84)90034-4; Kite AV, 1996, RADIAT PROT DOSIM, V67, P23, DOI 10.1093/oxfordjournals.rpd.a031792; Lord BI, 1998, BRIT J CANCER, V78, P301, DOI 10.1038/bjc.1998.491; MACFARLANE A, 1984, BIRTH COUNTS STAT PR; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; National Council on Radiation Protection and Measurements, 1997, 126 NCRP; Neel J V, 1991, CHILDREN ATOMIC BOMB; *OFF POP CENS SURV, 1974, BIRT STAT FM1; *OFF POP CENS SURV, 1974, MORT SER; Office of Population Censuses and Surveys, 1990, STAND OCC CLASS, V3; Office of Population Censuses and Surveys, 1990, STAND OCC CLASS, V1; Office of Population Censuses and Surveys, 1990, STAND OCC CLASS, V2; PARKER L, 1993, BRIT MED J, V307, P966, DOI 10.1136/bmj.307.6910.966; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; Russell WL, 1998, GENETICS, V148, P1567; SEVER LE, 1988, AM J EPIDEMIOL, V127, P226, DOI 10.1093/oxfordjournals.aje.a114799; *UN, 1994, SCI COMM EFF AT RAD; *UN, 1993, SCI COMM EFF AT RAD; Wakeford R., 1994, Journal of Radiological Protection, V14, P3, DOI 10.1088/0952-4746/14/1/001; [No title captured]	40	81	88	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1999	354	9188					1407	1414		10.1016/S0140-6736(99)04138-0	http://dx.doi.org/10.1016/S0140-6736(99)04138-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543666				2022-12-28	WOS:000083277400009
J	Ramsay, S				Ramsay, S			More developments in developing-world research ethics	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Ramsay, S (corresponding author), The Lancet, London WC1B 3SL, England.							Ahmed AH, 1996, J MED ETHICS, V22, P263, DOI 10.1136/jme.22.5.263; CRAWLEY F, 1998, APPL CLIN TRIALS, V7, P36; *NUFF COUNC BIOETH, 1999, ETH RES DEV COUNTR; Ramsay S, 1999, LANCET, V354, P928, DOI 10.1016/S0140-6736(05)75680-4	4	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1405	1406		10.1016/S0140-6736(99)00352-9	http://dx.doi.org/10.1016/S0140-6736(99)00352-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	248LY	10543664				2022-12-28	WOS:000083277400007
J	Wang, H; Tessier-Lavigne, M				Wang, H; Tessier-Lavigne, M			En passant neurotrophic action of an intermediate axonal target in the developing mammalian CNS	NATURE			English	Article							SENSORY NEURONS; COMMISSURAL AXONS; NERVOUS-SYSTEM; SPINAL-CORD; SURVIVAL; PROMOTE; DEATH; GUIDANCE; NETRINS	During development, neurons extend axons to their targets, then become dependent for their survival on trophic substances secreted by their target cells. Competition for limiting amounts of these substances is thought to account for much of the extensive naturally-occurring cell death that is seen throughout the nervous system. Here we show that spinal commissural neurons, a group of long projection neurons in the central nervous system (CNS), are also dependent for their survival on trophic support from one of their intermediate targets, the floor plate of the spinal cord. This dependence occurs during a several-day-long period when their axons extend along the floor plate, following which they develop additional trophic requirements. A dependence of neurons on trophic support derived en passant from their intermediate axonal targets provides a mechanism for rapidly eliminating misprojecting neurons, which may help to prevent the formation of aberrant neuronal circuits during the development of the nervous system.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Tessier-Lavigne, M (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA.							ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; COMPENOT RB, 1982, DEV BIOL, V93, P1; COWAN W, 1984, S CEL HARV MED SCH B, P643; Davies AM, 1997, CURR OPIN NEUROBIOL, V7, P110, DOI 10.1016/S0959-4388(97)80128-6; Farinas I, 1996, NEURON, V17, P1065, DOI 10.1016/S0896-6273(00)80240-8; Huang EJ, 1999, DEVELOPMENT, V126, P2191; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Liebl DJ, 1997, J NEUROSCI, V17, P9113; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Oppenheim RW, 1996, NEURON, V17, P195, DOI 10.1016/S0896-6273(00)80151-8; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Pinon LGP, 1996, DEVELOPMENT, V122, P3255; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PURVES D, 1985, PRINCIPLES NEURAL DE; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; Wilkinson GA, 1996, J NEUROSCI, V16, P7661; WRIGHT EM, 1992, NEURON, V9, P139, DOI 10.1016/0896-6273(92)90229-7	21	53	55	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					765	769		10.1038/44521	http://dx.doi.org/10.1038/44521			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548102				2022-12-28	WOS:000083368700045
J	Hu, FB; Sigal, RJ; Rich-Edwards, JW; Colditz, GA; Solomon, CG; Willett, WC; Speizer, FE; Manson, JAE				Hu, FB; Sigal, RJ; Rich-Edwards, JW; Colditz, GA; Solomon, CG; Willett, WC; Speizer, FE; Manson, JAE			Walking compared with vigorous physical activity and risk of type 2 diabetes in women - A prospective study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VISCERAL ADIPOSE-TISSUE; CORONARY HEART-DISEASE; MIDDLE-AGED MEN; INSULIN SENSITIVITY; GLUCOSE-TOLERANCE; WESTERN-SAMOA; UNITED-STATES; WEIGHT-GAIN; EXERCISE; MELLITUS	Context Although many studies suggest that physical activity may reduce risk of type 2 diabetes, the role of moderate-intensity activity such as walking is not well understood. Objectives To examine the relationship of total physical activity and incidence of type 2 diabetes in women and to compare the benefits of walking vs vigorous activity as predictors of subsequent risk of type 2 diabetes. Design and Setting The Nurses' Health Study, a prospective cohort study that included detailed data for physical activity from women surveyed in 11 US states in 1986, with updates in 1988 and 1992. Participants A total of 70 102 female nurses aged 40 to 65 years who did not have diabetes, cardiovascular disease, or cancer at baseline (1986). Main Outcome Measure Risk of type 2 diabetes by quintile of metabolic equivalent task (MET) score, based on time spent per week on each of 8 common physical activities, including walking. Results During 8 years of follow-up (534 928 person-years), we documented 1419 incident cases of type 2 diabetes. After adjusting for age, smoking, alcohol use, history of hypertension, history of high cholesterol level, and other covariates, the relative risks (RRs) of developing type 2 diabetes across quintiles of physical activity (least to most) were 1.0, 0.77, 0.75, 0.62, and 0.54 (P for trend <.001); after adjusting for body mass index (BMI), RRs were 1.0, 0.84, 0.871 0.77, and 0.74 (P for trend = .002). Among women who did not perform vigorous activity, multivariate RRs of type 2 diabetes across quintiles of MET score for walking were 1.0, 0.91, 0.73, 0.69, and 0.58 (P for trend <.001). After adjusting for BMI, the trend remained statistically significant (RRs were 1.0, 0.95, 0.80, 0.81, 0.74; P for trend = .01). Faster usual walking pace was independently associated with decreased risk. Equivalent energy expenditures from walking and vigorous activity resulted in comparable magnitudes of risk reduction. Conclusions Our data suggest that greater physical activity level is associated with substantial reduction in risk of type 2 diabetes, including physical activity of moderate intensity and duration.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Med Sch, Channing Lab, Boston, MA USA; Harvard Med Sch, Dept Med, Div Prevent Med, Boston, MA USA; Harvard Med Sch, Dept Ambulatory Care & Prevent, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Ottawa, Loeb Hlth Res Inst, Clin Epidemiol Unit, Ottawa, ON, Canada	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Ottawa; Ottawa Hospital Research Institute	Hu, FB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	Frank.hu@channing.harvard.edu	Sigal, Ron/AAK-7627-2020; Colditz, Graham/A-3963-2009; Sigal, Ronald/AAU-6081-2020	Colditz, Graham/0000-0002-7307-0291; 	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline; NIDDK NIH HHS [DK 36798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; Andersen RE, 1999, JAMA-J AM MED ASSOC, V281, P335, DOI 10.1001/jama.281.4.335; ANNUZZI G, 1991, EUR J CLIN INVEST, V21, P6, DOI 10.1111/j.1365-2362.1991.tb01351.x; [Anonymous], 1996, JAMA, V276, P241; BLAIR SN, 1993, ANN INTERN MED, V119, P702, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00015; BURCHFIEL CM, 1995, AM J EPIDEMIOL, V141, P360, DOI 10.1093/aje/141.4.360; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; COLLINS VR, 1994, DIABETES CARE, V17, P288, DOI 10.2337/diacare.17.4.288; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DEVLIN JT, 1992, DIABETES CARE, V15, P1690, DOI 10.2337/diacare.15.11.1690; Dunn AL, 1999, JAMA-J AM MED ASSOC, V281, P327, DOI 10.1001/jama.281.4.327; ERIKSSON KF, 1991, DIABETOLOGIA, V34, P891, DOI 10.1007/BF00400196; Gavin JR, 1997, DIABETES CARE, V20, P1183; GOHDES D, 1993, DIABETES CARE, V16, P239, DOI 10.2337/diacare.16.1.239; GOODYEAR LJ, 1992, MED SPORT SCI, V37, P201; GURWITZ JH, 1994, J AM GERIATR SOC, V42, P1235, DOI 10.1111/j.1532-5415.1994.tb06503.x; Haapanen N, 1997, INT J EPIDEMIOL, V26, P739, DOI 10.1093/ije/26.4.739; HARRIS M, 1979, DIABETES, V28, P1039; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Henriksson J, 1995, J Cardiovasc Risk, V2, P303, DOI 10.1097/00043798-199508000-00004; HODGE AM, 1994, INT J OBESITY, V18, P419; HODGE AM, 1995, INT J OBESITY, V19, P689; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; JACOBS DR, 1993, MED SCI SPORT EXER, V25, P81, DOI 10.1249/00005768-199301000-00012; Lynch J, 1996, ARCH INTERN MED, V156, P1307, DOI 10.1001/archinte.156.12.1307; MANSON JE, 1994, AM J PREV MED, V10, P172, DOI 10.1016/S0749-3797(18)30615-9; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; Mayer-Davis EJ, 1998, JAMA-J AM MED ASSOC, V279, P669, DOI 10.1001/jama.279.9.669; Mourier A, 1997, DIABETES CARE, V20, P385, DOI 10.2337/diacare.20.3.385; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PERRY IJ, 1995, BRIT MED J, V310, P560, DOI 10.1136/bmj.310.6979.560; REWERS M, 1995, DIABETES AM, P179; Ross R, 1996, J APPL PHYSIOL, V81, P2445, DOI 10.1152/jappl.1996.81.6.2445; ROSS R, 1994, AM J CLIN NUTR, V60, P695, DOI 10.1093/ajcn/60.5.695; SCHRANZ A, 1991, DIABETES RES CLIN PR, V11, P127, DOI 10.1016/0168-8227(91)90102-J; SIGAL RJ, 1996, CURR OPIN ENDOCRINOL, V3, P3; Smith SR, 1999, INT J OBESITY, V23, P329, DOI 10.1038/sj.ijo.0800834; Weller I, 1998, EPIDEMIOLOGY, V9, P632, DOI 10.1097/00001648-199811000-00012; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; YAMANOUCHI K, 1995, DIABETES CARE, V18, P775, DOI 10.2337/diacare.18.6.775; Yusuf HR, 1996, ARCH INTERN MED, V156, P1321, DOI 10.1001/archinte.156.12.1321	45	577	590	3	61	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1433	1439		10.1001/jama.282.15.1433	http://dx.doi.org/10.1001/jama.282.15.1433			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535433	Bronze			2022-12-28	WOS:000083111000028
J	Horton, R				Horton, R			Genetically modified foods: "absurd" concern or welcome dialogue?	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Horton, R (corresponding author), The Lancet, London WC1B 3SL, England.							[Anonymous], 1999, LANCET, V353, P1811; DOBSON R, 1999, INDEPENDENT SUN 0926, P16; DONALDSON L, 1999, HLTH IMPLICATIONS GE; FINN G, 1999, INDEPENDENT     1005, P1; Lachmann P, 1999, LANCET, V354, P69, DOI 10.1016/S0140-6736(99)00117-8; LEAN G, 1999, INDEPENDENT SUN 1003, P1; May R. M., 1999, GENETICALLY MODIFIED; QUINN S, 1999, GUARDIAN        0927, P4; ROYAL SOCIETY, 1998, GEN MOD PLANTS FOOD	9	21	22	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1999	354	9187					1314	1315		10.1016/S0140-6736(99)00340-2	http://dx.doi.org/10.1016/S0140-6736(99)00340-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533853				2022-12-28	WOS:000083149900002
J	Casadio, A; Martin, KC; Giustetto, M; Zhu, HX; Chen, M; Bartsch, D; Bailey, CH; Kandel, ER				Casadio, A; Martin, KC; Giustetto, M; Zhu, HX; Chen, M; Bartsch, D; Bailey, CH; Kandel, ER			A transient, neuron-wide form of CREB-mediated long-term facilitation can be stabilized at specific synapses by local protein synthesis	CELL			English	Article							APLYSIA SENSORY NEURONS; CAMP-RESPONSIVE ELEMENT; SYNAPTIC FACILITATION; STRUCTURAL-CHANGES; TRANSLATION INITIATION; MEMORY STORAGE; SEROTONIN; SENSITIZATION; VARICOSITIES; POTENTIATION	In a culture system where a bifurcated Aplysia sensory neuron makes synapses with two motor neurons, repeated application of serotonin (5-HT) to one synapse produces a CREB-mediated, synapse-specific, longterm facilitation, which can be captured at the opposite synapse by a single pulse of 5-HT. Repeated pulses of 5-HT applied to the cell body of the sensory neuron produce a CREB-dependent, cell-wide facilitation, which, unlike synapse-specific facilitation, is not associated with growth and does not persist beyond 48 hr. Persistent facilitation and synapse-specific growth can be induced by a single pulse of 5-HT applied to a peripheral synapse. Thus, the short-term process initiated by a single pulse of 5-HT serves not only to produce transient facilitation, but also to mark and stabilize any synapse of the neuron for long-term facilitation by means of a covalent mark and rapamycin-sensitive local protein synthesis.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University	Kandel, ER (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA.	erk5@columbia.edu	giustetto, maurizio/D-6606-2011	giustetto, maurizio/0000-0003-1323-4060	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037134] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 37134] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; BAILEY CH, 1989, J NEUROSCI, V9, P1774; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bartsch D, 1998, CELL, V95, P211, DOI 10.1016/S0092-8674(00)81752-3; Berset C, 1998, P NATL ACAD SCI USA, V95, P4264, DOI 10.1073/pnas.95.8.4264; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; CLARK GA, 1993, P NATL ACAD SCI USA, V90, P11411, DOI 10.1073/pnas.90.23.11411; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; Frey U, 1998, NEUROPHARMACOLOGY, V37, P545, DOI 10.1016/S0028-3908(98)00040-9; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GOLDBERG DJ, 1980, J PHYSIOL-LONDON, V307, P259, DOI 10.1113/jphysiol.1980.sp013434; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; KISTLER HB, 1985, J NEUROSCI, V5, P72; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sun ZY, 1998, J NEUROSCI, V18, P3991; Yanow SK, 1998, J NEUROCHEM, V70, P572; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZHANG ZS, 1991, J COMP NEUROL, V311, P259, DOI 10.1002/cne.903110207	36	400	410	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					221	237		10.1016/S0092-8674(00)81653-0	http://dx.doi.org/10.1016/S0092-8674(00)81653-0			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535740	hybrid			2022-12-28	WOS:000083159700012
J	Yamey, G				Yamey, G			UK's yellow card scheme to be extended	BRITISH MEDICAL JOURNAL			English	News Item																		1999, PHARM J, V263, P786	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1322	1322						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567125	Green Published			2022-12-28	WOS:000083930200014
J	Sereno, PC; Beck, AL; Dutheil, DB; Larsson, HCE; Lyon, GH; Moussa, B; Sadleir, RW; Sidor, CA; Varricchio, DJ; Wilson, GP; Wilson, JA				Sereno, PC; Beck, AL; Dutheil, DB; Larsson, HCE; Lyon, GH; Moussa, B; Sadleir, RW; Sidor, CA; Varricchio, DJ; Wilson, GP; Wilson, JA			Cretaceous sauropods from the Sahara and the uneven rate of skeletal evolution among dinosaurs	SCIENCE			English	Article							PHYLOGENY; AFRICA	Lower Cretaceous fossils from central Niger document the succession of sauropod dinosaurs on Africa as it drifted into geographic isolation. A new broad-toothed genus of Neocomian age (similar to 135 million years ago) shows few of the specializations of other Cretaceous sauropods. A new smalt-bodied sauropod of Aptian-Albian age (similar to 110 million years ago), in contrast, reveals the highly modified cranial form of rebbachisaurid diplodocoids. Rates of skeletal change in sauropods and other major groups of dinosaurs are estimated quantitatively and shown to be highly variable.	Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; Museum Natl Hist Nat, EPHE, Lab Paleontol, F-75231 Paris, France; Project Explorat, Chicago, IL 60637 USA; CNRS, Ctr Sci Terre, F-2100 Dijon, France; Univ Illinois, Dept Earth & Environm Sci, Chicago, IL 60607 USA; Montana State Univ, Museum Rockies, Bozeman, MT 59717 USA; Univ Calif Berkeley, Museum Paleontol, Berkeley, CA 94720 USA; Univ Michigan, Museum Paleontol, Ann Arbor, MI 48109 USA	University of Chicago; Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Montana State University System; Montana State University Bozeman; University of California System; University of California Berkeley; University of Michigan System; University of Michigan	Sereno, PC (corresponding author), Univ Chicago, Dept Organismal Biol & Anat, 1027 E 57th St, Chicago, IL 60637 USA.		Wilson, Jeffrey/C-2737-2008; Larsson, Hans/AAD-4579-2019; Wilson, Gregory P/A-2363-2009	Larsson, Hans/0000-0002-6377-4770; Wilson Mantilla, Gregory/0000-0003-3604-5473; Dutheil, Didier/0000-0002-4856-0918				Calvo Jorge O., 1995, Gaia, V11, P13; de LAPPARENT ALBERT F., 1960, MEM SOC GEOL FRANCE, V88 A, P1; FAURE H, 1966, MEMOIRES BUREAU RECH, V47, P1; Filla B. J., 1994, DINOSAURS WYOMING, P159; Fox DL, 1999, SCIENCE, V284, P1816, DOI 10.1126/science.284.5421.1816; GAUTHIER J, 1988, CLADISTICS, V4, P105, DOI 10.1111/j.1096-0031.1988.tb00514.x; Gilmore C. W., 1925, Memoirs of the Carnegie Museum, V10, P347; GRADSTEIN FM, 1995, SEPM SPEC PUBL, V54, P95; Greigert J., 1967, MEM BUR RECH GEOL MI, V48, P1; JACOBS LL, 1993, PALAEONTOLOGY, V36, P523; LAVOCAT R, 1954, COMPT REND 19 SESS C, V3, P65; MARSH OC, 1896, 16 US GEOL SURV, P133; McIntosh J.S., 1990, P345; McIntosh John S., 1996, Bulletin of Gunma Museum of Natural History, V1, P1; MOLINAS E, 1965, RAPP CEA MARSEILLE, P1; MOODY RTJ, 1991, CRETACEOUS RES, V12, P137, DOI 10.1016/S0195-6671(05)80021-7; NORELL MA, 1993, AM J SCI, V293A, P407, DOI 10.2475/ajs.293.A.407; NORELL MA, 1992, CLADISTICS, V8, P319, DOI 10.1111/j.1096-0031.1992.tb00074.x; SALGADO L, 1991, Ameghiniana, V28, P333; Sereno PC, 1999, SCIENCE, V284, P2137, DOI 10.1126/science.284.5423.2137; Sereno PC, 1997, ANNU REV EARTH PL SC, V25, P435, DOI 10.1146/annurev.earth.25.1.435; SERENO PC, 1994, SCIENCE, V266, P267, DOI 10.1126/science.266.5183.267; Sereno PC, 1998, SCIENCE, V282, P1298, DOI 10.1126/science.282.5392.1298; Sidor CA, 1998, PALEOBIOLOGY, V24, P254; Smith A.G., 1994, ATLAS MESOZOIC CENOZ; SMITH AB, 1992, PHILOS T R SOC B, V338, P365, DOI 10.1098/rstb.1992.0155; Stevens KA, 1999, SCIENCE, V284, P798, DOI 10.1126/science.284.5415.798; Stromer E., 1934, ABH BAYER AKAD WISS, V22, P1; Taquet P, 1976, CAHIERS PALEONTOLOGI, P1; Taquet Philippe, 1999, Annales de Paleontologie, V85, P85, DOI 10.1016/S0753-3969(99)80009-3; von Huene F.F., 1929, ANALES MUSEO LA PLAT, V3, P1; WAGNER PJ, IN PRESS SYST BIOL; Wilson JA, 1998, J VERTEBR PALEONTOL, V18, P1, DOI 10.1080/02724634.1998.10011115; Wilson JA, 1999, THESIS U CHICAGO; Zhang YH., 1988, MIDDLE JURASSIC DINO	35	202	208	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1342	1347		10.1126/science.286.5443.1342	http://dx.doi.org/10.1126/science.286.5443.1342			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558986	Green Submitted			2022-12-28	WOS:000083675500038
J	Botto, LD; Moore, CA; Khoury, MJ; Erickson, JD				Botto, LD; Moore, CA; Khoury, MJ; Erickson, JD			Neural-tube defects	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SPINA-BIFIDA; FOLIC-ACID; RISK FACTOR; METHYLENETETRAHYDROFOLATE REDUCTASE; PERICONCEPTIONAL USE; DIETARY-FOLATE; IN-UTERO; VITAMIN SUPPLEMENTATION; AFFECTED PREGNANCIES; FOOD FORTIFICATION		Ctr Dis Control & Prevent, Birth Defects & Genet Dis Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Off Genet & Dis Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Botto, LD (corresponding author), Ctr Dis Control & Prevent, Birth Defects & Genet Dis Branch, Natl Ctr Environm Hlth, Mailstop F-45,4770 Buford Hwy NE, Atlanta, GA 30341 USA.							Adzick NS, 1998, LANCET, V352, P1675, DOI 10.1016/S0140-6736(98)00070-1; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BECERRA JE, 1990, PEDIATRICS, V85, P1; Bekkers RLM, 1999, LANCET, V353, P292, DOI 10.1016/S0140-6736(05)74936-9; BELL JE, 1978, CLIN GENET, V13, P387; Berry RJ, 1999, NEW ENGL J MED, V341, P1485, DOI 10.1056/NEJM199911113412001; Botto LD, 1998, CLIN GENET, V53, P456; Botto LD, 1999, AM J EPIDEMIOL, V150, P323; BOTTO LD, 1999, MTHFR BIRTH DEFECTS; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; Bruner JP, 1999, AM J OBSTET GYNECOL, V180, P153, DOI 10.1016/S0002-9378(99)70167-5; CAMPBELL LR, 1990, J CHILD NEUROL, V5, P336, DOI 10.1177/088307389000500413; Christensen B, 1999, AM J MED GENET, V84, P151, DOI 10.1002/(SICI)1096-8628(19990521)84:2<151::AID-AJMG12>3.3.CO;2-K; Copp AJ, 1998, CURR OPIN NEUROL, V11, P97, DOI 10.1097/00019052-199804000-00003; COPP AJ, 1997, EMBRYOS GENES BIRTH, P133; Cornel MC, 1997, TERATOLOGY, V55, P134; Cragan J D, 1995, MMWR CDC Surveill Summ, V44, P1; Cremer R, 1998, ALLERGY, V53, P709, DOI 10.1111/j.1398-9995.1998.tb03958.x; Cuskelly GJ, 1996, LANCET, V347, P657, DOI 10.1016/S0140-6736(96)91205-2; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; Daly S, 1997, LANCET, V350, P1666, DOI 10.1016/S0140-6736(97)07247-4; DATE I, 1993, SURG NEUROL, V40, P471, DOI 10.1016/0090-3019(93)90049-7; de Walle HEK, 1999, LANCET, V353, P1187, DOI 10.1016/S0140-6736(05)74409-3; den Quden A L, 1996, Ned Tijdschr Geneeskd, V140, P2092; Drewek MJ, 1997, PEDIATR NEUROSURG, V27, P190, DOI 10.1159/000121250; EDWARDS MJ, 1995, REPROD TOXICOL, V9, P411, DOI 10.1016/0890-6238(95)00043-A; ELWOOD JM, 1992, MONOGRAPHS EPIDEMIOL, V20, P168; ELWOOD JM, 1992, MONOGRAPHS EPIDEMIOL, V20, P414; Food and Drug Administration, 1996, FED REGISTER, V61, P8781; FORREST JD, 1994, AM J OBSTET GYNECOL, V170, P1485, DOI 10.1016/S0002-9378(94)05008-8; Graham JM, 1998, TERATOLOGY, V58, P209, DOI 10.1002/(SICI)1096-9926(199811)58:5<209::AID-TERA8>3.0.CO;2-Q; Hall J, 1998, EUR J PEDIATR, V157, P445, DOI 10.1007/s004310050850; HOLMES LB, 1976, NEW ENGL J MED, V294, P365, DOI 10.1056/NEJM197602122940704; Hunt GM, 1997, DEV MED CHILD NEUROL, V39, P568; HUNTER AGW, 1993, OXFORD MONOGRAPHS ME, V27, P109; *I CTR BIRT DEF, 1998, EUROCAT WORLD ATL BI, P20; Institute of Medicine (US), 1998, NATL ACAD COLLECTION, V8; *INT CLEAR BIRTH D, 1998, ANN REP 1998 DAT 199, P100; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Juriloff DM, 1998, MENT RETARD DEV D R, V4, P254; Kinsman SL, 1996, EUR J PEDIATR SURG, V6, P17, DOI 10.1055/s-2008-1071031; KIRKE PN, 1993, Q J MED, V86, P703; LAMMER EJ, 1987, TERATOLOGY, V35, P465, DOI 10.1002/tera.1420350319; Lary J M, 1996, MMWR CDC Surveill Summ, V45, P15; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; Lawrence JM, 1999, LANCET, V354, P915, DOI 10.1016/S0140-6736(99)03227-4; LEMIRE RJ, 1988, JAMA-J AM MED ASSOC, V259, P558, DOI 10.1001/jama.259.4.558; Liptak GS, 1998, MENT RETARD DEV D R, V4, P296, DOI 10.1002/(SICI)1098-2779(1998)4:4<296::AID-MRDD9>3.0.CO;2-U; LITTLE J, 1992, MONOGRAPHS EPIDEMIOL, V20, P195; LITTLE J, 1992, MONOGRAPHS EPIDEMIOL, V20, P456; LITTLE J, 1992, MONOGRAPHS EPIDEMIOL, P146; LITTLE J, 1992, MONOGRAPHS EPIDEMIOL, V20, P324; LITTLE J, 1992, MONOGRAPHS EPIDEMIOL, V20, P96; Lynberg M C, 1990, MMWR CDC Surveill Summ, V39, P1; MCDONALD CM, 1995, NEUROSURG CLIN N AM, V6, P393; Meuli M, 1997, J PEDIATR SURG, V32, P448, DOI 10.1016/S0022-3468(97)90603-5; MEULI M, 1995, NAT MED, V1, P342, DOI 10.1038/nm0495-342; MILLS JL, 1989, NEW ENGL J MED, V321, P430, DOI 10.1056/NEJM198908173210704; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; Moore CA, 1997, AM J MED GENET, V73, P113; Morrison K, 1998, ANN HUM GENET, V62, P379, DOI 10.1046/j.1469-1809.1998.6250379.x; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; Oakley GP, 1997, AM J CLIN NUTR, V65, P1889, DOI 10.1093/ajcn/65.6.1889; Owen J, 1998, CLIN OBSTET GYNECOL, V41, P393, DOI 10.1097/00003081-199806000-00021; Ramsbottom D, 1997, CLIN GENET, V51, P39; Rosenblatt DS., 1995, METABOLIC MOL BASES, VSeventh, P3111; Rotenstein D, 1996, J PEDIATR-US, V128, pS28, DOI 10.1016/S0022-3476(96)70007-0; Rozen R, 1997, THROMB HAEMOSTASIS, V78, P523; Sadler TW, 1998, MENT RETARD DEV D R, V4, P247, DOI 10.1002/(SICI)1098-2779(1998)4:4<247::AID-MRDD3>3.0.CO;2-P; SAKAI Y, 1989, ANAT RECORD, V223, P194, DOI 10.1002/ar.1092230212; SEVER LE, 1995, ENVIRON HEALTH PERSP, V103, P165, DOI 10.2307/3432369; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; Shaw GM, 1996, JAMA-J AM MED ASSOC, V275, P1093, DOI 10.1001/jama.275.14.1093; Shaw GM, 1998, AM J EPIDEMIOL, V148, P30, DOI 10.1093/oxfordjournals.aje.a009555; Shaw GM, 1997, TERATOLOGY, V56, P295, DOI 10.1002/(SICI)1096-9926(199711)56:5<295::AID-TERA1>3.0.CO;2-X; SHIBUYA K, 1998, HLTH DIMENSIONS SEX, V3, P455; SHURTLEFF DB, 1994, CIBA F SYMP, V181, P270; SMITHELLS RW, 1976, ARCH DIS CHILD, V51, P944, DOI 10.1136/adc.51.12.944; SMITHELLS RW, 1983, LANCET, V1, P1027; STEEGERSTHEUNISSEN RPM, 1994, METABOLISM, V43, P1475, DOI 10.1016/0026-0495(94)90004-3; Szepfalusi Z, 1999, J PEDIATR-US, V134, P344, DOI 10.1016/S0022-3476(99)70461-0; Trembath D, 1999, TERATOLOGY, V59, P331, DOI 10.1002/(SICI)1096-9926(199905)59:5<331::AID-TERA4>3.0.CO;2-L; Tulipan N, 1998, PEDIATR NEUROSURG, V28, P177, DOI 10.1159/000028645; Tulipan N, 1999, LANCET, V353, P406, DOI 10.1016/S0140-6736(99)00021-5; van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825; VANALLEN MI, 1993, AM J MED GENET, V47, P723, DOI 10.1002/ajmg.1320470528; WAITZMAN NJ, 1996, COST BIRTH DEFECTS E, P145; WALD N, 1991, LANCET, V338, P131; Wald NJ, 1998, LANCET, V351, P834, DOI 10.1016/S0140-6736(05)78966-2; WALD NJ, 1997, EMERY RIMOINS PRINCI, V1, P545; WALLER DK, 1994, AM J OBSTET GYNECOL, V170, P541, DOI 10.1016/S0002-9378(94)70224-1; Wasserman CR, 1998, AM J PUBLIC HEALTH, V88, P1674, DOI 10.2105/AJPH.88.11.1674; Watkins ML, 1996, EPIDEMIOLOGY, V7, P507, DOI 10.1097/00001648-199609000-00009; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; Werler MM, 1996, JAMA-J AM MED ASSOC, V275, P1089, DOI 10.1001/jama.275.14.1089; Wilson A, 1999, MOL GENET METAB, V67, P317, DOI 10.1006/mgme.1999.2879; Zurmohle UM, 1998, J CHILD NEUROL, V13, P64, DOI 10.1177/088307389801300204; 1999, MMWR MORB MORTAL WKL, V48, P325	99	601	628	4	78	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1999	341	20					1509	1519		10.1056/NEJM199911113412006	http://dx.doi.org/10.1056/NEJM199911113412006			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RK	10559453				2022-12-28	WOS:000083625800006
J	Ham, C				Ham, C			Tragic choices in health care: lessons from the Child B case	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of Birmingham	Ham, C (corresponding author), Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England.	c.j.ham@bham.ac.uk						Daniels N, 1997, PHILOS PUBLIC AFF, V26, P303, DOI 10.1111/j.1088-4963.1997.tb00082.x; Daniels N, 1998, HEALTH AFFAIR, V17, P50, DOI 10.1377/hlthaff.17.5.50; DRAPER H, 1996, ETHICS VALUES COMMIS, V44; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HADORN DC, 1992, AM J LAW MED, V18, P73; Ham C, 1998, TRAGIC CHOICES HLTH	6	33	34	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	1999	319	7219					1258	1261		10.1136/bmj.319.7219.1258	http://dx.doi.org/10.1136/bmj.319.7219.1258			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	254RH	10550097	Green Published			2022-12-28	WOS:000083625600033
J	Pocklington, S				Pocklington, S			A principle to die for	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1277	1277		10.1136/bmj.319.7219.1277	http://dx.doi.org/10.1136/bmj.319.7219.1277			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550117	Green Published			2022-12-28	WOS:000083625600069
J	Francis, D; Diorio, J; Liu, D; Meaney, MJ				Francis, D; Diorio, J; Liu, D; Meaney, MJ			Nongenomic transmission across generations of maternal behavior and stress responses in the rat	SCIENCE			English	Article							CORTICOTROPIN-RELEASING FACTOR; INTERGENERATIONAL TRANSMISSION; CARE	In the rat, variations in maternal care appear to influence the development of behavioral and endocrine responses to stress in the offspring. The results of cross-fostering studies reported here provide evidence for (i) a causal relationship between maternal behavior and stress reactivity in the offspring and (ii) the transmission of such individual differences in maternal behavior from one generation of females to the next. Moreover, an environmental manipulation imposed during early development that alters maternal behavior can then affect the pattern of transmission in subsequent generations. Taken together, these findings indicate that variations in maternal care can serve as the basis for a nongenomic behavioral transmission of individual differences in stress reactivity across generations.	McGill Univ, Dept Psychiat, Douglas Hosp Res Ctr, Dev Neuroendocrinol Lab, Verdun, PQ H4H 1R3, Canada; McGill Univ, Dept Neurol & Neurosurg, Douglas Hosp Res Ctr, Dev Neuroendocrinol Lab, Verdun, PQ H4H 1R3, Canada	McGill University; McGill University	Meaney, MJ (corresponding author), McGill Univ, Dept Psychiat, Douglas Hosp Res Ctr, Dev Neuroendocrinol Lab, Verdun, PQ H4H 1R3, Canada.	mdmm@musica.mcgill.ca	Meaney, Michael/N-5931-2019					ALBERTS JR, 1989, HDB BEHAV NEUROBIOLO, V9; [Anonymous], 1994, SEMIN NEUROSCI; BARNETT SA, 1967, NATURE, V213, P150, DOI 10.1038/213150a0; BHATNAGAR S, 1995, J NEUROENDOCRINOL, V7, P97, DOI 10.1111/j.1365-2826.1995.tb00672.x; BOWLBY J, 1951, MATERNAL CARE MENT H; BUREAU MH, 1993, J NEUROCHEM, V61, P1479, DOI 10.1111/j.1471-4159.1993.tb13643.x; Caldji C, 1998, P NATL ACAD SCI USA, V95, P5335, DOI 10.1073/pnas.95.9.5335; DALLMAN MF, 1992, J NEUROENDOCRINOL, V4, P517, DOI 10.1111/j.1365-2826.1992.tb00200.x; DENENBERG VH, 1967, NATURE, V216, P549, DOI 10.1038/216549a0; DUNN AJ, 1990, BRAIN RES REV, V15, P71, DOI 10.1016/0165-0173(90)90012-D; EISENBERG L, 1990, MAMMALIAN PARENTING; Fairbanks LA., 1996, ADV STUD BEHAV, V25, P579, DOI [10.1016/S0065-3454(08)60343-5, DOI 10.1016/S0065-3454(08)60343-5]; Field T, 1998, PREV MED, V27, P200, DOI 10.1006/pmed.1998.0293; FLEMING AS, 1988, PSYCHONEUROENDOCRINO, V13, P189, DOI 10.1016/0306-4530(88)90014-5; FRANCIS D, UNPUB; Gray J.A., 1987, PSYCHOL FEAR STRESS, V2nd, P422; GROSSMAN KE, 1993, ATTACHMENT LIFE CYCL; HARLOW HF, 1958, AM PSYCHOL, V13, P673, DOI 10.1037/h0047884; HENNESSY MB, 1982, PHYSIOL PSYCHOL, V10, P153; Herman JP, 1997, TRENDS NEUROSCI, V20, P78, DOI 10.1016/S0166-2236(96)10069-2; HESS JL, 1969, PHYSIOL BEHAV, V4, P109, DOI 10.1016/0031-9384(69)90023-7; LEE MHS, 1974, ANIM BEHAV, V22, P679, DOI 10.1016/S0003-3472(74)80016-3; LEVINE S, 1967, PHYSIOL BEHAV, V2, P55, DOI 10.1016/0031-9384(67)90011-X; LEVINE S, 1962, SCIENCE, V135, P795, DOI 10.1126/science.135.3506.795-a; Levine S., 1975, SOC STRESS DIS; LEVINE S, 1970, POSTNATAL DEV PHENOT; LIGHTMAN SL, 1994, CIBA F SYMP, V172, P173; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; MACCARI S, 1995, J NEUROSCI, V15, P110; MALIZIA AL, 1995, GABAA RECEPTORS ANXI; McCarty Richard, 1996, Physiology and Behavior, V59, P71, DOI 10.1016/0031-9384(95)02034-9; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MEANEY MJ, 1989, NEUROENDOCRINOLOGY, V50, P597, DOI 10.1159/000125287; Miller L, 1997, J AM ACAD CHILD PSY, V36, P1134, DOI 10.1097/00004583-199708000-00022; MYERS MM, 1989, DEV PSYCHOBIOL, V22, P55, DOI 10.1002/dev.420220105; Noone R. J., 1995, FAMILY SYSTEMS, V2, P116; OWENS MJ, 1991, PHARMACOL REV, V43, P425; Paxinos G., 2004, J CHEM INF MODEL, V5th; Plomin R., 1997, BEHAV GENET; PLOTSKY PM, 1991, J NEUROENDOCRINOL, V3, P1, DOI 10.1111/j.1365-2826.1991.tb00231.x; ROSENBLATT JS, 1994, ACTA PAEDIATR, V83, P3, DOI 10.1111/j.1651-2227.1994.tb13259.x; RoyByrne P, 1996, AM J PSYCHIAT, V153, P1444; Rutter ML, 1997, AM PSYCHOL, V52, P390; SCHULKIN J, 1994, NEUROSCI BIOBEHAV R, V18, P385, DOI 10.1016/0149-7634(94)90051-5; Smotherman W.P., 1980, MATERNAL INFLUENCES; Stern JM, 1997, DEV PSYCHOBIOL, V31, P19, DOI 10.1002/(SICI)1098-2302(199707)31:1<19::AID-DEV3>3.0.CO;2-X; Suomi SJ, 1997, BRIT MED BULL, V53, P170; Vallee M, 1997, J NEUROSCI, V17, P2626; VAN IJZENDOORN MH, 1992, DEV REV, V12, P76, DOI 10.1016/0273-2297(92)90004-L; ZARROW MX, 1973, P SOC EXP BIOL MED, V356, P141; ZARROW WD, 1973, PHYSIOL BEHAV, V356, P141	51	1322	1349	4	205	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1155	1158		10.1126/science.286.5442.1155	http://dx.doi.org/10.1126/science.286.5442.1155			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	253AJ	10550053				2022-12-28	WOS:000083534200043
J	Henney, JE				Henney, JE			Continuing shortage of IGIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.							1999, MMWR, V48, P159	1	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1613	1613		10.1001/jama.282.17.1613	http://dx.doi.org/10.1001/jama.282.17.1613			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553774				2022-12-28	WOS:000083368400006
J	Bowman, C; Johnson, M; Venables, D; Foote, C; Kane, RL				Bowman, C; Johnson, M; Venables, D; Foote, C; Kane, RL			Geriatric care in the United Kingdom: aligning services to needs	BRITISH MEDICAL JOURNAL			English	Article							LONG-TERM-CARE; ELDERLY PEOPLE; MANAGED CARE; COMMUNITY; PACE; HOME; NHS		Univ Bristol, Int Inst Hlth & Ageing, Bristol BS8 1TX, Avon, England; Brunelcare, Bristol BS1 6SL, Avon, England; Amersham Hosp, Amersham HP7 0JD, Bucks, England; Univ Minnesota, Sch Publ Hlth, Div Hlth Serv Res & Policy, Minneapolis, MN 55455 USA	University of Bristol; University of Minnesota System; University of Minnesota Twin Cities	Bowman, C (corresponding author), Univ Bristol, Int Inst Hlth & Ageing, Bristol BS8 1TX, Avon, England.							ABERCROMBIE M, 1995, AGE AGEING, V25, P12; Audit Commission, 1997, COM AG IMPR CAR SERV; AVERY T, 1998, IMPACT NURSING HOME; Bernabei R., 1998, BRIT MED J, V316, P148; Black D, 1997, BRIT MED J, V315, P441, DOI 10.1136/bmj.315.7106.441; BOWMAN C, 1998, REV CLIN GERATOL, V8, P275; BOWMAN C, 1994, ACUTE HOSP ADMISSION; Burl JB, 1998, J AM GERIATR SOC, V46, P506, DOI 10.1111/j.1532-5415.1998.tb02475.x; CHALLIS DJ, 1996, ASSESSMENT CONTINUIN; Department of Health, 1998, PARTN ACT NEW OPP JO; Department of Health, 1998, CM4169; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; FIATARONE MA, 1995, J AM GERIATR SOC, V43, P1439, DOI 10.1111/j.1532-5415.1995.tb06628.x; Fried TR, 1997, J AM GERIATR SOC, V45, P302, DOI 10.1111/j.1532-5415.1997.tb00944.x; JOHNSON M, 1996, SCH POLICY STUDIES; Kane RL, 1998, J AM GERIATR SOC, V46, P1034; KANE RL, 1996, J AM GERIATR SOC, V44, P251; KANE RL, 1998, J IR COLL PHYS SURG, V27, P25; Leveille SG, 1998, J AM GERIATR SOC, V46, P1191, DOI 10.1111/j.1532-5415.1998.tb04533.x; PEARSON J, 1990, BRIT MED J, V301, P371, DOI 10.1136/bmj.301.6748.371; ROBINSON R, 1998, MANAGED HLTH CARE US; *ROYAL COLL PHYS L, 1997, MANP CENS PHYS; Royal Commission on Long Term Care, 1999, CM41921; Rubenstein L.Z., 1995, GERIATRIC ASSESSMENT; *SECR STAT HLTH, 1997, CMND3807; SMITH G, 1998, CHANGING TIMES SURVE; Snape J, 1997, AGE AGEING, V26, P320, DOI 10.1093/ageing/26.4.320; STEINER A, 1977, INTERMEDIATE CARE CO; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; Turrell AR, 1998, BRIT MED J, V317, P942; Wasson JH, 1998, J AM GERIATR SOC, V46, P829, DOI 10.1111/j.1532-5415.1998.tb02715.x; Williams TF, 1997, J AM GERIATR SOC, V45, P244, DOI 10.1111/j.1532-5415.1997.tb04516.x; Young J, 1998, BMJ-BRIT MED J, V316, P1108, DOI 10.1136/bmj.316.7138.1108	34	14	15	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1119	1121		10.1136/bmj.319.7217.1119	http://dx.doi.org/10.1136/bmj.319.7217.1119			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	250ZE	10531110	Green Published			2022-12-28	WOS:000083419500032
J	Lawrence, CM; Ray, S; Babyonyshev, M; Galluser, R; Borhani, DW; Harrison, SC				Lawrence, CM; Ray, S; Babyonyshev, M; Galluser, R; Borhani, DW; Harrison, SC			Crystal structure of the ectodomain of human transferrin receptor	SCIENCE			English	Article							INTERMOLECULAR DISULFIDE BONDS; INDUCED CONFORMATIONAL CHANGE; LINKED GLYCOSYLATION SITE; X-RAY-DIFFRACTION; GLUTAMATE CARBOXYPEPTIDASE; SERUM TRANSFERRIN; LIGAND-BINDING; EXPRESSION; HEMOCHROMATOSIS; ASSOCIATION	The transferrin receptor (TfR) undergoes multiple rounds of clathrin-mediated endocytosis and reemergence at the cell surface, importing iron-loaded transferrin (Tf) and recycling apotransferrin after discharge of iron in the endosome. The crystal structure of the dimeric ectodomain of the human TfR, determined here to 3.2 angstroms resolution, reveals a three-domain subunit. One domain closely resembles carboxy- and aminopeptidases, and features of membrane glutamate carboxypeptidase can be deduced from the TfR structure. A model is proposed for Tf binding to the receptor.	Howard Hughes Med Inst, Boston, MA 02115 USA; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Harrison, SC (corresponding author), Howard Hughes Med Inst, 320 Longwood Ave, Boston, MA 02115 USA.		Lawrence, C. Martin/AAH-3420-2020; Borhani, David/O-2692-2019	Lawrence, C. Martin/0000-0002-5398-466X; Borhani, David/0000-0002-8486-8792				ALVAREZ E, 1989, EMBO J, V8, P2231, DOI 10.1002/j.1460-2075.1989.tb08347.x; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BORHANI DW, 1991, J MOL BIOL, V218, P685, DOI 10.1016/0022-2836(91)90255-5; BRUNGER A, 1992, XPLOR VERSION 3 0 SY; Buchegger F, 1996, EUR J BIOCHEM, V235, P9, DOI 10.1111/j.1432-1033.1996.0009u.x; Bzdega T, 1997, J NEUROCHEM, V69, P2270; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; Chevrier B, 1996, EUR J BIOCHEM, V237, P393, DOI 10.1111/j.1432-1033.1996.0393k.x; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Fuchs H, 1998, STRUCTURE, V6, P1235, DOI 10.1016/S0969-2126(98)00124-5; HEMMAPLARDH D, 1976, BIOCHIM BIOPHYS ACTA, V426, P3852; Jeffrey PD, 1998, BIOCHEMISTRY-US, V37, P13978, DOI 10.1021/bi9812064; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KORNFELD S, 1968, BIOCHEMISTRY-US, V7, P945, DOI 10.1021/bi00843a010; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Luthi-Carter R, 1998, P NATL ACAD SCI USA, V95, P3215, DOI 10.1073/pnas.95.6.3215; MASON AB, 1993, BIOCHEMISTRY-US, V32, P5472, DOI 10.1021/bi00071a025; Mason AB, 1997, BIOCHEM J, V326, P77, DOI 10.1042/bj3260077; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Rawlings ND, 1997, BBA-PROTEIN STRUCT M, V1339, P247, DOI 10.1016/S0167-4838(97)00008-3; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; RUTLEDGE EA, 1994, BLOOD, V83, P580; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SIPE DM, 1991, J BIOL CHEM, V266, P8002; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P16309; WILLIAMS AM, 1993, J BIOL CHEM, V268, P12780; ZAK O, 1994, J BIOL CHEM, V269, P7110	40	240	255	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					779	782		10.1126/science.286.5440.779	http://dx.doi.org/10.1126/science.286.5440.779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531064				2022-12-28	WOS:000083303200056
J	Haycock, J; Stanley, A; Edwards, N; Nicholls, R				Haycock, J; Stanley, A; Edwards, N; Nicholls, R			The hospital of the future - Changing hospitals	BRITISH MEDICAL JOURNAL			English	Article									NHS Confederat, London SW1P 4ND, England; Univ London London Sch Hyg & Trop Med, London Hlth Econ Consortium, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Edwards, N (corresponding author), NHS Confederat, London SW1P 4ND, England.							Gaffney D, 1999, BMJ-BRIT MED J, V319, P48, DOI 10.1136/bmj.319.7201.48; Hersey P., 1988, MANAGEMENT ORG BEHAV, V5th; JARMAN B, 1993, BRIT MED J, V306, P979, DOI 10.1136/bmj.306.6883.979; JARMAN B, 1994, CRISIS LONDON MED MA; RAFTERY J, 1995, BEDS LONDONERS REV E; Rivett G, 1986, DEV LONDON HOSP SYST; TURNBURG L, 1998, HLTH SERVICES LONDON	7	5	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1262	1264		10.1136/bmj.319.7219.1262	http://dx.doi.org/10.1136/bmj.319.7219.1262			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550100	Green Published			2022-12-28	WOS:000083625600035
J	Whitcup, SM; Fortin, E; Lindblad, AS; Griffiths, P; Metcalf, JA; Robinson, MR; Manischewitz, J; Baird, B; Perry, C; Kidd, IM; Vrabec, T; Davey, RT; Falloon, J; Walker, RE; Kovacs, JA; Lane, HC; Nussenblatt, RB; Smith, J; Masur, H; Polis, MA				Whitcup, SM; Fortin, E; Lindblad, AS; Griffiths, P; Metcalf, JA; Robinson, MR; Manischewitz, J; Baird, B; Perry, C; Kidd, IM; Vrabec, T; Davey, RT; Falloon, J; Walker, RE; Kovacs, JA; Lane, HC; Nussenblatt, RB; Smith, J; Masur, H; Polis, MA			Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMBINATION ANTIRETROVIRAL THERAPY; IMMUNE-DEFICIENCY-SYNDROME; RELEASE GANCICLOVIR IMPLANT; POLYMERASE CHAIN-REACTION; MAINTENANCE THERAPY; AIDS; DISEASE; VIRUS; TRIAL	Context Persons with cytomegalovirus (CMV) retinitis and acquired immunodeficiency syndrome (AIDS) have required lifelong anti-CMV therapy to prevent the progression of retinal disease and subsequent loss of vision. Objective To determine whether patients who were taking highly active antiretroviral therapy (HAART) and who had stable CMV retinitis could safely discontinue anti-CMV therapy without reactivation of their retinitis or increase in human immunodeficiency virus (HIV) viral load. Design Prospective nonrandomized interventional trial performed from July 1997 to August 1999. Setting Clinical Center of the National Institutes of Health, Bethesda, Md. Patients Fourteen patients with stable CMV retinitis and HIV infection and CD4(+) cell counts higher than 0.15 x 10(9)/L and being treated with systemic anti-CMV medications and HAART. Interventions Discontinuation of specific anti-CMV therapy. Main Outcome Measures Reactivation of CMV retinitis, development of extraocular CMV infection, detection of CMV in blood and urine, HIV burden, immunologic function; quality of life, morbidity, and mortality. Results Twelve (89.7%) of 14 patients had evidence of immune recovery uveitis before anti-CMV drugs were discontinued. No patient had reactivation of CMV retinitis or development of extraocular CMV disease during mean follow-up of 16.4 months (range, 8.3-22.0 months) without anti-CMV therapy. Human immunodeficiency viral load remained stable following cessation of anti-CMV medications, Blood and urine assays for CMV were briefly positive in 9 patients but did not predict reactivation of CMV disease. Worsening immune recovery uveitis was associated with a substantial (>3 lines) vision loss in 3 patients. Conclusions Maintenance anti-CMV medications were safely stopped in those patients who had stable CMV retinitis and elevated CD4(+) cell counts and who were taking HAART, The study demonstrates that immune recovery following potent antiretroviral therapy is effective in controlling a major opportunistic infection, even in patients with a history of severe immunosuppression.	NEI, Clin Branch, NIH, Bethesda, MD 20892 USA; NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD USA; NIH, Ctr Clin, Dept Crit Care Med, Bethesda, MD 20892 USA; EMMES Corp, Potomac, MD USA; US FDA, CBER, Lab Virol Retrovirol, Rockville, MD 20857 USA; Royal Free Hosp, Sch Med, Dept Virol, London, England; Wills Eye Hosp & Res Inst, Dept Ophthalmol, Philadelphia, PA USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Emmes Corporation; US Food & Drug Administration (FDA); University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Jefferson University	Whitcup, SM (corresponding author), NEI, Clin Branch, NIH, 10 10S221,10 Ctr Dr,MSC 1863, Bethesda, MD 20892 USA.	scottw@helix.nih.gov	Kidd, Ian Michael/CAH-4551-2022; Kovacs, Joseph/AAU-6105-2021	Kidd, Ian Michael/0000-0002-5264-9712; Kovacs, Joseph/0000-0002-5191-9880; Fortin, Eric/0000-0003-0457-5306; Polis, Michael/0000-0002-9151-2268	NIAID NIH HHS [1R01AI41687] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041687, Z01AI000390, ZIAAI000390] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1992, MMWR Recomm Rep, V41, P1; Bowen EF, 1997, AIDS, V11, P889, DOI 10.1097/00002030-199707000-00008; Carpenter C, 1998, ANN INTERN MED, V128, P1057, DOI 10.7326/0003-4819-128-12_Part_2-199806151-00002; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; FREEMAN WR, 1984, AM J OPHTHALMOL, V97, P133, DOI 10.1016/S0002-9394(14)76082-9; JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401; Jabs DA, 1997, AM J OPHTHALMOL, V124, P227, DOI 10.1016/S0002-9394(14)70789-5; Jabs DA, 1998, AM J OPHTHALMOL, V126, P817, DOI 10.1016/S0002-9394(98)00285-2; JACOBSON MA, 1988, Q J MED, V67, P473; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; Karavellas MP, 1999, J INFECT DIS, V179, P697, DOI 10.1086/314639; Karavellas MP, 1998, ARCH OPHTHALMOL-CHIC, V116, P169; KIDD IM, 1993, TRANSPLANTATION, V56, P867, DOI 10.1097/00007890-199310000-00018; Lalezari JP, 1997, ANN INTERN MED, V126, P257, DOI 10.7326/0003-4819-126-4-199702150-00001; Lewis RA, 1997, ANN INTERN MED, V126, P264, DOI 10.7326/0003-4819-126-4-199702150-00002; Macdonald JC, 1998, J INFECT DIS, V177, P1182, DOI 10.1086/515281; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203; PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092; Reed JB, 1997, AM J OPHTHALMOL, V124, P199, DOI 10.1016/S0002-9394(14)70784-6; *STUD OC COMPL AID, 1997, AM J OPHTHALMOL, V121, P61; Tural C, 1998, J INFECT DIS, V177, P1080, DOI 10.1086/517399; Vrabec TR, 1998, OPHTHALMOLOGY, V105, P1259, DOI 10.1016/S0161-6420(98)97031-2; Weinberg DV, 1996, RETINA-J RET VIT DIS, V16, P343, DOI 10.1097/00006982-199616040-00013; Whitcup SM, 1998, BRIT J OPHTHALMOL, V82, P845; Whitcup SM, 1997, JAMA-J AM MED ASSOC, V277, P1519, DOI 10.1001/jama.277.19.1519; Zegans ME, 1998, AM J OPHTHALMOL, V125, P292, DOI 10.1016/S0002-9394(99)80134-2	28	114	121	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1633	1637		10.1001/jama.282.17.1633	http://dx.doi.org/10.1001/jama.282.17.1633			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553789				2022-12-28	WOS:000083368400028
J	Schasfoort, RBM; Schlautmann, S; Hendrikse, L; van den Berg, A				Schasfoort, RBM; Schlautmann, S; Hendrikse, L; van den Berg, A			Field-effect flow control for microfabricated fluidic networks	SCIENCE			English	Article							CAPILLARY ZONE ELECTROPHORESIS; APPLIED RADIAL VOLTAGE; ELECTROOSMOSIS; CHIP; DNA; SEPARATIONS; DEVICES	The magnitude and direction of the electro-osmotic flow (EOF) inside a microfabricated fluid channel can be controlled by a perpendicular electric field of 1.5 megavolts per centimeter generated by a voltage of only 50 volts. A microdevice called a "flowFET," with functionality comparable to that of a field-effect transistor (FET) in microelectronics, has been realized. Two flowFETs integrated with a channel junction have been used to generate opposite flows inside a single EOF-pumped channel, thus illustrating the potential of the flowFET as a controlling and switching element in microfluidic networks.	Univ Twente, Inst Res, MESA, NL-7500 AE Enschede, Netherlands	University of Twente	van den Berg, A (corresponding author), Univ Twente, Inst Res, MESA, POB 217, NL-7500 AE Enschede, Netherlands.		van den Berg, Albert/B-4648-2013	van den Berg, Albert/0000-0001-9019-933X; Schasfoort, Richard/0000-0003-1601-3853				Burns MA, 1998, SCIENCE, V282, P484, DOI 10.1126/science.282.5388.484; EFFENHAUSER CS, 1995, ANAL CHEM, V67, P2284, DOI 10.1021/ac00109a057; EHRFELD W, 1997, P 1 INT C MICR TECHN; Fintschenko Y, 1998, J CHROMATOGR A, V819, P3, DOI 10.1016/S0021-9673(98)00544-5; FINTSCHENKO Y, 1998, MICRO TOTAL ANAL SYS, P327; Freemantle M, 1999, CHEM ENG NEWS, V77, P27, DOI 10.1021/cen-v077n008.p027; Gallardo BS, 1999, SCIENCE, V283, P57, DOI 10.1126/science.283.5398.57; Gau H, 1999, SCIENCE, V283, P46, DOI 10.1126/science.283.5398.46; GHOWSI K, 1991, J CHROMATOGR, V559, P95, DOI 10.1016/0021-9673(91)80061-K; HARRISON DJ, 1993, SCIENCE, V261, P895, DOI 10.1126/science.261.5123.895; HARRISON DJ, 1998, MICRO TOTAL ANAL SYS; HAYES MA, 1993, ANAL CHEM, V65, P27, DOI 10.1021/ac00049a007; HAYES MA, 1992, ANAL CHEM, V64, P512, DOI 10.1021/ac00029a012; HAYES MA, 1993, ANAL CHEM, V65, P2010, DOI 10.1021/ac00063a014; He B, 1998, ANAL CHEM, V70, P3790, DOI 10.1021/ac980028h; JACOBS E, 1993, CLIN CHEM, V39, P1069; JACOBSON SC, 1994, ANAL CHEM, V66, P1107, DOI 10.1021/ac00079a028; Jacobson SC, 1997, HDB CAPILLARY ELECTR, P827; Kopp MU, 1998, SCIENCE, V280, P1046, DOI 10.1126/science.280.5366.1046; LEE CS, 1990, ANAL CHEM, V62, P1550, DOI 10.1021/ac00213a043; Mastrangelo CH, 1998, P IEEE, V86, P1769, DOI 10.1109/5.704282; Moos WH, 1997, PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON LABORATORY AUTOMATION AND ROBOTICS 1996, P1; Service RF, 1998, SCIENCE, V282, P396, DOI 10.1126/science.282.5388.396; Tjerkstra RW, 1997, PROC IEEE MICR ELECT, P147, DOI 10.1109/MEMSYS.1997.581790; van den Berg A, 1998, TOP CURR CHEM, V194, P21; Weigl BH, 1999, SCIENCE, V283, P346, DOI 10.1126/science.283.5400.346; WOOLLEY AT, 1994, P NATL ACAD SCI USA, V91, P11348, DOI 10.1073/pnas.91.24.11348; WU CT, 1992, ANAL CHEM, V64, P886, DOI 10.1021/ac00032a011	28	396	506	4	141	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					942	945		10.1126/science.286.5441.942	http://dx.doi.org/10.1126/science.286.5441.942			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542145				2022-12-28	WOS:000083368500040
J	Frischknecht, F; Moreau, V; Rottger, S; Gonfloni, S; Reckmann, I; Superti-Furga, G; Way, M				Frischknecht, F; Moreau, V; Rottger, S; Gonfloni, S; Reckmann, I; Superti-Furga, G; Way, M			Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling	NATURE			English	Article							LISTERIA-MONOCYTOGENES; ARP2/3 COMPLEX; PROTEIN; SRC; NUCLEATION; CORTACTIN; PATHOGENS; DOMAINS; NCK	Studies of the actin-based motility of the intracellular pathogens Listeria monocytogenes and Shigella flexneri have provided important insight into the events occurring at the leading edges of motile cells(1-5). Like the bacteria Listeria and Shigella, vaccinia virus, a relative of the causative agent of smallpox, uses actin-based motility to spread between cells(6). In contrast to Listeria or Shigella, the actin-based motility of vaccinia is dependent on an unknown phosphotyrosine protein, but the underlying mechanism remains obscure(7). Here we show that phosphorylation of tyrosine 112 in the viral protein A36R by Src-family kinases is essential for the actin-based motility of vaccinia. Tyrosine phosphorylation of A36R results in a direct interaction with the adaptor protein Nck(8) and the recruitment of the Ena/VASP family member N-WASP(9) to the site of actin assembly. We also show that Nck and N-WASP are essential for the actin-based motility of vaccinia virus. We suggest that vaccinia virus spreads by mimicking the signalling pathways that are normally involved in actin polymerization at the plasma membrane.	European Mol Biol Lab, Cell Programme, D-69117 Heidelberg, Germany; European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Way, M (corresponding author), European Mol Biol Lab, Cell Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Superti-Furga, Giulio/AAE-5681-2019; Superti-Furga, Giulio/F-4755-2015	Superti-Furga, Giulio/0000-0002-0570-1768; Frischknecht, Friedrich/0000-0002-8332-6668; GONFLONI, STEFANIA/0000-0002-9392-4258; Moreau, Violaine/0000-0002-4513-7022; Way, Michael/0000-0001-7207-2722				Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; Dramsi S, 1998, ANNU REV CELL DEV BI, V14, P137, DOI 10.1146/annurev.cellbio.14.1.137; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Frischknecht F, 1999, CURR BIOL, V9, P89, DOI 10.1016/S0960-9822(99)80020-7; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rottger S, 1999, J VIROL, V73, P2863; Sanderson CM, 1998, J VIROL, V72, P1235, DOI 10.1128/JVI.72.2.1235-1243.1998; Sanderson CM, 1998, J GEN VIROL, V79, P1415, DOI 10.1099/0022-1317-79-6-1415; Sanderson CM, 1998, J VIROL, V72, P9924, DOI 10.1128/JVI.72.12.9924-9933.1998; Snapper SB, 1999, ANNU REV IMMUNOL, V17, P905, DOI 10.1146/annurev.immunol.17.1.905; SONG MY, 1995, SUPERCOND SCI TECH, V8, P20, DOI 10.1088/0953-2048/8/1/004; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Wolffe EJ, 1998, VIROLOGY, V244, P20, DOI 10.1006/viro.1998.9103; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	27	333	342	2	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					926	929		10.1038/44860	http://dx.doi.org/10.1038/44860			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553910				2022-12-28	WOS:000083464700062
J	Morris-Stiff, G; Khan, A; Quiroga, I; Baboo, R; Jurewicz, WA				Morris-Stiff, G; Khan, A; Quiroga, I; Baboo, R; Jurewicz, WA			Immunosuppression in renal transplantation - Meta-analysis should not have included one of the studies	BRITISH MEDICAL JOURNAL			English	Letter							FK-506		Univ Hosp Wales NHS Trust, Dept Transplant Surg, Cardiff CF4 4XN, S Glam, Wales		Morris-Stiff, G (corresponding author), Univ Hosp Wales NHS Trust, Dept Transplant Surg, Cardiff CF4 4XN, S Glam, Wales.			Knoll, Greg/0000-0001-5442-9310				Knoll GA, 1999, BRIT MED J, V318, P1104, DOI 10.1136/bmj.318.7191.1104; Morris-Stiff G, 1998, TRANSPLANT P, V30, P1285, DOI 10.1016/S0041-1345(98)00243-7; SHAPIRO R, 1991, TRANSPLANT P, V23, P3065	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1136	1136		10.1136/bmj.319.7217.1136	http://dx.doi.org/10.1136/bmj.319.7217.1136			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531121	Green Published			2022-12-28	WOS:000083419500053
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1976: Baruch S Blumberg (b 1925); Daniel Carleton Gajdusek (1923)	LANCET			English	Article									Univ Illinois, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60607 USA.							McCarthy M, 1997, LANCET, V349, P623, DOI 10.1016/S0140-6736(97)23009-6	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533898				2022-12-28	WOS:000083149900067
J	Tomita, H; Ohbayashi, M; Nakahara, K; Hasegawa, I; Miyashita, Y				Tomita, H; Ohbayashi, M; Nakahara, K; Hasegawa, I; Miyashita, Y			Top-down signal from prefrontal cortex in executive control of memory retrieval	NATURE			English	Article							INFERIOR TEMPORAL NEURONS; LONG-TERM-MEMORY; FRONTAL DISCONNECTION; COGNITIVE INTERACTION; WORKING-MEMORY; MONKEYS; TASK; ORGANIZATION; ACTIVATION	Knowledge or experience is voluntarily recalled from memory by reactivation of the neural representations in the cerebral association cortex(1-4). In inferior temporal cortex, which serves as the storehouse of visual long-term memory(5-8), activation of mnemonic engrams through electric stimulation results in imagery recall in humans(9), and neurons can be dynamically activated by the necessity for memory recall in monkeys(10,11). Neuropsychological studies(12) and previous split-brain experiments(13) predicted that prefrontal cortex exerts executive control upon inferior temporal cortex in memory retrieval; however, no neuronal correlate of this process has ever been detected. Here we show evidence of the top-down signal from prefrontal cortex. In the absence of bottom-up visual inputs, single inferior temporal neurons were activated by the top-down signal, which conveyed information on semantic categorization imposed by visual stimulus-stimulus association. Behavioural performance was severely impaired with loss of the top-down signal. Control experiments confirmed that the signal was transmitted not through a subcortical but through a frontotemporal cortical pathway. Thus, feedback projections from prefrontal cortex to the posterior association cortex(2,3,14) appear to serve the executive control of voluntary recall.	Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, ICORP, Mind Articulat Project, Bunkyo Ku, Tokyo 1130034, Japan; Natl Inst Physiol Sci, Okazaki, Aichi 4448585, Japan	University of Tokyo; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Tomita, H (corresponding author), Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	hyoe@m.u-tokyo.ac.jp; yasushi_miyashita@m.u-tokyo.ac.jp	Miyashita, Yasushi/B-7171-2019; Hasegawa, Isao/AAW-5682-2021; Ohbayashi, Machiko/A-6910-2018	Miyashita, Yasushi/0000-0003-3496-8637; Hasegawa, Isao/0000-0002-8633-2502; Ohbayashi, Machiko/0000-0003-2563-9049; Nakahara, Kiyoshi/0000-0001-6701-6216				Buckner RL, 1996, J NEUROSCI, V16, P6219; Chafee MV, 1998, J NEUROPHYSIOL, V79, P2919, DOI 10.1152/jn.1998.79.6.2919; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DOTY RW, 1988, BEHAV BRAIN RES, V29, P267, DOI 10.1016/0166-4328(88)90031-9; EACOTT MJ, 1992, EUR J NEUROSCI, V4, P1320, DOI 10.1111/j.1460-9568.1992.tb00157.x; EACOTT MJ, 1989, EXP BRAIN RES, V74, P348; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Fletcher PC, 1998, BRAIN, V121, P1249, DOI 10.1093/brain/121.7.1249; Fuster J., 2015, PREFRONTAL CORTEX, V5th; FUSTER JM, 1985, BRAIN RES, V330, P299, DOI 10.1016/0006-8993(85)90689-4; GAZZANIGA MS, 1995, NEURON, V14, P217, DOI 10.1016/0896-6273(95)90280-5; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; GoldmanRakic PS, 1996, P NATL ACAD SCI USA, V93, P13473, DOI 10.1073/pnas.93.24.13473; GROSS CG, 1977, BRAIN RES, V131, P227, DOI 10.1016/0006-8993(77)90517-0; Gutnikov SA, 1997, EUR J NEUROSCI, V9, P1524, DOI 10.1111/j.1460-9568.1997.tb01507.x; Hasegawa I, 1998, SCIENCE, V281, P814, DOI 10.1126/science.281.5378.814; MACPHERSON JM, 1979, BRAIN RES, V175, P183, DOI 10.1016/0006-8993(79)90530-4; MISHKIN M, 1982, PHILOS T R SOC B, V298, P85, DOI 10.1098/rstb.1982.0074; MIYASHITA Y, 1993, ANNU REV NEUROSCI, V16, P245, DOI 10.1146/annurev.ne.16.030193.001333; MIYASHITA Y, IN PRESS COGNITIVE N; Naya Y, 1996, P NATL ACAD SCI USA, V93, P2664, DOI 10.1073/pnas.93.7.2664; PENFIELD W, 1963, BRAIN, V86, P595, DOI 10.1093/brain/86.4.595; Petrides M, 1994, HDB NEUROPSYCHOLOGY, V9, P59; Rainer G, 1999, J NEUROSCI, V19, P5493; RINGO JL, 1993, J NEUROPHYSIOL, V70, P2215, DOI 10.1152/jn.1993.70.6.2215; Rolls E T, 1991, Curr Opin Neurobiol, V1, P274, DOI 10.1016/0959-4388(91)90090-T; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SARY G, 1993, SCIENCE, V260, P995, DOI 10.1126/science.8493538; SIDTIS JJ, 1981, SCIENCE, V212, P344, DOI 10.1126/science.6782673	29	448	458	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	1999	401	6754					699	703		10.1038/44372	http://dx.doi.org/10.1038/44372			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537108				2022-12-28	WOS:000083207400057
J	Moins-Teisserenc, HT; Gadola, SD; Cella, M; Dunbar, PR; Exley, A; Blake, N; Baykal, C; Lambert, J; Bigliardi, P; Willemsen, M; Jones, M; Buechner, S; Colonna, M; Gross, WL; Cerundolo, V				Moins-Teisserenc, HT; Gadola, SD; Cella, M; Dunbar, PR; Exley, A; Blake, N; Baykal, C; Lambert, J; Bigliardi, P; Willemsen, M; Jones, M; Buechner, S; Colonna, M; Gross, WL; Cerundolo, V			Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules	LANCET			English	Article							NATURAL-KILLER-CELLS; RECEPTORS; PHENOTYPE	Background Granulomatous syndromes, such as Wegener's granulomatosis, are defined according to complex criteria, but the underlying cause is rarely identified. We present evidence for a new aetiology for chronic granulomatous lesions associated with a recessive genetic defect, which is linked to the human leucocyte antigen (HLA) locus. Methods Five adults with necrotising granulomatous lesions in the upper respiratory tract and skin, associated with recurrent bacterial respiratory infections and skin vasculitis, were identified. A diagnosis of Wegener's granulomatosis was considered in all of them, but abandoned because of an incompatible disease course and resistance to immunosuppressive treatments. Peripheral-blood samples were taken and analysed by immunohistochemistry and fluorescent-activated-cell-sorter analysis. Since all five patients were homozygous for the HLA locus, we looked for genetic defects located within the HLA-locus with PCR and restriction fragment length polymorphism. Findings A severe decrease in cell-surface expression of HLA class-I molecule was seen in all patients. Defective expression of the transporter associated with antigen presentation (TAP) genes was responsible for the HLA class-I down-regulation, and in two patients we identified a mutation in the TAP2 gene responsible for the defective expression of the TAP complex. We showed the presence of autoreactive natural killer (NK) cells and gamma delta T lymphocytes in the peripheral blood cells of two patients. Correction of the genetic defect in vitro restored normal expression of HLA class-I molecules and prevented self-reactivity in the patients' cells. Histology of granulomatous lesions showed the presence of a large proportion of activated NK cells. Interpretation Our findings define the cause and pathogenesis of a new syndrome that affects patients with a defective surface expression of HLA class-I molecules. The syndrome resembles Wegener's granulomatosis both clinically and histologically. Patients have chronic necrotising granulomatous lesions in the upper respiratory tract and skin, recurrent infections of the respiratory tract, and skin vasculitis. A predominant NK population within the granulomatous lesions suggests that the pathophysiology of the skin lesions may relate to the inability of HLA class-I molecules to turn off NK cell responses. Accurate genetic analysis of a defined syndrome can provide a better understanding of the cause and pathogenesis of a disease.	Inst Mol Med, Nuffield Dept Med, Oxford OX3 9DS, England; Univ Lubeck, Rheumaklin Bad Bramstedt, D-2400 Lubeck, Germany; Basel Inst Immunol, Basel, Switzerland; CRC, Inst Canc Studies, Birmingham, W Midlands, England; Istanbul Fac Med, Dept Dermatol, Istanbul, Turkey; Univ Basel, Dept Dermatol, CH-4003 Basel, Switzerland; Univ Birmingham, Dept Immunol, Birmingham B15 2TT, W Midlands, England; Div Cellular Sci, Oxford, England; Univ Ziekenhuis Antwerpen, Dept Dermatol, Edegem, Belgium; Dept Dermatol, Brussels, Belgium; Hop St Louis, INSERM, U0396, F-75010 Paris, France	University of Oxford; University of Lubeck; University of Birmingham; Istanbul University; University of Basel; University of Birmingham; University of Antwerp; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Cerundolo, V (corresponding author), Inst Mol Med, Nuffield Dept Med, Oxford OX3 9DS, England.	vcerundo@worf.molbiol.ox.ac.uk	Cella, Marina/G-8850-2011; Cella, Marina/ABA-8564-2020; Moins-Teisserenc, helene/AAL-1566-2021; Dunbar, Rod/C-2570-2012; Jones, Margaret/B-4083-2009	Moins-Teisserenc, helene/0000-0003-1602-7534; Dunbar, Rod/0000-0001-9626-2600; Cella, Marina/0000-0003-1230-1313; Colonna, Marco/0000-0001-5222-4987; Cerundolo, Vincenzo/0000-0003-0040-3793; Exley, Andrew/0000-0002-2628-6129				CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; Colonna M, 1997, IMMUNOL REV, V155, P127, DOI 10.1111/j.1600-065X.1997.tb00945.x; de la Salle H, 1999, J CLIN INVEST, V103, pR9, DOI 10.1172/JCI5687; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; Furukawa H, 1999, J CLIN INVEST, V103, P755, DOI 10.1172/JCI5335; Furukawa H, 1999, HUM IMMUNOL, V60, P32, DOI 10.1016/S0198-8859(98)00097-4; GROSS WL, 1998, OXFORD TXB RHEUMATOL, V2, P1331; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Lanier LL, 1996, IMMUNOL TODAY, V17, P86, DOI 10.1016/0167-5699(96)80585-8; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; Orange JS, 1996, J IMMUNOL, V156, P4746; Plebani A, 1996, J AM ACAD DERMATOL, V35, P814, DOI 10.1016/S0190-9622(96)90091-2; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; TAKASHIMA T, 1993, J IMMUNOL, V150, P3002; Teisserenc H, 1997, IMMUNOL LETT, V57, P183, DOI 10.1016/S0165-2478(97)00072-2; WATANABE S, 1987, J AM ACAD DERMATOL, V17, P1006, DOI 10.1016/S0190-9622(87)70290-4; WILLEMSEN M, 1995, J AM ACAD DERMATOL, V33, P887, DOI 10.1016/0190-9622(95)90429-8; Zimmer J, 1998, J EXP MED, V187, P117, DOI 10.1084/jem.187.1.117; Zimmer J, 1999, EUR J IMMUNOL, V29, P1286, DOI 10.1002/(SICI)1521-4141(199904)29:04<1286::AID-IMMU1286>3.0.CO;2-L	21	100	100	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	1999	354	9190					1598	1603		10.1016/S0140-6736(99)04206-3	http://dx.doi.org/10.1016/S0140-6736(99)04206-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560675				2022-12-28	WOS:000083551000012
J	Ginzberg, E				Ginzberg, E			Ten encounters with the US health sector, 1930-1999	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Columbia Univ, Eisenhower Ctr Conservat Human Resources, New York, NY 10027 USA	Columbia University	Ginzberg, E (corresponding author), Columbia Univ, Interchurch Ctr, 2960 Broadway,Mail Code 7740,Room 248, New York, NY 10027 USA.							CAMPION FD, 1984, AMA US HLTH POLICY 1; *DEP HLTH HUM SERV, 1980, GRAD MED ED NAT ADV, V1; Ginzberg E, 1999, ACAD MED, V74, P522, DOI 10.1097/00001888-199905000-00018; GINZBERG E, 1994, ROAD REFORM; GINZBERG E, IN PRESS ACAD HLTH C; GINZBERG E, 1993, EYE ILLUSION, P186; GINZBERG E, 1961, PLANNING BETTER HOSP; II. Graduate Medical Education, 1999, JAMA, V282, P893; Smith S, 1998, HEALTH AFFAIR, V17, P128, DOI 10.1377/hlthaff.17.5.128; [No title captured]	10	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1665	1668		10.1001/jama.282.17.1665	http://dx.doi.org/10.1001/jama.282.17.1665			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553794				2022-12-28	WOS:000083368400033
J	Rayson, D				Rayson, D			Lisa's stories	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Rayson, Daniel/W-2800-2019	Rayson, Daniel/0000-0002-2438-3128					0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1605	1606		10.1001/jama.282.17.1605	http://dx.doi.org/10.1001/jama.282.17.1605			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553770				2022-12-28	WOS:000083368400001
J	Rifkin, DE				Rifkin, DE			Community considerations: The many effects of miscoding	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL COMMONS; CARE		Yale Univ, Sch Med, New Haven, CT 06510 USA	Yale University	Rifkin, DE (corresponding author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06510 USA.			Rifkin, Dena/0000-0002-1278-5795				Bodenheimer T, 1997, NEW ENGL J MED, V337, P651, DOI 10.1056/NEJM199708283370923; Cunningham PJ, 1997, HEALTH AFFAIR, V16, P167, DOI 10.1377/hlthaff.16.4.167; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; HIATT HH, 1975, NEW ENGL J MED, V293, P235, DOI 10.1056/NEJM197507312930506; Iglehart JK, 1999, NEW ENGL J MED, V340, P70, DOI 10.1056/NEJM199901073400122; RAWLS J, 1971, THEORY JUSTICE, P58; UBEL PA, 1995, ARCH INTERN MED, V155, P1837, DOI 10.1001/archinte.155.17.1837; Weissman J, 1996, JAMA-J AM MED ASSOC, V276, P823, DOI 10.1001/jama.276.10.823; Wynia MK, 1997, J INVEST MED, V45, P35	9	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1676	+		10.1001/jama.282.17.1676	http://dx.doi.org/10.1001/jama.282.17.1676			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553799	hybrid			2022-12-28	WOS:000083368400038
J	Dowie, R; Langman, M				Dowie, R; Langman, M			The hospital of the future - Staffing of hospitals: future needs, future provision	BRITISH MEDICAL JOURNAL			English	Article							DOCTORS		Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England; Univ Birmingham, Queen Elizabeth Hosp, Dept Med, Birmingham B15 2TH, W Midlands, England	Brunel University; University of Birmingham	Dowie, R (corresponding author), Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England.							Bagust A, 1999, BRIT MED J, V319, P155, DOI 10.1136/bmj.319.7203.155; Beecham L, 1998, BRIT MED J, V317, P1473, DOI 10.1136/bmj.317.7171.1473a; *BIRM HLTH AUTH, 1997, BIRM HLTH FUT MED PE; *BRIT MED ASS, 1998, PROV AC GEN HOSP SER; BUCHAN J, 1998, EMPLOYING NURSES SEP, P6; *DEP HLTH, 1998, 1 CLASS SERV; *DEP HLTH, 1993, HOSP DOCT TRAIN FUT; *DEP HLTH, 1999, STAT B; *DEP HLTH, 1998, EXTR 1000 MED STUD E; DOWIE R, 1997, CONCENTRATION CHOICE, P51; *GEN MED COUNC, 1998, ANN REV 1998; GOULD M, 1998, HLTH SERV J, V108, P2; Lambert TW, 1998, BRIT MED J, V317, P1429, DOI 10.1136/bmj.317.7170.1429; *NHS, 1997, EL9758 NHS; *NHS, 1991, JUN DOCT NEW DEAL; *NHS, 1996, EFFECTIVE HLTH CARE, V8; *NHS, 1998, WORK TOG SEC QUAL WO; *SECR STAT HLTH, 1997, CM3807; 1999, CM4243	19	10	10	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1193	1195		10.1136/bmj.319.7218.1193	http://dx.doi.org/10.1136/bmj.319.7218.1193			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541518	Green Published			2022-12-28	WOS:000083536200033
J	Peacock, SM; Wang, K				Peacock, SM; Wang, K			Seismic consequences of warm versus cool subduction metamorphism: Examples from southwest and northeast Japan	SCIENCE			English	Article							OCEANIC-CRUST; UPPER-MANTLE; ECLOGITE; BENEATH; ARC; DEPTH; PLATE; ZONES; AGE	Warm and cool subduction zones exhibit differences in seismicity, seismic structure, and are magmatism, which reflect differences in metamorphic reactions occurring in subducting oceanic crust. In southwest Japan, are volcanism is sparse and intraslab earthquakes extend to 65 kilometers depth; in northeast Japan, are volcanism is more common and intraslab earthquakes reach 200 kilometers depth. Thermal-petrologic models predict that oceanic crust subducting beneath southwest Japan is 300 degrees to 500 degrees C warmer than beneath northeast Japan, resulting in shallower eclogite transformation and slab dehydration reactions, and possible slab melting.	Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; Geol Survey Canada, Pacific Geosci Ctr, Sidney, BC V8L 4B2, Canada	Arizona State University; Arizona State University-Tempe; Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada	Peacock, SM (corresponding author), Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA.							AHRENS TJ, 1975, REV GEOPHYS, V13, P383, DOI 10.1029/RG013i002p00383; ASHI J, 1993, THERMAL EVOLUTION TE, P137; Batchelor G.K., 2000, INTRO FLUID DYNAMICS; Carswell D. A., 1990, ECLOGITE FACIES ROCK; DEFANT MJ, 1990, NATURE, V347, P662, DOI 10.1038/347662a0; EVANS BW, 1990, LITHOS, V25, P3, DOI 10.1016/0024-4937(90)90003-J; FUKAO Y, 1983, NATURE, V303, P413, DOI 10.1038/303413a0; Gill J., 1981, OROGENIC ANDESITES P; HASEGAWA A, 1994, J GEOPHYS RES-SOL EA, V99, P22295, DOI 10.1029/93JB02797; HELFFRICH GR, 1996, SUBDUCTION TOP BOTTO, P215; HIBBARD JP, 1990, TECTONICS, V9, P207, DOI 10.1029/TC009i002p00207; HIRAHARA K, 1981, TECTONOPHYSICS, V79, P1, DOI 10.1016/0040-1951(81)90231-6; HORI S, 1990, TECTONOPHYSICS, V176, P355, DOI 10.1016/0040-1951(90)90078-M; Kincaid C, 1997, J GEOPHYS RES-SOL EA, V102, P12295, DOI 10.1029/96JB03553; KIRBY S, 1996, SUBDUCTION TOP BOTTO, P195, DOI DOI 10.1029/GM096P0195; MATSUZAWA T, 1986, GEOPHYS J INT, V86, P767, DOI 10.1111/j.1365-246X.1986.tb00659.x; MORRIS PA, 1995, GEOLOGY, V23, P395, DOI 10.1130/0091-7613(1995)023<0395:SMAAEO>2.3.CO;2; NAKAMURA M, 1997, 40B1 KYOT U ANN DIS, P1; Oh CW, 1998, ISL ARC, V7, P36, DOI 10.1046/j.1440-1738.1998.00180.x; PEACOCK SM, 1994, EARTH PLANET SC LETT, V121, P227, DOI 10.1016/0012-821X(94)90042-6; PEACOCK SM, 1993, GEOL SOC AM BULL, V105, P684, DOI 10.1130/0016-7606(1993)105<0684:TIOBED>2.3.CO;2; PEACOCK SM, 1996, SUBDUCTION TOP BOTTO, P119; POLI S, 1995, J GEOPHYS RES-SOL EA, V100, P22299, DOI 10.1029/95JB01570; Simkin T., 1994, VOLCANOES WORLD; STEIN CA, 1992, NATURE, V359, P123, DOI 10.1038/359123a0; SUYEHIRO K, 1994, J GEOPHYS RES-SOL EA, V99, P22331, DOI 10.1029/94JB01337; WANG KL, 1995, TECTONOPHYSICS, V248, P53, DOI 10.1016/0040-1951(95)00028-L	27	608	657	3	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					937	939		10.1126/science.286.5441.937	http://dx.doi.org/10.1126/science.286.5441.937			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542143				2022-12-28	WOS:000083368500038
J	Gupta, R; Perry, M				Gupta, R; Perry, M			Lesson of the week - Digital examination for oral cancer	BRITISH MEDICAL JOURNAL			English	Article							CARCINOMA; TONGUE		Univ London Kings Coll Hosp, Maxillofacial Unit, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Perry, M (corresponding author), Royal Surrey Cty Hosp, Maxillofacial Unit, Surrey GU2 5XX, England.							Bhaskar SN, 1986, ODONTOGENIC TUMORS J, V7th, P292; EVANS SJW, 1982, CANCER, V49, P773, DOI 10.1002/1097-0142(19820215)49:4<773::AID-CNCR2820490428>3.0.CO;2-K; Fukano H, 1997, HEAD NECK-J SCI SPEC, V19, P205, DOI 10.1002/(SICI)1097-0347(199705)19:3<205::AID-HED7>3.0.CO;2-6; Johnson N W, 1991, Int Dent J, V41, P365; Johnson N W, 1993, Community Dent Health, V10 Suppl 1, P13; JOHNSON NW, 1995, ANN ROY COLL SURG, V77, P321; MACFARLANE GJ, 1987, LANCET, V2, P912; SHAH JP, 1995, BRIT J ORAL MAX SURG, V33, P3, DOI 10.1016/0266-4356(95)90077-2	8	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1113	1114		10.1136/bmj.319.7217.1113	http://dx.doi.org/10.1136/bmj.319.7217.1113			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531106	Green Published			2022-12-28	WOS:000083419500028
J	Hankey, GJ; Warlow, CI				Hankey, GJ; Warlow, CI			Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations	LANCET			English	Article; Proceedings Paper	Lancets Conference on the Challenge of Stroke	OCT, 1998	MONTREAL, CANADA	Lancet			ACUTE CEREBROVASCULAR-DISEASE; PERTH-COMMUNITY-STROKE; CASE-FATALITY; PROJECT 1981-86; PREVALENCE; AUCKLAND; TRIALS	This review of the effectiveness of treatment for acute stroke and methods of secondary prevention shows that the highest priority for providers of a stroke service must be to establish a stroke unit and multidisciplinary team that delivers organised stroke care. Acute ischaemic stroke patients should be immediately started on aspirin 300 mg daily, and, if possible, many of them should be entered into further trials of thrombolysis and other promising treatments. After the acute phase, aspirin should be continued in a lower dose, 75 mg daily; smoking should be discouraged; high blood pressure treated initially with a diuretic; and fibrillating ischaemic stroke/transient ischaemic attack survivors anticoagulated long-term with warfarin or given aspirin if anticoagulation is not sensible. Statins are probably indicated in patients who already have symptomatic coronary heart disease. Adding dipyridamole to aspirin, substituting clopidogrel for aspirin, and carotid endarterectomy are all expensive interventions to prevent stroke, but if ways could be found to focus them on those patients at especially high risk, they would become more affordable.	Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA 6001, Australia; Univ Western Australia, Dept Med, Nedlands, WA 6009, Australia; Univ Edinburgh, Western Gen Hosp NHS Trust, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland	Royal Perth Hospital; University of Western Australia; University of Western Australia; University of Edinburgh	Hankey, GJ (corresponding author), Royal Perth Hosp, Dept Neurol, Stroke Unit, Wellington St, Perth, WA 6001, Australia.	gjhankey@cyllene.uwa.edu.au	Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				Algra A, 1996, J NEUROL NEUROSUR PS, V60, P197, DOI 10.1136/jnnp.60.2.197; Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON CS, 1994, STROKE, V25, P1935, DOI 10.1161/01.STR.25.10.1935; ASPLUND K, 1993, CEREBROVASC DIS, V3, P34, DOI 10.1159/000108747; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BERGMAN L, 1995, STROKE, V26, P1830, DOI 10.1161/01.STR.26.10.1830; Bonita R, 1997, STROKE, V28, P1898, DOI 10.1161/01.STR.28.10.1898; BONITA R, 1994, STROKE, V25, P552, DOI 10.1161/01.STR.25.3.552; Brown RD, 1998, STROKE, V29, P2109, DOI 10.1161/01.STR.29.10.2109; Bucher HC, 1998, ANN INTERN MED, V128, P89, DOI 10.7326/0003-4819-128-2-199801150-00002; Chalmers J, 1996, J HYPERTENS, V14, pS41; Chen ZM, 1999, STROKE, V30, P243; *COCHR LIB, 1999, COCHR COLL 1999; *COMM DEP HLTH FAM, 1998, SCHED PHARM BEN APPR; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; *ESPRIT, 1999, STROKE, V30, P487; Fagan SC, 1998, NEUROLOGY, V50, P883, DOI 10.1212/WNL.50.4.883; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; GLANVILLE J, 1909, BMJ-BRIT MED J, V317, P200; Gueyffier F, 1997, STROKE, V28, P2557, DOI 10.1161/01.STR.28.12.2557; HANKEY GJ, 1991, J NEUROL NEUROSUR PS, V54, P793, DOI 10.1136/jnnp.54.9.793; Hankey GJ, 1999, J CARDIOVASC RISK, V6, P207; Hankey GJ, 1998, CEREBROVASC DIS, V8, P1, DOI 10.1159/000047512; Hankey GJ, 1998, STROKE, V29, P2491, DOI 10.1161/01.STR.29.12.2491; Hankey GJ, 1999, ARCH NEUROL-CHICAGO, V56, P748, DOI 10.1001/archneur.56.6.748; Hankey GJ, 1994, TRANSIENT ISCHAEMIC; HANKEY GJ, 1999, COCHRANE LIB; Holloway RG, 1996, NEUROLOGY, V46, P854; JAMROZIK K, 1994, STROKE, V25, P51, DOI 10.1161/01.STR.25.1.51; Jorgensen HS, 1999, BRIT MED J, V319, P288, DOI 10.1136/bmj.319.7205.288; Katzan IL, 1999, STROKE, V30, P266; Kelly-Hayes M, 1998, STROKE, V29, P1274, DOI 10.1161/01.STR.29.6.1274; KOUDSTAAL P, 1999, COCHRANE LIB; *NAT HLTH MED RES, 1996, QUAL CAR HLTH OUTC C, P4; Plehn JF, 1999, CIRCULATION, V99, P216, DOI 10.1161/01.CIR.99.2.216; Qizilbash N, 1995, LANCET, V346, P1647; Roberts L, 1998, STROKE, V29, P986, DOI 10.1161/01.STR.29.5.986; Rodgers A, 1998, LANCET, V352, P1801; RODGERS A, 1997, NEUROL REV INT, V2, P12; Rose G., 1992, STRATEGY PREVENTIVE; Rothwell PM, 1999, LANCET, V353, P2105, DOI 10.1016/S0140-6736(98)11415-0; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; Sandercock PA, 1999, STROKE, V30, P248; Smurawska LT, 1998, STROKE, V29, P2014, DOI 10.1161/01.STR.29.10.2014; *STROK UN TRIAL CO, 1999, COCHR LIB; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; Taylor TN, 1996, STROKE, V27, P1459, DOI 10.1161/01.STR.27.9.1459; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; WARDLAW JM, COCHRANE LIB; WARLOW CP, 1996, PRACTICAL MANAGEMENT, pCH11; WARLOW CP, 1996, PRACTICAL MANAGEMENT, pCH17	57	352	366	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1999	354	9188					1457	1463		10.1016/S0140-6736(99)04407-4	http://dx.doi.org/10.1016/S0140-6736(99)04407-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	248LY	10543686				2022-12-28	WOS:000083277400040
J	Hojris, I; Overgaard, M; Christensen, JJ; Overgaard, J				Hojris, I; Overgaard, M; Christensen, JJ; Overgaard, J			Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials	LANCET			English	Article							POSTOPERATIVE RADIOTHERAPY; RADIATION-THERAPY; MYOCARDIAL-INFARCTION; IRRADIATION; SURGERY; WOMEN; PREMENOPAUSAL; TAMOXIFEN	Background Radiotherapy in addition to systemic treatment after mastectomy prolongs survival in high-risk breast-cancer patients. However, adjuvant radiotherapy has a potential association with ischaemic heart disease. We assessed morbidity and mortality from ischaemic heart disease in patients treated with postmastectomy radiotherapy. Methods Between 1982 and 1990, we randomly assigned 3083 women at high risk of breast cancer, after mastectomy, adjuvant systemic treatment with (n=1538) or without (n=1545) radiotherapy. An anterior photon field was used against the periclavicular region and the axilla. The chest wall was treated through two anterior shaped electron fields, one including the internal mammary nodes. The intended dose was 48-50 Gy in 22-25 fractions, at four to five fractions per week. We obtained information on morbidity and mortality of ischaemic heart disease over a median of 10 years. Analysis was by intention to treat. Findings More women in the no-radiotherapy group than in the radiotherapy group died of breast cancer (799 [52.5%] vs 674 [44.2%]), whereas similar proportions of each group died from ischaemic heart disease (13 [0.9%] vs 12 [0.8%]). The relative hazard of morbidity from ischaemic heart disease among patients in the radiotherapy compared with the no-radiotherapy group was 0.86 (95% CI 0.6-1.3), and that for death from ischaemic heart disease was 0.84 (0.4-1.8). The hazard rate of morbidity from ischaemic heart disease in the radiotherapy group compared with the no-radiotherapy group did not increase with time from treatment. Interpretation Postmastectomy radiotherapy with this regimen does not increase the actuarial risk of ischaemic heart disease after 12 years.	Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Med Phys, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Danish Canc Soc, Dept Expt Clin Oncol, DK-8000 Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; Danish Cancer Society	Hojris, I (corresponding author), Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark.							ABE O, 1995, NEW ENGL J MED, V333, P1444; ANDERSEN KW, 1988, ACTA ONCOL, V27, P627, DOI 10.3109/02841868809091763; CONSTANTINO JP, 1997, JNCI-J NATL CANCER I, V89, P776; CUZICK J, 1987, CANCER TREAT REP, V71, P15; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; DOMBERNOWSKY P, 1988, ACTA ONCOL, V27, P691, DOI 10.3109/02841868809091771; FULLER SA, 1992, RADIOTHER ONCOL, V25, P19, DOI 10.1016/0167-8140(92)90190-6; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; Gyenes G, 1998, RADIOTHER ONCOL, V48, P185, DOI 10.1016/S0167-8140(98)00062-0; HAYBITTLE JL, 1989, BRIT MED J, V298, P1611, DOI 10.1136/bmj.298.6688.1611; HOST H, 1986, INT J RADIAT ONCOL, V12, P727, DOI 10.1016/0360-3016(86)90029-5; Janjan N A, 1989, Med Dosim, V14, P81; JOHANSEN H, 1990, ACTA ONCOL, V29, P709, DOI 10.3109/02841869009092988; JONES JM, 1989, CLIN RADIOL, V40, P204, DOI 10.1016/S0009-9260(89)80099-6; Kuske RR, 1998, J CLIN ONCOL, V16, P2579, DOI 10.1200/JCO.1998.16.8.2579; MADSEN M, 1990, Ugeskrift for Laeger, V152, P308; MCDONALD CC, 1995, BRIT MED J, V311, P977; Mosbech J, 1995, Ugeskr Laeger, V157, P3741; MOURIDSEN HT, 1988, ACTA ONCOL, V27, P699, DOI 10.3109/02841868809091772; Nixon AJ, 1998, J CLIN ONCOL, V16, P1374, DOI 10.1200/JCO.1998.16.4.1374; OVERGAARD M, 1988, ACTA ONCOL, V27, P707, DOI 10.3109/02841868809091773; Overgaard M, 1999, LANCET, V353, P1641, DOI 10.1016/S0140-6736(98)09201-0; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Paszat LF, 1998, J CLIN ONCOL, V16, P2625, DOI 10.1200/JCO.1998.16.8.2625; Rutqvist LE, 1998, INT J RADIAT ONCOL, V40, P359, DOI 10.1016/S0360-3016(97)00765-7; RUTQVIST LE, 1990, BRIT J CANCER, V61, P866, DOI 10.1038/bjc.1990.193; RUTQVIST LE, 1992, INT J RADIAT ONCOL, V22, P887, DOI 10.1016/0360-3016(92)90784-F; RUTQVIST LE, 1993, J NATL CANCER I, V85, P1398, DOI 10.1093/jnci/85.17.1398; Shapiro CL, 1998, J CLIN ONCOL, V16, P3493, DOI 10.1200/JCO.1998.16.11.3493; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2nd	30	260	265	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1425	1430		10.1016/S0140-6736(99)02245-X	http://dx.doi.org/10.1016/S0140-6736(99)02245-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543669				2022-12-28	WOS:000083277400012
J	Robinson, S; Inyang, V				Robinson, S; Inyang, V			The nurse practitioner in emergency medicine-valuable but undefined	LANCET			English	Editorial Material							ACCIDENT		Addenbrookes NHS Trust, Emergency Dept, Cambridge CB2 2QQ, England	Addenbrooke's Hospital	Robinson, S (corresponding author), Addenbrookes NHS Trust, Emergency Dept, Cambridge CB2 2QQ, England.							*AUD COMM, 1996, ACC DES IMPR A E SER; *BRIT ASS ACC EM M, 1998, WAY AH; Freij RM, 1996, J ACCID EMERG MED, V13, P41; Hooker RS, 1996, AM J EMERG MED, V14, P245, DOI 10.1016/S0735-6757(96)90167-9; HUNT MT, 1991, ARCH EMERG MED, V8, P17; Marshall J, 1997, J ACCID EMERG MED, V14, P233; Tye CC, 1998, J ACCID EMERG MED, V15, P31; *UK CENTR COUNC NU, 1992, SCOP PROF PRACT	8	7	7	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1319	1320		10.1016/S0140-6736(99)00342-6	http://dx.doi.org/10.1016/S0140-6736(99)00342-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533857				2022-12-28	WOS:000083149900006
J	Beecham, L				Beecham, L			NHS doctors in England face audit and annual appraisals	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1319	1319						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567118	Green Published			2022-12-28	WOS:000083930200006
J	Donald, A				Donald, A			Political economy of technology transfer	BRITISH MEDICAL JOURNAL			English	Article								Every year, new health products and know-how become available: statins, new antibiotics, telemedicine, insurance know-how, imaging techniques, and genomics, to name a few. At the same time, major barriers to transferring information and technology between countries are falling with expansion of the internet and online health training programmes, the growth of information about the relative effectiveness of different technologies,(1) and the liberalisation of trade. It might be reasonable to expect that global transfer of health technologies would take plate more rapidly and in greater quantity to benefit "haves" and "have nets" alike. There is no evidence, however, that this is taking place. On the contrary, appropriate health technologies may become more unequally distributed than ever. Why?	UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London	Donald, A (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	a.donald@ucl.ac.uk						ABBASI K, 1999, BRIT MED J, V318, P1067; BLACK ME, 1993, BRIT MED J, V307, P1135, DOI 10.1136/bmj.307.6912.1135; *BRIT MED ASS, 1998, ROYAL PHARM SOC GREA; CHETLEY A, 1990, HLTH BUSINESS WORLD, P68; Chowdhury, 2018, CREATING CULTURE INN; Ferguson J., 1990, ANTIPOLITICS MACHINE; Heymann SJ, 1999, JAMA-J AM MED ASSOC, V281, P2138, DOI 10.1001/jama.281.22.2138; Murray CJL, 1996, GLOBAL BURDEN DIS SU, P37; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; REICH MR, 1999, ASSESSMENT PHARM DON; *RUR ADV FDN INT, 1994, CONS IND KNOWL 2 SYS; SIMMS A, 1999, SELLING SUICIDE FARM; Veeken H, 1998, BRIT MED J, V317, P1649, DOI 10.1136/bmj.317.7173.1649; WARNER DC, 1998, INT TRADE HLTH SERVI, P71; WAUD DR, 1992, NEW ENGL J MED, V327, P351, DOI 10.1056/NEJM199207303270511; *WHO, 1996, GUID DRUG DON; WHO (World Health Organization), 1998, WORLD HLTH REP 1998; *WORLD BANK, 1999, KNOWL DEV; WUYTS M, 1992, DEV POLICY PUBLIC AC, P99; 1999, ECONOMIST       0814, P69; [No title captured]	21	8	8	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 13	1999	319	7220					1298	U57		10.1136/bmj.319.7220.1298	http://dx.doi.org/10.1136/bmj.319.7220.1298			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	257MZ	10559051	Green Submitted, Green Published			2022-12-28	WOS:000083786900020
J	Viskin, S				Viskin, S			Long QT syndromes and torsade de pointes	LANCET			English	Article							COMPLETE ATRIOVENTRICULAR-BLOCK; NA+ CHANNEL BLOCKADE; DE-POINTES; VENTRICULAR TACHYARRHYTHMIAS; CARDIAC-ARRHYTHMIAS; ATRIAL-FIBRILLATION; POTASSIUM CURRENT; IONIC MECHANISMS; LQT1 FORM; REPOLARIZATION	In the long QT syndromes (LQTS), malfunction of ion channels impairs ventricular repolarisation and triggers a characteristic ventricular tachyarrhythmia: torsade de pointes. Symptoms in the LQTS (syncope or cardiac arrest) are caused by this arrhythmia. In congenital LQTS, mutations in the genes encoding for ion chanels cause this channel malfunction. Six genotypes (LQT1 to LQT6) have been identified, and attempts are being made to correlate different mutations with clinical signs and specific therapy. In acquired LQTS, channel malfunction is caused by metabolic abnormalities or drugs. The list of drugs that may impair ion-channel function expands continuously. Moreover, attributes that increase the risk for drug-induced torsade (eg, female sex, recent heart-rate slowing, or hypokalaemia) and electrocardiographic "warning signs" are recognised. Recent data suggest that patients with an acquired LQTS have some underlying predisposition to proarrhythmia. Mutations causing "silent" forms of congenital LQTS, in which the patient remains free of arrhythmias until exposed to drugs that further impair repolarisation, are now recognised.	Sourasky Tel Aviv Med Ctr, Dept Cardiol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-64239 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Viskin, S (corresponding author), Sourasky Tel Aviv Med Ctr, Dept Cardiol, Weizman 6, IL-64239 Tel Aviv, Israel.							Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; ANDREOLI A, 1987, STROKE, V18, P558, DOI 10.1161/01.STR.18.3.558; Antzelevitch C, 1996, J AM COLL CARDIOL, V28, P1836, DOI 10.1016/S0735-1097(96)00377-4; ANTZELEVITCH C, 1994, J AM COLL CARDIOL, V23, P259, DOI 10.1016/0735-1097(94)90529-0; BAILIE DS, 1988, CIRCULATION, V77, P1395, DOI 10.1161/01.CIR.77.6.1395; Benton RE, 1996, CLIN PHARMACOL THER, V59, P383, DOI 10.1016/S0009-9236(96)90105-8; Bernstein DI, 1997, ANN ALLERG ASTHMA IM, V79, P443, DOI 10.1016/S1081-1206(10)63041-4; CHAO CL, 1995, INT J CARDIOL, V51, P199, DOI 10.1016/0167-5273(95)02407-N; CHOY A, 1997, CIRCULATION, V97, P2149; Compton SJ, 1996, CIRCULATION, V94, P1018, DOI 10.1161/01.CIR.94.5.1018; COOKE RA, 1994, BRIT HEART J, V72, P69; Donger C, 1997, CIRCULATION, V96, P2778, DOI 10.1161/01.CIR.96.9.2778; Drolet B, 1998, CIRCULATION, V97, P204, DOI 10.1161/01.CIR.97.2.204; Duggal P, 1998, CIRCULATION, V97, P142, DOI 10.1161/01.CIR.97.2.142; EIVINSSON G, 1980, ACTA MED SCAND, V208, P449; ELDAR M, 1987, J AM COLL CARDIOL, V10, P600, DOI 10.1016/S0735-1097(87)80203-6; ElSherif N, 1996, CIRC RES, V79, P474, DOI 10.1161/01.RES.79.3.474; GARSON A, 1993, CIRCULATION, V87, P1866, DOI 10.1161/01.CIR.87.6.1866; GROSSMAN MA, 1976, ARCH INTERN MED, V136, P203, DOI 10.1001/archinte.136.2.203; Hanrahan John P., 1995, Annals of Epidemiology, V5, P201, DOI 10.1016/1047-2797(94)00039-V; Hill SL, 1998, PEDIATRICS, V101, P1053, DOI 10.1542/peds.101.6.1053; Houltz B, 1998, PACE, V21, P1044, DOI 10.1111/j.1540-8159.1998.tb00150.x; ISNER JM, 1979, CIRCULATION, V60, P1401, DOI 10.1161/01.CIR.60.6.1401; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; KAWASAKI R, 1995, J CARDIOVASC ELECTR, V6, P1032, DOI 10.1111/j.1540-8167.1995.tb00380.x; KAY GN, 1983, J AM COLL CARDIOL, V2, P806; Krebs ME, 1998, J CARDIOVASC ELECTR, V9, P1036, DOI 10.1111/j.1540-8167.1998.tb00881.x; Kurita T, 1997, PACE, V20, P695, DOI 10.1111/j.1540-8159.1997.tb03888.x; KURITA T, 1992, AM J CARDIOL, V69, P628, DOI 10.1016/0002-9149(92)90154-Q; LOCATI EH, 1995, J AM COLL CARDIOL, V25, P1564, DOI 10.1016/0735-1097(95)00100-I; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; MARUYAMA T, 1995, EUR HEART J, V16, P667, DOI 10.1093/oxfordjournals.eurheartj.a060971; MICHAELSSON M, 1995, CIRCULATION, V92, P442, DOI 10.1161/01.CIR.92.3.442; MINARDO JD, 1988, NEW ENGL J MED, V319, P257, DOI 10.1056/NEJM198808043190501; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; MOSS AJ, 1991, CIRCULATION, V84, P1524, DOI 10.1161/01.CIR.84.4.1524; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; Napolitano C, 1997, CIRCULATION, V96, pI; NATTEL S, 1988, CARDIOVASC RES, V22, P808, DOI 10.1093/cvr/22.11.808; OTTENI JC, 1983, ANESTHESIOLOGY, V59, P358, DOI 10.1097/00000542-198310000-00019; Pinto YM, 1999, LANCET, V353, P980, DOI 10.1016/S0140-6736(99)01009-0; Priori SG, 1999, CIRCULATION, V99, P529, DOI 10.1161/01.CIR.99.4.529; Priori SG, 1998, CIRCULATION, V97, P2420, DOI 10.1161/01.CIR.97.24.2420; Priori SG, 1996, CIRC RES, V78, P1009, DOI 10.1161/01.RES.78.6.1009; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; Rampe D, 1998, J PHARMACOL EXP THER, V286, P788; Roden DM, 1998, PACE, V21, P1029, DOI 10.1111/j.1540-8159.1998.tb00148.x; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; ROTEM M, 1988, NEUROSURGERY, V23, P89, DOI 10.1227/00006123-198807000-00015; SCHEARTZ PJ, 1998, PROGR CLIN PACING; SCHULZEBAHR E, 1977, CIRCULATION S1, V96, P211; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; SCHWARTZ PJ, 1991, CIRCULATION, V84, P503, DOI 10.1161/01.CIR.84.2.503; SCHWARTZ PJ, 1998, CLIN APPROACHES TACH, P1; Shimizu W, 1998, CIRCULATION, V97, P1581, DOI 10.1161/01.CIR.97.16.1581; Shimizu W, 1998, CIRCULATION, V98, P2314, DOI 10.1161/01.CIR.98.21.2314; Shimizu W, 1999, J CARDIOVASC ELECTR, V10, P154, DOI 10.1111/j.1540-8167.1999.tb00656.x; Shimizu W, 1997, CIRCULATION, V96, P2038, DOI 10.1161/01.CIR.96.6.2038; Splawski I, 1997, NEW ENGL J MED, V336, P1562, DOI 10.1056/NEJM199705293362204; TAN HL, 1995, ANN INTERN MED, V122, P701, DOI 10.7326/0003-4819-122-9-199505010-00009; TURGEON J, 1994, CIRC RES, V75, P879, DOI 10.1161/01.RES.75.5.879; TZIVONI D, 1988, CIRCULATION, V77, P392, DOI 10.1161/01.CIR.77.2.392; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; VINCENT GM, 1996, CIRCULATION S1, V94, P204; Viskin S, 1996, J AM COLL CARDIOL, V28, P1262, DOI 10.1016/S0735-1097(96)00311-7; Viskin S, 1998, HEART, V79, P417, DOI 10.1136/hrt.79.4.417; Viskin S, 1998, PROG CARDIOVASC DIS, V41, P17, DOI 10.1016/S0033-0620(98)80020-0; Viskin S, 1997, Curr Probl Cardiol, V22, P37, DOI 10.1016/S0146-2806(97)80014-X; VISKIN S, 1998, PACING CLIN ELECTROP, V21, P851; Vorperian VR, 1996, J AM COLL CARDIOL, V28, P1556, DOI 10.1016/S0735-1097(96)00352-X; WESLEY RC, 1992, AM HEART J, V123, P794, DOI 10.1016/0002-8703(92)90525-Z; Wilde AAM, 1999, J AM COLL CARDIOL, V33, P327, DOI 10.1016/S0735-1097(98)00578-6; Wysowski DK, 1996, NEW ENGL J MED, V335, P290, DOI 10.1056/NEJM199607253350416; Yang T, 1996, CIRCULATION, V93, P407, DOI 10.1161/01.CIR.93.3.407; Zareba W, 1997, AM J CARDIOL, V80, P1168, DOI 10.1016/S0002-9149(97)00634-6; Zareba W, 1998, NEW ENGL J MED, V339, P960, DOI 10.1056/NEJM199810013391404; ZHANG ZH, 1994, CIRC RES, V75, P711, DOI 10.1161/01.RES.75.4.711	78	476	493	0	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1625	1633		10.1016/S0140-6736(99)02107-8	http://dx.doi.org/10.1016/S0140-6736(99)02107-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560690				2022-12-28	WOS:000083551000044
J	[Anonymous]				[Anonymous]			GPC advises on becoming a primary care trust	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	1999	319	7219					1274	1274						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550113				2022-12-28	WOS:000083625600065
J	Dauphinee, WD				Dauphinee, WD			Revalidation of doctors in Canada	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Med Council Canada, Ottawa, ON K1G 3H7, Canada		Dauphinee, WD (corresponding author), Med Council Canada, PB Box 8234,Stn T, Ottawa, ON K1G 3H7, Canada.	dauphine@mcc.ca						Cunnington JPW, 1997, ACAD MED, V72, P9; *FED MED LIC AUTH, 1996, POS PAP CAN MOD MON; *FED MED LIC AUTH, 1996, P AYBN 3 WORKSH MON; Fidler M, 1999, ACAD MED, V74, P702, DOI 10.1097/00001888-199906000-00019; Hall W, 1999, CAN MED ASSOC J, V161, P52; MCAULEY RG, 1990, CAN MED ASSOC J, V143, P1193; MODESETTE D, 1998, FED B, V85, P154; Page G G, 1996, Int J Risk Saf Med, V8, P217, DOI 10.3233/JRS-1996-8304	8	29	29	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	1999	319	7218					1188	1190		10.1136/bmj.319.7218.1188	http://dx.doi.org/10.1136/bmj.319.7218.1188			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541516	Green Published, Green Submitted			2022-12-28	WOS:000083536200031
J	Hartley, S; Macfarlane, F; Gantley, M; Murray, E				Hartley, S; Macfarlane, F; Gantley, M; Murray, E			Influence on general practitioners of teaching undergraduates: qualitative study of London general practitioner teachers	BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY; MEDICINE	Objective To examine the perceived effect of teaching clinical skills and associated teacher training programmes on general practitioners' morale and clinical practice Design Qualitative semistructured interview study. Setting General practices throughout north London. Subjects 30 general practitioners who taught clinical skills were asked about the effect of teaching and teacher training on their morale confidence in clinical and teaching skills, and clinical practice. Results The main theme nas a positive effect on morale. Within teacher training this was attributed to developing peer and professional support; improved teaching skills; and revision of clinical knowledge and skills. Within teaching this was attributed to a broadening of horizons; contact with enthusiastic students; increased time with patients; improved clinical practice; improved teaching skills; and an improved image of the practice. Problems with teaching were due to external factors such as lack of time and space and anxieties about adequacy of clinical cover while teaching Conclusions Teaching clinical skills can have a positive effect on the morale of general practitioner teachers as a result of contact with students and peers, as long as logistic and funding issues are adequately dealt with.	Dept Primary Hlth Care & Gen Practice, London W2 1PG, England; Granville Sansom Personnel & Management Consultan, London Colney AL2 1BG, Herts, England; St Bartholomews & Royal London Sch Med & Dent, Dept Gen Practice & Primary Care, Univ London Queen Mary & Westfield Coll, London E1 4NS, England; Univ Coll Med Sch, Whittington Hosp, Dept Primary Hlth Care & Populat Hlth Sci, London N19 5NF, England	University of London; Queen Mary University London; University of London; University College London	Hartley, S (corresponding author), Dept Primary Hlth Care & Gen Practice, London W2 1PG, England.			Hartley, Sarah/0000-0003-3028-4430; Murray, Elizabeth/0000-0002-8932-3695				*ASS STUD MED ED, 1997, CURR INN DESCR UND M; BAKER M, 1995, BRIT MED J, V310, P1301, DOI 10.1136/bmj.310.6990.1301; *BMA, 1998, BMA COH STUD 1995 ME; DAVIS WK, 1997, MOVING MED ED HOSP C; Fields SA, 1998, ACAD MED, V73, P95, DOI 10.1097/00001888-199801000-00019; Fine B, 1996, ED GEN PRACT, V7, P42; Gray J, 1997, BRIT J GEN PRACT, V47, P623; Green J, 1998, BMJ-BRIT MED J, V316, P1064; Inui TS, 1998, ACAD MED, V73, P245, DOI 10.1097/00001888-199803000-00012; Kolb David, 1975, THEORIES GROUP PROCE; LEFFORD F, 1994, MED EDUC, V28, P312, DOI 10.1111/j.1365-2923.1994.tb02718.x; MACFARLANE F, 1998, CEMENT PROJECT REPOR; Martens FMJG, 1997, FAM PRACT, V14, P153, DOI 10.1093/fampra/14.2.153; Mathie T, 1997, BRIT J GEN PRACT, V47, P3; MCBRIDE M, 1995, BRIT J GEN PRACT, V45, P227; *MED WORKF STAND A, 1997, 3 DEP HLTH MED WORF; Murray E, 1997, MED EDUC, V31, P369, DOI 10.1046/j.1365-2923.1997.00678.x; *N THAM NHS, 1997, NHSE PUBL; OSWALD NTA, 1993, MED EDUC, V27, P351, DOI 10.1111/j.1365-2923.1993.tb00280.x; Parle JV, 1997, MED EDUC, V31, P99, DOI 10.1111/j.1365-2923.1997.tb02466.x; Ruston A, 1998, BRIT MED J, V316, P1060; TOWLE A, 1992, COMMUNITY BASED TEAC, V1; WHITEHOUSE CR, 1996, ED HLTH, V9, P45; WILSON A, 1996, BR J GEN PRACT, V45, P227	24	57	60	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1168	1171		10.1136/bmj.319.7218.1168	http://dx.doi.org/10.1136/bmj.319.7218.1168			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541508	Green Published, Bronze			2022-12-28	WOS:000083536200023
J	Dundas, S; Murphy, J; Soutar, RL; Jones, GA; Hutchinson, SJ; Todd, WTA				Dundas, S; Murphy, J; Soutar, RL; Jones, GA; Hutchinson, SJ; Todd, WTA			Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157 : H7 outbreak	LANCET			English	Article							HEMOLYTIC-UREMIC SYNDROME; THROMBOTIC THROMBOCYTOPENIC PURPURA; HEMORRHAGIC COLITIS	Background The haemolytic uraemic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP) during an Escherichia coli O157 outbreak occurred in 1996 in central Scotland. Adults who develop HUS/TTP induced by E coli O157 tend to be elderly and have a historical mortality rate of almost 90% when treated conservatively, Therefore the decision was made to treat adults who developed HUS/TTP during this outbreak with therapeutic plasma exchange (TPE). We report our outcome with this controversial treatment. largest number of adult cases of uraemic syndrome (HUS)/thrombotic Methods A case definition for HUS/TTP was developed at the beginning of the outbreak. All cases meeting this definition were considered for TPE. Information on demographics, clinical features, treatment and outcome of patients was obtained by retrospective case note review. Findings 22 adults developed HUS/TTP. They had a mean age of 71 years. 16 cases received TPE. Six cases had contraindications to TPE or died before the procedure could be done. Ten of the 22 (45%) adults with HUS/TTP died. Five of the 16 (31%) TPE treated cases died, four of eight aged over 70 years compared with one of eight aged less than 70 years. Premorbid illness, neurological features, treatment with ciprofloxacin or prostacyclin, and the laboratory severity of HUS/TTP were not associated with death; the number of cases, however, was too small to allow statistical conclusion. Interpretation The mortality rate is high in adults who develop HUS/TTP induced by E coli O157. TPE appears to be a promising treatment that was well tolerated in our elderly patients. A national register of adult cases of HUS/TTP induced by E coli O157 should be established.	Monklands Hosp, Dept Infect Dis, Airdrie ML6 0JS, Lanark, Scotland; Monklands Hosp, Dept Haematol, Airdrie ML6 0JS, Lanark, Scotland; Dumfries & Galloway Royal Infirm, Dept Med, Dumfries, Scotland; Scottish Ctr Infect & Environm Hlth, Glasgow, Lanark, Scotland	Monklands Hospital; Monklands Hospital	Todd, WTA (corresponding author), Monklands Hosp, Dept Infect Dis, Airdrie ML6 0JS, Lanark, Scotland.	andrew@todds.demon.co.uk						Armstrong GL, 1996, EPIDEMIOL REV, V18, P29, DOI 10.1093/oxfordjournals.epirev.a017914; Begue RE, 1998, SOUTHERN MED J, V91, P798, DOI 10.1097/00007611-199809000-00001; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; CIMOLAI N, 1990, J PEDIATR-US, V116, P589, DOI 10.1016/S0022-3476(05)81609-9; DELAHUNT MN, 1991, BRIT J SURG, V78, P1469, DOI 10.1002/bjs.1800781220; DRUMMOND KN, 1985, NEW ENGL J MED, V312, P116, DOI 10.1056/NEJM198501103120211; Duncan L., 1986, ONTARIO DIS SURVEILL, V7, P604; DUNDAS S, 1996, IN PRESS CENTRAL SCO; GRIFFIN PM, 1990, GASTROENTEROLOGY, V99, P142, DOI 10.1016/0016-5085(90)91241-W; HUGHES DA, 1991, SCOT MED J, V36, P9, DOI 10.1177/003693309103600105; Karch H, 1996, J CLIN MICROBIOL, V34, P516, DOI 10.1128/JCM.34.3.516-519.1996; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; LOUSI CB, 1991, INFECT IMMUN, V59, P4173; MCBRIEN AD, 1983, LANCET, V1, P702; Mead PS, 1998, LANCET, V352, P1207, DOI 10.1016/S0140-6736(98)01267-7; MOAKE JL, 1989, AM J MED, V87, P3; PETITT RM, 1980, SEMIN THROMB HEMOST, V6, P350, DOI 10.1055/s-2007-1005108; REILLY WJ, 1997, SCIEH WKLY REP, V97, P4; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Rock G, 1996, BRIT J HAEMATOL, V94, P383, DOI 10.1046/j.1365-2141.1996.d01-1800.x; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; RUGGENENTI P, 1997, KIDNEY INT S, V58, pS97; TESH VL, 1991, MOL MICROBIOL, V5, P1817, DOI 10.1111/j.1365-2958.1991.tb00805.x; WALTERS MDS, 1989, PEDIATR NEPHROL, V3, P130, DOI 10.1007/BF00852893; 1986, MMWR MORB MORTAL WKL, V35, P549	25	116	122	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1999	354	9187					1327	1330		10.1016/S0140-6736(99)01251-9	http://dx.doi.org/10.1016/S0140-6736(99)01251-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533860				2022-12-28	WOS:000083149900009
J	Neri, P; Parker, AJ; Blakemore, C				Neri, P; Parker, AJ; Blakemore, C			Probing the human stereoscopic system with reverse correlation	NATURE			English	Article							BINOCULAR DISPARITY; DEPTH-PERCEPTION; NEURONS; CORTEX	Our two eyes obtain slightly different views of the world. The resulting differences in the two retinal images, called binocular disparities, provide us with a stereoscopic sense of depth(1). The primary visual cortex (V1) contains neurons that are selective for the disparity(2-4) of individual elements in an image, but this information must be further analysed to complete the stereoscopic process(5,6). Here we apply the psychophysical technique of reverse correlation(7) to investigate disparity processing in human vision. Observers viewed binocular random-dot patterns, with 'signal' dots in a specific depth plane plus 'noise' dots with randomly assigned disparities. By examining the correlation between the observers' ability to detect the plane and the particular sample of 'noise' disparities presented on each trial, we revealed detection 'filters: whose disparity selectivity was remarkably similar to that of individual neurons in monkey V1. Moreover, if the noise dots were of opposite contrast in the two eyes, the tuning inverted, just like the response patterns of V1 neurons(5,6). Reverse correlation appears to probe disparity processing at the earliest stages of binocular combination, prior to the generation of a full stereoscopic depth percept.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	University of Oxford	Neri, P (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.		Parker, Andrew J/I-7867-2013; Neri, Peter/G-1066-2012	Parker, Andrew J/0000-0001-5800-0407; Blakemore, Colin/0000-0003-2659-7899; Neri, Peter/0000-0003-1981-5309	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; Beard BL, 1998, P SOC PHOTO-OPT INS, V3299, P79, DOI 10.1117/12.320099; COGAN AI, 1995, PERCEPTION, V24, P33, DOI 10.1068/p240033; COGAN AI, 1993, VISION RES, V33, P1959, DOI 10.1016/0042-6989(93)90021-N; CORMACK LK, 1993, VISUAL NEUROSCI, V10, P585, DOI 10.1017/S0952523800005290; Cumming BG, 1997, NATURE, V389, P280, DOI 10.1038/38487; Cumming BG, 1998, PERCEPTION, V27, P1367, DOI 10.1068/p271367; Efron B., 1994, MONOGRAPHS STAT APPL; Fleet DJ, 1996, VISION RES, V36, P1839, DOI 10.1016/0042-6989(95)00313-4; GREEN DM, 1966, SIGNAL DETECTION THE; Julesz B., 1971, FDN CYCLOPEAN PERCEP; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; Masson GS, 1997, NATURE, V389, P283, DOI 10.1038/38496; NIKARA T, 1968, EXP BRAIN RES, V6, P353; OHZAWA I, 1990, SCIENCE, V249, P1037, DOI 10.1126/science.2396096; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; SCHOR C, 1984, VISION RES, V24, P661, DOI 10.1016/0042-6989(84)90207-4; STEVENSON SB, 1992, VISION RES, V32, P1685, DOI 10.1016/0042-6989(92)90161-B; WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828; Wheatstone C., 1838, PHILOS T ROY SOC LON, P371, DOI DOI 10.1098/RSTL.1838.0019	20	94	95	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					695	698		10.1038/44409	http://dx.doi.org/10.1038/44409			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537107				2022-12-28	WOS:000083207400056
J	Furman, JM; Cass, SP				Furman, JM; Cass, SP			Benign paroxysmal positional vertigo.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CANALITH REPOSITIONING PROCEDURE; MANAGEMENT; OCCLUSION; MANEUVER; ROTATION; THERAPY; TRIAL		Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA; Univ Colorado, Hlth Sci Ctr, Dept Otolaryngol, Denver, CO USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Furman, JM (corresponding author), Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA.	furman@pitt.edu						BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; Beynon GJ, 1997, BRIT J AUDIOL, V31, P11, DOI 10.3109/03005364000000005; BLAKLEY BW, 1994, OTOLARYNG HEAD NECK, V110, P391, DOI 10.1177/019459989411000407; BRANDT T, 1994, NEUROLOGY, V44, P796, DOI 10.1212/WNL.44.5.796; BRANDT T, 1980, ARCH OTOLARYNGOL, V106, P484; DIX MR, 1952, P ROY SOC MED, V45, P341, DOI 10.1177/003591575204500604; Drachman DA, 1998, JAMA-J AM MED ASSOC, V280, P2111, DOI 10.1001/jama.280.24.2111; Drachman DA, 1999, JAMA-J AM MED ASSOC, V281, P899; Dunniway HM, 1998, OTOLARYNG HEAD NECK, V118, P429, DOI 10.1016/S0194-5998(98)70197-4; EPLEY JM, 1995, OTOLARYNG HEAD NECK, V112, P154, DOI 10.1016/S0194-5998(95)70315-2; EPLEY JM, 1992, OTOLARYNG HEAD NECK, V107, P399, DOI 10.1177/019459989210700310; Fife TD, 1998, AM J OTOL, V19, P345; FROEHLING DA, 1991, MAYO CLIN PROC, V66, P596, DOI 10.1016/S0025-6196(12)60518-7; Furman JM, 1998, ANN OTO RHINOL LARYN, V107, P1046, DOI 10.1177/000348949810701209; GACEK RR, 1984, ANN OTO RHINOL LARYN, V93, P25, DOI 10.1177/00034894840930S405; GACEK RR, 1995, ACTA OTO-LARYNGOL, V115, P154, DOI 10.3109/00016489509139280; Gregorius F K, 1976, Surg Neurol, V6, P283; HALL SF, 1979, J OTOLARYNGOL, V8, P151; HAWTHORNE M, 1994, J LARYNGOL OTOL, V108, P935, DOI 10.1017/S0022215100128579; HERDMAN SJ, 1993, ARCH OTOLARYNGOL, V119, P450; Herdman SJ, 1997, PHYS THER, V77, P602, DOI 10.1093/ptj/77.6.602; Hotson JR, 1998, NEW ENGL J MED, V339, P680, DOI 10.1056/NEJM199809033391007; Lanska DJ, 1997, NEUROLOGY, V48, P1167, DOI 10.1212/WNL.48.5.1167; Lempert T, 1996, LARYNGOSCOPE, V106, P476, DOI 10.1097/00005537-199604000-00015; Lempert T, 1997, NEUROLOGY, V49, P729, DOI 10.1212/WNL.49.3.729; LevyReis I, 1997, NEUROLOGY, V48, P2136; LI JC, 1995, OTOLARYNG HEAD NECK, V112, P670, DOI 10.1016/S0194-5998(95)70174-5; Lynn S, 1995, OTOLARYNG HEAD NECK, V113, P712, DOI 10.1016/S0194-5998(95)70010-2; MCCLURE J, 1977, LARYNGOSCOPE, V87, P1434; MCCLURE JA, 1985, J OTOLARYNGOL, V14, P30; MIZUKOSHI K, 1988, ACTA OTO-LARYNGOL, P67; MORIARTY B, 1992, LARYNGOSCOPE, V102, P56; Naganuma H, 1996, ACTA OTO-LARYNGOL, P9; NEDZELSKI JM, 1986, J OTOLARYNGOL, V15, P101; Nuti D, 1998, ACTA OTO-LARYNGOL, V118, P455, DOI 10.1080/00016489850154559; PARNES LS, 1990, ANN OTO RHINOL LARYN, V99, P330, DOI 10.1177/000348949009900502; PARNES LS, 1993, ANN OTO RHINOL LARYN, V102, P325, DOI 10.1177/000348949310200501; PARNES LS, 1992, LARYNGOSCOPE, V102, P988; POOL AF, 1994, AM J AUDIOL, V3, P55; SAKATA E, 1991, ACTA OTO-LARYNGOL, P254; Schuknecht H F, 1973, Adv Otorhinolaryngol, V20, P434; SCHUKNECHT HF, 1969, ARCH OTOLARYNGOL, V90, P765; SEIDMAN SH, 1989, BRAIN RES, V504, P264, DOI 10.1016/0006-8993(89)91366-8; Semont A, 1988, Adv Otorhinolaryngol, V42, P290; WATSON CP, 1982, ARCH NEUROL-CHICAGO, V39, P601, DOI 10.1001/archneur.1982.00510210071027; WEIDER DJ, 1994, AM J OTOL, V15, P321; Welling DB, 1997, LARYNGOSCOPE, V107, P90, DOI 10.1097/00005537-199701000-00018; WELLING DB, 1994, LARYNGOSCOPE, V104, P946; Zappia JJ, 1996, AM J OTOL, V17, P749	49	192	211	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1999	341	21					1590	1596		10.1056/NEJM199911183412107	http://dx.doi.org/10.1056/NEJM199911183412107			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	256GF	10564690				2022-12-28	WOS:000083717000007
J	Nachum, Z; Ben-Shlomo, I; Weiner, E; Shalev, E				Nachum, Z; Ben-Shlomo, I; Weiner, E; Shalev, E			Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							GLYCEMIC CONTROL; MELLITUS; PREVENTION; INFANT; WOMEN	Objective To compare perinatal outcome and glycaemic control in two groups of pregnant diabetic patients receiving two insulin regimens. Design Randomised controlled open label study. Setting University affiliated hospital, Israel. Participants 138 patients with gestational diabetes mellitus and 58 patients with pregestational diabetes mellitus received insulin four times daily, and 136 patients with gestational diabetes and 60 patients with pregestational diabetes received insulin twice daily. Intervention Three doses of regular insulin before meals and an intermediate insulin dose before bedtime (four times daily regimen), and a combination of regular and intermediate insulin in the morning and evening (twice daily regimen). Main outcome measures Maternal glycaemic control and perinatal outcome. Results Mean daily insulin concentration before birth was higher in the women receiving insulin four times daily compared with twice daily: by 22 units (95% confidence interval 12 to 32) in patients with gestational diabetes and by 28 units (15 to 41) in patients with pregestational diabetes. Glycaemic control was better with the four times daily regimen than with the twice daily regimen: in patients with gestational diabetes mean blood glucose concentrations decreased by 0.19 mmol/l(0.13 to 0.25), HbA(1c) by 0.3% (0.2% to 0.4%), and fructosamine by 41 mu mol/l (37 to 45), and adequate glycaemic control (mean blood glucose concentration < 5.8 mmol/l) was achieved in 17% (8% to 26%) more women; in patients with pregestational diabetes mean blood glucose concentration decreased by 0.44 mmol/l(0.28 to 0.60), HbA(1c) by 0.5% (0.2% to 0.8%), and fructosamine by 51 mu mol/l (45 to 57), and adequate glycaemic control was achieved in 31% (15% to 47%) more women. Maternal severe hypoglycaemic events, caesarean section, preterm birth, macrosomia, and low Apgar scores were similar in both dose groups. In women with gestational diabetes the four times daily regimen resulted in a lower rate of overall neonatal morbidity than the twice daily regimen (relative risk 0.59, 0.38 to 0.92), and the relative risk for hyperbilirubinaemia and hypoglycaemia was lower (0.51, 0.29 to 0.91 and 0.12, 0.02 to 0.97 respectively). The relative risk of hypoglycaemia in newborn infants to mothers with pregestational diabetes was 0.17 (0.04 to 0.74). Conclusions Giving insulin four times rather than twice daily in pregnancy improved glycaemic control and perinatal outcome without further risking the mother.	HaEmek Med Ctr, Dept Obstet & Gynecol, Afula, Israel; HaEmek Med Ctr, Ultrasound Unit, Afula, Israel	Emek Medical Center; Emek Medical Center	Shalev, E (corresponding author), HaEmek Med Ctr, Dept Obstet & Gynecol, Afula, Israel.		shalev, eliezer/C-8223-2014					*AM COLL OBST GYN, 1994, TECHN B ACOG, V200; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; DEVACIANA M, 1995, NEW ENGL J MED, V333, P1237; Diabet Control Complications Trial Res Grp, 1996, AM J OBSTET GYNECOL, V174, P1343; DORNER G, 1984, EXP CLIN ENDOCRINOL, V84, P134; DREXEL H, 1988, DIABETES CARE, V11, P761, DOI 10.2337/diacare.11.10.761; DUNBAR JM, 1994, DIABETES CARE, V17, P874, DOI 10.2337/diacare.17.8.874; GREEN JR, 1991, OBSTET GYNECOL, V78, P235; HAGAY ZJ, 1992, MED FETUS MOTHER; HARE JW, 1980, DIABETES CARE, V3, P394, DOI 10.2337/diacare.3.2.394; HARRIS M, 1979, DIABETES, V28, P1039; JARRETT RJ, 1981, LANCET, V2, P1220; JOVANOVIC L, 1981, AM J MED, V71, P921, DOI 10.1016/0002-9343(81)90301-6; LANGER O, 1994, AM J OBSTET GYNECOL, V170, P1036, DOI 10.1016/S0002-9378(94)70097-4; LANGER O, 1988, AM J OBSTET GYNECOL, V159, P1478, DOI 10.1016/0002-9378(88)90578-9; Leonardi M. R., 1996, American Journal of Obstetrics and Gynecology, V174, P393; MARTIN AO, 1985, AM J OBSTET GYNECOL, V151, P471, DOI 10.1016/0002-9378(85)90272-8; MOUNTAIN KR, 1991, BAILLIERE CLIN OB GY, V5, P413, DOI 10.1016/S0950-3552(05)80105-1; Pedersen J., 1967, PREGNANT DIABETIC HE; PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SPELLACY WN, 1985, OBSTET GYNECOL, V66, P158; VAUGHAN NJA, 1986, CLIN OBSTET GYNAECOL, V13, P291; WEISS PAM, 1984, OBSTET GYNECOL, V64, P629	25	92	97	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1223	1227		10.1136/bmj.319.7219.1223	http://dx.doi.org/10.1136/bmj.319.7219.1223			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550081	Green Published, Bronze			2022-12-28	WOS:000083625600020
J	Chen, CY; Li, YM; Bailey, K; O'Connor, TP; Young, L; Lu, ZT				Chen, CY; Li, YM; Bailey, K; O'Connor, TP; Young, L; Lu, ZT			Ultrasensitive isotope trace analyses with a magneto-optical trap	SCIENCE			English	Article							ICE CORE; SAMPLES; ATOMS; KR-81	Laser manipulation of neutral atoms has been used to count individual krypton-85 and krypton-81 atoms present in a natural krypton gas sample with isotopic abundances in the range of 10(-11) and 10(-13), respectively. This method of isotope trace analysis is free of contamination from other isotopes and elements and can be applied to several different isotope tracers for a wide range of applications. The demonstrated detection efficiency is 1 x 10(-7). System improvements could increase the efficiency by many orders of magnitude.	Argonne Natl Lab, Div Phys, Argonne, IL 60439 USA; Argonne Natl Lab, Div Chem, Argonne, IL 60439 USA	United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory	Lu, ZT (corresponding author), Argonne Natl Lab, Div Phys, 9700 S Cass Ave, Argonne, IL 60439 USA.		Lu, Zheng-Tian/G-1131-2017	Lu, Zheng-Tian/0000-0002-1887-0018				ARNOLD JR, 1951, SCIENCE, V113, P111, DOI 10.1126/science.113.2927.111; Baumgartner S, 1998, SCIENCE, V279, P1330, DOI 10.1126/science.279.5355.1330; CANNON BD, 1985, APPL PHYS B-PHOTO, V38, P57, DOI 10.1007/BF00691771; CANNON BD, 1993, PHYS REV A, V47, P1148, DOI 10.1103/PhysRevA.47.1148; Chao JH, 1996, NUCL INSTRUM METH A, V372, P275, DOI 10.1016/0168-9002(95)01296-6; Collon P, 1997, NUCL INSTRUM METH B, V123, P122, DOI 10.1016/S0168-583X(96)00674-X; COLLON P, 1999, THESIS U VIENNA AUST; DAVIS R, 1989, ANNU REV NUCL PART S, V39, P467; Haubrich D, 1996, EUROPHYS LETT, V34, P663, DOI 10.1209/epl/i1996-00512-5; HENNING W, 1987, SCIENCE, V236, P725, DOI 10.1126/science.236.4802.725; HU Z, 1994, OPT LETT, V19, P1888, DOI 10.1364/OL.19.001888; Hurst G.S, 1988, PRINCIPLES APPL RESO; HURST GS, 1980, PHYS TODAY, V33, P24, DOI 10.1063/1.2914274; HURST GS, 1984, J APPL PHYS, V55, P1278, DOI 10.1063/1.333216; *INT AT EN AG, 1992, IS NOBL GAS TRAC ENV; KRAMER SD, 1986, NUCL INSTRUM METH B, V17, P395, DOI 10.1016/0168-583X(86)90171-0; LaBelle RD, 1996, PHYS REV A, V54, P4461, DOI 10.1103/PhysRevA.54.4461; LEHMANN BE, 1987, NUCL INSTRUM METH B, V28, P571, DOI 10.1016/0168-583X(87)90505-2; Letokhov V.S, 1987, LASER PHOTOIONIZATIO; LOOSLI HH, 1969, EARTH PLANET SC LETT, V7, P67, DOI 10.1016/0012-821X(69)90014-4; LORIUS C, 1985, NATURE, V316, P591, DOI 10.1038/316591a0; MULLER RA, 1977, SCIENCE, V196, P521, DOI 10.1126/science.196.4289.521; MULLER RA, 1977, SCIENCE, V196, P489, DOI 10.1126/science.196.4289.489; OESCHGER H, 1987, NUCL INSTRUM METH B, V29, P196, DOI 10.1016/0168-583X(87)90235-7; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; PHILLIPS WD, 1982, PHYS REV LETT, V48, P596, DOI 10.1103/PhysRevLett.48.596; RAAB EL, 1987, PHYS REV LETT, V59, P2631, DOI 10.1103/PhysRevLett.59.2631; ROOJAKKERS W, 1996, OPT COMMUN B, V123, P321; VONHIPPEL F, 1985, SCI AM, V253, P40, DOI 10.1038/scientificamerican0985-40; WALHOUT M, 1993, PHYS REV A, V48, P879; ZIMMER K, 1994, APPL PHYS B-LASERS O, V59, P117, DOI 10.1007/BF01081161; 1997, NUCL INSTR METH, V123	32	164	173	3	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1139	1141		10.1126/science.286.5442.1139	http://dx.doi.org/10.1126/science.286.5442.1139			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550048	Green Submitted			2022-12-28	WOS:000083534200038
J	Mueller, K; Champion, J; Guccione, M; Kelson, K				Mueller, K; Champion, J; Guccione, M; Kelson, K			Fault slip rates in the modern New Madrid seismic zone	SCIENCE			English	Article							DEFORMATION	Structural and geomorphic analysis of Late Holocene sediments in the Lake County region of the New Madrid seismic zone indicates that they are deformed by fault-related folding above the blind Reelfoot thrust fault. The widths of narrow kink bands exposed in trenches were used to model the Reelfoot scarp as a forelimb on a fault-bond fold; this, coupled with the age of folded sediment, yields a slip rate on the blind thrust of 6.1 +/- 0.7 mm/year for the past 2300 +/- 100 years. An alternative method used structural relief across the scarp and the estimated dip of the underlying blind thrust to calculate a slip rate of 4.8 +/- 0.2 mm/year. Geometric relations suggest that the right lateral slip rate on the New Madrid seismic zone is 1.8 to 2.0 mm/year.	Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA; Univ Arkansas, Dept Geol, Fayetteville, AR 72701 USA; William Lettis & Associates, Walnut Creek, CA 94596 USA	University of Colorado System; University of Colorado Boulder; University of Arkansas System; University of Arkansas Fayetteville	Mueller, K (corresponding author), Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA.							FULLER M.L, 1912, USGS BULL, V494, P119; Kelson KI, 1996, J GEOPHYS RES-SOL EA, V101, P6151, DOI 10.1029/95JB01815; KERKELA S, 1998, EOS S, V79, pF201; Medwedeff DA, 1997, J STRUCT GEOL, V19, P279, DOI 10.1016/S0191-8141(97)83026-X; Newman A, 1999, SCIENCE, V284, P619, DOI 10.1126/science.284.5414.619; Odum JK, 1998, GEOL SOC AM BULL, V110, P149, DOI 10.1130/0016-7606(1998)110<0149:NSSMFD>2.3.CO;2; PUJOL J, 1997, ENG GEOL, V46, P21; Purser JL, 1998, B SEISMOL SOC AM, V88, P1204; RUSS DP, 1982, US GEOL SURV PROF PA, V1236, P94; Saucier R. T., 1994, GEOMORPHOLOGY QUATER, V2; SCHWEIG ES, 1994, SCIENCE, V264, P1308, DOI 10.1126/science.264.5163.1308; SEXTON JL, 1986, GEOPHYSICS, V51, P1760, DOI 10.1190/1.1442224; SHAW JH, 1994, GEOL SOC AM BULL, V106, P607, DOI 10.1130/0016-7606(1994)106<0607:AFAGFI>2.3.CO;2; SUPPE J, 1983, AM J SCI, V283, P684, DOI 10.2475/ajs.283.7.684; Tuttle M. P. R. H, 1996, GEOARCHAEOLOGY, V11, P451, DOI DOI 10.1002/(SICI)1520-6548(199612)11:6<451::AID-GEA1>3.0.CO;2-5	15	26	26	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1135	1138		10.1126/science.286.5442.1135	http://dx.doi.org/10.1126/science.286.5442.1135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550047				2022-12-28	WOS:000083534200037
J	Langenberg, AGM; Corey, L; Ashley, RL; Leong, WP; Straus, SE				Langenberg, AGM; Corey, L; Ashley, RL; Leong, WP; Straus, SE		Chiron HSV Vaccine Study Grp	A prospective study of new infections with herpes simplex virus type 1 and type 2	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; GENITAL HERPES; ENZYME-IMMUNOASSAY; ANTIBODIES; WOMEN; PREVALENCE; IMMUNOBLOT; MENINGITIS; LESIONS; ASSAY	Background Herpes simplex virus (HSV) infections are endemic, but the clinical characteristics of newly acquired HSV type 1 (HSV-1) and HSV type 2 (HSV-2) infections in adults have not been rigorously defined. Methods We monitored 2393 sexually active HSV-2-seronegative persons for clinical and serologic evidence of new HSV infection. Of the participants, 1508 were seropositive for HSV-1 and 885 were seronegative. Charts were reviewed in a blinded manner for classification of those with genitourinary or oropharyngeal symptoms. Charts were also reviewed for all 174 persons with HSV seroconversion. Results The rates of new HSV-1 and HSV-2 infections were 1.6 and 5.1 cases per 100 person-years, respectively. Of the 155 new HSV-2 infections, 57 (37 percent) were symptomatic, 47 of which (82 percent) were correctly diagnosed at presentation. Among the 74 patients given a clinical diagnosis of genital HSV-2 infection during the study, 60 were given a correct diagnosis and 14 were given an incorrect diagnosis, for a ratio of true positive results to false positive results of 4:1. Among the 98 persons with asymptomatic HSV-2 seroconversion, 15 percent had genital lesions at some time during follow-up. Women were more likely than men to acquire HSV-2 (P<0.01) and to have symptomatic infection. Previous HSV-1 infection did not reduce the rate of HSV-2 infection, but it did increase the likelihood of asymptomatic seroconversion, as compared with symptomatic seroconversion, by a factor of 2.6 (P<0.001). Of the 19 new HSV-1 infections, 12 were symptomatic. The rates of symptomatic genital HSV-1 infection and oropharyngeal HSV-1 infection were the same (0.5 case per 100 person-years). Conclusions Nearly 40 percent of newly acquired HSV-2 infections and nearly two thirds of new HSV-1 infections are symptomatic. Among sexually active adults, new genital HSV-1 infections are as common as new oropharyngeal HSV-1 infections. (N Engl J Med 1999;341:1432-8.) (C)1999, Massachusetts Medical Society.	Chiron Corp, Emeryville, CA 94608 USA; Univ Washington, Seattle, WA 98195 USA; NIH, Bethesda, MD 20892 USA	Novartis; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA	Corey, L (corresponding author), 1100 Fairview Ave N,D3-100, Seattle, WA 98109 USA.		Leong, Wai Yie/J-8181-2017					ANDERSSONELLSTROM A, 1995, SCAND J INFECT DIS, V27, P315, DOI 10.3109/00365549509032723; ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; ASHLEY R, 1995, DIAGNOSTIC PROCEDURE, P375; Ashley RL, 1999, J CLIN MICROBIOL, V37, P1632, DOI 10.1128/JCM.37.5.1632-1633.1999; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; Ashley RL, 1998, J CLIN MICROBIOL, V36, P294, DOI 10.1128/JCM.36.1.294-295.1998; BERNSTEIN DI, 1984, AM J MED, V77, P1055, DOI 10.1016/0002-9343(84)90188-8; Brown ZA, 1997, NEW ENGL J MED, V337, P509, DOI 10.1056/NEJM199708213370801; CONE RW, 1994, JAMA-J AM MED ASSOC, V272, P792, DOI 10.1001/jama.272.10.792; Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; Cowan FM, 1996, J INFECT DIS, V174, P470, DOI 10.1093/infdis/174.3.470; Diamond C, 1999, SEX TRANSM DIS, V26, P221, DOI 10.1097/00007435-199904000-00007; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; Hashido M, 1998, EPIDEMIOL INFECT, V120, P179, DOI 10.1017/S095026889700856X; HOLMES KK, 1975, NEW ENGL J MED, V292, P1199, DOI 10.1056/NEJM197506052922301; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; Puthavathana Pilaipan, 1998, Journal of the Medical Association of Thailand, V81, P260; SAFRIN S, 1992, J CLIN MICROBIOL, V30, P1312, DOI 10.1128/JCM.30.5.1312-1314.1992; SCHLESINGER Y, 1995, CLIN INFECT DIS, V20, P842, DOI 10.1093/clinids/20.4.842; Schomogyi M, 1998, INFECT DIS CLIN N AM, V12, P47, DOI 10.1016/S0891-5520(05)70408-6; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V268, P1702, DOI 10.1001/jama.268.13.1702; Venot C, 1998, J INFECTION, V36, P233, DOI 10.1016/S0163-4453(98)80024-8; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; WEISS NS, 1986, MONOGRAPHS EPIDEMIOL, V11, P14; Whitley Richard J., 1993, P69	30	341	351	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1999	341	19					1432	1438		10.1056/NEJM199911043411904	http://dx.doi.org/10.1056/NEJM199911043411904			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XR	10547406				2022-12-28	WOS:000083472100004
J	Fox, E; Landrum-McNiff, K; Zhong, ZS; Dawson, NV; Wu, AW; Lynn, J				Fox, E; Landrum-McNiff, K; Zhong, ZS; Dawson, NV; Wu, AW; Lynn, J		SUPPORT Investigators	Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ILL HOSPITALIZED ADULTS; TERMINAL CARE; SURVIVAL; LIFE	Context Many individuals involved with care of the dying advocate expanding access to hospice care for persons with advanced lung, heart, or liver disease. However, to be eligible, these patients generally must have a prognosis for survival of less than 6 months. Objective To test the ability of currently available criteria to identify a population with a survival prognosis of 6 months or less among seriously ill hospitalized patients with 1 of 3 commonly fatal chronic diseases. Design Validation study using data from the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT) phase 1 (June 1989-June 1991) and phase 2 (January 1992-January 1994), with a 6-month follow-up. Setting and Patients Consecutive sample of 2607 seriously ill patients from 5 US medical centers who were hospitalized with chronic obstructive pulmonary disease, congestive heart failure, or end-stage liver disease, and who survived to hospital discharge. Main Outcome Measures Descriptive and operating characteristics of 5 general and 2 disease-specific clinical criteria for identifying patients with a survival prognosis of 6 months or less, and 3 sets of combination criteria (broad, intermediate, and narrow inclusion) aimed at providing low, medium, and high thresholds for hospice eligibility based on National Hospice Organization guidelines. Results Seventy-five percent of the sample survived more than 6 months after hospital discharge; 44% expressed a preference for palliative care. Broad inclusion criteria identified 923 patients eligible for hospice care, of whom 70% survived longer than 6 months. Intermediate inclusion criteria identified 300 patients, of whom 65% survived longer than 6 months. Narrow inclusion criteria identified 19 patients, of whom 53% Survived longer than 6 months. Sensitivities and specificities of the combination criteria were 41.7% and 66.7% (broad inclusion), 16.2% and 90.1% (intermediate inclusion), and 1.4% and 99.5% (narrow inclusion), respectively. Conclusions These data indicate that for seriously ill hospitalized patients with advanced chronic obstructive pulmonary disease, congestive heart failure, or end-stage liver disease, recommended clinical prediction criteria are not effective in identifying a population with a survival prognosis of 6 months or less.	Dept Vet Affairs, Vet Hlth Adm, Natl Eth Ctr, Washington, DC 20420 USA; George Washington Univ, Sch Med & Hlth Sci, Ctr Improve Care Dying, Washington, DC USA; Case Western Reserve Univ, Metrohlth Med Ctr, Dept Med, Cleveland, OH USA; Case Western Reserve Univ, Metrohlth Med Ctr, Ctr Hlth Care Res & Policy, Cleveland, OH USA; Johns Hopkins Univ, Hlth Serv Res & Dev Ctr, Baltimore, MD USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); George Washington University; Case Western Reserve University; MetroHealth System; Case Western Reserve University; MetroHealth System; Johns Hopkins University	Fox, E (corresponding author), Dept Vet Affairs, Vet Hlth Adm, Natl Eth Ctr, 810 Vermont Ave NW, Washington, DC 20420 USA.		Wu, Albert/AAJ-4780-2021	Fox, Ellen/0000-0001-9029-7052				American Heart Association, 1999, 1999 HEART STROK STA; BROOKS CH, 1984, MED CARE, V22, P691, DOI 10.1097/00005650-198408000-00002; *CDCP, 1999, MONTHL VIT STAT REP; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; DAWSON NJ, 1991, SOC SCI MED, V32, P83, DOI 10.1016/0277-9536(91)90131-U; FIELD MJ, 1997, APPROACHING DEATH IM, P30; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hamel MB, 1996, J AM GERIATR SOC, V44, P1043, DOI 10.1111/j.1532-5415.1996.tb02935.x; Hanrahan P, 1999, Am J Hosp Palliat Care, V16, P395, DOI 10.1177/104990919901600110; *HLTH CAR FIN ADM, 1999, A9834 HLTH CAR FIN A; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Layde PM, 1996, J CLIN EPIDEMIOL, V49, P835, DOI 10.1016/0895-4356(96)00006-6; Lynn J, 1997, New Horiz, V5, P56; Lynn J, 1997, JAMA-J AM MED ASSOC, V277, P1633, DOI 10.1001/jama.277.20.1633; LYNN J, 1995, WESTERN J MED, V163, P250; Lynn J, 1996, Duquesne Law Rev, V35, P311; MOR V, 1988, HOSPICE EXPT; MORRIS JN, 1986, J CHRON DIS, V39, P47, DOI 10.1016/0021-9681(86)90106-2; *NAT HOSP ORG, 1999, HOSP FACT SHEET; *OFF INSP GEN, 1999, OFF INSP GEN PUBL; PEARLMAN RA, 1987, CHEST, V91, P515, DOI 10.1378/chest.91.4.515; STUART B, IN PRESS HOSPICE J; Stuart B, 1996, MED GUIDELINES DETER; VLADECK BC, 1999, COMMENTS HLTH CARE F; vonGunten CF, 1996, CLIN GERIATR MED, V12, P349; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; Yeager H, 1997, CHEST, V112, P8, DOI 10.1378/chest.112.1.8	30	237	241	1	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1638	1645		10.1001/jama.282.17.1638	http://dx.doi.org/10.1001/jama.282.17.1638			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	250BD	10553790	Bronze			2022-12-28	WOS:000083368400029
J	Smith, PEM; Saunders, J; Dawson, A; Kerr, MP				Smith, PEM; Saunders, J; Dawson, A; Kerr, MP			Intractable seizures in pregnancy	LANCET			English	Article							EPILEPTICUS		Univ Wales Hosp, Epilepsy Unit, Cardiff CF4 4XW, S Glam, Wales; Nevill Hall Hosp, Abergavenny, Gwent, Wales	Cardiff University	Smith, PEM (corresponding author), Univ Wales Hosp, Epilepsy Unit, Cardiff CF4 4XW, S Glam, Wales.							Gunatilake SB, 1997, SEIZURE, V6, P71, DOI 10.1016/S1059-1311(97)80057-X; HOWELL SJ, 1989, Q J MED, V266, P507; Walker MC, 1996, QJM-INT J MED, V89, P913	3	12	12	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1522	1522		10.1016/S0140-6736(99)09164-3	http://dx.doi.org/10.1016/S0140-6736(99)09164-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551500				2022-12-28	WOS:000083411300014
J	[Anonymous]				[Anonymous]			Sixty one PCTs could be in place in 2000	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	1999	319	7218					1206	1206						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541534				2022-12-28	WOS:000083536200068
J	Francastel, C; Walters, MC; Groudine, M; Martin, DIK				Francastel, C; Walters, MC; Groudine, M; Martin, DIK			A functional enhancer suppresses silencing of a transgene and prevents its localization close to centromeric heterochromatin	CELL			English	Article							BETA-GLOBIN LOCUS; POSITION-EFFECT VARIEGATION; PROTEIN DNA INTERACTIONS; TRANSCRIPTION FACTORS; NUCLEAR-ORGANIZATION; GENE-EXPRESSION; CONTROL REGION; CHROMATIN; DROSOPHILA; YEAST	To explore the mechanism by which enhancers maintain gene expression, we have assessed the ability of an enhancer and derivative mutants to influence silencing and nuclear location of a transgene. Using site-specific recombination to place different constructs at the same integration sites, we find that disruption of Gore enhancer motifs impairs the enhancer's ability to suppress silencing. FISH analysis reveals that active transgenes linked to a functional enhancer localize away from centromeres. However, enhancer mutations that result in increased rates of transgene silencing fail to localize the transgene away from centromeric heterochromatin, even when the transgene is in an active state. These mutations thus dissociate transcriptional activity and subnuclear location. Together, our results suggest that the functional enhancer antagonizes gene silencing by preventing localization of a gene near centromeric heterochromatin.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Radiat Oncol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Groudine, M (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Francastel, Claire/AAI-4798-2021	Francastel, Claire/0000-0002-6353-4320				Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Bouhassira EE, 1997, BLOOD, V90, P3332, DOI 10.1182/blood.V90.9.3332; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; Gotta M, 1996, EXPERIENTIA, V52, P1136, DOI 10.1007/BF01952113; Gregory PD, 1998, EUR J BIOCHEM, V251, P9, DOI 10.1046/j.1432-1327.1998.2510009.x; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; Henikoff S, 1992, CURR OPIN GENET DEV, V2, P907, DOI 10.1016/S0959-437X(05)80114-5; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Sutherland HGE, 1997, MOL CELL BIOL, V17, P1607, DOI 10.1128/MCB.17.3.1607; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Walters MC, 1999, MOL CELL BIOL, V19, P3714; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676	41	209	211	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 29	1999	99	3					259	269		10.1016/S0092-8674(00)81657-8	http://dx.doi.org/10.1016/S0092-8674(00)81657-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	251HX	10555142	Bronze			2022-12-28	WOS:000083440600004
J	de Abajo, FJ; Rodriguez, LAG; Montero, D				de Abajo, FJ; Rodriguez, LAG; Montero, D			Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study	BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FLUOXETINE; PERFORATION; DISORDER; THERAPY; RISK	Objective To examine the association between selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Design Population based case-control study. Setting General practices included in the UK general practice research database. Subjects 1651 incident cases of upper gastrointestinal bleeding and 248 cases of ulcer perforation among patients aged 40 to 79 years between April 1993 and September 1997, and 10 000 controls matched for age, sex, and year that the case was identified. Interventions Review of computer profiles for all potential cases, and an internal validation study to confirm the accuracy of the diagnosis on the basis of the computerised information. Main outcome measures Current use of selective serotonin reuptake inhibitors or other antidepressants within 30 days before the index date. Results Current exposure to selective serotonin reuptake inhibitors was identified in 3.1% (52 of 1651) of patients with upper gastrointestinal bleeding but only 1.0% (95 of 10 000) of controls, giving an adjusted rate ratio of 3.0 (95% confidence interval 2.1 to 4.4). This effect measure was not modified by sex, age, dose, or treatment duration. A crude incidence of 1 case per 8000 prescriptions was estimated. A small association was found with non-selective serotonin reuptake inhibitors (relative risk 1.4, 1.1 to 1.9) but not with antidepressants lacking this inhibitory effect None of the groups of antidepressants was associated with ulcer perforation. The concurrent use of select-ive serotonin reuptake inhibitors with non-steroidal anti-inflammatory drugs increased the risk of upper gastrointestinal bleeding beyond the sum of their independent effects (15.6, 6.6 to 36.6). A smaller interaction was also found between selective serotonin reuptake inhibitors and low dose-aspirin (7.2, 3.1 to 17.1). Conclusions Selective serotonin reuptake inhibitors increase the risk of upper gastrointestinal bleeding The absolute effect is, however, moderate and about equivalent to low dose ibuprofen. The concurrent use of non-steroidal anti-inflammatory drugs or aspirin with selective serotonin reuptake inhibitors greatly increases the risk of upper gastrointestinal bleeding.	Agencia Espanola Medicamento, Div Farmacoepidemiol, Madrid 28220, Spain; Agencia Espanola Medicamento, Div Parmacoepidemiol & Farmacovigilancia, Safety Evaluat Unit, Madrid 28220, Spain; Ctr Espanol Invest Farmacoepidemiol, Madrid, Spain		de Abajo, FJ (corresponding author), Agencia Espanola Medicamento, Div Farmacoepidemiol, Madrid 28220, Spain.		rodriguez, luis a garcia/B-1980-2010; de Abajo, Fancisco/Z-1711-2019	de Abajo, Fancisco/0000-0001-9119-8646				ALDERMAN CP, 1992, ANN PHARMACOTHER, V26, P1517, DOI 10.1177/106002809202601205; [Anonymous], [No title captured]; Baldessarini RJ, 1996, GOODMAN GILMANS PHAR, P431; EVANS TG, 1991, NEW ENGL J MED, V324, P1671; Gutthann SP, 1997, EPIDEMIOLOGY, V8, P18, DOI 10.1097/00001648-199701000-00003; ISHIKAWA K, 1986, EUR J PHARMACOL, V120, P63, DOI 10.1016/0014-2999(86)90640-0; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; LANCASTER SG, 1989, DRUGS, V38, P123, DOI 10.2165/00003495-198938010-00005; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; Li N, 1997, BLOOD COAGUL FIBRIN, V8, P517, DOI 10.1097/00001721-199711000-00006; MAREK GJ, 1992, PSYCHOPHARMACOLOGY, V109, P2, DOI 10.1007/BF02245475; MONTERO DR, 1996, 4 ANN M EUR SOC PHAR; OTTERVANGER JD, 1994, AM J PSYCHIAT, V151, P781; POTTER WZ, 1991, NEW ENGL J MED, V325, P633; Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; ROSS SB, 1980, PSYCHOPHARMACOLOGY, V67, P1, DOI 10.1007/BF00427588; ROTHMAN KJ, 1986, MODER EPIDEMIOLOGY; Skop BP, 1996, PSYCHOSOMATICS, V37, P12, DOI 10.1016/S0033-3182(96)71592-X; TIELENS JAE, 1997, AM J PSYCHIAT, V153, P883; WAGNER A, 1990, J AFFECT DISORDERS, V20, P101, DOI 10.1016/0165-0327(90)90123-P; YARYURATOBIAS JA, 1991, AM J PSYCHIAT, V148, P949; 1998, WHO ADR NEWSLETTER, V3, P1	24	285	288	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1106	1109		10.1136/bmj.319.7217.1106	http://dx.doi.org/10.1136/bmj.319.7217.1106			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	250ZE	10531103	Bronze, Green Published			2022-12-28	WOS:000083419500025
J	Shay, DK; Holman, RC; Newman, RD; Liu, LL; Stout, JW; Anderson, LJ				Shay, DK; Holman, RC; Newman, RD; Liu, LL; Stout, JW; Anderson, LJ			Bronchiolitis-associated hospitalizations among US children, 1980-1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-SYNCYTIAL-VIRUS; GROUP-A; GROUP-B; UNITED-STATES; INFECTION; EPIDEMIOLOGY; CARE; WASHINGTON; EMERGENCY; ILLNESS	Context Respiratory syncytial virus (RSV) causes more lower respiratory tract infections, often manifested as bronchiolitis, among young children than any other pathogen. Few national estimates exist of the hospitalizations attributable to RSV, and recent advances in prophylaxis warrant an update of these estimates. Objectives To describe rates of bronchiolitis-associated hospitalizations and to estimate current hospitalizations associated with RSV infection. Design and Setting Descriptive analysis of US National Hospital Discharge Survey data from 1980 through 1996. Participants Children younger than 5 years who were hospitalized in short-stay, nonfederal hospitals for bronchiolitis. Main Outcome Measure Bronchiolitis-associated hospitalization rates by age and year. Results During the 17-year study period, an estimated 1.65 million hospitalizations for bronchiolitis occurred among children younger than 5 years, accounting for 7.0 million inpatient days. Fifty-seven percent of these hospitalizations occurred among children younger than 6 months and 81 % among those younger than 1 year. Among children younger than 1 year, annual bronchiolitis hospitalization rates increased 2.4-fold, from 12.9 per 1000 in 1980 to 31.2 per 1000 in 1996. During 1988-1995, infant hospitalization rates for bronchiolitis increased significantly (P for trend <.001), while hospitalization rates for lower respiratory tract diseases excluding bronchiolitis did not vary significantly (P for trend = .20). The proportion of hospitalizations for lower respiratory tract illnesses among children younger than 1 year associated with bronchiolitis increased from 2.2% in 1980 to 47.4% in 1996; among total hospitalizations, this proportion increased from 5.4% to 16.4%, Averaging bronchiolitis hospitalizations during 1994-1996 and assuming that RSV was the etiologic agent in 50% to 80% of November through April hospitalizations, an estimated 51 240 to 81 985 annual bronchiolitis hospitalizations among children younger than 1 year were related to RSV infection. Conclusions During 1980-1996, rates of hospitalization of infants with bronchiolitis increased substantially, as did the proportion of total and lower respiratory tract hospitalizations associated with bronchiolitis. Annual bronchiolitis hospitalizations associated with RSV infection among infants may be greater than previous estimates for RSV bronchiolitis and pneumonia hospitalizations combined.	Ctr Dis Control & Prevent, Resp & Enter Viruses Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, Off Director, Atlanta, GA USA; Univ Washington, Sch Med, Dept Pediat, Div Gen Pediat, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Shay, DK (corresponding author), Ctr Dis Control & Prevent, Resp & Enter Viruses Branch, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30333 USA.	dks4@cdc.gov		Shay, David/0000-0001-9619-4820				ANDERSON LJ, 1988, PEDIATRICS, V82, P300; ANDERSON LJ, 1985, J INFECT DIS, V151, P626, DOI 10.1093/infdis/151.4.626; ANDERSON LJ, 1991, J INFECT DIS, V163, P687, DOI 10.1093/infdis/163.4.687; [Anonymous], 1998, Pediatrics, V102, P1211; BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355, DOI 10.1093/oxfordjournals.aje.a121565; BREESE C, 1975, NEW ENGL J MED, V293, P1343, DOI 10.1056/NEJM197512252932604; CAUL EO, 1976, J HYG-CAMBRIDGE, V77, P383, DOI 10.1017/S0022172400055765; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1163; CRAIN EF, 1995, ARCH PEDIAT ADOL MED, V149, P893, DOI 10.1001/archpedi.1995.02170210067012; DAGAN R, 1993, PEDIATR INFECT DIS J, V12, P381, DOI 10.1097/00006454-199305000-00006; FOY HM, 1973, AM J EPIDEMIOL, V97, P80, DOI 10.1093/oxfordjournals.aje.a121492; GARDNER PS, 1973, BMJ-BRIT MED J, V2, P571, DOI 10.1136/bmj.2.5866.571; GILCHRIST S, 1994, J INFECT DIS, V170, P986, DOI 10.1093/infdis/170.4.986; Gillum B S, 1996, Vital Health Stat 13, P1; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GLEZEN WP, 1981, J PEDIATR-US, V98, P708, DOI 10.1016/S0022-3476(81)80829-3; GLEZEN WP, 1977, PEDIATR RES, V11, P239; GLEZEN WP, 1987, PEDIAT VIROL, V2, P1; GRAVES EJ, 1999, VITAL HLTH STAT, V13, P1; HALL CB, 1975, J INFECT DIS, V131, P1, DOI 10.1093/infdis/131.1.1; HALL CB, 1994, SCIENCE, V265, P1393, DOI 10.1126/science.7915433; HALL CB, 1990, J INFECT DIS, V162, P1283, DOI 10.1093/infdis/162.6.1283; HALL CB, 1998, TXB PEDIAT INFECT DI, P2087; HAUPT BJ, 1992, VITAL HLTH STAT, V13, P1; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; Hofferth SL, 1996, FUTURE CHILD, V6, P41, DOI 10.2307/1602418; *I MED, 1986, NEW VACC DEV EST PRI, V2, P299; Institute of Medicine, 1986, NEW VACC DEV EST PRI, V1, P397; Karron RA, 1997, J INFECT DIS, V176, P1428, DOI 10.1086/514138; KIM HW, 1973, AM J EPIDEMIOL, V98, P216, DOI 10.1093/oxfordjournals.aje.a121550; Kozak L J, 1995, Adv Data, P1; LAW BJ, 1993, PEDIATR INFECT DIS J, V12, P659, DOI 10.1097/00006454-199308000-00007; MANEKER AJ, 1995, ANN EMERG MED, V25, P36, DOI 10.1016/S0196-0644(95)70352-7; MCCONNOCHLE KM, 1990, J PEDIAT, V162, P1283; MCINTOSH EDG, 1993, PEDIATR INFECT DIS J, V12, P815, DOI 10.1097/00006454-199310000-00004; MONTO AS, 1971, AM J EPIDEMIOL, V94, P290, DOI 10.1093/oxfordjournals.aje.a121322; Murphy BR, 1997, B WORLD HEALTH ORGAN, V75, P307; *NAT CTR HLTH STAT, 1998, NAT HOSP DISCH SURV; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; PARROTT RH, 1973, AM J EPIDEMIOL, V98, P289, DOI 10.1093/oxfordjournals.aje.a121558; Peret TCT, 1998, J GEN VIROL, V79, P2221, DOI 10.1099/0022-1317-79-9-2221; *RES COUNC SUBC RE, 1978, BRIT MED J, V2, P796; Saijo Masayuki, 1993, Acta Paediatrica Japonica, V35, P233; Shah BV, 1996, SUDAAN USERS MANUAL; SIMS DG, 1976, BRIT MED J, V2, P1095, DOI 10.1136/bmj.2.6044.1095; SINGLETON RJ, 1995, PEDIATR INFECT DIS J, V14, P26, DOI 10.1097/00006454-199501000-00005; SIRKEN MG, 1992, MANUAL STANDARDS PRO; *US BUR CENS, 1998, INT EST POP AG SEX R; *US DHHS, 1998, DET DAT 1979 96 PUBL; *US PHS HLTH CAR F, 1998, INT CLASS DIS; Walsh EE, 1997, J INFECT DIS, V175, P814, DOI 10.1086/513976; YAMAMOTO LG, 1993, AM J EMERG MED, V11, P109, DOI 10.1016/0735-6757(93)90101-G; Yun BY, 1995, PEDIATR INFECT DIS J, V14, P1054, DOI 10.1097/00006454-199512000-00005	53	1029	1106	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1440	1446		10.1001/jama.282.15.1440	http://dx.doi.org/10.1001/jama.282.15.1440			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535434	Bronze			2022-12-28	WOS:000083111000029
J	Sakr, M; Angus, J; Perrin, J; Nixon, C; Nicholl, J; Wardrope, J				Sakr, M; Angus, J; Perrin, J; Nixon, C; Nicholl, J; Wardrope, J			Care of minor injuries by emergency nurse practitioners or junior doctors: a randomised controlled trial	LANCET			English	Article							ACCIDENT; RADIOGRAPHS; MULTICENTER	Background We aimed to assess the care and outcome of patients with minor injuries who were managed by a nurse practitioner or a junior doctor in our accident and emergency department. Methods 1453 eligible patients, over age 16 years, who presented at our department with minor injuries were randomly assigned care by a nurse practitioner (n=704) or by a junior doctor (n=749). Each patient was first assessed by the nurse practitioner or junior doctor who did a clinical assessment; the assessments were transcribed afterwards to maintain masked conditions. Patients were then assessed by an experienced accident and emergency physician (research registrar) who completed a research assessment, but took no part in the clinical management of the patient. A standard form was used to compare the clinical assessment of the nurse practitioner or junior doctor with the assessment of the research registrar. The primary outcome measure was the adequacy of care (history taking, examination of patient, interpretation of radiographs, treatment decision, advice, and follow-up). Findings Compared with the rigorous standard of the experienced accident and emergency research registrar, nurse practitioners and junior doctors made clinically important errors in 65 (9.2%) of 704 patients and in 80 (10.7%) of 749 patients, respectively. This difference was not significant. The nurse practitioners were better than junior doctors at recording medical history and fewer patients seen by a nurse practitioner had to seek unplanned follow-up advice about their injury. There were no significant differences between nurse practitioners and junior doctors in the accuracy of examination, adequacy of treatment, planned follow-up, or requests for radiography, Interpretation of radiographs was similar in the two groups. Interpretation Properly trained accident and emergency nurse practitioners, who work within agreed guidelines can provide care for patients with minor injuries that is equal or in some ways better than that provided by junior doctors.	No Gen Hosp, Dept Accid & Emergency Med, Sheffield S5 7AU, S Yorkshire, England; Univ Sheffield, Med Care Res Unit, Sheffield, S Yorkshire, England	Northern General Hospital; University of Sheffield	Wardrope, J (corresponding author), No Gen Hosp, Dept Accid & Emergency Med, Sheffield S5 7AU, S Yorkshire, England.		Nicholl, Jon/B-8257-2008					CAREY RG, 1993, MED CARE, V31, P834, DOI 10.1097/00005650-199309000-00008; FRIJ RM, 1996, J ACCID EMERG MED, V13, P41; Leaman AM, 1996, J ACCID EMERG MED, V13, P304; MACLEOD AJ, 1992, ARCH EMERG MED, V9, P19; Marshall J, 1997, J ACCID EMERG MED, V14, P233; Meek S, 1998, J ACCID EMERG MED, V15, P105; Powers M J, 1984, Nurse Pract, V9, P44; RHEE KJ, 1995, ANN EMERG MED, V26, P130, DOI 10.1016/S0196-0644(95)70141-9; Stewart IP, 1996, J ACCID EMERG MED, V13, P412; Thurston J, 1996, J ACCID EMERG MED, V13, P86	10	161	161	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1321	1326		10.1016/S0140-6736(99)02447-2	http://dx.doi.org/10.1016/S0140-6736(99)02447-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533859				2022-12-28	WOS:000083149900008
J	Brogan, DJ; Frank, E; Elon, L; Sivanesan, SP; O'Hanlan, KA				Brogan, DJ; Frank, E; Elon, L; Sivanesan, SP; O'Hanlan, KA			Harassment of lesbians as medical students and physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN PHYSICIANS		Emory Univ, Atlanta, GA 30322 USA; Stanford Med Ctr, Stanford, CA USA	Emory University; Stanford University	Frank, E (corresponding author), Emory Univ, Atlanta, GA 30322 USA.		; O'Hanlan, Katherine/A-4073-2017	Frank, Erica/0000-0001-7159-5417; O'Hanlan, Katherine/0000-0002-7577-4188				Frank E, 1995, J Am Med Womens Assoc (1972), V50, P64; Frank E, 1998, ARCH INTERN MED, V158, P342, DOI 10.1001/archinte.158.4.342; Frank E, 1998, ARCH INTERN MED, V158, P352, DOI 10.1001/archinte.158.4.352; MATHEWS WC, 1986, WESTERN J MED, V144, P106; ORIEL KA, 1996, FAM MED, V28, P7205; Schatz B, 1994, ANTIGAY DISCRIMINATI; STEVENS PE, 1991, INT J HEALTH SERV, V21, P291, DOI 10.2190/R2AW-MTCR-U0Q7-XMMY	7	31	31	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1290	+		10.1001/jama.282.13.1290	http://dx.doi.org/10.1001/jama.282.13.1290			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	241UM	10532853	hybrid			2022-12-28	WOS:000082901100042
J	Wilson, CB				Wilson, CB			The impart of medical technologies on the future of hospitals	BRITISH MEDICAL JOURNAL			English	Article							DRUG DISCOVERY	During the next decade diseases requiring medical intervention will be much the same as those being treated today. The site of tate may, however, be moved away from the community general hospital to a non-hospital site or to a higher order or specialty hospital at a distance.	Inst Future, Menlo Park, CA 94025 USA		Wilson, CB (corresponding author), Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.							Binder S, 1999, SCIENCE, V284, P1311, DOI 10.1126/science.284.5418.1311; Friend SH, 1998, NEW ENGL J MED, V338, P125, DOI 10.1056/NEJM199801083380211; Ganem D, 1999, SCIENCE, V284, P1279, DOI 10.1126/science.284.5418.1279; Hynes DM, 1997, LANCET, V350, P657, DOI 10.1016/S0140-6736(97)08157-9; KALES D, 1998, CARDIOL MANAGE   NOV, P27; Stratton K, 1999, VACCINES 21 CENTURY; STRYKER J, 1998, CALIFORNIA HEAL 0803; VANN L, 1997, SENSORS          MAR, P12; Vastag B, 1998, J NATL CANCER I, V90, P1771, DOI 10.1093/jnci/90.23.1771; Wakhloo AK, 1998, NEUROSURGERY, V43, P377, DOI 10.1097/00006123-199808000-00126	10	9	10	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1999	319	7220					1287	U24		10.1136/bmj.319.7220.1287	http://dx.doi.org/10.1136/bmj.319.7220.1287			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257MZ	10559040	Green Published			2022-12-28	WOS:000083786900009
J	Fenlon, HM; Nunes, DP; Schroy, PC; Barish, MA; Clarke, PD; Ferrucci, JT				Fenlon, HM; Nunes, DP; Schroy, PC; Barish, MA; Clarke, PD; Ferrucci, JT			A comparison of virtual and conventional colonoscopy for the detection of colorectal polyps	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTRAST BARIUM ENEMA; OCCULT-BLOOD-TEST; COLONIC POLYPS; SCREENING SIGMOIDOSCOPY; CT COLONOGRAPHY; LARGE BOWEL; CANCER; COLOGRAPHY; ENDOSCOPY; NEOPLASMS	Background Virtual colonoscopy is a new method of imaging the colon in which thin-section, helical computed tomography (CT) is used to generate high-resolution, two-dimensional axial images. Three-dimensional images of the colon simulating those obtained with conventional colonoscopy are then reconstructed off-line. We compared the performance of virtual and conventional colonoscopy for the detection of colorectal polyps. Methods We prospectively studied 100 patients at high risk for colorectal neoplasia (60 men and 40 women; mean age, 62 years). We performed virtual colonoscopy immediately before conventional colonoscopy. We inserted a rectal tube and insufflated the colon with air to the maximal level that the patient could tolerate. We administered 1 mg of glucagon intravenously immediately before CT scanning to minimize the degree of smooth-muscle spasm and peristalsis and to reduce the patient's discomfort. Results The entire colon was clearly seen by virtual colonoscopy in 87 patients and by conventional colonoscopy in 89. Fifty-one patients had normal findings on conventional colonoscopy. In the other 49, we identified a total of 115 polyps and 3 carcinomas. Virtual colonoscopy identified all 3 cancers, 20 of 22 polyps that were 10 mm or more in diameter (91 percent), 33 of 40 that were 6 to 9 mm (82 percent), and 29 of 53 that were 5 mm or smaller (55 percent). There were 19 false positive findings of polyps and no false positive findings of cancer. Of the 69 adenomatous polyps, 46 of the 51 that were 6 mm or more in diameter (90 percent) and 12 of the 18 that were 5 mm or smaller (67 percent) were correctly identified by virtual colonoscopy. Although discomfort was not specifically recorded, none of the patients requested that virtual colonoscopy be stopped because of discomfort or pain. Conclusions In patients at high risk for colorectal neoplasia, virtual and conventional colonoscopy have similar efficacy for the detection of polyps 6 mm or more in diameter. (N Engl J Med 1999;341:1496-503.) (C) 1999, Massachusetts Medical Society.	Boston Univ, Boston Med Ctr, Sch Med, Dept Radiol, Boston, MA 02118 USA; Boston Univ, Boston Med Ctr, Sch Med, Dept Gastroenterol, Boston, MA 02118 USA	Boston Medical Center; Boston University; Boston Medical Center; Boston University	Barish, MA (corresponding author), Boston Univ, Boston Med Ctr, Sch Med, Dept Radiol, Boston, MA 02118 USA.			Barish, Matthew/0000-0002-7521-8878; Schroy, Paul/0000-0001-9273-7832; Nunes, David/0000-0002-6808-2247				Ahlquist D A, 1997, Gastrointest Endosc Clin N Am, V7, P439; AHLQUIST DA, 1989, CANCER, V63, P1826; American Cancer Society, 1999, CANC FACTS FIG 1999; APPEL MF, 1982, DIS COLON RECTUM, V25, P427, DOI 10.1007/BF02553647; Beaulieu CF, 1998, J COMPUT ASSIST TOMO, V22, P656, DOI 10.1097/00004728-199807000-00028; BERTONI G, 1994, GASTROINTEST ENDOSC, V40, P588, DOI 10.1016/S0016-5107(94)70259-4; BRADY AP, 1994, RADIOLOGY, V192, P373, DOI 10.1148/radiology.192.2.8029400; Dachman AH, 1997, RADIOLOGY, V203, P427, DOI 10.1148/radiology.203.2.9114099; Dachman AH, 1998, AM J ROENTGENOL, V171, P989, DOI 10.2214/ajr.171.4.9762982; Fenlon HM, 1998, AM J ROENTGENOL, V170, P1303, DOI 10.2214/ajr.170.5.9574607; Fenlon HM, 1997, AM J ROENTGENOL, V169, P453, DOI 10.2214/ajr.169.2.9242753; Fenlon HM, 1998, GUT, V43, P806, DOI 10.1136/gut.43.6.806; Fenlon HM, 1999, RADIOLOGY, V210, P423, DOI 10.1148/radiology.210.2.r99fe21423; FORK FT, 1983, GUT, V24, P672, DOI 10.1136/gut.24.7.672; Glick S, 1998, AM J ROENTGENOL, V170, P629, DOI 10.2214/ajr.170.3.9490943; GRANQVIST S, 1981, SCAND J GASTROENTERO, V16, P1025, DOI 10.3109/00365528109181023; HARA A, 1996, 82 SCI ASS ANN M RAD; Hara AK, 1997, GASTROENTEROLOGY, V112, pA575; Hara AK, 1997, AM J ROENTGENOL, V168, P1181, DOI 10.2214/ajr.168.5.9129408; Hara AK, 1997, RADIOLOGY, V205, P59, DOI 10.1148/radiology.205.1.9314963; Hara AK, 1996, RADIOLOGY, V200, P49, DOI 10.1148/radiology.200.1.8657944; Hara AK, 1996, GASTROENTEROLOGY, V110, P284, DOI 10.1053/gast.1996.v110.pm8536869; HIXSON LJ, 1990, JNCI-J NATL CANCER I, V82, P1769, DOI 10.1093/jnci/82.22.1769; HIXSON LJ, 1991, GASTROINTEST ENDOSC, V37, P125, DOI 10.1016/S0016-5107(91)70668-8; Johnson CD, 1999, GUT, V44, P301, DOI 10.1136/gut.44.3.301; Johnson CD, 1997, ENDOSCOPY, V29, P454, DOI 10.1055/s-2007-1004250; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; Morales TG, 1996, GASTROINTEST ENDOSC, V43, P25; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; Nusko G, 1997, ENDOSCOPY, V29, P626, DOI 10.1055/s-2007-1004268; REILLY JM, 1990, AM SURGEON, V56, P119; REX DK, 1995, AM J GASTROENTEROL, V90, P353; Rex DK, 1997, GASTROENTEROLOGY, V112, P24, DOI 10.1016/S0016-5085(97)70214-2; Royster AP, 1998, ACAD RADIOL, V5, P282, DOI 10.1016/S1076-6332(98)80229-8; Royster AP, 1997, AM J ROENTGENOL, V169, P1237, DOI 10.2214/ajr.169.5.9353434; Rubin GD, 1996, RADIOLOGY, V199, P321, DOI 10.1148/radiology.199.2.8668772; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; STEINE S, 1993, FAM PRACT, V10, P288, DOI 10.1093/fampra/10.3.288; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; Vining D J, 1997, Gastrointest Endosc Clin N Am, V7, P285; Vining DJ, 1996, RADIOLOGY, V200, P30, DOI 10.1148/radiology.200.1.8657938; Vining DJ, 1994, AM J ROENTGENOL, V162, P104; WAYE JD, 1988, AM J GASTROENTEROL, V83, P120; WILLIAMS CB, 1974, BRIT J SURG, V61, P673, DOI 10.1002/bjs.1800610902; Winawer SJ, 1998, GASTROENTEROLOGY, V114, P625; WINAWER SJ, 1993, J NATL CANCER I, V85, P1311, DOI 10.1093/jnci/85.16.1311; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	50	549	558	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1999	341	20					1496	1503		10.1056/NEJM199911113412003	http://dx.doi.org/10.1056/NEJM199911113412003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RK	10559450				2022-12-28	WOS:000083625800003
J	Duggan, AE; Elliott, C; Logan, RFA				Duggan, AE; Elliott, C; Logan, RFA			Testing for Helicobacter pylori infection: validation and diagnostic yield of a near patient test in primary care	BRITISH MEDICAL JOURNAL			English	Article								Objective To evaluate the performance of a near patient test for Helicobacter pylori infection in primary care. Design Validation study performed within a randomised trial of four management strategies for dyspepsia. Setting 43 general practices around Nottingham. Subjects 394 patients aged 18-70 years presenting with recent onset dyspepsia. Main outcome measures Results of the FlexSure test compared with an enzyme linked immunosorbent assay (ELISA; HM-CAP) with an identical antigen profile and with results of an earlier validation study in secondary care. Diagnostic yield of patients undergoing endoscopy on the basis of their FlexSure result compared with those of patients referred directly for endoscopy. Results When used in primary care FlexSure test had a sensitivity and specificity of 67% (95% confidence interval 59% to 15%) and 98% (95% to 99%) compared with a sensitivity and specificity of 92% (87% to 97%) and 90% (83% to 97%) when used previously in secondary care. Of the H pylori test and refer group 14% (28/199) were found to have conditions for which H pylori eradication was appropriate compared with 23% (39/170) of the group referred directly for endoscopy. Conclusions When used in primary care the sensitivity of the FlexSure test was significantly poorer than in secondary care. About a third of patients who would have benefited from H pylori eradication were not detected. Near patient tests need to be validated in primary care before they are incorporated into management policies for dyspepsia.	Univ Nottingham, Div Gastroenterol, Nottingham NG7 2UH, England	University of Nottingham	Logan, RFA (corresponding author), Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2UH, England.							*AM GASTR ASS, 1998, GASTROENTEROLOGY, V114, P579; *BRIT SOC GASTR, 1996, DYSP MAN GUID; Churchill RD, 1998, BRIT MED J, V316, P1389; Duggan A, 1996, LANCET, V348, P617, DOI 10.1016/S0140-6736(05)64835-0; JONES R, 1997, ALIMENT PHARM THERAP, V11, P1; Kroser JA, 1998, DIGEST DIS SCI, V43, P103, DOI 10.1023/A:1018832306135; Moayyedi P, 1997, BRIT MED J, V314, P119, DOI 10.1136/bmj.314.7074.119; *OFF HLTH EC, 1997, COMP HLTH STAT; PEITZ U, 1996, GASTROENTEROLOGY S, V110, P226; Reilly TG, 1997, GUT, V40, P454, DOI 10.1136/gut.40.4.454; STONE M, 1996, GUT, V39, P110; Talley NJ, 1998, ALIMENT PHARM THERAP, V12, P641	12	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1236	1239		10.1136/bmj.319.7219.1236	http://dx.doi.org/10.1136/bmj.319.7219.1236			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550087	Green Published, Bronze			2022-12-28	WOS:000083625600024
J	McIlroy, J; Dryburgh, F; Hinnie, J; Dargie, R; Al-Rawi, A				McIlroy, J; Dryburgh, F; Hinnie, J; Dargie, R; Al-Rawi, A			Oestrogen and calcium homeostasis in women with hypoparathyroidism	BRITISH MEDICAL JOURNAL			English	Article							DISEASE		Glasgow Royal Infirm, Dept Clin Biochem, Glasgow G4 0SF, Lanark, Scotland	University of Glasgow	McIlroy, J (corresponding author), Glasgow Royal Infirm, Dept Clin Biochem, Macewen Bldg, Glasgow G4 0SF, Lanark, Scotland.							BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CUNDY T, 1987, CLIN ENDOCRINOL, V26, P667, DOI 10.1111/j.1365-2265.1987.tb00824.x; DEDEUXCHAISNES CN, 1979, BRIT MED J, V1, P1563; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; GANN DS, 1979, ANN SURG, V190, P508, DOI 10.1097/00000658-197910000-00010; GENNARI C, 1990, J CLIN ENDOCR METAB, V71, P1288, DOI 10.1210/jcem-71-5-1288; HEPBURN NC, 1989, POSTGRAD MED J, V65, P849, DOI 10.1136/pgmj.65.769.849; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; OURSLER MJ, 1993, ENDOCRINOLOGY, V132, P1373, DOI 10.1210/en.132.3.1373; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; REYNOLDS JJ, 1976, CALC TISS RES, V21, P207, DOI 10.1007/BF02547397; VERBEELEN D, 1979, BRIT MED J, V1, P522, DOI 10.1136/bmj.1.6162.522-a; WRIGHT AD, 1969, BRIT MED J, V1, P23, DOI 10.1136/bmj.1.5635.23	13	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1252	1253		10.1136/bmj.319.7219.1252	http://dx.doi.org/10.1136/bmj.319.7219.1252			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550094	Green Published			2022-12-28	WOS:000083625600029
J	Gerber, AP; Keller, W				Gerber, AP; Keller, W			An adenosine deaminase that generates inosine at the wobble position of tRNAs	SCIENCE			English	Article							TRANSITION-STATE ANALOG; CYTIDINE DEAMINASE; TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; MUTATIONS; ENZYME; MECHANISM	Several transfer RNAs (tRNAs) contain inosine (I) at the first. position of their anticodon (position 34): this modification is thought. to enlarge the codon recognition capacity during protein synthesis. The tRNA-specific adenosine deaminase of Saccharomyces cerevisiae that forms I-34 in tRNAs is described. The heteroclimeric enzyme consists of two sequence-related subunits (Tad2p/ADAT2 and Tad3p/ADAT3), both of which contain cytidine deaminase (CDA) motifs. Each subunit is encoded by an essential gene (TAD2 and TAD3), indicating that I-34 is an indispensable base modification in elongating tRNAs. These results provide an evolutionary Link between the CDA superfamily and RNA-dependent adenosine deaminases (ADARs/ADATs).	Univ Basel, Bioctr, Dept Cell Biol, CH-4056 Basel, Switzerland	University of Basel	Keller, W (corresponding author), Univ Basel, Bioctr, Dept Cell Biol, CH-4056 Basel, Switzerland.	walter.keller@unibas.ch		Gerber, Andre/0000-0002-2398-6592				Amrani N, 1996, MOL GEN GENET, V252, P552, DOI 10.1007/BF02172401; Auxilien S, 1996, J MOL BIOL, V262, P437, DOI 10.1006/jmbi.1996.0527; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; Bass BL, 1997, RNA, V3, P947; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Carlow D, 1998, BIOCHEMISTRY-US, V37, P11873, DOI 10.1021/bi980959n; Carter Jr C. W., 1998, MODIFICATION EDITING, P363; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; Gerber A, 1998, EMBO J, V17, P4780, DOI 10.1093/emboj/17.16.4780; Grosjean H, 1996, BIOCHIMIE, V78, P488, DOI 10.1016/0300-9084(96)84755-9; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLLEY RW, 1965, J BIOL CHEM, V240, P2122; Keller W, 1999, FEBS LETT, V452, P71, DOI 10.1016/S0014-5793(99)00590-6; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; Maas S, 1999, P NATL ACAD SCI USA, V96, P8895, DOI 10.1073/pnas.96.16.8895; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; OConnell MA, 1997, CURR BIOL, V7, pR437, DOI 10.1016/S0960-9822(06)00212-0; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; Spingola M, 1999, RNA, V5, P221, DOI 10.1017/S1355838299981682; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539	25	222	236	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1146	1149		10.1126/science.286.5442.1146	http://dx.doi.org/10.1126/science.286.5442.1146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550050				2022-12-28	WOS:000083534200040
J	Andersson, GBJ; Lucente, T; Davis, AM; Kappler, RE; Lipton, JA; Leurgans, S				Andersson, GBJ; Lucente, T; Davis, AM; Kappler, RE; Lipton, JA; Leurgans, S			A comparison of osteopathic spinal manipulation with standard care for patients with low back pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CLINICAL-TRIALS; COSTS; VALIDITY; THERAPY	Background The effect of osteopathic manual therapy (i.e., spinal manipulation) in patients with chronic and subchronic back pain is largely unknown, and its use in such patients is controversial. Nevertheless, manual therapy is a frequently used method of treatment in this group of patients. Methods We performed a randomized, controlled trial that involved patients who had had back pain for at least three weeks but less than six months. We screened 1193 patients; 178 were found to be eligible and were randomly assigned to treatment groups; 23 of these patients subsequently dropped out of the study. The patients were treated either with one or more standard medical therapies (72 patients) or with osteopathic manual therapy (83 patients). We used a variety of outcome measures, including scores on the Roland-Morris and Oswestry questionnaires, a visual-analogue pain scale, and measurements of range of motion and straight-leg raising, to assess the results of treatment over a 12-week period. Results Patients in both groups improved during the 12 weeks. There was no statistically significant difference between the two groups in any of the primary outcome measures. The osteopathic-treatment group required significantly less medication (analgesics, antiinflammatory agents, and muscle relaxants) (P<0.001) and used less physical therapy (0.2 percent vs. 2.6 percent, P<0.05). More than 90 percent of the patients in both groups were satisfied with their care. Conclusions Osteopathic manual care and standard medical care have similar clinical results in patients with subacute low back pain. However, the use of medication is greater with standard care. (N Engl J Med 1999;341:1426-31.) (C)1999, Massachusetts Medical Society.	Rush Presbyterian St Lukes Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA; Chicago Coll Osteopath Med, Downers Grove, IL USA	Rush University; Rush University; Midwestern University; Midwestern University - Chicago College of Osteopathic Medicine	Andersson, GBJ (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Orthoped Surg, 1653 W Congress Pkwy,1471 Jelke, Chicago, IL 60612 USA.	ganderss@rush.edu						ANDERSSON GBJ, 1983, SPINE, V8, P880, DOI 10.1097/00007632-198311000-00011; Armitage P., 2001, STAT METHODS MED RES; BIGOS SJ, 1994, CLIN PRACTICE GUIDEL, V14; BLOCH R, 1987, SPINE, V12, P430, DOI 10.1097/00007632-198706000-00002; CAREY TS, 1995, NEW ENGL J MED, V333, P913, DOI 10.1056/NEJM199510053331406; CONRAD DA, 1994, SPINE, V19, pS2101; Daltroy LH, 1996, SPINE, V21, P741, DOI 10.1097/00007632-199603150-00017; Deyo RA, 1996, SPINE, V21, P2840, DOI 10.1097/00007632-199612150-00007; Deyo RA, 1996, SPINE, V21, P2826, DOI 10.1097/00007632-199612150-00003; DEYO RA, 1986, SPINE, V11, P951, DOI 10.1097/00007632-198611000-00017; Fairbank J C, 1980, Physiotherapy, V66, P271; Gabriel SE, 1997, ARTHRIT CARE RES, V10, P56, DOI 10.1002/art.1790100109; HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012; HRUBY RJ, 1995, OSTEOPATHIC MED PAST, P49; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Koes BW, 1996, SPINE, V21, P2860, DOI 10.1097/00007632-199612150-00013; KOES BW, 1995, SPINE, V20, P228, DOI 10.1097/00007632-199501150-00021; KOES BW, 1991, BRIT MED J, V303, P1298, DOI 10.1136/bmj.303.6813.1298; MACDONALD RS, 1991, SPINE, V16, P104; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; Palmer BF, 1996, ADV INTERNAL MED, V41, P605; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROSEN M, 1994, REPORT CSAG COMMITTE; ROSSLEE B, 1995, OSTEOPATHIC MED PAST, P89; *ROYAL COLL GEN PR, 1996, CLIN GUID MAN AC LOW; SHEKELLE PG, 1994, SPINE, V19, P858, DOI 10.1097/00007632-199404000-00026; SHEKELLE PG, 1992, ANN INTERN MED, V117, P590, DOI 10.7326/0003-4819-117-7-590; SHEKELLE PG, 1995, SPINE, V20, P221, DOI 10.1097/00007632-199501150-00018; Smalley WE, 1996, J GEN INTERN MED, V11, P461, DOI 10.1007/BF02599040; Spitzer WO, 1987, SPINE, V12, P1, DOI DOI 10.1097/00007632-198701000-00001; VONKORFF M, 1994, ANN INTERN MED, V121, P187, DOI 10.7326/0003-4819-121-3-199408010-00005; VonKorff M, 1996, SPINE, V21, P2833, DOI 10.1097/00007632-199612150-00004; Ward RC, 1997, FDN OSTEOPATHIC MED; *WORKC CORP, 1993, GUID MAN BACK INJ EM, P1	34	200	203	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1999	341	19					1426	1431		10.1056/NEJM199911043411903	http://dx.doi.org/10.1056/NEJM199911043411903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XR	10547405				2022-12-28	WOS:000083472100003
J	Feldman, DS				Feldman, DS			How to avoid missing congenital dislocation of the hip	LANCET			English	Editorial Material									NYU, Hosp Joint Dis, New York, NY 10003 USA	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC	Feldman, DS (corresponding author), NYU, Hosp Joint Dis, New York, NY 10003 USA.							BENNET GC, 1992, J BONE JOINT SURG BR, V74, P643, DOI 10.1302/0301-620X.74B5.1527106; Godward S, 1998, LANCET, V351, P1149, DOI 10.1016/S0140-6736(97)10466-4; GRAF R, 1984, J PEDIATR ORTHOPED, V4, P735, DOI 10.1097/01241398-198411000-00015	3	10	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1490	1491		10.1016/S0140-6736(99)00239-1	http://dx.doi.org/10.1016/S0140-6736(99)00239-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551491	hybrid			2022-12-28	WOS:000083411300005
J	Hodge, JG; Gostin, LO; Jacobson, PD				Hodge, JG; Gostin, LO; Jacobson, PD			Legal issues concerning electronic health information - Privacy, quality, and liability	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WORLD-WIDE-WEB; PERSONAL PRIVACY; E-MAIL; PATIENT; CARE; INSURANCE; INTERNET; SYSTEMS; TOOL		Georgetown Univ, Ctr Law, Washington, DC 20013 USA; Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA	Georgetown University; University of Michigan System; University of Michigan	Hodge, JG (corresponding author), Georgetown Univ, Ctr Law, POB 76305, Washington, DC 20013 USA.							ASHTON G, 1998, AM MED NEWS, V41, P26; Bashshur R L, 1995, Telemed J, V1, P19, DOI 10.1089/tmj.1.1995.1.19; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; BOODMAN SG, 1999, WASHINGTON POST 0608, pH12; Borowitz SM, 1998, JAMA-J AM MED ASSOC, V280, P1321, DOI 10.1001/jama.280.15.1321; CHANDRASEKARAN R, 1998, WASH POST       0308, pA1; CHANDRASEKARAN R, 1998, WASHINGTON POST 0309, pA12; CORCORAN E, 1998, WASHINGTON POST 0712, pA8; Department of Agriculture Department of Energy National Aeronautics and Space Administration Department of Commerce Consumer Product Safety Commission International Development Cooperation Agency Agency for International Development Department of Housing and Urban Development Department of Justice Department of Defense Department of Education Department of Veterans Affairs Environmental Protection Agency Department of Health and Human Services National Science Foundation and Department of Transportation, 1991, FED REGISTER, V56, P28003; Eysenbach G, 1998, JAMA-J AM MED ASSOC, V280, P1333, DOI 10.1001/jama.280.15.1333; FARRELL MJ, 1992, AM J TRIAL ADVOC, V16, P65; FEIN E, 1997, NY TIMES        1123, pA1; FEIN EB, 1997, NY TIMES        1120, pA18; FIELD MJ, 1994, TELEMEDICINE GUIDE A; FISHER M, 1998, WASHINGTON POST 0719, P21; FISHER M, 1998, WASHINGTON POST 0719, P8; Flahault A, 1998, JAMA-J AM MED ASSOC, V280, P1330, DOI 10.1001/jama.280.15.1330; Furrow BarryR., 2018, HLTH LAW CASES MAT P; Gostin L, 1997, ANN INTERN MED, V127, P683, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00050; Gostin LO, 1998, ANN INTERN MED, V129, P833, DOI 10.7326/0003-4819-129-10-199811150-00017; Gostin LO, 1996, JAMA-J AM MED ASSOC, V275, P1921, DOI 10.1001/jama.275.24.1921; GOSTIN LO, 1995, CORNELL LAW REV, V80, P451; Gostin LO, 1997, KENNEDY INST ETHIC J, V7, P361, DOI 10.1353/ken.1997.0033; Gostin LO, 1995, J LAW MED ETHICS, V23, P320, DOI 10.1111/j.1748-720X.1995.tb01374.x; GOSTIN LO, 1998, ALB L REV, V61, P679; Hayes KA, 1996, M D COMPUT, V13, P330; Hersh WR, 1998, JAMA-J AM MED ASSOC, V280, P1307, DOI 10.1001/jama.280.15.1307; Hodge J G Jr, 1997, J Contemp Health Law Policy, V14, P93; Hodge JG, 1999, ADMIN LAW REV, V51, P117; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; KAAR JF, 1998, ARMED FORCES I PATHO, P32; KACMAR DE, 1997, OHIO ST LJ, V58, P617; Kane B, 1998, J AM MED INFORM ASSN, V5, P104, DOI 10.1136/jamia.1998.0050104; KAUFMAN M, 1999, WASHINGTON POST 0216, pH17; Lindberg DAB, 1998, JAMA-J AM MED ASSOC, V280, P1303, DOI 10.1001/jama.280.15.1303; Mitka M, 1998, JAMA-J AM MED ASSOC, V280, P1295, DOI 10.1001/jama.280.15.1295; *NAT RES COUNC, 1997, REC PROT EL HLTH INF; National Research Council System Security Study Committee, 1990, COMP RISK SAF COMP I; Neill R A, 1994, Arch Fam Med, V3, P268, DOI 10.1001/archfami.3.3.268; NELSON R, 1996, J HEALTHCARE INFORMA, V8, P33; Nenov V, 1996, J AM MED INFORM ASSN, V3, P318, DOI 10.1136/jamia.1996.97035023; OHARROW R, 1998, WASHINGTON POST 0308, pA18; OHARROW R, 1998, WASH POST       0308, pA1; OHARROW R, 1998, WASHINGTON POST 0308, pA19; OHARROW R, 1998, WASHINTON POST  0927, pA26; Raschke RA, 1998, JAMA-J AM MED ASSOC, V280, P1317, DOI 10.1001/jama.280.15.1317; RIBBLESMITH B, 1986, DEPAUL LAW REV, V36, P69; Rothenberg KH, 1995, J LAW MED ETHICS, V23, P312, DOI 10.1111/j.1748-720X.1995.tb01373.x; Sanders J H, 1995, Telemed J, V1, P115, DOI 10.1089/tmj.1.1995.1.115; SCHWARTZ P, 1996, DATA PRIVACY LAW STU; SCHWARTZ PM, 1995, VANDERBILT LAW REV, V48, P310; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Spielberg AR, 1998, JAMA-J AM MED ASSOC, V280, P1353, DOI 10.1001/jama.280.15.1353; *US DHHS, 1997, CONF IND ID HLTH INF; VARNEY CA, 1996, PRIV AM BUS NAT C OC; VICKERY AB, 1982, COLUMBIA LAW REV, V82, P1426, DOI 10.2307/1122268; Wyatt JC, 1997, BRIT MED J, V314, P1879, DOI 10.1136/bmj.314.7098.1879; ZELIN JE, 1988, AM LAW REP, V48, P668	59	114	114	2	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1466	1471		10.1001/jama.282.15.1466	http://dx.doi.org/10.1001/jama.282.15.1466			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	245LT	10535438				2022-12-28	WOS:000083111000033
J	Magee, JT; Pritchard, EL; Fitzgerald, KA; Dunstan, FDJ; Howard, AJ				Magee, JT; Pritchard, EL; Fitzgerald, KA; Dunstan, FDJ; Howard, AJ		Welsh Antibiotic Study Grp	Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-8	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Wales Hosp, Dept Med Microbiol, Cardiff CF14 4XW, S Glam, Wales; Univ Wales Hosp, Publ Hlth Lab, Cardiff CF14 4XW, S Glam, Wales; Univ Wales Coll Cardiff, Coll Med, Cardiff CF14 4XW, S Glam, Wales; Bro Taf Hlth Author, Cardiff CF1 4TW, S Glam, Wales; Univ Wales Coll Cardiff, Coll Med, Dept Med Comp & Stat, Cardiff CF1 3NS, S Glam, Wales	Cardiff University; Cardiff University; Cardiff University; Cardiff University	Howard, AJ (corresponding author), Univ Wales Hosp, Dept Med Microbiol, Cardiff CF14 4XW, S Glam, Wales.	tony.howard@phls.wales.nhs.uk						AMYES SGB, 1989, J MED MICROBIOL, V28, P73, DOI 10.1099/00222615-28-2-73; LONDON N, 1994, J ANTIMICROB CHEMOTH, V34, P239, DOI 10.1093/jac/34.2.239; Standing Medical Advisory Committee: Sub-group on Antimicrobial Resistance, 1998, PATH LEAST RES	3	152	155	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	1999	319	7219					1239	1240		10.1136/bmj.319.7219.1239	http://dx.doi.org/10.1136/bmj.319.7219.1239			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550088	Bronze, Green Published			2022-12-28	WOS:000083625600025
J	Anda, RF; Croft, JB; Felitti, VJ; Nordenberg, D; Giles, WH; Williamson, DF; Giovino, GA				Anda, RF; Croft, JB; Felitti, VJ; Nordenberg, D; Giles, WH; Williamson, DF; Giovino, GA			Adverse childhood experiences and smoking during adolescence and adulthood	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	4th International Conference on Prevention Cardiology	JUN 29-JUL 03, 1997	MONTREAL, CANADA				HEALTH RISK BEHAVIORS; SEXUAL ABUSE; MAJOR DEPRESSION; DRUG-ABUSE; TOBACCO; ALCOHOL; WOMEN; MALTREATMENT; EPIDEMIOLOGY; DYSFUNCTION	Context In recent years, smoking among adolescents has increased and the decline of adult smoking has slowed to nearly a halt; new insights into tobacco dependency are needed to correct this situation. Long-term use of nicotine has been linked with self-medicating efforts to cope with negative emotional, neurobiological, and social effects of adverse childhood experiences. Objective To assess the relationship between adverse childhood experiences and 5 smoking behaviors. Design The ACE Study, a retrospective cohort survey including smoking and exposure to 8 categories of adverse childhood experiences (emotional, physical, and sexual abuse; a battered mother; parental separation or divorce; and growing up with a substance-abusing, mentally ill, or incarcerated household member), conducted from August to November 1995 and January to March 1996. Setting A primary care clinic for adult members of a large health maintenance organization in San Diego, Calif. Participants A total of 9215 adults (4958 women and 4257 men with mean [SD] ages of 55.3 [15.7] and 58.1 [14.5] years, respectively) who responded to a survey questionnaire, which was mailed to all patients 1 week after a clinic visit. Main Outcome Measures Smoking initiation by age 14 years or after age 18 years, and status as ever, current, or heavy smoker. Results At least 1 of 8 categories of adverse childhood experiences was reported by 63% of respondents, After adjusting for age, sex, race, and education, each category showed an increased risk for each smoking behavior, and these risks were comparable for each category of adverse childhood experiences. Compared with those reporting no adverse childhood experiences, persons reporting 5 or more categories had substantially higher risks of early smoking initiation (odds ratio [OR], 5.4; 95% confidence interval [CI], 4.1-7.1), ever smoking (OR, 3.1; 95% CI, 2.6-3.8), current smoking (OR, 2.1; 95% CI, 1.6-2.7), and heavy smoking (OR, 2.8; 95% CI, 1.9-4.2), Each relationship between smoking behavior and the number of adverse childhood experiences was strong and graded (P<.001). For any given number of adverse childhood experiences, recent problems with depressed affect were more common among smokers than among nonsmokers. Conclusions Smoking was strongly associated with adverse childhood experiences. Primary prevention of adverse childhood experiences and improved treatment of exposed children could reduce smoking among both adolescents and adults.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; So Calif Permanente Med Grp, Dept Prevent Med, San Diego, CA 92120 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA	Centers for Disease Control & Prevention - USA; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; Emory University	Anda, RF (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop K-47,4770 Buford Hwy NE, Atlanta, GA 30341 USA.				ATSDR CDC HHS [TS-44-10/11] Funding Source: Medline	ATSDR CDC HHS		ANDA RF, 1990, JAMA-J AM MED ASSOC, V264, P1541, DOI 10.1001/jama.264.12.1541; [Anonymous], 1978, MAIL TELEPHONE SURVE; BALL DM, 1994, BRIT MED BULL, V50, P18, DOI 10.1093/oxfordjournals.bmb.a072876; BREO DL, 1993, JAMA-J AM MED ASSOC, V270, P1978, DOI 10.1001/jama.270.16.1978; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P161, DOI 10.1001/archpsyc.55.2.161; BRIERE J, 1988, CHILD ABUSE NEGLECT, V12, P331, DOI 10.1016/0145-2134(88)90046-4; BRIERE J, 1990, CHILD ABUSE NEGLECT, V14, P357, DOI 10.1016/0145-2134(90)90007-G; Bryant S L, 1995, Violence Vict, V10, P195; CARMODY TP, 1992, J PSYCHOACTIVE DRUGS, V24, P111, DOI 10.1080/02791072.1992.10471632; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P1229; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P962; *CDCP, 1996, AHCPR PUBL; Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P413; Centers for Disease Control and Prevention, 1994, PREV TOB US YOUNG PE; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1217; CLAUSSEN AH, 1991, CHILD ABUSE NEGLECT, V15, P5, DOI 10.1016/0145-2134(91)90085-R; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; DEFRONZO J, 1993, J SOC PSYCHOL, V133, P635, DOI 10.1080/00224545.1993.9713918; DEMBO R, 1988, INT J ADDICT, V23, P351, DOI 10.3109/10826088809039203; *FED TRAD COMM, 1998, REP C 1996 PURS FED; FEIGHERY E, 1991, JAMA-J AM MED ASSOC, V266, P3168; FELITTI VJ, 1993, SOUTHERN MED J, V86, P732, DOI 10.1097/00007611-199307000-00002; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; FINKELHOR D, 1990, CHILD ABUSE NEGLECT, V14, P19, DOI 10.1016/0145-2134(90)90077-7; Forster JL, 1998, ANNU REV PUBL HEALTH, V19, P203, DOI 10.1146/annurev.publhealth.19.1.203; GELINAS DJ, 1983, PSYCHIATRY, V46, P312, DOI 10.1080/00332747.1983.11024207; GIOVINO GA, 1995, EPIDEMIOL REV, V17, P48, DOI 10.1093/oxfordjournals.epirev.a036185; Giovino Gary A., 1994, Morbidity and Mortality Weekly Report, V43, P1; GLASS RM, 1990, JAMA-J AM MED ASSOC, V264, P1583; GLASSMAN AH, 1990, JAMA-J AM MED ASSOC, V264, P1546, DOI 10.1001/jama.264.12.1546; Gostin LO, 1997, JAMA-J AM MED ASSOC, V277, P410; HUDMON KS, 1998, SOC RES NICOTINE TOP, V4, P10; Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; HUTCHINSON RR, 1985, PSYCHOL REC, V35, P491; Kellam SG, 1998, AM J PUBLIC HEALTH, V88, P1490, DOI 10.2105/AJPH.88.10.1490; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P36; Lykken DT, 1997, CHILD PSYCHIAT HUM D, V27, P129, DOI 10.1007/BF02353693; MacMillan HL, 1997, JAMA-J AM MED ASSOC, V278, P131, DOI 10.1001/jama.278.2.131; McEndree B, 1996, Nurse Pract, V21, P150; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MOELLER TP, 1993, CHILD ABUSE NEGLECT, V17, P623, DOI 10.1016/0145-2134(93)90084-I; MOORE S, 1994, JAMA-J AM MED ASSOC, V272, P1171, DOI 10.1001/jama.272.15.1171; *NAT CTR HLTH STAT, 1994, VITAL HLTH STAT, V32, P1; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; Patton GC, 1998, AM J PUBLIC HEALTH, V88, P1518, DOI 10.2105/AJPH.88.10.1518; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043; Pollay RW, 1996, J MARKETING, V60, P1, DOI 10.2307/1251927; POMERLEAU OF, 1984, NEUROSCI BIOBEHAV R, V8, P503, DOI 10.1016/0149-7634(84)90007-1; Resnick MD, 1997, JAMA-J AM MED ASSOC, V278, P823, DOI 10.1001/jama.278.10.823; RIGGS S, 1990, J PEDIATR-US, V116, P815, DOI 10.1016/S0022-3476(05)82679-4; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rothman K, 1986, MODERN EPIDEMIOLOGY; SCHOENBORN CA, 1995, ADV DATA VITAL HLTH, V205; SPRINGS FE, 1992, MAYO CLIN PROC, V67, P527, DOI 10.1016/S0025-6196(12)60458-3; Stockwell T F, 1997, Tob Control, V6, P282, DOI 10.1136/tc.6.4.282; Strauss M.A., 1990, PHYS VIOLENCE AM FAM, P29; Wills TA, 1985, COPING SUBSTANCE USE, P3; WYATT GE, 1985, CHILD ABUSE NEGLECT, V9, P507, DOI 10.1016/0145-2134(85)90060-2	58	774	782	2	94	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1652	1658		10.1001/jama.282.17.1652	http://dx.doi.org/10.1001/jama.282.17.1652			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	250BD	10553792				2022-12-28	WOS:000083368400031
J	Swinkels, JA				Swinkels, JA			Reregistration of medical specialists in the Netherlands	BRITISH MEDICAL JOURNAL			English	Article									Univ Amsterdam, Acad Med Ctr, NL-1000 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Swinkels, JA (corresponding author), Univ Amsterdam, Acad Med Ctr, POB 22700, NL-1000 DE Amsterdam, Netherlands.							KLAZINGA NS, 1996, THESIS OVERVEEN BELV; *LAND SPEC VER, 1995, KWAL MED SPE	2	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1191	1192		10.1136/bmj.319.7218.1191	http://dx.doi.org/10.1136/bmj.319.7218.1191			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541517	Green Published, Green Submitted			2022-12-28	WOS:000083536200032
J	Lang, C; Leuenberger, M; Schwander, J; Johnsen, S				Lang, C; Leuenberger, M; Schwander, J; Johnsen, S			16 degrees C rapid temperature variation in Central Greenland 70,000 years ago	SCIENCE			English	Article							PAST 110,000 YEARS; DEEP ICE CORE; ATMOSPHERIC CIRCULATION; CLIMATE OSCILLATIONS; ISOTOPE PROFILES; EVENTS; RECORD; SEA	Variations in the (29)N(2)/(28)N(2) ratio of air bubbles trapped in polar ice cores and their relation to variations of the (18)O/(16)O Of th, ice allow past surface temperature variations and ice age-gas age differences to be determined. High-resolution measurements of (29)N(2)/(28)N(2) in Dansgaard-Oeschger event 19 (around 70,000 years before the present) in ice from Central Greenland show that at the beginning of the event, the ice age-gas age difference was 1090 +/- 100 years. With the use of a combined firn densification, temperature, and gas diffusion model, the delta(18)O(ice)-temperature coefficient alpha was determined to be 0.42 +/- 0.05 per mil per kelvin. This coefficient implies a mean surface temperature change of 16.0 kelvin (between 14.3 and 18.1 kelvin), which differs substantially from values derived from borehole temperatures and modern spatial delta(18)O(ice)-surface temperature correlations.	Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; Univ Copenhagen, Dept Geophys, Niels Bohr Inst, DK-2100 Copenhagen, Denmark; Univ Iceland, Inst Sci, IS-107 Reykjavik, Iceland	University of Bern; University of Copenhagen; Niels Bohr Institute; University of Iceland	Lang, C (corresponding author), Univ Bern, Inst Phys, Sidlerstr 5, CH-3012 Bern, Switzerland.	lang@climate.unibe.ch; leuenberger@climate.unibe.ch	Leuenberger, Markus C/K-9655-2016	Leuenberger, Markus C/0000-0003-4299-6793				Adkins JF, 1997, NATURE, V390, P154, DOI 10.1038/36540; Behl RJ, 1996, NATURE, V379, P243, DOI 10.1038/379243a0; BOERSMAKLEIN V, 1966, PHYSICA, V32, P717, DOI 10.1016/0031-8914(66)90004-8; Brook EJ, 1996, SCIENCE, V273, P1087, DOI 10.1126/science.273.5278.1087; Chapman S., 1970, MATH THEORY NONUNIFO; CHAPPELLAZ J, 1993, NATURE, V366, P443, DOI 10.1038/366443a0; Charles C, 1997, NATURE, V385, P681, DOI 10.1038/385681a0; Charles CD, 1996, EARTH PLANET SC LETT, V142, P19, DOI 10.1016/0012-821X(96)00083-0; CRAIG H, 1988, SCIENCE, V242, P1675, DOI 10.1126/science.242.4886.1675; CUFFEY KM, 1994, J GLACIOL, V40, P341, DOI 10.3189/S0022143000007425; DAHLJENSEN D, 1993, NATO ASI SER, V112, P517; DALLENBACH A, UNPUB; DANSGAARD W, 1982, SCIENCE, V218, P1273, DOI 10.1126/science.218.4579.1273; GRIMM EC, 1993, SCIENCE, V261, P198, DOI 10.1126/science.261.5118.198; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Hutterli MA, 1999, GEOPHYS RES LETT, V26, P1691, DOI 10.1029/1999GL900327; Johnsen SJ, 1989, TELLUS B, V41, P452, DOI 10.1111/j.1600-0889.1989.tb00321.x; JOHNSEN SJ, 1972, NATURE, V235, P429, DOI 10.1038/235429a0; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; Johnsen SJ, 1997, J GEOPHYS RES-OCEANS, V102, P26397, DOI 10.1029/97JC00167; JOHNSEN SJ, 1995, TELLUS B, V47, P624, DOI 10.1034/j.1600-0889.47.issue5.9.x; JOUZEL J, 1989, QUATERNARY RES, V31, P135, DOI 10.1016/0033-5894(89)90003-3; Jouzel J, 1997, J GEOPHYS RES-OCEANS, V102, P26471, DOI 10.1029/97JC01283; KAPSNER WR, 1995, NATURE, V373, P52, DOI 10.1038/373052a0; KEIGWIN LD, 1994, NATURE, V371, P323, DOI 10.1038/371323a0; Leuenberger MC, 1999, J GEOPHYS RES-ATMOS, V104, P22163, DOI 10.1029/1999JD900436; MARIOTTI A, 1983, NATURE, V303, P685, DOI 10.1038/303685a0; Mayewski PA, 1997, J GEOPHYS RES-OCEANS, V102, P26345, DOI 10.1029/96JC03365; MOMMERSTEEG H, 1998, THESIS U AMSTERDAM; PHILLPOT HR, 1970, J GEOPHYS RES, V75, P4161, DOI 10.1029/JC075i021p04161; Schulz H, 1998, NATURE, V393, P54, DOI 10.1038/31750; SCHWANDER J, 1989, PHYS CH EAR, V8, P53; SCHWANDER J, 1993, J GEOPHYS RES-ATMOS, V98, P2831, DOI 10.1029/92JD02383; Schwander J, 1997, J GEOPHYS RES-ATMOS, V102, P19483, DOI 10.1029/97JD01309; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; THOUVENY N, 1994, NATURE, V371, P503, DOI 10.1038/371503a0; Trudinger CM, 1997, J GEOPHYS RES-ATMOS, V102, P6747, DOI 10.1029/96JD03382	37	147	158	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					934	937		10.1126/science.286.5441.934	http://dx.doi.org/10.1126/science.286.5441.934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542142				2022-12-28	WOS:000083368500037
J	Kaufman, J; Milne, S; Gobel, TWF; Walker, BA; Jacob, JP; Auffray, C; Zoorob, R; Beck, S				Kaufman, J; Milne, S; Gobel, TWF; Walker, BA; Jacob, JP; Auffray, C; Zoorob, R; Beck, S			The chicken B locus is a minimal essential major histocompatibility complex	NATURE			English	Article							MHC CLASS-I; CELL-INTERACTION; POLYMORPHISM; TRANSPORTERS; MOLECULES; GENE; RAT	Here we report the sequence of the region that determines rapid allograft rejection in chickens, the chicken major histocompatibility complex (MHC). This 92-kilobase region of the B locus(1-4) contains only 19 genes, making the chicken MHC roughly 20-fold smaller than the human MHC5. Virtually all the genes have counterparts in the human MHC, defining a minimal essential set of MHC genes conserved over 200 million years of divergence between birds and mammals. They are organized differently, with the class III region genes located outside the class II and class I region genes. The absence of proteasome genes(5,6) is unexpected and might explain unusual peptide-binding specificities of chicken class I molecules. The presence of putative natural killer receptor gene(s)(5,7) is unprecedented and might explain the importance of the B locus in the response to the herpes virus responsible for Marek's diseases(8-10). The small size and simplicity of the chicken MHC allows co-evolution of genes as haplotypes over considerable periods of time, and makes it possible to study the striking MHC-determined pathogen-specific disease resistances(8-10) at the molecular level.	Inst Anim Hlth, Compton RG20 7NN, England; Sanger Ctr, Hinxton CB10 1SA, England; Inst Anim Physiol, D-80539 Munich, Germany; CNRS, UPR420, Villejuif, France	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Wellcome Trust Sanger Institute; University of Munich; Centre National de la Recherche Scientifique (CNRS)	Kaufman, J (corresponding author), Inst Anim Hlth, Compton RG20 7NN, England.	jim.kaufman@bbsrc.ac.uk	Walker, Brian/A-4984-2013; Gobel, Thomas/A-9919-2009	Walker, Brian/0000-0002-8615-6254; Kaufman, Jim/0000-0002-7216-8422	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bacon L D, 1987, Prog Clin Biol Res, V238, P219; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; BRILES WE, 1950, GENETICS, V35, P633; BRILES WE, 1983, SCIENCE, V219, P977, DOI 10.1126/science.6823560; Bumstead N, 1998, AVIAN PATHOL, V27, pS78, DOI 10.1080/03079459808419296; Frangoulis B, 1999, IMMUNOGENETICS, V49, P328, DOI 10.1007/s002510050500; GERMAIN RN, 1985, CELL, V43, P233, DOI 10.1016/0092-8674(85)90028-5; GUILLEMOT F, 1988, EMBO J, V7, P2775, DOI 10.1002/j.1460-2075.1988.tb03132.x; Henry J, 1999, IMMUNOL TODAY, V20, P285, DOI 10.1016/S0167-5699(98)01418-2; Joly E, 1998, CURR BIOL, V8, P169, DOI 10.1016/S0960-9822(98)70065-X; Kandil E, 1996, J IMMUNOL, V156, P4245; KAUFMAN J, 1995, IMMUNOL REV, V143, P63, DOI 10.1111/j.1600-065X.1995.tb00670.x; KAUFMAN J, 1991, CRIT REV IMMUNOL, V11, P113; KAUFMAN J, 1996, MAJOR HISTOCOMPATIBI; Kaufman J., 1995, ADV AVIAN IMMUNOLOGY, P119; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Miller MM, 1996, P NATL ACAD SCI USA, V93, P3958, DOI 10.1073/pnas.93.9.3958; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; Nonaka M, 1997, P NATL ACAD SCI USA, V94, P5789, DOI 10.1073/pnas.94.11.5789; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PAZDERKA F, 1975, IMMUNOGENETICS, V2, P101, DOI 10.1007/BF01572280; Pharr GT, 1998, IMMUNOGENETICS, V47, P350, DOI 10.1007/s002510050369; PINK JRL, 1977, IMMUNOGENETICS, V5, P203, DOI 10.1007/BF01570477; PLACHY J, 1992, CRIT REV IMMUNOL, V12, P47; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; SKJODT K, 1985, TISSUE ANTIGENS, V25, P278, DOI 10.1111/j.1399-0039.1985.tb00450.x; Thorpe KL, 1996, IMMUNOGENETICS, V44, P391, DOI 10.1007/s002510050142; VAINIO O, 1984, IMMUNOGENETICS, V19, P131, DOI 10.1007/BF00387856; VAINIO O, 1988, J IMMUNOL, V140, P2864	29	486	514	2	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	1999	401	6756					923	925		10.1038/44856	http://dx.doi.org/10.1038/44856			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553909				2022-12-28	WOS:000083464700061
J	Helweg-Larsen, J; Benfield, TL; Eugen-Olsen, J; Lundgren, JD; Lundgren, B				Helweg-Larsen, J; Benfield, TL; Eugen-Olsen, J; Lundgren, JD; Lundgren, B			Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P carinii pneumonia	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SULFONAMIDE RESISTANCE; PROGNOSTIC FACTORS; ESCHERICHIA-COLI; INFECTION; CORTICOSTEROIDS; PROPHYLAXIS; THERAPY; PCR	Background Sulpha drugs are widely used for the treatment and long-term prophylaxis of Pneumocystis carinii pneumonia (PCP) in HIV-1-infected individuals. Sulpha resistance in many microorganisms Is caused by point mutations in dihydropteroate synthase (DHPS), an enzyme that Is essential for folate biosynthesis. We assessed whether mutations in the DHPS gene of P carinii were associated with exposure to sulpha drugs and influenced outcome from PCP. Methods We studied bronchoalveolar samples collected in 1989-99 from prospective cohort of HIV-1-infected patients who had PCP. In 144 patients with 152 episodes of PCP, we analysed portions of DHPS using PCR and direct sequencing. The relation between survival, P carinii DHPS mutations, and other predictors of treatment failure was assessed by Kaplan-Meier and multivariate Cox regression analysis. Findings P carinii DHPS mutations were found in 31 (20.4%) of 152 PCP episodes. 3-month survival was significantly lower in patients infected with mutant P carinii DHPS strains than in those with wild-type strains (p=0.002). After adjustment for other prognostic variables, presence of DHPS mutations remained the most important predictor of mortality (hazard ratio 3.1 [95% CI 1.2-8.1]). DHPS mutations were significantly more common in patients who had previous exposure to sulpha drugs (18 of 29 [62%]) than in those who had no exposure (13 of 123 [10.5%]; p<0.0001). A significant increase with time in the rate of DHPS mutations (p=0.01 for trend) was closely correlated with the rate of previous or current use of sulpha drugs as chemoprophylaxis. Interpretation Mutations in DHPS are associated with impaired prognosis in PCP, and may develop as a result of exposure to sulpha drugs.	Univ Copenhagen, Hvidovre Hosp, Dept Infect Dis, Copenhagen, Denmark; Univ Copenhagen, Hvidovre Hosp, Climat Res Unit, Copenhagen, Denmark; State Serum Inst, Dept Mycobacteriol, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Statens Serum Institut	Helweg-Larsen, J (corresponding author), Hvidovre Hosp, Dept Infect Dis, DK-2650 Hvidovre, Denmark.		Lundgren, Jens/AAE-6876-2019	Helweg-Larsen, Jannik/0000-0001-7192-0144; Benfield, Thomas/0000-0003-0698-9385; Eugen-Olsen, Jesper/0000-0002-4630-4275; Lundgren, Jens/0000-0001-8901-7850				Balslev U, 1997, SCAND J INFECT DIS, V29, P337, DOI 10.3109/00365549709011827; BENFIELD TL, 1995, AM J RESP CRIT CARE, V151, P1058; BOZZETTE SA, 1990, J INFECT DIS, V162, P1365, DOI 10.1093/infdis/162.6.1365; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; DALLAS WS, 1992, J BACTERIOL, V174, P5961, DOI 10.1128/jb.174.18.5961-5970.1992; FERNANDEZ P, 1995, THORAX, V50, P668, DOI 10.1136/thx.50.6.668; Fishman JA, 1998, ANTIMICROB AGENTS CH, V42, P1309, DOI 10.1128/AAC.42.6.1309; Fishman JA, 1998, ANTIMICROB AGENTS CH, V42, P995, DOI 10.1128/AAC.42.5.995; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; Helweg-Larsen J, 1998, J CLIN MICROBIOL, V36, P2068, DOI 10.1128/JCM.36.7.2068-2072.1998; Helweg-Larsen J, 1998, QJM-INT J MED, V91, P813, DOI 10.1093/qjmed/91.12.813; HelwegLarsen J, 1997, LANCET, V350, P1363, DOI 10.1016/S0140-6736(97)24045-6; Kazanjian P, 1998, AIDS, V12, P873, DOI 10.1097/00002030-199808000-00009; Kirk O, 1998, AIDS, V12, P2031, DOI 10.1097/00002030-199815000-00015; Kumar SD, 1998, CHEST, V113, P430, DOI 10.1378/chest.113.2.430; Lane BR, 1997, J INFECT DIS, V175, P482, DOI 10.1093/infdis/175.2.482; LUNDGREN JD, 1996, CLIN PULM MED, V3, P304; MASON GR, 1989, AM REV RESPIR DIS, V139, P1336, DOI 10.1164/ajrccm/139.6.1336; Mei Q, 1998, LANCET, V351, P1631, DOI 10.1016/S0140-6736(05)77687-X; MONTANER JSG, 1990, ANN INTERN MED, V113, P14, DOI 10.7326/0003-4819-113-1-14; NIELSEN TL, 1992, J ACQ IMMUN DEF SYND, V5, P726; Stringer JR, 1996, AIDS, V10, P561, DOI 10.1097/00002030-199606000-00001; Swedberg G, 1998, ANTIMICROB AGENTS CH, V42, P1062, DOI 10.1128/AAC.42.5.1062; Triglia T, 1997, P NATL ACAD SCI USA, V94, P13944, DOI 10.1073/pnas.94.25.13944; Vedantam G, 1998, ANTIMICROB AGENTS CH, V42, P88, DOI 10.1128/AAC.42.1.88; VOLPE F, 1993, EUR J BIOCHEM, V216, P449, DOI 10.1111/j.1432-1033.1993.tb18163.x; Wakefield AE, 1998, FEMS IMMUNOL MED MIC, V22, P59, DOI 10.1111/j.1574-695X.1998.tb01187.x; WALZER PD, 1992, ANTIMICROB AGENTS CH, V36, P1935, DOI 10.1128/AAC.36.9.1935; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0	29	198	202	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1347	1351		10.1016/S0140-6736(99)03320-6	http://dx.doi.org/10.1016/S0140-6736(99)03320-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533864				2022-12-28	WOS:000083149900013
J	Tan, LB; Murphy, R				Tan, LB; Murphy, R			Shifts in mortality curves: saving or extending lives?	LANCET			English	Editorial Material							CONGESTIVE-HEART-FAILURE; FLOSEQUINAN; SURVIVAL		Univ Leeds, Gen Infirm, Yorkshire Heart Ctr, Inst Cardiovasc Res, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary; University of Leeds	Tan, LB (corresponding author), Univ Leeds, Gen Infirm, Yorkshire Heart Ctr, Inst Cardiovasc Res, Leeds LS1 3EX, W Yorkshire, England.							BOBBIO M, 1994, LANCET, V343, P1209, DOI 10.1016/S0140-6736(94)92407-4; COLLINS R, 1995, LANCET, V345, P669; CONSENSUS trial study group, 1987, NEW ENGL J MED, V316, P429; ELBORN JS, 1989, BRIT HEART J, V61, P331; FEINSTEIN AR, 1985, HYPERTENSION, V7, P313, DOI 10.1161/01.HYP.7.3_Pt_1.313; Ferreira A, 1997, J Card Fail, V3, P295, DOI 10.1016/S1071-9164(97)90029-4; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; Huff D., 1954, LIE STAT; *ISIS 2 COLL GROUP, 1998, LANCET, V352, P349; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PACKER M, 1993, J AM COLL CARDIOL, V22, P65, DOI 10.1016/0735-1097(93)90816-J; PACKER M, 1987, CIRCULATION, V75, P55; PAUL SD, 1994, ARCH INTERN MED, V154, P1143, DOI 10.1001/archinte.154.10.1143; RYDEN L, 1990, LANCET, V336, P1; Stafford RS, 1997, ARCH INTERN MED, V157, P2460, DOI 10.1001/archinte.157.21.2460; Swedberg K, 1999, EUR HEART J, V20, P136, DOI 10.1053/euhj.1998.1098; TORPPEDERSEN C, 1997, CIRCULATION S1, V96, P90; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	22	37	38	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1378	1381		10.1016/S0140-6736(98)11472-1	http://dx.doi.org/10.1016/S0140-6736(98)11472-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533880				2022-12-28	WOS:000083149900042
J	Sallusto, F; Lenig, D; Forster, R; Lipp, M; Lanzavecchia, A				Sallusto, F; Lenig, D; Forster, R; Lipp, M; Lanzavecchia, A			Two subsets of memory T lymphocytes with distinct homing potentials and effector functions	NATURE			English	Article							IMMUNOLOGICAL MEMORY; T-HELPER-2 CELLS; B-CELL; EXPRESSION; IMMUNITY; NAIVE; CHEMOKINES; ADHESION	Naive T lymphocytes travel to T-cell areas of secondary lymphoid organs in search of antigen presented by dendritic cells(1,2). Once activated, they proliferate vigorously, generating effector cells that can migrate to B-cell areas or to inflamed tissues(3-6). A fraction of primed T lymphocytes persists as circulating memory cells that can confer protection and give, upon secondary challenge, a qualitatively different and quantitatively enhanced response(7-9) The nature of the cells that mediate the different facets of immunological memory remains unresolved. Here we show that expression of CCR7, a chemokine receptor that controls homing to secondary lymphoid organs, divides human memory T cells into two functionally distinct subsets, CCR7(-) memory cells express receptors for migration to inflamed tissues and display immediate effector function. In contrast, CCR7(+) memory cells express lymph-node homing receptors and lack immediate effector function, but efficiently stimulate dendritic cells and differentiate into CCR7(-) effector cells upon secondary stimulation. The CCR7(+) and CCR7(-) T cells, which we have named central memory (T-CM) and effector memory (T-EM), differentiate in a step-wise fashion from naive T cells, persist for years after immunization and allow a division of labour in the memory response.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sallusto, F (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.		Förster, Reinhold/D-6770-2011; Lipp, Martin/G-2235-2010	Lipp, Martin/0000-0002-0087-2672; Forster, Reinhold/0000-0001-6190-7923				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CASAMAYORPALLEJA M, 1995, J EXP MED, V181, P1293, DOI 10.1084/jem.181.4.1293; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Garside P, 1998, SCIENCE, V281, P96, DOI 10.1126/science.281.5373.96; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Kagi D, 1996, ANNU REV IMMUNOL, V14, P207, DOI 10.1146/annurev.immunol.14.1.207; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; MacLennan ICM, 1997, IMMUNOL REV, V156, P53, DOI 10.1111/j.1600-065X.1997.tb00958.x; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sprent J, 1997, IMMUNOL REV, V156, P79, DOI 10.1111/j.1600-065X.1997.tb00960.x; Tanchot C, 1998, IMMUNOL TODAY, V19, P575, DOI 10.1016/S0167-5699(98)01344-9; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333	29	4446	4577	6	230	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					708	712		10.1038/44385	http://dx.doi.org/10.1038/44385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537110				2022-12-28	WOS:000083207400059
J	Sweetnam, R				Sweetnam, R			Royal Medical Benevolent Fund reminds readers of its Christmas appeal	BRITISH MEDICAL JOURNAL			English	Letter									Royal Med Benevolent Fund, London SW19 8QN, England		Sweetnam, R (corresponding author), Royal Med Benevolent Fund, 24 Kings Rd, London SW19 8QN, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1369	1369		10.1136/bmj.319.7221.1369	http://dx.doi.org/10.1136/bmj.319.7221.1369			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567158	Green Published			2022-12-28	WOS:000083930200042
J	Berger, K; Ajani, UA; Kase, CS; Gaziano, JM; Buring, JE; Glynn, RJ; Hennekens, CH				Berger, K; Ajani, UA; Kase, CS; Gaziano, JM; Buring, JE; Glynn, RJ; Hennekens, CH			Light-to-moderate alcohol consumption and the risk of stroke among US male physicians.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; TISSUE PLASMINOGEN-ACTIVATOR; CARDIOVASCULAR MORTALITY; CAROTID ATHEROSCLEROSIS; JAPANESE POPULATION; CIGARETTE-SMOKING; SHAPED CURVE; BRITISH MEN; LIPOPROTEINS; HYPERTENSION	Background: Several studies have shown U- or J-shaped relations between alcohol consumption and the risk of stroke. We evaluated the effect of light-to-moderate alcohol intake on the risk of stroke, with separate analyses of ischemic stroke and hemorrhagic stroke. Methods: Our analyses were based on a prospective cohort study of 22,071 male physicians, 40 to 84 years old, who were participating in the Physicians' Health Study. At base line, the participants reported that they had no history of stroke, transient ischemic attack, or myocardial infarction and were free of cancer. Alcohol intake, reported by 21,870 participants at base line, ranged from none or almost none to two or more drinks per day. Results: During an average of 12.2 years of follow-up, 679 strokes were reported. As compared with participants who had less than one drink per week, those who drank more had a reduced overall risk of stroke (relative risk, 0.79; 95 percent confidence interval, 0.66 to 0.94) and a reduced risk of ischemic stroke (relative risk, 0.77; 95 percent confidence interval, 0.63 to 0.94). There was no statistically significant association between alcohol consumption and hemorrhagic stroke. The overall relative risks of stroke for the men who had one drink per week, two to four drinks per week, five or six drinks per week, or one or more drinks per day were 0.78 (95 percent confidence interval, 0.59 to 1.04), 0.75 (95 percent confidence interval, 0.58 to 0.96), 0.83 (95 percent confidence interval, 0.62 to 1.11), and 0.80 (95 percent confidence interval, 0.64 to 0.99), respectively, in an analysis in which we controlled for major risk factors for stroke. Conclusions: Light-to-moderate alcohol consumption reduces the overall risk of stroke and the risk of ischemic stroke in men. The benefit is apparent with as little as one drink per week. Greater consumption, up to one drink per day, does not increase the observed benefit. (N Engl J Med 1999;341:1557-64.) (C) 1999, Massachusetts Medical Society.	Brigham & Womens Hosp, Div Prevent Med, Dept Med, Boston, MA 02215 USA; Dept Vet Affairs Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Univ Munster, Inst Epidemiol & Social Med, Munster, Germany; Univ Munster, Dept Neurol, Munster, Germany; Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL USA	Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Boston University; University of Munster; University of Munster; University of Miami	Ajani, UA (corresponding author), Brigham & Womens Hosp, Div Prevent Med, Dept Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.	uajani@rics.bwh.harvard.edu		Kase, Carlos/0000-0002-3047-5010	NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34944, CA 40360] Funding Source: Medline; NHLBI NIH HHS [HL 26490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RJ, 1989, STROKE, V20, P448, DOI 10.1161/01.STR.20.4.448; ALTURA BM, 1994, ALCOHOL CLIN EXP RES, V18, P1057, DOI 10.1111/j.1530-0277.1994.tb00082.x; ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; Berger K, 1996, STROKE, V27, P238, DOI 10.1161/01.STR.27.2.238; BIHARIVARGA M, 1981, ATHEROSCLEROSIS, V40, P337, DOI 10.1016/0021-9150(81)90144-1; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CAMARGO CA, 1989, STROKE, V20, P1611, DOI 10.1161/01.STR.20.12.1611; Camargo CA, 1997, ARCH INTERN MED, V157, P79, DOI 10.1001/archinte.157.1.79; Camargo CA, 1996, CLIN CHIM ACTA, V246, P107, DOI 10.1016/0009-8981(96)06231-6; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; DUARTE APT, 1995, THROMB RES, V78, P107, DOI 10.1016/0049-3848(95)00039-9; DURANTE W, 1995, BIOCHEM J, V308, P231, DOI 10.1042/bj3080231; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; Fields C E, 1998, Semin Vasc Surg, V11, P181; Flegal K M, 1985, Recent Dev Alcohol, V3, P165; GILL JS, 1991, AM J MED, V90, P489, DOI 10.1016/0002-9343(91)80090-9; GILL JS, 1988, INT J EPIDEMIOL, V17, P542, DOI 10.1093/ije/17.3.542; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GLUECK CJ, 1995, J LAB CLIN MED, V125, P319; GORDON T, 1981, ARCH INTERN MED, V141, P1128, DOI 10.1001/archinte.141.9.1128; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HILLBOM M, 1982, NEUROLOGY, V32, P706, DOI 10.1212/WNL.32.7.706; JURGENS G, 1987, NEUROLOGY, V37, P513, DOI 10.1212/WNL.37.3.513; JUVELA S, 1993, STROKE, V24, P639, DOI 10.1161/01.STR.24.5.639; JUVELA S, 1995, STROKE, V26, P1558, DOI 10.1161/01.STR.26.9.1558; KASTURI R, 1992, STROKE, V23, P1257, DOI 10.1161/01.STR.23.9.1257; Kauhanen J, 1997, BMJ-BRIT MED J, V315, P846, DOI 10.1136/bmj.315.7112.846; Kiechl S, 1998, STROKE, V29, P900, DOI 10.1161/01.STR.29.5.900; KIECHL S, 1994, STROKE, V25, P1593, DOI 10.1161/01.STR.25.8.1593; KIYOHARA Y, 1995, STROKE, V26, P368, DOI 10.1161/01.STR.26.3.368; Klag M J, 1993, Ann Epidemiol, V3, P442; KONO S, 1986, INT J EPIDEMIOL, V15, P527, DOI 10.1093/ije/15.4.527; LANDOLFI R, 1984, BLOOD, V64, P679; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; MANSON JE, 1991, AM J PREV MED, V7, P150, DOI 10.1016/S0749-3797(18)30931-0; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; NAGO N, 1995, AM J EPIDEMIOL, V141, P815, DOI 10.1093/oxfordjournals.aje.a117516; PALMER AJ, 1995, J HYPERTENS, V13, P957, DOI 10.1097/00004872-199509000-00004; PALOMAKI H, 1993, STROKE, V24, P1828, DOI 10.1161/01.STR.24.12.1828; Quyyumi Arshed A., 1998, American Journal of Medicine, V105, p32S, DOI 10.1016/S0002-9343(98)00209-5; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; REED DM, 1988, STROKE, V19, P820, DOI 10.1161/01.STR.19.7.820; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RENAUD S, 1993, HLTH ISSUES RELATED, P81; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RIDKER PM, 1993, ARTERIOSCLER THROMB, V13, P1587, DOI 10.1161/01.ATV.13.11.1587; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; RODGERS H, 1993, STROKE, V24, P1473, DOI 10.1161/01.STR.24.10.1473; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; RUF JC, 1995, ARTERIOSCL THROM VAS, V15, P140, DOI 10.1161/01.ATV.15.1.140; Sacco RL, 1999, JAMA-J AM MED ASSOC, V281, P53, DOI 10.1001/jama.281.1.53; SCHERR PA, 1992, J AM GERIATR SOC, V40, P651, DOI 10.1111/j.1532-5415.1992.tb01954.x; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; Wannamethee SG, 1996, STROKE, V27, P1033, DOI 10.1161/01.STR.27.6.1033; WATTS GF, 1995, QJM-MON J ASSOC PHYS, V88, P321; WILLIAMS GD, 1985, J STUD ALCOHOL, V46, P223, DOI 10.15288/jsa.1985.46.223; WOLF PA, 1988, ANN NEUROL, V24, P177	66	219	225	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1999	341	21					1557	1564		10.1056/NEJM199911183412101	http://dx.doi.org/10.1056/NEJM199911183412101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	256GF	10564684				2022-12-28	WOS:000083717000001
J	Singhal, S; Mehta, J; Desikan, R; Ayers, D; Roberson, P; Eddlemon, P; Munshi, N; Anaissie, E; Wilson, C; Dhodapkar, M; Zeldis, J; Barlogie, B; Siegel, D; Crowley, J				Singhal, S; Mehta, J; Desikan, R; Ayers, D; Roberson, P; Eddlemon, P; Munshi, N; Anaissie, E; Wilson, C; Dhodapkar, M; Zeldis, J; Barlogie, B; Siegel, D; Crowley, J			Antitumor activity of thalidomide in refractory multiple myeloma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW; AUTOLOGOUS TRANSPLANTATION; CYTOKINE PRODUCTION; ANGIOGENESIS; THERAPY; CHEMOTHERAPY; DISEASES; MODEL	Background: Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, in patients with refractory disease. Methods: Eighty-four previously treated patients with refractory myeloma (76 with a relapse after high-dose chemotherapy) received oral thalidomide as a single agent for a median of 80 days (range, 2 to 465). The starting dose was 200 mg daily, and the dose was increased by 200 mg every two weeks until it reached 800 mg per day. Response was assessed on the basis of a reduction of the myeloma protein in serum or Bence Jones protein in urine that lasted for at least six weeks. Results: The serum or urine levels of paraprotein were reduced by at least 90 percent in eight patients (two had a complete remission), at least 75 percent in six patients, at least 50 percent in seven patients, and at least 25 percent in six patients, for a total rate of response of 32 percent. Reductions in the paraprotein levels were apparent within two months in 78 percent of the patients with a response and were associated with decreased numbers of plasma cells in bone marrow and increased hemoglobin levels. The microvascular density of bone marrow did not change significantly in patients with a response. At least one third of the patients had mild or moderate constipation, weakness or fatigue, or somnolence. More severe adverse effects were infrequent (occurring in less than 10 percent of patients), and hematologic effects were rare. As of the most recent follow-up, 36 patients had died (30 with no response and 6 with a response). After 12 months of follow-up, Kaplan-Meier estimates of the mean (+/-SE) rates of event-free survival and overall survival for all patients were 22+/-5 percent and 58+/-5 percent, respectively. Conclusions: Thalidomide is active against advanced myeloma. It can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy. (N Engl J Med 1999;341:1565-71.) (C) 1999, Massachusetts Medical Society.	Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA; Univ S Carolina, S Carolina Canc Ctr, Myeloma & Lymphoma Program, Columbia, SC 29208 USA; Rockefeller Univ, Lab Cellular Physiol & Immunol, New York, NY USA	University of Arkansas System; University of Arkansas Medical Sciences; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Rockefeller University	Barlogie, B (corresponding author), Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, 4301 W Markham,Slot 623, Little Rock, AR 72205 USA.		Mehta, JL/AAG-7572-2020; Munshi, Nikhil/ABE-2338-2021		NCI NIH HHS [CA55819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANIAN R, 1994, NEW ENGL J MED, V330, P484; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Barlogie B, 1998, BLOOD, V92, p273B; Barlogie B, 1997, CLIN CANCER RES, V3, P2605; Barlogie B, 1997, BLOOD, V89, P789, DOI 10.1182/blood.V89.3.789; BARTL R, 1987, AM J CLIN PATHOL, V87, P342, DOI 10.1093/ajcp/87.3.342; BATTEGAY EJ, 1995, J MOL MED, V73, P333; Corral LG, 1996, MOL MED, V2, P506, DOI 10.1007/BF03401909; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Eisen T, 1998, P AN M AM SOC CLIN, V17, P441; Figg WD, 1997, P AN M AM SOC CLIN, V16, p333a; FINE HA, 1997, P AN M AM SOC CLIN, V16, pA385; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GAYNOR JJ, 1993, J AM STAT ASSOC, V88, P400, DOI 10.2307/2290318; Geitz H, 1996, IMMUNOPHARMACOLOGY, V31, P213, DOI 10.1016/0162-3109(95)00050-X; GREIPP PR, 1987, MAYO CLIN PROC, V62, P969, DOI 10.1016/S0025-6196(12)65066-6; Haslett PAJ, 1998, J EXP MED, V187, P1885, DOI 10.1084/jem.187.11.1885; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292; Long G, 1998, P AN M AM SOC CLIN, V17, P181; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCHUGH SM, 1995, CLIN EXP IMMUNOL, V99, P160; Minchinton AI, 1996, ANTI-CANCER DRUG, V7, P339, DOI 10.1097/00001813-199605000-00015; Munshi N, 1998, BLOOD, V92, p98A; Nguyen M, 1997, INT J ONCOL, V10, P965; OLSON KB, 1965, CLIN PHARMACOL THER, V6, P292; Rajkumar SV, 1999, LEUKEMIA, V13, P469, DOI 10.1038/sj.leu.2401336; SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699; Singhal S., 1996, Blood, V88, p611A; TRICOT G, 1995, BONE MARROW TRANSPL, V16, P7; TRICOT G, 1995, BLOOD, V86, P4250, DOI 10.1182/blood.V86.11.4250.bloodjournal86114250; Vacca A, 1999, BLOOD, V93, P3064; VACCA A, 1995, AM J HEMATOL, V50, P9, DOI 10.1002/ajh.2830500103; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Vacca A, 1995, LEUKEMIA LYMPHOMA, V20, P27, DOI 10.3109/10428199509054750; Yaccoby S, 1998, BLOOD, V92, P2908, DOI 10.1182/blood.V92.8.2908.420a32_2908_2913	37	2003	2125	4	148	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1999	341	21					1565	1571		10.1056/NEJM199911183412102	http://dx.doi.org/10.1056/NEJM199911183412102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	256GF	10564685				2022-12-28	WOS:000083717000002
J	Triadafilopoulos, G				Triadafilopoulos, G			Inverted colonic diverticulum	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University	Triadafilopoulos, G (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.			Triadafilopoulos, George/0000-0002-4233-3773					0	9	9	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1999	341	20					1508	1508		10.1056/NEJM199911113412005	http://dx.doi.org/10.1056/NEJM199911113412005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RK	10559452				2022-12-28	WOS:000083625800005
J	Burke, R				Burke, R			Surgeons' college launches campaign to save research	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1999	319	7219					1221	1221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RH	10550076	Green Published			2022-12-28	WOS:000083625600015
J	Cole, CR; Blackstone, EH; Pashkow, FJ; Snader, CE; Lauer, MS				Cole, CR; Blackstone, EH; Pashkow, FJ; Snader, CE; Lauer, MS			Heart-rate recovery immediately after exercise as a predictor of mortality	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EMISSION COMPUTED-TOMOGRAPHY; FOLLOW-UP; INFARCTION; STRESS; DEATH	Background The increase in heart rate that accompanies exercise is due in part to a reduction in vagal tone. Recovery of the heart rate immediately after exercise is a function of vagal reactivation. Because a generalized decrease in vagal activity is known to be a risk factor for death, we hypothesized that a delayed fall in the heart rate after exercise might be an important prognostic marker. Methods For six years we followed 2428 consecutive adults (mean [+/-SD] age, 57+/-12 years; 63 percent men) without a history of heart failure or coronary revascularization and without pacemakers. The patients were undergoing symptom-limited exercise testing and single-photon-emission computed tomography with thallium scintigraphy for diagnostic purposes. The value for the recovery of heart rate was defined as the decrease in the heart rate from peak exercise to one minute after the cessation of exercise. An abnormal value for the recovery of heart rate was defined as a reduction of 12 beats per minute or less from the heart rate at peak exercise. Results There were 213 deaths from all causes. A total of 639 patients (26 percent) had abnormal values for heart-rate recovery. In univariate analyses, a low value for the recovery of heart rate was strongly predictive of death (relative risk, 4.0; 95 percent confidence interval, 3.0 to 5.2; P<0.001). After adjustments were made for age, sex, the use or nonuse of medications, the presence or absence of myocardial perfusion defects on thallium scintigraphy, standard cardiac risk factors, the resting heart rate, the change in heart rate during exercise, and workload achieved, a low value for heart-rate recovery remained predictive of death (adjusted relative risk, 2.0; 95 percent confidence interval, 1.5 to 2.7; P<0.001). Conclusions A delayed decrease in the heart rate during the first minute after graded exercise, which may be a reflection of decreased vagal activity, is a powerful predictor of overall mortality, independent of workload, the presence or absence of myocardial perfusion defects, and changes in heart rate during exercise. (N Engl J Med 1999;341:1351-7.) (C) 1999, Massachusetts Medical Society.	Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplantat Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiothorac Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Epidemiol & Biostat, Cleveland, OH 44195 USA; Cleveland Clin Fdn, George M & Linda H Kaufman Ctr Heart Failure, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplantat Med, Desk F25,9500 Euclid Ave, Cleveland, OH 44195 USA.		Lauer, Michael S/L-9656-2013	Lauer, Michael S/0000-0002-9217-8177				ARAI Y, 1989, AM J PHYSIOL, V256, pH132, DOI 10.1152/ajpheart.1989.256.1.H132; COX DR, 1972, J R STAT SOC B, V34, P187; CURB JD, 1985, AM J EPIDEMIOL, V121, P754, DOI 10.1093/aje/121.5.754; ELLESTAD MH, 1975, CIRCULATION, V51, P363, DOI 10.1161/01.CIR.51.2.363; FLETCHER GF, 1995, CIRCULATION, V91, P580, DOI 10.1161/01.CIR.91.2.580; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GO RT, 1990, J NUCL MED, V31, P1899; Goldstein RE, 1999, JAMA-J AM MED ASSOC, V281, P565, DOI 10.1001/jama.281.6.565; Gottlieb SS, 1997, LANCET, V349, P662, DOI 10.1016/S0140-6736(97)22010-6; HOSMER DW, 1989, APPL LOGISTIC REGRES; IMAI K, 1994, J AM COLL CARDIOL, V24, P1529, DOI 10.1016/0735-1097(94)90150-3; La Rovere MT, 1998, LANCET, V351, P478; Lauer MS, 1999, JAMA-J AM MED ASSOC, V281, P524, DOI 10.1001/jama.281.6.524; Lauer MS, 1996, AM J CARDIOL, V78, P278, DOI 10.1016/S0002-9149(96)00277-9; LAUER MS, 1996, CIRCULATION, V93, P150; LEBLANC M, 1992, BIOMETRICS, V48, P411, DOI 10.2307/2532300; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; NALLAMOTHU N, 1995, J AM COLL CARDIOL, V25, P830, DOI 10.1016/0735-1097(94)00471-2; SANDVIK L, 1995, CORONARY ARTERY DIS, V6, P667, DOI 10.1097/00019501-199508000-00012; SCHWARTZ PJ, 1992, CIRCULATION, V85, P77; Snader CE, 1997, J AM COLL CARDIOL, V30, P641, DOI 10.1016/S0735-1097(97)00217-9; Wilkoff Bruce L., 1992, Cardiology Clinics, V10, P705	22	1257	1324	0	92	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1351	1357		10.1056/NEJM199910283411804	http://dx.doi.org/10.1056/NEJM199910283411804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249XE	10536127	Bronze			2022-12-28	WOS:000083357800004
J	Viswanathan, GM; Buldyrev, SV; Havlin, S; da Luz, MGE; Raposo, EP; Stanley, HE				Viswanathan, GM; Buldyrev, SV; Havlin, S; da Luz, MGE; Raposo, EP; Stanley, HE			Optimizing the success of random searches	NATURE			English	Article							N LEVY FLIGHTS; CHEMOSENSORY RESPONSES; MOVEMENT; PATTERNS; BEHAVIOR	We address the general question of what is the best statistical strategy to adapt in order to search efficiently for randomly located objects ('target sites'). It is often assumed in foraging theory that the flight lengths of a forager have a characteristic scale: from this assumption gaussian, Rayleigh and other classical distributions with well-defined variances have arisen. However, such theories cannot explain the long-tailed power-law distributions(1,2) of flight lengths or flight times(3-6) that are observed experimentally. Here we study how the search efficiency depends on the probability distribution of flight lengths taken by a forager that can detect target sites only in its limited vicinity. We show that, when the target sites are sparse and can be visited any number of times, an inverse square power-law distribution of flight lengths, corresponding to Levy flight motion, is an optimal strategy. We test the theory by analysing experimental foraging data on selected insect, mammal and bird species, and find that they are consistent with the predicted inverse square power-law distributions.	Boston Univ, Ctr Polymer Studies, Boston, MA 02215 USA; Boston Univ, Dept Phys, Boston, MA 02215 USA; Univ Fed Rio Grande do Norte, Int Ctr Complex Syst, BR-59072970 Natal, RN, Brazil; Univ Fed Rio Grande do Norte, Dept Fis Teor & Expt, BR-59072970 Natal, RN, Brazil; Univ Fed Alagoas, Dept Fis, BR-57075970 Maceio, AL, Brazil; Bar Ilan Univ, Gonda Goldshmied Ctr, Ramat Gan, Israel; Bar Ilan Univ, Dept Phys, Ramat Gan, Israel; Harvard Univ, Lyman Lab Phys, Cambridge, MA 02138 USA; Univ Fed Parana, Dept Fis, BR-81531970 Curitiba, Parana, Brazil; Univ Fed Pernambuco, Dept Fis, Lab Fis Teor & Computac, BR-50670901 Recife, PE, Brazil	Boston University; Boston University; Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte; Universidade Federal de Alagoas; Bar Ilan University; Bar Ilan University; Harvard University; Universidade Federal do Parana; Universidade Federal de Pernambuco	Viswanathan, GM (corresponding author), Boston Univ, Ctr Polymer Studies, Boston, MA 02215 USA.	gandhi@fis.ufal.br	da luz, marcos g e gomes eleuterio/H-7835-2012; Havlin, Shlomo/ABF-1527-2020; Buldyrev, Sergey V/I-3933-2015; Raposo, Ernesto P./ABA-7215-2020; Raposo, Ernesto P/N-2786-2017; Viswanathan, Gandhimohan M/J-8558-2012; Viswanathan, Gandhimohan/AAF-3937-2020	da luz, marcos g e gomes eleuterio/0000-0003-3865-2621; Raposo, Ernesto P./0000-0002-4178-8266; Raposo, Ernesto P/0000-0002-3595-4352; Viswanathan, Gandhimohan M/0000-0002-2301-5593; Buldyrev, Sergey/0000-0002-3008-1070				Berg H. C., 1983, RANDOM WALKS BIOL; Berkolaiko G, 1996, PHYS REV E, V53, P5774, DOI 10.1103/PhysRevE.53.5774; Berkolaiko G, 1997, PHYS REV E, V55, P1395, DOI 10.1103/PhysRevE.55.1395; COLE BJ, 1995, ANIM BEHAV, V50, P1317, DOI 10.1016/0003-3472(95)80047-6; Focardi S, 1996, J ANIM ECOL, V65, P606, DOI 10.2307/5740; HEINRICH B, 1979, OECOLOGIA, V40, P235, DOI 10.1007/BF00345321; Kot M, 1996, ECOLOGY, V77, P2027, DOI 10.2307/2265698; LARRALDE H, 1992, PHYS REV A, V45, P7128, DOI 10.1103/PhysRevA.45.7128; LARRALDE H, 1992, NATURE, V355, P423, DOI 10.1038/355423a0; LEVANDOWSKY M, 1988, B MAR SCI, V43, P758; MANTEGNA RN, 1994, PHYS REV LETT, V73, P2946, DOI 10.1103/PhysRevLett.73.2946; SCHLESINGER MF, 1986, GROWTH FORM, P279; SCHLESINGER MF, 1995, LEVY FLIGHTS RELATED; Schulman L. S., 1997, TIMES ARROWS QUANTUM; Schuster FL, 1996, J EUKARYOT MICROBIOL, V43, P150, DOI 10.1111/j.1550-7408.1996.tb04496.x; SHLESINGER MF, 1985, PHYS REV LETT, V54, P2551, DOI 10.1103/PhysRevLett.54.2551; SUGIHARA G, 1990, TRENDS ECOL EVOL, V5, P79, DOI 10.1016/0169-5347(90)90235-6; SZU H, 1988, DYNAMIC PATTERNS COM, P121; Tsallis C, 1997, PHYS WORLD, V10, P42; Viswanathan GM, 1996, NATURE, V381, P413, DOI 10.1038/381413a0	20	1023	1033	7	227	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 28	1999	401	6756					911	914		10.1038/44831	http://dx.doi.org/10.1038/44831			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553906				2022-12-28	WOS:000083464700057
J	Wee, CC; McCarthy, EP; Davis, RB; Phillips, RS				Wee, CC; McCarthy, EP; Davis, RB; Phillips, RS			Physician counseling about exercise	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; LIFE-STYLE; US ADULTS; HEALTH; MORTALITY; DISEASE; SMOKING; RECOMMENDATIONS; INTERVENTION; ASSOCIATION	Context The increase in sedentary lifestyle may contribute to the rise in obesity nationally. Although guidelines suggest that physicians counsel all patients about exercise, physicians counsel only a minority of their patients. Whether patient factors influence physician counseling is not well established. Objectives To examine and to identify factors associated with exercise counseling by US physicians. Design and Setting National population-based supplemental (Year 2000) survey to the 1995 National Health Interview Survey. Participants Of the 17 317 respondents to the Year 2000 supplemental survey, 9711 adults had seen a physician in the previous year, and 9299 responded when asked about physician counseling on exercise. Main Outcome Measure Physician counseling to begin or to continue to exercise. Results Of 9299 respondents, 34% reported being counseled about exercise at their last visit. After adjustment for other sociodemographic and clinical factors, women were slightly more likely to be counseled, with an adjusted odds ratio (AOR) of 1.15 (95% confidence interval [CI], 1.02-1.29). Physicians counseled older patients (>30 years) more often than younger patients; those aged 40 to 49 years were counseled most often (AOR, 1.71 [95% CI, 1.34-2.20]). Patients with incomes above $50 000, those with higher levels of physical activity, college graduates, and patients who were overweight to obese (body mass index: 25 to greater than or equal to 30 kg/m(2)) were more likely to be counseled, as were patients with cardiac disease (AOR, 1.81 [95% CI, 1.52-2.14]) and diabetes (AOR, 1.87 [95% CI, 1.46-2.38]), Counseling did not vary by physician specialty or patient race. Conclusion The rate of physician counseling about exercise is low nationally. Physicians appear to counsel as secondary prevention and are less likely to counsel patients at risk for obesity. The failure to counsel younger, disease-free adults and those from lower socioeconomic groups may represent important missed opportunities for primary prevention.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Wee, CC (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,Libby 330, Boston, MA 02215 USA.				BHP HRSA HHS [5T32PE11001] Funding Source: Medline	BHP HRSA HHS		BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Bull FC, 1998, AM J PREV MED, V15, P85, DOI 10.1016/S0749-3797(98)00040-3; BURTON LC, 1995, PREV MED, V24, P492, DOI 10.1006/pmed.1995.1078; COULTER A, 1995, BRIT MED J, V310, P1099; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; Donato KA, 1998, ARCH INTERN MED, V158, P1855, DOI 10.1001/archinte.158.17.1855; Eaton CB, 1998, BRIT J SPORT MED, V32, P11, DOI 10.1136/bjsm.32.1.11; FLETCHER GF, 1992, CIRCULATION, V86, P340, DOI 10.1161/01.CIR.86.1.340; HARRIS SS, 1989, JAMA-J AM MED ASSOC, V261, P3588, DOI 10.1001/jama.261.24.3588; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; KOCH GG, 1975, INT STAT REV, V43, P59, DOI 10.2307/1402660; Kreuter MW, 1997, PREV MED, V26, P825, DOI 10.1006/pmed.1997.0216; KUCZMARSKI R J, 1992, American Journal of Clinical Nutrition, V55, p495S, DOI 10.1093/ajcn/55.2.495s; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Kushi LH, 1997, JAMA-J AM MED ASSOC, V277, P1287, DOI 10.1001/jama.277.16.1287; LEWIS CE, 1991, ANN INTERN MED, V114, P54, DOI 10.7326/0003-4819-114-1-54; *NAT CTR HLTH STAT, 1997, CD ROM SER, V10; OCKENE JK, 1994, J GEN INTERN MED, V9, P379, DOI 10.1007/BF02629517; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; REED BD, 1991, AM J PREV MED, V7, P410, DOI 10.1016/S0749-3797(18)30880-8; *RES TRIANGL I, 1992, SUDAAN US MAN REL 5; Rosenberg IH, 1998, ANN INTERN MED, V129, P133, DOI 10.7326/0003-4819-129-2-199807150-00015; Swinburn BA, 1998, AM J PUBLIC HEALTH, V88, P288, DOI 10.2105/AJPH.88.2.288; Taira DA, 1997, JAMA-J AM MED ASSOC, V278, P1412, DOI 10.1001/jama.278.17.1412; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; WELLS KB, 1986, AM J PUBLIC HEALTH, V76, P1009, DOI 10.2105/AJPH.76.8.1009; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; WILLIAMSON DF, 1993, INT J OBESITY, V17, P279; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; 1998, MMWR MORB MORTAL WKL, V47, P91	32	239	239	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1583	1588		10.1001/jama.282.16.1583	http://dx.doi.org/10.1001/jama.282.16.1583			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546701	Bronze			2022-12-28	WOS:000083277800029
J	Brander, L; Kloeter, U; Henzen, C; Briner, V; Stulz, P				Brander, L; Kloeter, U; Henzen, C; Briner, V; Stulz, P			Right-sided pulmonary oedema	LANCET			English	Article									Kantonsspital, Dept Internal Med, CH-6000 Luzern 16, Switzerland; Kantonsspital, Dept Cardiol, CH-6000 Luzern, Switzerland; Kantonsspital, Dept Cardiothorac Surg, CH-6000 Luzern 16, Switzerland	Kantonsspital Aarau AG (KSA); Lucerne Cantonal Hospital; Kantonsspital Aarau AG (KSA); Lucerne Cantonal Hospital; Kantonsspital Aarau AG (KSA); Lucerne Cantonal Hospital	Brander, L (corresponding author), Kantonsspital, Dept Internal Med, CH-6000 Luzern 16, Switzerland.							BRYK D, 1970, CHEST, V58, P24, DOI 10.1378/chest.58.1.24; GAMSU G, 1981, WESTERN J MED, V135, P151; GURNEY JW, 1989, RADIOLOGY, V171, P397, DOI 10.1148/radiology.171.2.2704804; MIATAKE K, 1982, BRIT HEART J, V48, P449; ROIACH JM, 1993, CHEST, V103, P1286	5	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1440	1440		10.1016/S0140-6736(99)08426-3	http://dx.doi.org/10.1016/S0140-6736(99)08426-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543672				2022-12-28	WOS:000083277400015
J	Coulehan, J				Coulehan, J			An alternative view: listening to patients	LANCET			English	Article									SUNY Stony Brook, Hlth Sci Ctr, Dept Prevent Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Coulehan, J (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Prevent Med, L3-086, Stony Brook, NY 11794 USA.								0	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1467	1468		10.1016/S0140-6736(05)77604-2	http://dx.doi.org/10.1016/S0140-6736(05)77604-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543688				2022-12-28	WOS:000083277400042
J	Harris, AJ				Harris, AJ			Cortical origin of pathological pain	LANCET			English	Article							PRIMARY SOMATOSENSORY CORTEX; FOCAL HAND DYSTONIA; BRAILLE READERS; PHANTOM LIMBS; PLASTICITY; REPRESENTATION; REORGANIZATION; STIMULATION; AMPUTATION; MONKEYS	Pain without accompanying tissue pathology poses a classic puzzle, presented in extreme form by phantom pain in a non-existent amputated limb. A clue to the origin of such pain is given by the recent discovery of a region of cortex active in response to incongruence between motor intention, awareness of movement, and visual feedback. Phantom-limb sensation, and repetitive strain injuries or focal hand dystonias in writers, musicians, or keyboard operators, are accompanied by plastic changes in sensorimotor cortex and by pathological pain. Disorganised or inappropriate cortical representation of proprioception may falsely signal incongruence between motor intention and movement, which results in pathological pain in the same way that incongruence between vestibular and visual sensation results in motion sickness.	Univ Otago, Sch Med, Dev Biol Unit, Dunedin, New Zealand; Univ Otago, Sch Med, Dept Physiol, Dunedin, New Zealand	University of Otago; University of Otago	Harris, AJ (corresponding author), Univ Otago, Sch Med, Dev Biol Unit, POB 913, Dunedin, New Zealand.		Harris, Linda J/B-5030-2011	Harris, Linda J/0000-0002-1911-752X				Bara-Jimenez W, 1998, ANN NEUROL, V44, P828, DOI 10.1002/ana.410440520; BISIACH E, 1991, NEUROPSYCHOLOGIA, V29, P1029, DOI 10.1016/0028-3932(91)90066-H; Borsook D, 1998, NEUROREPORT, V9, P1013, DOI 10.1097/00001756-199804200-00011; Byl N, 1996, J ORTHOP SPORT PHYS, V23, P234, DOI 10.2519/jospt.1996.23.4.234; Byl N N, 1997, J Hand Ther, V10, P160; Byl NN, 1996, NEUROLOGY, V47, P508, DOI 10.1212/WNL.47.2.508; Elbert T, 1998, NEUROREPORT, V9, P3571, DOI 10.1097/00001756-199811160-00006; Fink GR, 1999, BRAIN, V122, P497, DOI 10.1093/brain/122.3.497; Flor H, 1998, EXP BRAIN RES, V119, P205, DOI 10.1007/s002210050334; Goodale MA, 1998, NOVART FDN SYMP, V218, P21; Hallett M, 1998, Adv Neurol, V78, P11; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KAAS JH, 1979, SCIENCE, V204, P521, DOI 10.1126/science.107591; Knecht S, 1998, BRAIN, V121, P717, DOI 10.1093/brain/121.4.717; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; PASCUALLEONE A, 1993, BRAIN, V116, P39, DOI 10.1093/brain/116.1.39; Ramachandran VS, 1996, P ROY SOC B-BIOL SCI, V263, P377, DOI 10.1098/rspb.1996.0058; RAMACHANDRAN VS, 1995, CONSCIOUS COGN, V4, P22, DOI 10.1006/ccog.1995.1002; Ramachandran VS, 1998, BRAIN, V121, P1603, DOI 10.1093/brain/121.9.1603; SLLARD T, 1991, J COMP NEUROL, V311, P563; Sterr A, 1998, J NEUROSCI, V18, P4417; Topp KS, 1999, MOVEMENT DISORD, V14, P295, DOI 10.1002/1531-8257(199903)14:2<295::AID-MDS1015>3.0.CO;2-J; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	24	231	238	0	31	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1464	1466		10.1016/S0140-6736(99)05003-5	http://dx.doi.org/10.1016/S0140-6736(99)05003-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543687				2022-12-28	WOS:000083277400041
J	Razum, O; Jahn, A; Snow, R				Razum, O; Jahn, A; Snow, R			Maternal mortality in the former East Germany before and after reunification: changes in risk by marital status	BRITISH MEDICAL JOURNAL			English	Article									Dept Trop Hyg & Publ Hlth, D-69120 Heidelberg, Germany		Razum, O (corresponding author), Dept Trop Hyg & Publ Hlth, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.			Razum, Oliver/0000-0002-1244-7649				DRAUSCHKE P, 1993, B ZENTRUMS INTERDISZ, V6, P50; Greenberg R A, 1984, J Public Health Policy, V5, P118, DOI 10.2307/3342388; HABICH R, 1997, STAT BUNDESAMT, P515; RAZUM O, IN PRESS INT J EPIDE; Welsch H, 1989, Arch Gynecol Obstet, V245, P321, DOI 10.1007/BF02417303	5	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1104	1105		10.1136/bmj.319.7217.1104	http://dx.doi.org/10.1136/bmj.319.7217.1104			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	250ZE	10531100	Green Published, Bronze			2022-12-28	WOS:000083419500023
J	Jorres, A; Gahl, GM; Dobis, C; Polenakovic, MH; Cakalaroski, K; Rutkowski, B; Kisielnicka, E; Krieter, DH; Rumpf, KW; Guenther, C; Gaus, W; Hoegel, J				Jorres, A; Gahl, GM; Dobis, C; Polenakovic, MH; Cakalaroski, K; Rutkowski, B; Kisielnicka, E; Krieter, DH; Rumpf, KW; Guenther, C; Gaus, W; Hoegel, J		Int Multicentre Study Grp	Haemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: a prospective randomised multicentre trial	LANCET			English	Article							FACTORS INFLUENCING SURVIVAL; APACHE-II; HEMODIALYSIS	Background There is controversy as to whether haemodialysis-membrane biocompatibility tie, the potential to activate complement and neutrophils) influences mortality of patients with acute renal failure. We did a prospective randomised multicentre trial in patients with dialysis-dependent acute renal failure treated with two different types of low-flux membrane. Methods 180 patients with acute renal failure were randomly assigned bioincompatible Cuprophan (n=90) or polymethylmethacrylate (n=90) membranes. The main outcome was survival 14 days after the end of therapy (treatment success). Odds ratios for survival were calculated and the two groups were compared by Fisher's exact test. Analyses were based on patients treated according to protocol (76 Cuprophan, 84 polymethyl methacrylate). Findings At the start of dialysis, the groups did not differ significantly in age, sex, severity of illness las calculated by APACHE II scores), prevalence of oliguria, or biochemical measures of acute renal failure. 44 patients (58% [95% CI 46-69]) assigned Cuprophan membranes and 50 patients (60% [48-70]) assigned polymethyl-methacrylate membranes survived. The odds ratio for treatment failure on Cuprophan compared with polymethyl-methacrylate membranes was 1.07 (054-2.11; p=0.87). No difference between Cuprophan and polymethyl-methacrylate membranes was detected when the analysis was adjusted for age and APACHE II score, 18 patients in the Cuprophan group and 20 in the polymethyl-methacrylate group had clinical complications of therapy (mainly hypotension). Interpretation There were no differences in outcome for patients with dialysis-dependent acute renal failure between those treated with Cuprophan membranes and those treated with polymethyl-methacrylate membranes.	Humboldt Univ, Fak Med, Univ Klinikum Charite, Dept Nephrol & Med Intens Care, D-13353 Berlin, Germany; Univ St Cyril & Methudius, Dept Nephrol, Skopje 91000, Macedonia; Med Univ Gdansk, Dept Nephrol, Gdansk, Poland; Univ Gottingen, Dept Nephrol & Rheumatol, D-3400 Gottingen, Germany; Membrana GmbH, Wuppertal, Germany; Univ Ulm, Dept Biometry & Med Documentat, Ulm, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Saints Cyril & Methodius University of Skopje; Fahrenheit Universities; Medical University Gdansk; University of Gottingen; Ulm University	Jorres, A (corresponding author), Humboldt Univ, Fak Med, Univ Klinikum Charite, Dept Nephrol & Med Intens Care, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.		Cakalaroski, Koco/L-4251-2019					BRADY HR, 1995, LANCET, V346, P1533, DOI 10.1016/S0140-6736(95)92057-9; CHEW SL, 1993, NEPHROL DIAL TRANSPL, V8, P101; COSENTINO F, 1994, NEPHROL DIAL TRANSPL, V9, P179; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; Himmelfarb J, 1998, J AM SOC NEPHROL, V9, P257; Jacobs C, 1997, NEPHROL DIAL TRANSPL, V12, P38, DOI 10.1093/ndt/12.1.38; KAPLAN AA, 1995, NEW ENGL J MED, V332, P961; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KURTAL H, 1995, ARTIF ORGANS, V19, P391, DOI 10.1111/j.1525-1594.1995.tb02347.x; Liano F, 1996, KIDNEY INT, V50, P811, DOI 10.1038/ki.1996.380; LIEN J, 1985, ARCH INTERN MED, V145, P2067, DOI 10.1001/archinte.145.11.2067; MAHER ER, 1989, Q J MED, V72, P857; MUJAIS S, 1994, LANCET, V344, P1362, DOI 10.1016/S0140-6736(94)90720-X; Mujais S K, 1995, ASAIO J, V41, P137; Neveu H, 1996, NEPHROL DIAL TRANSPL, V11, P293, DOI 10.1093/oxfordjournals.ndt.a027256; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; Shaldon S, 1996, LANCET, V347, P205, DOI 10.1016/S0140-6736(96)90392-X; SPIEGEL DM, 1991, AM J NEPHROL, V11, P44, DOI 10.1159/000168271; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Ward RA, 1997, NEPHROL DIAL TRANSPL, V12, P965, DOI 10.1093/ndt/12.5.965; WOODROW G, 1992, NEPHROL DIAL TRANSPL, V7, P230, DOI 10.1093/oxfordjournals.ndt.a092111	21	102	103	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1337	1341		10.1016/S0140-6736(99)01213-1	http://dx.doi.org/10.1016/S0140-6736(99)01213-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533862				2022-12-28	WOS:000083149900011
J	Dwyer, T; Blizzard, L; Morley, R; Ponsonby, AL				Dwyer, T; Blizzard, L; Morley, R; Ponsonby, AL			Within pair association between birth weight and blood pressure at age 8 in twins for a cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; FETAL GROWTH; ADULT LIFE; CHILDREN; CHILDHOOD; INUTERO; DEATH; WOMEN; RISK	Objectives To study the association between birth weight and blood pressure in children from multiple pregnancies (multiplets), mostly twins, to determine whether maternal or genetic factors are responsible for time association. Design Cohort study. Setting Southern Tasmania. Subjects 888 children including 104 multiplets (32 monozygotic, 72 dizygotic). Main outcome measure Systolic blood pressure (mm Hg). Results Blood pressure decreased with birth weight and increased with current body mass. After adjustment for age and body mass, systolic blood pressure changed by -1.94 mm Hg (95% confidence interval -2.89 to -0.98) per 1 kg increase in birth weighs of singletons; For multiplets, blood pressure changed by -7.0 mm Hg (-10.1 to -3.9) for each 1 kg increase in birth weight This was little altered in within pair analyses (-5.3, -13.8 to 3.2) and was similar fur both monozygotic (-6.5, -22.5 to 9.4) and dizygotic (-4.9, - 15.8 to 6.0) pairs. Conclusion Because the association between birth weight and blood pressure was largely unchanged in within pair analyses, exposures originating in the mother (such as nutritional status) cannot be wholly responsible. The association also remained within monozygotic pairs, suggesting that genetic predisposition is not wholly responsible either. The principal causal pathway must concern mechanisms within the fetoplacental unit. The stronger association in multiplets suggests that factors adversely influencing both blood pressure and birth weight are more prevalent in multiple pregnancies.	Univ Tasmania, Menzies Ctr Populat Hlth Res, Hobart, Tas 7001, Australia; Univ Melbourne, Clin Epidemiol & Biostat Unit, Dept Pediat, Royal Childrens Hosp, Melbourne, Vic, Australia; Univ Sydney, Acad Unit Gen Practice & Community Care, Canberra Clin Sch, Canberra, ACT, Australia	University of Tasmania; Royal Children's Hospital Melbourne; University of Melbourne; University of Sydney	Dwyer, T (corresponding author), Univ Tasmania, Menzies Ctr Populat Hlth Res, Hobart, Tas 7001, Australia.	T.Dwyer@utas.edu.au	Ponsonby, Anne-Louise/AAE-4351-2019	Ponsonby, Anne-Louise/0000-0002-6581-3657	NICHD NIH HHS [R01 HD028979, HD28979-01A1] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028979] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V30, P1111; Beeby PJ, 1996, J PAEDIATR CHILD H, V32, P512, DOI 10.1111/j.1440-1754.1996.tb00965.x; d'Espaignet E T, 1990, Paediatr Perinat Epidemiol, V4, P422, DOI 10.1111/j.1365-3016.1990.tb00670.x; Dwyer T, 1996, INT J OBESITY, V20, P472; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; Hales CN, 1997, BRIT MED BULL, V53, P109; Hofman PL, 1997, J CLIN ENDOCR METAB, V82, P402, DOI 10.1210/jc.82.2.402; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Langley-Evans SC, 1998, NUTRITION, V14, P39, DOI 10.1016/S0899-9007(97)00391-2; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; Lucas A, 1998, J NUTR, V128, p401S, DOI 10.1093/jn/128.2.401S; Moore VM, 1996, ARCH DIS CHILD, V74, P538, DOI 10.1136/adc.74.6.538; Phillips DIW, 1996, DIABETOLOGIA, V39, P1119; Poulsen P, 1997, DIABETOLOGIA, V40, P439, DOI 10.1007/s001250050698; Taylor SJC, 1997, BRIT MED J, V314, P475, DOI 10.1136/bmj.314.7079.475; WHINCUP P, 1995, BRIT MED J, V311, P773, DOI 10.1136/bmj.311.7008.773; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; Woelk G, 1998, ARCH DIS CHILD-FETAL, V79, pF119, DOI 10.1136/fn.79.2.F119; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x	24	85	85	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	1999	319	7221					1325	1329		10.1136/bmj.319.7221.1325	http://dx.doi.org/10.1136/bmj.319.7221.1325			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567134	Bronze, Green Published			2022-12-28	WOS:000083930200021
J	Rigas, B; Feretis, C; Papavassiliou, ED				Rigas, B; Feretis, C; Papavassiliou, ED			John Lykoudis: an unappreciated discoverer of the cause and treatment of peptic ulcer disease	LANCET			English	Biographical-Item									Rockefeller Univ, New York, NY 10021 USA; Hygela Hosp, Athens, Greece; NIMTS Hosp, Athens, Greece	Rockefeller University; Hygeia Hospital	Rigas, B (corresponding author), Rockefeller Univ, Box 330,1230 York Ave, New York, NY 10021 USA.								0	14	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	1999	354	9190					1634	1635		10.1016/S0140-6736(99)06034-1	http://dx.doi.org/10.1016/S0140-6736(99)06034-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560691				2022-12-28	WOS:000083551000045
J	Belovsky, GE; Mellison, C; Larson, C; Van Zandt, PA				Belovsky, GE; Mellison, C; Larson, C; Van Zandt, PA			Experimental studies of extinction dynamics	SCIENCE			English	Article							PERSISTENCE; POPULATIONS	Extinction of populations occurs naturally, but global extinction rates are accelerating, making understanding extinction a high priority for conservation. Extinction in experimental populations of brine shrimp (Artemia franciscana) was measured to assess hypothesized extinction processes. Greater initial population size, greater maximum population size supported by the environment, and Lower variation in environmental conditions reduced the Likelihood of extinction, as hypothesized. However, initial population size was less important, and maximum population size and environmental variation were more important than often hypothesized. Unexpectedly, deterministic oscillations in population size due to inherent nonlinear dynamics and overcrowding were as important or more important than hypothesized processes.	Utah State Univ, Dept Fisheries & Wildlife, Logan, UT 84321 USA; Utah State Univ, Ctr Ecol, Logan, UT 84321 USA	Utah System of Higher Education; Utah State University; Utah System of Higher Education; Utah State University	Belovsky, GE (corresponding author), Utah State Univ, Dept Fisheries & Wildlife, Logan, UT 84321 USA.		Belovsky, Gary/C-1255-2014	Larson, Chad/0000-0002-0329-8979				[Anonymous], 1991, EXTINCTION BAD GENES; Beissinger SR, 1998, J WILDLIFE MANAGE, V62, P821, DOI 10.2307/3802534; BERRYMAN AA, 1989, TRENDS ECOL EVOL, V4, P26, DOI 10.1016/0169-5347(89)90014-1; BROWN JH, 1977, ECOLOGY, V58, P445, DOI 10.2307/1935620; CAUGHLEY G, 1994, J ANIM ECOL, V63, P215, DOI 10.2307/5542; Caughley G., 1995, CONSERVATION BIOL TH; Diamond J.M., 1984, P191; Ewens W.J., 1987, P59, DOI 10.1017/CBO9780511623400.005; Goodman D., 1987, P11, DOI 10.1017/CBO9780511623400.003; Heath H, 1924, J MORPHOL, V38, P453, DOI 10.1002/jmor.1050380402; LEIGH EG, 1981, J THEOR BIOL, V90, P213; Lovejoy T.E., 1986, P257; MAC ARTHUR ROBERT H., 1967; MANGEL M, 1993, P NATL ACAD SCI USA, V90, P1083, DOI 10.1073/pnas.90.3.1083; Pimm S.L., 1989, P287; PIMM SL, 1988, AM NAT, V132, P757, DOI 10.1086/284889; Renshaw E., 1993, MODELLING BIOL POPUL; RICHTERDYN N, 1972, THEOR POPUL BIOL, V3, P406, DOI 10.1016/0040-5809(72)90014-7; Shaffer M., 1987, P69, DOI 10.1017/CBO9780511623400.006; Soule M.E., 1987, VIABLE POPULATIONS C, P1; STACEY PB, 1992, ECOL APPL, V2, P18, DOI 10.2307/1941886; TRACY CR, 1992, AM NAT, V139, P102, DOI 10.1086/285315; VANZANDT PA, 1997, THESIS UTAH STATE U	23	87	92	3	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1175	1177		10.1126/science.286.5442.1175	http://dx.doi.org/10.1126/science.286.5442.1175			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550058				2022-12-28	WOS:000083534200048
J	Cortez, D; Wang, Y; Qin, J; Elledge, SJ				Cortez, D; Wang, Y; Qin, J; Elledge, SJ			Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks	SCIENCE			English	Article							SUSCEPTIBILITY GENE BRCA2; ATAXIA-TELANGIECTASIA; CELL-CYCLE; IONIZING-RADIATION; NUCLEAR PHOSPHOPROTEIN; GEL-ELECTROPHORESIS; TARGETED DISRUPTION; GAMMA-IRRADIATION; MEIOTIC CELLS; C-ABL	The Brca1 (breast cancer gene 1) tumor suppressor protein is phosphorylated in response to DNA damage, Results from this study indicate that the checkpoint protein kinase ATM (mutated in ataxia telangiectasia) was required for phosphorylation of Brca1 in response to ionizing radiation. ATM resides in a complex with Brca1 and phosphorylated Brca1 in vivo and in vitro in a region that contains clusters of serine-glutamine residues. Phosphorylation of this domain appears to be functionally important because a mutated Brca1 protein lacking two phosphorylation sires failed to rescue the radiation hypersensitivity of a Brca1-deficient cell line. Thus, phosphorylation of Brca1 by the checkpoint kinase ATM may be critical for proper responses to DNA double-strand breaks and may provide a molecular explanation far the role of ATM in breast cancer.	Baylor Coll Med, Verna & Mars McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	Elledge, SJ (corresponding author), Baylor Coll Med, Verna & Mars McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044664, R01GM044664] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44664] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; BLOCHER D, 1991, INT J RADIAT BIOL, V60, P791, DOI 10.1080/09553009114552601; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen YM, 1996, CANCER RES, V56, P3168; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; CORTEZ D, UNPUB; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Goggins M, 1996, CANCER RES, V56, P5360; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Janin N, 1999, BRIT J CANCER, V80, P1042, DOI 10.1038/sj.bjc.6690460; Johnson RT, 1999, BIOCHEM BIOPH RES CO, V261, P317, DOI 10.1006/bbrc.1999.1024; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MAYNAHAN ME, IN PRESS MOL CELL; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vaughn JP, 1996, CANCER RES, V56, P4590; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	52	815	841	0	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1162	1166		10.1126/science.286.5442.1162	http://dx.doi.org/10.1126/science.286.5442.1162			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550055				2022-12-28	WOS:000083534200045
J	Schnitzler, MA; Hollenbeak, CS; Cohen, DS; Woodward, RS; Lowell, JA; Singer, GG; Tesi, RJ; Howard, TK; Mohanakumar, T; Brennan, DC				Schnitzler, MA; Hollenbeak, CS; Cohen, DS; Woodward, RS; Lowell, JA; Singer, GG; Tesi, RJ; Howard, TK; Mohanakumar, T; Brennan, DC			The economic implications of HLA matching in cadaveric renal transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KIDNEY-TRANSPLANTS; ALLOCATION; SURVIVAL; IMPACT	Background The potential economic effects of the allocation of cadaveric kidneys on the basis of tissue-matching criteria are controversial. We analyzed the economic costs associated with the transplantation of cadaveric kidneys with various numbers of HLA mismatches and examined the potential economic benefits of a local, as compared with a national, system designed to minimize HLA mismatches between donor and recipient in first cadaveric renal transplantations. Methods All data were supplied by the U.S. Renal Data System. Data on all payments made by Medicare from 1991 through 1997 for the care of recipients of a first cadaveric renal transplant were analyzed according to the number of HLA-A, B, and DR mismatches between donor and recipient and the duration of cold ischemia before transplantation. Results Average Medicare payments for renal-transplant recipients in the three years after transplantation increased from $60,436 per patient for fully HLA-matched kidneys (those with no HLA-A, B, or DR mismatches) to $80,807 for kidneys with six HLA mismatches between donor and recipient, a difference of 34 percent (P<0.001). By three years after transplantation, the average Medicare payments were $64,119 for transplantations of kidneys with less than 12 hours of cold-ischemia time and $74,997 for those with more than 36 hours (P<0.001). In simulations, the assignment of cadaveric kidneys to recipients by a method that minimized HLA mismatching within a local geographic area (i.e., within one of the approximately 50 organ-procurement organizations, which cover widely varying geographic areas) produced the largest cost savings ($4,290 per patient over a period of three years) and the largest improvements in the graft-survival rate (2.3 percent) when the potential costs of longer cold-ischemia time were considered. Conclusions Transplantation of better-matched cadaveric kidneys could have substantial economic advantages. In our simulations, HLA-based allocation of kidneys at the local level produced the largest estimated cost savings, when the duration of cold ischemia was taken into account. No additional savings were estimated to result from a national allocation program, because the additional costs of longer cold-ischemia time were greater than the advantages of optimizing HLA matching. (N Engl J Med 1999;341:1440-6.) (C)1999, Massachusetts Medical Society.	Washington Univ, Sch Med, Hlth Adm Program, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; SangStat Med Corp, Menlo Park, CA USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Schnitzler, MA (corresponding author), Washington Univ, Sch Med, Hlth Adm Program, 4547 Clayton Ave, St Louis, MO 63110 USA.		Hollenbeak, Christopher S./A-5309-2019	Hollenbeak, Christopher S./0000-0002-3362-814X				[Anonymous], 1982, JACKKNIFE BOOTSTRAP; GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; GJERTSON DW, 1991, NEW ENGL J MED, V324, P1032, DOI 10.1056/NEJM199104113241505; HELD PJ, 1994, NEW ENGL J MED, V331, P765, DOI 10.1056/NEJM199409223311203; Hollander M., 2014, NONPARAMETRIC STAT M, V3rd ed.; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; *NAT I DIAB DIG KI, 1999, USRDS 1999 ANN REP; *NAT I DIAB DIG KI, 1998, RES GUID USRDS DAT; TAKEMOTO S, 1992, NEW ENGL J MED, V327, P834, DOI 10.1056/NEJM199209173271202; TAKEMOTO S, 1994, CLIN TRANSPLANTS 199, P521; *UN NETW ORG SHAR, 1997, 1997 ANN REP US SCI	11	43	45	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1999	341	19					1440	1446		10.1056/NEJM199911043411906	http://dx.doi.org/10.1056/NEJM199911043411906			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XR	10547408	Bronze, Green Published			2022-12-28	WOS:000083472100006
J	Gabolde, M; Guilloud-Bataille, M; Feingold, J; Besmond, C				Gabolde, M; Guilloud-Bataille, M; Feingold, J; Besmond, C			Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study	BRITISH MEDICAL JOURNAL			English	Article									Hop Robert Debre, INSERM, U458, F-75019 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Besmond, C (corresponding author), Hop Robert Debre, INSERM, U458, F-75019 Paris, France.		BESMOND, Claude/L-8451-2018	BESMOND, Claude/0000-0001-9073-8225				Gabolde M, 1999, HUM MUTAT, V14, P80, DOI 10.1002/(SICI)1098-1004(1999)14:1<80::AID-HUMU10>3.0.CO;2-J; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; Hull J, 1998, THORAX, V53, P1018, DOI 10.1136/thx.53.12.1018; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8	5	79	79	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1166	1167		10.1136/bmj.319.7218.1166	http://dx.doi.org/10.1136/bmj.319.7218.1166			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541506	Green Published, Bronze			2022-12-28	WOS:000083536200022
J	Chinnery, NJ; Pawley, AR; Clark, SM				Chinnery, NJ; Pawley, AR; Clark, SM			In situ observation of the formation of 10 angstrom phase from talc plus H2O at mantle pressures and temperatures	SCIENCE			English	Article							SYSTEM MGO-SIO2-H2O MSH; 10-ANGSTROM PHASE; SUBDUCTION ZONES; STABILITY	Development of an x-ray-transparent capsule that is suitable for water-saturated experiments has allowed the high-pressure and high-temperature synthesis of 10 angstrom phase from talc + H2O to be observed in situ in a multianvil apparatus with synchrotron radiation. The reaction talc + H2O = 10 angstrom phase was observed within 20 minutes at 6 gigapascals and 500 degrees C, The higher pressure vapor-absent reaction talc = 10 angstrom phase + enstatite + coesite was also observed. The 10 angstrom phase is therefore a good candidate for transporting water into Earth's mantle at subduction zones. The in situ technique may allow the hydration of other high-pressure mantle phases to be observed under dynamic conditions.	Univ Manchester, Dept Earth Sci, Manchester M13 9PL, Lancs, England; SERC, Daresbury Lab, Warrington WA4 4AD, Cheshire, England	University of Manchester; STFC Daresbury Laboratory	Pawley, AR (corresponding author), Univ Manchester, Dept Earth Sci, Oxford Rd, Manchester M13 9PL, Lancs, England.		Clark, Simon/B-2041-2013	Clark, Simon/0000-0002-7488-3438				AYERS JC, 1992, AM MINERAL, V77, P1080; BAUER JF, 1981, AM MINERAL, V66, P576; CANNAT M, 1993, J GEOPHYS RES-SOL EA, V98, P4163, DOI 10.1029/92JB02221; CHINNERY NJ, 1999, THESIS U MANCHESTER; Clark SM, 1996, NUCL INSTRUM METH A, V381, P161, DOI 10.1016/0168-9002(96)00679-1; DECKER DL, 1971, J APPL PHYS, V42, P3239, DOI 10.1063/1.1660714; Gill J., 1981, OROGENIC ANDESITES P; Holland TJB, 1998, J METAMORPH GEOL, V16, P309, DOI 10.1111/j.1525-1314.1998.00140.x; Irifune T, 1996, SCIENCE, V272, P1468, DOI 10.1126/science.272.5267.1468; Manning C.E., 1995, INT GEOL REV, V37, P1074, DOI [10.1080/00206819509465440, DOI 10.1080/00206819509465440]; MILLER AK, 1991, AM MINERAL, V76, P106; PAWLEY AR, 1995, AM MINERAL, V80, P998; Pawley AR, 1995, CONTRIB MINERAL PETR, V122, P301, DOI 10.1007/s004100050129; RINGWOOD AE, 1967, EARTH PLANET SC LETT, V2, P130, DOI 10.1016/0012-821X(67)90114-8; WALKER D, 1990, AM MINERAL, V75, P1020; WUNDER B, 1992, J PETROL, V33, P877, DOI 10.1093/petrology/33.4.877; Wunder B, 1997, LITHOS, V41, P213, DOI 10.1016/S0024-4937(97)82013-0; YAMAMOTO K, 1977, AM J SCI, V277, P288, DOI 10.2475/ajs.277.3.288	18	46	47	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					940	942		10.1126/science.286.5441.940	http://dx.doi.org/10.1126/science.286.5441.940			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542144				2022-12-28	WOS:000083368500039
J	Simon, GE; VonKorff, M; Piccinelli, M; Fullerton, C; Ormel, J				Simon, GE; VonKorff, M; Piccinelli, M; Fullerton, C; Ormel, J			An international study of the relation between somatic symptoms and depression	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY-CARE; SOMATOFORM DISORDERS; DIFFERENT CULTURES; SOMATIZATION; SYMPTOMATOLOGY; QUESTIONNAIRE	Background Patients with depression, particularly those seen by primary care physicians, may report somatic symptoms, such as headache, constipation, weakness, or back pain. Some previous studies have suggested that patients in non-Western countries are more likely to report somatic symptoms than are patients in Western countries. Methods We used data from the World Health Organization's study of psychological problems in general health care to examine the relation between somatic symptoms and depression. The study, conducted in 1991 and 1992, screened 25,916 patients at 15 primary care centers in 14 countries on 5 continents. A total of 5447 of the patients underwent a structured assessment of depressive and somatoform disorders. Results A total of 1146 patients (weighted prevalence, 10.1 percent) met the criteria for major depression. The range of patients with depression who reported only somatic symptoms was 45 to 95 percent (overall prevalence, 69 percent; P=0.002 for the comparison among centers). A somatic presentation was more common at centers where patients lacked an ongoing relationship with a primary care physician than at centers where most patients had a personal physician (odds ratio, 1.8; 95 percent confidence interval, 1.2 to 2.7). Half the depressed patients reported multiple unexplained somatic symptoms, and 11 percent denied psychological symptoms of depression on direct questioning. Neither of these proportions varied significantly among the centers. Although the overall prevalence of depressive symptoms varied markedly among the centers, the frequencies of psychological and physical symptoms were similar. Conclusions Somatic symptoms of depression are common in many countries, but their frequency varies depending on how somatization is defined. There is substantial variation in how frequently patients with depression present with strictly somatic symptoms. In part, this variation may reflect characteristics of physicians and health care systems, as well as cultural differences among patients. (N Engl J Med 1999;341:1329-35.) (C) 1999, Massachusetts Medical Society.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Azienda Ospedaliera Osped Circolo & Fdn Macchi, Varese, Italy; Univ Verona, Ist Psichiat, Serv Psicol Med, Dipartimento Med & Sanita Pubbl, I-37100 Verona, Italy; Univ Chile, Dept Psichiat & Salud Mental, Santiago, Chile; Univ Groningen, Dept Psychiat, Groningen, Netherlands; Univ Groningen, Dept Hlth Sci, Groningen, Netherlands; Kings Coll London, Inst Psychiat, London, England	Group Health Cooperative; Ospedale Circolo & Fondazione Macchi; University of Verona; Universidad de Chile; University of Groningen; University of Groningen; University of London; King's College London	Simon, GE (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.	simon.g@ghc.org	Ormel, Johan/C-6094-2013; ormel, johan/AAC-5584-2019	ormel, johan/0000-0002-5463-037X; VonKorff, Michael/0000-0001-5386-8477	NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH047765] Funding Source: NIH RePORTER; NIMH NIH HHS [MH47765] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AHCPR, 1993, AHCPR PUBL, V1; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BARSKY AJ, 1992, PSYCHOSOMATICS, V33, P28, DOI 10.1016/S0033-3182(92)72018-0; BHATT A, 1989, J PSYCHOSOM RES, V33, P671, DOI 10.1016/0022-3999(89)90082-2; BRIDGES KW, 1985, J PSYCHOSOM RES, V29, P563, DOI 10.1016/0022-3999(85)90064-9; CHENG TA, 1989, PSYCHOL MED, V19, P697, DOI 10.1017/S0033291700024296; CHEUNG FM, 1981, INT J PSYCHIAT MED, V10, P361, DOI 10.2190/BVY5-YCCR-CT1V-20FR; Cochran W.G., 2007, SAMPLING TECHNIQUES; EBERT D, 1994, J AFFECT DISORDERS, V32, P253, DOI 10.1016/0165-0327(94)90089-2; ESCOBAR JI, 1983, AM J PSYCHIAT, V140, P47; ESCOBAR JI, 1987, AM J PUBLIC HEALTH, V77, P837, DOI 10.2105/AJPH.77.7.837; GOLDBERG DP, 1988, J PSYCHOSOM RES, V32, P137, DOI 10.1016/0022-3999(88)90048-7; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; JANCA A, 1995, SOC PSYCH PSYCH EPID, V30, P44, DOI 10.1007/BF00784434; KATON W, 1982, AM J MED, V72, P127, DOI 10.1016/0002-9343(82)90599-X; KELLNER R, 1990, J NERV MENT DIS, V178, P150, DOI 10.1097/00005053-199003000-00002; KESSLER LG, 1985, EPIDEMIOLOGIC FIELD; KIRMAYER LJ, 1991, J NERV MENT DIS, V179, P647, DOI 10.1097/00005053-199111000-00001; KLEINMAN A, 1982, CULT MED PSYCHIAT, V6, P117, DOI 10.1007/BF00051427; KLEINMAN AM, 1977, SOC SCI MED, V11, P3, DOI 10.1016/0037-7856(77)90138-X; Kroenke K, 1994, Arch Fam Med, V3, P774; Kroenke K, 1997, ARCH GEN PSYCHIAT, V54, P352; LEFF JP, 1973, BRIT J PSYCHIAT, V123, P299, DOI 10.1192/bjp.123.3.299; LERNER J, 1968, INT J SOC PSYCHIATR, V14, P145, DOI 10.1177/002076406801400209; LESSER IM, 1985, NEW ENGL J MED, V312, P690, DOI 10.1056/NEJM198503143121105; LIPOWSKI ZJ, 1987, PSYCHOTHER PSYCHOSOM, V47, P160, DOI 10.1159/000288013; MARMANIDIS H, 1994, AUST NZ J PSYCHIAT, V28, P274, DOI 10.1080/00048679409075639; MEZZICH JE, 1980, ARCH GEN PSYCHIAT, V37, P818; NEMIAH JC, 1982, PSYCHOTHER PSYCHOSOM, V38, P39, DOI 10.1159/000287612; PFEIFFER W, 1968, TRANSCULT PSYCHIATRY, V5, P121; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; SARTORIUS N, 1993, ARCH GEN PSYCHIAT, V50, P819; Shao J, 1996, STATISTICS, V27, P203, DOI 10.1080/02331889708802523; Simon G, 1996, PSYCHOSOM MED, V58, P481, DOI 10.1097/00006842-199609000-00010; SIMON GE, 1991, AM J PSYCHIAT, V148, P1494; TSENG WS, 1970, INT J SOC PSYCHIATR, V16, P5, DOI 10.1177/002076407001600101; ULUSAHIN A, 1994, SOC PSYCH PSYCH EPID, V29, P31; *UN DEV PROGR, 1992, HUM DEV REP 1992; USTUN TB, 1995, MENTAL ILLNESS GEN H, P347; USTUN TB, 1995, MENTAL ILLNESS GEN H; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; [No title captured]	42	820	858	0	78	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1329	1335		10.1056/NEJM199910283411801	http://dx.doi.org/10.1056/NEJM199910283411801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	249XE	10536124				2022-12-28	WOS:000083357800001
J	Yan, J; Magnasco, MO; Marko, JF				Yan, J; Magnasco, MO; Marko, JF			A kinetic proofreading mechanism for disentanglement of DNA by topoisomerases	NATURE			English	Article							STEADY-STATE ANALYSIS; ESCHERICHIA-COLI; ATP HYDROLYSIS; DOUBLE HELIX; TRANSPORT; TOPOLOGY	Cells must remove all entanglements between their replicated chromosomal DNAs to segregate them during cell division. Entanglement removal is done by ATP-driven enzymes that pass DNA strands through one another, called type II topoisomerases. In vitro, some type II topoisomerases can reduce entanglements much more than expected, given the assumption that they pass DNA segments through one another in a random way(1). These type II topoisomerases (of less than 10 nm in diameter) thus use ATP hydrolysis to sense and remove entanglements spread along flexible DNA strands of up to 3,000 nm long. Here we propose a mechanism for this, based on the higher rate of collisions along entangled DNA strands, relative to collision rates on disentangled DNA strands. We show theoretically that if a type II topoisomerase requires an initial 'activating' collision before a second strand-passing collision, the probability of entanglement may be reduced to experimentally observed levels. This proposed two-collision reaction is similar to 'kinetic proofreading' models of molecular recognition(2,3).	Univ Illinois, Dept Phys, Chicago, IL 60607 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rockefeller University	Marko, JF (corresponding author), Univ Illinois, Dept Phys, 845 W Taylor St, Chicago, IL 60607 USA.		Marko, John F./AAY-7111-2021; Yan, Jie/G-2725-2012	Marko, John F./0000-0003-4151-9530; Yan, Jie/0000-0002-8555-7291				DEGUCHI T, 1994, J KNOT THEOR RAMIF, V3, P321; FRANKKAMENETSKII MD, 1975, NATURE, V258, P398, DOI 10.1038/258398a0; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; KLENIN KV, 1988, J BIOMOL STRUCT DYN, V5, P1173, DOI 10.1080/07391102.1988.10506462; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; RYBENKOV VV, 1993, P NATL ACAD SCI USA, V90, P5307, DOI 10.1073/pnas.90.11.5307; Rybenkov VV, 1997, SCIENCE, V277, P690, DOI 10.1126/science.277.5326.690; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SINDEN RR, 1981, P NATL ACAD SCI-BIOL, V78, P224, DOI 10.1073/pnas.78.1.224; Vologodskii A, 1998, P 2 ANN INT C COMP M, P266; WORCEL A, 1972, J MOL BIOL, V71, P127, DOI 10.1016/0022-2836(72)90342-7	16	97	97	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	1999	401	6756					932	935		10.1038/44872	http://dx.doi.org/10.1038/44872			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553912				2022-12-28	WOS:000083464700064
J	Friedberg, M; Saffran, B; Stinson, TJ; Nelson, W; Bennett, CL				Friedberg, M; Saffran, B; Stinson, TJ; Nelson, W; Bennett, CL			Evaluation of conflict of interest in economic analyses of new drugs used in oncology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; COST-EFFECTIVENESS ANALYSIS; ADVANCED OVARIAN-CANCER; CELL LUNG-CANCER; PLACEBO-CONTROLLED TRIAL; BLOOD PROGENITOR CELLS; NON-HODGKINS-LYMPHOMA; FIRST-LINE THERAPY; FACTOR GM-CSF	Context Recent studies have found that when investigators have financial relationships with pharmaceutical or product manufacturers, they are less likely to criticize the safety or efficacy of these agents. The effects of health economics research on pharmaceutical company revenue make drug investigations potentially vulnerable to this bias. Objective To determine whether there is an association between pharmaceutical industry sponsorship and economic assessment of oncology drugs. Design MEDLINE and HealthSTAR databases (1988-1998) were searched for original English-language research articles of cost or cost-effectiveness analyses of 6 oncology drugs in 3 new drug categories (hematopoietic colony-stimulating factors, serotonin antagonist antiemetics, and taxanes), yielding 44 eligible articles. Two investigators independently abstracted each article based on specific criteria. Main Outcome Measure Relationships between funding source and (1) qualitative cost assessment (favorable, neutral, or unfavorable) and (2) qualitative conclusions that overstated quantitative results. Results Pharmaceutical company-sponsored studies were less likely than nonprofit-sponsored studies to report unfavorable qualitative conclusions (1/20 [5%] vs 9/24 [38%]; P = .04), whereas overstatements of quantitative results were not significantly different in pharmaceutical company-sponsored (6/20 [30%]) vs nonprofit-sponsored (3/24 [13%]) studies (P = .26). Conclusions Although we did riot identify bias in individual studies, these findings indicate that pharmaceutical company sponsorship of economic analyses is associated with reduced likelihood of reporting unfavorable results.	Lakeside Vet Adm Med Ctr, Chicago, IL 60611 USA; Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Evanston, IL USA; Northwestern Univ, Div Hematol Oncol, Evanston, IL USA; Swarthmore Coll, Dept Econ, Swarthmore, PA USA	Northwestern University; Northwestern University; Swarthmore College	Bennett, CL (corresponding author), Lakeside Vet Adm Med Ctr, 400 E Ontario Ave, Chicago, IL 60611 USA.	cbenne@nwu.edu	Friedberg, Mark William/Y-2607-2019; Bennett, Charles L/C-2050-2008	Friedberg, Mark William/0000-0002-7907-8358; 				Azimi NA, 1998, J GEN INTERN MED, V13, P664, DOI 10.1046/j.1525-1497.1998.00201.x; BALLATORI E, 1994, PHARMACOECONOMICS, V5, P227, DOI 10.2165/00019053-199405030-00006; Barnes DE, 1998, JAMA-J AM MED ASSOC, V279, P1566, DOI 10.1001/jama.279.19.1566; BENNETT CL, 1995, STEM CELLS, V13, P414, DOI 10.1002/stem.5530130412; Bennett CL, 1997, CANCER INVEST, V15, P227, DOI 10.3109/07357909709039720; BENNETT CL, 1995, J CLIN ONCOL, V13, P2457, DOI 10.1200/JCO.1995.13.9.2457; Bernini JC, 1996, J PEDIATR-US, V129, P551, DOI 10.1016/S0022-3476(96)70120-8; BLEIBERG H, 1994, SUPPORT CARE CANCER, V2, P145, DOI 10.1007/BF00417472; BRICE P, 1995, PHARMACOECONOMICS, V7, P238, DOI 10.2165/00019053-199507030-00007; BUXTON MJ, 1992, BRIT J CANCER, V66, pS64; Callaham ML, 1998, JAMA-J AM MED ASSOC, V280, P254, DOI 10.1001/jama.280.3.254; CHAO NJ, 1993, BLOOD, V81, P2031; Chouaid C, 1998, J CLIN ONCOL, V16, P2700, DOI 10.1200/JCO.1998.16.8.2700; Cieslak GD, 1996, ANESTHESIOLOGY, V85, P1076, DOI 10.1097/00000542-199611000-00016; CLARK RE, 1994, LEUKEMIA LYMPHOMA, V16, P141, DOI 10.3109/10428199409114151; Covens A, 1996, CANCER, V77, P2086, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2086::AID-CNCR18>3.0.CO;2-R; CUNNINGHAM D, 1993, EUR J CANCER, V29A, P303, DOI 10.1016/0959-8049(93)90372-M; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; Dranitsaris G, 1997, PHARMACOECONOMICS, V11, P566, DOI 10.2165/00019053-199711060-00005; DRANITSARIS G, 1995, LEUKEMIA LYMPHOMA, V17, P139, DOI 10.3109/10428199509051714; DRUMMOND M, 1994, PHARMACOECONOMICS, V6, P42, DOI 10.2165/00019053-199400061-00012; Duncan N, 1997, PHARMACOECONOMICS, V11, P169, DOI 10.2165/00019053-199711020-00006; DUNLOP DJ, 1994, BRIT J CANCER, V70, P943, DOI 10.1038/bjc.1994.425; Edwards G, 1998, BRIT MED J, V317, P336; Eichenwald Kurt, 1999, N Y Times Web, pA16; Eichenwald Kurt, 1999, N Y Times Web, P34; Elit LM, 1997, J CLIN ONCOL, V15, P632, DOI 10.1200/JCO.1997.15.2.632; ELKS ML, 1995, J LAB CLIN MED, V126, P19; FAUCHER C, 1994, BONE MARROW TRANSPL, V14, P895; GLASPY JA, 1993, EUR J CANCER, V29A, pS23, DOI 10.1016/0959-8049(93)90613-K; GULATI S, 1993, STEM CELLS, V11, P20, DOI 10.1002/stem.5530110105; GULATI S, 1993, ANTI-CANCER DRUG, V4, P13, DOI 10.1097/00001813-199305001-00003; GULATI SC, 1992, ANN INTERN MED, V116, P177, DOI 10.7326/0003-4819-116-3-177; GULATI SC, 1995, J CLIN ONCOL, V13, P2152, DOI 10.1200/JCO.1995.13.9.2152; HILLMAN AL, 1995, ANN INTERN MED, V123, P61; Jefferson T, 1998, JAMA-J AM MED ASSOC, V280, P275, DOI 10.1001/jama.280.3.275; Johnson N E, 1993, Pharmacoeconomics, V3, P471, DOI 10.2165/00019053-199303060-00007; Krimsky S, 1998, JAMA-J AM MED ASSOC, V280, P225, DOI 10.1001/jama.280.3.225; LUCE BR, 1994, PHARMACOECONOMICS, V6, P42, DOI 10.2165/00019053-199406010-00005; Lyman G H, 1995, Oncology (Williston Park), V9, P85; LYMAN GH, 1995, JNCI-J NATL CANCER I, V85, P488; Mapelli V, 1994, Pharmacoeconomics, V6 Suppl 2, P27; McGuire W, 1997, J CLIN ONCOL, V15, P640, DOI 10.1200/JCO.1997.15.2.640; McQuaker IG, 1997, J CLIN ONCOL, V15, P451, DOI 10.1200/JCO.1997.15.2.451; Messori A, 1996, CANCER, V78, P2366, DOI 10.1002/(SICI)1097-0142(19961201)78:11<2366::AID-CNCR15>3.3.CO;2-R; Messori A, 1996, J CLIN PHARM THER, V21, P57, DOI 10.1111/j.1365-2710.1996.tb00001.x; Mitchell PLR, 1997, J CLIN ONCOL, V15, P1163, DOI 10.1200/JCO.1997.15.3.1163; NICHOLS CR, 1994, J CLIN ONCOL, V12, P1245, DOI 10.1200/JCO.1994.12.6.1245; Ortega A, 1997, GYNECOL ONCOL, V66, P454, DOI 10.1006/gyno.1997.4786; PEROUTKA JA, 1995, FORMULARY, V30, P394; Pui CH, 1997, NEW ENGL J MED, V336, P1781, DOI 10.1056/NEJM199706193362503; RIIKONEN P, 1995, STEM CELLS, V13, P289, DOI 10.1002/stem.5530130310; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; Rundall P, 1998, BRIT MED J, V317, P338; Smith R, 1998, BMJ-BRIT MED J, V317, P291, DOI 10.1136/bmj.317.7154.291; SMITH TJ, 1993, JNCI-J NATL CANCER I, V85, P1460, DOI 10.1093/jnci/85.18.1460; Sorell T, 1998, BRIT MED J, V317, P334; Souetre E, 1996, EUR J CANCER, V32A, P1162, DOI 10.1016/0959-8049(95)00655-9; Splinter WM, 1997, CAN J ANAESTH, V44, P825, DOI 10.1007/BF03013158; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; Tang J, 1996, ANESTH ANALG, V83, P304, DOI 10.1097/00000539-199608000-00018; TANNEBERGER S, 1992, J CHEMOTHERAPY, V4, P326; Teoh G. K. H., 1994, Annals Academy of Medicine Singapore, V23, P823; UYLDEGROOT CA, 1994, EUR J CANCER, V30A, P1631; Vellenga E, 1996, J CLIN ONCOL, V14, P619, DOI 10.1200/JCO.1996.14.2.619; WATCHA MF, 1994, J CLIN ANESTH, V6, P370, DOI 10.1016/S0952-8180(05)80006-6; ZAGONEL V, 1994, ANN ONCOL, V5, pS127, DOI 10.1093/annonc/5.suppl_2.S127; ZBROZEK AS, 1994, AM J HOSP PHARM, V51, P1555, DOI 10.1093/ajhp/51.12.1555	68	311	320	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1453	1457		10.1001/jama.282.15.1453	http://dx.doi.org/10.1001/jama.282.15.1453			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535436	Bronze			2022-12-28	WOS:000083111000031
J	Eshed, Y; Baum, SF; Bowman, JL				Eshed, Y; Baum, SF; Bowman, JL			Distinct mechanisms promote polarity establishment in carpels of Arabidopsis	CELL			English	Article							HISTONE DEACETYLASE; OVULE DEVELOPMENT; GENE; THALIANA; PROTEINS; FAMILY; AINTEGUMENTA; PLANTS; MEMBER	Lateral organs of plants display asymmetry with abaxial identity being specified by members of the Arabidopsis YABBY gene family. Mutations in CRABS CLAW, the founding family member, display ectopic formation of adaxial carpel tissues only when the functions of other genes, such as GYMNOS or KANADI, are also compromised. Mutations in these genes alone do not result in loss of polar differentiation, and therefore, they act redundantly with CRABS CLAW to establish polarity. As GYMNOS encodes a uniformly expressed homolog of the chromatin-remodeling protein, Mi2, we argue that the unique genetic interactions do not reflect a molecular redundancy. Rather, CRABS CLAW regulates transcription spatially, whereas GYMNOS regulates downstream targets temporally to ensure proper differentiation of the carpels.	Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA	University of California System; University of California Davis	Bowman, JL (corresponding author), Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA.	jlbowman@ucdavis.edu	Bowman, John P./ABF-5108-2020	Bowman, John P./0000-0002-4528-9333; Eshed, Yuval/0000-0001-8290-0018; Bowman, John/0000-0001-7347-3691				Alvarez J, 1999, DEVELOPMENT, V126, P2377; Baker SC, 1997, GENETICS, V145, P1109; Baum SF, 1996, PROTOPLASMA, V192, P178, DOI 10.1007/BF01273890; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; Bowman JL, 1999, CURR TOP DEV BIOL, V45, P155, DOI 10.1016/S0070-2153(08)60316-6; Bowman JL, 1999, DEVELOPMENT, V126, P2387; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Elliott RC, 1996, PLANT CELL, V8, P155, DOI 10.1105/tpc.8.2.155; ESTRUCH JJ, 1991, SCIENCE, V254, P1364, DOI 10.1126/science.254.5036.1364; Grossniklaus U, 1998, SCIENCE, V280, P446, DOI 10.1126/science.280.5362.446; HAKE S, 1995, PHILOS T R SOC B, V350, P45, DOI 10.1098/rstb.1995.0136; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Klucher KM, 1996, PLANT CELL, V8, P137, DOI 10.1105/tpc.8.2.137; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; McConnell JR, 1998, DEVELOPMENT, V125, P2935; Ogas J, 1997, SCIENCE, V277, P91, DOI 10.1126/science.277.5322.91; Ori N, 1999, PLANT CELL, V11, P1073, DOI 10.1105/tpc.11.6.1073; Pearse A.G.E., 1985, ANAL TECHNOLOGY, V2, P748; Riou-Khamlichi C, 1999, SCIENCE, V283, P1541, DOI 10.1126/science.283.5407.1541; Sawa S, 1999, GENE DEV, V13, P1079, DOI 10.1101/gad.13.9.1079; Sessions A, 1999, GENE DEV, V13, P1051, DOI 10.1101/gad.13.9.1051; SESSIONS RA, 1995, DEVELOPMENT, V121, P1519; Siegfried KR, 1999, DEVELOPMENT, V126, P4117; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SUSSEX I. M., 1955, PHYTOMORPHOLOGY [DELHI], V5, P286; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	31	286	301	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	1999	99	2					199	209		10.1016/S0092-8674(00)81651-7	http://dx.doi.org/10.1016/S0092-8674(00)81651-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535738	Bronze			2022-12-28	WOS:000083159700010
J	Gottlieb, S				Gottlieb, S			Medical societies accused of being beholden to the drugs industry	BRITISH MEDICAL JOURNAL			English	News Item																		Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; 1999, W J MED, V171, P234	2	3	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1321	1321		10.1136/bmj.319.7221.1321	http://dx.doi.org/10.1136/bmj.319.7221.1321			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567123	Green Published			2022-12-28	WOS:000083930200010
J	Poulter, NR; Chang, CL; MacGregor, AJ; Snieder, H; Spector, TD				Poulter, NR; Chang, CL; MacGregor, AJ; Snieder, H; Spector, TD			Association between birthweight and adult blood pressure in twins: historical cohort study	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; IN-UTERO; HYPERTENSION; HYPOTHESIS; MORTALITY; INFANCY; LIFE; AGE	Objectives To evaluate the associations in twins between within pair differences in birth weight and subsequent blood pressures as adults thereby removing the impact of potential parental confounding variables. Design Historical cohort study. Setting St Thomas's UR adult twin register, June 1992 to September 1995. Participants 492 pairs of female twins (mean age 54 years). Main outcome measures Mean within pair differences in adult blood pressure in each of four strata of within pair differences in birth weight (0, 1-500 g, 501-1000 g, > 1000 g). Differences in blood pressure were analysed before and after adjustment for potential confounders between adult twins, after exclusion of those twin pairs including at least one twin taking antihypertensive drugs, and by zygosity. Results Reported mean birth weights of heavier and lighter twins were 2.51 (SD 0.61) v 2.12 (0.59) kg respectively A graded inverse relation between strata of within pair differences in birth weight and differences in adult blood pressure was apparent, with an adjusted blood pressure range of 8.7/5.1 mm Hg across the four strata (test for trend: systolic, P = 0.05; diastolic, P = 0.09). After excluding those women taking antihypertensive drugs the significance of the association was similar (systolic, P = 0.04; diastolic, P = 0.10). When differences in blood pressure were stratified for zygosity similar but non-significant trends were apparent. Conclusion It would seem that birth weight is inversely associated with adult blood pressure and that this association is independent of parental confounding variables probably including, in view of the findings in monozygotic twins, genetic factors. The observed blood pressure differences are likely to result from retarded intrauterine growth due to placental dysfunction rather than inadequate maternal nutrition.	Imperial Coll Sch Med, Cardiovasc Studies Unit, Dept Clin Pharmacol, London W2 1PG, England; St Thomas Hosp, Guys & St Thomass Hosp Trust, Twin Res & Genet Epidemiol Unit, London SE1 7EH, England	Imperial College London; Guy's & St Thomas' NHS Foundation Trust	Poulter, NR (corresponding author), Imperial Coll Sch Med, Cardiovasc Studies Unit, Dept Clin Pharmacol, St Marys Campus, London W2 1PG, England.		Spector, Tim D/F-6533-2012	MacGregor, Alex/0000-0003-2163-2325	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AELSSON G, 1984, INT J EPIDEMIOL, V13, P94; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Boomsma D I, 1998, Twin Res, V1, P34, DOI 10.1375/136905298320566465; BRENNER BM, 1994, AM J KIDNEY DIS, V23, P171, DOI 10.1016/S0272-6386(12)80967-X; CHRISTENSEN K, 1995, BRIT MED J, V310, P432, DOI 10.1136/bmj.310.6977.432; Colhoun HM, 1998, J HYPERTENS, V16, P747, DOI 10.1097/00004872-199816060-00005; Hashimoto N, 1996, ACTA PAEDIATR, V85, P132, DOI 10.1111/j.1651-2227.1996.tb13978.x; Koupilova I, 1997, J EPIDEMIOL COMMUN H, V51, P14, DOI 10.1136/jech.51.1.14; Law CM, 1996, J HYPERTENS, V14, P935; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LAW CM, 1991, J HYPERTENS, V303, P1019; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; LITTLE RE, 1986, AM J PUBLIC HEALTH, V76, P1350, DOI 10.2105/AJPH.76.11.1350; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MARTYN CN, 1995, BRIT HEART J, V73, P116; MATTHES JWA, 1994, BMJ-BRIT MED J, V308, P1074, DOI 10.1136/bmj.308.6936.1074; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; Spector TD, 1996, BRIT MED J, V312, P940; Troy LM, 1996, INT J EPIDEMIOL, V25, P122, DOI 10.1093/ije/25.1.122; Vancheri F, 1995, G Ital Cardiol, V25, P833; Walker BR, 1998, BRIT MED J, V316, P834, DOI 10.1136/bmj.316.7134.834; WHITE IR, 1994, STAT MED, V13, P1635, DOI 10.1002/sim.4780131604; Williams S, 1999, BRIT MED J, V318, P897, DOI 10.1136/bmj.318.7188.897; Zureik M, 1996, HYPERTENSION, V27, P339, DOI 10.1161/01.HYP.27.3.339	25	102	102	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1330	1333		10.1136/bmj.319.7221.1330	http://dx.doi.org/10.1136/bmj.319.7221.1330			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567135	Bronze, Green Published			2022-12-28	WOS:000083930200022
J	Vickers, A; Zollman, C				Vickers, A; Zollman, C			ABC of complementary medicine - Hypnosis and relaxation therapies	BRITISH MEDICAL JOURNAL			English	Review																		KARLE H, 1996, HYPNOTHERAPY PRACTIC; SIEGEL B, 1989, LOVE MED MIRACLES; WAXMAN D, 1988, MED DENTAL HYPNOSIS	3	31	31	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1346	1349		10.1136/bmj.319.7221.1346	http://dx.doi.org/10.1136/bmj.319.7221.1346			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567143	Green Published			2022-12-28	WOS:000083930200028
J	Yamey, G				Yamey, G			Government launches green paper on mental health	BRITISH MEDICAL JOURNAL			English	News Item																		Taylor PJ, 1999, BRIT J PSYCHIAT, V174, P9, DOI 10.1192/bjp.174.1.9; 1999, BRIT MED J, V319, P1146	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1322	1322						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	260CF	10567125	Green Accepted, Green Published			2022-12-28	WOS:000083930200012
J	Smilenov, LB; Mikhailov, A; Pelham, RJ; Marcantonio, EE; Gundersen, GG				Smilenov, LB; Mikhailov, A; Pelham, RJ; Marcantonio, EE; Gundersen, GG			Focal adhesion motility revealed in stationary fibroblasts	SCIENCE			English	Article							CONTRACTILITY; INHIBITORS; INTEGRINS; MIGRATION; CONTACTS; DYNAMICS; MATRIX	Focal adhesions (FAs) are clustered integrins and associated proteins that mediate cell adhesion and signaling. A green fluorescent protein-pi integrin chimera was used to label FAs in Living cells. in stationary cells, FAs were highly motile, moving linearly for several plaque lengths toward the cell center. FA motility was independent of cell density and resulted from contraction of associated actin fibers. In migrating cells, FAs were stationary and only moved in the tail. FA motility in stationary cells suggests that cell movement may be regulated by a clutch-like mechanism by which the affinity of integrins to substrate may be altered in response to migratory cues.	Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University	Gundersen, GG (corresponding author), Columbia Univ, Dept Pathol, New York, NY 10032 USA.				NIGMS NIH HHS [GM44585, GM42026] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044585, R01GM042026] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DANOWSKI BA, 1989, J CELL SCI, V93, P255; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IZZARD CS, 1976, J CELL SCI, V21, P129; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Mikhailov A, 1998, CELL MOTIL CYTOSKEL, V41, P325, DOI 10.1002/(SICI)1097-0169(1998)41:4<325::AID-CM5>3.0.CO;2-D; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SMILENOV L, 1994, MOL BIOL CELL, V5, P1215, DOI 10.1091/mbc.5.11.1215	13	284	287	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	1999	286	5442					1172	1174		10.1126/science.286.5442.1172	http://dx.doi.org/10.1126/science.286.5442.1172			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550057				2022-12-28	WOS:000083534200047
J	Chan, A; Cundy, PJ; Foster, BK; Keane, RJ; Byron-Scott, R				Chan, A; Cundy, PJ; Foster, BK; Keane, RJ; Byron-Scott, R			Late diagnosis of congenital dislocation of the hip and presence of a screening programme: South Australian population-based study	LANCET			English	Article							DEVELOPMENTAL DYSPLASIA; RISK-FACTORS; MANAGEMENT	Background The Medical Research Council Working Party on Congenital Dislocation of the Hip have reported an ascertainment-adjusted incidence of a first operative procedure for congenital dislocation of the hip (CDH) of 0.78 per 1000 livebirths, which is similar to the incidence of CDH before the start of the UK screening programme. The report showed that CDH had not been detected by routine screening before age 3 months in 70% of children reported to the national orthopaedic surveillance scheme. This report raised concerns about the merit of screening at birth for CDH. We aimed to find out the incidence of an operative procedure for CDH in the first 5 years of life among children born in South Australia between 1988 and 1993, and the proportion of these patients that were detected at age 3 months or older. Methods The state's database for inpatient separations between January, 1988, and April, 1998 was searched. Case records were examined for the age and circumstances of diagnosis, and type of operative procedures. Prevalence rates of CDH were obtained from the South Australian Birth Defects Register, which receives notifications from a statutory perinatal data collection of birth defects detected at birth and subsequent voluntary notifications for children up to age 5 years. Findings Of the 55 children born in South Australia between 1988 and 1993 identified as having non-teratological CDH and operative procedures, only 22 (40%) had been diagnosed at age 3 months or order. 18 had an open reduction of the hip joint or osteotomy, or both, and the remainder had arthrograms, closed reductions, and/or tenotomy. The prevalence of non-teratological CDH in children was 7.74 per 1000 livebirths. The incidence of surgery for CDH in the first 5 years of life was 0.46 per 1000 livebirths (95% CI 0.34-0.59) and only 0.19 per 1000 livebirths (0.11-0.26) for those diagnosed late (age 3 months or older). These children diagnosed late represented 2.4% of ail known cases of CDH. Interpretation Only 2.4% of known cases of CDH in children born in South Australia had been detected late and required surgery. These results shaw that a screening programme for CDH can be successful, contrary to the findings of the UK Medical Research Council Working Party.	Dept Human Serv, Pregnancy Outcome Unit, Adelaide, SA 5000, Australia; Womens & Childrens Hosp, Dept Orthopaed Surg, N Adelaide, SA 5006, Australia; Womens & Childrens Hosp, S Australian Birth Defects Register, N Adelaide, SA 5006, Australia		Chan, A (corresponding author), Dept Human Serv, Pregnancy Outcome Unit, POB 6 Rundle Mall, Adelaide, SA 5000, Australia.							BERMAN L, 1986, BRIT MED J, V293, P719, DOI 10.1136/bmj.293.6549.719; BURGER BJ, 1990, LANCET, V336, P1549, DOI 10.1016/0140-6736(90)93317-I; Chan A, 1997, ARCH DIS CHILD-FETAL, V76, pF94, DOI 10.1136/fn.76.2.F94; CUNNINGHAM KT, 1984, LANCET, V1, P668; Dezateux C, 1996, ARCH DIS CHILD, V74, P445, DOI 10.1136/adc.74.5.445; Dunn P, 1998, LANCET, V352, P317, DOI 10.1016/S0140-6736(98)26030-2; DUNN PM, 1985, ARCH DIS CHILD, V60, P407, DOI 10.1136/adc.60.5.407; FREDENSBORG N, 1976, ACTA PAEDIATR SCAND, V65, P323, DOI 10.1111/j.1651-2227.1976.tb04893.x; Godward S, 1998, LANCET, V351, P1149, DOI 10.1016/S0140-6736(97)10466-4; Hiertonn T, 1968, J Bone Joint Surg Br, V50, P542; JONES D, 1977, J BONE JOINT SURG BR, V59, P318, DOI 10.1302/0301-620X.59B3.893510; MACKENZIE IG, 1981, J BONE JOINT SURG BR, V63, P38, DOI 10.1302/0301-620X.63B1.7204472; McKee L, 1998, BRIT MED J, V316, P1265; MCKINNON B, 1984, J PEDIATR ORTHOPED, V4, P422, DOI 10.1097/01241398-198408000-00006; MITCHELL G P, 1972, Journal of Bone and Joint Surgery British Volume, V54, P4; PALMEN K, 1984, ACTA ORTHOP SCAND, V55, P1; PATERSON DC, 1976, CLIN ORTHOP RELAT R, P28; Raffle AE, 1998, LANCET, V352, P317, DOI 10.1016/S0140-6736(05)60288-7; *US DEP HHS, 1980, INT CLASS DIS, V1; *US DEP HHS, 1980, INT CLASS DIS, V3; WALKER G, 1971, BRIT MED J, V3, P147, DOI 10.1136/bmj.3.5767.147; Wilson JMG, 1968, 34 WHO PUBL HLTH, V34; Wynne-Davies R, 1970, J Bone Joint Surg Br, V52, P704; Yiv BC, 1997, J PAEDIATR CHILD H, V33, P151, DOI 10.1111/j.1440-1754.1997.tb01019.x; 1991, LANCET, V337, P947	25	48	49	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1514	1517		10.1016/S0140-6736(98)12469-8	http://dx.doi.org/10.1016/S0140-6736(98)12469-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551498				2022-12-28	WOS:000083411300012
J	Aoki, Y; Segall, P; Kato, T; Cervelli, P; Shimada, S				Aoki, Y; Segall, P; Kato, T; Cervelli, P; Shimada, S			Imaging magma transport during the 1997 seismic swarm off the Izu Peninsula, Japan	SCIENCE			English	Article							DEFORMATION; INVERSION; SYSTEM; EDGE	The spatio-temporal evolution of a propagating magma-filled crack was estimated from inversion of Global positioning System (CPS) data, tiltmeters, and leveling. The dike opened at a maximum rate of 50 millimeters per day and had a peak magma flux of 2 x 10(6) cubic meters per day. Although the spatial resolution was Limited, slow upward propagation was resolved during the 9-day-long intrusion. In contrast, the earthquakes migrated rapidly upward during the first 12 hours of the swarm, and nearly all of the seismic energy was released in the first 2 days. Comparison of inversion results with accurate hypocenter locations will Lead to improved understanding of magma transport through the brittle crust and of the causes of volcanic seismicity.	Stanford Univ, Dept Geophys, Stanford, CA 94305 USA; Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, Tokyo 1130032, Japan; Natl Res Inst Earth Sci & Disaster Prevent, Tsukuba, Ibaraki 3050006, Japan	Stanford University; University of Tokyo; National Research Institute for Earth Science & Disaster Resilience	Aoki, Y (corresponding author), Stanford Univ, Dept Geophys, Stanford, CA 94305 USA.		Aoki, Yosuke/I-8801-2019	Aoki, Yosuke/0000-0002-2539-4144; Cervelli, Peter/0000-0001-6765-1009				BASU A, 1990, SCIENCE, V249, P1409, DOI 10.1126/science.249.4975.1409; CERVELLI P, UNPUB; Du YJ, 1997, GEOPHYS RES LETT, V24, P2347, DOI 10.1029/97GL02341; Dvorak JJ, 1997, REV GEOPHYS, V35, P343, DOI 10.1029/97RG00070; *EARTHQ RES I, 1997, REP COORD COMM EARTH, V58, P239; Efron B., 1994, MONOGRAPHS STAT APPL; Gillard D, 1996, NATURE, V384, P343, DOI 10.1038/384343a0; HARRIS RA, 1987, J GEOPHYS RES-SOLID, V92, P7945, DOI 10.1029/JB092iB08p07945; ISHIDA M, 1984, B SEISMOL SOC AM, V74, P199; LINDE AT, 1993, NATURE, V365, P737, DOI 10.1038/365737a0; OKADA Y, 1991, J GEOPHYS RES-SOLID, V96, P10361, DOI 10.1029/91JB00427; OKADA YC, UNPUB; POLLARD DD, 1983, TECTONOPHYSICS, V94, P541, DOI 10.1016/0040-1951(83)90034-3; Rubin AM, 1998, J GEOPHYS RES-SOL EA, V103, P10017, DOI 10.1029/97JB03514; Savage JC, 1998, J GEOPHYS RES-SOL EA, V103, P2439, DOI 10.1029/97JB02562; Schaff DP, 1998, GEOPHYS RES LETT, V25, P4549, DOI 10.1029/1998GL900192; Segall P, 1997, J GEOPHYS RES-SOL EA, V102, P22391, DOI 10.1029/97JB01795; SHIMADA S, 1990, NATURE, V343, P631, DOI 10.1038/343631a0; UKAWA M, 1991, J GEOPHYS RES-SOLID, V96, P713, DOI 10.1029/90JB02142	19	60	60	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					927	930		10.1126/science.286.5441.927	http://dx.doi.org/10.1126/science.286.5441.927			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542140				2022-12-28	WOS:000083368500035
J	Annas, GJ				Annas, GJ			The last resort - The use of physical restraints in medical emergencies	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02118 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02118 USA.			Annas, George/0000-0001-5836-7831				ANNAS GJ, 1984, TOLEDO LAW REV, V15, P561; BOWMAN C, 1999, BNAS HLTH LAW R 0826, P1405; Donat DC, 1998, J BEHAV THER EXP PSY, V29, P13, DOI 10.1016/S0005-7916(97)00039-6; EVANS LK, 1989, J AM GERIATR SOC, V37, P65, DOI 10.1111/j.1532-5415.1989.tb01571.x; Greenlaw J, 1982, Law Med Health Care, V10, P125; Janelli L M, 1995, J Nurs Care Qual, V9, P86; MILES SH, 1992, GERONTOLOGIST, V32, P762, DOI 10.1093/geront/32.6.762; Parker KP, 1997, J AM GERIATR SOC, V45, P797, DOI 10.1111/j.1532-5415.1997.tb01504.x; PROSSER WL, 1984, TORTS, P117; WEISS EM, 1999, HARTFORD COURAN 0731, pA14; WEISS EM, 1998, HARTFORD COURAN 1011, pA1; 1998, HARTFORD COURAN 1022, pA18; 1998, FED REG, V64, P36070; 1998, HARTFORD COURAN 1011, pA12	14	34	35	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1408	1412		10.1056/NEJM199910283411820	http://dx.doi.org/10.1056/NEJM199910283411820			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	249XE	10536135	Green Published			2022-12-28	WOS:000083357800028
J	Auer, J; Eber, B				Auer, J; Eber, B			Homocysteine and fibrinolysis in acute occlusive coronary events	LANCET			English	Letter							PLASMA		Gen Hosp Wels, Dept Cardiol & Intens Care, A-4600 Wels, Austria		Auer, J (corresponding author), Gen Hosp Wels, Dept Cardiol & Intens Care, A-4600 Wels, Austria.		Pallardo, Federico/T-1156-2017	Pallardo, Federico/0000-0003-3715-1980				Egerton W, 1996, AM J CARDIOL, V77, P759, DOI 10.1016/S0002-9149(97)89213-2; GUTTORMSEN AB, 1994, J NUTR, V124, P1934, DOI 10.1093/jn/124.10.1934; Hankey GJ, 1999, LANCET, V354, P407, DOI 10.1016/S0140-6736(98)11058-9	3	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1474	1475		10.1016/S0140-6736(05)77615-7	http://dx.doi.org/10.1016/S0140-6736(05)77615-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543697				2022-12-28	WOS:000083277400054
J	Beecham, L				Beecham, L			Consultants endorse system of revalidation	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1140	1140						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531124				2022-12-28	WOS:000083419500069
J	Hensher, M; Fulop, N; Coast, J; Jefferys, E				Hensher, M; Fulop, N; Coast, J; Jefferys, E			The hospital of the future - Better out than in? Alternatives to acute hospital care	BRITISH MEDICAL JOURNAL			English	Article							COST MINIMIZATION ANALYSIS; HOME CARE; AT-HOME; ADMISSIONS; APPROPRIATENESS		Univ London London Sch Hyg & Trop Med, London Hlth Econ Consortium, London WC1E 7HT, England; Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Bristol	Hensher, M (corresponding author), Univ London London Sch Hyg & Trop Med, London Hlth Econ Consortium, Keppel St, London WC1E 7HT, England.		Hensher, Martin C/N-4635-2017	Hensher, Martin C/0000-0001-6444-6827; Fulop, Naomi/0000-0001-5306-6140; Coast, Joanna/0000-0002-3537-5166				ABELSMITH B, 1994, HEALTH POLICY, V28, P89, DOI 10.1016/0168-8510(94)90030-2; Apolone G, 1997, EUR J PUBLIC HEALTH, V7, P34, DOI 10.1093/eurpub/7.1.34; BAKER JE, 1986, J EPIDEMIOL COMMUN H, V40, P117, DOI 10.1136/jech.40.2.117; Coast J, 1998, BRIT MED J, V316, P1802, DOI 10.1136/bmj.316.7147.1802; COAST J, 1995, J EPIDEMIOL COMMUN H, V49, P194, DOI 10.1136/jech.49.2.194; Coast J, 1996, BRIT MED J, V312, P162; HAYES CB, 1995, IRISH MED J, V88, P124; Hensher M, 1996, J ROY SOC MED, V89, P548, DOI 10.1177/014107689608901003; Iliffe S, 1997, J ROY SOC MED, V90, P181, DOI 10.1177/014107689709000401; KNOWELDEN J, 1991, J PUBLIC HEALTH MED, V13, P182, DOI 10.1093/oxfordjournals.pubmed.a042616; Raftery J, 1998, J Health Serv Res Policy, V3, P149; READ S, 1994, PATIENTS MINOR INJUR; Richards SH, 1998, BRIT MED J, V316, P1796, DOI 10.1136/bmj.316.7147.1796; Shepperd S, 1998, BRIT MED J, V316, P1786, DOI 10.1136/bmj.316.7147.1786; Shepperd S, 1998, BRIT MED J, V316, P1791, DOI 10.1136/bmj.316.7147.1791; SHEPPERD S, 1998, COCHRANE LIB; Smith HE, 1997, J ROY COLL PHYS LOND, V31, P527; Steiner A, 1997, INTERMEDIATE CARE CO; Victor C, 1993, Health Trends, V25, P94; VICTOR CR, 1994, J PUBLIC HEALTH MED, V16, P286; Wilson A., 1997, J EPIDEMIOL COMMUNIT, V51, P593	21	37	37	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1127	1130		10.1136/bmj.319.7217.1127	http://dx.doi.org/10.1136/bmj.319.7217.1127			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	250ZE	10531112	Green Published			2022-12-28	WOS:000083419500035
J	Lee, DD; Seung, HS				Lee, DD; Seung, HS			Learning the parts of objects by non-negative matrix factorization	NATURE			English	Article							BLIND SEPARATION; RECOGNITION; ALGORITHM; REPRESENTATION	Is perception of the whole based on perception of its parts? There is psychological(1) and physiological(2,3) evidence for parts-based representations in the brain, and certain computational theories of object recognition rely on such representations(4,5). But little is known about how brains or computers might learn the parts of objects. Here we demonstrate an algorithm for non-negative matrix factorization that is able to learn parts of faces and semantic features of text. This is in contrast to other methods, such as principal components analysis and vector quantization, that learn holistic, not parts-based, representations. Non-negative matrix factorization is distinguished from the other methods by its use of non-negativity constraints. These constraints lead to a parts-based representation because they allow only additive, not subtractive, combinations. When non-negative matrix factorization is implemented as a neural network, parts-based representations emerge by virtue of two properties: the firing rates of neurons are never negative and synaptic strengths do not change sign.	AT&T Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs; Massachusetts Institute of Technology (MIT)	Seung, HS (corresponding author), AT&T Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.		Lee, Daniel D./B-5753-2013					Bartlett MS, 1998, P SOC PHOTO-OPT INS, V3299, P528, DOI 10.1117/12.320144; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; BIEDERMAN I, 1987, PSYCHOL REV, V94, P115, DOI 10.1037/0033-295X.94.2.115; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; FIELD DJ, 1994, NEURAL COMPUT, V6, P559, DOI 10.1162/neco.1994.6.4.559; FOLDIAK P, 1995, HDB BRAIN THEORY NEU, P895; HINTON GE, 1995, SCIENCE, V268, P1158, DOI 10.1126/science.7761831; JUTTEN C, 1991, SIGNAL PROCESS, V24, P1, DOI 10.1016/0165-1684(91)90079-X; Landauer TK, 1997, PSYCHOL REV, V104, P211, DOI 10.1037/0033-295X.104.2.211; Lee DD, 1997, ADV NEUR IN, V9, P515; Logothetis NK, 1996, ANNU REV NEUROSCI, V19, P577, DOI 10.1146/annurev.ne.19.030196.003045; LUCY LB, 1974, ASTRON J, V79, P745, DOI 10.1086/111605; NAKAYAMA K, 1992, SCIENCE, V257, P1357, DOI 10.1126/science.1529336; Olshausen BA, 1996, NATURE, V381, P607, DOI 10.1038/381607a0; Paatero P, 1997, CHEMOMETR INTELL LAB, V37, P23, DOI 10.1016/S0169-7439(96)00044-5; PALMER SE, 1977, COGNITIVE PSYCHOL, V9, P441, DOI 10.1016/0010-0285(77)90016-0; RICHARDSON WH, 1972, J OPT SOC AM, V62, P55, DOI 10.1364/JOSA.62.000055; SALTON G, 1983, INTRO MODERN INFORMA; SAUL L, 1997, P 2 C EMP METH NAT L, P81; Shepp L A, 1982, IEEE Trans Med Imaging, V1, P113, DOI 10.1109/TMI.1982.4307558; TURK M, 1991, J COGNITIVE NEUROSCI, V3, P71, DOI 10.1162/jocn.1991.3.1.71; Ullman S., 1996, HIGH LEVEL VISION OB	22	7740	8375	59	789	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					788	791		10.1038/44565	http://dx.doi.org/10.1038/44565			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	250BG	10548103				2022-12-28	WOS:000083368700052
J	Vazquez-Torres, A; Jones-Carson, J; Baumler, AJ; Falkow, S; Valdivia, R; Brown, W; Le, M; Berggren, R; Parks, WT; Fang, FC				Vazquez-Torres, A; Jones-Carson, J; Baumler, AJ; Falkow, S; Valdivia, R; Brown, W; Le, M; Berggren, R; Parks, WT; Fang, FC			Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes	NATURE			English	Article							PEYERS-PATCHES; M-CELLS; TYPHIMURIUM; IDENTIFICATION; MUTANTS; IMMUNIZATION; CONSTRUCTION; EXPRESSION; MUTATIONS; INFECTION	Specialized epithelia known as M cells overlying the lymphoid follicles of Peyer's patches are important in the mucosal immune system, but also provide a portal of entry for pathogens such as Salmonella typhimurium, Mycobacterium bovis, Shigella flexneri, Yersinia enterocolitica and reoviruses(1-4). Penetration of intestinal M cells and epithelial cells by Salmonella typhimurium requires the invasion genes of Salmonella Pathogenicity Island 1 (SPI1)(3,5-9) SPI1-deficient S, typhimurium strains gain access to the spleen following oral administration and cause lethal infection in mice(5) without invading M cells(3,9) or localizing in Payer's patches(10), which indicates that Salmonella uses an alternative strategy to disseminate from the gastrointestinal tract, Here we report that Salmonella is transported from the gastrointestinal tract to the bloodstream by CD18-expressing phagocytes, and that CD18-deficient mice are resistant to dissemination of Salmonella to the liver and spleen after oral administration. This CD18-dependent pathway of extraintestinal dissemination may be important for the development of systemic immunity to gastrointestinal pathogens, because oral challenge with SPI1-deficient S. typhimurium elicits a specific systemic Ige humoral immune response, despite an inability to stimulate production of specific mucosal IgA.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA; Natl Jewish Ctr Immunol & Resp Med, Dept Immunol, Denver, CO 80262 USA; Texas A&M Univ, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Vet Affairs Med Ctr, Dept Med, Denver, CO 80262 USA; NCI, Cel Regulat & Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; Texas A&M University System; Texas A&M University College Station; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fang, FC (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA.	ferric.fang@uchsc.edu	Valdivia, Raphael/R-5377-2019; Baumler, Andreas J/H-2301-2011	Valdivia, Raphael/0000-0003-0961-073X; Baumler, Andreas J/0000-0001-9152-7809; Parks, W. Tony/0000-0001-7341-3277; Fang, Ferric/0000-0002-3243-110X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044486] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Autenrieth IB, 1996, INFECT IMMUN, V64, P1357, DOI 10.1128/IAI.64.4.1357-1368.1996; Baumler AJ, 1997, INFECT IMMUN, V65, P2254; Baumler AJ, 1996, P NATL ACAD SCI USA, V93, P279, DOI 10.1073/pnas.93.1.279; BERGGREN RE, 1995, J ACQ IMMUN DEF SYND, V10, P489; Bernstein CN, 1996, CLIN EXP IMMUNOL, V106, P160; Collazo CM, 1997, GENE, V192, P51, DOI 10.1016/S0378-1119(96)00825-6; CONLAN JW, 1994, INFECT IMMUN, V62, P2702, DOI 10.1128/IAI.62.7.2702-2706.1994; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GERICHTER C. B., 1960, JOUR HYG, V58, P307; JONES BD, 1994, J EXP MED, V180, P15, DOI 10.1084/jem.180.1.15; KINDER SA, 1993, GENE, V136, P271, DOI 10.1016/0378-1119(93)90478-L; KISHIMOTO TK, 1992, INFLAMMATION BASIC P, P353; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3; Neutra MR, 1998, AM J PHYSIOL-GASTR L, V274, pG785, DOI 10.1152/ajpgi.1998.274.5.G785; OSKOUI R, 1993, ARCH INTERN MED, V153, P517, DOI 10.1001/archinte.153.4.517; PEHHEITER KL, 1997, MOL MICROBIOL, V24, P697; RAHN K, 1992, MOL CELL PROBE, V6, P271, DOI 10.1016/0890-8508(92)90002-F; Shang XZ, 1998, EUR J IMMUNOL, V28, P1970, DOI 10.1002/(SICI)1521-4141(199806)28:06<1970::AID-IMMU1970>3.0.CO;2-H; STOJILJKOVIC I, 1995, J BACTERIOL, V177, P1357, DOI 10.1128/jb.177.5.1357-1366.1995; TSOLIS RM, 1995, J BACTERIOL, V177, P4628, DOI 10.1128/jb.177.16.4628-4637.1995; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x; Valentine PJ, 1998, INFECT IMMUN, V66, P3378, DOI 10.1128/IAI.66.7.3378-3383.1998; WASSEF JS, 1989, INFECT IMMUN, V57, P858, DOI 10.1128/IAI.57.3.858-863.1989; WILSON RW, 1993, J IMMUNOL, V151, P1571; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737	29	509	518	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 21	1999	401	6755					804	808		10.1038/44593	http://dx.doi.org/10.1038/44593			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548107				2022-12-28	WOS:000083368700056
J	Doris, A; Ebmeier, K; Shajahan, P				Doris, A; Ebmeier, K; Shajahan, P			Depressive illness	LANCET			English	Article							SEASONAL AFFECTIVE-DISORDER; SEROTONIN TRANSPORTER GENE; TRANSCRANIAL MAGNETIC STIMULATION; BONE-MINERAL DENSITY; MAJOR DEPRESSION; ELECTROCONVULSIVE-THERAPY; MENTAL-DISORDERS; LIGHT THERAPY; TRYPTOPHAN DEPLETION; RECURRENT DEPRESSION	WHO estimate that by the beginning of the next century major unipolar depression will be one of the most important causes of ill health overall. Whereas the cause of depression is still obscure, it is becoming clear that a number of diverse factors are likely to be implicated, both genetic and environmental. Effective treatment of depression similarly involves a variety of methods, from electro-convulsive therapy to inter-personal psychotherapy. The pathophysiology of depression is gradually becoming accessible through research strategies, such as functional neuroimaging paired with mood altering interventions.	Univ Edinburgh, Royal Edinburgh Hosp, MRC, Brain Metab Unit, Edinburgh EH10 5HF, Midlothian, Scotland; Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Ebmeier, K (corresponding author), Univ Edinburgh, Royal Edinburgh Hosp, MRC, Brain Metab Unit, Morningside Pk, Edinburgh EH10 5HF, Midlothian, Scotland.		Ebmeier, Klaus Peter/B-4789-2008	Ebmeier, Klaus Peter/0000-0002-5190-7038				Amsterdam JD, 1998, J PSYCHOPHARMACOL, V12, pS99, DOI 10.1177/0269881198012003061; [Anonymous], 1992, JAMA, V268, P3098; AXELSON DA, 1993, PSYCHIAT RES, V47, P163, DOI 10.1016/0165-1781(93)90046-J; Battersby S, 1996, PSYCHIATR GENET, V6, P177, DOI 10.1097/00041444-199624000-00001; BEBBINGTON P, 1981, PSYCHOL MED, V11, P561, DOI 10.1017/S0033291700052879; BENCH CJ, 1995, PSYCHOL MED, V25, P247, DOI 10.1017/S0033291700036151; BENKELFAT C, 1994, ARCH GEN PSYCHIAT, V51, P687; BLACKBURN IM, 1981, BRIT J PSYCHIAT, V139, P181, DOI 10.1192/bjp.139.3.181; BOYD JH, 1982, HDB AFFECTIVE DISORD, P112; BUCHAN H, 1992, BRIT J PSYCHIAT, V160, P355, DOI 10.1192/bjp.160.3.355; BYRNE A, 1993, J PSYCHOSOM RES, V37, P565, DOI 10.1016/0022-3999(93)90050-P; COFFEY CE, 1993, ARCH GEN PSYCHIAT, V50, P7; COWEN PJ, 1996, SELECTIVE SEROTONIN, P63; DELGADO PL, 1990, ARCH GEN PSYCHIAT, V47, P411; DEVANAND DP, 1994, AM J PSYCHIAT, V151, P957; DUFORT GG, 1994, PSYCHOL MED, V24, P431, DOI 10.1017/S0033291700027409; EATON WW, 1989, ACTA PSYCHIAT SCAND, V79, P163, DOI 10.1111/j.1600-0447.1989.tb08584.x; Ebert D, 1998, ADV BIOL P, V19, P153; Ebmeier KP, 1997, BRIT J PSYCHIAT, V170, P77, DOI 10.1192/bjp.170.1.77; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; ERNST E, 1998, ARCH GEN PSYCHIAT, V173, P449; EVANS MD, 1992, ARCH GEN PSYCHIAT, V49, P802; Fava GA, 1998, ARCH GEN PSYCHIAT, V55, P816, DOI 10.1001/archpsyc.55.9.816; FOMBONNE E, 1994, ACTA PSYCHIAT SCAND, V90, P145, DOI 10.1111/j.1600-0447.1994.tb01571.x; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; FREELING P, 1985, BMJ-BRIT MED J, V290, P1880, DOI 10.1136/bmj.290.6485.1880; Freeman C.P., 1995, ECT HDB; Furlong RA, 1998, AM J MED GENET, V81, P58, DOI 10.1002/(SICI)1096-8628(19980207)81:1<58::AID-AJMG11>3.0.CO;2-V; George MS, 1997, AM J PSYCHIAT, V154, P1752, DOI 10.1176/ajp.154.12.1752; GEORGE MS, 1998, BIOL PSYCHIAT NEW MO, P94; Goldstein BJ, 1998, J PSYCHOPHARMACOL, V12, pS55, DOI 10.1177/0269881198012003041; Goodnick PJ, 1998, J PSYCHOPHARMACOL, V12, pS21, DOI 10.1177/0269881198012003031; GOODWIN GM, 1993, J AFFECT DISORDERS, V29, P243, DOI 10.1016/0165-0327(93)90014-B; HALBREICH U, 1995, PSYCHOSOM MED, V57, P485, DOI 10.1097/00006842-199509000-00011; Heils A, 1996, J NEUROCHEM, V66, P2621; Joffe R, 1996, CAN J PSYCHIAT, V41, P613, DOI 10.1177/070674379604101002; JOHNSTONE EC, 1980, LANCET, V2, P1317; KELLER MB, 1982, JAMA-J AM MED ASSOC, V248, P1848, DOI 10.1001/jama.248.15.1848; KELLER MB, 1982, AM J PSYCHIAT, V139, P438; KELLER MB, 1994, BRIT J PSYCHIAT, V165, P9, DOI 10.1192/S0007125000293239; KENDLER KS, 1993, AM J PSYCHIAT, V150, P1139; Kendler KS, 1997, PSYCHOL MED, V27, P539, DOI 10.1017/S0033291797004716; KENNER TA, 1995, PSYCHOL MED, V25, P247; KESSLER RC, 1993, J AFFECT DISORDERS, V29, P85, DOI 10.1016/0165-0327(93)90026-G; KLERMAN GL, 1989, JAMA-J AM MED ASSOC, V261, P2229, DOI 10.1001/jama.261.15.2229; Kogan AO, 1998, AM J PSYCHIAT, V155, P293; Lee TMC, 1997, ACTA PSYCHIAT SCAND, V96, P117, DOI 10.1111/j.1600-0447.1997.tb09915.x; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; McAskill R, 1998, BRIT J PSYCHIAT, V173, P203, DOI 10.1192/bjp.173.3.203; MERIKANGAS KR, 1982, PSYCHOL MED, V12, P753, DOI 10.1017/S0033291700049059; Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602; MONTGOMERY SA, 1994, ANNU REV MED, V45, P447; *MRC, 1965, BMJ-BRIT MED J, V1, P881; MUIRRAY CJL, 1996, GLOBAL BURDEN DIS; Murray GW, 1997, AUST NZ J PSYCHIAT, V31, P279, DOI 10.3109/00048679709073832; Neumeister A, 1997, ARCH GEN PSYCHIAT, V54, P133; Partonen T, 1998, LANCET, V352, P1369, DOI 10.1016/S0140-6736(98)01015-0; PascualLeone A, 1996, LANCET, V348, P233, DOI 10.1016/S0140-6736(96)01219-6; Paykel ES, 1998, BRIT J PSYCHIAT, V173, P519, DOI 10.1192/bjp.173.6.519; Perry PJ, 1996, J AFFECT DISORDERS, V39, P1, DOI 10.1016/0165-0327(96)00014-6; PICCINELLI M, 1994, BRIT J PSYCHIAT, V164, P297, DOI 10.1192/bjp.164.3.297; POUNDER DJ, 1991, FORENSIC SCI INT, V51, P79, DOI 10.1016/0379-0738(91)90207-Y; PraschakRieder N, 1997, J CLIN PSYCHIAT, V58, P389, DOI 10.4088/JCP.v58n0903; PRIEN RF, 1986, AM J PSYCHIAT, V143, P18; PRIEN RF, 1973, ARCH GEN PSYCHIAT, V29, P420; Rabheru K, 1997, CAN J PSYCHIAT, V42, P476, DOI 10.1177/070674379704200503; Reid PD, 1998, BRIT J PSYCHIAT, V173, P449, DOI 10.1192/bjp.173.6.449; Remick RA, 1996, AM J MED GENET, V67, P347; RUBIN RT, 1995, ARCH GEN PSYCHIAT, V52, P213; Ruhrmann S, 1998, PSYCHOL MED, V28, P923, DOI 10.1017/S0033291798006813; SAPOLSKY RM, 1986, ENDOCR REV, V7, P284, DOI 10.1210/edrv-7-3-284; Shah PJ, 1997, PSYCHOL MED, V27, P1247, DOI 10.1017/S0033291797005382; Shah PJ, 1998, BRIT J PSYCHIAT, V172, P527, DOI 10.1192/bjp.172.6.527; Shajahan PM, 1998, BRIT MED J, V316, P1496, DOI 10.1136/bmj.316.7143.1496; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; SPENCE MA, 1993, HUM HERED, V43, P166; Staley JK, 1998, BIOL PSYCHIAT, V44, P534, DOI 10.1016/S0006-3223(98)00185-1; Thase ME, 1997, ARCH GEN PSYCHIAT, V54, P1009; Walsh D, 1998, BRIT MED J, V317, P1158; WEISSMAN MM, 1993, J AFFECT DISORDERS, V29, P77, DOI 10.1016/0165-0327(93)90025-F; WITTCHEN HU, 1994, BRIT J PSYCHIAT, V165, P16, DOI 10.1192/S0007125000293240; WITTCHEN HU, 1992, EUR ARCH PSY CLIN N, V241, P247, DOI 10.1007/BF02190261; WU JC, 1990, AM J PSYCHIAT, V147, P14; Young MA, 1997, J ABNORM PSYCHOL, V106, P554, DOI 10.1037/0021-843X.106.4.554; Zulman DM, 1999, CURR OPIN PSYCHIATR, V12, P81, DOI 10.1097/00001504-199901000-00022	85	122	132	2	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1999	354	9187					1369	1375		10.1016/S0140-6736(99)03121-9	http://dx.doi.org/10.1016/S0140-6736(99)03121-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	246DV	10533878				2022-12-28	WOS:000083149900040
J	Mostov, K; ter Beest, MBA; Chapin, SJ				Mostov, K; ter Beest, MBA; Chapin, SJ			Catch the mu 1B train to the basolateral surface	CELL			English	Review							DARBY CANINE KIDNEY; EPITHELIAL-CELLS; MDCK CELLS; CYTOPLASMIC DOMAIN; MEMBRANE; RECEPTOR; TRAFFICKING; TRANSPORT; SIGNALS		Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Mostov, K (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.			mostov, keith/0000-0002-8123-6247				Aroeti B, 1998, BBA-REV BIOMEMBRANES, V1376, P57, DOI 10.1016/S0304-4157(98)00005-7; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; Distel B, 1998, J BIOL CHEM, V273, P186, DOI 10.1074/jbc.273.1.186; Foletti DL, 1999, NEURON, V23, P641, DOI 10.1016/S0896-6273(01)80022-2; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; Orzech E, 1999, J BIOL CHEM, V274, P2201, DOI 10.1074/jbc.274.4.2201; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Stowell JN, 1999, NEURON, V22, P525, DOI 10.1016/S0896-6273(00)80707-2	17	19	19	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					121	122		10.1016/S0092-8674(00)81643-8	http://dx.doi.org/10.1016/S0092-8674(00)81643-8			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535730	Bronze			2022-12-28	WOS:000083159700002
J	Lyden, D; Young, AZ; Zagzag, D; Yan, W; Gerald, W; O'Reilly, R; Bader, BL; Hynes, RO; Zhuang, Y; Manova, K; Benezra, R				Lyden, D; Young, AZ; Zagzag, D; Yan, W; Gerald, W; O'Reilly, R; Bader, BL; Hynes, RO; Zhuang, Y; Manova, K; Benezra, R			Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts	NATURE			English	Article							LOOP-HELIX PROTEIN; MUSCLE DIFFERENTIATION; TRANSCRIPTION FACTORS; EXPRESSION PATTERNS; CELL DEVELOPMENT; E2A PROTEINS; MOUSE EMBRYO; NEURAL-TUBE; GENE FAMILY; T-CELL	Id proteins may control cell differentiation by interfering with DNA binding of transcription factors. Here we show that targeted disruption of the dominant negative helix-loop-helix proteins Id1 and ld3 in mice results in premature withdrawal of neuroblasts from the cell cycle and expression of neural-specific differentiation markers. The ld1-ld3 double knockout mice also display vascular malformations in the forebrain and an absence of branching and sprouting of blood vessels into the neuroectoderm. As angiogenesis both in the brain and in tumours requires invasion of avascular tissue by endothelial cells, we examined the Id knockout mice for their ability to support the growth of tumour xenografts, Three different tumours failed to grow and/or metastasize in ld1(+/-)ld3(-/-) mice, and any tumour growth present showed poor vascularization and extensive necrosis, Thus, the Id genes are required to maintain the timing of neuronal differentiation in the embryo and invasiveness of the vasculature, Because the Id genes are expressed at very low levels in adults, they make attractive new targets for anti-angiogenic drug design.	Mem Sloan Kettering Canc Ctr, Dept Cell Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Mol Cytol Core Facil, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; NYU, Kaplan Canc Ctr, Dept Pathol, Div Neuropathol, New York, NY 10016 USA; MIT, Howard Hughes Med Inst Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Max Planck Inst Biochem, Dept Prot Chem, D-82152 Martinsried, Germany; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; New York University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Max Planck Society; Duke University	Benezra, R (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Cell Biol, 1275 York Ave, New York, NY 10021 USA.			zhuang, yuan/0000-0002-2964-3654				AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Deed RW, 1998, J BIOL CHEM, V273, P8278, DOI 10.1074/jbc.273.14.8278; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ELLMEIER W, 1995, DEV DYNAM, V203, P163, DOI 10.1002/aja.1002030205; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; Heemskerk MHM, 1997, J EXP MED, V186, P1597, DOI 10.1084/jem.186.9.1597; HOGAN BLM, 1986, J EMBRYOL EXP MORPH, V97, P95; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Jen Y, 1996, DEV DYNAM, V207, P235; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1995, J CELL BIOL, V128, P713; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Manova K, 1998, DEV DYNAM, V213, P293, DOI 10.1002/(SICI)1097-0177(199811)213:3<293::AID-AJA6>3.0.CO;2-D; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; McCormick MB, 1996, MOL CELL BIOL, V16, P5792; Melnikova IN, 1996, CELL GROWTH DIFFER, V7, P1067; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pan LH, 1999, MOL CELL BIOL, V19, P5969; PERLMAN JM, 1986, AM J DIS CHILD, V140, P1122, DOI 10.1001/archpedi.1986.02140250048034; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SHERWOOD A, 1978, NEUROPATH APPL NEURO, V4, P245, DOI 10.1111/j.1365-2990.1978.tb00543.x; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SIMONSON MS, 1993, NUCLEIC ACIDS RES, V21, P5767, DOI 10.1093/nar/21.24.5767; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	51	738	775	1	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					670	677		10.1038/44334	http://dx.doi.org/10.1038/44334			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537105				2022-12-28	WOS:000083207400048
J	Snijder, HJ; Ubarretxena-Belandia, I; Blaauw, M; Kalk, KH; Verheij, HM; Egmond, MR; Dekker, N; Dijkstra, BW				Snijder, HJ; Ubarretxena-Belandia, I; Blaauw, M; Kalk, KH; Verheij, HM; Egmond, MR; Dekker, N; Dijkstra, BW			Structural evidence for dimerization-regulated activation of an integral membrane phospholipase	NATURE			English	Article							ESCHERICHIA-COLI; ENZYMATIC-ACTIVITY; CRYSTAL-STRUCTURES; DIFFRACTION DATA; MOLSCRIPT	Dimerization is a biological regulatory mechanism employed by both soluble and membrane proteins'. However, there are few structural data on the factors that govern dimerization of membrane proteins. Outer membrane phospholipase A (OMPLA) is an integral membrane enzyme which participates in secretion of colicins in Escherichia coli. In Campilobacter(2) and Helicobacter pylori strains(3), OMPLA is implied in virulence. Its activity is regulated by reversible dimerization(4,5) Here we report X-ray structures of monomeric and dimeric OMPLA from E. coli. Dimer interactions occur almost exclusively in the apolar membrane-embedded parts, with two hydrogen bonds within the hydrophobic membrane area being key interactions. Dimerization results in functional oxyanion holes and substrate-binding pockets, which are absent in monomeric OMPLA. These results provide a detailed view of activation by dimerization of a membrane protein.	Univ Groningen, BIOSON Res Inst, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Dept Enzymol & Prot Engn, NL-3584 CH Utrecht, Netherlands	University of Groningen; Utrecht University	Dijkstra, BW (corresponding author), Univ Groningen, BIOSON Res Inst, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Ubarretxena-Belandia, Iban/A-8389-2009; Dijkstra, Bauke W./H-4308-2019; Ubarretxena-Belandia, Iban/AAA-8939-2019	Dijkstra, Bauke W./0000-0001-9731-6586; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLAAUW M, 1995, FEBS LETT, V373, P10, DOI 10.1016/0014-5793(95)01002-V; Brok RGPM, 1996, BIOCHEMISTRY-US, V35, P7787, DOI 10.1021/bi952970i; Brok RGPM, 1995, EUR J BIOCHEM, V234, P934, DOI 10.1111/j.1432-1033.1995.934_a.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Bukholm G, 1997, SCAND J GASTROENTERO, V32, P445, DOI 10.3109/00365529709025079; Dekker N, 1999, J BACTERIOL, V181, P3281, DOI 10.1128/JB.181.10.3281-3283.1999; Dekker N, 1997, J BIOL CHEM, V272, P3179, DOI 10.1074/jbc.272.6.3179; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Grant KA, 1997, INFECT IMMUN, V65, P1172, DOI 10.1128/IAI.65.4.1172-1180.1997; HORREVOETS AJG, 1989, BIOCHEMISTRY-US, V28, P1139, DOI 10.1021/bi00429a031; HORREVOETS AJG, 1991, EUR J BIOCHEM, V198, P247, DOI 10.1111/j.1432-1033.1991.tb16008.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Merck KB, 1997, J BACTERIOL, V179, P3443, DOI 10.1128/jb.179.11.3443-3450.1997; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Ubarretxena-Belandia I, 1999, BIOCHEMISTRY-US, V38, P7398, DOI 10.1021/bi983077x; Ubarretxena-Belandia I, 1998, BIOCHEMISTRY-US, V37, P16011, DOI 10.1021/bi9814181; WEI YY, 1995, NAT STRUCT BIOL, V2, P218, DOI 10.1038/nsb0395-218; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242	29	202	210	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	1999	401	6754					717	721		10.1038/44890	http://dx.doi.org/10.1038/44890			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537112	Green Published			2022-12-28	WOS:000083207400061
J	Myneni, SCB; Brown, JT; Martinez, GA; Meyer-Ilse, W				Myneni, SCB; Brown, JT; Martinez, GA; Meyer-Ilse, W			Imaging of humic substance macromolecular structures in water and soils	SCIENCE			English	Article							MICROSCOPY; ACIDS	Humic substances (HSs) are the natural organic polyelectrolytes formed from the biochemical weathering of plant and animal remains. Their macromolecular structure and chemistry determine their role in biogeochemical processes. In situ spectromicroscopic evidence showed that the HS macromolecular structures (size and shape) vary as a function of HS origin (soil versus fluvial), solution chemistry, and the associated mineralogy. The HSs do not simply form coils in acidic or strong electrolyte solutions and elongated structures in dilute alkaline solutions. The macromolecular structural changes of HSs are likely to modify contaminant solubility, biotransformation, and the carbon cycle in soils and sediments.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Earth Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Xray Opt, Berkeley, CA 94720 USA; Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; Univ Puerto Rico, Agr Expt Stn, Rio Piedras, PR 00928 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Princeton University; University of Puerto Rico; University of Puerto Rico Mayaguez; University of Puerto Rico Rio Piedras	Myneni, SCB (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Earth Sci, Berkeley, CA 94720 USA.							AVERETT RC, 1995, 2373 US GEOL SURV; Buffle J, 1998, ENVIRON SCI TECHNOL, V32, P2887, DOI 10.1021/es980217h; CHEN Y, 1976, SOIL SCI SOC AM J, V40, P682, DOI 10.2136/sssaj1976.03615995004000050024x; GHOSH K, 1980, SOIL SCI, V129, P266, DOI 10.1097/00010694-198005000-00002; Hedges JI, 1997, ORG GEOCHEM, V27, P319, DOI 10.1016/S0146-6380(97)00056-9; Jenny H., 1941, FACTORS SOIL FORMATI; Jochum E., 1995, SYNCHROTRON RAD NEWS, V8, P29; KIRZ J, 1995, Q REV BIOPHYS, V28, P33, DOI 10.1017/S0033583500003139; Maurice PA, 1999, ENVIRON SCI TECHNOL, V33, P1538, DOI 10.1021/es981113+; NamjesnikDejanovic K, 1997, COLLOID SURFACE A, V120, P77, DOI 10.1016/S0927-7757(96)03678-3; Orlov D.S., 1995, HUMIC SUBSTANCES SOI, V1, DOI [10.1201/9781003079460, DOI 10.1201/9781003079460]; SCHMAHL G, 1993, OPTIK, V93, P95; SCHNITZER M, 1991, SOIL SCI, V151, P41, DOI 10.1097/00010694-199101000-00008; Schwarzenbach R., 1993, ENV ORGANIC CHEM; Senesi N, 1997, COLLOID SURFACE A, V127, P57, DOI 10.1016/S0927-7757(96)03949-0; Spark DL, 1996, METHODS SOIL ANAL 3; STEVENSON F. J, 1994, HUMUS CHEM; STEVENSON IL, 1982, SOIL SCI, V133, P179, DOI 10.1097/00010694-198203000-00007; Stumm W, 1993, CHEM SOLID WATER INT; Thieme J., 1998, XRAY MICROSCOPY SPEC; [No title captured]	21	221	239	8	179	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	1999	286	5443					1335	1337		10.1126/science.286.5443.1335	http://dx.doi.org/10.1126/science.286.5443.1335			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558983				2022-12-28	WOS:000083675500035
J	Siders, CW; Cavalleri, A; Sokolowski-Tinten, K; Toth, C; Guo, T; Kammler, M; von Hoegen, MH; Wilson, KR; von der Linde, D; Barty, CPJ				Siders, CW; Cavalleri, A; Sokolowski-Tinten, K; Toth, C; Guo, T; Kammler, M; von Hoegen, MH; Wilson, KR; von der Linde, D; Barty, CPJ			Detection of nonthermal melting by ultrafast X-ray diffraction	SCIENCE			English	Article							LATTICE INSTABILITY; LASER; SI; GE; TRANSITIONS; DYNAMICS; DISORDER; DIAMOND; SILICON; PULSES	Using ultrafast, time-resolved, 1.54 angstrom x-ray diffraction, thermal and ultrafast nonthermal melting of germanium, involving passage through nonequilibrium extreme states of matter, was observed. Such ultrafast, optical-pump, x-ray diffraction probe measurements provide a way to study many other transient processes in physics, chemistry, and biology, including direct observation of the atomic motion by which many solid-state processes and chemical and biochemical reactions take place.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Inst Nonlinear Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Appl Mech Engn Sci, La Jolla, CA 92093 USA; Univ Essen Gesamthsch, Inst Laser & Plasmaphys, D-45117 Essen, Germany; Leibniz Univ Hannover, Inst Halbleitertech, D-30167 Hannover, Germany; Leibniz Univ Hannover, Inst Festkorperphys, D-30167 Hannover, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Duisburg Essen; Leibniz University Hannover; Leibniz University Hannover	Siders, CW (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.	csiders@ucsd.edu	Siders, Craig/AFU-8557-2022; Sokolowski-Tinten, Klaus/A-5415-2015; Toth, Csaba/AAD-3106-2019; von Hoegen, Michael Horn/E-4969-2012	von Hoegen, Michael Horn/0000-0003-0324-3457; Guo, Ting/0000-0002-6700-0967; Toth, Csaba/0000-0002-4599-4550				Barty CPJ, 1996, OPT LETT, V21, P668, DOI 10.1364/OL.21.000668; BLOEMBERGEN N, 1992, NATURE, V356, P110, DOI 10.1038/356110a0; CAVALLERI A, 1999, QUANT EL LAS SCI C Q; Chin AH, 1998, SPRINGER SERIES CHEM, V63, P401; DOWNER MC, 1986, PHYS REV LETT, V56, P761, DOI 10.1103/PhysRevLett.56.761; FABRICIUS N, 1986, SOLID STATE COMMUN, V58, P239, DOI 10.1016/0038-1098(86)90209-7; GALLI G, 1990, SCIENCE, V250, P1547, DOI 10.1126/science.250.4987.1547; HORNVONHOEGEN M, 1994, APPL PHYS A-MATER, V59, P503, DOI 10.1007/BF00348268; HORNVONHOEGEN M, 1994, PHYS REV B, V50, P10811, DOI 10.1103/PhysRevB.50.10811; Huang L, 1998, PHYS REV LETT, V80, P185, DOI 10.1103/PhysRevLett.80.185; LARSON BC, 1982, PHYS REV LETT, V48, P337, DOI 10.1103/PhysRevLett.48.337; Larsson J, 1998, APPL PHYS A-MATER, V66, P587, DOI 10.1007/s003390050719; LINDENBERG AM, 1999, QELS 99 SESS QTHJ4 B; LIU JM, 1982, OPT LETT, V7, P196, DOI 10.1364/OL.7.000196; MUMANE MM, 1991, SCIENCE, V25, P531; REITZE DH, 1992, PHYS REV B, V45, P2677, DOI 10.1103/PhysRevB.45.2677; Rischel C, 1997, NATURE, V390, P490, DOI 10.1038/37317; Rose-Petruck C, 1999, NATURE, V398, P310, DOI 10.1038/18631; ROUSSE A, 1999, C LAS EL CLEO 99 SES; SAETA P, 1991, PHYS REV LETT, V67, P1023, DOI 10.1103/PhysRevLett.67.1023; Schoenlein RW, 1996, SCIENCE, V274, P236, DOI 10.1126/science.274.5285.236; SHANK CV, 1983, PHYS REV LETT, V50, P454, DOI 10.1103/PhysRevLett.50.454; Sokolowski-Tinten K, 1998, PHYS REV LETT, V81, P224, DOI 10.1103/PhysRevLett.81.224; Sokolowski-Tinten K, 1998, PHYS REV B, V58, P11805, DOI 10.1103/PhysRevB.58.R11805; SOKOLOWSKITINTEN K, 1995, PHYS REV B, V51, P14186, DOI 10.1103/PhysRevB.51.14186; Spaepen F., 1982, Laser annealing of semiconductors, P15; STAMPFLI P, 1990, PHYS REV B, V42, P7163, DOI 10.1103/PhysRevB.42.7163; STAMPFLI P, 1992, PHYS REV B, V46, P10686, DOI 10.1103/PhysRevB.46.10686; STAMPFLI P, 1994, PHYS REV B, V49, P7299, DOI 10.1103/PhysRevB.49.7299; TOM HWK, 1988, PHYS REV LETT, V60, P1438, DOI 10.1103/PhysRevLett.60.1438; VANVECHTEN JA, 1979, PHYS LETT A, V74, P422, DOI 10.1016/0375-9601(79)90242-1; VONDERLINDE D, 1990, RESONANCES; Wood R F, 1984, PULSED LASER PROCESS, V23	33	458	465	2	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1999	286	5443					1340	1342		10.1126/science.286.5443.1340	http://dx.doi.org/10.1126/science.286.5443.1340			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255NF	10558985				2022-12-28	WOS:000083675500037
J	Berry, RJ; Li, Z; Erickson, JD; Li, S; Moore, CA; Wang, H; Mulinare, J; Zhao, P; Wong, LYC; Gindler, J; Hong, SX; Correa, A				Berry, RJ; Li, Z; Erickson, JD; Li, S; Moore, CA; Wang, H; Mulinare, J; Zhao, P; Wong, LYC; Gindler, J; Hong, SX; Correa, A		China-US Collaborative Project Neu	Prevention of neural-tube defects with folic acid in China	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERICONCEPTIONAL VITAMIN SUPPLEMENTATION; DIETARY-FOLATE; PREVALENCE; RISK	Background Periconceptional use of multivitamins containing folic acid can reduce a woman's risk of having a baby with a neural-tube defect. Methods As part of a public health campaign conducted from 1993 to 1995 in an area of China with high rates of neural-tube defects (the northern region) and one with low rates (the southern region), we evaluated the outcomes of pregnancy in women who were asked to take a pill containing 400 mu g of folic acid alone daily from the time of their premarital examination until the end of their first trimester of pregnancy. Results Among the fetuses or infants of 130,142 women who took folic acid at any time before or during pregnancy and 117,689 women who had not taken folic acid, we identified 102 and 173, respectively, with neural-tube defects. Among the fetuses or infants of women who registered before their last menstrual period and who did not take any folic acid, the rates of neural-tube defects were 4.8 per 1000 pregnancies of at least 20 weeks' gestation in the northern region and 1.0 per 1000 in the southern region. Among the fetuses or infants of the women with periconceptional use of folic acid, the rates were 1.0 per 1000 in the northern region and 0.6 per 1000 in the southern region. The greatest reduction in risk occurred among the fetuses or infants of a subgroup of women in the northern region with periconceptional use who took folic acid pills more than 80 percent of the time. In the southern region the reduction in risk among the fetuses or infants of women with periconceptional use of folic acid was also significant (reduction in risk, 41 percent; 95 percent confidence interval, 3 to 64 percent). Conclusions Periconceptional intake of 400 mg of folic acid daily can reduce the risk of neural-tube defects in areas with high rates of these defects and in areas with low rates. (N Engl J Med 1999;341:1485-90.) (C) 1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Birth Defects & Genet Dis Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Beijing Med Univ, Natl Ctr Maternal & Infant Hlth, Beijing 100083, Peoples R China; Beijing Med Univ, Dept Hlth Care Epidemiol, Beijing 100083, Peoples R China	Centers for Disease Control & Prevention - USA; Peking University; Peking University	Berry, RJ (corresponding author), Ctr Dis Control & Prevent, Birth Defects & Genet Dis Branch, Natl Ctr Environm Hlth, 4770 Buford Hwy,MS F-45, Atlanta, GA 30341 USA.			Berry, Robert/0000-0002-7162-5046				[Anonymous], 1991, MMWR MORB MORTAL WKL, V40, P513; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; Cornel MC, 1997, TERATOLOGY, V55, P134; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; KIRKE PN, 1992, ARCH DIS CHILD, V67, P1442, DOI 10.1136/adc.67.12.1442; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; Moore CA, 1997, AM J MED GENET, V73, P113; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; MURRAY CJL, 1996, GLOBAL BURDEN DIS IN, V10; Olney R, 1998, MENT RETARD DEV D R, V4, P241, DOI 10.1002/(SICI)1098-2779(1998)4:4<241::AID-MRDD2>3.3.CO;2-P; SAS Institute, 1997, SAS STAT SOFTW CHANG; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; SMITHELLS RW, 1980, LANCET, V1, P339; SMITHELLS RW, 1983, LANCET, V1, P1027; WALD N, 1991, LANCET, V338, P131; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; XIAO KZ, 1990, INT J EPIDEMIOL, V19, P978	18	1034	1099	4	87	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1999	341	20					1485	1490		10.1056/NEJM199911113412001	http://dx.doi.org/10.1056/NEJM199911113412001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RK	10559448				2022-12-28	WOS:000083625800001
J	Zipfel, GJ; Lee, JM; Choi, DW				Zipfel, GJ; Lee, JM; Choi, DW			Reducing calcium overload in the ischemic brain	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HIPPOCAMPAL-NEURONS; CHANNEL; EXCITOTOXICITY; DEPENDENCE; GELSOLIN		Washington Univ, Sch Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Zipfel, GJ (corresponding author), Washington Univ, Sch Med, St Louis, MO 63110 USA.		Lee, Jin-Moo/K-2024-2015	Lee, Jin-Moo/0000-0002-3979-0906	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS032636] Funding Source: NIH RePORTER; NINDS NIH HHS [NS32636] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Endres M, 1999, J CLIN INVEST, V103, P347, DOI 10.1172/JCI4953; FURUKAWA K, 1995, EXP NEUROL, V133, P153, DOI 10.1006/exnr.1995.1018; Furukawa K, 1997, J NEUROSCI, V17, P8178, DOI 10.1523/jneurosci.17-21-08178.1997; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y	7	62	65	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	1999	341	20					1543	1544		10.1056/NEJM199911113412011	http://dx.doi.org/10.1056/NEJM199911113412011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254RK	10559458				2022-12-28	WOS:000083625800011
J	Bergh, T; Ericson, A; Hillensjo, T; Nygren, KG; Wennerholm, UB				Bergh, T; Ericson, A; Hillensjo, T; Nygren, KG; Wennerholm, UB			Deliveries and children born after in-vitro fertilisation in Sweden 1982-95: a retrospective cohort study	LANCET			English	Article							CONGENITAL-MALFORMATIONS; INVITRO FERTILIZATION; CRYOPRESERVED EMBRYOS; SINGLETON PREGNANCIES; ASSISTED CONCEPTION; BIRTHS; REGISTRY; TWINS; HEALTH	Background In-vitro fertilisation is an effective treatment for infertility, but there is concern about the health of children. We investigated, in a retrospective registry study, malformations, cancers, and deaths In the complete Swedish in-vitro-fertilisation birth cohort compared with the general population. Methods We collected data from all in-vitro-fertilisation clinics in Sweden and compared the obstetric outcomes of babies (n=5856) born between 1982 and 1995 with all babies born in the general population (n=1 505 724) during the same period, according to data from the Swedish Medical Birth Registry and the Registry of Congenital Malformations. We investigated the incidence of childhood cancer through the Swedish Cancer Registry. Data were stratified for maternal age, parity, previous subfertility, year of birth, and multiple of pregnancies. Findings Multiple births occurred in 27% of pregnancies compared with 1% in the control group. In the in-vitro-fertilisation group, more babies were born preterm (<37 weeks) than controls (30.3 vs 6.3%) and more had low birthweights (<2500 g, 27.4 vs 4.6%). The perinatal mortality was 1.9% in the in-vitro fertilisation group and 11% in the controls. For in-vitro-fertilisation singletons, the risk ratios, adjusted for year of birth, for very preterm birth (<32 weeks) and very low birthweight (<1500 g) were 3.54 (95% CI 2.90-4.32) and 4.39 (3.62-5.32), respectively. Malformations occurred in 5.4% of all babies in the in-vitro fertilisation group (1.39 [1.25-1.54]), and the rates of neural-tube defects and oesophageal atresia were higher than those in the controls. There was no increase in childhood cancer in the in-vitro-fertilisation group. Interpretation A high frequency of multiple births and maternal characteristics were the main factors that led to adverse outcomes, and not the in-vitro-fertilisation technique itself. The clinical practice of in-vitro-fertilisation needs to be changed to lower the rate of multiple pregnancy.	Sophiahemmet, S-11486 Stockholm, Sweden; Carl von Linneklin, Uppsala, Sweden; Socialstyrelsen, Epidemiol Ctr, Gothenburg, Sweden; Fertil Ctr, Gothenburg, Sweden; Sahlgrens Univ Hosp, Gothenburg, Sweden	National Board of Health & Welfare; Sahlgrenska University Hospital	Nygren, KG (corresponding author), Sophiahemmet, POB 5605, S-11486 Stockholm, Sweden.							BERAL V, 1990, BMJ-BRIT MED J, V300, P1229; Bonduelle M, 1996, HUM REPROD, V11, P131, DOI 10.1093/humrep/11.suppl_4.131; BONDUELLE M, 1998, PROSPECTIVE FOLLOW U; Bustillo M, 1999, FERTIL STERIL, V71, P798; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; DEMOUZON J, 1997, J ASSIST REPROD GE S, V14, P251; DEROM R, 1995, MULTIPLE PREGNANCY; Dhont M, 1997, J ASSIST REPROD GEN, V14, P575, DOI 10.1023/A:1022576500894; DOYLE P, 1992, HUM REPROD, V7, P425, DOI 10.1093/oxfordjournals.humrep.a137663; DOYLE PE, 1991, J EPIDEMIOL COMMUN H, V45, P43, DOI 10.1136/jech.45.1.43; FRIEDLER S, 1992, HUM REPROD, V7, P1159, DOI 10.1093/oxfordjournals.humrep.a137813; GHAZI HA, 1991, FERTIL STERIL, V55, P726; GISSLER M, 1995, HUM REPROD, V10, P1856, DOI 10.1093/oxfordjournals.humrep.a136191; KALLEN B, 1986, ACTA GENET MED GEMEL, V35, P167; LANCASTER PAL, 1987, LANCET, V2, P1392; LANCASTER PAL, 1985, BRIT MED J, V291, P1160; LOGEROTLEBRUN H, 1995, FERTIL STERIL, V64, P746; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239; Reubinoff BE, 1997, FERTIL STERIL, V67, P1077, DOI 10.1016/S0015-0282(97)81442-2; ROBERT E, 1993, REPROD TOXICOL, V7, P405, DOI 10.1016/0890-6238(93)90085-L; STEPTOE PC, 1978, LANCET, V2, P366; Sutcliffe AG, 1995, HUM REPROD, V10, P3332, DOI 10.1093/oxfordjournals.humrep.a135915; TANBO T, 1995, OBSTET GYNECOL, V86, P188, DOI 10.1016/0029-7844(95)00159-O; VELD PI, 1995, LANCET, V346, P773, DOI 10.1016/S0140-6736(95)91531-1; von During V, 1995, Tidsskr Nor Laegeforen, V115, P2054; WANG JX, 1994, HUM REPROD, V9, P141, DOI 10.1093/oxfordjournals.humrep.a138304; Weinberg W, 1901, ARCH GESAMTE PHYSIOL, V88, P346, DOI 10.1007/BF01657695; Wennerholm UB, 1998, LANCET, V351, P1085, DOI 10.1016/S0140-6736(97)08247-0; WHITE L, 1990, LANCET, V336, P1577, DOI 10.1016/0140-6736(90)93350-X	29	505	519	4	32	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	1999	354	9190					1579	1585		10.1016/S0140-6736(99)04345-7	http://dx.doi.org/10.1016/S0140-6736(99)04345-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253HM	10560671				2022-12-28	WOS:000083551000008
J	Martzen, MR; McCraith, SM; Spinelli, SL; Torres, FM; Fields, S; Grayhack, EJ; Phizicky, EM				Martzen, MR; McCraith, SM; Spinelli, SL; Torres, FM; Fields, S; Grayhack, EJ; Phizicky, EM			A biochemical genomics approach for identifying genes by the activity of their products	SCIENCE			English	Article							TRANSFER-RNA LIGASE; SACCHAROMYCES-CEREVISIAE; SPLICE JUNCTION; YEAST; 2'-PHOSPHATE; PURIFICATION; EXPRESSION; PHOSPHATE; CLONING	For the identification of yeast genes specifying biochemical activities, a genomic strategy that is rapid, sensitive, and widely applicable was developed with an array of 6144 individual yeast strains, each containing a different yeast open reading frame (ORF) fused to glutathione S-transferase (GSI). For the identification of ORF-associated activities, strains were grown in defined pools, and GST-ORFs were purified. Then, pools were assayed for activities, and active pools were deconvoluted to identify the source strains. Three previously unknown ORF-associated activities were identified with this strategy: a cyclic phosphodiesterase that acts on adenosine diphosphate-ribose 1 "-2 " cyclic phosphate (Appr>p), an Appr-1 "-p-processing activity, and a cytochrome c methyltransferase.	Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Rochester; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Phizicky, EM (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA.	eric_phizicky@urmc.rochester.edu	McCraith, Stephen/AAX-9625-2020; Torres, Filipa/G-9742-2016; Grayhack, Elizabeth J/G-4386-2012	Grayhack, Elizabeth J/0000-0003-2400-5490	NCRR NIH HHS [P41 RR11823] Funding Source: Medline; NIGMS NIH HHS [GM52347] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052347] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Culver GM, 1997, J BIOL CHEM, V272, P13203, DOI 10.1074/jbc.272.20.13203; CULVER GM, 1994, J BIOL CHEM, V269, P24928; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; DELANGE RJ, 1970, J BIOL CHEM, V245, P3325; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; LIAO HH, 1979, J BACTERIOL, V138, P853, DOI 10.1128/JB.138.3.853-860.1979; MACREADIE IG, 1991, GENE, V104, P107, DOI 10.1016/0378-1119(91)90474-P; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; MORINO H, 1987, J NEUROCHEM, V48, P1201, DOI 10.1111/j.1471-4159.1987.tb05647.x; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIMONSEN H, 1994, TRENDS PHARMACOL SCI, V15, P437, DOI 10.1016/0165-6147(94)90052-3; Spinelli SL, 1999, J BIOL CHEM, V274, P2637, DOI 10.1074/jbc.274.5.2637; Spinelli SL, 1997, RNA, V3, P1388	18	331	347	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1999	286	5442					1153	1155		10.1126/science.286.5442.1153	http://dx.doi.org/10.1126/science.286.5442.1153			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	253AJ	10550052				2022-12-28	WOS:000083534200042
J	Gray, WA; Barrett, DM; Benge, JW				Gray, WA; Barrett, DM; Benge, JW			Heart or head?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBCLAVIAN STEAL SYNDROME; RENAL-ARTERY STENOSIS; DISEASE; EXPERIENCE; PRESSURE; INDEX		Swedish Heart Inst, Seattle, WA 98104 USA; Presbyterian Hosp, Albuquerque, NM USA	Swedish Medical Center	Gray, WA (corresponding author), Swedish Heart Inst, 1221 Madison St,Suite 1020, Seattle, WA 98104 USA.							AGEE OF, 1966, AMER J ROENTGENOL RA, V97, P447, DOI 10.2214/ajr.97.2.447; [Anonymous], 1961, N ENGL J MED, V265, P912; BACHMAN DM, 1980, AM J ROENTGENOL, V135, P995, DOI 10.2214/ajr.135.5.995; CONTORNI L, 1960, Minerva Chir, V15, P268; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; DARDIK H, 1966, ANN SURG, V164, P171, DOI 10.1097/00000658-196607000-00021; EDWARDS WH, 1994, ANN SURG, V219, P673, DOI 10.1097/00000658-199406000-00010; Grossman E, 1996, JAMA-J AM MED ASSOC, V276, P1328, DOI 10.1001/jama.276.16.1328; Hadjipetrou P, 1999, J AM COLL CARDIOL, V33, P1238, DOI 10.1016/S0735-1097(98)00690-1; HARRISON R, 1829, SURG ANATOMY ARTERIE; HENNERICI M, 1988, NEUROLOGY, V38, P669, DOI 10.1212/WNL.38.5.669; JEAN WJ, 1994, CATHETER CARDIO DIAG, V32, P8, DOI 10.1002/ccd.1810320103; KUMAR K, 1995, CATHETER CARDIO DIAG, V34, P281, DOI 10.1002/ccd.1810340202; Leng GC, 1996, BMJ-BRIT MED J, V313, P1440, DOI 10.1136/bmj.313.7070.1440; MACRAE IM, 1991, J CARDIOVASC PHARM, V17, pS496, DOI 10.1097/00005344-199100177-00141; MUFTI SI, 1994, CATHETER CARDIO DIAG, V33, P172, DOI 10.1002/ccd.1810330220; NISHIMURA M, 1990, JPN CIRC J, V54, P662, DOI 10.1253/jcj.54.662; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; ROJAS RH, 1966, J THORAC CARDIOV SUR, V51, P113, DOI 10.1016/S0022-5223(19)43279-0; SAMMARTINO WF, 1964, ARCH NEUROL-CHICAGO, V10, P590, DOI 10.1001/archneur.1964.00460180056005; SAMOIL D, 1993, AM HEART J, V126, P1463, DOI 10.1016/0002-8703(93)90547-M; Tatay J, 1998, REV NEUROLOGIA, V26, P803, DOI 10.33588/rn.26153.981016; Uzu T, 1997, AM J KIDNEY DIS, V29, P733, DOI 10.1016/S0272-6386(97)90127-X; VANDERVLIET JA, 1995, EUR J VASC ENDOVASC, V9, P454, DOI 10.1016/S1078-5884(05)80015-2; VITTI MJ, 1994, J VASC SURG, V20, P411, DOI 10.1016/0741-5214(94)90140-6; WALKER PM, 1985, J VASC SURG, V2, P154, DOI 10.1067/mva.1985.avs0020154; Zheng ZJ, 1997, ATHEROSCLEROSIS, V131, P115, DOI 10.1016/S0021-9150(97)06089-9	27	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	1999	341	19					1458	1462		10.1056/NEJM199911043411908	http://dx.doi.org/10.1056/NEJM199911043411908			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XR	10547410				2022-12-28	WOS:000083472100008
J	Dornadula, G; Zhang, H; VanUitert, B; Stern, J; Livornese, L; Ingerman, MJ; Witek, J; Kedanis, RJ; Natkin, J; DeSimone, J; Pomerantz, RJ				Dornadula, G; Zhang, H; VanUitert, B; Stern, J; Livornese, L; Ingerman, MJ; Witek, J; Kedanis, RJ; Natkin, J; DeSimone, J; Pomerantz, RJ			Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE TRANSCRIPTION; PROLONGED SUPPRESSION; COMBINATION THERAPY; VIRAL LOAD; INFECTION; TYPE-1; ZIDOVUDINE; RESERVOIR; INDINAVIR	Context Despite suppressive treatment with highly active antiretroviral therapy (HAART), replication-competent virus can still be isolated from peripheral blood mononuclear cells and genital cells of many individuals receiving suppressive HAART. Objective To determine whether free virion RNA can be detected in the blood plasma and/or genital tract fluids from patients receiving suppressive HAART. Design Prospective cohort study conducted from November 1998 to May 1999. Setting Academic medical center. Patients Human immunodeficiency virus 1-infected individuals (20 men and 2 women) shown in our laboratories to have fewer than 50 copies/mL of HIV-1 RNA in peripheral blood plasma while taking suppressive HAART. Main Outcome Measures Free virion RNA levels in peripheral blood plasma and genital fluids, quantified using an ultrasensitive reverse transcriptase polymerase chain reaction able to quantify cell-free virion RNA to a lower limit of 5 copies/mL and qualitatively detect viral RNA below this level. Results In all 22 patients, residual viral RNA could be detected in the peripheral blood plasma (mean level, 17 copies/mL). The presence of viral RNA suggests that ongoing viral replication is occurring, albeit at low levels, in each patient evaluated, Viral RNA levels were lower in most patients' genital fluids compared with blood plasma and in 12 patients were undetectable. Conclusions These data suggest that low-level replication of HIV-1 in patients taking suppressive HAART may be demonstrated not only in peripheral blood mononuclear cells but also in peripheral plasma as cell-free virion RNA. Complete ablation of viral replication may require intensification of antiretroviral therapies beyond standard suppressive HAART.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Div Infect Dis, Ctr Human Virol,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA; Penn Hosp, Philadelphia, PA 19107 USA; Med Coll Penn & Hahnemann Univ, Partnership Comprehens Care, Philadelphia, PA USA	Jefferson University; University of Pennsylvania; Pennsylvania Medicine; Drexel University	Pomerantz, RJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Div Infect Dis, Ctr Human Virol,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA.	roger.j.pomerantz@mail.tju.edu			NIAID NIH HHS [AI38666] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038666] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Enting RH, 1998, AIDS, V12, P1941, DOI 10.1097/00002030-199815000-00005; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Garcia F, 1999, AIDS, V13, pF79, DOI 10.1097/00002030-199907300-00002; Grossman Z, 1999, NAT MED, V5, P1099, DOI 10.1038/13410; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1987, NEW ENGL J MED, V317, P278; Hockett RD, 1999, J EXP MED, V189, P1545, DOI 10.1084/jem.189.10.1545; Lafeuillade A, 1998, J INFECT DIS, V177, P235, DOI 10.1086/517362; Lewin SR, 1999, J VIROL, V73, P6099, DOI 10.1128/JVI.73.7.6099-6103.1999; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Markowitz M, 1999, J INFECT DIS, V179, P527, DOI 10.1086/314628; Martinez MA, 1999, VIROLOGY, V256, P180, DOI 10.1006/viro.1999.9601; Montaner JSG, 1998, AIDS, V12, P1398, DOI 10.1097/00002030-199811000-00028; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Pomerantz RJ, 1999, NEW ENGL J MED, V340, P1672, DOI 10.1056/NEJM199905273402110; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; POMERANTZ RJ, 1999, HIV ADV RES THER, V9, P17; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang H, 1996, J VIROL, V70, P628, DOI 10.1128/JVI.70.1.628-634.1996; Zhang H, 1996, J VIROL, V70, P2809, DOI 10.1128/JVI.70.5.2809-2824.1996; ZHANG H, 1993, AIDS RES HUM RETROV, V9, P1287, DOI 10.1089/aid.1993.9.1287; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; ZHANG ZQ, 1999, 6 C RETR OPP INF FEB; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	39	362	368	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1627	1632		10.1001/jama.282.17.1627	http://dx.doi.org/10.1001/jama.282.17.1627			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553788	Bronze			2022-12-28	WOS:000083368400027
J	Ubel, PA				Ubel, PA			Physicians' duties in an era of cost containment: Advocacy or betrayal?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Ubel, PA (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.							EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; Levinsky NG, 1998, NEW ENGL J MED, V338, P913, DOI 10.1056/NEJM199803263381313; MORREIM EH, 1991, ARCH INTERN MED, V151, P443, DOI 10.1001/archinte.151.3.443; NEUHAUSER D, 1976, POLICY ANAL, V2, P175; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920; UBEL PA, 1995, ARCH INTERN MED, V155, P1837, DOI 10.1001/archinte.155.17.1837	6	8	8	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1999	282	17					1675	1675		10.1001/jama.282.17.1675	http://dx.doi.org/10.1001/jama.282.17.1675			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250BD	10553798	hybrid			2022-12-28	WOS:000083368400037
J	Hotz, P; Buchet, JP; Bernard, A; Lison, D; Lauwerys, R				Hotz, P; Buchet, JP; Bernard, A; Lison, D; Lauwerys, R			Renal effects of low-level environmental cadmium exposure: 5-year follow-up of a subcohort from the Cadmibel study	LANCET			English	Article							BLOOD-PRESSURE; TUBULAR DYSFUNCTION; GENERAL-POPULATION; POLLUTED AREA; BODY BURDEN; MORTALITY; INHABITANTS; RESIDENTS; REDUCTION; DISEASES	Background The clinical relevance of renal effects of cadmium in people exposed in the environment remains uncertain. This study examined the evolution of renal effects observed in a population exposed to cadmium in the environment. Methods 208 men and 385 women surveyed in 1985-89 (Cadmium in Belgium study [Cadmibel]; baseline) were reexamined on average 5 years later (Public health and environmental exposure to cadmium study [PheeCad]; follow-up). Urinary and blood cadmium and markers of renal tubular dysfunction and glomerular effects were measured. The association between cadmium body burden and renal factors was examined by multivariate logistic and linear regression. Findings In men, mean urinary cadmium excretion and blood cadmium concentration measured at follow-up were 7.5 nmol/24 h (SD 1.9) and 6.1 nmol/L (2.2), reductions of 16% and 35% from baseline, respectively. In women, the corresponding values were 7.6 nmol/24 h (1.9) and 7.8 nmol/L (2.1), reductions of 14% and 28% from baseline. No indication of progressive renal damage was found and the overall results suggest that the effects of low environmental exposure to cadmium on the kidney are weak, stable, or reversible. Interpretation Subclinical renal effects that have been reported in Belgium in patients with increased cadmium body burden are not associated with progressive renal dysfunction and most likely represent non-adverse manifestations.	Univ Catholique Louvain, Ind Toxicol & Occupat Med Unit, B-1200 Brussels, Belgium; Univ Zurich, ISPMZ, Abt Arbeits & Umweltmed, CH-8006 Zurich, Switzerland	Universite Catholique Louvain; University of Zurich	Lison, D (corresponding author), Univ Catholique Louvain, Ind Toxicol & Occupat Med Unit, Clos Chapelle aux Champs 30-54, B-1200 Brussels, Belgium.		BERNARD, Alfred M/A-6511-2010; Lison, Dominique/A-8985-2010	BERNARD, Alfred M/0000-0003-3171-3743; Lison, Dominique/0000-0001-6557-2518				Agency for Toxic Substance and Disease Registry, 1997, TOX PROF CADM; Buchet JP, 1996, OCCUP ENVIRON MED, V53, P320, DOI 10.1136/oem.53.5.320; BUCHET JP, 1990, LANCET, V336, P699, DOI 10.1016/0140-6736(90)92201-R; Cirillo M, 1998, ARCH INTERN MED, V158, P1933, DOI 10.1001/archinte.158.17.1933; GANONG WF, 1997, REV MED PHYSL, P264; Goetz FC, 1997, AM J EPIDEMIOL, V145, P91; HERBER RFM, 1994, PURE APPL CHEM, V66, P915, DOI 10.1351/pac199466040915; INSKIP H, 1982, LANCET, V1, P896; IWATA K, 1991, TOHOKU J EXP MED, V164, P93, DOI 10.1620/tjem.164.93; IWATA K, 1993, ARCH ENVIRON HEALTH, V48, P157, DOI 10.1080/00039896.1993.9940814; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KIDO T, 1990, ARCH ENVIRON HEALTH, V45, P35, DOI 10.1080/00039896.1990.9935922; KIDO T, 1988, ARCH ENVIRON HEALTH, V43, P213, DOI 10.1080/00039896.1988.9934935; LAUWERYS R, 1981, LANCET, V1, P383; LAUWERYS R, 1990, ENVIRON HEALTH PERSP, V87, P283, DOI 10.2307/3431036; Massey LK, 1996, J BONE MINER RES, V11, P731; NAKAGAWA H, 1993, ARCH ENVIRON HEALTH, V48, P428, DOI 10.1080/00039896.1993.10545965; NISHIJO M, 1994, ENVIRON RES, V64, P112, DOI 10.1006/enrs.1994.1010; NISHIJO M, 1995, OCCUP ENVIRON MED, V52, P181, DOI 10.1136/oem.52.3.181; NOGAWA K, 1984, ENVIRON HEALTH PERSP, V54, P163, DOI 10.2307/3429803; Roels HA, 1997, AM J IND MED, V31, P645, DOI 10.1002/(SICI)1097-0274(199705)31:5<645::AID-AJIM21>3.3.CO;2-M; ROELS HA, 1991, BRIT J IND MED, V48, P365; SARTOR FA, 1992, ARCH ENVIRON HEALTH, V47, P347, DOI 10.1080/00039896.1992.9938373; Shigematsu I., 1982, KANKYO HOKEN REPORT, V48, P118; Shigematsu I., 1980, KANKYO HOKEN REPOR 2, V46, P1; STAESSEN J, 1991, AM J EPIDEMIOL, V134, P257, DOI 10.1093/oxfordjournals.aje.a116079; STAESSEN J, 1988, J HYPERTENS, V6, P965, DOI 10.1097/00004872-198812000-00003; Staessen JA, 1999, LANCET, V353, P1140, DOI 10.1016/S0140-6736(98)09356-8; STAESSEN JA, 1994, LANCET, V343, P1523, DOI 10.1016/S0140-6736(94)92936-X; Tsuchiya K, 1992, IARC Sci Publ, P35	30	108	110	1	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	1999	354	9189					1508	1513		10.1016/S0140-6736(99)91145-5	http://dx.doi.org/10.1016/S0140-6736(99)91145-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250WB	10551497				2022-12-28	WOS:000083411300011
J	Alter, DA; Naylor, CD; Austin, P; Tu, JV				Alter, DA; Naylor, CD; Austin, P; Tu, JV			Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; UNITED-STATES; SOCIAL-CLASS; CATHETERIZATION FACILITIES; CARDIOVASCULAR-DISEASE; RISK-FACTORS; HEALTH; CANADA; IMPACT; CARE	Background Universal health care systems seek to ensure access to care on the basis of need rather than income and to improve the health status of all citizens. We examined the performance of the Canadian health system with respect to these goals in the province of Ontario by assessing the effects of neighborhood income on access to invasive cardiac procedures and on mortality one year after acute myocardial infarction. Methods We linked claims for payment for physicians' services, hospital-discharge abstracts, and vital-status data for all patients with acute myocardial infarction who were admitted to hospitals in Ontario between April 1994 and March 1997. Patients' income levels were imputed from the median incomes of their residential neighborhoods as determined in Canada's 1996 census. We determined rates of use and waiting times for coronary angiography and revascularization procedures after the index admission for acute myocardial infarction and determined death rates at one year. In multivariate analyses, we controlled for the patient's age, sex, and severity of disease; the specialty of the attending physician; the volume of cases, teaching status, and on-site facilities for cardiac procedures at the admitting hospital; and the geographic proximity of the admitting hospital to tertiary care centers. Results The study cohort consisted of 51,591 patients. With respect to coronary angiography, increases in neighborhood income from the lowest to the highest quintile were associated with a 23 percent increase in rates of use and a 45 percent decrease in waiting times. There was a strong inverse relation between income and mortality at one year (P<0.001). Each $10,000 increase in the neighborhood median income was associated with a 10 percent reduction in the risk of death within one year (adjusted hazard ratio, 0.90; 95 percent confidence interval, 0.86 to 0.94). Conclusions In the province of Ontario, despite Canada's universal health care system, socioeconomic status had pronounced effects on access to specialized cardiac services as well as on mortality one year after acute myocardial infarction. (N Engl J Med 1999;341:1359-67.) (C) 1999, Massachusetts Medical Society.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Clin Epidemiol & Hlth Care Res Program, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Cardiol, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Gen Internal Med, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Deans Off, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto	Tu, JV (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Inst Clin Evaluat Sci, G-106,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.			Austin, Peter/0000-0003-3337-233X; Tu, Jack/0000-0003-0111-722X				ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; [Anonymous], 1994, Circulation, V89, P1545; [Anonymous], CARDIOVASCULAR HLTH; BADGLEY RF, 1992, CANADIAN HLTH CARE S, P193; Beaudet M P, 1996, Health Rep, V7, P11; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boden WE, 1998, NEW ENGL J MED, V339, P1091; Cairney J, 1996, CAN J PUBLIC HEALTH, V87, P199; CarrHill R, 1995, J EPIDEMIOL COMMUN H, V49, pS28, DOI 10.1136/jech.49.Suppl_2.S28; *COMM PROF HOSP AC, 1992, ICD9CM COMM PROF HOS; COS JL, 1994, J GEN INTERN MED, V9, P674, DOI 10.1007/BF02599007; Efron B., 1994, MONOGRAPHS STAT APPL; ENTERLINE PE, 1973, NEW ENGL J MED, V289, P1174, DOI 10.1056/NEJM197311292892206; Evans R. G., 1994, WHY ARE SOME PEOPLE, P3; Every NR, 1997, CIRCULATION, V96, P1770, DOI 10.1161/01.CIR.96.6.1770; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; JAMES SA, 1987, CIRCULATION, V76, P60; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; KATZ SJ, 1994, JAMA-J AM MED ASSOC, V272, P530, DOI 10.1001/jama.272.7.530; Katz SJ, 1996, CAN J PUBLIC HEALTH, V87, P253; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Krumholz HM, 1998, CIRCULATION, V98, P2010, DOI 10.1161/01.CIR.98.19.2010; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MARMOT MG, 1983, J PSYCHOSOM RES, V27, P377, DOI 10.1016/0022-3999(83)90069-7; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; McIsaac W, 1997, J Health Serv Res Policy, V2, P94; Naylor C D, 1992, Health Econ, V1, P19, DOI 10.1002/hec.4730010106; Roos NP, 1997, MILBANK Q, V75, P89, DOI 10.1111/1468-0009.00045; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P399, DOI 10.1136/jech.52.6.399; STERN MP, 1984, AM J EPIDEMIOL, V120, P834, DOI 10.1093/oxfordjournals.aje.a113956; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; TOFLER GH, 1993, AM J CARDIOL, V71, P1031, DOI 10.1016/0002-9149(93)90568-W; Tu JV, 1997, NEW ENGL J MED, V337, P139; Tu JV., 1999, CARDIOVASCULAR HLTH, P83; WEINBLATT E, 1978, NEW ENGL J MED, V299, P60, DOI 10.1056/NEJM197807132990202	40	500	506	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1359	1367		10.1056/NEJM199910283411806	http://dx.doi.org/10.1056/NEJM199910283411806			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	249XE	10536129				2022-12-28	WOS:000083357800006
J	van Raaij, MJ; Mitraki, A; Lavigne, G; Cusack, S				van Raaij, MJ; Mitraki, A; Lavigne, G; Cusack, S			A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein	NATURE			English	Article							CRYSTAL-STRUCTURE; TYPE-2 FIBER; RECEPTOR; CRYSTALLOGRAPHY; ATTACHMENT; DOMAIN; LONG	Human adenoviruses(1) are responsible for respiratory, gastroenteric and ocular infections(2) and can serve as gene therapy vectors(3). They form icosahedral particles with 240 copies of the trimeric hexon protein arranged on the planes and a penton complex at each of the twelve vertices. The penton consists of a pentameric base, implicated in virus internalization(4), and a protruding trimeric fibre, responsible for receptor attachment(5). The fibres are homo-trimeric proteins containing an aminoterminal penton base attachment domain, a long, thin central shaft and a carboxy-terminal cell attachment or head domain. The shaft domain contains a repeating sequence motif with an invariant glycine or proline and a conserved pattern of hydrophobic residues(6). Here we describe the crystal structure at 2.4 Angstrom resolution of a recombinant protein containing the four distal repeats of the adenovirus type 2 fibre shaft plus the receptor-binding head domain. The structure reveals a novel triple beta-spiral fibrous fold for the shaft. Implications for folding of fibrous proteins (mis-folding of shaft peptides leads to amyloid-like fibrils) and for the design of a new class of artificial, silk-like fibrous materials are discussed.	Inst Max Von Laue Paul Langevin, European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France; CEA, CNRS, Inst Biol Struct, F-38027 Grenoble 1, France	European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Cusack, S (corresponding author), Inst Max Von Laue Paul Langevin, European Mol Biol Lab, Grenoble Outstn, BP 156, F-38042 Grenoble 9, France.	cusack@embl-grenoble.fr	van Raaij, Mark J/B-3678-2009; MITRAKI, Anna/A-6034-2014	van Raaij, Mark J/0000-0002-4781-1375; Cusack, Stephen/0000-0002-9324-0796				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Betts S, 1999, STRUCT FOLD DES, V7, pR131, DOI 10.1016/S0969-2126(99)80078-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cerritelli ME, 1996, J MOL BIOL, V260, P767, DOI 10.1006/jmbi.1996.0436; Chroboczek J, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P163; DEVAUX C, 1987, VIROLOGY, V161, P121, DOI 10.1016/0042-6822(87)90177-2; DEVAUX C, 1990, J MOL BIOL, V215, P567, DOI 10.1016/S0022-2836(05)80169-X; GREEN NM, 1983, EMBO J, V2, P1357, DOI 10.1002/j.1460-2075.1983.tb01592.x; HESS M, 1995, J MOL BIOL, V252, P379, DOI 10.1006/jmbi.1995.0504; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; HORWITZ MS, 1996, FIELDS VIROLOGY, P2149; LOUIS N, 1994, THESIS U J FOURIER G; MARSH RE, 1955, ACTA CRYSTALLOGR, V8, P710, DOI 10.1107/S0365110X5500217X; Mitraki A, 1999, EUR J BIOCHEM, V264, P599, DOI 10.1046/j.1432-1327.1999.00683.x; OBRIEN JP, 1993, ACS SYM SER, V544, P104; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; Robbins PD, 1998, TRENDS BIOTECHNOL, V16, P35, DOI 10.1016/S0167-7799(97)01137-2; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; RUIGROK RWH, 1990, J MOL BIOL, V215, P589, DOI 10.1016/S0022-2836(05)80170-6; RUIGROK RWH, 1994, J GEN VIROL, V75, P2069, DOI 10.1099/0022-1317-75-8-2069; SCHENK TS, 1996, FIELDS VIROLOGY, P2111; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STOUTEN PFW, 1992, J MOL BIOL, V226, P1073, DOI 10.1016/0022-2836(92)91053-R; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; van Raaij MJ, 1999, VIROLOGY, V262, P333, DOI 10.1006/viro.1999.9849; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	30	264	275	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	1999	401	6756					935	938		10.1038/44880	http://dx.doi.org/10.1038/44880			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	251UL	10553913				2022-12-28	WOS:000083464700065
J	Wei, M; Kampert, JB; Barlow, CE; Nichaman, MZ; Gibbons, LW; Paffenbarger, RS; Blair, SN				Wei, M; Kampert, JB; Barlow, CE; Nichaman, MZ; Gibbons, LW; Paffenbarger, RS; Blair, SN			Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; PHYSICAL-ACTIVITY; ATTRIBUTABLE RISK; ALL-CAUSE; HEALTH; TRIAL; WOMEN	Context Recent guidelines for treatment of overweight and obesity include recommendations for risk stratification by disease conditions and cardiovascular disease (CVD) risk factors, but the role of physical inactivity is not prominent in these recommendations. Objective To quantify the influence of low cardiorespiratory fitness, an objective marker of physical inactivity, on CVD and all-cause mortality in normal-weight, overweight, and obese men and compare low fitness with other mortality predictors. Design Prospective observational data from the Aerobics Center Longitudinal Study. Setting Preventive medicine clinic in Dallas, Tex. Participants A total of 25 714 adult men (average age, 43.8 years [SD, 10.1 years]) who received a medical examination during 1970 to 1993, with mortality follow-up to December 31, 1994, Main Outcome Measures Cardiovascular disease and all-cause mortality based on mortality predictors (baseline CVD, type 2 diabetes mellitus, high serum cholesterol level, hypertension, current cigarette smoking, and low cardiorespiratory fitness) stratified by body mass index. Results During the study period, there were 1025 deaths (439 due to CVD) during 258 781 man-years of follow up. Overweight and obese men with baseline CVD or CVD risk factors were at higher risk for all-cause and CVD mortality compared with normal-weight men without these predictors. Using normal-weight men without CVD as the referent, the strongest predictor of CVD death in obese men was baseline CVD (age- and examination year-adjusted relative risk [RR], 14.0; 95% confidence interval [CI], 9.4-20.8); RRs for obese men with diabetes mellitus, high cholesterol, hypertension, smoking, and low fitness were similar and ranged from 4.4 (95% CI, 2.7-7.1) for smoking to 5.0 (95% CI, 3.6-7.0) for low fitness. Relative risks for all-cause mortality in obese men ranged from 2.3 (95% CI, 1.7-2.9) for men with hypertension to 4.7 (95% CI, 3.6-6.1) for those with CVD at baseline. Relative risk for all-cause mortality in obese men with low fitness was 3.1 (95% CI, 2.5-3.8) and in obese men with diabetes mellitus 3.1 (95 % CI, 2.3-4.2) and as slightly higher than the RRs for obese men who smoked or had high cholesterol levels. Low fitness was an independent predictor of mortality in all body mass index groups after adjustment for other mortality predictors. Approximately 50% (n = 1674) of obese men had low fitness, which led to a population-attributable risk of 39% for CVD mortality and 44% for all-cause mortality. Baseline CVD had population attributable risks of 51% and 27% for CVD and all-cause mortality, respectively. Conclusions In this analysis, low cardiorespiratory fitness was a strong and independent predictor of CVD and all-cause mortality and of comparable importance with that of diabetes mellitus and other CVD risk factors.	Cooper Inst Aerob Res, Dallas, TX 75230 USA; Cooper Clin, Dallas, TX USA; Westat Corp, Rockville, MD USA; Stanford Univ, Sch Med, Stanford, CA USA	Cooper Institute; Cooper Institute; Westat; Stanford University	Blair, SN (corresponding author), Cooper Inst Aerob Res, 12330 Preston Rd, Dallas, TX 75230 USA.	sblair@cooperinst.org	wright, beth/V-7496-2019		NIA NIH HHS [AG06945] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG006945, R01AG006945] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1996, JAMA, V276, P241; BALKE B, 1959, U S Armed Forces Med J, V10, P675; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Bouchard C., 1994, PHYSICAL ACTIVITY FI, P106; Bouchard C., 1986, SPORT HUMAN GENETICS, P59; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; Calfas KJ, 1996, PREV MED, V25, P225, DOI 10.1006/pmed.1996.0050; Calfas KJ, 1997, PREV MED, V26, P297, DOI 10.1006/pmed.1997.0141; COX DR, 1972, J R STAT SOC B, V34, P187; Dorn JM, 1997, AM J EPIDEMIOL, V146, P919, DOI 10.1093/oxfordjournals.aje.a009218; Dunn AL, 1998, MED SCI SPORT EXER, V30, P1076, DOI 10.1097/00005768-199807000-00009; Dunn AL, 1997, PREV MED, V26, P883, DOI 10.1006/pmed.1997.0218; Dunn AL, 1999, JAMA-J AM MED ASSOC, V281, P327, DOI 10.1001/jama.281.4.327; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FROHLICH ED, 1988, CIRCULATION, V77, pA502; Gavin JR, 1997, DIABETES CARE, V20, P1183; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Kampert JB, 1996, ANN EPIDEMIOL, V6, P452, DOI 10.1016/S1047-2797(96)00059-2; KOHL HW, 1992, DIABETES CARE, V15, P184, DOI 10.2337/diacare.15.2.184; *NIH, 1997, NIH PUBL; *NIH NAT HEART LUN, 1998, CLIN GUID ID EV TREA, P1; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; Pollock ML, 1998, MED SCI SPORT EXER, V30, P975, DOI 10.1097/00005768-199806000-00032; Rothman KJ., 2008, MODERN EPIDEMIOLOGY; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; WALTER SD, 1983, AM J EPIDEMIOL, V117, P598, DOI 10.1093/oxfordjournals.aje.a113582; World Health Organization,, 1998, WHO TECHN REP SER	30	746	767	1	54	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1999	282	16					1547	1553		10.1001/jama.282.16.1547	http://dx.doi.org/10.1001/jama.282.16.1547			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248MB	10546694	Bronze			2022-12-28	WOS:000083277800022
J	Zakany, J; Duboule, D				Zakany, J; Duboule, D			Hox genes and the making of sphincters	NATURE			English	Article							COMPLEX; EXPRESSION; MICE		Univ Geneva, Dept Zool & Anim Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Zakany, J (corresponding author), Univ Geneva, Dept Zool & Anim Biol, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.			duboule, denis/0000-0001-9961-2960				BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; CONDIE BG, 1993, DEVELOPMENT, V119, P579; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; GERARD M, 1993, EMBO J, V12, P3539, DOI 10.1002/j.1460-2075.1993.tb06028.x; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; Kondo T, 1996, DEVELOPMENT, V122, P2651; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Rijli FM, 1997, CURR OPIN GENET DEV, V7, P481, DOI 10.1016/S0959-437X(97)80074-3; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; Sekimoto T, 1998, GENES CELLS, V3, P51, DOI 10.1046/j.1365-2443.1998.00167.x; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; Zakany J, 1996, NATURE, V384, P69, DOI 10.1038/384069a0	13	65	65	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 21	1999	401	6755					761	762		10.1038/44511	http://dx.doi.org/10.1038/44511			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BG	10548099				2022-12-28	WOS:000083368700040
J	Wilson, AM; Sims, EJ; Orr, LC; Lipworth, BJ				Wilson, AM; Sims, EJ; Orr, LC; Lipworth, BJ			Differences in lung bioavailability between different propellants for fluticasone propionate	LANCET			English	Article								The lung bioavailability las adrenal suppression) of fluticasone propionate was about two-fold greater with chlorofluorocarbons than hydrofluoroalkane as propellant. Direct switching between formulations on a mu g equivalent may therefore be inadvisable.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland	University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland.			McSwiggan, Linda/0000-0001-7168-0750				Ayres J., 1995, European Respiratory Journal, V8, p157S; CRIPPS AL, 1997, J AEROSOL MED, V10; Wilson AM, 1999, THORAX, V54, P20, DOI 10.1136/thx.54.1.20	3	19	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1357	1358		10.1016/S0140-6736(99)03581-3	http://dx.doi.org/10.1016/S0140-6736(99)03581-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533870				2022-12-28	WOS:000083149900019
J	[Anonymous]				[Anonymous]			Perinatal HIV prevention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					625	625		10.1001/jama.282.7.625	http://dx.doi.org/10.1001/jama.282.7.625			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10532854				2022-12-28	WOS:000082033700005
